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ABSTRACT 
The current literature on COPD treatment, in particular the impact of treatment on 
exacerbations, demonstrates that confounding by indication has not been adequately 
addressed in observational studies.  The goal of this research was to develop better 
methods for describing the effectiveness of COPD treatment in the general population.  
The central hypothesis of this research is that marginal structural model (MSM) methods 
are an effective way of addressing the bias introduced by confounding by indication in 
this clinical situation.  
To test this hypothesis, we compared the effectiveness of monotherapy with the 
long-acting muscarinic antagonist (LAMA) tiotropium or dual therapy  with an inhaled 
corticosteroid/long-acting beta-agonist (ICS/LABA) combination inhaler, as compared 
with use of both concurrently (triple therapy).  The primary outcome measure was severe 
exacerbation risk over a two-year period. Three different analysis design methods were 
evaluated: an intent-to-treat (ITT) approach, an as protocol (As Protocol) approach that 
considered discontinuation of initial treatment during the follow-up period, and an MSM 
analysis that incorporated time-varying covariates related to prior period moderate 
exacerbations, use of short-acting beta-agonist (SABA) rescue medication, and 
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discontinuation of the treatment during the follow-up period. Claims data from two 
managed care health plans in New Mexico for the time period July 1, 2004 through 
September 31, 2013 was used to identify 5,475 study subject age 40 or older with a 
diagnosis of COPD who were “new” users (no use in the prior six months) of ICS/LABA, 
LAMA or triple therapy.   
In the two-year period after initial receipt of therapy, 855 study subjects had a 
severe exacerbation (15.6% of 5,475).  Among the 855 subjects, 411 had a severe 
exacerbation while still using their index therapy (events for the As Protocol analysis), 
and 476 while using ICS/LABA and/or LAMA medication that may or may not have 
been their index therapy. Discontinuation of therapy was very prevalent. By six months 
after index, 53.5% of the study sample had no evidence of use of ICS/LABA or LAMA 
medication. Factors related to discontinuation were considered in the MSM analysis.  
Important differences among these three approaches were revealed by these 
analyses. In the MSM analysis, triple therapy was not more effective than use of either 
ICS/LABA or LAMA in reducing the risk of severe exacerbation (HR 1.11, 95% CI 0.68 
to 1.81). The ITT analysis using Cox proportional hazard models suggested that triple 
therapy was associated with increased risk of severe exacerbation over a 24 month period 
after initiation of therapy (HR 1.24, 95% confidence interval (CI) 1.00 to 1.53), however 
over 50% of the study sample discontinued use of ICS/LABA or LAMA by six months 
post-index, suggesting bias in the ITT risk estimate.  No increased risk was seen in the As 
Protocol analysis (HR 1.00, 95% CI 0.73 to 1.36), suggesting that the increased risk 
observed in the ITT analysis is largely attributable to events occurring after study 
subjects have discontinued use of ICS/LABA or LAMA.  Important relationships that 
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were discerned in the MSM analyses were that use of SABA medication in a prior period 
were strongly associated with both use of triple therapy at the start of the next period, and 
with continuation of therapy and that moderate exacerbations in a prior period were 
strongly associated with use of triple therapy at the start of the next period. 
The MSM approach offered some insights into the relationships between 
treatment and outcomes in this observational database that would have been difficult to 
identify using either the traditional ITT approach or the As Protocol approach.  MSM is a 
useful and informative complementary analysis to include in studies of treatment 
effectiveness. 
 
x 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES ..................................................................................................... XVI 
LIST OF TABLES ..................................................................................................... XVII 
CHAPTER 1 INTRODUCTION ..................................................................................... 1 
Role of COPD Medications in Managing Exacerbations .............................................. 3 
Newer Analysis Methods for Managing Bias ............................................................... 10 
Study Aims ....................................................................................................................... 12 
Importance....................................................................................................................... 13 
Study Limitations ............................................................................................................ 15 
CHAPTER 2 REVIEW OF THE RELATED LITERATURE .................................. 17 
COPD ............................................................................................................................... 17 
COPD Exacerbations ............................................................................................... 19 
COPD Hospitalizations ...................................................................................... 21 
Readmission and Mortality Post-Discharge ....................................................... 24 
Management of COPD ............................................................................................ 25 
Pharmacologic Management of COPD .............................................................. 26 
Impact of Comorbidities .......................................................................................... 32 
Identifying Exacerbations in Claims Data .............................................................. 33 
Burden of COPD ..................................................................................................... 37 
Comparative-Effectiveness Analysis in Observational Research ............................... 40 
Propensity Score Analyses ...................................................................................... 42 
Instrumental Variables ............................................................................................ 44 
xi 
 
Marginal Structural Models .................................................................................... 45 
Conclusion ....................................................................................................................... 56 
CHAPTER 3 METHODOLOGY .................................................................................. 58 
Study Approvals .............................................................................................................. 58 
Study Design .................................................................................................................... 58 
Study Population and Focus .......................................................................................... 59 
Inclusion Criteria ..................................................................................................... 60 
Exclusion Criteria .................................................................................................... 61 
Medications of Interest ............................................................................................ 61 
Measured Variables ........................................................................................................ 63 
Identification of Exacerbations ............................................................................... 64 
Cost of Healthcare Utilization ................................................................................. 66 
Patient Demographics and COPD-Related Utilization Variables ........................... 69 
Data Management and Review ...................................................................................... 72 
Statistical Analyses.......................................................................................................... 73 
Analyses by Aim ..................................................................................................... 73 
Aim 1 .................................................................................................................. 73 
Aim 2 .................................................................................................................. 74 
Aim 3 .................................................................................................................. 75 
Aim 4 .................................................................................................................. 76 
Aim 5 .................................................................................................................. 79 
Aim 6 .................................................................................................................. 80 
Power Analyses................................................................................................................ 82 
xii 
 
CHAPTER 4 RESULTS ................................................................................................. 85 
COPD Medications ......................................................................................................... 85 
Standardized Costs ......................................................................................................... 86 
Study Sample Selection................................................................................................... 87 
LHP Population ....................................................................................................... 87 
PHP Population ....................................................................................................... 88 
Aim 1 ................................................................................................................................ 91 
Patient Demographics ............................................................................................. 92 
Health Insurance ...................................................................................................... 94 
Comorbidities .......................................................................................................... 94 
COPD-related Utilization ........................................................................................ 96 
Healthcare Costs ...................................................................................................... 98 
Discontinuation of ICS/LABA or LAMA Therapies ............................................ 100 
Status at Three Months ..................................................................................... 100 
Status at Six Months ......................................................................................... 104 
Switching from the Index Treatment .................................................................... 108 
Status at Three Months ..................................................................................... 108 
Status at Six Months ......................................................................................... 109 
Aim 2 .............................................................................................................................. 167 
Severe Exacerbations ............................................................................................ 167 
Status at Three Months ..................................................................................... 167 
Status at Six Months ......................................................................................... 171 
Moderate/Severe Exacerbations ............................................................................ 207 
xiii 
 
Status at Three Months ..................................................................................... 207 
Status at Six Months ......................................................................................... 212 
Summary of Results from Aim 1 and Aim 2 .............................................................. 247 
Aim 3 .............................................................................................................................. 250 
Treatment Propensity ............................................................................................ 250 
Counterfactual Treatments .................................................................................... 256 
Time Period Intervals for the Study ...................................................................... 259 
Estimated Weights ................................................................................................. 262 
Summary of Weight Estimation Probability Models ............................................ 268 
Analyses Using Weighted Population ................................................................... 275 
Aim 4 .............................................................................................................................. 288 
Intent to Treat ........................................................................................................ 288 
Analysis Using GEE Method ........................................................................... 293 
As Protocol ............................................................................................................ 294 
Status at 12 months Post-Index ........................................................................ 298 
Weighted MSM Analysis ...................................................................................... 300 
Aim 5 .............................................................................................................................. 303 
Intent to Treat ........................................................................................................ 305 
Analysis Using GEE method ............................................................................ 308 
As Protocol ............................................................................................................ 310 
Weighted MSM Analysis ...................................................................................... 313 
Summary of Aim 4 and Aim5 – ITT and As Protocol ............................................... 313 
Aim 6 .............................................................................................................................. 316 
xiv 
 
ITT Estimates ........................................................................................................ 317 
As Protocol Estimates ........................................................................................... 319 
Weighted MSM Analysis ...................................................................................... 321 
CHAPTER 5 DISCUSSION......................................................................................... 323 
Summary ........................................................................................................................ 323 
Discussion of the Results .............................................................................................. 330 
Aim 1 ..................................................................................................................... 331 
Index Treatment ................................................................................................ 331 
Discontinuation of Therapy .............................................................................. 335 
Treatment Switching ........................................................................................ 339 
Aim 2 ..................................................................................................................... 340 
Severe Exacerbations ........................................................................................ 341 
Any Moderate or Severe Exacerbation ............................................................. 344 
Aim 3 ..................................................................................................................... 347 
Aim 4 ..................................................................................................................... 352 
Aim 5 ..................................................................................................................... 356 
Aim 6 ..................................................................................................................... 360 
Limitations of the Study ............................................................................................... 365 
Strengths of the Study .................................................................................................. 368 
Implications for Future Research................................................................................ 369 
Conclusions .................................................................................................................... 370 
APPENDICES ............................................................................................................... 372 
Appendix A: Abbreviations ......................................................................................... 373 
xv 
 
Appendix B: Formulary Summaries ........................................................................... 375 
Appendix C: Additional Procedure and Diagnosis Codes ........................................ 380 
Appendix D: NCQA Standardized Prices by BETOS Categories ............................ 390 
REFERENCES .............................................................................................................. 401 
 
  
xvi 
 
LIST OF FIGURES 
 
Figure 1 Diagram of Relationship between Exacerbations and Treatment ........................ 5 
Figure 2 Illustration of Time Intervals, MSM .................................................................. 49 
Figure 3 Illustration of Time Intervals and Censoring, MSM .......................................... 50 
Figure 4 Study Period ....................................................................................................... 60 
Figure 5 Power Analysis for Hazard Ratio ....................................................................... 83 
Figure 6 Power Analysis for Poisson Regression ............................................................. 84 
Figure 7 Flow Diagram LHP Patient Selection ................................................................ 88 
Figure 8 Flow Diagram PHP Patient Selection................................................................. 89 
Figure 9 Histograms, Propensity for Index Therapy ...................................................... 254 
Figure 10 Box Plots for Standardized Weights............................................................... 267 
Figure 11 Lifetest Survival Distribution Function by Index Treatment, ITT ................. 289 
Figure 12 Log-Log Survival Plot, Severe Exacerbations, ITT ....................................... 293 
Figure 13 Lifetest Survival Distribution Function by Index Treatment, As Protocol .... 295 
Figure 14 Lifetest Survival Distribution Function by Index Treatment, As Protocol .... 299 
Figure 15 Composite Moderate and Severe Exacerbation Endpoint, ITT ...................... 305 
Figure 16 Composite Moderate and Severe Exacerbation Endpoint, As Protocol ......... 311 
Figure 17 Histogram of Estimated Annual Costs, ITT ................................................... 319 
Figure 18 Relationship Between Drug Therapy and Symptom Severity, Hernandez et al.
......................................................................................................................................... 334 
  
xvii 
 
LIST OF TABLES 
 
Table 1 Summary of RCT Studies Comparing Triple Therapy to Either Combination or 
Monotherapy ....................................................................................................................... 8 
Table 2 Summary of Observational Studies Comparing Triple Therapy to Either 
Combination or Monotherapy ............................................................................................. 9 
Table 3 Exacerbation Events ............................................................................................ 21 
Table 4 Most Common Secondary Diagnoses Associated with a Principal Diagnosis of 
COPD, 2008 ...................................................................................................................... 22 
Table 5 Most Common Principal Diagnoses for Patients with COPD as a Secondary 
Diagnosis, 2008................................................................................................................. 23 
Table 6 30-day Readmissions Among COPD Patients 40 years and Older, 15 States, 2008
........................................................................................................................................... 24 
Table 7 Pharmacologic Management of COPD................................................................ 27 
Table 8 Medications of Interest for Index Date ................................................................ 61 
Table 9 Example of Calculations for Periods of ICS/LABA and LAMA Use ................. 63 
Table 10 Database Tables ................................................................................................. 64 
Table 11 Exacerbation Definitions ................................................................................... 65 
Table 12 DRG codes for Severe Exacerbations ................................................................ 65 
Table 13 ICD-9-CM Codes Used for COPD Related Symptoms ..................................... 71 
Table 14 Models for Aim 4, 5 and 6 ................................................................................. 78 
Table 15 Summary of Study Sample Size by Health Plan and Study Year ...................... 90 
Table 16 LHP Baseline Characteristics .......................................................................... 111 
Table 17 PHP Baseline Characteristics........................................................................... 117 
Table 18 Combined LHP and PHP Baseline Characteristic ........................................... 123 
Table 19 LHP Baseline Healthcare Costs (Means) ......................................................... 129 
Table 20 LHP Baseline Healthcare Costs (Medians) ..................................................... 130 
xviii 
 
Table 21 PHP Baseline Healthcare Costs (Means) ......................................................... 131 
Table 22 PHP Baseline Healthcare Costs (Medians) ...................................................... 132 
Table 23 Combined Baseline Healthcare Costs (Means) ............................................... 133 
Table 24 Combined Baseline Healthcare Costs (Medians) ............................................ 134 
Table 25 Baseline Characteristics – Discontinuation in First 3 Months ......................... 135 
Table 26 Baseline Characteristics – Discontinuation in First 6 Months ......................... 141 
Table 27 Baseline Characteristics –Switching from Index therapy in First 3 Months ... 147 
Table 28 Baseline Characteristics –Switching from Index therapy in First 6 Months ... 153 
Table 29 Discontinuation Within 3 Months, Baseline Healthcare Costs (Means) ......... 159 
Table 30 Discontinuation Within 3 Months, Baseline Healthcare Costs (Medians) ...... 160 
Table 31 Discontinuation Within 6 Months, Baseline Healthcare Costs (Means) ......... 161 
Table 32 Discontinuation Within 6 Months, Baseline Healthcare Costs (Medians) ...... 162 
Table 33 Switching Within 3 Months, Baseline Healthcare Costs (Means) ................... 163 
Table 34 Switching Within 3 Months, Baseline Healthcare Costs (Medians) ............... 164 
Table 35 Switching Within 6 Months, Baseline Healthcare Costs (Means) ................... 165 
Table 36 Switching Within 6 Months, Baseline Healthcare Costs (Medians) ............... 166 
Table 37 Baseline Characteristics – Severe Exacerbation in 3 Months.......................... 175 
Table 38 Severe Exacerbations Within 3 Months, Without Discontinuation ................. 181 
Table 39 Baseline Characteristics – Severe Exacerbation in 6 Months.......................... 187 
Table 40 Severe Exacerbation Within 6 Months, Without Discontinuation .................. 193 
Table 41 Severe Exacerbation in 3 Months: Healthcare Utilization Costs (Means) ...... 199 
Table 42 Severe Exacerbation in 3 Months: Healthcare Utilization Costs (Medians) ... 200 
Table 43 Severe Exacerbation Within 3 Months, without Discontinuation, Baseline 
Healthcare Costs (Means) ............................................................................................... 201 
Table 44 Severe Exacerbation Within 3 Months, without Discontinuation, Baseline 
Healthcare Costs (Medians) ............................................................................................ 202 
xix 
 
Table 45 Severe Exacerbation in 6 Months: Healthcare Utilization Costs (Means) ...... 203 
Table 46 Severe Exacerbation in 6 Months: Healthcare Utilization Costs (Medians) ... 204 
Table 47 Severe Exacerbation Within 6 Months, without Discontinuation, Baseline 
Healthcare Costs (Means) ............................................................................................... 205 
Table 48 Severe Exacerbation Within 6 Months, without Discontinuation, Baseline 
Healthcare Costs (Medians) ............................................................................................ 206 
Table 49 Baseline Characteristics: Any Moderate/Severe Exacerbation in First Three 
Months ............................................................................................................................ 217 
Table 50 Baseline Characteristics: Any Moderate/Severe Exacerbation in First 3 Months, 
Without Discontinuation ................................................................................................. 223 
Table 51 Baseline Characteristics: Any Moderate/Severe Exacerbation in First Six 
Months ............................................................................................................................ 228 
Table 52 Baseline Characteristics: Any Moderate/Severe Exacerbation in First 6 Months, 
Without Discontinuation ................................................................................................. 234 
Table 53 Moderate or Severe Exacerbation Within 3 Months, Baseline Healthcare Costs 
(Means) ........................................................................................................................... 239 
Table 54 Moderate or Severe Exacerbation Within 3 Months, Baseline Healthcare Costs 
(Median) .......................................................................................................................... 240 
Table 55 Moderate or Severe Exacerbation Within 3 Months Without Discontinuation, 
Baseline Healthcare Costs (Means) ................................................................................ 241 
Table 56 Moderate or Severe Exacerbation Within 3 Months Without Discontinuation, 
Baseline Healthcare Costs (Medians) ............................................................................. 242 
Table 57 Moderate or Severe Exacerbation Within 6 Months, Baseline Healthcare Costs 
(Means) ........................................................................................................................... 243 
Table 58 Moderate or Severe Exacerbation Within 6 Months, Baseline Healthcare Costs 
(Median) .......................................................................................................................... 244 
Table 59 Moderate or Severe Exacerbation Within 6 Months Without Discontinuation, 
Baseline Healthcare Costs (Means) ................................................................................ 245 
Table 60 Moderate or Severe Exacerbation Within 6 Months Without Discontinuation, 
Baseline Healthcare Costs (Medians) ............................................................................. 246 
Table 61 Summary of Results from Aims 1 and 2.......................................................... 248 
Table 62 Estimated Odds Ratios, Receipt of Index Therapy .......................................... 252 
xx 
 
Table 63 Estimated Sample Sizes Using Baseline Propensity for Treatment ................ 256 
Table 64 Example of Counter Factual Treatment Scenarios .......................................... 258 
Table 65 Study Subjects by Follow-up Time Period ...................................................... 261 
Table 66 Study Subjects Uncensored by Time Period and Treatment Therapy ............. 262 
Table 67 Distribution Statistics for Stabilized Treatment Weights ................................ 266 
Table 68 Odds Ratios, MSM Regression Models for Stabilized Weight Estimation ..... 273 
Table 69 Baseline Characteristics, By Index Treatment, Original versus Weighted ...... 277 
Table 70 Baseline Characteristics – Discontinuation 6 Months, Original versus Weighted
......................................................................................................................................... 280 
Table 71 Severe Exacerbation in 6 Months, Original versus Weighted ......................... 283 
Table 72 Combined Baseline Healthcare Costs (Means), Original versus Weighted .... 286 
Table 73 Combined Baseline Healthcare Costs (Medians), Original versus Weighted . 287 
Table 74 Summary of Severe Exacerbation Events and Censored Values, ITT ............ 288 
Table 75 Hazard Ratio Estimates Severe Exacerbation, ITT ......................................... 289 
Table 76 Summary of Severe Exacerbation Events and Censored Values, As Protocol 294 
Table 77 Hazard Ratio Estimates Severe Exacerbation, As Protocol ............................. 296 
Table 78 Severe Exacerbation Events and Censored Values, As Protocol, One Year 
Follow-up ........................................................................................................................ 299 
Table 79 Hazard Ratio Estimates Severe Exacerbation, MSM ...................................... 301 
Table 80 Hazard Ratio Estimates Severe Exacerbation, all baseline covariates, MSM . 301 
Table 81 Incidence Rate Ratio Estimates Moderate/Severe Exacerbation, ITT ............. 306 
Table 82 Incidence Rate Ratio Estimates Moderate/Severe Exacerbation, GEE, ITT ... 309 
Table 83 Incidence Rate Ratio Estimates Moderate/Severe Exacerbation, As Protocol 312 
Table 84 Summary of Aim 4 and 5 Results, ITT and As Protocol ................................. 314 
Table 85 Estimated Annual Healthcare Costs, ITT ........................................................ 318 
Table 86 Estimated Annual Healthcare Costs, As Protocol ........................................... 320 
xxi 
 
Table 87 Comparison of Mean Cost Effect Estimates, ITT, As Protocol, MSM ........... 322 
Table 88 Summary of Analysis Approach Features ....................................................... 330 
Table 89 Severe Exacerbations by Index Therapy ......................................................... 343 
Table 90 Any Moderate or Severe Exacerbation, by Index Therapy ............................. 345 
Table C-1 COPD-Related Service Procedure Codes ...................................................... 380 
Table C-2 COPD-Complexity Diagnosis Codes............................................................. 385 
Table D-1 NCQA Standardized Prices for BETOS categories ....................................... 390 
Table D-2 Standardized Prices LHP Utilization ............................................................. 393 
Table D-3 Standardized Prices PHP Utilization ............................................................. 397 
 1 
 
CHAPTER 1 INTRODUCTION 
Chapter 1 
Introduction 
 
Chronic obstructive pulmonary disease (COPD) is “characterized by persistent 
airflow limitation that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases” (GOLD 
2011). Chronic inflammation is the chief cause of damage leading to airflow limitation, 
causing both airway structural changes and narrowing as well as causing physiological 
changes that diminish the ability of the airways to remain open during expiration. The 
pathophysiology of COPD varies from patient to patient and includes small airways 
disease (e.g., obstructive bronchiolitis) and parenchymal destruction (e.g., emphysema). 
Episodes of acute worsening of symptoms beyond normal day-to-day variations are 
considered COPD exacerbations (GOLD 2011) and are associated with increased 
morbidity and mortality for COPD patients (Anzueto 2010). Exacerbations can be 
initiated by a bacterial or viral infection or by environmental factors such as air pollution 
(GOLD 2011; Wedzicha and Seemungal 2007) and range from mild episodes which may 
just require minimal treatment, to severe exacerbations requiring hospitalization.  
There is a large degree of variation in exacerbation frequency among patients with 
COPD, and recent research has highlighted that an individual’s propensity for 
experiencing exacerbations should be considered as part of the severity of disease 
assessment. Hurst and colleagues have been very active in this research area and 
demonstrated, using a definition of exacerbations as meeting “common clinical criteria” 
and including a prescription for antibiotics or systemic corticosteroids, that the strongest 
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predictor of having an exacerbation was having had a previous exacerbation (Hurst et al. 
2010). This finding of a frequent-exacerbation phenotype of COPD that is independent of 
disease severity defined by airflow limitation lends support to previous findings that 
exacerbations are associated with acceleration of disease progression (Celli et al. 2003; 
Gelb et al. 2009).  
As further support a recent study assessing patient understanding of COPD 
exacerbations found that among patients with mostly moderate or more severe airflow 
limitation, patients experienced on average 4.6 exacerbations per year, defined as 
worsening of respiratory symptoms requiring an intervention (Kessler et al. 2006). The 
average recovery period following an exacerbation was 10 days, with approximately 20% 
of surveyed patients stating they did not believe they fully recovered after an 
exacerbation (Kessler et al. 2006). Interestingly, in that same study of patient 
understanding of COPD exacerbations, over two-thirds reported some warning signs or 
symptoms prior to the onset of an exacerbation (Kessler et al. 2006). Another recent 
study also noted that healthcare utilization increases prior to initiating or having a change 
in therapy and can remain elevated in the immediate post-period (Blanchette et al. 2011). 
There are clear medical and economic benefits to avoiding COPD exacerbations. 
Individuals with frequent exacerbations have been shown to be not only at higher risk for 
hospitalizations due to COPD but also for longer lengths of stay when hospitalized 
(Donaldson et al. 2002). Moreover, individuals who have been hospitalized for COPD 
have a substantial risk for re-hospitalization and mortality. Reported readmission rates 
have varied, mostly due to differences in defined study populations, but are as high as 
20% to 30% within 7-8 weeks (Wedzicha and Seemungal 2007).  Mortality in the year 
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following discharge is similarly varied, with estimates as high as 20-50% (Holguin et al. 
2005; Ranieri et al. 2008; Steer, Gibson, and Bourke 2010).   
Role of COPD Medications in Managing Exacerbations 
Use of an inhaled corticosteroid (ICS) in combination with a long-acting beta2-
agonist (LABA) therapy as a COPD treatment as well as the long-acting muscarinic 
antagonist (LAMA) tiotropium (TIO) have been shown to prevent exacerbations, with 
similar effectiveness observed for either treatment therapy.  The ICS/LABA combination 
therapy fluticasone/salmeterol (FSC) was approved in late 2003 for the treatment of 
COPD associated with chronic bronchitis and additionally approved in mid 2008 for the 
reduction of exacerbations in patients with COPD. Budesonide/formoterol (BFC), the 
other ICS/LABA combination therapy used in the U.S., arrived later, gaining FDA 
approval in early 2009 as a treatment for COPD.  We have previously demonstrated that 
these two ICS/LABA therapies demonstrate comparable effectiveness in patients with 
COPD (Roberts et al. 2011). TIO, which up through the summer of 2012 was the only 
LAMA approved by the FDA for use in the U.S., was approved in February 2004 for the 
treatment of COPD and in December 2009 it was additionally approved for the reduction 
of exacerbations in patients with COPD.   
The INSPIRE (Investigating New Standards for Prophylaxis in Reducing 
Exacerbations) study, a multicenter randomized double-blind, double-dummy controlled 
trial, showed that there were no significant differences in the overall rate of exacerbations 
experienced by individuals with severe COPD who used either LAMA or the ICS/LABA 
therapy FSC over a two year period (Wedzicha et al. 2008). Based on a health care 
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utilization definition for exacerbations, approximately 60% of each therapy group had at 
least one exacerbation in the two year period, and the overall rate of moderate/severe 
exacerbations for each therapy group was approximately 1.3 per year.  Some differences 
were noted though in other events occurring in the treatment groups.  Patients treated 
with ICS/LABA had fewer events requiring treatment with oral corticosteroids (OCS) but 
more patients treated with ICS/LABA required antibiotic treatment and reported 
pneumonia events.  The authors, noting that ICS/LABA therapies are known to have anti-
inflammatory properties and that TIO has been shown to reduce exacerbations in the 
absence of any anti-inflammatory activity (Wedzicha et al. 2008), felt there may be 
advantages from triple therapy (combining ICS/LABA and TIO), and was a question 
warranting further study.  
To date there have been few studies that have compared the effectiveness of these 
two treatment therapies used in combination (ICS/LABA and TIO), to either therapy 
alone. In one comparison study, use of triple therapy (ICS/LABA+TIO) in comparison to 
TIO by patients with severe COPD was found to significantly reduce the rate of severe 
exacerbations (Welte et al. 2009), however few studies have compared triple therapy 
effectiveness when used in real world situations and among broader populations than 
those with just severe COPD. While the patients enrolled in the INSPIRE trial all had 
“severe” disease using a definition of post-bronchodilator FEV1 (forced expiratory 
volume in 1-second), patients with “moderate” disease have also been shown to have 
similar response to ICS/LABA therapy (Jenkins et al. 2009; Jones 2009). Triple therapy 
may provide a benefit for individuals with moderate COPD who are at higher risk for 
experiencing exacerbations. 
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One difficulty with studying the effectiveness of triple therapy in an observational 
analysis is that there is the potential for a strong confounding by indication bias in the 
persons who are receiving triple therapy as opposed to those who are receiving 
monotherapy or combination therapy; constructing an appropriate comparison group can 
be challenging.  Theoretically, triple therapy would be used when either combination 
therapy or monotherapy alone was not sufficient in alleviating patient symptoms and 
preventing exacerbation events.  Factors that are strongly associated with receipt of 
treatment are also factors related to an elevated risk for adverse outcomes.  The impact of 
past outcomes on treatment choice and on future outcomes are intertwined, often leading 
to treatment choices that vary in time depending on the occurrence of respiratory related 
events; for example, mild, moderate and severe COPD exacerbation events.  Figure 1 
provides an illustration of this, where Eprior are a summary of a patient’s prior 
exacerbation experience, Trmt0 is the treatment received by the patient, M1 are the 
potential moderate exacerbations that the patient may experience after initiating Trmt0, 
Trmt1  is the treatment status of the patient in the next period, and S represents the 
outcome of a severe exacerbation.  
Figure 1 Diagram of Relationship between Exacerbations and Treatment 
 
EPrior
Trmt0
M1
Trmt1
S
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There have been three randomized control trials and two observational studies 
that have reviewed the effectiveness of triple therapy in comparison to either TIO or to 
ICS/LABA combination therapy. These studies are summarized in Table 1 and Table 2. 
Only one of the studies included both TIO and an ICS/LABA combination therapy as 
comparators to triple therapy (Cazzola et al. 2007). However, the focus of that RCT study 
was on the effect of treatment on lung function, dyspnea and use of short-acting beta2-
agonists; exacerbation experience was not reviewed. Both of the other RCT studies 
involved intent-to-treat analyses. One was of a short duration (12 weeks), and while the 
other RCT reviewed outcomes up to one year after initiation of therapy, there were 
substantial numbers of patients who discontinued therapy and of those included in 
analyses, substantial numbers completed the study using an open label ICS/LABA 
combination inhaler (Aaron et al. 2007).   
The two observational studies were each very different.  In the study with a U.S. 
population (Chatterjee et al. 2012), patients on triple therapy were younger than patients 
on TIO (64.6 vs 66.1 years, P<0.001), and while a higher percentage of triple therapy 
patients were hospitalized for COPD in the baseline period (26.8% vs 18.8%, P<0.0001), 
baseline utilization of SABAs, OCS, ipratropium, and home oxygen was lower in the 
triple therapy group than in the TIO group. This was somewhat surprising as higher 
utilization of these resources would seem to indicate more severe disease and greater 
potential need for triple therapy. Estimated hazard ratios were adjusted for baseline 
characteristics, but analyses did not incorporate any adjustment for patient propensity to 
receive either TIO or triple therapy.  The U.K. study on the other hand (Short et al. 2012), 
did include a sub-analysis of patients propensity matched for ICS/LABA vs triple 
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therapy.  The populations in the U.K. study however were almost opposite in proportional 
size to those in the U.S. study. In the U.S. study, the triple therapy group was 
approximately one-third the size of the TIO group, while in the U.K. study the triple 
therapy group was twice the size of the ICS/LABA group.  The differing proportional 
sizes may be due to the U.K. study requiring spirometry information, which would tend 
to reduce the number of individuals included with mild and moderate disease.  The U.K. 
study results showed that while the ICS/LABA patients had on average better lung 
function than the triple therapy patients (ICS/LABA FEV1% of predicted = 62.7% 
compared to 50.8% for triple therapy patients), the triple therapy patients had 15% lower 
risk of hospitalization due to respiratory disease (HR=0.85, 95% CI 0.73-0.99) and a 29% 
lower risk of moderate exacerbation based on an OCS prescription (HR=0.71, 95% CI 
0.63-0.80) (Short et al. 2012). The U.K. study did not include patients using TIO as a 
comparison group.
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Table 1 Summary of RCT Studies Comparing Triple Therapy to Either Combination or Monotherapy 
 
Study 
Comparisons / 
Sample Size 
Study Design/ 
Duration / 
Time Period Findings Limitations 
(Aaron et al. 
2007) 
TIO (N=156), 
TIO+salmeterol 
(SAL) 
(N=148),  
TIO+ 
fluticasone-
salmeterol 
(FSC) (N=145) 
Moderate or 
Severe COPD 
Multicenter 
(27 sites in 
Canada) RCT 
/ One year /  
Oct 2003 – 
Jan 2006 
1. Primary The main analysis of the study consisted of an intention to treat 
analysis which did not find any significant differences in treatment groups 
for the primary outcome of at least 1 COPD exacerbation during the trial. 
A sensitivity analysis censoring patients who discontinued use of study 
medication supported the nonsignificant findings from the main analyses, 
although there was a shift toward favoring TIO/SAL and TIO/FSC over 
TIO monotherapy  
2. Secondary: Lower rate ratio for COPD hospitalizations for TIO+FSC 
compared to TIO, and for all-cause hospitalizations; significant 
improvement in HRQoL for TIO+FSC compared to TIO; TIO+FSC 
improved lung function scores more than TIO. 
1. 47% of TIO group, 43% of 
TIO/SAL and 26% of TIO/FSC 
group discontinued use of the 
study medication prior to 
completing one year of therapy  
2. Of patients discontinuing 
therapy, 74% of TIO, 70% of 
TIO/SAL and 54% of TIO/FSC 
patients completed the study 
using an open-label ICS/LABA 
combination inhaler.  
(Cazzola et 
al. 2007) 
TIO (N=30), 
FSC (N=30), 
TIO+FSC 
(N=30) 
Severe COPD 
RCT Pilot 
study (Spain) /  
12 weeks /  
Pre-2007 
1. Primary: Significant improvement in FEV1 for FSC+TIO compared to 
TIO, but not compared to FSC 
2. Secondary: FSC+TIO and TIO showed greater improvement in dyspnea 
than FSC. Daily use of SABA use lower in all groups compared to 
baseline. 
1. Short evaluation period 
2. Small sample sizes 
3. Patients hospitalized or treated 
with an ICS or OCS were 
withdrawn from the study 
(Welte et al. 
2009) 
TIO (N=331 -> 
302 
completed), 
TIO+BFC 
(N=329 -> 303 
completed) 
 
Severe COPD 
Multicenter 
RCT study (9 
countries) /  
12 weeks/ 
Pre-2009 
1. Primary: Significantly greater lung function improvements for TIO+BFC  
a. HRQoL: TIO+BFC increased 3.8 units compared to 1.5 in TIO (4.5 
considered clinically meaningful) 
b. Other: reduction in reliever use in TIO+BFC group; rate ratio for severe 
exacerbations was 0.38, 95% CI 0.25-0.57 for TIO+BFC compared to 
TIO. Time to first severe exacerbation and time to first 
hospitalization/ED visit both significantly lower for TIO+BFC group 
(0.39, 95% CI 0.24-0.62; 0.39, 95% CI 0.17-0.89,  respectively) [Note: 
all patients had a 2 week run-in period with TIO; start time for hazard 
ratios was beginning of treatment – went through 90 days of study) 
2. Secondary: FSC+TIO and TIO showed greater improvement in dyspnea 
than FSC. Daily use of SABA use lower in all groups compared to 
baseline. 
1. Short evaluation period 
2. No ICS/LABA comparison 
group 
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Table 2 Summary of Observational Studies Comparing Triple Therapy to Either Combination or Monotherapy 
 
Study 
Comparisons / 
Sample Size 
Study Design/ 
Duration / 
Time Period Findings Limitations 
(Chatterjee et 
al. 2012) 
TIO+FSC 
(prescriptions 
on same date, 
N=852), 
TIO (no FSC 
use in follow-
up period, 
N=2,481) 
Retrospective 
(IMS LifeLink 
Health Plan 
data) /  
Baseline of 12 
months; Post-
index, 
minimum of 30 
days / 
Jan 2003 – 
April 2008 
1. TIO+FSC lower adjusted HR (Cox proportional hazard regression) for 
moderate (adj.HR 0.77, 95% CI 0.64-0.93) and any exacerbation 
(adj.HR 0.76, 95% CI 0.65-0.95) experienced 30 -365 days after 
therapy initiation;  
2. unadjusted lower total direct healthcare costs and lower total medical 
costs 
1. Attempt to mimic a randomized 
clinical trial 
2. Did not include ICS/LABA as a 
comparator group 
3. Did not adjust for selection bias in 
initial treatment therapies (other than 
traditional multivariate regression).  
Omission of individuals in TIO group 
who later may have switched to FSC 
or to triple therapy also limited 
generalizability of study.   
(Short et al. 
2012) 
TIO+FSC 
(prescriptions 
on same date, 
N=1,857), 
ICS/LABA 
(N=996) 
 
Retrospective 
(National 
Health Service 
database, 
Scotland)/ 
 No baseline 
period, 
minimum 
follow-up not 
stated/ 
2001 through 
2010 
1. All-cause mortality: adj.  HR of 0.65, 95% CI 0.57-0.75 for 
TIO+ICS/LABA compared to ICS/LABA 
a. TIO as time-dependent variable: adj. HR=0.74, 95% CI 0.63-0.88 
b. Matched propensity analysis: adj.  HR=0.64, 95% CI 0.53-0.77 
2. Similar result for deaths due to respiratory disease; adj.  HR for 
cardiovascular deaths = 0.49, 95% CI 0.33-0.73 
3. COPD exacerbations: OCS - adj.  HR=0.71, 95% CI 0.63-0.80; 
hospital admissions – adj. HR =0.85, 95% CI 0.73-0.99 
4. Lung function improvement: No significant differences 
1. Only compared TIO+ICS/LABA to 
ICS/LABA 
2. Very wide time range reviewed – no 
mention of changes in other 
treatments over time 
3. Did not adjust for use of other 
medications or prior history of 
exacerbations.   
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Newer Analysis Methods for Managing Bias 
Marginal structural models (MSMs) have been proposed as a means of addressing 
confounding by indication in observational studies by incorporating time-varying 
treatment choices and time-dependent confounders of treatment into effectiveness 
analyses.  The term MSM is used as model estimates are population-average effects, thus 
marginal estimates, and estimates describe causal effects and thus are considered 
structural models (Moodie and Stephens 2011; Robins, Hernan, and Brumback 2000). 
MSMs are a form of analysis that can be used to adjust for confounding by indication and 
may provide better assessments of the effectiveness of treatment therapies in studies 
where substantial portions of treatment populations discontinue or switch treatments 
(Faries, Ascher-Svanum, and Belger 2007). In MSMs, weights are used to balance 
confounding characteristics across the treatment groups and to consider censoring that 
may be informative. Through use of the weights, a balanced “pseudo-population” is 
created that is similar to that achieved in the randomization process in a randomized 
controlled trial. The most common MSM means, use of inverse-probability-treatment-
weights (IPTWs) are similar to propensity score weights but are slightly different 
(Rosenbaum and Rubin 1983; Stuart 2010; Sturmer et al. 2006; Xu et al. 2010; Xu et al. 
2012). MSMs may accommodate multiple treatments, treatment changes and time-
dependent confounders (Curtis et al. 2007; Hernan et al. 2006; Segal et al. 2007; Suarez 
et al. 2008; Young et al. 2010). To date, MSMs have not been used in COPD treatment 
effectiveness analyses. 
Few studies have compared use of MSMs to traditional methods for comparing 
treatment effectiveness. Faries and colleagues utilized an effectiveness study of three 
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treatment strategies over one year for schizophrenia patients, focusing on differences 
between two of the strategies for illustrative purposes.  Approximately 50% of 
individuals on conventional therapy (CON) and 13% of those on olanzapine (OLZ) 
switched to another initial medication.  Intention to treat analyses found no statistical 
differences between the two treatment groups.  However, using MSM analyses a 
significant treatment effect was found, with statistically significantly greater symptom 
reduction seen among OLZ patients compared to CON patients (Faries et al. 2007).  The 
lack of a significant finding using the intention to treat may have been due to the 
tendency of differences in treatment groups to move toward the null when there is 
crossover in treatment. 
Yu and colleagues in an examination of the impact of medication adherence levels 
and risk for first indication of a diabetic microvascular complication among patients with 
type two diabetes similarly found different results using conventional methods in 
comparison to a MSM method (Yu, Yu, and Nichol 2010). The authors constructed six 
alternative models with varying levels of assumptions, starting with a Cox proportional 
hazard model with no adjustment for baseline characteristics and no time-varying 
covariates, then sequentially adding in baseline adjustment and time-varying covariates, 
culminating in a MSM with IPTW estimation.  Using conventional methods higher 
adherence was found to be associated with poorer outcomes, while in the MSM, higher 
adherence was found to be associated with reduced risk of adverse complications. 
In this study we propose to use three different methods for comparative 
effectiveness – intention to treat, as protocol, and as treated – to compare COPD 
exacerbation risk among patients using triple therapy – inhaled corticosteroid/long-acting 
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beta2-agonists (ICS/LABA) combination therapy in conjunction with long-acting inhaled 
muscarinic antagonist (LAMA) – in comparison to use of either ICS/LABA or LAMA 
alone.  In the intention to treat method, treatment groups will remain unchanged from 
what they are at treatment initiation; individuals discontinuing or switching medications 
will still be included.  In the as protocol method, individuals will only be included in a 
treatment group as long as they continue to take their initial treatment.  The as treated 
analysis will utilize MSM methods and individuals will be allowed to switch treatment 
groups. 
Study Aims 
The goal of this research is to develop better methods for describing the 
effectiveness of COPD treatment in the general population. The current literature on 
COPD treatment, in particular the impact of treatment on exacerbations, demonstrates 
that confounding by indication has not been adequately addressed in observational 
studies.   The central hypothesis of this research is that MSM methods are an effective 
way of addressing the bias introduced by confounding by indication in this clinical 
situation.  To test this hypothesis, we will conduct comparative effectiveness analyses of 
the combined use in comparison to the individual use of the two major inhaled controller 
therapies (ICS/LABA or LAMA) in terms of their ability to reduce exacerbations.  
Additionally, we will compare the costs associated with the various treatment strategies. 
The proposed analyses will address the following specific aims with respect to the 
study population: 
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Aim 1. Assess baseline characteristics of individuals who are “new” initiators of 
LAMA monotherapy, ICS/LABA combination therapy, and triple therapy, plus 
individuals who later switch therapies. 
Aim 2. Assess characteristics of individuals who have severe and/or moderate 
exacerbations post-therapy initiation. 
Aim 3. Create a “pseudo-population” using MSM weighting. 
Aim 4. Compare risk for severe COPD exacerbations among patients using triple 
therapy compared to use of either ICS/LABA combination or LAMA monotherapy.  
Comparisons are made using both conventional methods and MSM methods.  
Aim 5. Compare risk for moderate exacerbations experienced up to and including 
the first severe COPD exacerbation among patients using triple therapy compared to use 
of either ICS/LABA combination or LAMA monotherapy. Comparisons are made using 
both conventional methods and MSM methods.  
Aim 6. Compare cost and effectiveness of therapy in extending time until first 
COPD-related hospitalization among patients using triple therapy compared to use of 
either ICS/LABA combination or LAMA monotherapy. 
Importance 
The newer COPD treatment guidelines now emphasize a more aggressive 
approach to treatment aimed at reducing the risk for exacerbations and preserving lung 
function. This change in treatment philosophy has come about due to the development of 
medication therapies that have only existed in the last 10 to 15 years, but which reduce 
chronic symptoms, improve the quality of life and physical functioning, and decrease the 
risk of acute COPD exacerbations.  Avoiding COPD exacerbations is of primary 
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importance as exacerbations are potentially life-threatening episodes and may result in 
permanent decrease in lung function.   
The natural history of COPD exacerbations in the general population is not well 
understood.  Only recently the ECLIPSE study, a large study population created to help 
identify new COPD treatment end points, defined a ‘frequent exacerbator’ phenotype, 
which they defined as persons who average two or more moderate or severe 
exacerbations per year (Hurst et al. 2010). This study adds emphasis to the point that 
exacerbation experience and treatment are heavily confounded. It is very important to 
describe the epidemiology of COPD exacerbations and COPD treatment effectiveness so 
that we can better identify the individuals who are at risk and the risk factors associated 
with exacerbation events. Knowledge gained from the research described in this proposal 
will have direct application for observational research studies of COPD patients 
everywhere, including those enrolled in the health plans included in this study.   
A strength of this study is that it will have both LAMA and ICS/LABA groups to 
compare to the triple therapy group.  This study will demonstrate how MSM analysis 
may be a useful tool in better elucidating treatment effectiveness when factors that are 
related to treatment are also related to the experience of outcomes.  Additionally, this 
study will provide further information about factors related to treatment changes and to 
treatment discontinuation. 
COPD is a leading cause of death in the United States, with increasing prevalence 
of COPD among women.  The annual direct medical costs for COPD in the United States 
are currently $20 billion per year, and approximately half of these costs are attributable to 
hospitalizations for acute exacerbations of COPD.  Newer COPD treatments can reduce 
  
 15   
the risk of serious exacerbations by as much as 50% and could have a tremendous impact 
on the health of millions of persons with COPD.  Furthermore, improved care can reduce 
the number of costly hospitalizations that are a growing burden to our health care system.  
Our study will provide information that will help characterize persons at risk for COPD 
exacerbations, and provide information on evaluating treatment effectiveness. It is our 
hope that the information we collect, analyze, and report in this project will directly 
benefit many of the same patients who are represented in the administrative data used in 
our analysis.  
Study Limitations 
As in any retrospective study, there are concerns about validity, confounding, and 
bias that must be addressed.  In this analysis the main concerns for internal validity will 
be measurement error and misclassification of patients in treatment groups.  The intention 
is to minimize these through careful review of the literature and through use of subject 
experts in constructing and conducting analyses. 
Accurate assessment of moderate and severe exacerbations within the claims data 
will be a key component of the study. Utilizing claims data may undercount exacerbation 
events, however this is a systematic issue that affects all study patients similarly.  
Outpatient pharmacy claim data will be used to determine COPD pharmaceutical 
treatment use.  Patients may fill prescriptions but may not utilize them as prescribed. In 
addition, some patients may have dual insurance coverage and may have prescriptions 
filled under an alternate health insurance plan.  These patients may thus be misclassified 
regarding treatment in the model.  Nevertheless, these limitations are present in any 
database study of medication use in COPD, and prior experience with one of this 
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project’s databases including a comprehensive validation of ICD-9 codes by chart review 
indicates that any misclassification errors that may exist are not overwhelming. 
The study populations are from two managed care plans that have members 
predominantly residing in New Mexico, potentially limiting generalizability to other 
regions of the country.   
Several potential selection biases may impact the study.  Analyses will be 
constructed using claims data and will have the perspective of the health insurer, thus 
COPD patients will only be identified if they have had a claim for medications or 
services that was associated with a diagnosis of COPD.  Clinical data such as spirometry 
results, other laboratory results, or patient self-reported information will not be 
considered in analyses (beyond symptoms captured in ICD-9 codes). Any one of these 
could potentially be a causal factor toward better or worse outcomes.  We will be 
capturing both prior exacerbation experience, which has been shown to be strongly 
correlated both to treatment and to future exacerbation experience, and symptoms 
recorded via ICD-9 symptom diagnosis codes.  We anticipate that these measures will 
serve to mitigate the additional impact unmeasured factors may also have.   
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 CHAPTER 2 REVIEW OF THE RELATED LITERATURE 
Chapter 2 
Review of the Related Literature 
 
This chapter presents an overview of COPD disease and comparative 
effectiveness analyses of pharmaceutical treatments for chronic disease. It is structured 
into two parts. The first part considers the current understanding of COPD, the role of 
COPD exacerbations, management of COPD, the importance of comorbidities in COPD, 
processes for identifying exacerbations in claims data and the overall burden of COPD.  
Following that is a discussion of comparative effectiveness analysis methods that are 
relevant to evaluating pharmaceutical treatments for chronic disease. 
COPD 
COPD is “characterized by persistent airflow limitation that is usually progressive 
and associated with an enhanced chronic inflammatory response in the airways and the 
lung to noxious particles or gases” (GOLD 2011). The pathophysiology of COPD varies 
from patient to patient and includes small airways disease (e.g., obstructive bronchiolitis) 
and parenchymal destruction (e.g., emphysema). Chronic inflammation is the chief cause 
of damage leading to airflow limitation, causing both airway structural changes and 
narrowing as well as causing physiological changes that diminish the ability of the 
airways to remain open during expiration (GOLD 2011).  
There is a high degree of disease heterogeneity exhibited in individuals with 
COPD and not surprisingly there is not complete agreement about processes that lead to 
development of COPD. Though still an area of investigation, the most widely known 
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hypotheses about key processes leading to COPD development are the British hypothesis 
(cough and sputum) and the Dutch hypothesis (presence of increased airways 
responsiveness); however two other hypotheses also exist: the Swedish hypothesis 
(genetic factors) and the American hypothesis (impaired repair processes) (Anthonisen 
2004; Mannino and Buist 2007). While COPD may be found in young adults, it is 
predominantly diagnosed in individuals over age 40. For the great majority of patients, 
the disease is a result of progressive damage and chronic inflammation from cigarette 
smoking, though other known causes include smoke from home cooking and heating 
fuels, and exposure to occupational dusts and chemicals.   
Globally, the prevalence of COPD has been found to vary greatly.  Prevalence 
rates for COPD, and rates for other chronic diseases, are tied to underlying trends of risk 
factors in populations. Among the 12 different countries represented in the Burden of 
Obstructive Lung Disease (BOLD) initiative, the prevalence of individuals with 
spirometry measured airflow obstruction ranged from a low of 11% in China to a high of 
26% in Austria (Buist et al. 2007). In both Canada and the United States the prevalence 
rate was approximately 20%.  These estimates based on lung function testing in selected 
population samples are higher than have been self-reported among individuals in the U.S. 
who have participated in large national surveys. For example, it has been reported that 
among individuals 45-64, approximately 6% have COPD and of those >65, 
approximately 9% have COPD (NHLBI 2009).  Past and current smoking prevalence 
rates, improvement over time in effectiveness of COPD treatments and treatments for 
comorbid diseases impacting COPD, age mix of populations, and the extent to which 
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other COPD risk factors are present in the population all impact the prevalence of COPD 
in populations  (Buist et al. 2007). 
COPD Exacerbations 
COPD exacerbation events are episodes of acute worsening of symptoms beyond 
normal day-to-day variations (GOLD 2011). Exacerbations can range from mild episodes 
which may just require minimal treatment, to severe exacerbations that cause respiratory 
failure.  Exacerbations can be initiated by a bacterial or viral infection or by 
environmental factors such as air pollution (GOLD 2011; Wedzicha and Seemungal 
2007). The time for recovery from an exacerbation has been found to be highly variable, 
with time ranging from 7 days for approximately half of exacerbations, to five weeks or 
more, or never for other exacerbations (Seemungal et al. 2000; Wedzicha and Seemungal 
2007).  
There are no universally agreed upon definitions for exacerbation levels. 
Exacerbations have been defined based on symptoms, utilization, or a combination of the 
two (Seemungal, Hurst, and Wedzicha 2009). Frequently used symptoms for defining 
exacerbations are dyspnea, sputum production, cough, sputum purulence, and to a lesser 
extent, wheezing (Effing et al. 2009). For healthcare utilization defined exacerbations, 
hospitalizations due to COPD are considered severe exacerbations, with moderate 
exacerbations frequently defined as an ambulatory clinic or emergency department visit 
associated with a course of antibiotics or oral corticosteroids, (Effing et al. 2009; Tashkin 
2010) and mild as increased use of short-acting bronchodilators (Seemungal et al. 2009). 
(GOLD 2011).  Comparisons of symptom-based definitions of exacerbations have found 
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incidence rates approximately double those that are utilization/treatment based 
(Seemungal et al. 2009). 
Recognizing that the degree to which patients with COPD experience 
exacerbations is an important component in assessing risk of future adverse events, 
GOLD recommendations now incorporate symptomatic assessment and exacerbation risk 
in addition to the previous sole measure of disease severity, spirometry assessment (i.e., 
forced expiratory volume in one second (FEV1), forced vital capacity (FVC)).  When 
assessing risk, the highest risk according to GOLD spirometry level or exacerbation 
history should be chosen. Individuals are determined to be at low risk if spirometry 
indicates GOLD level 1 or 2 (mild or moderate airflow limitation), and the individual has 
only 1 or fewer exacerbations per year.  Individuals are determined to be at high risk if 
spirometry indicates GOLD level 3 or 4 (severe or very severe airflow limitation), or the 
individual has 2 or more exacerbations per year (GOLD 2011). 
There is a large degree of variation in exacerbation frequency among patients with 
COPD, and recent research has highlighted that an individual’s propensity for 
experiencing exacerbations should be considered as part of the severity of disease 
assessment. In the study by Hurst and colleagues, using a definition of exacerbations as 
meeting “common clinical criteria” and including a prescription for antibiotics or 
systemic corticosteroids, the strongest predictor of having an exacerbation was having 
had a previous exacerbation (Hurst et al. 2010). These findings of a frequent-exacerbation 
phenotype of COPD that is independent of  disease severity as measured by GOLD 
criteria lend support to previous findings that exacerbations are associated with 
acceleration of disease progression (Celli et al. 2003; Gelb et al. 2009).  
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Shown in Table 3 is a summary of exacerbation estimates included in the latest 
GOLD report (GOLD 2011) that illustrates the correlation with exacerbation experience 
and GOLD spirometric levels. Shown are summary data from three large multi-site 
randomized clinical trials – 1) Toward a Revolution in COPD Health (TORCH) Study 
(Jenkins et al. 2009), 2) Understanding Potential Long-Term Impacts on Function with 
Tiotropium (UPLIFT) Study (Decramer et al. 2009), and 3) Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study (Hurst et al. 
2010). Little is known about the experience of Mild patients since these patients were not 
in the targeted population of these trials. 
Table 3 Exacerbation Events 
 
COPD Hospitalizations 
As shown in Table 3, hospitalizations due to COPD are experienced not only by 
those with severe and very severe disease, but also those with moderate disease. A study 
using nine years of Medicare data (1997-2005) found that over 50% of individuals with 
COPD had at least one hospitalization annually (Stuart et al. 2010), a higher percentage 
that would be expected given the rates in Table 3, but the Medicare data represent real-
world experience.  
GOLD airflow 
severity level 
Exacerbations  
(per year) 
Hospitalizations  
(per year) 
3-year Mortality 
1: Mild ? ? ? 
2: Moderate 0.7 – 0.9 0.11 – 0.20 11% 
3: Severe 1.1 – 1.3 0.25 – 0.30 15% 
4: Very severe 1.2 – 2.0 0.40 – 0.54 24% 
GOLD, global strategy for obstructive lung disease 
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A previous study using National Hospital Discharge Survey data found that from 
1997 through 2001, hospital discharges due to a primary or secondary diagnosis of COPD 
accounted for approximately 12% of discharges (Holguin et al. 2005). In that survey, 
patients hospitalized with COPD were found to have a higher likelihood of hypertension, 
ischemic heart disease, diabetes, pneumonia, chronic heart failure, and respiratory failure  
than patients hospitalized without COPD as primary or secondary diagnosis (Holguin et 
al. 2005). Similar findings for presence of comorbidities were found by Wier and 
colleagues in their analysis of the Healthcare Cost and Utilization Project (HCUP) 2008 
data. Table 4 provides a summary of the most common secondary diagnoses for 
individuals hospitalized with a principal diagnosis of COPD.  
Table 4 Most Common Secondary Diagnoses Associated with a Principal Diagnosis of 
COPD, 2008 
(Values represent % of discharges) All COPD 
Acute 
Exacerbation 
Without acute 
exacerbation 
Heart disease  29.9 31.0 28.0 
Lipid metabolism disorders  27.8 27.5 28.3 
Diabetes mellitus (wo/complication)  25.2 24.7 26.2 
Congestive heart failure  23.9 25.3 21.7 
Fluid and electrolyte disorders  21.7 22.1 21.2 
Cardiac dysrhythmias  20.7 21.6 19.3 
Esophageal disorders  20.2 19.5 21.6 
Respiratory failure  18.6 20.6 15.4 
Pneumonia  17.9 20.6 13.3 
Most common (but not shown) are hypertension and current and/or past use/abuse of 
tobacco; Acute exacerbations in the study are defined as hospitalizations with ICD-9-
CM code 491.21 
 
 
Table 5 is a summary of the most common principal diagnoses for individuals 
hospitalized with a secondary diagnosis of COPD (Wier et al. 2011).  Acute exacerbation 
was defined as a hospitalization with an International Classification of Diseases, Ninth 
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Revision, Clinical Modification (ICD-9-CM) code 491.21 (obstructive chronic bronchitis 
with acute exacerbation). 
Table 5 Most Common Principal Diagnoses for Patients with COPD as a Secondary 
Diagnosis, 2008 
(Values represent % of 
discharges) 
All COPD 
(N=3,827,100) 
Acute 
Exacerbation 
(N=619,200) 
Without acute 
exacerbation 
(N=3,207,900) 
Pneumonia  9.7 22.3 7.3 
Congestive heart failure  8.1 13.0 7.2 
Respiratory Failure  6.4 21.4 3.5 
Septicemia  3.8 6.3 3.3 
Acute myocardial infarction  2.8 3.0 2.8 
Aspiration pneumonia, 
food/emesis  
1.8 2.7 1.2 
Cardiac dysrhythmias  3.0 1.9 3.2 
Acute exacerbations in the study are defined as hospitalizations with ICD-9-CM code 
491.21 
 
For hospitalizations contained in the HCUP 2008 data, Wier and colleagues 
estimated the average length of stay for a hospitalization with a principal diagnosis of 
COPD at 4.8 days (Wier et al. 2011). Other characteristics associated with an inpatient 
stay will necessarily vary by exacerbation severity. Oxygen therapy will be used in 
almost all cases, while use of ventilator support (either noninvasive [nasal or facial mask] 
or invasive [oro-tracheal tube or tracheostomy]) will be utilized in the presence of 
indications that may include respiratory acidosis, severe dyspnea, respiratory arrest, 
massive aspiration, and severe ventricular arrhythmias (GOLD 2011). As use of these 
indicates a more severe exacerbation, it is not surprising that these are also factors 
associated with an increased risk of readmission (Bahadori and FitzGerald 2007). 
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Readmission and Mortality Post-Discharge 
Persons who have been hospitalized for COPD have a substantial risk for re-
hospitalization and mortality. Reported readmission rates have varied, mostly due to 
differences in defined study populations, but are as high as 20% to 30% within 7-8 weeks 
(Wedzicha and Seemungal 2007).  With regard to U.S. populations, Stuart and colleagues 
found 30 day readmission rates for Medicare beneficiaries with at least one 
hospitalization over a nine year period (1997-2005) to be 16% for those with evidence of 
a prescription for a COPD maintenance medication and 21% for those without (Stuart et 
al. 2010). Lower rates for readmission following a hospitalization with a principal 
diagnosis of COPD were reported from HCUP 2008 data (Table 6 
Table 6) (Elixhauser, Au, and Podulka 2011).  
Table 6 30-day Readmissions Among COPD Patients 40 years and Older, 15 States, 
2008 
 
A review of published studies found the following factors to be significantly 
associated with readmission for COPD: older age; low monthly income, disease duration; 
comorbidities of asthma, ischemic heart disease, congestive cardiac failure, chronic liver 
disease, chronic renal failure, and diabetes; depression at discharge; hospitalizations in 
the year prior; poor nutritional status (surrogate marker, low body mass index [BMI]); 
severity of dyspnea; indicators of organ dysfunction (e.g., hypoalbuminemia, elevated 
 
Index admissions 
(Principal diagnosis 
of COPD) 
30-day readmissions 
Principal 
diagnosis, 
COPD 
Any 
diagnosis 
of COPD 
All-Cause 
Number of discharges  190,700 13,600 33,000 39,100 
Index admissions followed 
by a readmission (%) 
-- 7.1% 17.3% 20.5% 
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serum troponin); use of maintenance oral corticosteroids (OCS), high dose inhaled 
corticosteroids (ICS), and oral theophylline (Steer et al. 2010). 
In-hospital mortality estimates are varied, from 6-8% to as high as 25%, and are 
similarly varied in the year following discharge, with estimates as high as 20-50% 
(Holguin et al. 2005; Ranieri et al. 2008; Steer et al. 2010). Known confounders for post-
discharge mortality are the underlying severity of COPD disease, as well as specific 
comorbidities such as cardiac disease (Steer et al. 2010). Factors not found to be 
associated with increased risk of mortality following discharge were sex, Charlson 
comorbidity score, and long-term oxygen therapy (Steer et al. 2010). 
Management of COPD 
The most important intervention for COPD is smoking cessation for those who 
are still smoking, and avoidance of hazardous exposures among those who don’t.  Daily 
physical activity is recommended, and pulmonary rehabilitation may also provide benefit, 
especially for patients with more intense breathlessness (more than just shortness of 
breath when moving quickly or walking uphill) (GOLD 2011). Furthermore, annual 
vaccination for flu plus intermittent vaccination for pneumococcal pneumonia per CDC 
guidelines may be of benefit since pneumonia and influenza events weaken the 
respiratory system.  
The benefits of systemic corticosteroids and antibiotics in treating acute 
exacerbations are well-recognized, with recommended lengths of treatment being 10-14 
days for corticosteroids and 5-10 days for antibiotics (GOLD 2011).  Otherwise, short-
acting bronchodilators (SABDs) are recommended first-line therapy for treating 
exacerbations, with intravenous methylxanthine therapy considered as second-line 
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therapy when response to SABDs is insufficient (GOLD 2011).   Dalal and colleagues in 
the review of 2008 Medicare inpatient stays and emergency department (ED) visits due to 
COPD found that for almost 90% of inpatient stays and 60% of ED visits individuals 
were prescribed a systemic corticosteroid, and individuals received an antibiotic for 85-
90% inpatient stays and 30% of ED visits (Dalal et al. 2011). Use of SABDs was also 
high; individuals with an inpatient stays were prescribed a short-acting antimuscarinic 
agent (SAMA) approximately 60-70% of the time, a short-acting beta2-agonist (SABA) 
30-40% of the time, and a SAMA/beta2-agonist combination approximately 20-50% of 
the time (Dalal et al. 2011). Following an ED visit, 40% were prescribed a SAMA, 14% a 
SABA, and 14% a SAMA/beta2-agonist combination (Dalal et al. 2011). 
Guidelines for patients who have been hospitalized due to COPD recommend that 
prior to discharge, in addition to a SABD, patients should begin LABD therapy (with or 
without corticosteroids) (GOLD 2011).   As well, it is recommended that the need for 
long-term oxygen therapy be assessed in patients and that patients have a follow-up visit 
in 4-6 weeks at which time their need for oxygen therapy would be reassessed in 
conjunction with their lung function and disease state of other morbidities (GOLD 2011).  
Pharmacologic Management of COPD 
For stabilized patients, pharmacologic treatment is dependent on patient 
symptoms and past history. Table 7 provides a summary of the current pharmacologic 
management strategies for patients that are recommended in the GOLD guidelines.  
Treatment recommendations consider not only the GOLD airflow limitation stages (1 
through 4, mild to very severe, assessed through spirometry measurement), but also 
patient symptoms and exacerbation experience. 
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Table 7 Pharmacologic Management of COPD 
Patient First choice Second choice Alternative Choices 
A: Few symptoms, 0-1 
exac, GOLD 1/2  
SAMA  prn 
or SABA prn 
LAMA or LABA or 
SABA and SAMA 
Theophylline 
B: More symptoms, 0-
1 exac, GOLD 1/2  
LAMA or 
LABA 
LAMA and LABA 
SABA and/or SAMA 
Theophylline 
C: Few symptoms, 2+ 
exac, GOLD 3/ 4  
ICS + LABA 
or LAMA 
LAMA and LABA 
PDE4-inh., SABA and/or 
SAMA, Theophylline 
D: More symptoms, 
2+ exac, GOLD 3/ 4  
ICS + LABA 
or 
LAMA 
ICS and LAMA or  
ICS + LABA and LAMA or 
ICS+LABA and PDE4-inh. or 
LAMA and LABA or 
LAMA and PDE4-inh. 
Carbocysteine 
SABA and/or SAMA 
Theophylline 
exac, exacerbations; ICS,inhaled corticosteroid; GOLD, global strategy for obstructive lung disease; 
LABA = long acting beta2-agonists; LAMA, long-acting antimuscarinic agent, PDE4-inh, 
Phosphodiesterase4 inhibitor; SABA, short-acting beta2-agonists; SAMA, short-acting antimuscarinic 
agent 
 
Bronchodilators 
Bronchodilator medications for COPD consist of beta2-agonists, muscarinic 
agonists (anticholinergics), and methylxanthines. The impact bronchodilator medications 
have for COPD patients is that they serve to widen airways, usually by altering airway 
smooth muscle tone, as opposed to causing changes in lung elastic recoil (GOLD 2011). 
For COPD patients, widening the airways improves emptying of the lungs, and tends to 
reduce dynamic hyperinflation at rest and during exercise (GOLD 2011). For the most 
part, bronchodilator medications are delivered via inhaler devices (methylxanthines are 
an oral medication), and inhaled bronchodilator therapy is the preferred delivery method 
(GOLD 2011).  There are two types of inhalers, metered-dose inhalers (MDI) and dry 
powder inhalers (DPI).  With MDIs, a liquid medication is converted into an aerosol 
spray that individuals slowly breathe in as they press down on the inhaler, with the 
inhaler held 1 to 2 inches from the mouth.  DPIs work similarly, but instead of an aerosol 
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spray from a liquid medication, the inhaler releases a puff of dry powder. For individuals 
who have problems using an MDI, spacer devices (a hollow plastic tube) are available 
which as well as helping to overcome coordination problems, can improve the degree to 
which the medication is deposited into the lower airway and at the same time decrease 
residual amounts that may be left in the mouth.  Nebulizers are electronic devices that 
create a fine mist that can be inhaled deep into the lungs.  Nebulizers are more expensive, 
are not portable devices and so tend to be used in medical facilities or by individuals with 
more complicated disease or frailty issues. 
Bronchodilators are classified as short or long-acting, which refers to their 
duration of action.  The effect of short-acting bronchodilators (SABD) is at most 8 hours, 
while the impact of long-acting bronchodilators (LABD) is 12 hours or more. The effect 
of short-acting beta2-agonists (SABA) tends to be somewhat shorter than that of short-
acting muscarinic antagonists (SAMA) – 4-6 hours for SABAs compared to 6-8 hours for 
SAMAs, although the SABA levalbuterol also has a duration of action of 6-8 hours.  The 
SABA/SAMA combination inhalers have a duration equivalent to SAMAs – 6-8 hours. 
SABDs have a rapid onset of action and are used mainly as rescue medications, although 
the SAMA medication ipratropium has a slower onset of action than SABA medications. 
LABDs are recommended for patients with moderate COPD disease and those 
experiencing more symptoms Table 7. The most-widely used long-acting beta2-agonists 
(LABA) have been formoterol and salmeterol, which have a duration of action of 12 
hours, which is the same as for the less used LABA, arformoterol (approved in 2006 for 
use in treating COPD).  More recently (mid-2011) a newer LABA, indacaterol, was 
approved for use in treating COPD and has a longer duration of action – 24 hours.  
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Indacaterol has been found to achieve results similar to formoterol and the long-acting 
muscarinic agonist (LAMA), tiotropium (Cope et al. 2012), but as a newly approved drug 
however, there is a lack of evidence about its long-term safety and currently its cost is 
significantly higher than formoterol or the long-acting muscarinic agonist (LAMA), 
tiotropium. 
Beta2-agonists work by stimulating beta2-agonist adrenergic receptors in airway 
cells, the main ultimate effect of which is to relax airway smooth muscle, whereas 
muscarinic agonist medications create bronchodilation by blocking acetylcholine’s effect 
on muscarinic receptors in bronchial smooth muscle (GOLD 2011).  
Theophylline is the methylxanthine predominantly used in the U.S., although it is 
considered less effective and is less well-tolerated than inhaled LABD medications 
(GOLD 2011).  
Corticosteroids 
Corticosteroids play a major role in reducing inflammation and mucus production 
in the lungs. Delivering corticosteroids through an inhaler serves to limit systemic 
exposure to corticosteroids compared with oral, injected corticosteroids (Christensson, 
Thoren, and Lindberg 2008). Inhaled corticosteroids (ICS) are often prescribed for long-
term maintenance use, while use of oral corticosteroids (OCS) is less common because of 
the numerous side effects such as steroid myopathy associated with long-term use of 
OCS. The beneficial anti-inflammatory impact of ICS medications is less dramatic for 
COPD than for asthma, potentially because of the lack of eosinophilic inflammation in 
COPD that is a characteristic feature of asthma (Bjerg, Lundback, and Lotvall 2012).  
However regular treatment with inhaled corticosteroids (ICS) has been demonstrated to 
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improve symptoms, lung function, and quality of life and to reduce the frequency of 
exacerbations (GOLD 2011). In addition to a greater risk of pneumonia, side effects 
associated with ICS include a higher prevalence of oral candidiasis, hoarseness, and skin 
bruising (GOLD 2011).  The use of an ICS in combination with a LABA is more 
effective than use of either alone and the ICS/LABA combination inhalers  
fluticasone/salmeterol and budesonide/formoterol have both been approved by the FDA 
as medications that reduce exacerbations in COPD. 
Phosphodiesterase4 inhibitors 
Roflumilast, the only phosphodiesterase4 inhibitors approved for use in treating 
COPD patients in the U.S. is a novel oral medication (approved for use by the FDA in 
mid-2011).  It serves to reduce inflammation but does not have a direct bronchodilator 
effect (GOLD 2011). Use of roflumilast has been associated with more adverse effects 
than inhaled medications  and should be used with caution in patients with depression 
(GOLD 2011).   
Effectiveness of LABDs 
The long-acting bronchodilator and ICS combination maintenance therapies 
(LAMA, ICS/LABA) have proven their effectiveness in reducing the risk of 
hospitalization in not only randomized controlled trials but also in retrospective analyses. 
For example, in analyses of annual medication and healthcare utilization of Medicare 
recipients for the years 1997-2005, use of COPD maintenance drugs (compared to no 
use) was associated with a reduced risk of both hospitalization (OR 0.70, 95% confidence 
interval (CI) 0.61 to 0.79) and with readmission within 30 days (OR 0.74, 95% 
confidence interval (CI) 0.63 to 0.87) (Stuart et al. 2010). Although this study had the 
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limitation that use of medication and hospitalization were analyzed at the same time; 
information was not available on the sequence of medication and hospitalization events.   
With regard to intensity of medication use, evidence has been reported in 
observational studies that higher levels of adherence and longer periods for duration of 
therapy are associated with lower counts of hospitalizations among Medicare 
beneficiaries (Simoni-Wastila et al. 2012). Adherence to therapy among patients with 
COPD varies widely, with adherence reported to be on average 40% to 60% (Restrepo et 
al. 2008). In the TORCH trial, which compared the combination therapy fluticasone 
propionate/salmeterol to each of the separate therapies and to placebo, over a 3 year 
period not only was the mortality rate lower (11.3% for those with adherence measures of 
over 0.80 compared to 26.4% for those with poor adherence), but the rate ratio for 
hospital admission was also lower (95% confidence interval 0.44 to 0.73)  (Vestbo et al. 
2009).  The adherence finding was independent of treatment. This is an important 
finding, and along with examining the potential impact of use of prior therapies in 
individuals who have switched treatments, has been little studied (Seemungal et al. 2009; 
Suissa et al. 2008).   
In general combination therapies work better than therapies in isolation (GOLD 
2011).  Gold guidelines recommend using a LABA in combination with LAMA 
medication when either alone is not sufficient to maintain control. However, while the 
increase in mortality risk associated with LABA monotherapy use in asthma has not been 
demonstrated in COPD, the heightened awareness of the associated risks may be a factor 
in the overall low number of prescription fills for LABA monotherapy among COPD 
patients.   
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Use of an ICS/LABA in combination with LAMA therapy in not uncommon in 
clinical practice, particularly in patients with frequent exacerbations or more severe 
disease. There is some evidence that “triple therapy” – use of ICS/LABA combination 
therapy and a LAMA may reduce exacerbation rates and hospitalizations in particular, 
but as was discussed in Chapter 1, very few studies – RCTs or observational studies – 
have been published on the effectiveness of triple therapy. Information to-date on the 
cost-effectiveness evidence from published studies is weak and more research is needed 
to determine particular populations in which this therapy may prove the most cost-
effective (Kostikas and Bouros 2010; Rabe et al. 2008; Singh et al. 2008).  In particular, a 
better understanding of particular phenotypes of patients using triple therapy and the 
impact of use of triple therapy among those phenotypes is desired (Bjerg et al. 2012).  
Impact of Comorbidities 
Systemic consequences of and comorbidities associated with COPD increasingly 
are recognized to affect disease progression, morbidity and mortality (Decramer et al. 
2008; Maclay, McAllister, and MacNee 2007).Comorbidities that are associated with risk 
of hospitalization and readmission have been identified in previous research (Chen et al. 
2005; Holguin et al. 2005; McGhan et al. 2007) and include the following conditions that 
may aggravate exacerbations: pneumonia, pulmonary embolism, congestive heart failure, 
cardiac arrhythmia, pneumothorax,  and pleural effusion.  Other important comorbidities 
include: cardiovascular disease (ischemic heart disease, heart failure, atrial fibrillation), 
osteoporosis, anxiety/depression, lung cancer, diabetes, and infections (particularly 
respiratory infections). For most comorbidities, however, treatment recommendations for 
managing COPD are unchanged (GOLD 2011). 
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For hospitalized patients, comorbidities can complicate treatment and recovery. A 
5-year study of patients aged > 40 years hospitalized for COPD found that among the 
10% who had comorbid pneumonia-influenza; these patients were twice as likely to have 
a length of stay (LOS) > 7 days and were three times as likely to die while hospitalized 
than were COPD patients without the conditions (Chen et al. 2005). Cancer, weight loss, 
pulmonary hypertension, and heart failure , or having multiple comorbidities, have been 
found to be significant risk factors for an increased risk of death or rehospitalization after 
a severe exacerbation of COPD (Chen et al. 2005; Ranieri et al. 2008; Wong et al. 2008).  
Because their symptoms and clinical presentation can be very similar to COPD 
exacerbations, comorbidities of hospitalized COPD patients may go unrecognized, 
particularly pulmonary embolism (Mascarenhas, Azevedo, and Bettencourt 2010; 
Zvezdin et al. 2009).   
Identifying Exacerbations in Claims Data 
Within the ICD-9-CM classification system, the 490-496 series encompass 
chronic obstructive pulmonary disease and other allied conditions. According to its 
definition, the ICD-9-CM code 496 – chronic airway obstruction not elsewhere classified 
– is to be used for individuals who do not otherwise have one of the specific conditions 
referenced in the 490-495 codes (bronchitis [490], chronic bronchitis [491.xx], 
emphysema [492.x], asthma [493.xx], bronchiectasis [494.x], allergic 
alveolitis/pneumonitis [495.x]).  Some codes contained within the 490-496 series 
specifically mention acute exacerbation, but many individuals with COPD may also be 
hospitalized with an exacerbation that was triggered by an infection, and the infection 
may be the primary diagnosis code used for the hospitalization (Marcus and Braman 
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2010).  Terminology, particularly in light of the most recent GOLD guidelines which 
specifically excludes using the terms “emphysema” and “chronic bronchitis” as 
automatically being synonymous with COPD (GOLD 2011), and differential use through 
time by primary healthcare providers, specialists and coders, is not a trivial issue (Marcus 
and Braman 2010). 
Mapel and colleagues utilized one year (July 2004 to June 2005) of a national 
claims dataset (PharMetrics Inc., Watertown, MA, USA) to develop a claims based 
classification system of COPD complexity (Mapel et al. 2011).  Exacerbations were 
classified as inpatient (primary diagnosis of COPD [ICD-9-CM 491.xx, 492.x, or 496]), 
ED exacerbation (ED visit with primary diagnosis of COPD), outpatient exacerbation-
diagnosis based (ICD-9-CM primary diagnosis of 136.3, 466-466.19, 480-486, 487.0, 
490, 491.21, 491.22, 493.02, 493.12, 493.22, 493.92, 494.1, 506.0-506.3, 507-507.8, 
511.0-511.1, 512-512.8, 517.1, 518.0, 518.81, 518.82, 518.84, 770.84) or outpatient 
exacerbation-drug based (a pharmacy claim for the following oral antibiotics commonly 
used for respiratory infections amoxicillin, beta-lactamase inhibitors, second or third-
generation cephalosporins, macrolides, or doxycycline) or a claim for systemic steroids 
(oral, intramuscular, or intravenous) (Mapel et al. 2011).  Patients were assigned one of 
three disease complexity levels based on an extensive list of diagnosis codes. Inpatient 
utilization was found to have a high positive correlation with complexity level.  
Approximately 35% of those with high complexity level had an inpatient exacerbation, 
while approximately 20% of those with moderate complexity did, and less than 5% of 
those with low complexity did (Mapel et al. 2011).   
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In the studies mentioned using HCUP data, hospitalizations representing acute 
COPD exacerbations were defined as those hospitalizations with a principal diagnosis of 
491.21 (obstructive chronic bronchitis with acute exacerbation).  Recently Stein and 
colleagues published a study (Stein et al. 2012) comparing test characteristics (sensitivity, 
specificity, positive predictive value [PPV], and negative predictive value [NPV]) of four 
different coding algorithms using ICD-9-CM codes to identify acute exacerbations of 
COPD (AE-COPD) using a method that had previously been used by Ginde and 
colleagues in their review of ED records (Ginde et al. 2008). Reviewing hospitalizations 
for individuals age 40 or older, using the single code 491.21 resulted in the highest PPV 
(97.2%), but the lowest sensitivity (12.3%); whereas using a multi-criteria of primary 
discharge diagnosis of COPD (ICD-9-CM 491.xx [chronic bronchitis; 491.20 (without 
exacerbation), was excluded], 492.x [emphysema], 493.22 [chronic obstructive asthma 
with acute exacerbation] , or 496 [COPD, not elsewhere classified]) or primary discharge 
diagnosis of respiratory failure (ICD-9-CM 518.81, 518.82, 518.84) and secondary 
diagnosis of COPD (as defined for primary diagnosis criteria) resulted in a sensitivity of 
24.3% but a PPV of 85.4%.  Specificity was high for all (>99%) and NPV was 
approximately 93% for all (Stein et al. 2012).  A third algorithm using multiple primary 
discharge COPD diagnosis codes (ICD-9-CM 491.xx, 492.x, and 496) resulted in scores 
in-between those of the two just mentioned.  The authors concluded that using any of the 
methods underestimated the actual number of acute exacerbations of COPD, and further 
speculated that use of codes for patient identification may not be optimal since code use 
is a factor of both clinical evidence in the medical record and reimbursement algorithms.   
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In the study by Ginde and colleagues that preceded that of Stein and colleagues, 
three separate identification techniques were used: 1) ICD-9-CM code 491.2x (no 
exclusions), 2) ICD-9-CM 492.8, and 3) ICD-9-CM code 496; the PPV values for the 
three techniques were 100%, 75%, and 60% respectively.  Although in the Ginde study 
out of the 200 charts reviewed, 193 were in fact found to be AE-COPD visits, 181 of 
which were identified using ICD-9-CM code 491.2x (Ginde et al. 2008).  For the 7 
individuals with ED visits not determined to be AE-COPD visits, all individuals had a 
history of COPD: 4 visits were preoperative for lung transplant, one visit was a 
medication refill for inhalers (but no notes indicating acute respiratory symptoms), one 
visit was primarily for back pain and mild wheezing was noted, and the seventh was for 
hyperglycemia/diabetes with no mention of respiratory symptoms (Ginde et al. 2008).   
McGhan and colleagues performed a review of hospitalizations for COPD 
occurring between 1999 to 2003 to identify predictors of re-hospitalization after a severe 
exacerbation of COPD (McGhan et al. 2007). Hospitalizations for COPD were defined as 
ICD-9 code 490.x-492.x, or 496 or a diagnosis related group (DRG) code of COPD (code 
88 during the time period of the study).  Patients were excluded who only had a COPD 
DRG code but not an accompanying ICD-9 COPD code, or patients who had a length of 
stay longer than 90 days. The authors identified 54,269 patients with COPD 
hospitalizations and found a high percentage for readmission (25%) and for mortality 
(21%) within one year of discharge. The authors did not report a validation of their case 
identification method (McGhan et al. 2007).   
Sharma and colleagues however also used COPD DRG code 88 to identify 
Medicare beneficiaries hospitalized for COPD between 1996 and 2006 (Sharma et al. 
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2010). Among identified hospitalizations, 88% also had an COPD ICD-9 code listed as a 
principal diagnosis, with asthma listed as the principal diagnosis in an additional 11% 
(Sharma et al. 2010). The 30 day readmission rate for identified hospitalizations was 
approximately 20% (Sharma et al. 2010).  A similar, though slightly higher readmission 
rate for COPD hospitalizations identified using DRG code (MS-DRG code 190-192) was 
found using more recent data (Oct 2007 through Sep 2008) for patients in Southwestern 
Pennsylvania; among 12,137 identified admissions, 23% were readmitted within 30 days, 
and 50% within one year (Kanel, Elster, and Vrbin 2010). 
As with diagnosis coding, there are nuances to DRG coding, particularly since the 
implementation of the MS-DRG codes which distinguish between conditions with or 
without complication or comorbidity.  In a review of 2009 Medicare claims the payment 
for MS-DRG 192 (COPD without complication or comorbidity) was $3,946 at a hospital 
rate of $5,500 with the geometric mean length of stay being 3.3 days (Hale 2010).  
Whereas, if a patient presented with an acute exacerbation of COPD and arterial blood 
gases indicated severe hypoxemia, MS-DRG 189 (Respiratory failure) with an 
accompanying diagnosis of acute exacerbation of COPD might be documented in which 
case the payment was $7,400 and the geometric mean length of stay was 4.7 days (Hale 
2010), means that were almost identical to those calculated for the 2008 HCUP data 
(Wier et al. 2011).   
Burden of COPD 
Hospital care accounts for the largest share of direct health care expenditures for 
COPD.  Using HCUP 2008 data, Wier and colleagues estimated that the average cost of 
stay for a hospitalization with a principal diagnosis of COPD was $7,500 (Wier et al. 
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2011). Dalal and colleagues in their review of cost of inpatient stays and emergency 
department visits for individuals with COPD in 2008 found a similar estimate for 
inpatient stays as that of Wier and colleagues - $7,242 for simple inpatient admissions 
(with an average stay of 4.5 days), but they also estimated an average cost for complex 
admissions (defined as a stay with intubation and/or an intensive care stay) of $20,757 , 
with patients having both intubation and intensive care having the highest average cost, 
$44,909 (with an average stay of 16.0 days) (Dalal et al. 2011).  
Readmissions following a hospitalization with a principal diagnosis of COPD 
were estimated to be even higher using the HCUP 2008 data, with  the average 30-day 
readmission cost being $8,400 for a readmission with a principal diagnosis of COPD, 
$10,900 for a readmission with any diagnosis of COPD, and $11,100 for any readmission  
(Elixhauser et al. 2011).  
Of the $29.5 million estimated to be spent in the U.S. on COPD in 2010, $13.2 
million was for hospital care, with prescription drug treatments and physician services 
accounting for the next highest portions at $5.8 and $5.5, respectively (NHLBI 2009).  
The further direct cost of care tangentially related to hospitalizations, home health care 
and nursing home care, was estimated to be approximately $5 million in 2010 (NHLBI 
2009).  Dalal and colleagues in their review of 2008 Medicare data estimated an average 
cost for emergency room visits due to COPD (that did not lead to an inpatient stay) of 
$647 (Dalal et al. 2011). 
While there is agreement that hospitalizations are the primary driver of overall 
cost for individuals with COPD, direct cost estimates for exacerbations other than 
hospitalizations have varied considerably, mostly owing to differential definitions of an 
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exacerbation, but also to geographical and socio-economic differences in populations 
(Bustacchini et al. 2011; Toy et al. 2010). Most U.S. economic burden studies for COPD 
have used the categories of inpatient, outpatient and pharmacy as these are the most 
easily summarized categories of care (Foster et al. 2006; Menzin et al. 2008), with the 
focus of economic burden being between individuals with COPD and similarly age and 
sex matched individuals without COPD.  The usual conclusion is that caring for patients 
with COPD is expensive.  One criticism of COPD economic studies is that factors that 
contribute to the expense of COPD have been reviewed in isolation, as opposed to the 
identification of subgroups of patients, or phenotypes that may benefit from treatment 
(Kostikas and Bouros 2010).  Coincidentally there is a recognition that identification of 
clusters of attributes may provide information in comparative effectiveness analyses as to 
which patients show evidence of greater responsiveness to treatment (Disantostefano et 
al. 2013).  
It should also be recognized that exacerbations not only have a financial impact 
but they adversely impact the mental and physical well-being of physicians. In one study 
seeking to gain better understanding of the exacerbation experience among moderate to 
severe COPD patients, in addition to the terms “chest infection” and “attack” patients 
frequently used the term “crisis” to describe their exacerbation experience (Kessler et al. 
2006). Almost all patients (90%) reported that exacerbations adversely impacted their 
ability to perform activities of daily living, with a majority reporting that exacerbations 
were accompanied by increased levels of anxiety, depression and isolation, and half 
reporting near cessation of all activities (Kessler et al. 2006).  These comments support 
earlier studies that found significant levels of impaired health status even among 
  
 40   
individuals with moderate disease (Jones 1995, 2001). Notably, these negative aspects of 
exacerbations have been included in the recently developed COPD assessment  test 
(CAT), which is a short disease specific patient questionnaire for COPD patients 
assessing not only cough, phlegm, chest tightness, and breathlessness going up 
hills/stairs, but also activity limitation at home, confidence leaving home, sleep, and 
energy levels (Jones et al. 2009; Mackay et al. 2012).  
Comparative-Effectiveness Analysis in Observational Research 
Porta defines effectiveness as “a measure of the extent to which a specific 
intervention, procedure, regimen, or service, when deployed in the field in the usual 
circumstances, does what it is intended to do for a specified population. A measure of the 
extent to which a health care intervention fulfills its objectives in practice”(Porta and 
International Epidemiological Association. 2008), and this is the operative definition 
primarily used in comparative effectiveness research. Within health services research, 
effectiveness evaluations are a foundation for continuous quality improvement of 
structures, processes and outcomes. Using effectiveness evidence for decision making is 
intuitively appealing and the use of formal evidence based methods has expanded 
dramatically since the first use of the term “evidence based medicine” in the early 1990s 
in the U.S (Eddy 1990; Guyatt 1992; Sackett et al. 1996).  
Clearly knowledge about the effectiveness of COPD treatments in reducing 
exacerbations is important. Two design features that aid in capturing a truer measure of 
the impact of treatments are use of a control group, and randomization of subjects to 
treatment (Little and Rubin 2000). The latter, randomization, is obviously impossible in a 
retrospective observational study, and the attributes of an observational study vs RCT 
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have been much discussed.  There has been discussion of increasing the use of pragmatic 
clinical trials, that is studies that retain randomization as a core design element, but that 
do not impose as many restrictions on the study population as RCTS have traditionally 
done  in order to answer clinically relevant questions of interest to decision makers, be 
they health plans, practitioners, or patients (Tunis, Stryer, and Clancy 2003). However 
even these would still have the disadvantage of being extremely expensive as most seek 
to investigate issues that require large sample sizes and long periods of follow-up. 
Observational studies have a place, in particular for helping to review not only 
populations for whom the requirement for equipoise in a prospective RCT is proscriptive, 
but also for investigating how treatments are utilized in the real world. 
 The lack of randomization however does create specific challenges for 
investigations of treatments related to chronic disease. There is always the potential for a 
strong confounding by indication bias, a term that as used here emphasizes the 
confounding role of disease symptoms and severity with medications used to treat COPD 
(Salas, Hofman, and Stricker 1999).  With COPD, factors that are strongly associated 
with receipt of treatment are also factors related to an elevated risk for adverse outcomes.  
The impact of past outcomes on treatment choice and on future outcomes is intertwined, 
often leading to treatment choices that vary in time depending on the occurrence of 
respiratory related events.  Thus, individuals who are prescribed and who actively fill 
prescriptions for both ICS/LABA and LAMA concurrently are more likely to be 
individuals for whom either ICS/LABA or LAMA alone was insufficient to control 
maintain a stable condition.  
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Fortunately methods exist that enable a retrospective observational study to be 
structured so that the chances of obtaining “valid, reliable, and precise causal answers” 
are improved (Little and Rubin 2000).  These methods seek to compare equivalent groups 
– that is, to insure similar distributions of key characteristics for each treatment group. 
Propensity Score Analyses 
The use of propensity scores is one method that has been widely used to achieve 
roughly equivalent study samples (Rosenbaum and Rubin 1983).  The propensity score is 
a measure of the likelihood of treatment. For treatment effectiveness analyses a 
propensity score is usually calculated using a binary logistic regression model – with the 
dependent variable being receipt of treatment or not, although multinomial logistic 
regression can also accommodate propensity for being prescribed more than one 
treatment therapy. Other methods used include discriminant analysis and probit analysis.  
Factors believed to be associated with receipt of treatments are included in the 
regression model.  There is no agreed upon method for model building, particularly 
concerning whether omitting variables related to outcomes may or may not reduce the 
efficiency of the propensity analysis, but there is agreement that the overall objective is to 
achieve balance between the two treatment groups being compared  (D'Agostino 1998; 
Weitzen et al. 2005).  D’Agostino and D’Agostino maintain that the focus should be on 
including variables that are unbalanced between the treatment groups (D'Agostino 2007). 
The three main ways propensity scores have been used are to match populations 
on propensity scores, stratify populations using the propensity score, and to use the 
propensity score as another adjustment factor in regression analyses.  All three methods 
serve to accomplish the objective of a balanced population by adjusting the sample 
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population for the conditional probability of treatment given the measured covariates.  A 
increasingly widely used measure to assess the success in achieving balance between 
groups is the absolute standardized difference, defined as the absolute difference in 
sample means divided by an estimate of the pooled standard deviation of the variable 
(Austin 2008; D'Agostino 1998). The attractiveness of this measure is that the 
measurement is a property of the sample population and not affected by sample size.  
Standardized differences >0.10  are considered to indicate meaningful differences 
between groups (Normand et al. 2001).  
It bears mentioning however that forcing balance of measured covariates using 
propensity score methods has been posited to exacerbate imbalance in unmeasured 
covariates (Brooks and Ohsfeldt 2012).  The difficulty with unmeasured confounders 
however is that they are unmeasured and has such their influence cannot be estimated by 
the researcher. The underlying assumption is that achieving balance in measured 
confounders between treatment groups also achieves balance in unmeasured confounders.  
Brooks and Ohsfeldt have offered the hypothetical question (Brooks and Ohsfeldt 2012) 
– why would patients with the same or similar propensity scores have received different 
treatments? Brooks and Ohsfeldt present a simulation analysis to support their criticism 
of propensity score methods. Simulations however can have their own faults, as was the 
case in the differing opinions summarized by Basu, Polsky and Manning, of Frölich’s 
finding that in some cases propensity weighting estimators are worse than matching on 
covariates which was refuted by Busso and colleagues who found issues with Frölich’s 
results to include not normalizing the weights used in the analysis (Basu, Polsky, and 
Manning 2011; Busso, DiNardo, and McCrary 2009; Frölich 2004). The simulated study 
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results provided by Brooks and Ohsfeldt does serve though to reinforce the underlying 
requirement for all research, that researchers assess the extent to which unmeasured 
confounders may be impacting observed treatment selection and subsequent outcomes. 
Instrumental Variables 
Use of propensity scores, which make use of measured and observed variables, is 
a method that is now used fairly extensively in health outcomes research. Use of 
instrumental variables (IV) on the other hand is an approach that has been more common 
in economics and social sciences as a means of capturing residual confounding due to 
unmeasured confounders.  Through IV approaches, variables are identified that are 
associated with a given treatment being chosen or prescribed, but which are not 
associated with the outcome of interest.   
Practitioner prescribing behavior, formulary restrictions, and gatekeeper access 
restrictions are all examples of instrumental variables that have been used in analyses 
(Brookhart et al. 2007; Crown et al. 2004; Fang, Liu, and Rizzo 2009).  Strong 
instruments are difficult to identify and pitfalls have been identified with using IV 
approaches in administrative claims data studies (Baser 2009; D'Agostino 2007).   
For most studies however, the biggest limitation is the difficulty in obtaining 
information that would allow the identification of useful instruments.  For example, the 
more useful level of patient geographical information is at the census block level (as 
opposed to the zip code), which requires patient addresses.  Identification of practitioner 
behavior requires accurate information on the prescribing physician, individual making 
the diagnosis, or ordering the procedure.  While most databases have a field for an ID for 
individuals associated with utilization, often the field is not populated. This is particularly 
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true for practitioner specialty. In addition, practitioners can have multiple codes, 
particularly if they are affiliated with more than one organization, if they get married, 
move etc.  Outpatient pharmacy databases are often maintained separately from 
healthcare encounter data and identification codes for practitioners in one may not link to 
practitioner codes in another.  (Note that this is the case with the two managed health care 
plans that are the data sources for this study.)  For these latter reasons, an IV approach 
was not considered for this study. 
Marginal Structural Models 
Specific challenges to using observational analyses for treatment effectiveness 
studies for chronic disease treatments are that patients may exhibit a high degree of 
treatment switching or discontinuance. Their likelihood to continue with the same 
therapy, switch or discontinue is often associated with time-varying confounders that may 
not only be related to treatment selection, but also to the outcome of interest. As 
discussed in Chapter 1, a complicating factor in pharmaceutical treatment effectiveness 
studies is that factors that are confounders for treatment are often also an intermediate 
outcome and a factor associated with the primary outcome of interest.  In COPD, 
exacerbation experience is one of the factors considered in determining treatment. 
Ultimately the goal is to avoid severe exacerbations and reduce the occurrence of mild 
and moderate exacerbations, exacerbations which can in turn increase the risk of a severe 
exacerbation event occurring. The approach in most analyses to date has been to identify 
an “index date” – the point at which treatment initiation begins, and then to assess 
effectiveness based on the occurrence or non-occurrence of events over a period 
following treatment initiation.  Characteristics of the population determined at baseline 
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and at index are included in regression models.  While some time-to-event analyses have 
considered the impact of time-varying factors in models, in general, there has not been 
consideration of post-index occurring events that impact both treatment choice and 
likelihood of observing the outcome of interest. Added to the issue of capturing the 
impact of post-index events is the added issue of having an analysis model that may 
support causal interpretation, such as a propensity model analysis. 
MSMs have been proposed as a means of addressing confounding by indication in 
longitudinal, observational studies by incorporating time-varying treatment choices and 
time-dependent confounders of treatment into effectiveness analyses.  The term MSM is 
used as model estimates are population-average effects, thus marginal estimates, and 
estimates describe causal effects and thus are considered structural models (Moodie and 
Stephens 2011; Robins et al. 2000). MSMs are a form of analysis that can be used to 
adjust for confounding by indication and may provide better assessments of the 
effectiveness of treatment therapies in studies where substantial portions of treatment 
populations discontinue or switch treatments (Faries et al. 2007).  
MSMs are a specific type of weighted repeated measures analysis in which 
treatment is a time-varying covariate (Faries and Kadziola 2010). In MSMs, weights are 
used to balance confounding characteristics across the treatment groups and to consider 
censoring that may be informative. Through use of the weights, a balanced “pseudo-
population” is created that is similar to that achieved in the randomization process in a 
randomized controlled trial. The most common MSM means, use of inverse-probability-
treatment-weights (IPTWs) are similar to propensity score weights but are slightly 
different (Rosenbaum and Rubin 1983; Stuart 2010; Sturmer et al. 2006; Xu et al. 2010; 
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Xu et al. 2012). MSMs may accommodate multiple treatments, treatment changes and 
time-dependent confounders (Curtis et al. 2007; Hernan et al. 2006; Segal et al. 2007; 
Suarez et al. 2008; Young et al. 2010).  
An MSM analysis consists of two parts.  The first part is the estimation of the 
weights, which are estimated using the inverse probability of treatment.  For each time 
point, for each study subject, probability of treatment is determined from a propensity 
model constructed to calculate likelihood of treatment at each time point.  Weights may 
also consider the likelihood of study discontinuation (loss to follow-up or discontinuation 
of treatment), which is also estimated through a propensity model.  The treatment model 
and the discontinuation models can incorporate both time-dependent and time-dependent 
factors. Because the weight is an inverse probability,  
 
           
, very low estimated 
probabilities will result in very large weights, which may reduce the efficiency of the 
model and thus stabilized weights are recommended (Faries and Kadziola 2010; Hernan, 
Brumback, and Robins 2002).   
    
                
                   
 
   
  
Equation 1 Stabilized Weight Notation 
 
Equation 1, from Hernan (Faries and Kadziola 2010; Hernan et al. 2002), 
provides the notation for the stabilized weight (note that overbars indicate a covariate 
history), where time periods (k) are measured from time 0 to time t,  A(k) represents 
treatment at time k, and        represents the treatment history prior to time k, V 
represents a vector of time-independent variables (baseline covariates), and      
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represents a vector of time-varying covariates through time k (that includes the baseline 
variables V).  If both propensity for treatment and propensity for discontinuation of 
treatment (or censoring) are both considered, stabilized weights are calculated for each 
and the MSM weight for each subject at each time point is the stabilized treatment weight 
multiplied by the stabilized censoring weight.  For the MSM analyses that include time-
varying treatments, the estimation of probability of treatment at each time point, is the 
product of the individual’s probability for receiving the treatment received at that time 
point and the probabilities estimated for previous time points.   
If two treatment options are being compared (A = 1 or A = 0 ) and a logistic 
regression is used to estimate the probability of treatment (the denominator in Equation 
1), then the probability of treatment at time k (given the individual has not been censored 
[     = 0] ) for an individual who at the previous time point k-1 did not receive 
treatment, is conditional on the history of measured confounders (Brumback et al. 2004) 
and can be stated as: 
                                                 
      
      
Equation 2 Model Notation, Probability of Treatment 
 
Figure 2 illustrates how the time intervals might appear for a study with two time 
periods after the index date.  For a study with two treatment options, the probability for 
treatment at each time point (T0, T1, and T2) is modeled using the information prior to 
that time point, and is assessing the probability the patient would be using the therapy 
actually associated with the patient at that time point. Treatment at time t is thus a 
function of treatment at time t-1 and confounders for treatment measured from t-1 up 
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through t.  Effects for treatment at time t are then estimated for outcomes in the time 
period after t, up through t+1.   
 
Figure 2 Illustration of Time Intervals, MSM 
 
 
For probability of treatment at T0 (probT0), baseline characteristics are 
considered.  For probability of treatment at T1 (probT1), baseline characteristics and 
time-varying covariates between T0 and T1 are considered.  For treatment at T2, baseline 
characteristics, time-varying covariates between T1 and T2 are considered.  In calculating 
the probability of treatment, study subjects who have an event during the time period and 
thus are not “present” at the end of a time period would not be included in the population 
used to determine treatment probabilities. 
To summarize again, weights are constructed for observations for each time 
period based on the probabilities for treatment at the start of the time period.  Thus, the 
weight for observations for the period T0 to T1 is      
 
      
, for the period T1 to 
T2,       
 
               
, for the period after T2,       
 
                        
.  
(For simplicity, the discussion here is limited to unstabilized weights.) 
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In the pooled logistic analysis, effect estimates for treatments on outcomes after 
the index date and before T1 are estimated by weighting observations in the period T0 to 
T1 by wgt0, for outcomes in the period T1 to T2, wgt1 is used, for outcomes in the period 
after T2, wgt2 is used. 
If censoring is considered, it is considered on a forward looking basis (Figure 3).  
That is, given a treatment at the end of a time point, who then might not appear for the 
“next visit?”  Censoring is separately determined according to each study, but can include 
dropping out of a study (e.g., discontinuation of a treatment therapy), termination of 
insurance coverage, death.  Probability for NOT being censored (continuing in the study) 
over the next time interval is estimated for each time point, T0, T1, and T2, since the 
weighted model for effect of treatment on outcomes only includes uncensored subjects.  
Figure 3 Illustration of Time Intervals and Censoring, MSM 
 
 
Censoring probabilities are estimated in a similar fashion to the treatment 
probabilities. Thus, the censoring weight for T0 (     ), is the probability of not being 
censored for the interval T0 to T1, for T1(     ), the probability of not being censored 
for the interval T1 to T2, and for T2(     ), the probability of not being censored for the 
after T2. Thus, using the same notation as before, the logistic regression model used to 
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estimate the probability of remaining uncensored at the next time point, k+1, can be 
stated as: 
                                                 
      
      
Equation 3 Model Notation, Probability of Censoring 
 
If censoring probabilities are used, the observation weight used in estimating 
treatment effects from T0 to T1 is           , for the interval T1 to T2,      
     , and for post-T2,           .   
Robins and colleagues emphasized that “to want to adjust for censoring is only to 
say that our interest is in the causal effect of treatment A, if contrary fact, all subjects had 
remained uncensored, rather than following their observed censoring history” (Robins et 
al. 2000). This can be accomplished if there are no unmeasured confounders for both 
treatment and censoring. When censoring is incorporated, censoring and treatment are 
considered a “joint treatment” (Robins et al. 2000). 
The second part of the MSM analysis is the weighted repeated measures analysis. 
Treatment is included as a time-dependent factor in the repeated regression analyses.  
Time-dependent confounders that were included in the propensity models to derive the 
weights are not, as their effects have already been included in the estimation of the 
weights.  If the analysis is modeling a binary outcome (Y = 1, Y = 0), and a logistic 
regression used, the MSM logistic model for the effect of treatment A used prior to time 
k, with stabilized weights of SW, would then be stated as: 
    
            
               
           
      
      
Equation 4 Pooled Logistic Regression Model Notation, MSM 
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Inherent in MSM analysis is the concept of the counterfactual event (and related 
to this the positivity assumption).  That is, for each treatment history actually observed 
for a study subject, the assumption is that the individual could have had an alternative 
treatment history.  If Sally was prescribed Treatment A, she theoretically could also have 
been prescribed Treatment B.  Thus, if two treatments are being compared, and there are 
n time periods, the number of treatment options for any one individual would be 2
n
, and 
there would also be 2
n
 alternative scenarios that could have occurred.  As an example, if 
there were two treatment options and 5 intervals, there would be 32 different options for 
what actually occurs and 32 alternative versions (for 6 intervals, 64 different options). 
As when results from propensity model analyses are used to infer a causal effect, 
there are strong assumptions for the model, although a recognition that in practice they 
may not be precisely held (Brumback et al. 2004; Hernan et al. 2002; Robins et al. 2000): 
1. Correctness of the MSM and the models for probability of treatment 
initiation conditional on measured confounders (both time-independent 
and dependent) 
2. No additional confounding due to unmeasured factors 
3. Positivity (all study subjects have a positive probability for receipt of 
treatment – that is, individuals are not included at a given time point 
whose covariates indicate they have no probability of receipt of treatment 
[this might occur for example, if someone has a co-morbid condition for 
which the treatment is specifically contra-indicated]) 
Researchers should have a heightened awareness of the potential for the existence of 
these in the study and the degree to which results may be impacted.  
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Robins, Hernan, and Brumback constructed a formal method for assessing the 
potential impact for unmeasured confounding (Robins et al. 2000),and then Brumback 
and colleagues later demonstrated it through a series of sensitivity analyses in a 
reanalysis of previously published work which utilized a MSM in investigating treatment 
for HIV disease (Brumback et al. 2004). Faries and Kadziola devised a simpler method 
that incorporates an unmeasured confounding function (Faries and Kadziola 2010).   
The positivity assumption has also been termed the experimental (or 
exchangeable) treatment assumption (Lefebvre, Delaney, and Platt 2008; Mortimer et al. 
2005). Under this assumption, all combinations of covariates must be possible.  However, 
as Lefebvre and colleagues point out, even when all combinations of treatment are 
possible, a very low probability of treatment (probabilities close to 0 or 1) may still be 
estimated (Lefebvre et al. 2008). Platt and colleagues provided an example in their study 
of warfarin treatment on gastrointestinal bleeds, showing how inclusion of individuals 
extremely unlikely to receive a treatment (in this case, those older than 80 or those being 
treated with aspirin) may severely bias results, whereas restricting analyses to those likely 
to receive treatment results in findings similar to those achieved in randomized trials 
(Platt, Delaney, and Suissa 2012). Mortimer and colleagues demonstrated a simple 
technique for assessing robustness of the model for the positivity assumption that is also 
supported by Faries and Kadziola (Faries and Kadziola 2010; Mortimer et al. 2005). It 
may be that some subjects should be excluded or censored at some time point.  Platt and 
colleagues present a compelling case that this may not be a negative with respect to 
insuring generalizability of study results, in that rare cases should not drive the results 
(Platt et al. 2012). 
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Several studies have discussed model specification.  Through sensitivity analyses, 
Lefebvre and colleagues concluded that inclusion of factors purely related to treatment 
(similar to the concept of instrumental variables) could reduce efficiency and increase 
bias (Lefebvre et al. 2008). They concluded that the optimal treatment model was one 
that included only pure risk factors (for the outcome of interest) and confounders and 
therefore recommend inclusion of all known risk factors in the treatment model when 
constructing a MSM. The issue they sought to resolve was that treatment models in 
IPTW analyses are different from propensity analyses in that probabilities for a given 
treatment are used only to reweigh observations for those receiving the specific 
treatment.  Observations for individuals not receiving the treatment are weighted 
according to their probability for non-receipt of treatment.  The treatment models also 
must meet conditions of completeness (to avoid unmeasured confounding) and also 
parsimony (to avoid model computation issues related to infrequent combinations of 
variables) (Lefebvre et al. 2008). 
 A couple of examples of MSM studies were discussed in Chapter 1 and that 
discussion will not be repeated here. One study that was not mentioned however was one 
of the first MSM analyses on chronic disease by Choi and colleagues (Choi et al. 2002).  
That study involved a weighted Cox proportional hazards model to estimate mortality 
risk of methotrexate use compared to no use among a cohort of rheumatoid arthritis 
patients followed for up to 17 years.  The authors chose to use MSM because of the 
confounding by indication bias inherent in this population, i.e., patients initiating 
treatment were more likely to have a worse prognosis compared to patients not initiating 
treatment (Choi et al. 2002).  Additionally, the authors did not consider that a treatment 
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time-dependent Cox model was appropriate since many of the prognostic factors in the 
causal path between treatment and the measured outcome, mortality, were also factors 
impacted by methotrexate therapy, and the authors wanted to avoid underestimating the 
magnitude of the treatment effect (Choi et al. 2002).  The authors fitted a pooled logistic 
model to determine probability of treatment and incorporated time-dependent factors that 
they estimated the treating physician would utilize in making the decision as to whether 
to initiate methotrexate therapy, as well as time-dependent factors that were predictive of 
mortality in the general population.  A separate pooled logistic model was fit for 
probability of censoring. The stabilized weight used in the model was the product of the 
treatment and censoring weights that were estimated from the respective pooled logistic 
models.  Since the time-dependent factors had been already considered in the stabilized 
weights, the MSM included only baseline covariates and a time-dependent methotrexate 
treatment variable (Choi et al. 2002).  The effect estimate from the MSM model was a 
reduced hazard ratio (HR) for methotrexate use for all-cause mortality of 0.4 (95% 
confidence interval (CI) 0.2 – 0.8).  The HR estimate without use of the MSM model was 
0.8 (95% CI 0.6 – 1.0).  In sensitivity analyses the authors repeated the same analyses, 
but for treatment with other disease modifying antirheumatoid treatments (e.g., 
sulfasalazine, penicillamine, hydroxychloroquine), but did not observe the same similar 
beneficial effect.  A strength of the study was that this was a cohort that had been 
followed specifically for outcomes related to rheumatoid arthritis and so the authors had 
more complete information on patients and treatment than might otherwise be available 
for a retrospective analysis. A noted limitation was that there may have been differential 
loss to follow-up that was not captured by the available measured information. Not 
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mentioned was whether the others investigated the possibility of a “healthy worker 
effect” whereby patients with an increased risk of mortality may have preferentially 
dropped out (Naimi et al. 2011). 
To date, MSMs have not been used in COPD treatment effectiveness analyses, 
although Mortimer and colleagues did utilize a MSM approach to investigate the impact 
of using asthma recue mediation on peak expiratory flow rate (PEFR) measurement 
(Mortimer et al. 2005). The authors had previously utilized traditional statistical methods 
for repeated measures and found no improvement in pulmonary function as a result of 
using rescue medication.  The authors then tried several methods for constructing the 
treatment model that obtained results demonstrating a 7% in PEFR (confidence intervals 
not stated), which was in the middle range of the 5-10% improvement that had been 
found in clinical settings (Mortimer et al. 2005). 
Conclusion 
Factors other than pharmaceutical treatment have been found to be associated 
with increased risk of exacerbation, readmission following a severe exacerbation, and 
mortality. Comorbidities can have a significant impact on the incidence of COPD 
exacerbations and the severity and duration of exacerbations, particularly those 
associated with cardiovascular disease or respiratory infections.  
There is no agreed upon definition for utilization defined exacerbations, however 
there is substantive support for a claims based definition of exacerbation, even though use 
of claims may underestimate mild and moderate exacerbations. There is also consensus 
for a definition of moderate exacerbations that is an event involving antibiotic or 
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systemic corticosteroids.  A claims based method additionally offers an objective by 
which research findings across studies may be compared.   
It is known that combinations of COPD medications achieve better results than 
use of the medications in isolation. LAMA and ICS/LABA medications are being used in 
combination but there is little information as to the effectiveness of their use versus use 
of either alone. LAMA and ICS/LABA have different pharmaceutical mechanisms of 
action that indicate their combined use may have beneficial impacts on exacerbations. 
Additionally, there is a desire for analyses that provide better information about specific 
phenotypes of individuals who receive treatments and who might benefit differentially 
from treatment.  
A MSM approach shows promise as a method that may better adjust for 
confounding by indication, which is a common problem in retrospective observational 
comparative effectiveness analyses of chronic disease treatment.  Like other causal 
inference approaches, validity of MSM results rests on the key assumptions of positivity, 
no unmeasured confounders, and correct model specification. In using MSM approaches, 
researchers must be mindful of these requirements when constructing models and review 
models to the extent possible for assumption violations. 
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CHAPTER 3 METHODOLOGY 
Chapter 3 
Methods 
 
In this section the logistics of the study are presented: the institutional review 
board approval of the study, the study design, underlying populations represented in the 
data, the study inclusion criteria, data elements considered, data review and analysis 
methods utilized, and analyses specific to each of the study aims. 
Study Approvals 
This study was approved by three separate reviews. This study utilizes data from 
two separate health plans, and each provided approval.  Lovelace Health Plan provided 
approval February 22, 2013, and Presbyterian Health Plan on February 26, 2013.  After 
obtaining these two approvals from the entities involved, we obtained approval from the 
University of New Mexico Health Science Center Human Research Review Committee 
(HRRC) on April 12, 2013.  This approval included approval for waiver of informed 
consent and waiver of Health Insurance Portability and Accountability Act (HIPAA) for 
protected health information (dates of service). 
Study Design 
The study uses a longitudinal case-control design, identifying individuals who 
received triple therapy (ICS/LABA+LAMA) and comparing them to individuals who 
received either ICS/LABA or LAMA. The study is a retrospective analysis, using 
administrative claims data from two managed care plans pertaining to individuals known 
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to have COPD.  Individuals are followed using their claims history for up to 36 months 
after treatment initiation. 
Study Population and Focus 
The study population was identified from two separate managed care organization 
populations in New Mexico, Lovelace Health Plan (LHP), a health insurance provider 
affiliated with Lovelace Health Systems, and Presbyterian Health Plan (PHP), a health 
insurance provider affiliated with Presbyterian Healthcare Services. Annually, LHP 
covers approximately 213,000 persons, and PHP over 400,000 persons. Both health plans 
offer traditional commercial insurance, HMO, and PPO plans that are usually employer 
based, in addition to Medicaid and Medicare managed care plans.  
Lovelace Clinic Foundation, as a long standing member of the HMO Research 
Network (HMORN), maintains a data warehouse with comprehensive utilization 
information for all LHP members that is organized in a standard format that meets 
HMORN data warehouse specifications.  The basic structure is a relational database 
which stores different types of data elements about patients and their use of health care in 
different tables.  This also allows for removal of most protected health information (PHI) 
creating a limited dataset (service dates are still a part of the data warehouse).  Tables in 
the relational database are either linked by an assigned database individual identifier or 
an encounter identifier. Data warehouse tables that will be utilized for this study include 
enrollment, demographics, utilization, diagnosis, procedures, and outpatient pharmacy 
use. Data for PHP members used for this study have been set up in the same format as for 
LHP members.  For the study, interest lies in examining patient level characteristics and 
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characteristics associated with hospitalizations. Outcome comparisons between systems 
of care were not examined in this study. 
Inclusion Criteria 
Individuals included were 40 years or older with COPD who were “new” users of 
the medication therapies.  Presence of COPD was identified by having at least one 
hospitalization due to COPD or at least two outpatient encounters with a diagnosis of 
COPD (International Classification of Disease, 9
th
 Edition [ICD-9] diagnosis codes 
491.xx [chronic bronchitis], 492.xx [emphysema], or 496 [chronic airway obstruction, 
not elsewhere classified]). The earliest treatment initiation date was July 1, 2005 and the 
latest, March 31, 2012. Included individuals had at least one year of continuous 
enrollment prior to treatment initiation, and at least 6 months of enrollment after 
treatment initiation.  Thus the total time period for the data is July 1, 2004 through 
September 30, 2012 (see Figure 4). A “new” user is defined as an individual without 
evidence of use of either ICS/LABA or LAMA in the 6 months prior to therapy initiation. 
 
 
 
 
  
July 1, 2004 
July 1, 2005 
Sep  30, 2012 
Mar 31,  2012 
Claims Data for Study 
Period Treatment Initiation Can Occur 
Figure 4 Study Period 
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Exclusion Criteria 
Patients were excluded from the study sample if in the 12 months prior to the 
index date they had an inpatient stay lasting for more than 90 days, or if they were 
admitted to an inpatient stay within 30 days after the index date. 
Medications of Interest 
Table 8 shows the ICS/LABA and LAMA medications that were of interest in this 
study.  Additionally, use of Advair HFA inhaler  (fluticasone propionate /salmeterol 
[strengths 45-21 mcg, 115-21 mcg, and 230-21 mcg]) and Dulera inhaler (mometasone 
furoate/formoterol fumarate [strengths 100-5 mcg, 200-5 mcg ) was examined among 
individuals meeting COPD ICD-9 diagnosis code criteria to determine if patients appear 
to be using it in combination with the LAMA medication Spiriva.   
 
Table 8 Medications of Interest for Index Date 
 
Brand Name  (Generic) Strength 
ICS/LABA ADVAIR DISKUS 100-50MCG 
 
(fluticasone propionate/salmeterol [FSC]) 250-50MCG 
    500-50MCG 
 
SYMBICORT INHALER 80-4.5MCG 
  (budesonide/formoterol fumarate dihydrate [BFC]) 160-4.5MCG 
LAMA SPIRIVA capsule or handihaler inhalation powder (tiotropium) 18(MCG) 
 
Based on preliminary analyses the majority of claims for these medications have 
an associated days’ supply of 30 days.  In practice medications may be used over a 
shorter or longer period than is stated.  For example, an individual may not have evidence 
of a second fill until, for example, 40 days after the date of the first claim for a 30 days’ 
supply, thus having a “gap” of 10 days between fills.  It is standard practice for studies of 
chronic disease medication to allow for a gap period between fills in which individuals 
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are still considered to be in possession of and using their medications, with the gap period 
determined based on the drugs.  In a study of persistence to COPD medications, 
persistence was found to be highest among individuals using LAMA or FSC, with 47% 
of individuals initiating on LAMA still using the medication after 18 months (Cramer, 
Bradley-Kennedy, and Scalera 2007).  In that study a 60-day gap period was allowed 
between the end of one claim and the date of a subsequent claim.  Sensitivity analyses 
were done using a 30-day gap and judged to not materially differ.   
Patients were assigned to the index group of “Triple therapy” if they had 
prescription claims for both ICS/LABA and LAMA on the same day or if they had a 
prescription claim for either ICS/LABA or LAMA and within 30 days had a prescription 
filled for the alternate medication. In the case of the latter, the index date was the date of 
the first prescription claims for either ICS/LABA or LAMA.  This choice was made since 
patients with an inpatient stay in the first 30 days were excluded from the study sample, 
and thus no severe exacerbation events would occur within the first 30 days. 
For our study the allowed gap period between fills was defined based on the days 
supply field associated with the prescription claim. Patients were considered to be using 
the medication for a period that was twice the days’ supply. If patients filled a subsequent 
prescription for the same type of medication (e.g., ICS/LABA) prior to the end of the 
allowance period, the period was adjusted.  If the subsequent prescription fill was more 
than 14 days earlier than the estimated end date for the allowance period based on the 
doubling of the days’ supply for the previous fill, the end date based on the subsequent 
prescription would be twice the days’ supply of the subsequent prescription plus 14 days.  
If the subsequent fill was within 14 days prior to the estimated end date, the estimated 
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end date was not changed and the days’ supply for the subsequent prescription was added 
on to the previously estimated end date.  Table 9 provides some examples of this 
calculation. For ICS/LABA and LAMA prescription claims with a days’ supply less than 
30, the days’ supply was considered to be 30 days.   
A longer allowance period was not considered since a main focus of the study was 
on patients who use ICS/LABA and LAMA medications concurrently.  A longer period 
would have resulted in a study population that had wide variability in its use of the index 
treatments, from patients who have regularly use their medications to patients who only 
use their medications sporadically.    
Table 9 Example of Calculations for Periods of ICS/LABA and LAMA Use 
Patient Prescription 
Prescription 
Date 
Previous 
Estimated End 
Date 
Days 
Supply 
Days 
remaining 
from 
Previous Rx 
Estimated End 
Date 
Sally 1st fill  6/1/2008 n/a 30 n/a 7/31/2008 
Sally 2nd fill 7/10/2008 7/31/2008 30 22 9/22/2008 
Fred 1st fill  6/1/2008 n/a 30 n/a 7/31/2008 
Fred 2nd fill 7/25/2008 7/31/2008 30 7 9/29/2008 
Horatio 1st fill  6/1/2008 n/a 30 n/a 7/31/2008 
Horatio 2nd fill 8/1/2008 7/31/2008 30 0 9/30/2008 
Measured Variables 
A comprehensive set of morbidity and utilization factors and demographic 
characteristics using the data tables listed in Table 10 was captured. We were especially 
interested in capturing chronic comorbidities commonly associated with COPD such as 
cardiovascular disease, which are potential confounding factors. Factors associated with 
severity of disease and receipt of treatment such as prior exacerbations, home oxygen 
use, and pulmonary rehabilitation, were of interest and were identified using both 
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diagnosis and procedure codes.  NDC codes were used to identify COPD medications 
other than the treatments of interest that may have been prescribed. 
Table 10 Database Tables 
Enrollment Enrollment start and end dates. Type of coverage (commercial, Medicare, Medicaid, etc) 
Demographics Basic demographics on enrolled members (birth year, sex, ethnicity) 
Utilization 
Dates and types of encounters for enrolled members (inpatient, emergency department, 
laboratory, etc.)   
Diagnosis Diagnosis and DRG (for inpatient) codes associated with an encounter 
Procedure Procedure codes associated with an encounter (CPT-4, HCPCS, ICD-9, revenue codes) 
Pharmacy 
Outpatient prescribed medication claims information for enrolled members (national 
drug code (NDC), brand name, generic name, dose, strength, quantity, days’ supply) 
CPT-4, Current Procedure Terminology, 4
th
 Edition; HCPCS, Healthcare Common Procedure Coding 
System 
 
Identification of Exacerbations 
Moderate exacerbations were identified using two components – an ambulatory 
visit and a subsequent outpatient systemic corticosteroid (SCS) or antibiotic prescription. 
Medications included as systemic corticosteroid treatments (oral or parenteral) consisted 
of prednisone, prednisolone, methylprednisolone, cortisone, hydrocortisone, 
betamethasone, dexamethasone, and triamcinalone (Schweiger and Zdanowicz 2010).  
Antibiotic medications (oral or parenteral) comprised cephalosporins (e.g., cefuroxime, 
cefpodoxime,  cefdinir), fluroquinolones (e.g., ciprofloxacin, gatifloxacin, levofoxacin, 
moxifloxacin), macrolides (e.g., azithromycin, clarithromycin, erythromycin), penicillins 
(e.g., amoxicillin, amoxicillin with clavulante, ampicillin, ticarcillin with clavulante, 
vancomycin), sulfonamides (trimethoprim-sulfamethoxazole), and tetracyclines 
(doxycycline) (Iyer Parameswaran and Murphy 2009; Siddiqi and Sethi 2008).  
Severe exacerbations were acute inpatient stays that were due to COPD or a 
COPD-related diagnosis. Table 11  provides the definitions that were used to identify 
exacerbations in the analysis.  If another exacerbation event occurred within 10 days of 
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the same type of exacerbation event (moderate or severe), it was considered a 
continuation of the previous exacerbation event, and not counted as a new event.  If a 
severe exacerbation event occurred within 10 days of a moderate exacerbation event, it 
was counted as a new, severe event.  If a moderate exacerbation event occurred within 10 
days of a severe exacerbation event, it was considered a continuation of the severe event 
and not counted.  
Table 12 contains the DRG codes for Severe Exacerbations. 
Table 11 Exacerbation Definitions 
Moderate Prescription claim for an systemic corticosteroid (SCS) or antibiotic within 3 
days of an ambulatory encounter (outpatient or ED) where there was a COPD or 
COPD-related diagnosis associated with the visit  
Severe Inpatient stay with a primary COPD or COPD-related diagnosis associated with 
the visit, or a COPD-related DRG (“respiratory infections & inflammations”,” 
pulmonary edema & respiratory failure”, “chronic obstructive pulmonary 
disease”) 
 
Table 12 DRG codes for Severe Exacerbations 
 
Category  DRG DRG Description 
P
re
-2
0
0
8
 D
R
G
 
Other 
Respiratory 
79 respiratory infections & inflammations age >17 w cc 
80 respiratory infections & inflammations age >17 w/o cc 
Respiratory 
Failure 
87 pulmonary edema & respiratory failure 
COPD 88 chronic obstructive pulmonary disease 
M
S
-D
R
G
 (
>
2
0
0
8
) 
Other 
Respiratory 
177 respiratory infections & inflammations w mcc 
178 respiratory infections & inflammations w cc 
179 respiratory infections & inflammations w/o cc/mcc 
Respiratory 
Failure 
189 pulmonary edema & respiratory failure 
COPD 
190 chronic obstructive pulmonary disease w mcc 
191 chronic obstructive pulmonary disease w cc 
192 chronic obstructive pulmonary disease w/o cc/mcc 
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The, COPD and COPD-related International Classification of Disease, 9
th
 Edition 
(ICD-9) diagnosis codes for this study were: 
COPD: 491.xx (chronic bronchitis), 492.xx (emphysema), 496 (COPD) 
COPD-Related:  
493.22 (chronic obstructive asthma with acute exacerbation) 
493.92 (unspecified asthma with acute exacerbation) 
494.1 (bronchiectasis with acute exacerbation) 
518.81-518.84 (interstitial emphysema; compensatory emphysema; 
pulmonary eosinophilia; acute edema of lung, unspecified) 
Cost of Healthcare Utilization 
Estimated costs in analyses are from the perspective of the health plan and are 
standardized costs.  The standardized costs utilized in this study were from two sources.  
The first source is NCQA and the second is actual costs for one of the health plans. 
NCQA prices were used as a primary source because both health plans providing patient 
populations for this study are managed care organizations and report Healthcare 
Effectiveness Data and Information Set (HEDIS) measures for their enrolled populations. 
Approval from the NCQA Publications Manager for the use of the standardized price 
tables in this research was obtained via email on June 4, 2013. 
NCQA standardized prices are used in HEDIS cost of care measures (NCQA 
2011).  NCQA standardized prices for HEDIS for 2011, 2012, and 2013 were utilized in 
this study.  These are standardized prices for service codes for inpatient facility charges; 
imaging, labs, and surgery procedures; evaluation and management (E&M) services; and 
outpatient pharmacy.  Standardized inpatient facility prices include services provided by 
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the facility during an inpatient stay and include room and board and ancillary services.  
Inpatient charges are estimated according to the Aggregate Diagnostic Service Category 
(ADSC) assigned to the inpatient stay (which is based on the primary diagnosis code 
assigned to the stay), whether the stay was an acute inpatient stay or non-acute (skilled 
nursing facility, rehabilitation hospital, etc.), whether major surgery was a part of the 
inpatient stay, and the length of stay. Evaluation and management services pertain to both 
inpatient and outpatient visits, as well as consultations.  Imaging, labs and surgery 
procedures also pertain to both inpatient and outpatient visits.  Service codes for imaging 
and labs also include revenue codes.  Outpatient pharmacy standardized prices are listed 
by NDC code (NCQA 2011). 
NCQA standardized prices for 2013 were considered to be standardized prices as 
of 2012.  NCQA standardized prices for 2012 were adjusted to September 2012 by 
multiplying prices by the ratio estimated by the U.S. Medical Care Consumer Price Index 
1982-84=100 for September 2012 divided by the Price Index for December 2011. NCQA 
standardized prices for 2011 were similarly adjusted using the ratio for September 2012 
divided by the Price Index for December 2010.  
Because the NCQA standardized prices were not all-inclusive, actual LHP costs 
were used to supplement them.  Mean costs for procedure codes used 30 or more times in 
the claims data were calculated for a chronic disease population identified within the 
LHP enrolled population for the period January 1, 2006 through December 31, 2010.  
Paid claim amounts were adjusted to September 2012 using monthly index adjustments 
calculated as a ratio adjustment in the same manner as for the NCQA standardized prices, 
although instead of using an end of year Price Index, the Price Index for the month 
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incurred was used. Mean costs for procedure codes in the LHP data were then compared 
to NCQA standardized prices for codes with dollar values for both.  LHP standardized 
prices were then adjusted by the mean differential. 
The Berenson-Eggers Type of Service (BETOS) coding system files for 2010 
through 2013 were used to review the degree to which NCQA standardized prices could 
be applied to utilization and the degree to which LHP actual prices could be used to 
supplement the NCQA standardized prices (CMS 2012). The BETOS coding system was 
developed to track growth in Medicare expenditures and organizes CPT and HCPCS 
codes into 7 categories that each includes subcategories.  Appendix Table D-1 provides a 
summary of the mean NCQA standardized by BETOS category and subcategory. The 
seven major categories are:  
1. Evaluation and management (E&M: consultations, ED visits, hospital visits, 
home visits, office visits, specialist) 
2. Procedures (e.g., ambulatory, dialysis, endoscopy, eye, major, minor) 
3. Imaging 
4. Tests 
5. Durable medical equipment (DME) 
6. Other (e.g., ambulance, chemotherapy, chiropractic) 
7. Exceptions/unclassified 
For this study standardized costs were summarized as: 
 Outpatient – outpatient, ED, laboratory, other encounter 
 Inpatient – inpatient (acute) and institutional stays (non-acute) 
 Pharmacy – outpatient pharmacy claims 
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 Total – sum of outpatient, inpatient, and pharmacy 
Patient Demographics and COPD-Related Utilization Variables 
Patient demographics utilized in the study were abstracted from the claims. Age 
was calculated as age at the treatment initiation date (index date). Hispanic ethnicity was 
only available for LHP patients and so was only considered in LHP analyses. Healthcare 
insurance was captured at the index date.  Administrative claims data were utilized to 
review healthcare utilization and utilization was categorized using procedure codes, 
diagnoses and NDC codes.   
The formulary plans for the two health plans were reviewed for any differences 
with regard to ICS/LABA and LAMA medications.  For both health plans, the LAMA 
medication Spiriva was a Tier 2 medication with no further restrictions (e.g., quantity 
limits, step edits, or prior approvals).  There were differences however with respect to 
ICS/LABA medications.  Symbicort was a Tier 2 medication for both health plan 
formularies. But while LHP did not have any further restrictions for Symbicort, the PHP 
formularies for Medicare, Medicaid/SCI, and the Commercial Group all had “step edit” 
requirements. Commercial Group and Medicaid insured patients had to have a 
prescription claim history of an orally inhaled corticosteroid or orally inhaled 
anticholinergics within the past 120 days, while Medicare patients had to have a 
prescription claim history of Spiriva, or ipratropium or albuterol/ipratropium in the past 
120 days. Advair medications were also Tier 2 medications on the LHP formulary, with 
only a quantity limit restriction.  Advair medications were Tier 3 however for PHP 
enrollees, resulting in a higher copayment for patients. And Advair medications, like 
Symbicort, had a step edit requirement.  For PHP Commercial Group and Medicare 
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enrollees, the step edit requirement was the same as for Symbicort.  Medicaid insured 
patients had to have a documented trial and failure of either Dulera or Symbicort in the 
past 120 days.  Because of the different restrictions on ICS/LABA medications between 
the two health plans, a variable for health plan was also used to characterize patients.  
Comorbidities were assessed using two schemes.  One method assessed major 
comorbidities tracked by the Centers for Medicare and Medicaid (CMS) Chronic 
Condition Data Warehouse (CCW), and the other considered morbidities summarized by 
Elixhauser and colleagues (Baldwin et al. 2006; Elixhauser et al. 1998). In addition, 
evidence of asthma (ICD-9-CM 493.xx) was identified among individuals, as the 
presence of asthma may increase the propensity of patients to utilize ICS/LABA over 
LAMA therapy, pneumonia (ICD-9-CM 480.xx through 486.xx) and influenza (ICD-9-
CM 487.xx through 488.xx), as individuals who have had episodes of pneumonia and 
influenza in the past are at increased risk for adverse respiratory events,  and hypoxemia 
(ICD-9-CM 799.02) since hypoxemia can have a large negative impact on quality of life 
as patients with hypoxemia often require mechanical ventilation and/or supplemental 
oxygen therapy. 
COPD-related symptoms identified in claims using ICD-9-CM codes are 
summarized in Table 13.  Appendix Table B-1 provides a summary of COPD-related 
service procedures. 
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Table 13 ICD-9-CM Codes Used for COPD Related Symptoms  
ICD-9-CM code Description 
Dyspnea: 786.00 dyspnea and respiratory abnormalities 
 786.02 orthopnea 
 786.05 shortness of breath 
 786.07 wheezing 
 786.09 breathlessness 
Other general: 719.7 difficulty in walking 
 780.71 chronic fatigue 
 780.72 functional quadriplegic 
 780.79 other malaise/fatigue 
 780.93 memory loss 
 786.2 cough 
 786.3 hemoptysis 
 786.4 abnormal sputum 
 786.7 abnormal chest sounds 
 V46.2 supplemental oxygen status 
Pain: 780.96 generalized pain 
 786.50 chest pain, unspecified 
 786.51 precordial pain 
 786.52 painful respiration 
 786.59 chest pain, other 
Sleep disturbances: 780.50 sleep disturb unspecified 
 780.51 insomnia with sleep apnea 
 780.52 insomnia unspecified 
 780.53 hypersomnia with sleep apnea 
 780.55 hypersomnia unspecified 
 780.57 sleep apnea unspecified 
 780.58 sleep disorder 
 780.59 sleep disturb other 
 
Additionally, diagnosis codes for the COPD complexity categorization method 
developed by Mapel and colleagues were utilized to characterize patients as low, 
medium, or high complexity COPD patients (Mapel et al. 2011). Codes for the medium 
and high complexity groups are contained in Appendix Table B-2.  Individuals without 
evidence of medium or high complexity were classified as low complexity. 
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Data Management and Review 
Administrative claims data for LHP are currently stored on a password-protected, 
secure server and are backed up on a secure password protected section of the network 
server at LCF Research (LCF). The servers are located in a locked, climate-controlled 
server room having separate electronic passkey access limited to select LCF information 
technology personnel. Data is only accessed through a secure server connection.  
Analyses are performed on a password-protected, PGP encrypted computers. Data for 
LHP is summarized in a data warehouse for current and future research studies.   
The basic structure of the data warehouse is a relational database which stores 
different types of data elements about patients and their use of health care in different 
tables.  Members represented in the data warehouse are assigned a data warehouse ID and 
it is this ID by which data for members is accessed in the data warehouse. This allows for 
removal of most protected health information (PHI), creating a limited dataset (dates are 
still part of the data warehouse).  Administrative claims data for Presbyterian Health Plan 
for this study was similarly stored.  Since the system is behind multiple firewalls, is 
monitored regularly, and is accessible only to key personnel, the risk of unlawful 
penetration is not a significant data safeguard concern. 
Many quality checks were run on the data. In particular the data pulled for the 
Presbyterian Health Plan members, since Ms. Roberts did not have the same degree of 
familiarity with this data as with information for LHP members.  In reviewing the data, 
comparisons were made between the LHP and PHP datasets with regard to percentages of 
COPD patients meeting the study inclusion criteria.  Specifically, percentages of 
members with CMS and Elixhauser defined comorbidities, members with use of specific 
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types of COPD medications (e.g., SABA, SAMA, ICS), members with COPD-related 
procedure services (e.g., CT scans, chest x-rays), members with COPD-related symptom 
ICD-9-CM codes, and members with durable medical equipment (DME) use were 
reviewed.   
Statistical Analyses 
All analyses were carried out in SAS (Version 9.2) statistical software. Analyses 
were two-tailed with a p-value of <0.05 to determine statistical significance. 
Dichotomous and polychotomous variables are reported as numbers and percentages; 
continuous variables as means, standard deviations (SDs), and medians. 
Identification of exacerbation events and potential predictors of events and change 
in treatment therapy were significant focus areas of the study.  To date, identification of 
exacerbation events has often been simplistic (e.g., ambulatory COPD-related visit 
followed by an antibiotic prescription within 3 days).  Literature and COPD management 
guidelines will be investigated to determine whether alternative definitions may provide 
more information about the frequency and severity of exacerbation events. 
Analyses by Aim 
Aim 1 
Assess baseline characteristics of individuals who are “new” initiators of LAMA 
monotherapy, ICS/LABA combination therapy, and triple therapy, plus individuals who 
later switch therapies. 
Comparisons were made for the baseline period between triple therapy users and 
each of the ICS/LABA and LAMA therapy users. Comparisons were made of the 
following baseline characteristics: 
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 Patient demographics (sex, age at therapy initiation, insurance coverage) 
 Comorbidities (e.g., heart disease, atrial fibrillation) 
 COPD-related utilization (pharmaceutical treatments, outpatient care, 
hospitalizations) 
 Clinical characteristics identified in the scientific literature, associated with 
receipt of treatment, progression of COPD, or with risk of exacerbations 
 Healthcare costs (all-cause, COPD-related) by type (ambulatory, inpatient, 
Rx) 
Statistical significance of differences between groups was determined using chi-
square test for frequency differences and Student’s t-test for continuous variables. In 
addition, absolute standardized differences were calculated for estimating the influence of 
percentage differentials. Lastly, for continuous variables with non-normal distributions, 
nonparametric tests such as the Wilcoxon signed rank-sum test, which tests for 
significant differences in distributions, were utilized. 
Aim 2 
Assess characteristics of individuals who have severe, and/or moderate 
exacerbations post-therapy initiation. 
This analysis was similar to that identified for Aim 1. Comparisons were made for 
the period immediately following initiation of treatment between: 1) individuals who 
have any severe exacerbation compared to those who without any, and 2) between those 
who have any moderate or severe exacerbation compared to those who without any 
moderate or severe. All individuals included in the cohort had a minimum of 6 months of 
follow-up.  Comparisons were of the same baseline characteristics reviewed in Aim 1 and 
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included whether individuals discontinued therapy or stepped down therapy (triple to 
ICS/LABA or LAMA) or stepped up therapy (ICS/LABA or LAMA to triple). 
Statistical significance of differences between groups was determined using chi-
square test for frequency differences and Student’s t-test for continuous variables. In 
addition, absolute standardized differences were calculated for estimating the influence of 
percentage differentials. Lastly, for continuous variables with non-normal distributions, 
nonparametric tests such as the Wilcoxon signed rank-sum test, which tests for 
significant differences in distributions, were utilized. 
Aim 3 
Create a “pseudo-population” using MSM weighting. 
The pseudo-population was estimated using observation weights that were the 
product of the treatment weight and the censoring weight (Cole and Hernan 2008; Curtis 
et al. 2007; Moodie and Stephens 2011). Weights were estimated for the cohort using 
MSM methods that incorporated time dependent covariates.  Stabilized weights for 
probability of treatment and probability of remaining uncensored (remaining in the study) 
were utilized (Robins et al. 2000). Probabilities were calculated for each individual 
observation at each time interval using pooled logistic models (D'Agostino 1998).  
Reasons for censoring consisted of discontinuation of therapy or disenrollment. 
The steps involved in creating the MSM weights were essentially: 
1. Determine the appropriate time intervals for the follow-up period.  Studies 
have varied in the time intervals used and have included days, months, 
quarters.  The time interval chosen has usually depended on exacerbation 
events observed in the data.  Since exacerbations were considered to last 
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approximately two weeks, a minimum of a two week interval was utilized for 
grouping the post-index data. 
2. Estimate the numerator and denominator for the stabilized treatment weights 
(swt) and stabilized censoring weights (swc) at each time point.  
3. Using the numerator and denominator estimates, calculate stabilized weights 
for treatment and censoring by individual ID and time point. 
4. The observation stabilized weight at each time point i was then calculated as: 
swi = swti x  swci 
5. Redo the analyses under Aim 1 using the stabilized weight “pseudo-
population” to examine the degree to which the populations were now 
balanced on factors related to treatment. 
Probabilities for weights will be estimated using logistic regression analyses for 
treatment at the beginning of each time period and for not being censored in the period. 
Analyses will consider time-dependent covariates and will also include an adjustment for 
the longitudinal nature of the data with a variable for time period, as well as an 
adjustment for the repeated observations for individuals. In SAS this is accomplished 
through use of the repeated statement in PROC GENMOD with a specification for the 
underlying correlation of observations (e.g., independent, exchangeable, auto-regressive).   
Aim 4 
Compare risk for severe COPD exacerbations among patients using triple 
therapy compared to use of either ICS/LABA combination or LAMA monotherapy.  
Comparisons are made using both conventional methods and MSM methods.  
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The conventional methods used for Aim4 and also for Aims 5 and 6 refer both to 
how populations for analyses are defined, and the statistical methods used for the 
analyses. Essentially, all analyses other than the MSM analyses are conventional 
analyses.  
The period for assessing severe exacerbation experience begins 30 days after the 
index date since patients were excluded from the analysis with an inpatient stay for any 
reason within 30 days after the index date. Patients were followed for up to 36 months or 
until they are lost to follow-up (due to disenrollment), whichever occurred first. 
Three distinct definitions were used for the analysis populations. The first, Intent-
to-Treat (ITT) defined treatment populations based on treatment received at the index 
date , similar to how data from many clinical trials and retrospective analyses are 
analyzed.  For these analyses, all study subjects remained in the study until the end of the 
follow-up period, the date of a severe exacerbation, or they were lost to follow-up, 
whichever occurred first. 
The second definition, As Protocol, defined treatment populations as those who 
continued on the treatment received at the index date. For these analyses, all study 
subjects remained in the study until the end of the follow-up period, the date of a severe 
exacerbation, they were lost to follow-up, or they discontinued using the treatment they 
received on the index date, whichever occurred first. 
For these first two defined populations, the conventional analysis methods utilized 
to examine severe exacerbations were Cox proportional hazard models and pooled 
logistic regression models.  Survival analysis results from pooled logistic regression, that 
is grouped time intervals, such as the structure of data in prospective clinical trials when 
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patients are evaluated at periodic intervals, has been demonstrated to be equivalent to 
those obtained from survival analysis models (D'Agostino et al. 1990).  Pooled logistic 
regression consisted of using the generalized linear model procedure in SAS (Proc 
GENMOD) with generalized estimating equations (GEE) to adjust for the repeated, and 
therefore correlated, observations for each study subject. For the severe exacerbation 
analysis, the outcome was a binary event (yes, happens; no, does not) and therefore the 
model utilized a binary distribution with a log linking function.  GEE models produce a 
population-average estimate for the effect, as opposed to subject-specific estimate for 
logistic regression, and are therefore characterized as marginal models (Stokes, Davis, 
and Koch 2000). 
The third definition was the MSM analysis, in which treatment for patients was 
allowed to be variable.  Patients remained in the analysis if they were taking one of the 
index therapies or until the end of the follow-up period, the date of a severe exacerbation, 
or they were lost to follow-up, whichever occurred first. Analyses for this population also 
utilized a pooled logistic approach, but incorporated time-dependent variables and 
weighting. 
Table 14 provides a summary of the variations in which individual observations 
were included or not included in a treatment group for each analysis.  
Table 14 Models for Aim 4, 5 and 6 
Model Parameters 
Analysis Models 
Intent-to-Treat (ITT) As Protocol As Treated 
Treatment Group 
Assignment 
Based on initial 
therapy 
Only included as 
long as still using 
initial therapy 
Included in group 
for which have 
medication on hand 
Weighted observations 
(Pseudo Population) used?  
No No Yes 
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Aim 5 
Compare risk for moderate exacerbations experienced up to and including the 
first severe COPD exacerbation among patients using triple therapy compared to use of 
either ICS/LABA combination or LAMA monotherapy. Comparisons are made using both 
conventional methods and MSM methods.  
Moderate exacerbations were compared for the time period up until the first 
severe exacerbation, the end of the follow-up period (36 months) or the individual being 
lost to follow-up, whichever occurred first. In Aim 4 analyses assessed the risk for severe 
exacerbations among an ITT study sample, an As Protocol study sample, and a MSM 
study sample.  For Aim 5, those same populations are again evaluated, but for the risk of 
a composite endpoint that is count of all moderate exacerbations occurring prior to and 
including a severe exacerbation or in the event of a severe exacerbation not occurring, the 
count of all moderate exacerbations occurring prior to the end of the follow-up period or 
loss to follow-up point, whichever is earliest. 
Of interest in Aim 5 is the rate at which moderate exacerbations occurred over the 
follow-up period.  As previously states, but repeated here, the follow-up period could be 
terminated by one of three events: a severe exacerbation, loss to follow-up, or the end of 
the follow-up period.  Events occurring between individual patients are assumed to be 
independent, but events occurring for individual patients are not. 
For a long time in health care research, recurrent events were modeled as a 
Poisson distribution in regression models.  Poisson regression models however assume 
that multiple events for individuals are independent of one another and that the 
distribution mean is equal to the variance, assumptions that are recognized as rarely 
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applying to health care research.  Consequently, models frequently exhibit overdispersion 
(and sometimes underdispersion), when the observed variance is larger than the nominal 
variance.  While methods exist to handle overdispersion in Poisson models (use a scaling 
factor – either the scaled deviance or Pearson Chi-Square statistic), an alternative 
approach has been to use the negative binomial distribution, which is a generalization of 
the Poisson distribution. Negative binomial models incorporate a dispersion term which 
adjusts for any overdispersion that may be present (Allison 2001). 
An alternative method for handling the overdispersion is to use GEE models 
(introduced in the Aim 4 discussion). Where in Poisson or negative binomial models, the 
number of events occurring over a time period is modeled, the GEE approach is to 
instead break up the time period into smaller intervals and evaluate whether an event 
occurred or not in the interval (the pooled logistic model). Sample size needs to be large 
enough to approximate normal distributions of parameters; for example if 5-12 variables 
are included in the model, a minimum of 100 subject units would be needed (Stokes et al. 
2000). 
For Aim 4 therefore, analyses for the ITT and As Protocol populations consist of 
Poisson or negative binomial models. Additionally for the ITT population, as in Aim 4, a 
GEE approach will be used to demonstrate how results may differ (if at all) using a 
pooled logistic model in comparison to an analysis of counts over a single interval.   
Aim 6 
Compare costs and effectiveness of therapy in extending time until first COPD-
related hospitalization among patients using triple therapy compared to use of either 
ICS/LABA combination or LAMA monotherapy. 
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Having the data structured into time intervals, essentially a partitioned dataset, 
facilitates estimating costs associated with treatments over the follow-up period (Bang 
and Tsiatis 2000; Curtis et al. 2007). Individuals who are censored are able to contribute 
cost information for the period of time they are observed.  Lin and colleagues highlighted 
how standard survival analyses cannot be used for analyzing “censored” total costs since 
there is usually not independence between censoring and the outcome of interest (Lin et 
al. 1997). Bang and Tsiatis improved the method suggested by Lin and colleagues by 
introducing a weighted method (Bang and Tsiatis 2000).  Anstrom and Tsiatis expanded 
this approach to encompass inverse probability of weighting (Anstrom and Tsiatis 2001).  
This method of partitioning costs and using weighted regression was previously used in a 
cost-effectiveness study of ICS/LABA combination therapy for COPD (Gagnon et al. 
2005).  In the analysis by Gagnon and colleagues, the weight was the inverse probability 
of remaining uncensored and was estimated by the Kaplan-Meier survivor function for 
time-to-censoring. Costs were estimated on a monthly basis from the index date using a 
generalized least squares estimator the included the same covariates as in the analysis of 
survival time.  The monthly cost estimates were then multiplied by the probability 
weight, summed and averaged by treatment group over the total study subjects within the 
treatment group to estimate an average treatment cost per study subject.  
We analyzed costs in a similar method in our study.  Costs were assigned to the 
time period in which they were accrued and summarized by four week periods.  
Probability of remaining uncensored is estimated by PROC LIFETEST in SAS.   
Costs to avoid a severe hospitalization for triple therapy in comparison to each of 
the ICS/LABA and LAMA treatment strategies were compared to the survival time 
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(avoiding a severe hospitalization) for the respective treatment strategies. Should triple 
therapy have greater effectiveness in avoiding a severe hospitalization, but at a higher 
cost, we will evaluate the incremental cost-effectiveness (ICER) of triple therapy by 
estimating the ratio of the difference in mean therapy costs over the difference in survival 
time.  To evaluate uncertainty around the ICER estimate we will use the bootstrapping 
method, with 1000 resamples from the original cohort (Blackhouse, Briggs, and O'Brien 
2002). 
Power Analyses 
In the randomized controlled trial study by Welte and colleagues, they observed 
similar estimates for the rate ratio for severe exacerbations and the hazard ratio for time 
to first hospitalization/ED visit, both were estimated to be 0.38.  In the U.S. observational 
study (Chatterjee et al. 2012), an adjusted HR of 0.77 was reported for moderate 
exacerbation, and 0.76 for any exacerbation, risk estimates that were higher than those 
observed in the RCT by Welte, but this is not unexpected given that the observational 
data reflects “real world” use. The U.K. study reported an adjusted HR of 0.71 for 
moderate exacerbation and 0.85 for respiratory related hospital admissions (Short et al. 
2012).  The total sample size for the U.K. study was approximately 2850.  
NCSS PASS software (Kaysville, Utah) was used for the power analyses.  
Estimates for hazard ratio using Cox Regression (Figure 5) showed that a total 
sample size of 1800 individuals would achieve 80% power at a 0.05 significance level to 
detect a hazard ratio of 0.75. This assumed an overall probability of the event of 26%.  
Preliminary analyses showed that by 24 months after the index date, approximately 27% 
of those initiating with ICS/LABA or LAMA had experienced a severe exacerbation, and 
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34% of those initiating with triple therapy had.  Calculations assumed that other 
covariates in the regression would have an R
2
 of 0.20 when treatment was the dependent 
variable. 
Figure 5 Power Analysis for Hazard Ratio 
 
While we anticipated performing a negative binomial regression analysis for the 
rate of moderate/severe exacerbations, we utilized a Poisson regression model for the 
power estimates as these models are similar. Estimates for the rate ratio using Poisson 
regression (Figure 6) showed that a total sample size of 1000 individuals would achieve 
80% power at a 0.05 significance level to detect a hazard ratio of 0.80, and would achieve 
95% power to detect a hazard ratio of 0.75. This assumed a baseline rate of 0.22 and that 
the rate is measured over a 12 month period.  Calculations assumed that other covariates 
in the regression would have an R
2
 of 0.20 when treatment was the dependent variable.   
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Figure 6 Power Analysis for Poisson Regression 
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CHAPTER 4 RESULTS 
Chapter 4 
Results 
Summarized in this chapter are first the efforts in creating tables that supported 
the analyses – the tables categorizing pharmaceuticals of interest according to NDC code, 
tables categorizing procedure codes for specific COPD-related procedures, and the 
standardized cost tables.  Following that is a description of the sample subject 
identification process, and then the results pertaining to the specific study aims.  
COPD Medications 
Creation of the tables used to categorize the COPD medications of interest was a 
multi-step process.  NDC codes for the years 2010, 2011 and 2012 for COPD-related 
HEDIS related measures were used as the foundation for the created tables. These tables 
consisted of the HEDIS tables for the measures relating to pharmacotherapy management 
of COPD exacerbations (systemic corticosteroids and bronchodilators), as well as the 
table for asthma medications since these latter tables break out beta2-agonist medications 
into short and long-acting medications and break out ICS/LABA medications, and tables 
for antibiotic medications.  Asthma medications that are not of interest for this study for 
treatment of COPD were excluded (for example leukotriene modifiers).  Antibiotic 
medications were reviewed and medications not utilized for treating COPD exacerbations 
were excluded. All tables underwent review by the clinician member of the team. 
NDC prescriptions for LHP and PHP members were reviewed for NDC codes for 
medications with the same brand and generic names of the drugs of interest.  NDC codes 
that had not been captured in the HEDIS tables were added.   
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Standardized Costs 
NCQA standardized price tables were first applied to LHP data.  The LHP data 
consisted of all outpatient and inpatient utilization for study subjects for the period July 1, 
2004 through September 2013.  For this data there were 948,320 CPT procedure codes 
that included HCPCS codes for non-physician services such as durable medical 
equipment (DME), ambulance services, prosthetics, orthotics and supplies. The 948,320 
procedure codes represented 5,813 distinct procedure codes. Approximately 20% 
(n=202,100) were for evaluation and management codes, another 20% for laboratory tests 
(n=218,060), approximately 10% for imaging (n=114,505), approximately 25% for 
DME, and other supplies and services (n=244,982), with the remaining 25% representing 
major and minor procedures, dialysis, endoscopy, eye procedures, and other ambulatory 
procedures.   
Overall, one-half of the LHP procedures could be mapped to NCQA standardized 
procedure prices, but the mapping varied greatly depending on the BETOS category for 
the procedure.  Approximately 70% of the imaging, 75% of the evaluation and 
management and ambulatory procedure codes, 85% of major procedures, and over 90% 
of the endoscopy, eye procedure, and major lab tests could be mapped.  However none of 
the anesthesia codes, dialysis service procedure codes, other lab tests, and almost none of 
the DME, and other supplies and services could be mapped.   
For procedure codes that could not be mapped, LHP standardized prices were 
utilized.  A comparison between NCQA standardized prices and LHP standardized prices 
for procedure codes in both showed that LHP standardized prices were on average 14% 
lower than NCQA standardized prices, so LHP standardized prices were increased by that 
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differential in order to be equivalent to NCQA national prices.  After mapping to the LHP 
standardized prices, only 6.9% of the 948,320 procedure codes remained that could not 
be matched to a price.  For these missing values, prices were imputed using the mean 
NCQA standardized prices for the associated BETOS category.  Appendix Table D-2 
provides a summary for the LHP data of the mean NCQA standardized prices by BETOS 
category. 
The same process was applied to the PHP claims data for sample subjects for the 
period August 1, 2005 through September 30, 2012.  Appendix Table D-3 provides a 
summary of the results.  Overall the matching patterns were very similar to those for the 
LHP data. The codes that could initially be matched to NCQA standardized prices made 
up 55% of the total 736,305 procedure codes.  After matching the remaining 45% to LHP 
standardized prices, approximately 5% remained unmatched.  Prices for these codes were 
then imputed using mean NCQA standardized prices for each BETOS category and 
subcategory. 
Almost all outpatient pharmacy prescriptions could be matched to the NCQA 
standardized price tables. Less than 1% of either health plan pharmacy claims could not 
be matched.  For prescriptions that could not be matched, a price of $0.01 per days’ 
supply was used as an imputed price. 
Study Sample Selection 
LHP Population 
Figure 7 shows the process by which the LHP patients were selected for the study 
sample. Ultimately 3,599 patients were included in the study sample, 59% of whom had 
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an index date for ICS/LABA use (n=2,129), 32% for LAMA use (n=1,158), and 9% for 
triple therapy use (n=312).  
Figure 7 Flow Diagram LHP Patient Selection 
 
PHP Population 
Figure 8 shows the process by which PHP patients were selected for the study 
sample.  Healthcare utilization claims data was only available starting from August 1, 
Excluded  
1. Individuals with only 1 ambulatory encounter (n= 8,578)
2. Patients without a Rx for ICS/LABA or LAMA >Jul 1, 2005 (n=10,390)
Individuals (n= 5,771)  Rx > Jul 1, 2005 for ICS/LABA or LAMA (af ter a COPD diagnosis) 
Excluded  (n= 2,068)
1. Less than 12 months enrollment pre-treatment prescription 
2. Less than 6 months enrollment post treatment prescription 
3. Prescription for ICS/LABA or LAMA in 6 months prior
4. Inpatient stay on Index date or within 30 days af ter index date 
Individuals with at least one COPD diagnosis (inpatient or ambulatory [outpatient or ED visit]) 
Jul 1, 2004 and Sep 30, 2012 (n=24,739)
ICS/LABA = 2,129 (59% of group)
LAMA = 1,158 (32% of group)
Triple therapy = 312 (9% of group)
Individuals (n= 3,657)  Potential patients for analysis
Excluded  (n= 58)
1. Age <40 years at index date (n=49)
2. Inpatient stay >90 days (n=9)
Individuals (n= 3,599)  Individuals meeting inclusion criteria
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2005, so the earliest index date for the PHP was August 1, 2006 as opposed to July 1, 
2005 for the LHP patients.  Ultimately 1,876 patients were included in the study sample, 
49% of whom had an index date for ICS/LABA use (n=923), 42% for LAMA use 
(n=781), and 9% for triple therapy use (n=172). 
Figure 8 Flow Diagram PHP Patient Selection 
 
 
Excluded  
1. Individuals with only 1 ambulatory encounter (n= 7,197)
2. Patients without a Rx for ICS/LABA or LAMA >Jul 1, 2005 (n=13,094)
Individuals (n= 3,122)  Rx > Aug 1, 2006 for ICS/LABA or LAMA (af ter a COPD diagnosis) 
Excluded  (n= 1,245)
1. Less than 12 months enrollment pre-treatment prescription
2. Less than 6 months enrollment post treatment prescription 
3. Prescription for ICS/LABA or LAMA in 6 months prior
4. Inpatient stay on Index date or within 30 days af ter index date 
Individuals with at least one COPD diagnosis (inpatient or ambulatory [outpatient or ED visit]) 
Aug 1, 2005 and Mar 31, 2012 (n=23,413)
ICS/LABA = 923 (49% of group)
LAMA = 781 (42% of group)
Triple therapy = 172 (9% of group)
Individuals (n= 1,877)  Potential patients for analysis
Excluded  (n= 58)
1. Age <40 years at index date (n=0) [Age considered in initial pull of  data]
2. Inpatient stay >90 days (n=1)
Individuals (n= 1,876)  Individuals meeting inclusion criteria
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Table 15 provides a summary of the final study population by study year, health 
plan and index therapy. In both the LHP and PHP study samples because of the inclusion 
criteria and because the initial study years were not complete years, there were fewer 
patients selected for the study from the initial data years.  The year 2012 also had a 
smaller number of patients since the last index date was March 31, 2012. While the 
number of patients from the LHP data that were included for the intervening years was 
fairly consistent, the numbers from the PHP data were more variable.  In particular, the 
years 2008 and 2009 were low in comparison to the years 2007, 2010 and 2011.  Within 
each health plan the portion of patients each year that were included in the triple therapy 
were lower in the initial years than in the later years. 
Table 15 Summary of Study Sample Size by Health Plan and Study Year 
        LHP Study Sample PHP Study Sample 
Year Total LHP PHP Triple ICSLABA LAMA Triple ICSLABA LAMA 
  N N % of 
Tot 
N % of 
Tot 
N % of 
LHP 
N % of 
LHP 
N % of 
LHP 
N % of 
PHP 
N % of 
PHP 
N % of 
PHP 
2005 217 217 100.0   0.0 15 6.9 141 65.0 61 28.1             
2006 776 588 75.8 188 24.2 31 5.3 379 64.5 178 30.3 13 6.9 128 68.1 47 25.0 
2007 1004 540 53.8 464 46.2 56 10.4 300 55.6 184 34.1 37 8.0 261 56.3 166 35.8 
2008 804 591 73.5 213 26.5 56 9.5 301 50.9 234 39.6 16 7.5 86 40.4 111 52.1 
2009 693 529 76.3 164 23.7 48 9.1 297 56.1 184 34.8 20 12.2 78 47.6 66 40.2 
2010 924 517 56.0 407 44.0 44 8.5 319 61.7 154 29.8 41 10.1 198 48.6 168 41.3 
2011 861 492 57.1 369 42.9 54 11.0 305 62.0 133 27.0 38 10.3 144 39.0 187 50.7 
2012 196 125 63.8 71 36.2 8 6.4 87 69.6 30 24.0 7 9.9 28 39.4 36 50.7 
All 5475 3599 65.7 1876 34.3 312 8.7 2129 59.2 1158 32.2 172 9.2 923 49.2 781 41.6 
  
In designing the study, there was a question about whether to categorize 
ICS/LABA medications approved for use in treating asthma, but not COPD; specifically, 
Advair HFA and Dulera.  The data was reviewed to determine the number of patients 
who appeared to be using these medications along with LAMA.  There were a few 
patients, but the numbers were small.  Among the LHP patients there were 24 and among 
the PHP patients there were 16.  Because of the small numbers and the differential in 
dosing strength of these medications compared to the medications listed in Table 8, these 
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two medications were not classified as ICS/LABA medications for this analysis, but 
instead were identified as another concurrent medication patients might be using, along 
with ICS, SABA, SAMA, and SABA/SAMA combination inhalers.  
Aim 1 
Assess baseline characteristics of individuals who are “new” initiators of LAMA 
monotherapy, ICS/LABA combination therapy, and triple therapy, plus individuals who 
later switch therapies.  
Comparisons were made for the baseline period between triple therapy users and 
each of the ICS/LABA and LAMA therapy users, as well as between triple therapy users 
and ICS/LABA and LAMA users combined. Comparisons also were made for patients by 
health plan, and for the combined total population. Comparisons were made of the 
following baseline characteristics: 
 Patient demographics (sex, age at therapy initiation) 
 Health insurance (type of coverage, length of enrollment post-index) 
 Comorbidities (e.g., heart disease, atrial fibrillation) 
 COPD-related utilization (pharmaceutical treatments, outpatient care, 
hospitalizations) 
 Healthcare costs (all-cause, COPD-related) by type (ambulatory, inpatient, 
Rx) 
Table 16 through Table 18 provide summaries of the baseline characteristics for 
patients for each health plan and the combined study sample. Table 19 through Table 24 
provide summaries of the mean and median healthcare costs for each health plan and the 
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combined study sample, to include summaries of costs for those incurring costs within 
each utilization category. 
Table 25 and Table 26 provide summaries of the baseline characteristics first of 
individuals who discontinued use of any of the index treatment therapies by 3 months and 
6 months into the follow-up period.  Recall that to be included in the study all patients 
had to have a minimum of 6 months of health plan enrolled coverage after the index date.  
The summary reflects the status of patients up until the earlier of a severe exacerbation 
event, or discontinuation of therapy.  For patients having a severe exacerbation within 3 
months or 6 months, use of therapy was assessed in the two-week period prior to the 
exacerbation event. 
Table 27 and Table 28 provide summaries of the baseline characteristics of 
individuals who at 3 and 6 months still appeared to be using one of the index treatments.  
Similar to the discontinuation tables, for patients having a severe exacerbation within 3 
months or 6 months, use of therapy was assessed in the two-week period prior to the 
exacerbation event  
Table 29 through Table 36 provide summaries of the mean and median healthcare 
costs for patients discontinuing and patients switching therapies by 3 and 6 months. 
Patient Demographics 
The average age of the LHP sample (Table 16) was slightly older than the PHP 
sample (Table 17), with a mean age of 71.6 (standard deviation [SD], 11.3) for the LHP 
sample and 68.8 (SD, 11.6) for the PHP sample.  Because the LHP sample was almost 
twice the size of the PHP sample, the overall age of the combined group was closer to the 
LHP mean age and was 70.6 years (SD, 11.5).  A minority of patients in the study sample 
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were men, 45% in the LHP sample, 41% in the PHP sample, and 44% in the combined 
sample.   
The treatment group percentages differed between the two health plans.  While 
the percentage of study subjects in the triple therapy group was similar between the two 
health plans (8.7% for LHP, 9.2% for PHP), the ICS/LABA group was a larger 
percentage of the LHP sample than the PHP sample – 59.2% compared to 49.2%.  
In comparisons between the three treatment groups on age characteristics 
however, there was a similar pattern between the two health plans.  Within each health 
plan, LAMA users were on average older than ICS/LABA users and the average age of 
triple therapy users was between that of ICS/LABA users and LAMA users.  In the 
combined sample the average age of the ICS/LABA group was 69.8 (SD, 11.9), 71.8 
(SD, 10.8) for the LAMA group, and 70.0 (SD, 11.3) for the triple therapy group.  
Men were less likely to be in the ICS/LABA group compared to the LAMA or 
triple therapy group.  In the LHP sample, men were 42.4% of the ICS/LABA group, 
47.3% of the LAMA group, and 52.9% of the triple therapy group.  For the PHP sample, 
the percentages were 38.6%, 43.3%, and 48.3%, respectively.  Overall, the ICS/LABA 
treatment group was 41.3% male, the LAMA group 45.7%, and the triple therapy group 
51.2% male. 
Study subjects in the LHP sample were more likely to have an index date that was 
in the first quarter of the year (Table 16), while for the subjects in the PHP sample, the 
last quarter had the highest percentage, with the first quarter having the second highest.  
There was not a significant difference in months of follow-up (through 24 months) 
between the three treatment groups. 
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Health Insurance 
Medicare patients were the majority of patients in both the LHP and PHP samples 
– 54.7% of the LHP sample and 58.8% of the PHP sample.  For the remaining 45% of 
LHP patients, the majority had Commercial health insurance, with only 7.9% of the LHP 
sample having Medicaid coverage.  Medicaid patients were a larger portion of the PHP 
sample, with 19.8% having Medicaid coverage.  In both health plans, Medicaid patients 
were more likely to be in the ICS/LABA treatment group. Otherwise there were not 
significant differences in health insurance coverage between triple therapy users and 
those using either ICS/LABA or LAMA medications. 
Comorbidities 
Patients were very similar between the two health plans regarding prevalences of 
CMS defined and Elixhauser defined comorbidities.  Among LHP patients 67% had at 
least one of the CMS defined comorbidities and among PHP patients, 65% did; 93% of 
LHP patients had at least one Elixhauser defined comorbidity and 90.4% of the PHP 
patients did. The CMS comorbidities with the highest prevalances were rheumatoid/osteo 
arthritis (RA/OA) (LHP, 26.5%; PHP, 26.1%), diabetes (LHP, 24.6%; PHP, 25.3%), and 
heart failure (LHP, 17.9%; PHP, 18.2%).  A higher percentage of LHP patients also had 
chronic kidney disease (LHP, 17.4%; PHP, 13.0%).  
Among the LHP sample, slightly higher percentages were present for 
cardiovascular diseases (congestive heart failure [CHF]: LHP, 17.1%; PHP, 15.3%, 
peripheral vascular disease: LHP, 17.1%; PHP, 14.1%, pulmonary circulation disease: 
LHP, 12.1%; PHP, 10.1%), while a higher percentage of the PHP sample had evidence of 
depression in the baseline period (LHP, 14.9%; PHP, 20.3%). 
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The percentage of patients with a diagnosis of asthma was similar between the 
two health plans; 32.4% of the LHP sample, and 34.5% of the PHP sample.   The 
percentage of patients with pneumonia in the baseline was slightly higher for the LHP 
sample (LHP, 37.5%; PHP, 29.9%), while the percentage of patients with hypoxemia was 
slightly higher for the PHP sample (LHP, 34.1%; PHP, 40.8%).  
In comparisons of morbidities across the three treatment groups, there were no 
consistent statistically significant findings between the two health plans.  Though there 
were statistically significant differences, the differences were not substantive. Because of 
the increased sample size of the combined health plan sample, there were a couple of 
comorbidities with trends that were similar between the two health plans, but not 
necessarily significant in both, which were found to have significant p-values when the 
two health plans were combined.  For example, in the LHP sample, patients with the 
CMS defined RA/OA were significantly less likely to be triple therapy patients (triple 
therapy 18.6% vs ICS/LABA 27.6%, P=0.003; vs LAMA 26.7%, P=0.0008), while in the 
PHP sample, the differences were not significant (triple therapy 20.9% vs ICS/LABA 
26.2%, P=0.14; vs LAMA 27.0%, P=0.10). P-values in the combined dataset were thus 
stronger than those for the LHP sample (triple therapy 19.4% vs ICS/LABA 27.2%, 
P=0.0008; vs LAMA 26.8%, P=0.0003).  
Likewise, a review of symptoms associated with reduced physical and cognitive 
functioning showed no distinct patterns across the two health plans. There were no strong 
significant differences between the groups in regard to chest pain, chronic fatigue, 
memory loss, or other malaise/fatigue.  
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Nor were there strong indications of differences between treatment groups across 
the two health plans in regard to evidence in the baseline period of at least one chest CT 
scan, chest x-ray, or EKG. 
Patients with comorbid asthma were more likely to be in the ICS/LABA treatment 
groups and less likely to be in the LAMA group, but the percentage within the triple 
therapy group was between the other two.  Thus while overall, 41.7% of the ICS/LABA 
group had evidence of an asthma diagnosis, only 20.4% of the LAMA group did 
(P<0.0001), and the percentage for the triple therapy group, 29.8%, was still lower than 
the ICS/LABA group (P<0.0001), but was higher than the LAMA group (P<0.0001). 
Alternatively, patients with a diagnosis of hypoxemia were more likely to be in 
the triple therapy group, with 49.2% of the triple therapy group having a diagnosis 
compared to 33.4% of the ICS/LABA group (P=0.0007) and 38.1% of the LAMA group 
((P<0.0001).  Patients in the triple therapy group were also significantly more likely to 
have a diagnosis of emphysema.  Overall 33.5% of the triple therapy group had 
emphysema compared to 18.3% of the ICS/LABA group (P<0.0001), and 25.2% of the 
LAMA group (P<0.0001). 
Patients classified as low complexity using the classification scheme of Mapel 
and colleagues (Mapel et al. 2011), were less likely to be among the triple therapy users, 
with 34.9% having low complexity compared to 49.2% among the ICS/LABA users 
(P<0.0001) and 54.3% among the LAMA users (P<0.0001). 
COPD-related Utilization 
While there were significant differences between ICS/LABA users and LAMA 
users for categories of COPD-related medications in the prior year, and between triple 
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therapy users and LAMA users, there were not consistent differences between triple 
therapy users and both ICS/LABA and LAMA users. LAMA users were less likely to use 
SABA medications on a frequent basis in the baseline period.  Overall, 12.9% of LAMA 
users had prescription claims for SABA medications indicating SABA use for more than 
40% of the year compared to 19.0% of ICS/LABA users (P<0.0001) and 19.4% of triple 
therapy users (P<0.0001). Similarly, LAMA users were less likely to have had a 
prescription claim for a SAMA medication or a SABA/SAMA medication in the baseline 
period.  Among LAMA users, 20.4% had at least one prescription claims for SAMA or a 
SABA/SAMA combination inhaler compared to 27.7% of ICS/LABA users (P<0.0001) 
and 28.9% of triple therapy users (P<0.0001). 
Between the two dyspnea diagnosis codes relating to symptoms, shortness of 
breath (ICD-9 786.05) appeared to be more consistently used between the two health 
plans than breathlessness (ICD-9 786.09).   Among LHP patients, 37.2% had evidence of 
shortness of breath that was associated with at least one healthcare encounter.  Among 
PHP patients, the percentage was similar, 36.6%.  Whereas the respective percentages for 
breathlessness were 41.6% of the LHP sample, and 27.9% of the PHP sample. Overall, 
43.2% of triple therapy users had at least one episode of shortness of breath compared to 
36.9% of ICS/LABA users (P=0.0084) and 35.6% of LAMA users (P=0.0018). 
Patients in the triple therapy group however were more likely to have evidence in 
the baseline period of a nebulizer treatment procedure.  Overall, 38.2% of triple therapy 
users compared to 33.1% of ICS/LABA users (P=0.0257) and 29.8% of LAMA users 
(P=0.0003) had at least one occurrence of a nebulizer treatment procedure in the baseline 
period. A higher percentage of patients in the triple therapy group also had at least one 
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spirometry procedure in the baseline period than the other treatment groups.  Among 
triple therapy users, 50.2% had at least one spirometry procedure compared to 37.8% of 
ICS/LABA patients (P<0.0001) and 45.7% of LAMA patients (P=0.08). 
Patients in the triple therapy group were significantly more likely to have been 
discharged from a COPD-related inpatient stay in the two week period immediately 
preceding and including the index date; 13.8% compared to 8.9% of ICS/LABA users 
(P=0.0006) and 5.0% of LAMA users (P<0.0001).   Triple therapy users were also more 
likely to additionally have had a severe exacerbation in the 2-12 weeks prior to the index 
date; 9.1% of triple therapy users had a severe exacerbation compared to 6.2% of 
ICS/LABA users (P=0.02) and 5.4% of  LAMA users (0.002).  Looking farther back, to 
the 13-52 weeks prior to the index date, the magnitude of the differences was diminished; 
9.9% of triple therapy users had a severe exacerbation during this period compared to 
7.8% of ICS/LABA users (P=0.11) and 6.4% of LAMA users (0.007).  Looking at the 
entire baseline period, 27.7% of the triple therapy users had at least one severe 
exacerbation compared to 21.3% of the ICS/LABA group and 17.1% of the LAMA 
group. 
There were no strong differences in the percentages of patients with moderate 
exacerbations in the baseline period. 
Healthcare Costs 
Overall, triple therapy patients had significantly higher COPD-related outpatient 
utilization costs than either ICS/LABA or LAMA users (Table 23).  This was true with 
respect to either the mean or the median value, and both across all study patients and for 
those with some COPD outpatient utilization in the baseline period.  Overall, mean 
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COPD-related outpatient costs for triple therapy users were $2,277 (SD, 2781) compared 
to $1,903 (SD, 2411) for ICS/LABA users (P=0.005), and $1,974 (SD, 2378) for LAMA 
users (P=0.03).  Median COPD-related outpatient costs across treatment groups were 
$1,697 for triple therapy users compared to $1,299 for ICS/LABA users (P=0.0007) and 
$1,437 for LAMA users (P=0.01) (Table 24). Non-COPD outpatient utilization on the 
other hand was lower among triple therapy users than ICS/LABA or LAMA users.  
While mean costs were not significantly different between triple therapy users and 
ICS/LABA or LAMA users, there was a difference using the Wilcoxon signed rank-sum 
test for differences in the cost distributions. Overall, median non-COPD related 
outpatient utilization was $2,600 compared to $3,239 for ICS/LABA or LAMA users 
(P=0.003).   
Among patients with inpatient utilization during the baseline period, there were 
no differences between treatment groups in mean inpatient utilization costs or median 
values.  
Similar to the pattern for outpatient utilization, triple therapy users had higher 
COPD-related outpatient pharmacy utilization and lower non-COPD outpatient pharmacy 
utilization.  Although differences were only significant for COPD-related outpatient 
pharmacy between triple therapy users and LAMA patients; differences for non-COPD-
related outpatient pharmacy costs were significantly different between triple therapy 
users and ICS/LABA users.  Overall, mean COPD-related costs were $482 (SD, 995) 
compared to $438 (SD, 789) for ICS/LABA users (P=0.36) and $342 (SD, 688) for 
LAMA users (P=0.004).  Among patients incurring non-COPD-related outpatient 
pharmacy costs, mean costs were $2,120 (SD, 3003) for triple therapy users compared to 
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$2,557 (SD, 3998) for ICS/LABA users (P=0.006) and $2,392 (SD, 4358) for LAMA 
users (P=0.12). 
There were some differences in costs for patients between the two health plans.  
Overall, costs were lower for LHP patients.  Mean non-COPD outpatient utilization was 
similar between the two health plans; $5,426 (SD, 8291) for the LHP population (Table 
19), and $5,614 (SD, 11,366) for the PHP population (Table 21).  COPD-related 
outpatient utilization was higher for PHP patients however; $1,786 (SD, 2213) for LHP 
compared to $2,297 (SD, 2786) for PHP patients. Total inpatient utilization was higher 
for LHP patients than for PHP patients.  While mean COPD-related inpatient utilization 
for patients with an inpatient stay in the baseline period was similar – mean for LHP was 
$28,403 (SD, 39151) compared to $32,778 (SD, 34258) for PHP patients, the mean non-
COPD inpatient utilization costs for LHP patients were $36,213 (SD, 45208), an amount 
that was more than double that of the mean cost of $17,434 (SD, 14833) for PHP 
patients.  Overall, mean inpatient utilization for LHP patients was $37,244 (SD, 48767) 
compared to $34,716 (SD, 36619) for PHP patients.  Costs for inpatient stays were 
directly proportional to length of stay and the mean length of stay was 7.3 days (SD, 8.6) 
for LHP patients compared to 5.3 days (SD, 5.0) for PHP patients.  
Discontinuation of ICS/LABA or LAMA Therapies 
Status at Three Months 
For the 5,475 study sample patients, 37.8% (n=2,072) by three months did not 
have evidence of still using either ICS/LABA or LAMA medications (Table 25).  This 
analysis included an assessment of therapy for patients who had a severe exacerbation 
earlier than three months after the index date.  For patients having a severe exacerbation 
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prior to or at the end of 3 months, therapy was assessed in the two week period prior to 
the occurrence of the severe exacerbation. Otherwise, use of therapy was assessed at the 
end of three months. The 2,072 was comprised of 1,472 LHP patients (40.9% of the LHP 
sample), and 600 PHP patients (32.0% of the PHP sample). 
There was a higher percentage of patients age 40 to 54 among those discontinuing 
within 3 months compared to those still using an ICS/LABA or LAMA medication 
(12.5% compared to 9.6%, P=0.0008), and a higher percentage were patients with 
Medicaid coverage (13.4% compared to 11.1%, P=0.01).  
Patients with diabetes without chronic complications were more likely to 
discontinue (26.1% compared to 22.5%, P=0.002) as were patients with depression 
(18.2% compared to 15.9%, P=0.03) and patients with deficiency anemias (15.5% 
compared to 13.3%, P=0.02). Patients with hypoxemia were less likely to discontinue 
(34.6% compared to 37.6%, P=0.03) as were patients with emphysema (19.2% compared 
to 23.9%, P<0.0001).  Patients who in the baseline period had a diagnosis code 
recognizing any chest pain symptom also were more likely to discontinue ICS/LABA or 
LAMA use (35.7% compared to 29.5%, P<0.0001). 
The overall percentage of patients discontinuing any therapy was 37.8%, while 
among ICS/LABA patients, 43.2% discontinued therapy.  Among LAMA patients, 33.7% 
had discontinued therapy and among triple therapy patients, only 19.8% discontinued 
therapy.  The lower percentage among triple therapy patients however could be an artifact 
of the method by which patients were assigned to the triple therapy category (earlier date 
for when a prescription claim for ICS/LABA or LAMA is followed within 30 days by a 
prescription for the other medication). 
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Interestingly, both patients with no SABA use in the baseline period and patients 
with SABA use for more than 40% of the baseline period were less likely to discontinue 
(40.1% compared to 43.6%, P=0.01 and 14.5% compared to 18.3%, P=0.0003, 
respectively), while patients with SABA use <15% of the baseline period or >15% and 
<40% were more likely  (28.9% compared to 24.6%, P=0.0004 and 16.5% compared to 
13.5%, P=0.003, respectively).  This pattern was consistently observed among patients 
for both health plans. 
Patients taking any SAMA or SABA/SAMA medication in the baseline period 
were less likely to discontinue, however this was not a consistent finding across the two 
health plans, and appeared to be driven by the LHP study sample. There were no 
significant differences in the percentage of patients with some ICS use in the baseline 
period between those discontinuing and still using an ICS/LABA or LAMA medication, 
however though the overall percentage of patients with a LABA prescription in the 
baseline period was small, these patients constituted a smaller percentage of those 
discontinuing any therapy compared to those still taking a medication of interest (2.8% 
compared to 5.0%, P<0.0001). 
Patients who had minimal use of ICS/LABA medications in the 27 to 52 weeks 
prior to the index date were a larger percentage of those who discontinued use; 8.9% 
compared to 6.0% (P<0.0001) for 1-2 previous claims for ICS/LABA, and 2.8% 
compared to 1.9% (P=0.04) for 1-2 previous claims for LAMA. 
Patients with no use of oxygen in the baseline period constituted a slightly larger 
percentage of those discontinuing ICS/LABA or LAMA use (58.6% compared to 55.1%, 
P=0.01).  Significant differences in dyspnea symptoms (breathlessness, shortness of 
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breath) were not observed between patients discontinuing and still using one of the index 
medications. Patients who had evidence of a spirometry procedure in the baseline period 
were less likely to discontinue therapy (36.9% compared to 44.6%, P<0.0001).  This was 
consistent across the two health plans. 
There was some evidence that patients who experienced moderate or severe 
exacerbations in the baseline period were more likely to discontinue therapy. Among 
those discontinuing therapy, 16.4% had a moderate exacerbation in the two week period 
leading up to the index date compared to 13.0% of those still on a medication 
(P=0.0007), and 25.9% of those discontinuing had at least one moderate exacerbation in 
the 13-52 weeks prior to the index date compared to 21.7% of those still on a medication 
(P=0.0004).  Although having a moderate exacerbation in the 2-12 weeks prior to the 
index date was not associated with a significant discontinuation difference.   
Patients who were discharged from an inpatient stay for a severe exacerbation in 
the two week period leading up to the index date were more likely to discontinue 
medication by the end of three months (9.0% compared to 7.3%, P=0.02), as were 
patients discharged from a stay where COPD was noted as a secondary condition (3.0% 
compared to 1.8%, P=0.003).  However the evidence for an association between 
discontinuation and a prior severe exacerbation was weaker for severe exacerbations in 
the 2-12 weeks prior to the index date (5.3% among those discontinuing compared to 
6.7%, P=0.04) and was nonexistent for severe exacerbations in the 13-52 weeks prior to 
the index date (7.0% among those discontinuing compared to 7.8%, P=0.30).   
Having any inpatient stay in the baseline period was associated with 
discontinuation.  Among those discontinuing ICS/LABA or LAMA, 33.3% had at least 
  
 104   
one inpatient stay compared to 29.4% of those still using one of the medications 
(P=0.002). 
Table 29 shows that there were no significant differences in outpatient utilization 
costs between patients discontinuing therapy by three months after the index date and 
those still using an ICS/LABA or LAMA medication.  Patients discontinuing did 
however have higher total inpatient utilization costs in the baseline period of $12,588 
(SD, $32,459) compared to $10,432 (SD, $28,813) among patients still on medication 
(P=0.013). However, mean inpatient costs did not differ for those patients incurring 
inpatient costs (P=0.30).  Patients discontinuing had lower mean COPD outpatient 
pharmacy costs of $290 (SD, $619) compared to $480 (SD, $852) among patients still on 
one of the index therapies.  However, patients discontinuing had higher non-COPD 
outpatient pharmacy costs.  Among patients with non-COPD outpatient pharmacy 
utilization, the mean baseline cost among those discontinuing by three months was 
$2,609 (SD, $4519) compared to $2,370 (SD, $3736) among patients still on one of the 
index medications (P<0.05).  The same pattern for outpatient pharmacy costs was also 
observed for median costs. 
Status at Six Months 
By six months, approximately one-half of the patients had discontinued their 
index medication – 57.1% of the LHP patients and 46.7% of the PHP patients, for a 
combined percentage of 53.5%. (Table 26)  As at 3 months, among those discontinuing, 
there was a higher percentage of patients age 40 to 54 (12.2% compared to 8.9%, 
P<0.0001), and the percentage of patients with Medicaid coverage was again higher 
  
 105   
among those discontinuing ICS/LABA or LAMA therapy (13.1% compared to 10.7%, 
P=0.01). 
Patients with diabetes and without chronic complications were again more likely 
to be among those discontinuing therapy (25.2% compared to 22.2%, P=0.008), as were 
patients with depression (17.7% compared to 15.6%, P=0.04).  Deficiency anemias were 
no longer significantly associated with discontinuation, however RA/OA was now found 
to be associated with discontinuation (27.8% compared to 24.7%, P=0.01), as was 
congestive heart failure (17.5% compared to 15.4%, P=0.04), both of which were 
associated with discontinuation at three months, but the association was not significant 
(P=0.08).   
The presence of an asthma comorbidity was still not associated with 
discontinuation, and patients with hypoxemia or emphysema remained less likely to 
discontinue treatment (35.1% compared to 37.9%, P=0.03 and 19.7% compared to 
24.9%, P<0.0001, respectively).  Patients with a history of pneumonia were more likely 
to discontinue therapy by six months, but not significantly so (35.9% compared to 33.6%, 
P=0.07), while a history of influenza was significantly associated with discontinuation 
(3.7% compared to 2.7%, P=0.04). 
By six months, a higher percentage of those discontinuing ICS/LABA or LAMA 
were patients taking ICS/LABA at the index date (61.1% compared to 49.6%, P<0.0001).  
Among those taking ICS/LABA medication at the index date, 58.7% had discontinued 
therapy (1791 out of 3052) compared to the overall discontinuation percentage of 53.5% 
for the study sample.  Among patients using LAMA medication at the index date, 49.9% 
discontinued treatment by six months (967 out of 1939), but only 35.7% of patients 
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identified as triple therapy users (173 out of 484 patients) at index had discontinued use 
of ICS/LABA or LAMA by six months. 
Patients with no SABA use in the baseline period or with SABA use for more 
than 40% of the year were still less likely to discontinue therapy (41.1% compared to 
43.6%, P=0.06 and 14.7% compared to 19.3%, P=<0.0001, respectively).  By six months, 
patients with any SAMA or SABA/SAMA use were less likely to discontinue (23.1% 
compared to 27.6%, P=0.0001), although this result was not consistent for both health 
plan populations.  There was no significant association between any SAMA or 
SABA/SAMA use among the PHP sample (26.1% compared to 25.1%, P=0.61). 
As at three months, patients with at least one LABA claim in the baseline period 
were less likely to discontinue therapy (3.2% compared to 5.3%, P=0.0001). A significant 
association was also observed between ICS use in the baseline period and less likelihood 
of discontinuation (30.7% compared to 33.5%, P=0.02), although again this was not a 
consistent finding across both health plans.  Overall, use of any COPD medication in the 
baseline period was significantly associated with discontinuation of therapy by six 
months (47.1% discontinuing compared to 51.4% still on medication, P=0.002), but 
interestingly, the direction of the association was reversed between the two health plans.  
In the LHP sample the percentage with any use was smaller among those discontinuing 
(44.8% compared to 53.6%, P<0.0001), while in the PHP sample it was the opposite 
(52.6% compared to 47.9%, P=0.04). 
The presence of dyspnea symptom codes in the baseline period was again not 
found to be significantly associated with discontinuation of therapy, while use of oxygen 
was associated with less likelihood of discontinuation (41.4% compared to 46.1%, 
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P=0.0005).  Having symptoms of chest pain in the baseline period was again associated 
with a greater likelihood of discontinuation (34.3% compared to 29.0%, P<0.0001). And 
additionally, symptoms in the baseline period of other malaise/fatigue at six months were 
associated with discontinuation of therapy (26.9% compared to 23.2%, P=0.002) as was 
having cough as a symptom in the baseline period (37.7% compared to 33.7%, P=0.002). 
A smaller percentage of those discontinuing medication again had a spirometry 
procedure in the baseline period compared to those still on an ICS/LABA or LAMA 
medication (38.7% compared to 45.2%, P<0.0001).  
Approximately one-fifth of the study sample had a moderate or severe 
exacerbation in the two weeks leading up to the index date. Moderate and severe 
exacerbation episodes in the two weeks leading up to the index date were still more 
influential at six months than episodes occurring in the baseline period more distant from 
the index date.  Among those discontinuing therapy by six months, 15.8% compared to 
12.6% still on ICS/LABA or LAMA had a moderate exacerbation proximate to the index 
date (p=0.0009) and 8.9% compared to 6.8% had a severe exacerbation (P=0.004).  
Table 31 shows that the same pattern for healthcare utilization costs observed at 
three months for patients discontinuing therapy was still observed at six months.  Patients 
discontinuing had lower COPD outpatient pharmacy costs in the baseline of $303 (SD, 
$621) compared to $528 (SD, $911) for those still on one of the index medications 
(P<0.0001), but had higher non-COPD outpatient pharmacy costs. Although for non-
COPD outpatient pharmacy costs, the difference was no longer significant (P=0.08).  For 
patients who discontinued therapy by six months, the mean COPD outpatient utilization 
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costs were also less than those for patients still on therapy ($2030 [SD, $2517] compared 
to $2180 [SD, $2397], P=0.03).  The same patterns were observed for median costs. 
Switching from the Index Treatment 
Status at Three Months 
At three months, the number of individuals who had not discontinued use of an 
ICS/LABA or LAMA medication was 3,403 (Table 27).  Of these, 9% (n=306) were 
using a different medication than they were at the index date.  Approximately half (49%) 
had been using either an ICS/LABA or LAMA medication and were now using both.  
This was consistent across the two health plans. One third (33.3%) had been in the triple 
therapy group and were now using only an ICS/LABA or LAMA medication and the 
remaining patients (17.6%) had switched between the ICS/LABA and LAMA groups.  
The percentage of patients using LAMA medication at index was essentially the same 
between those switching and those remaining on the same medication (37.6% compared 
to 37.7%, P=0.95). 
There were no significant differences in age or sex between those still using the 
same medication at three months and those changing.  The percentage of patients with 
Medicaid coverage was less among those switching than among those on the same 
medication as at index (7.2% compared to 11.5%, P=0.02). 
There were no significant associations observed for any of the CMS defined or 
Elixhauser defined comorbidities and switching treatments.  Among those switching 
however, there was a higher percentage of patients with a diagnosis of hypoxemia in the 
baseline period (43.8% compared to 36.9%, P=0.02) as well as a higher percentage with a 
diagnosis of emphysema (29.4% compared to 23.3%, P=0.02). 
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Few other significant differences were noted among patients switching, a higher 
percentage had two or more diagnoses of breathlessness in the baseline period (23.5% 
compared to 17.5%, P=0.009), a higher percentage had a diagnosis of cough in the 
baseline period (42.8% compared to 34.1%, P=0.002), and a higher percentage had a 
severe exacerbation in the two weeks leading to the index date (12.4% compared to 6.7%, 
P=0.0003). 
As Table 33 shows, there were no significant differences observed in mean 
healthcare utilization costs between those switching and those with the same medication 
as at index.  A significant difference was found in median non-COPD outpatient 
utilization costs for the sample ($2674 for those switching compared to $3223 for those 
not, P=0.04), but for those with non-COPD outpatient utilization, there was not a 
significant difference (P=0.08). Among patients with an inpatient stay in the baseline 
period, those switching a median length of stay that was greater than those not switching 
(5 days compared to 4 days, P=0.02). 
Status at Six Months 
By six months, the number of individuals who had not discontinued one of the 
index therapies was 2,544 (Table 28).  Of these, oddly enough, again 306 (12%) were 
using a different medication than at index.  The 306 was comprised of 169 patients 
(55.2%) who were now considered triple therapy users, 28.1% who were no longer using 
triple therapy, and 16.7% who had switched between ICS/LABA and LAMA.   
As at three months, there were no significant differences in age or sex with those 
who changed therapies.  And again, among those switching, patients with Medicaid 
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coverage were a smaller percentage than among those not switching (6.2% compared to 
11.3%, P=0.007). 
Among those switching, there was a higher percentage of patients with fluid and 
electrolyte disorders of 15.4% compared to 11.1% among those on the same medication 
as at index (P=0.03), and there was a higher percentage of patients with medium COPD 
complexity (53.6% compared to 45.6%, P=0.008).  Patients with no SABA use in the 
baseline period were less prevalent among those that switched by six months (37.9% 
compared to 44.4%, P=0.03), while patients with some SAMA or SABA/SAMA use in 
the baseline were more prevalent (32.7% compared to 26.9%, P=0.04). 
As at three months, among those switching by six months there was a higher 
percentage with two or more diagnoses of breathlessness (22.9% compared to 17.8%, 
P=0.03), and a higher percentage with a severe exacerbation in the two week period 
leading to the index date (11.8% compared to 6.1%, P=0.0002). 
There were no notable differences in mean or median baseline healthcare 
utilization costs (Table 35 and Table 36).
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Table 16 LHP Baseline Characteristics 
LHP  
Baseline Characteristic 
Total % ICSLABA 
or LAMA  
% Triple % pval  
ICSLABA 
or LAMA 
vs Triple 
ICS  
LABA 
% LAMA % Triple % pval ICS 
LABA vs 
LAMA 
pval ICS 
LABA vs 
Triple 
pval 
LAMA 
vs Triple 
Number of Patients 3599   3287   312     2129   1158   312         
Age Categories                                 
age 40-54 332 9.2 309 9.4 23 7.4 0.2366 238 11.2 71 6.1 23 7.4 <0.0001 0.0421 0.4267 
age 55-64 591 16.4 526 16.0 65 20.8 0.0277 382 17.9 144 12.4 65 20.8 <0.0001 0.2176 0.0002 
age 65-74 1059 29.4 974 29.6 85 27.2 0.3763 599 28.1 375 32.4 85 27.2 0.0108 0.7433 0.0822 
age 75 and older 1617 44.9 1478 45.0 139 44.6 0.8883 910 42.7 568 49.1 139 44.6 0.0005 0.5468 0.1581 
age (Mean, SD) 71.58 11.31 71.56 11.35 71.80 10.90 0.7222 70.76 11.78 73.04 10.37 71.80 10.90 <0.0001 0.1406 0.0637 
                                  
Men 1616 44.9 1451 44.1 165 52.9 0.0030 903 42.4 548 47.3 165 52.9 0.0068 0.0005 0.0811 
Hispanic Ethnicity 935 26.0 860 26.2 75 24.0 0.4133 609 28.6 251 21.7 75 24.0 <0.0001 0.0935 0.3725 
Quarter of Year, Index Date             0.1864             0.0426 0.4598 0.0251 
Q1 1111 30.9 998 30.4 113 36.2   680 31.9 318 27.5 113 36.2       
Q2 800 22.2 739 22.5 61 19.6   467 21.9 272 23.5 61 19.6       
Q3 846 23.5 776 23.6 70 22.4   482 22.6 294 25.4 70 22.4       
Q4 842 23.4 774 23.5 68 21.8   500 23.5 274 23.7 68 21.8       
Months enrollment post-Index             0.2621             0.3783 0.4177 0.1343 
7 44 1.2 41 1.2 3 1.0   30 1.4 11 0.9 3 1.0       
8 39 1.1 36 1.1 3 1.0   25 1.2 11 0.9 3 1.0       
9 50 1.4 44 1.3 6 1.9   27 1.3 17 1.5 6 1.9       
10 70 1.9 60 1.8 10 3.2   39 1.8 21 1.8 10 3.2       
11 95 2.6 84 2.6 11 3.5   59 2.8 25 2.2 11 3.5       
12 71 2.0 67 2.0 4 1.3   51 2.4 16 1.4 4 1.3       
13 67 1.9 61 1.9 6 1.9   38 1.8 23 2.0 6 1.9       
14 75 2.1 68 2.1 7 2.2   43 2.0 25 2.2 7 2.2       
15 62 1.7 60 1.8 2 0.6   40 1.9 20 1.7 2 0.6       
16 82 2.3 77 2.3 5 1.6   52 2.4 25 2.2 5 1.6       
17 77 2.1 69 2.1 8 2.6   45 2.1 24 2.1 8 2.6       
18 72 2.0 63 1.9 9 2.9   42 2.0 21 1.8 9 2.9       
19 69 1.9 60 1.8 9 2.9   43 2.0 17 1.5 9 2.9       
20 67 1.9 63 1.9 4 1.3   47 2.2 16 1.4 4 1.3       
21 63 1.8 54 1.6 9 2.9   40 1.9 14 1.2 9 2.9       
22 79 2.2 69 2.1 10 3.2   50 2.3 19 1.6 10 3.2       
23 64 1.8 55 1.7 9 2.9   36 1.7 19 1.6 9 2.9       
24 2453 68.2 2256 68.6 197 63.1   1422 66.8 834 72.0 197 63.1       
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LHP  
Baseline Characteristic 
Total % ICSLABA 
or LAMA  
% Triple % pval  
ICSLABA 
or LAMA 
vs Triple 
ICS  
LABA 
% LAMA % Triple % pval ICS 
LABA vs 
LAMA 
pval ICS 
LABA vs 
Triple 
pval 
LAMA 
vs Triple 
Number of Patients 3599   3287   312     2129   1158   312         
Insurance at Index                                 
Commercial 1376 38.2 1247 37.9 129 41.3 0.2364 828 38.9 419 36.2 129 41.3 0.1263 0.4069 0.0941 
Medicaid 284 7.9 257 7.8 27 8.7 0.6010 202 9.5 55 4.7 27 8.7 <0.0001 0.6370 0.0077 
Medicare 1968 54.7 1810 55.1 158 50.6 0.1335 1118 52.5 692 59.8 158 50.6 <0.0001 0.5364 0.0038 
                                  
CMS comorbidities                                  
acute myocardial infarction 
(AMI) 
114 3.2 104 3.2 10 3.2 0.9684 69 3.2 35 3.0 10 3.2 0.7324 0.9734 0.8680 
Alzheimer’s 111 3.1 104 3.2 7 2.2 0.3688 70 3.3 34 2.9 7 2.2 0.5820 0.3243 0.5097 
atrial fibrillation 362 10.1 330 10.0 32 10.3 0.9031 204 9.6 126 10.9 32 10.3 0.2366 0.7066 0.7520 
cancers 265 7.4 245 7.5 20 6.4 0.5001 155 7.3 90 7.8 20 6.4 0.6082 0.5779 0.4171 
lung cancer 75 2.1 66 2.0 9 2.9 0.3002 31 1.5 35 3.0 9 2.9 0.0022 0.0634 0.8991 
chronic kidney disease 626 17.4 569 17.3 57 18.3 0.6695 367 17.2 202 17.4 57 18.3 0.8816 0.6535 0.7341 
diabetes 884 24.6 812 24.7 72 23.1 0.5236 533 25.0 279 24.1 72 23.1 0.5497 0.4543 0.7086 
heart failure 645 17.9 580 17.6 65 20.8 0.1606 376 17.7 204 17.6 65 20.8 0.9746 0.1738 0.1921 
ischemic heart dis. (IHD; incl. 
AMI) 
908 25.2 817 24.9 91 29.2 0.0938 499 23.4 318 27.5 91 29.2 0.0108 0.0273 0.5507 
rheumatoid/osteo arthritis  954 26.5 896 27.3 58 18.6 0.0009 587 27.6 309 26.7 58 18.6 0.5851 0.0008 0.0034 
stroke/TIA 256 7.1 232 7.1 24 7.7 0.6771 147 6.9 85 7.3 24 7.7 0.6414 0.6107 0.8332 
no CMS Comorbidity 1194 33.2 1086 33.0 108 34.6 0.5720 701 32.9 385 33.2 108 34.6 0.8519 0.5539 0.6495 
                                  
Elixhauser comorbidities                                 
AIDS 9 0.3 8 0.2 1 0.3 0.7943 7 0.3 1 0.1 1 0.3 0.1778 0.9809 0.3193 
alcohol abuse 108 3.0 97 3.0 11 3.5 0.5697 71 3.3 26 2.2 11 3.5 0.0778 0.8614 0.2000 
chronic blood loss anemia 28 0.8 24 0.7 4 1.3 0.2890 15 0.7 9 0.8 4 1.3 0.8152 0.2784 0.3979 
coagulopathy 96 2.7 83 2.5 13 4.2 0.0855 51 2.4 32 2.8 13 4.2 0.5207 0.0675 0.2016 
congestive heart failure 616 17.1 561 17.1 55 17.6 0.8015 369 17.3 192 16.6 55 17.6 0.5842 0.8974 0.6604 
deficiency anemias 498 13.8 452 13.8 46 14.7 0.6275 301 14.1 151 13.0 46 14.7 0.3824 0.7749 0.4330 
depression 537 14.9 496 15.1 41 13.1 0.3559 338 15.9 158 13.6 41 13.1 0.0877 0.2128 0.8176 
diabetes (wo/chr complications) 867 24.1 799 24.3 68 21.8 0.3212 526 24.7 273 23.6 68 21.8 0.4701 0.2630 0.5085 
diabetes (w/chr complications) 332 9.2 308 9.4 24 7.7 0.3277 192 9.0 116 10.0 24 7.7 0.3478 0.4412 0.2143 
drug abuse 115 3.2 106 3.2 9 2.9 0.7440 89 4.2 17 1.5 9 2.9 <0.0001 0.2762 0.0920 
fluid and electrolyte disorders 422 11.7 372 11.3 50 16.0 0.0135 252 11.8 120 10.4 50 16.0 0.2026 0.0358 0.0055 
hypertension 2301 63.9 2110 64.2 191 61.2 0.2958 1361 63.9 749 64.7 191 61.2 0.6668 0.3531 0.2583 
hypothyroidism 684 19.0 621 18.9 63 20.2 0.5760 410 19.3 211 18.2 63 20.2 0.4682 0.6965 0.4274 
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Number of Patients 3599   3287   312     2129   1158   312         
liver disease 144 4.0 126 3.8 18 5.8 0.0954 87 4.1 39 3.4 18 5.8 0.3054 0.1712 0.0512 
lymphoma 31 0.9 30 0.9 1 0.3 0.2794 16 0.8 14 1.2 1 0.3 0.1877 0.3926 0.1658 
metastatic cancer 41 1.1 37 1.1 4 1.3 0.8035 23 1.1 14 1.2 4 1.3 0.7384 0.7503 0.9170 
obesity 480 13.3 451 13.7 29 9.3 0.0280 301 14.1 150 13.0 29 9.3 0.3457 0.0195 0.0794 
other neurological disorders 363 10.1 330 10.0 33 10.6 0.7632 232 10.9 98 8.5 33 10.6 0.0265 0.8652 0.2447 
paralysis 48 1.3 46 1.4 2 0.6 0.2644 30 1.4 16 1.4 2 0.6 0.9490 0.2653 0.2910 
peripheral vascular disease 614 17.1 559 17.0 55 17.6 0.7802 343 16.1 216 18.7 55 17.6 0.0639 0.4980 0.6787 
psychoses 399 11.1 375 11.4 24 7.7 0.0457 281 13.2 94 8.1 24 7.7 <0.0001 0.0060 0.8062 
pulmonary circulation disease 435 12.1 370 11.3 65 20.8 <0.0001 232 10.9 138 11.9 65 20.8 0.3768 <0.0001 <0.0001 
renal failure 338 9.4 307 9.3 31 9.9 0.7301 202 9.5 105 9.1 31 9.9 0.6922 0.8015 0.6384 
rheumatoid arthritis/collagen 
vas 
209 5.8 196 6.0 13 4.2 0.1948 122 5.7 74 6.4 13 4.2 0.4453 0.2591 0.1396 
solid tumor wo/metastasis 368 10.2 340 10.3 28 9.0 0.4455 205 9.6 135 11.7 28 9.0 0.0680 0.7133 0.1803 
ulcers     3 0.1     0.5934 2 0.1 1 0.1     0.9452 0.5881 0.6036 
valvular disease 478 13.3 431 13.1 47 15.1 0.3316 282 13.2 149 12.9 47 15.1 0.7587 0.3797 0.3109 
weight loss 219 6.1 197 6.0 22 7.1 0.4550 118 5.5 79 6.8 22 7.1 0.1398 0.2844 0.8871 
any Elixhauser diagnosis 3333 92.6 3056 93.0 277 88.8 0.0069 1994 93.7 1062 91.7 277 88.8 0.0368 0.0016 0.1072 
Other comorbidities                                 
asthma 1166 32.4 1085 33.0 81 26.0 0.0110 866 40.7 219 18.9 81 26.0 <0.0001 <0.0001 0.0061 
hypoxemia 1229 34.1 1079 32.8 150 48.1 <0.0001 662 31.1 417 36.0 150 48.1 0.0041 <0.0001 0.0001 
pneumonia 1348 37.5 1229 37.4 119 38.1 0.7933 830 39.0 399 34.5 119 38.1 0.0104 0.7751 0.2265 
influenza 124 3.4 113 3.4 11 3.5 0.9352 82 3.9 31 2.7 11 3.5 0.0775 0.7788 0.4245 
                                  
COPD Complexity ^                                 
Low complexity 1761 48.9 1652 50.3 109 34.9 <0.0001 1034 48.6 618 53.4 109 34.9 0.0086 <0.0001 <0.0001 
Med complexity 1686 46.8 1505 45.8 181 58.0 <0.0001 1023 48.1 482 41.6 181 58.0 0.0004 0.0010 <0.0001 
High complexity 152 4.2 130 4.0 22 7.1 0.0094 72 3.4 58 5.0 22 7.1 0.0223 0.0017 0.1580 
Emphysema diagnosis (492.x) 694 19.3 598 18.2 96 30.8 <0.0001 343 16.1 255 22.0 96 30.8 <0.0001 <0.0001 0.0013 
                                  
COPD Medications                                 
Index - ICSLABA     2129 64.8                         
Index - LAMA     1158 35.2                         
SABA use                                 
no SABA use 1479 41.1 1350 41.1 129 41.3 0.9248 790 37.1 560 48.4 129 41.3 <0.0001 0.1489 0.0276 
SABA <=15% of year 973 27.0 877 26.7 96 30.8 0.1202 584 27.4 293 25.3 96 30.8 0.1875 0.2193 0.0520 
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SABA <=40% of year 555 15.4 524 15.9 31 9.9 0.0050 363 17.1 161 13.9 31 9.9 0.0186 0.0014 0.0649 
SABA >40% of year 592 16.4 536 16.3 56 17.9 0.4546 392 18.4 144 12.4 56 17.9 <0.0001 0.8434 0.0117 
SAMA use                                 
any ipratropium (SAMA) 391 10.9 346 10.5 45 14.4 0.0345 236 11.1 110 9.5 45 14.4 0.1570 0.0845 0.0120 
any SABA/SAMA 591 16.4 527 16.0 64 20.5 0.0412 387 18.2 140 12.1 64 20.5 <0.0001 0.3209 0.0001 
any SAMA or SABA/SAMA 901 25.0 802 24.4 99 31.7 0.0043 565 26.5 237 20.5 99 31.7 0.0001 0.0542 <0.0001 
Other COPD medications                                 
any ICS 1143 31.8 1050 31.9 93 29.8 0.4386 717 33.7 333 28.8 93 29.8 0.0038 0.1752 0.7164 
any LABA 118 3.3 108 3.3 10 3.2 0.9391 64 3.0 44 3.8 10 3.2 0.2228 0.8481 0.6203 
any methylxanthines 29 0.8 25 0.8 4 1.3 0.3248 17 0.8 8 0.7 4 1.3 0.7343 0.3877 0.3030 
Any use of above COPD 
medications 
1748 48.6 1591 48.4 157 50.3 0.5172 1097 51.5 494 42.7 157 50.3 <0.0001 0.6906 0.0156 
Use of Index Trmts Prior Year§                                 
No ICSLABA in prior year 3206 89.1 2927 89.0 279 89.4 0.8390 1814 85.2 1113 96.1 279 89.4 <0.0001 0.0465 <0.0001 
1-2 Rxs ICSLABA (wks 27-52) 255 7.1 238 7.2 17 5.4 0.2384 206 9.7 32 2.8 17 5.4 <0.0001 0.0155 0.0190 
>2 Rxs ICSLABA (wks 27-52) 138 3.8 122 3.7 16 5.1 0.2130 109 5.1 13 1.1 16 5.1 <0.0001 0.9950 <0.0001 
No LAMA in prior year 3472 96.5 3183 96.8 289 92.6 0.0001 2092 98.3 1091 94.2 289 92.6 <0.0001 <0.0001 0.2997 
1-2 Rxs LAMA (wks 27-52) 86 2.4 72 2.2 14 4.5 0.0111 30 1.4 42 3.6 14 4.5 <0.0001 0.0001 0.4811 
>2 Rxs LAMA (wks 27-52) 41 1.1 32 1.0 9 2.9 0.0024 7 0.3 25 2.2 9 2.9 <0.0001 <0.0001 0.4491 
Oxygen Use                                 
no oxygen 2097 58.3 1928 58.7 169 54.2 0.1244 1283 60.3 645 55.7 169 54.2 0.0112 0.0405 0.6288 
oxygen <=50% of year 619 17.2 559 17.0 60 19.2 0.3197 350 16.4 209 18.0 60 19.2 0.2409 0.2181 0.6316 
oxygen >50% of year 883 24.5 800 24.3 83 26.6 0.3744 496 23.3 304 26.3 83 26.6 0.0593 0.1999 0.9007 
Symptoms                                 
Dyspnea                                 
Breathlessness                                 
no periods breathlessness 2101 58.4 1940 59.0 161 51.6 0.0111 1307 61.4 633 54.7 161 51.6 0.0002 0.0010 0.3357 
1 period breathlessness 757 21.0 679 20.7 78 25.0 0.0720 459 21.6 220 19.0 78 25.0 0.0832 0.1706 0.0193 
>1 period breathlessness 741 20.6 668 20.3 73 23.4 0.1992 363 17.1 305 26.3 73 23.4 <0.0001 0.0063 0.2914 
Shortness of Breath                                 
no periods shortness breath 2260 62.8 2089 63.6 171 54.8 0.0023 1335 62.7 754 65.1 171 54.8 0.1708 0.0074 0.0008 
1 period shortness breath 785 21.8 710 21.6 75 24.0 0.3189 483 22.7 227 19.6 75 24.0 0.0401 0.5954 0.0852 
>1 period shortness breath 554 15.4 488 14.8 66 21.2 0.0032 311 14.6 177 15.3 66 21.2 0.6020 0.0028 0.0133 
any wheezing 302 8.4 267 8.1 35 11.2 0.0595 199 9.3 68 5.9 35 11.2 0.0005 0.2945 0.0010 
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any dyspnea 2126 59.1 1911 58.1 215 68.9 0.0002 1221 57.4 690 59.6 215 68.9 0.2148 0.0001 0.0027 
supplemental oxygen use (V46.2) 112 3.1 102 3.1 10 3.2 0.9210 62 2.9 40 3.5 10 3.2 0.3919 0.7752 0.8294 
Other symptoms                                 
chest pain unspecified 1082 30.1 981 29.8 101 32.4 0.3522 676 31.8 305 26.3 101 32.4 0.0012 0.8263 0.0344 
painful respiratory 165 4.6 149 4.5 16 5.1 0.6310 103 4.8 46 4.0 16 5.1 0.2545 0.8240 0.3673 
precordial pain 72 2.0 68 2.1 4 1.3 0.3429 45 2.1 23 2.0 4 1.3 0.8062 0.3280 0.4110 
any chestpain 1137 31.6 1029 31.3 108 34.6 0.2294 706 33.2 323 27.9 108 34.6 0.0019 0.6109 0.0206 
chronic fatigue 67 1.9 58 1.8 9 2.9 0.1619 33 1.6 25 2.2 9 2.9 0.2053 0.0905 0.4491 
other malaise/fatigue 884 24.6 804 24.5 80 25.6 0.6433 548 25.7 256 22.1 80 25.6 0.0206 0.9703 0.1870 
difficulty walking 105 2.9 98 3.0 7 2.2 0.4592 56 2.6 42 3.6 7 2.2 0.1085 0.6874 0.2270 
memory loss 94 2.6 84 2.6 10 3.2 0.4917 56 2.6 28 2.4 10 3.2 0.7124 0.5588 0.4368 
cough 1394 38.7 1285 39.1 109 34.9 0.1497 862 40.5 423 36.5 109 34.9 0.0262 0.0613 0.6034 
hemoptysis 52 1.4 46 1.4 6 1.9 0.4589 23 1.1 23 2.0 6 1.9 0.0347 0.1995 0.9433 
Procedures                                 
chest CT 551 15.3 495 15.1 56 17.9 0.1756 273 12.8 222 19.2 56 17.9 <0.0001 0.0133 0.6246 
chest x-ray 2234 62.1 2039 62.0 195 62.5 0.8707 1312 61.6 727 62.8 195 62.5 0.5144 0.7665 0.9275 
echocardiography 819 22.8 748 22.8 71 22.8 1.0000 450 21.1 298 25.7 71 22.8 0.0027 0.5143 0.2817 
EKG 1621 45.0 1485 45.2 136 43.6 0.5900 948 44.5 537 46.4 136 43.6 0.3099 0.7554 0.3811 
heart catheterization 51 1.4 47 1.4 4 1.3 0.8328 31 1.5 16 1.4 4 1.3 0.8637 0.8092 0.8927 
nebulizer treatment 1326 36.8 1190 36.2 136 43.6 0.0097 783 36.8 407 35.1 136 43.6 0.3527 0.0204 0.0061 
non-invasive ventilator 210 5.8 195 5.9 15 4.8 0.4179 120 5.6 75 6.5 15 4.8 0.3300 0.5498 0.2751 
spirometry 1578 43.8 1419 43.2 159 51.0 0.0080 819 38.5 600 51.8 159 51.0 <0.0001 <0.0001 0.7893 
any vaccination (flu or 
pneumonia) 
1799 50.0 1646 50.1 153 49.0 0.7261 1047 49.2 599 51.7 153 49.0 0.1626 0.9633 0.3991 
COPD-related exacerbations                                 
Index and 2 weeks prior                                 
any moderate 525 14.6 474 14.4 51 16.3 0.3571 341 16.0 133 11.5 51 16.3 0.0004 0.8824 0.0213 
any severe 266 7.4 224 6.8 42 13.5 <0.0001 190 8.9 34 2.9 42 13.5 <0.0001 0.0107 <0.0001 
any other hospitalizations* 112 3.1 97 3.0 15 4.8 0.0711 80 3.8 17 1.5 15 4.8 0.0002 0.3704 0.0003 
Prior 2-12 weeks                                 
any moderate 585 16.3 536 16.3 49 15.7 0.7831 336 15.8 200 17.3 49 15.7 0.2696 0.9722 0.5128 
any severe 179 5.0 155 4.7 24 7.7 0.0208 101 4.7 54 4.7 24 7.7 0.9169 0.0274 0.0341 
any other hospitalizations* 169 4.7 153 4.7 16 5.1 0.7056 105 4.9 48 4.1 16 5.1 0.3064 0.8814 0.4501 
Prior 13-52 weeks                                 
no moderate 2733 75.9 2505 76.2 228 73.1 0.2161 1596 75.0 909 78.5 228 73.1 0.0231 0.4736 0.0423 
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1 moderate 694 19.3 627 19.1 67 21.5 0.3046 419 19.7 208 18.0 67 21.5 0.2309 0.4587 0.1579 
>1 moderate 172 4.8 155 4.7 17 5.4 0.5618 114 5.4 41 3.5 17 5.4 0.0191 0.9451 0.1244 
any severe 215 6.0 189 5.7 26 8.3 0.0658 136 6.4 53 4.6 26 8.3 0.0331 0.1973 0.0090 
any other hospitalizations* 313 8.7 286 8.7 27 8.7 0.9775 190 8.9 96 8.3 27 8.7 0.5377 0.8754 0.8369 
All Inpatient Utilization                                 
Non-COPD Inpatient (Any) 687 19.1 623 19.0 64 20.5 0.5030 430 20.2 193 16.7 64 20.5 0.0136 0.8969 0.1124 
COPD Inpatient (Any) 636 17.7 555 16.9 81 26.0 <0.0001 403 18.9 152 13.1 81 26.0 <0.0001 0.0036 <0.0001 
Total Inpatient (Any) 1153 32.0 1027 31.2 126 40.4 0.0009 724 34.0 303 26.2 126 40.4 <0.0001 0.0272 <0.0001 
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis  
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity  
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Table 17 PHP Baseline Characteristics 
PHP  
Baseline Characteristic 
Total % ICSLABA 
or LAMA 
% Triple % pval 
ICSLABA 
or LAMA vs 
Triple 
ICS  
LABA 
% LAMA % Triple % pval ICS 
LABA vs 
LAMA 
pval ICS 
LABA 
vs 
Triple 
pval 
LAMA 
vs Triple 
Number of Patients 1876   1704   172     923   781   172         
Age Categories                                 
age 40-54 252 13.4 229 13.4 23 13.4 0.9804 149 16.1 80 10.2 23 13.4 0.0004 0.3592 0.2315 
age 55-64 435 23.2 382 22.4 53 30.8 0.0129 219 23.7 163 20.9 53 30.8 0.1589 0.0483 0.0048 
age 65-74 578 30.8 525 30.8 53 30.8 0.9991 269 29.1 256 32.8 53 30.8 0.1054 0.6590 0.6183 
age 75 and older 611 32.6 568 33.3 43 25.0 0.0262 286 31.0 282 36.1 43 25.0 0.0254 0.1159 0.0054 
age (Mean, SD) 68.57 11.62 68.75 11.64 66.80 11.31 0.0357 67.69 11.91 70.00 11.18 66.80 11.31 <0.0001 0.3639 0.0007 
                                  
Men 777 41.4 694 40.7 83 48.3 0.0561 356 38.6 338 43.3 83 48.3 0.0487 0.0173 0.2340 
                                  
Quarter of Year, Index Date             0.4407             0.0858 0.5159 0.2908 
Q1 534 28.5 479 28.1 55 32.0   252 27.3 227 29.1 55 32.0       
Q2 360 19.2 334 19.6 26 15.1   165 17.9 169 21.6 26 15.1       
Q3 346 18.4 316 18.5 30 17.4   185 20.0 131 16.8 30 17.4       
Q4 636 33.9 575 33.7 61 35.5   321 34.8 254 32.5 61 35.5       
                                  
Months enrollment post-Index             0.6223             0.1006 0.7874 0.3483 
7 34 1.8 28 1.6 6 3.5   14 1.5 14 1.8 6 3.5       
8 27 1.4 24 1.4 3 1.7   14 1.5 10 1.3 3 1.7       
9 35 1.9 32 1.9 3 1.7   18 2.0 14 1.8 3 1.7       
10 29 1.5 25 1.5 4 2.3   11 1.2 14 1.8 4 2.3       
11 22 1.2 21 1.2 1 0.6   12 1.3 9 1.2 1 0.6       
12 21 1.1 19 1.1 2 1.2   11 1.2 8 1.0 2 1.2       
13 32 1.7 31 1.8 1 0.6   13 1.4 18 2.3 1 0.6       
14 36 1.9 30 1.8 6 3.5   20 2.2 10 1.3 6 3.5       
15 35 1.9 31 1.8 4 2.3   14 1.5 17 2.2 4 2.3       
16 45 2.4 41 2.4 4 2.3   22 2.4 19 2.4 4 2.3       
17 37 2.0 34 2.0 3 1.7   11 1.2 23 2.9 3 1.7       
18 34 1.8 33 1.9 1 0.6   11 1.2 22 2.8 1 0.6       
19 35 1.9 33 1.9 2 1.2   13 1.4 20 2.6 2 1.2       
20 38 2.0 36 2.1 2 1.2   20 2.2 16 2.0 2 1.2       
21 42 2.2 38 2.2 4 2.3   22 2.4 16 2.0 4 2.3       
22 35 1.9 33 1.9 2 1.2   15 1.6 18 2.3 2 1.2       
23     27 1.6       15 1.6 12 1.5           
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Number of Patients 1876   1704   172     923   781   172         
24 1312 69.9 1188 69.7 124 72.1   667 72.3 521 66.7 124 72.1       
Insurance at Index                                 
Commercial 402 21.4 359 21.1 43 25.0 0.2310 202 21.9 157 20.1 43 25.0 0.3686 0.3681 0.1533 
Medicaid 371 19.8 337 19.8 34 19.8 0.9976 212 23.0 125 16.0 34 19.8 0.0003 0.3557 0.2309 
Medicare 1103 58.8 1008 59.2 95 55.2 0.3192 509 55.1 499 63.9 95 55.2 0.0003 0.9833 0.0339 
                                  
CMS comorbidities                                  
acute myocardial infarction (AMI) 61 3.3 57 3.3 4 2.3 0.4725 29 3.1 28 3.6 4 2.3 0.6122 0.5653 0.4065 
Alzheimer’s 78 4.2 73 4.3 5 2.9 0.3886 34 3.7 39 5.0 5 2.9 0.1833 0.6138 0.2378 
atrial fibrillation 172 9.2 160 9.4 12 7.0 0.2960 86 9.3 74 9.5 12 7.0 0.9115 0.3235 0.3006 
cancers 105 5.6 99 5.8 6 3.5 0.2068 45 4.9 54 6.9 6 3.5 0.0730 0.4280 0.0940 
lung cancer 38 2.0 34 2.0 4 2.3 0.7695 14 1.5 20 2.6 4 2.3 0.1246 0.4437 0.8585 
chronic kidney disease 244 13.0 220 12.9 24 14.0 0.6984 112 12.1 108 13.8 24 14.0 0.2987 0.5066 0.9657 
diabetes 474 25.3 431 25.3 43 25.0 0.9327 261 28.3 170 21.8 43 25.0 0.0021 0.3782 0.3568 
heart failure 341 18.2 311 18.3 30 17.4 0.7931 173 18.7 138 17.7 30 17.4 0.5676 0.6868 0.9434 
ischemic heart dis. (IHD; incl. 
AMI) 
435 23.2 397 23.3 38 22.1 0.7212 206 22.3 191 24.5 38 22.1 0.2984 0.9480 0.5115 
rheumatoid/osteo arthritis  489 26.1 453 26.6 36 20.9 0.1074 242 26.2 211 27.0 36 20.9 0.7103 0.1434 0.0991 
stroke/TIA 131 7.0 121 7.1 10 5.8 0.5279 61 6.6 60 7.7 10 5.8 0.3899 0.6975 0.3951 
no CMS Comorbidity 666 35.5 590 34.6 76 44.2 0.0125 310 33.6 280 35.9 76 44.2 0.3274 0.0076 0.0408 
                                  
Elixhauser comorbidities                                  
AIDS     1 0.1%     0.7506 1 0.1%         0.3575 0.6658   
alcohol abuse 83 4.4 73 4.3 10 5.8 0.3524 42 4.6 31 4.0 10 5.8 0.5550 0.4744 0.2804 
chronic blood loss anemia     21 1.2     0.1432 14 1.5 7 0.9     0.2474 0.1040 0.2127 
coagulopathy 67 3.6 62 3.6 5 2.9 0.6222 39 4.2 23 2.9 5 2.9 0.1596 0.4189 0.9787 
congestive heart failure 287 15.3 264 15.5 23 13.4 0.4615 147 15.9 117 15.0 23 13.4 0.5909 0.3957 0.5895 
deficiency anemias 275 14.7 252 14.8 23 13.4 0.6166 131 14.2 121 15.5 23 13.4 0.4513 0.7762 0.4820 
depression 380 20.3 341 20.0 39 22.7 0.4076 201 21.8 140 17.9 39 22.7 0.0477 0.7939 0.1489 
diabetes (wo/chr complications) 437 23.3 402 23.6 35 20.3 0.3376 250 27.1 152 19.5 35 20.3 0.0002 0.0645 0.7910 
diabetes (w/chr complications) 110 5.9 98 5.8 12 7.0 0.5144 58 6.3 40 5.1 12 7.0 0.3045 0.7331 0.3322 
drug abuse 66 3.5 59 3.5 7 4.1 0.6803 33 3.6 26 3.3 7 4.1 0.7818 0.7510 0.6305 
fluid and electrolyte disorders 264 14.1 242 14.2 22 12.8 0.6120 125 13.5 117 15.0 22 12.8 0.3968 0.7905 0.4613 
hypertension 1073 57.2 988 58.0 85 49.4 0.0305 553 59.9 435 55.7 85 49.4 0.0790 0.0104 0.1343 
hypothyroidism 348 18.6 315 18.5 33 19.2 0.8219 178 19.3 137 17.5 33 19.2 0.3556 0.9759 0.6101 
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liver disease 68 3.6 66 3.9 2 1.2 0.0699 41 4.4 25 3.2 2 1.2 0.1859 0.0421 0.1447 
lymphoma     15 0.9     0.2167 10 1.1 5 0.6     0.3291 0.1703 0.2927 
metastatic cancer 15 0.8 14 0.8 1 0.6 0.7360 5 0.5 9 1.2 1 0.6 0.1641 0.9484 0.5059 
obesity 237 12.6 220 12.9 17 9.9 0.2548 146 15.8 74 9.5 17 9.9 <0.0001 0.0447 0.8689 
other neurological disorders 151 8.0 141 8.3 10 5.8 0.2582 70 7.6 71 9.1 10 5.8 0.2606 0.4128 0.1630 
paralysis 20 1.1 19 1.1 1 0.6 0.5160 13 1.4 6 0.8 1 0.6 0.2098 0.3754 0.7950 
peripheral vascular disease 264 14.1 234 13.7 30 17.4 0.1824 106 11.5 128 16.4 30 17.4 0.0034 0.0296 0.7368 
psychoses 174 9.3 159 9.3 15 8.7 0.7927 93 10.1 66 8.5 15 8.7 0.2505 0.5843 0.9084 
pulmonary circulation disease 190 10.1 175 10.3 15 8.7 0.5210 101 10.9 74 9.5 15 8.7 0.3201 0.3847 0.7583 
renal failure 130 6.9 118 6.9 12 7.0 0.9796 57 6.2 61 7.8 12 7.0 0.1853 0.6913 0.7097 
rheumatoid arthritis/collagen vas 134 7.1 123 7.2 11 6.4 0.6896 69 7.5 54 6.9 11 6.4 0.6555 0.6172 0.8070 
solid tumor wo/metastasis 165 8.8 153 9.0 12 7.0 0.3769 67 7.3 86 11.0 12 7.0 0.0069 0.8955 0.1148 
ulcers 4 0.2 3 0.2 1 0.6 0.2720 3 0.3     1 0.6 0.1108 0.6089 0.0330 
valvular disease 152 8.1 136 8.0 16 9.3 0.5451 79 8.6 57 7.3 16 9.3 0.3387 0.7505 0.3710 
weight loss 108 5.8 101 5.9 7 4.1 0.3189 53 5.7 48 6.1 7 4.1 0.7250 0.3762 0.2905 
any Elixhauser diagnosis 1695 90.4 1545 90.7 150 87.2 0.1430 852 92.3 693 88.7 150 87.2 0.0115 0.0277 0.5715 
Other comorbidities                                 
asthma 647 34.5 584 34.3 63 36.6 0.5356 407 44.1 177 22.7 63 36.6 <0.0001 0.0693 0.0001 
hypoxemia 765 40.8 677 39.7 88 51.2 0.0036 356 38.6 321 41.1 88 51.2 0.2874 0.0020 0.0158 
pneumonia 560 29.9 501 29.4 59 34.3 0.1807 287 31.1 214 27.4 59 34.3 0.0954 0.4060 0.0699 
influenza 54 2.9 45 2.6 9 5.2 0.0527 32 3.5 13 1.7 9 5.2 0.0208 0.2628 0.0048 
                                  
COPD Complexity ^                                 
Low complexity 979 52.2 904 53.1 75 43.6 0.0181 469 50.8 435 55.7 75 43.6 0.0441 0.0826 0.0040 
Med complexity 824 43.9 734 43.1 90 52.3 0.0198 427 46.3 307 39.3 90 52.3 0.0039 0.1436 0.0017 
High complexity 73 3.9 66 3.9 7 4.1 0.8989 27 2.9 39 5.0 7 4.1 0.0275 0.4269 0.6088 
Emphysema diagnosis (492.x) 516 27.5 450 26.4 66 38.4 0.0008 216 23.4 234 30.0 66 38.4 0.0022 <0.0001 0.0316 
                                  
COPD Medications                                  
Index - ICSLABA     923 54.2                         
Index - LAMA     781 45.8                         
SABA use                                 
no SABA use 835 44.5 769 45.1 66 38.4 0.0892 391 42.4 378 48.4 66 38.4 0.0126 0.3300 0.0170 
SABA <=15% of year 462 24.6 410 24.1 52 30.2 0.0734 207 22.4 203 26.0 52 30.2 0.0862 0.0270 0.2555 
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SABA <=40% of year 248 13.2 232 13.6 16 9.3 0.1115 138 15.0 94 12.0 16 9.3 0.0804 0.0504 0.3098 
SABA >40% of year 331 17.6 293 17.2 38 22.1 0.1083 187 20.3 106 13.6 38 22.1 0.0003 0.5849 0.0047 
SAMA use                                 
any ipratropium (SAMA) 241 12.8 226 13.3 15 8.7 0.0898 143 15.5 83 10.6 15 8.7 0.0032 0.0203 0.4562 
any SABA/SAMA 285 15.2 257 15.1 28 16.3 0.6768 165 17.9 92 11.8 28 16.3 0.0005 0.6137 0.1074 
any SAMA or SABA/SAMA 480 25.6 439 25.8 41 23.8 0.5812 280 30.3 159 20.4 41 23.8 <0.0001 0.0856 0.3105 
Other COPD medications                                 
any ICS 609 32.5 566 33.2 43 25.0 0.0283 323 35.0 243 31.1 43 25.0 0.0901 0.0107 0.1132 
any LABA 109 5.8 103 6.0 6 3.5 0.1720 49 5.3 54 6.9 6 3.5 0.1659 0.3156 0.0940 
any methylxanthines 58 3.1 54 3.2 4 2.3 0.5425 38 4.1 16 2.0 4 2.3 0.0152 0.2614 0.8186 
Any use of above COPD 
medications 
940 50.1 870 51.1 70 40.7 0.0096 503 54.5 367 47.0 70 40.7 0.0020 0.0009 0.1337 
Use of Index Trmts Prior Year§                                 
No ICSLABA in prior year 1662 88.6 1507 88.4 155 90.1 0.5096 751 81.4 756 96.8 155 90.1 <0.0001 0.0053 0.0001 
1-2 Rxs ICSLABA (wks 27-52) 132 7.0 126 7.4 6 3.5 0.0563 110 11.9 16 2.0 6 3.5 <0.0001 0.0010 0.2550 
>2 Rxs ICSLABA (wks 27-52) 82 4.4 71 4.2 11 6.4 0.1730 62 6.7 9 1.2 11 6.4 <0.0001 0.8765 <0.0001 
No LAMA in prior year 1808 96.4 1650 96.8 158 91.9 0.0009 910 98.6 740 94.8 158 91.9 <0.0001 <0.0001 0.1412 
1-2 Rxs LAMA (wks 27-52) 38 2.0 32 1.9 6 3.5 0.1530 11 1.2 21 2.7 6 3.5 0.0233 0.0253 0.5673 
>2 Rxs LAMA (wks 27-52) 30 1.6 22 1.3 8 4.7 0.0008 2 0.2 20 2.6 8 4.7 <0.0001 <0.0001 0.1417 
Oxygen Use                                 
no oxygen 993 52.9 923 54.2 70 40.7 0.0007 494 53.5 429 54.9 70 40.7 0.5610 0.0020 0.0007 
oxygen <=50% of year 257 13.7 222 13.0 35 20.3 0.0078 115 12.5 107 13.7 35 20.3 0.4483 0.0057 0.0266 
oxygen >50% of year 626 33.4 559 32.8 67 39.0 0.1031 314 34.0 245 31.4 67 39.0 0.2458 0.2123 0.0550 
Symptoms                                 
Dyspnea                                 
Breathlessness                                 
no periods breathlessness 1353 72.1 1230 72.1 123 71.5 0.8608 551 80.0 557 80.7 57 86.4 0.7247 0.2102 0.2625 
1 period breathlessness 295 15.7 265 15.5 30 17.4 0.5142 83 12.0 89 12.9 5 7.6 0.6321 0.2796 0.2106 
>1 period breathlessness 229 12.2 210 12.3 19 11.0 0.6276 55 8.0 44 6.4 4 6.1 0.2481 0.5784 0.9198 
Shortness of Breath                                 
no periods shortness breath 1190 63.4 1086 63.7 104 60.5 0.4020 515 74.7 520 75.4 44 66.7 0.7914 0.1527 0.1210 
1 period shortness breath 343 18.3 311 18.2 32 18.6 0.9062 114 16.5 119 17.2 14 21.2 0.7285 0.3345 0.4189 
>1 period shortness breath 344 18.3 308 18.1 36 20.9 0.3545 60 8.7 51 7.4 8 12.1 0.3688 0.3548 0.1711 
any wheezing 117 6.2 107 6.3 10 5.8 0.8113 32 4.6 26 3.8 3 4.5 0.4176 0.9709 0.7534 
any dyspnea 932 49.7 841 49.3 91 52.9 0.3706 260 37.7 261 37.8 28 42.4 0.9724 0.4538 0.4627 
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supplemental oxygen use (V46.2) 206 11.0 178 10.4 28 16.3 0.0195 60 8.7 46 6.7 7 10.6 0.1547 0.6045 0.2311 
Other symptoms                                 
chest pain unspecified 580 30.9 525 30.8 55 32.0 0.7523 294 31.9 231 29.6 55 32.0 0.3108 0.9744 0.5342 
painful respiratory 107 5.7 99 5.8 8 4.7 0.5323 55 6.0 44 5.6 8 4.7 0.7750 0.4989 0.6075 
precordial pain 35 1.9 33 1.9 2 1.2 0.4747 19 2.1 14 1.8 2 1.2 0.6914 0.4316 0.5606 
any chestpain 605 32.2 549 32.2 56 32.6 0.9276 304 32.9 245 31.4 56 32.6 0.4907 0.9228 0.7615 
chronic fatigue 18 1.0 17 1.0 1 0.6 0.5935 9 1.0 8 1.0 1 0.6 0.9188 0.6183 0.5866 
other malaise/fatigue 495 26.4 448 26.3 47 27.3 0.7692 238 25.8 210 26.9 47 27.3 0.6063 0.6726 0.9069 
difficulty walking 34 1.8 31 1.8 3 1.7 0.9439 22 2.4 9 1.2 3 1.7 0.0581 0.6063 0.5286 
memory loss 38 2.0 32 1.9 6 3.5 0.1530 21 2.3 11 1.4 6 3.5 0.1891 0.3462 0.0621 
cough 569 30.3 519 30.5 50 29.1 0.7059 283 30.7 236 30.2 50 29.1 0.8430 0.6771 0.7662 
hemoptysis 24 1.3 21 1.2 3 1.7 0.5692 10 1.1 11 1.4 3 1.7 0.5446 0.4626 0.7404 
Procedures                                 
chest CT 271 14.4 241 14.1 30 17.4 0.2409 144 15.6 97 12.4 30 17.4 0.0604 0.5444 0.0794 
chest x-ray 1198 63.9 1079 63.3 119 69.2 0.1271 575 62.3 504 64.5 119 69.2 0.3400 0.0851 0.2456 
echocardiography 294 15.7 271 15.9 23 13.4 0.3841 149 16.1 122 15.6 23 13.4 0.7691 0.3592 0.4572 
EKG 831 44.3 753 44.2 78 45.3 0.7706 404 43.8 349 44.7 78 45.3 0.7044 0.7018 0.8743 
heart catheterization 20 1.1 17 1.0 3 1.7 0.3636 7 0.8 10 1.3 3 1.7 0.2800 0.2121 0.6350 
nebulizer treatment 445 23.7 396 23.2 49 28.5 0.1230 226 24.5 170 21.8 49 28.5 0.1856 0.2664 0.0579 
non-invasive ventilator 129 6.9 115 6.7 14 8.1 0.4921 67 7.3 48 6.1 14 8.1 0.3615 0.6854 0.3372 
spirometry 706 37.6 622 36.5 84 48.8 0.0015 335 36.3 287 36.7 84 48.8 0.8465 0.0019 0.0032 
any vaccination (flu or 
pneumonia) 
833 44.4 758 44.5 75 43.6 0.8250 412 44.6 346 44.3 75 43.6 0.8898 0.8025 0.8676 
COPD-related exacerbations                                 
Index and 2 weeks prior                                 
any moderate 258 13.8 234 13.7 24 14.0 0.9360 117 12.7 117 15.0 24 14.0 0.1684 0.6461 0.7312 
any severe 168 9.0 143 8.4 25 14.5 0.0072 81 8.8 62 7.9 25 14.5 0.5346 0.0190 0.0065 
any other hospitalizations* 12 0.6 10 0.6 2 1.2 0.3665 3 0.3 7 0.9 2 1.2 0.1240 0.1346 0.7436 
Prior 2-12 weeks                                 
any moderate 309 16.5 270 15.8 39 22.7 0.0214 152 16.5 118 15.1 39 22.7 0.4439 0.0489 0.0155 
any severe 158 8.4 138 8.1 20 11.6 0.1122 88 9.5 50 6.4 20 11.6 0.0182 0.3978 0.0174 
any other hospitalizations* 40 2.1 37 2.2 3 1.7 0.7117 17 1.8 20 2.6 3 1.7 0.3103 0.9300 0.5275 
Prior 13-52 weeks                                 
no moderate 1467 78.2 1330 78.1 137 79.7 0.6282 701 75.9 629 80.5 137 79.7 0.0226 0.2928 0.7910 
1 moderate 324 17.3 293 17.2 31 18.0 0.7841 168 18.2 125 16.0 31 18.0 0.2312 0.9556 0.5173 
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>1 moderate 85 4.5 81 4.8 4 2.3 0.1445 54 5.9 27 3.5 4 2.3 0.0207 0.0581 0.4489 
any severe 194 10.3 172 10.1 22 12.8 0.2683 101 10.9 71 9.1 22 12.8 0.2061 0.4810 0.1388 
any other hospitalizations* 71 3.8 66 3.9 5 2.9 0.5268 40 4.3 26 3.3 5 2.9 0.2842 0.3868 0.7776 
All Inpatient Utilization                                 
Non-COPD Inpatient (Any) 165 8.8 150 8.8 15 8.7 0.9712 87 9.4 63 8.1 15 8.7 0.3238 0.7703 0.7769 
COPD Inpatient (Any) 481 25.6 428 25.1 53 30.8 0.1030 248 26.9 180 23.0 53 30.8 0.0699 0.2873 0.0319 
Total Inpatient (Any) 537 28.6 483 28.3 54 31.4 0.3990 284 30.8 199 25.5 54 31.4 0.0158 0.8704 0.1118 
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity  
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Table 18 Combined LHP and PHP Baseline Characteristic 
LHP & PHP  
Baseline Characteristic 
Total % ICS LABA 
or LAMA 
% Triple % pval ICS 
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Number of Patients 5475   4991   484     3052   1939   484         
Age Categories                                 
age 40-54 584 10.7 538 10.8 46 9.5 0.3855 387 12.7 151 7.8 46 9.5 <0.0001 0.0477 0.2164 
age 55-64 1026 18.7 908 18.2 118 24.4 0.0009 601 19.7 307 15.8 118 24.4 0.0006 0.0173 <0.0001 
age 65-74 1637 29.9 1499 30.0 138 28.5 0.4851 868 28.4 631 32.5 138 28.5 0.0021 0.9740 0.0884 
age 75 and older 2228 40.7 2046 41.0 182 37.6 0.1471 1196 39.2 850 43.8 182 37.6 0.0011 0.5068 0.0131 
age (Mean, SD) 70.55 11.51 70.60 11.53 70.02 11.29 0.2903 69.83 11.90 71.82 10.80 70.02 11.29 <0.0001 0.7386 0.0012 
                                  
Men 2393 43.7 2145 43.0 248 51.2 0.0005 1259 41.3 886 45.7 248 51.2 0.0020 <0.0001 0.0287 
                                  
Quarter of Year for Index Date             0.0801             0.1949 0.2450 0.0176 
Q1 1645 30.0 1477 29.6 168 34.7   932 30.5 545 28.1 168 34.7       
Q2 1160 21.2 1073 21.5 87 18.0   632 20.7 441 22.7 87 18.0       
Q3 1192 21.8 1092 21.9 100 20.7   667 21.9 425 21.9 100 20.7       
Q4 1478 27.0 1349 27.0 129 26.7   821 26.9 528 27.2 129 26.7       
                                  
Months of enrollment post-Index             0.7583             0.4954 0.7715 0.7212 
7 78 1.4 69 1.4 9 1.9   44 1.4 25 1.3 9 1.9       
8 66 1.2 60 1.2 6 1.2   39 1.3 21 1.1 6 1.2       
9 85 1.6 76 1.5 9 1.9   45 1.5 31 1.6 9 1.9       
10 99 1.8 85 1.7 14 2.9   50 1.6 35 1.8 14 2.9       
11 117 2.1 105 2.1 12 2.5   71 2.3 34 1.8 12 2.5       
12 92 1.7 86 1.7 6 1.2   62 2.0 24 1.2 6 1.2       
13 99 1.8 92 1.8 7 1.4   51 1.7 41 2.1 7 1.4       
14 111 2.0 98 2.0 13 2.7   63 2.1 35 1.8 13 2.7       
15 97 1.8 91 1.8 6 1.2   54 1.8 37 1.9 6 1.2       
16 127 2.3 118 2.4 9 1.9   74 2.4 44 2.3 9 1.9       
17 114 2.1 103 2.1 11 2.3   56 1.8 47 2.4 11 2.3       
18 106 1.9 96 1.9 10 2.1   53 1.7 43 2.2 10 2.1       
19 104 1.9 93 1.9 11 2.3   56 1.8 37 1.9 11 2.3       
20 105 1.9 99 2.0 6 1.2   67 2.2 32 1.7 6 1.2       
21 105 1.9 92 1.8 13 2.7   62 2.0 30 1.5 13 2.7       
22 114 2.1 102 2.0 12 2.5   65 2.1 37 1.9 12 2.5       
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23 91 1.7 82 1.6 9 1.9   51 1.7 31 1.6 9 1.9       
24 3765 68.8 3444 69.0 321 66.3   2089 68.4 1355 69.9 321 66.3       
Insurance at Index                                 
Commercial 1778 32.5 1606 32.2 172 35.5 0.1319 1030 33.7 576 29.7 172 35.5 0.0029 0.4402 0.0130 
Medicaid 655 12.0 594 11.9 61 12.6 0.6496 414 13.6 180 9.3 61 12.6 <0.0001 0.5644 0.0290 
Medicare 3071 56.1 2818 56.5 253 52.3 0.0762 1627 53.3 1191 61.4 253 52.3 <0.0001 0.6711 0.0002 
                                  
CMS comorbidities                                  
acute myocardial infarction (AMI) 175 3.2 161 3.2 14 2.9 0.6907 98 3.2 63 3.2 14 2.9 0.9408 0.7102 0.6891 
Alzheimer’s 189 3.5 177 3.5 12 2.5 0.2196 104 3.4 73 3.8 12 2.5 0.5060 0.2868 0.1691 
atrial fibrillation 534 9.8 490 9.8 44 9.1 0.6069 290 9.5 200 10.3 44 9.1 0.3470 0.7739 0.4236 
cancers 370 6.8 344 6.9 26 5.4 0.2033 200 6.6 144 7.4 26 5.4 0.2351 0.3236 0.1134 
lung cancer 113 2.1 100 2.0 13 2.7 0.3134 45 1.5 55 2.8 13 2.7 0.0008 0.0512 0.8576 
chronic kidney disease 870 15.9 789 15.8 81 16.7 0.5943 479 15.7 310 16.0 81 16.7 0.7821 0.5601 0.6891 
diabetes 1358 24.8 1243 24.9 115 23.8 0.5778 794 26.0 449 23.2 115 23.8 0.0228 0.2915 0.7785 
heart failure 986 18.0 891 17.9 95 19.6 0.3316 549 18.0 342 17.6 95 19.6 0.7528 0.3851 0.3084 
ischemic heart dis. (IHD; incl. 
AMI) 
1343 24.5 1214 24.3 129 26.7 0.2555 705 23.1 509 26.3 129 26.7 0.0114 0.0871 0.8574 
rheumatoid/osteo arthritis  1443 26.4 1349 27.0 94 19.4 0.0003 829 27.2 520 26.8 94 19.4 0.7893 0.0003 0.0008 
stroke/TIA 387 7.1 353 7.1 34 7.0 0.9687 208 6.8 145 7.5 34 7.0 0.3733 0.8653 0.7331 
no CMS Comorbidity 1860 34.0 1676 33.6 184 38.0 0.0491 1011 33.1 665 34.3 184 38.0 0.3935 0.0346 0.1248 
Elixhauser comorbidities (Baseline 
Per.) 
                                
AIDS 10 0.2 9 0.2 1 0.2 0.8971 8 0.3 1 0.1 1 0.2 0.0875 0.8218 0.2880 
alcohol abuse 191 3.5 170 3.4 21 4.3 0.2856 113 3.7 57 2.9 21 4.3 0.1476 0.4958 0.1187 
chronic blood loss anemia 49 0.9 45 0.9 4 0.8 0.8668 29 1.0 16 0.8 4 0.8 0.6488 0.7925 0.9978 
coagulopathy 163 3.0 145 2.9 18 3.7 0.3145 90 2.9 55 2.8 18 3.7 0.8178 0.3603 0.3096 
congestive heart failure 903 16.5 825 16.5 78 16.1 0.8147 516 16.9 309 15.9 78 16.1 0.3681 0.6653 0.9231 
deficiency anemias 773 14.1 704 14.1 69 14.3 0.9275 432 14.2 272 14.0 69 14.3 0.9002 0.9525 0.8972 
depression 917 16.7 837 16.8 80 16.5 0.8920 539 17.7 298 15.4 80 16.5 0.0347 0.5428 0.5292 
diabetes (wo/chr complications) 1304 23.8 1201 24.1 103 21.3 0.1701 776 25.4 425 21.9 103 21.3 0.0047 0.0500 0.7612 
diabetes (w/chr complications) 442 8.1 406 8.1 36 7.4 0.5912 250 8.2 156 8.0 36 7.4 0.8541 0.5723 0.6581 
drug abuse 181 3.3 165 3.3 16 3.3 0.9998 122 4.0 43 2.2 16 3.3 0.0006 0.4654 0.1647 
fluid and electrolyte disorders 686 12.5 614 12.3 72 14.9 0.1024 377 12.4 237 12.2 72 14.9 0.8918 0.1214 0.1175 
hypertension 3374 61.6 3098 62.1 276 57.0 0.0293 1914 62.7 1184 61.1 276 57.0 0.2415 0.0166 0.1044 
  
 
1
2
5 
LHP & PHP  
Baseline Characteristic 
Total % ICS LABA 
or LAMA 
% Triple % pval ICS 
LABA or 
LAMA vs 
Triple 
ICS 
LABA 
% LAMA % Triple % pval ICS 
LABA vs 
LAMA 
pval ICS 
LABA 
vs 
Triple 
pval 
LAMA vs 
Triple 
Number of Patients 5475   4991   484     3052   1939   484         
hypothyroidism 1032 18.8 936 18.8 96 19.8 0.5615 588 19.3 348 17.9 96 19.8 0.2447 0.7686 0.3370 
liver disease 212 3.9 192 3.8 20 4.1 0.7561 128 4.2 64 3.3 20 4.1 0.1097 0.9498 0.3710 
lymphoma 46 0.8 45 0.9 1 0.2 0.1097 26 0.9 19 1.0 1 0.2 0.6410 0.1297 0.0926 
metastatic cancer 56 1.0 51 1.0 5 1.0 0.9813 28 0.9 23 1.2 5 1.0 0.3575 0.8059 0.7780 
obesity 717 13.1 671 13.4 46 9.5 0.0142 447 14.6 224 11.6 46 9.5 0.0018 0.0024 0.2002 
other neurological disorders 514 9.4 471 9.4 43 8.9 0.6906 302 9.9 169 8.7 43 8.9 0.1648 0.4863 0.9066 
paralysis 68 1.2 65 1.3 3 0.6 0.1955 43 1.4 22 1.1 3 0.6 0.4048 0.1546 0.3161 
peripheral vascular disease 878 16.0 793 15.9 85 17.6 0.3381 449 14.7 344 17.7 85 17.6 0.0043 0.1037 0.9264 
psychoses 573 10.5 534 10.7 39 8.1 0.0699 374 12.3 160 8.3 39 8.1 <0.0001 0.0076 0.8895 
pulmonary circulation disease 625 11.4 545 10.9 80 16.5 0.0002 333 10.9 212 10.9 80 16.5 0.9801 0.0004 0.0007 
renal failure 468 8.5 425 8.5 43 8.9 0.7816 259 8.5 166 8.6 43 8.9 0.9264 0.7710 0.8208 
rheumatoid arthritis/collagen vas 343 6.3 319 6.4 24 5.0 0.2142 191 6.3 128 6.6 24 5.0 0.6290 0.2664 0.1825 
solid tumor wo/metastasis 533 9.7 493 9.9 40 8.3 0.2530 272 8.9 221 11.4 40 8.3 0.0041 0.6407 0.0467 
ulcers 7 0.1 6 0.1 1 0.2 0.6116 5 0.2 1 0.1 1 0.2 0.2646 0.8317 0.2880 
valvular disease 630 11.5 567 11.4 63 13.0 0.2757 361 11.8 206 10.6 63 13.0 0.1913 0.4547 0.1339 
weight loss 327 6.0 298 6.0 29 6.0 0.9852 171 5.6 127 6.5 29 6.0 0.1688 0.7308 0.6545 
any Elixhauser diagnosis 5028 91.8 4601 92.2 427 88.2 0.0024 2846 93.3 1755 90.5     0.0004   0.1325 
Other comorbidities                       427 88.2   <0.0001   
asthma 1813 33.1 1669 33.4 144 29.8 0.0997 1273 41.7 396 20.4 144 29.8 <0.0001 <0.0001 <0.0001 
hypoxemia 1994 36.4 1756 35.2 238 49.2 <0.0001 1018 33.4 738 38.1 238 49.2 0.0007 <0.0001 <0.0001 
pneumonia 1908 34.8 1730 34.7 178 36.8 0.3513 1117 36.6 613 31.6 178 36.8 0.0003 0.9398 0.0303 
influenza 178 3.3 158 3.2 20 4.1 0.2523 114 3.7 44 2.3 20 4.1 0.0039 0.6709 0.0222 
                                  
COPD Complexity ^                                 
Low complexity 2740 50.0 2556 51.2 184 38.0 <0.0001 1503 49.2 1053 54.3 184 38.0 0.0005 <0.0001 <0.0001 
Med complexity 2510 45.8 2239 44.9 271 56.0 <0.0001 1450 47.5 789 40.7 271 56.0 <0.0001 0.0005 <0.0001 
High complexity 225 4.1 196 3.9 29 6.0 0.0289 99 3.2 97 5.0 29 6.0 0.0018 0.0026 0.3806 
Emphysema diagnosis (492.x) 1210 22.1 1048 21.0 162 33.5 <0.0001 559 18.3 489 25.2 162 33.5 <0.0001 <0.0001 0.0002 
                                  
COPD Medications                                  
Index - ICSLABA     923 54.2                         
Index - LAMA     781 45.8                         
SABA use                                 
no SABA use 2314 42.3 2119 42.5 195 40.3 0.3568 1181 38.7 938 48.4 195 40.3 <0.0001 0.5042 0.0014 
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LHP & PHP  
Baseline Characteristic 
Total % ICS LABA 
or LAMA 
% Triple % pval ICS 
LABA or 
LAMA vs 
Triple 
ICS 
LABA 
% LAMA % Triple % pval ICS 
LABA vs 
LAMA 
pval ICS 
LABA 
vs 
Triple 
pval 
LAMA vs 
Triple 
Number of Patients 5475   4991   484     3052   1939   484         
SABA <=15% of year 1435 26.2 1287 25.8 148 30.6 0.0221 791 25.9 496 25.6 148 30.6 0.7907 0.0310 0.0260 
SABA <=40% of year 803 14.7 756 15.1 47 9.7 0.0012 501 16.4 255 13.2 47 9.7 0.0017 0.0002 0.0404 
SABA >40% of year 923 16.9 829 16.6 94 19.4 0.1147 579 19.0 250 12.9 94 19.4 <0.0001 0.8146 0.0002 
SAMA use                                 
any ipratropium (SAMA) 632 11.5 572 11.5 60 12.4 0.5383 379 12.4 193 10.0 60 12.4 0.0077 0.9894 0.1159 
any SABA/SAMA 876 16.0 784 15.7 92 19.0 0.0587 552 18.1 232 12.0 92 19.0 <0.0001 0.6254 <0.0001 
any SAMA or SABA/SAMA 1381 25.2 1241 24.9 140 28.9 0.0495 845 27.7 396 20.4 140 28.9 <0.0001 0.5722 <0.0001 
Other COPD medications                                 
any ICS 1752 32.0 1616 32.4 136 28.1 0.0540 1040 34.1 576 29.7 136 28.1 0.0013 0.0095 0.4875 
any LABA 227 4.1 211 4.2 16 3.3 0.3314 113 3.7 98 5.1 16 3.3 0.0207 0.6654 0.1042 
any methylxanthines 87 1.6 79 1.6 8 1.7 0.9063 55 1.8 24 1.2 8 1.7 0.1195 0.8177 0.4742 
Any use of above COPD 
medications 
2688 49.1 2461 49.3 227 46.9 0.3117 1600 52.4 861 44.4 227 46.9 <0.0001 0.0239 0.3233 
Use of Index Trmts Prior Year§                                 
No ICSLABA in prior year 4868 88.9 4434 88.8 434 89.7 0.5789 2565 84.0 1869 96.4 434 89.7 <0.0001 0.0014 <0.0001 
1-2 Rxs ICSLABA (wks 27-52) 387 7.1 364 7.3 23 4.8 0.0373 316 10.4 48 2.5 23 4.8 <0.0001 0.0001 0.0079 
>2 Rxs ICSLABA (wks 27-52) 220 4.0 193 3.9 27 5.6 0.0672 171 5.6 22 1.1 27 5.6 <0.0001 0.9827 <0.0001 
No LAMA in prior year 5280 96.4 4833 96.8 447 92.4 <0.0001 3002 98.4 1831 94.4 447 92.4 <0.0001 <0.0001 0.0852 
1-2 Rxs LAMA (wks 27-52) 124 2.3 104 2.1 20 4.1 0.0038 41 1.3 63 3.2 20 4.1 <0.0001 <0.0001 0.3393 
>2 Rxs LAMA (wks 27-52) 71 1.3 54 1.1 17 3.5 <0.0001 9 0.3 45 2.3 17 3.5 <0.0001 <0.0001 0.1375 
Oxygen Use                                 
no oxygen 3090 56.4 2851 57.1 239 49.4 0.0010 1777 58.2 1074 55.4 239 49.4 0.0486 0.0003 0.0176 
oxygen <=50% of year 876 16.0 781 15.6 95 19.6 0.0226 465 15.2 316 16.3 95 19.6 0.3145 0.0139 0.0807 
oxygen >50% of year 1509 27.6 1359 27.2 150 31.0 0.0769 810 26.5 549 28.3 150 31.0 0.1701 0.0408 0.2447 
Symptoms                                 
Dyspnea                                 
Breathlessness                                 
no periods breathlessness 3454 63.1 3170 63.5 284 58.7 0.0353 1964 64.4 1206 62.2 284 58.7 0.1233 0.0160 0.1546 
1 period breathlessness 1051 19.2 943 18.9 108 22.3 0.0681 605 19.8 338 17.4 108 22.3 0.0354 0.2045 0.0132 
>1 period breathlessness 970 17.7 878 17.6 92 19.0 0.4358 483 15.8 395 20.4 92 19.0 <0.0001 0.0779 0.5032 
Shortness of Breath                                 
no periods shortness breath 3450 63.0 3175 63.6 275 56.8 0.0031 1925 63.1 1250 64.5 275 56.8 0.3188 0.0084 0.0018 
1 period shortness breath 1128 20.6 1021 20.5 107 22.1 0.3913 644 21.1 377 19.4 107 22.1 0.1570 0.6150 0.1897 
>1 period shortness breath 897 16.4 795 15.9 102 21.1 0.0035 483 15.8 312 16.1 102 21.1 0.8030 0.0039 0.0092 
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LHP & PHP  
Baseline Characteristic 
Total % ICS LABA 
or LAMA 
% Triple % pval ICS 
LABA or 
LAMA vs 
Triple 
ICS 
LABA 
% LAMA % Triple % pval ICS 
LABA vs 
LAMA 
pval ICS 
LABA 
vs 
Triple 
pval 
LAMA vs 
Triple 
Number of Patients 5475   4991   484     3052   1939   484         
any wheezing 419 7.7 374 7.5 45 9.3 0.1540 268 8.8 106 5.5 45 9.3 <0.0001 0.7102 0.0018 
any dyspnea 3057 55.8 2751 55.1 306 63.2 0.0006 1686 55.2 1065 54.9 306 63.2 0.8262 0.0010 0.0010 
supplemental oxygen use (V46.2) 317 5.8 279 5.6 38 7.9 0.0420 169 5.5 110 5.7 38 7.9 0.8389 0.0440 0.0734 
Other symptoms                                 
chest pain unspecified 1662 30.4 1506 30.2 156 32.2 0.3473 970 31.8 536 27.6 156 32.2 0.0019 0.8438 0.0456 
painful respiratory 272 5.0 248 5.0 24 5.0 0.9921 158 5.2 90 4.6 24 5.0 0.3962 0.8400 0.7682 
precordial pain 107 2.0 101 2.0 6 1.2 0.2342 64 2.1 37 1.9 6 1.2 0.6443 0.2084 0.3190 
any chestpain 1742 31.8 1578 31.6 164 33.9 0.3065 1010 33.1 568 29.3 164 33.9 0.0049 0.7313 0.0491 
chronic fatigue 85 1.6 75 1.5 10 2.1 0.3384 42 1.4 33 1.7 10 2.1 0.3565 0.2414 0.5872 
other malaise/fatigue 1379 25.2 1252 25.1 127 26.2 0.5764 786 25.8 466 24.0 127 26.2 0.1717 0.8204 0.3124 
difficulty walking 139 2.5 129 2.6 10 2.1 0.4887 78 2.6 51 2.6 10 2.1 0.8715 0.5206 0.4785 
memory loss 132 2.4 116 2.3 16 3.3 0.1789 77 2.5 39 2.0 16 3.3 0.2423 0.3174 0.0872 
cough 1963 35.9 1804 36.1 159 32.9 0.1491 1145 37.5 659 34.0 159 32.9 0.0114 0.0481 0.6366 
hemoptysis 76 1.4 67 1.3 9 1.9 0.3532 33 1.1 34 1.8 9 1.9 0.0443 0.1420 0.8744 
Procedures                                 
chest CT 822 15.0 736 14.7 86 17.8 0.0756 417 13.7 319 16.5 86 17.8 0.0068 0.0163 0.4873 
chest x-ray 3432 62.7 3118 62.5 314 64.9 0.2965 1887 61.8 1231 63.5 314 64.9 0.2383 0.1988 0.5694 
echocardiography 1113 20.3 1019 20.4 94 19.4 0.6034 599 19.6 420 21.7 94 19.4 0.0823 0.9159 0.2811 
EKG 2452 44.8 2238 44.8 214 44.2 0.7915 1352 44.3 886 45.7 214 44.2 0.3342 0.9724 0.5589 
heart catheterization 71 1.3 64 1.3 7 1.4 0.7608 38 1.2 26 1.3 7 1.4 0.7693 0.7137 0.8580 
nebulizer treatment 1771 32.3 1586 31.8 185 38.2 0.0038 1009 33.1 577 29.8 185 38.2 0.0146 0.0257 0.0003 
non-invasive ventilator 339 6.2 310 6.2 29 6.0 0.8483 187 6.1 123 6.3 29 6.0 0.7576 0.9080 0.7753 
spirometry 2284 41.7 2041 40.9 243 50.2 <0.0001 1154 37.8 887 45.7 243 50.2 <0.0001 <0.0001 0.0784 
any vaccination (flu or 
pneumonia) 
2632 48.1 2404 48.2 228 47.1 0.6561 1459 47.8 945 48.7 228 47.1 0.5208 0.7754 0.5212 
COPD-related exacerbations                                 
Index and 2 weeks prior                                 
any moderate 783 14.3 708 14.2 75 15.5 0.4318 458 15.0 250 12.9 75 15.5 0.0370 0.7798 0.1328 
any severe 434 7.9 367 7.4 67 13.8 <0.0001 271 8.9 96 5.0 67 13.8 <0.0001 0.0006 <0.0001 
any other hospitalizations* 124 2.3 107 2.1 17 3.5 0.0533 83 2.7 24 1.2 17 3.5 0.0004 0.3283 0.0005 
Prior 2-12 weeks                                 
any moderate 894 16.3 806 16.1 88 18.2 0.2480 488 16.0 318 16.4 88 18.2 0.7008 0.2250 0.3478 
any severe 337 6.2 293 5.9 44 9.1 0.0049 189 6.2 104 5.4 44 9.1 0.2246 0.0170 0.0022 
any other hospitalizations* 209 3.8 190 3.8 19 3.9 0.8964 122 4.0 68 3.5 19 3.9 0.3775 0.9402 0.6579 
Prior 13-52 weeks                                 
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LHP & PHP  
Baseline Characteristic 
Total % ICS LABA 
or LAMA 
% Triple % pval ICS 
LABA or 
LAMA vs 
Triple 
ICS 
LABA 
% LAMA % Triple % pval ICS 
LABA vs 
LAMA 
pval ICS 
LABA 
vs 
Triple 
pval 
LAMA vs 
Triple 
Number of Patients 5475   4991   484     3052   1939   484         
no moderate 4200 76.7 3835 76.8 365 75.4 0.4788 2297 75.3 1538 79.3 365 75.4 0.0009 0.9429 0.0611 
1 moderate 1018 18.6 920 18.4 98 20.2 0.3272 587 19.2 333 17.2 98 20.2 0.0674 0.5998 0.1136 
>1 moderate 257 4.7 236 4.7 21 4.3 0.6988 168 5.5 68 3.5 21 4.3 0.0012 0.2895 0.3841 
any severe 409 7.5 361 7.2 48 9.9 0.0320 237 7.8 124 6.4 48 9.9 0.0685 0.1061 0.0069 
any other hospitalizations* 384 7.0 352 7.1 32 6.6 0.7167 230 7.5 122 6.3 32 6.6 0.0943 0.4707 0.7965 
All Inpatient Utilization                                 
Non-COPD Inpatient (Any) 852 15.6 773 15.5 79 16.3 0.6287 517 16.9 256 13.2 79 16.3 0.0004 0.7361 0.0753 
COPD Inpatient (Any) 1117 20.4 983 19.7 134 27.7 <0.0001 651 21.3 332 17.1 134 27.7 0.0003 0.0018 <0.0001 
Total Inpatient (Any) 1690 30.9 1510 30.3 180 37.2 0.0016 1008 33.0 502 25.9 180 37.2 <0.0001 0.0717 <0.0001 
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 19 LHP Baseline Healthcare Costs (Means) 
LHP  
Baseline Characteristic 
Total SD ICS 
LABA 
LAMA 
SD Triple SD pval 
Comb vs 
Triple 
ICS 
LABA 
SD LAMA SD Triple SD ICS 
LABA vs 
LAMA 
ICS 
LABA vs 
Triple 
LAMA 
vs Triple 
Number of Patients 3599   3287   312     2129   1158   312    p-values  
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient Utilization 5426 8291 5476 8473 4896 6028 0.1191 5574 8938 5298 7544 4896 6028 0.3487 0.0846 0.3236 
COPD Outpatient Utilization 1786 2213 1765 2184 2018 2483 0.0833 1704 2229 1875 2097 2018 2483 0.0289 0.0357 0.355 
Total Outpatient Utilization 7212 9094 7241 9240 6913 7392 0.4653 7278 9720 7173 8289 6913 7392 0.745 0.4367 0.5917 
                                  
Non-COPD Inpatient Utilization 6913 24336 6921 24700 6820 20140 0.9339 7143 25789 6513 22567 6820 20140 0.4675 0.7992 0.816 
COPD Inpatient Utilization 5019 19696 4779 18567 7548 28957 0.0985 5301 19359 3819 16980 7548 28957 0.0231 0.1852 0.0302 
Total Inpatient Utilization 11932 32612 11701 32213 14368 36518 0.2139 12445 33466 10332 29739 14368 36518 0.063 0.3806 0.0729 
Total Medical Utilization 19144 35393 18941 35145 21281 37904 0.2645 19722 36575 17505 32317 21281 37904 0.0732 0.4842 0.1083 
                                  
Non-COPD Outpatient Rx 2635 4381 2669 4467 2282 3331 0.0588 2724 4407 2567 4574 2282 3331 0.3359 0.0371 0.2189 
COPD Outpatient Rx 409 799 399 764 515 1101 0.0709 419 795 363 701 515 1101 0.0397 0.1385 0.0218 
Total Outpatient Rx 3043 4510 3067 4587 2797 3591 0.2167 3141 4534 2930 4684 2797 3591 0.2079 0.1276 0.5863 
                                  
Total Healthcare Services 22188 36262 22008 36016 24078 38763 0.3354 22864 37293 20436 33502 24078 38763 0.0567 0.5932 0.1307 
Cost of Utilization ($ mean, SD)  - for those with utilization within category  
Non-COPD Outpatient Utilization 5512 8328 5552 8507 5074 6063 0.2093 5667 8983 5344 7561 5074 6063 0.2773 0.1402 0.5163 
COPD Outpatient Utilization 1928 2239 1901 2209 2216 2517 0.0421 1851 2264 1991 2106 2216 2517 0.0883 0.0212 0.165 
Total Outpatient Utilization 7226 9097 7252 9242 6958 7395 0.5136 7295 9725 7173 8289 6958 7395 0.7053 0.4735 0.6576 
                                  
Non-COPD Inpatient Utilization 36213 45208 36517 46267 33248 33312 0.4751 35368 47942 39079 42304 33248 33312 0.3323 0.6573 0.2604 
COPD Inpatient Utilization 28403 39151 28305 37117 29073 51244 0.8968 28007 36694 29097 38327 29073 51244 0.758 0.8588 0.9971 
Total Inpatient Utilization 37244 48767 37448 48562 35578 50570 0.6847 36595 49105 39488 47257 35578 50570 0.3842 0.8309 0.445 
Total Medical Utilization 19144 35393 18941 35145 21281 37904 0.2645 19722 36575 17505 32317 21281 37904 0.0732 0.4842 0.1083 
                                  
Non-COPD Outpatient Rx 2693 4411 2719 4493 2405 3376 0.1389 2761 4426 2640 4618 2405 3376 0.4637 0.1041 0.3281 
COPD Outpatient Rx 409 799 399 764 515 1101 0.0709 419 795 363 701 515 1101 0.0397 0.1385 0.0218 
Total Outpatient Rx 3043 4510 3067 4587 2797 3591 0.2167 3141 4534 2930 4684 2797 3591 0.2079 0.1276 0.5863 
                                  
Total Healthcare Services 22188 36262 22008 36016 24078 38763 0.3354 22864 37293 20436 33502 24078 38763 0.0567 0.5932 0.1307 
Length of Stay  (for inpatient stays) 7.3 8.6 7.2 8.6 7.5 8.0 0.7046 7.1 8.3 7.7 9.5 7.5 8.0 0.344 0.544 0.9039 
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Table 20 LHP Baseline Healthcare Costs (Medians) 
  
Total   ICS 
LABA or 
LAMA 
  Triple   pval 
Comb vs 
Triple* 
ICS 
LABA 
  LAMA   Triple   ICS LABA 
vs LAMA 
ICS LABA 
vs Triple 
LAMA vs 
Triple 
Median 3599   3287   312     2129   1158   312    p-values  
Cost of Utilization ($)                                  
Non-COPD Outpatient Utilization 3361   3372   2944   0.1629 3324   3446   2944   0.9348 0.1641 0.2124 
COPD Outpatient Utilization 1038   1016   1215   0.1432 955   1143   1215   0.0003 0.0311 0.9258 
Total Outpatient Utilization 4924   4941   4553   0.5491 4881   5098   4553   0.2495 0.7219 0.3386 
                                  
Non-COPD Inpatient Utilization 0   0   0   0.4702 0   0   0   0.0279 0.8040 0.1305 
COPD Inpatient Utilization 0   0   0   <0.0001 0   0   0   <0.0001 0.0042 <0.0001 
Total Inpatient Utilization 0   0   0   0.0013 0   0   0   <0.0001 0.0268 <0.0001 
Total Medical Utilization 7552   7448   9165   0.0663 7740   6990   9165   0.0097 0.2051 0.0086 
                                  
Non-COPD Outpatient Rx 1442   1462   1281   0.024 1512   1362   1281   0.1864 0.0131 0.1060 
COPD Outpatient Rx 68   70   67   0.0093 94   46   67   <0.0001 0.2338 <0.0001 
Total Outpatient Rx 1869   1879   1724   0.1882 1931   1766   1724   0.0629 0.0975 0.5666 
                                  
Total Healthcare Services 10559   10402   11960   0.159 11055   9534   11960   0.0026 0.4380 0.0184 
Cost of Utilization ($)  - for those with utilization within category            
Non-COPD Outpatient Utilization 3417   3428   3296   0.4294 3396   3487   3296   0.6449 0.3762 0.5892 
COPD Outpatient Utilization 1185   1160   1373   0.0246 1103   1294   1373   0.0040 0.0052 0.2845 
Total Outpatient Utilization 4928   4951   4557   0.6467 4894   5098   4557   0.2974 0.8093 0.4318 
                                  
Non-COPD Inpatient Utilization 19872   19809   20757   0.6479 18391   23754   20757   0.0325 0.3589 0.5782 
COPD Inpatient Utilization 15300   15297   15304   0.8308 15771   14783   15304   0.6867 0.8741 0.7634 
Total Inpatient Utilization 18979   18979   19081   0.9585 18291   21316   19081   0.1186 0.7791 0.4429 
Total Medical Utilization 7552   7448   9165   0.0663 7740   6990   9165   0.0097 0.2051 0.0086 
                                  
Non-COPD Outpatient Rx 1499   1506   1401   0.1745 1544   1419   1401   0.5016 0.1445 0.3030 
COPD Outpatient Rx 68   70   67   0.0093 94   46   67   <0.0001 0.2338 <0.0001 
Total Outpatient Rx 1869   1879   1724   0.1882 1931   1766   1724   0.0629 0.0975 0.5666 
                                  
Total Healthcare Services 10559   10402   11960   0.159 11055   9534   11960   0.0026 0.4380 0.0184 
Length of Stay  (for inpatient stays) 5   4   5   0.1856 4   4   5   0.8538 0.1659 0.3262 
* Wilcoxon signed rank sum test for differences in distributions using median  
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Table 21 PHP Baseline Healthcare Costs (Means) 
PHP  
Baseline Characteristic 
Total SD ICS 
LABA 
LAMA 
SD Triple SD pval 
Comb vs 
Triple 
ICS 
LABA 
SD LAMA SD Triple SD ICS 
LABA vs 
LAMA 
ICS 
LABA 
vs Triple 
LAMA vs 
Triple 
Number of Patients 1876  1704  172   923  781  172  p-values 
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient Utilization 5614 11366 5662 11274 5140 12265 0.5663 5692 10423 5626 12211 5140 12265 0.9048 0.58 0.6372 
COPD Outpatient Utilization 2297 2786 2251 2737 2746 3208 0.0521 2361 2734 2121 2737 2746 3208 0.0706 0.1411 0.0184 
Total Outpatient Utilization 7911 12326 7913 12152 7887 13970 0.9809 8054 11334 7747 13058 7887 13970 0.6076 0.8824 0.9001 
                 
Non-COPD Inpatient Utilization 1533 6606 1560 6699 1274 5606 0.5322 1809 7545 1265 5526 1274 5606 0.0867 0.2796 0.9852 
COPD Inpatient Utilization 8404 22481 8267 22567 9763 21629 0.4057 9046 23856 7346 20918 9763 21629 0.1174 0.7136 0.1732 
Total Inpatient Utilization 9937 25094 9827 25128 11036 24799 0.5469 10855 26528 8611 23324 11036 24799 0.0634 0.9336 0.2227 
Total Medical Utilization 17848 29507 17740 29543 18923 29208 0.6163 18909 30404 16358 28449 18923 29208 0.0758 0.9954 0.287 
                 
Non-COPD Outpatient Rx 1859 3107 1905 3197 1408 1958 0.0034 1949 2610 1853 3776 1408 1958 0.5499 0.0018 0.0273 
COPD Outpatient Rx 405 735 404 733 422 764 0.7571 482 774 311 668 422 764 <0.0001 0.3457 0.0786 
Total Outpatient Rx 2265 3288 2309 3375 1829 2207 0.011 2431 2843 2164 3908 1829 2207 0.112 0.002 0.1272 
                 
Total Healthcare Services 20113 30003 20048 30027 20753 29851 0.7694 21340 30858 18522 28959 20753 29851 0.0535 0.8178 0.3634 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient Utilization 5740 11461 5770 11354 5424 12540 0.7129 5786 10483 5751 12317 5424 12540 0.9502 0.7284 0.7591 
COPD Outpatient Utilization 2423 2808 2381 2759 2829 3220 0.085 2494 2750 2248 2766 2829 3220 0.0742 0.2095 0.0319 
Total Outpatient Utilization 7936 12337 7932 12160 7979 14026 0.9659 8063 11337 7777 13074 7979 14026 0.6333 0.9418 0.8566 
                 
Non-COPD Inpatient Utilization 17434 14833 17717 14993 14603 13242 0.4398 19192 16519 15681 12428 14603 13242 0.1395 0.3104 0.7665 
COPD Inpatient Utilization 32778 34258 32913 34899 31683 28819 0.8056 33666 35947 31875 33474 31683 28819 0.6008 0.7069 0.9699 
Total Inpatient Utilization 34716 36619 34667 36986 35153 33473 0.9264 35278 37789 33796 35884 35153 33473 0.6651 0.9819 0.8028 
Total Medical Utilization 17877 29522 17771 29560 18923 29208 0.6258 18909 30404 16421 28486 18923 29208 0.0838 0.9954 0.2997 
                 
Non-COPD Outpatient Rx 1997 3177 2038 3265 1572 2006 0.0107 2065 2641 2005 3889 1572 2006 0.7215 0.0081 0.0468 
COPD Outpatient Rx 405 735 404 733 422 764 0.7571 482 774 311 668 422 764 <0.0001 0.3457 0.0786 
Total Outpatient Rx 2265 3288 2309 3375 1829 2207 0.011 2431 2843 2164 3908 1829 2207 0.112 0.002 0.1272 
                 Total Healthcare Services 20113 30003 20048 30027 20753 29851 0.7694 21340 30858 18522 28959 20753 29851 0.0535 0.8178 0.3634 
Length of Stay (for inpatient stays) 5.3 5.0 5.2 5.1 5.5 4.2 0.695 5.3 5.3 5.2 4.8 5.5 4.2 0.7715 0.7289 0.6134 
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Table 22 PHP Baseline Healthcare Costs (Medians) 
  
Total   ICS 
LABA or 
LAMA 
  Triple   pval 
Comb vs 
Triple* 
ICS 
LABA 
  LAMA   Triple   ICS 
LABA vs 
LAMA 
ICS 
LABA vs 
Triple 
LAMA 
vs Triple 
Median 1876  1704  172   923  781  172  p-values 
Cost of Utilization ($)                  
Non-COPD Outpatient Utilization 2879  2991  1945  0.0074 3110  2796  1945  0.0271 0.0003 0.0327 
COPD Outpatient Utilization 1685  1625  2064  0.0088 1695  1574  2064  0.0182 0.0556 0.0010 
Total Outpatient Utilization 4964  5046  4114  0.2742 5200  4794  4114  0.0236 0.0868 0.7888 
                 
Non-COPD Inpatient Utilization 0  0  0  0.8748 0  0  0  0.2904 0.7127 0.8048 
COPD Inpatient Utilization 0  0  0  0.0528 0  0  0  0.0697 0.2469 0.0270 
Total Inpatient Utilization 0  0  0  0.2565 0  0  0  0.0168 0.7731 0.0930 
Total Medical Utilization 6998  6965  7348  0.6306 7255  6557  7348  0.0105 0.7450 0.2251 
                 
Non-COPD Outpatient Rx 854  887  459  0.0017 1050  745  459  0.0017 0.0002 0.0350 
COPD Outpatient Rx 66  71  44  0.3480 138  34  44  <0.0001 0.3779 0.0026 
Total Outpatient Rx 1295  1309  1097  0.0298 1575  1010  1097  <0.0001 0.0017 0.4100 
                 
Total Healthcare Services 9209  9209  9208  0.9601 9792  8546  9208  0.0018 0.3294 0.3925 
Cost of Utilization ($)  - for those with utilization within category      
Non-COPD Outpatient Utilization 2993  3074  2148  0.0142 3215  2921  2148  0.0382 0.0027 0.1124 
COPD Outpatient Utilization 1792  1762  2114  0.0233 1832  1707  2114  0.0146 0.1307 0.0033 
Total Outpatient Utilization 4985  5065  4127  0.3685 5206  4818  4127  0.0298 0.1325 0.9132 
                 
Non-COPD Inpatient Utilization 13848  14108  7672  0.251 15218  11303  7672  0.1716 0.1634 0.4896 
COPD Inpatient Utilization 20654  20532  22415  0.5494 19256  20750  22415  0.8689 0.5585 0.5867 
Total Inpatient Utilization 21703  21609  22256  0.5207 20750  21708  22256  0.9101 0.5419 0.5397 
Total Medical Utilization 7014  6996  7348  0.7151 7255  6594  7348  0.0152 0.7450 0.2550 
                 
Non-COPD Outpatient Rx 1026  1050  796  0.0107 1208  888  796  0.0065 0.0021 0.0903 
COPD Outpatient Rx 66  71  44  0.3431 138  34  44  <0.0001 0.3779 0.0026 
Total Outpatient Rx 1295  1309  1097  0.0303 1575  1010  1097  <0.0001 0.0017 0.4100 
                 
Total Healthcare Services 9209  9209  9208  0.8921 9792  8546  9208  0.0018 0.3294 0.3925 
Length of Stay (for inpatient stays) 4  4  5  0.3014 4  4  5  0.6462 0.3599 0.2812 
* Wilcoxon signed rank sum test for differences in distributions using median  
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Table 23 Combined Baseline Healthcare Costs (Means) 
 
Baseline Characteristic 
Total SD ICS 
LABA 
LAMA 
SD Triple SD pval 
Comb vs 
Triple 
ICS 
LABA 
SD LAMA SD Triple SD ICS 
LABA vs 
LAMA 
ICS 
LABA 
vs Triple 
LAMA vs 
Triple 
Number of Patients 5475  4991  484  0 3052  1939  484  p-values 
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient Utilization 5490 9457 5540 9522 4983 8756 0.1854 5609 9410 5430 9697 4983 8756 0.516 0.148 0.3257 
COPD Outpatient Utilization 1961 2436 1931 2398 2277 2781 0.0085 1903 2411 1974 2378 2277 2781 0.3062 0.0054 0.0282 
Total Outpatient Utilization 7452 10320 7470 10330 7259 10222 0.6672 7512 10239 7404 10475 7259 10222 0.718 0.6129 0.7843 
                 
Non-COPD Inpatient Utilization 5069 20267 5091 20580 4849 16714 0.7665 5530 22070 4399 17971 4849 16714 0.0477 0.4278 0.6021 
COPD Inpatient Utilization 6179 20753 5970 20088 8335 26583 0.0573 6434 20889 5240 18741 8335 26583 0.036 0.1337 0.016 
Total Inpatient Utilization 11248 30260 11061 29994 13184 32848 0.1719 11964 31533 9639 27344 13184 32848 0.0059 0.4317 0.0287 
Total Medical Utilization 18700 33496 18531 33340 20443 35048 0.2305 19476 34821 17043 30815 20443 35048 0.0098 0.5708 0.0511 
                 
Non-COPD Outpatient Rx 2369 4007 2408 4093 1971 2946 0.0029 2489 3966 2279 4284 1971 2946 0.0825 0.0007 0.0628 
COPD Outpatient Rx 408 778 401 753 482 995 0.0819 438 789 342 688 482 995 <0.0001 0.3564 0.0037 
Total Outpatient Rx 2777 4148 2808 4228 2453 3201 0.0243 2926 4109 2621 4403 2453 3201 0.0144 0.0039 0.3396 
                 
Total Healthcare Services 21477 34258 21339 34100 22896 35854 0.3398 22403 35472 19665 31757 22896 35854 0.0046 0.7766 0.0703 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient Utilization 5589 9513 5626 9571 5197 8880 0.3234 5703 9460 5507 9743 5197 8880 0.4832 0.2802 0.5095 
COPD Outpatient Utilization 2100 2463 2067 2424 2443 2810 0.0062 2049 2442 2094 2397 2443 2810 0.5382 0.0051 0.0154 
Total Outpatient Utilization 7469 10326 7484 10335 7320 10243 0.7392 7527 10244 7416 10479 7320 10243 0.7101 0.6797 0.8568 
                 
Non-COPD Inpatient Utilization 32576 41773 32869 42702 29708 31336 0.4129 32646 44644 33321 38562 29708 31336 0.8282 0.4679 0.3989 
COPD Inpatient Utilization 30287 37170 30311 36222 30106 43657 0.9585 30163 36487 30603 35749 30106 43657 0.857 0.9887 0.907 
Total Inpatient Utilization 36441 45266 36559 45189 35451 46018 0.7563 36224 46184 37232 43161 35451 46018 0.6832 0.836 0.6409 
Total Medical Utilization 18710 33502 18542 33347 20443 35048 0.2334 19476 34821 17070 30832 20443 35048 0.0107 0.5708 0.053 
                 
Non-COPD Outpatient Rx 2462 4056 2494 4140 2120 3003 0.0153 2557 3998 2392 4358 2120 3003 0.1856 0.0063 0.1191 
COPD Outpatient Rx 408 778 401 753 482 995 0.0819 438 789 342 688 482 995 <0.0001 0.3564 0.0037 
Total Outpatient Rx 2777 4148 2808 4228 2453 3201 0.0243 2926 4109 2621 4403 2453 3201 0.0144 0.0039 0.3396 
Length of Stay (for inpatient stays) 6.6 7.7 6.6 7.6 6.7 8.0 0.8101 6.6 7.6 6.7 8.0 6.7 8.0 0.8101 0.5429 0.6744 
  
 
1
3
4 
 
Table 24 Combined Baseline Healthcare Costs (Medians) 
  
Total   ICS 
LABA or 
LAMA 
  Triple   pval 
Comb vs 
Triple* 
ICS 
LABA 
  LAMA   Triple   ICS LABA 
vs LAMA 
ICS LABA 
vs Triple 
LAMA vs 
Triple 
Median 5475  4991  484   3052  1939  484  p-values 
Cost of Utilization ($)                  
Non-COPD Outpatient Utilization 3181   3239   2600   0.0029 3273   3218   2600   0.1072 0.0010 0.0290 
COPD Outpatient Utilization 1201   1180   1405   0.0048 1128   1299   1405   0.0465 0.0015 0.0471 
Total Outpatient Utilization 4931   4977   4388   0.2520 5011   4956   4388   0.6514 0.2134 0.3806 
                                 
Non-COPD Inpatient Utilization 0   0   0   0.6365 0   0   0   0.0005 0.7444 0.0827 
COPD Inpatient Utilization 0   0   0   <.0001 0   0   0   0.0005 0.0018 <0.0001 
Total Inpatient Utilization 0   0   0   0.0017 0   0   0   <0.0001 0.0596 <0.0001 
Total Medical Utilization 7398   7305   8704   0.0922 7547   6800   8704   0.0002 0.4235 0.0044 
                                 
Non-COPD Outpatient Rx 1252   1270   1056   0.0002 1381   1114   1056   <0.0001 <0.0001 0.0356 
COPD Outpatient Rx 68   70   55   0.0079 103   41   55   <0.0001 0.6578 <0.0001 
Total Outpatient Rx 1685   1696   1539   0.0166 1854   1480   1539   <0.0001 0.0006 0.5763 
                                 
Total Healthcare Services 10052   9977   10777   0.3284 10585   9212   10777   <0.0001 0.9661 0.0155 
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient Utilization 3285   3337   2735   0.0341 3351   3248   2735   0.0721 0.0118 0.1941 
COPD Outpatient Utilization 1380   1351   1697   0.0013 1299   1437   1697   0.2054 0.0007 0.0095 
Total Outpatient Utilization 4942   4998   4401   0.3595 5015   4959   4401   0.6326 0.3039 0.5144 
                                 
Non-COPD Inpatient Utilization 17802   17764   18196   0.9315 17486   19406   18196   0.4828 0.9310 0.6872 
COPD Inpatient Utilization 17641   17642   17429   0.9755 17119   18488   17429   0.3543 0.8495 0.6696 
Total Inpatient Utilization 19907   19864   20186   0.8112 19051   21572   20186   0.1694 0.5848 0.7119 
Total Medical Utilization 7404   7318   8704   0.0963 7547   6815   8704   0.0003 0.4235 0.0051 
                                 
Non-COPD Outpatient Rx 1340   1357   1228   0.0105 1462   1238   1228   0.0022 0.0017 0.1591 
COPD Outpatient Rx 68   70   55   0.0079 103   41   55   <0.0001 0.6578 <0.0001 
Total Outpatient Rx 1685   1696   1539   0.0166 1854   1480   1539   <0.0001 0.0006 0.5763 
                                 
Total Healthcare Services 10052   9977   10777   0.3284 10585   9212    10777   <0.0001 0.9661 0.0155 
Length of Stay (for inpatient stays) 4   4   5   0.0919 4   4   5   0.5663 0.1161 0.0968 
* Wilcoxon signed rank sum test for differences in distributions using median 
  
 
1
3
5 
 
Table 25 Baseline Characteristics – Discontinuation in First 3 Months 
   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total % Discont 
1st 3 
months 
% Still 
using a 
Trmt 
% pval  Total % Discon
t 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  Total % Discont 
in 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475   2072 37.8 3403     3599   1472 40.9 2127     1876   600 32.0 1276     
Age Categories                                           
age 40-54 584 10.7 258 12.5 326 9.6 0.0008 332 9.2 162 11.0 170 8.0 0.0021 252 13.4 96 16.0 156 12.2 0.0254 
age 55-64 1026 18.7 380 18.3 646 19.0 0.5540 591 16.4 243 16.5 348 16.4 0.9068 435 23.2 137 22.8 298 23.4 0.8031 
age 65-74 1637 29.9 598 28.9 1039 30.5 0.1903 1059 29.4 419 28.5 640 30.1 0.2930 578 30.8 179 29.8 399 31.3 0.5297 
age 75 and older 2228 40.7 836 40.3 1392 40.9 0.6838 1617 44.9 648 44.0 969 45.6 0.3626 611 32.6 188 31.3 423 33.2 0.4334 
age (Mean, SD) 70.55 11.51 70.23 11.88 70.74 11.27 0.1125 71.58 11.31 71.18 11.66 71.86 11.06 0.0781 68.57 11.62 67.90 12.11 68.88 11.37 0.0870 
                                            
Men 2393 43.7 884 42.7 1509 44.3 0.2244 1616 44.9 654 44.4 962 45.2 0.6358 777 41.4 230 38.3 547 42.9 0.0629 
                                            
Quarter of Year, Index Date             0.0095             0.6436             0.0003 
Q1 1645 30.0 615 29.7 1030 30.3   1111 30.9 466 31.7 645 30.3   534 28.5 149 24.8 385 30.2   
Q2  1160 21.2 475 22.9 685 20.1   800 22.2 334 22.7 466 21.9   360 19.2 141 23.5 219 17.2   
Q3 1192 21.8 467 22.5 725 21.3   846 23.5 340 23.1 506 23.8   346 18.4 127 21.2 219 17.2   
Q4 1478 27.0 515 24.9 963 28.3   842 23.4 332 22.6 510 24.0   636 33.9 183 30.5 453 35.5   
                                            
Months enrollment post-Index             0.2316             0.4643             0.0297 
7 78 1.4 39 1.9 39 1.1   44 1.2 22 1.5 22 1.0   34 1.8 17 2.8 17 1.3   
8 66 1.2 26 1.3 40 1.2   39 1.1 14 1.0 25 1.2   27 1.4 12 2.0 15 1.2   
9 85 1.6 27 1.3 58 1.7   50 1.4 17 1.2 33 1.6   35 1.9 10 1.7 25 2.0   
10 99 1.8 42 2.0 57 1.7   70 1.9 33 2.2 37 1.7   29 1.5 9 1.5 20 1.6   
11 117 2.1 48 2.3 69 2.0   95 2.6 42 2.9 53 2.5   22 1.2 6 1.0 16 1.3   
12 92 1.7 41 2.0 51 1.5   71 2.0 33 2.2 38 1.8   21 1.1 8 1.3 13 1.0   
13 99 1.8 31 1.5 68 2.0   67 1.9 22 1.5 45 2.1   32 1.7 9 1.5 23 1.8   
14 111 2.0 43 2.1 68 2.0   75 2.1 28 1.9 47 2.2   36 1.9 15 2.5 21 1.6   
15 97 1.8 43 2.1 54 1.6   62 1.7 25 1.7 37 1.7   35 1.9 18 3.0 17 1.3   
16 127 2.3 56 2.7 71 2.1   82 2.3 44 3.0 38 1.8   45 2.4 12 2.0 33 2.6   
17 114 2.1 39 1.9 75 2.2   77 2.1 32 2.2 45 2.1   37 2.0 7 1.2 30 2.4   
18 106 1.9 34 1.6 72 2.1   72 2.0 25 1.7 47 2.2   34 1.8 9 1.5 25 2.0   
19 104 1.9 42 2.0 62 1.8   69 1.9 33 2.2 36 1.7   35 1.9 9 1.5 26 2.0   
20 105 1.9 46 2.2 59 1.7   67 1.9 27 1.8 40 1.9   38 2.0 19 3.2 19 1.5   
21 105 1.9 40 1.9 65 1.9   63 1.8 23 1.6 40 1.9   42 2.2 17 2.8 25 2.0   
22 114 2.1 40 1.9 74 2.2   79 2.2 32 2.2 47 2.2   35 1.9 8 1.3 27 2.1   
23 91 1.7 30 1.4 61 1.8   64 1.8 23 1.6 41 1.9   27 1.4 7 1.2 20 1.6   
24 3765 68.8 1405 67.8 2360 69.4   2453 68.2 997 67.7 1456 68.5   1312 69.9 408 68.0 904 70.8   
Insurance at Index                                           
Commercial 1778 32.5 675 32.6 1103 32.4 0.8996 1376 38.2 555 37.7 821 38.6 0.5869 402 21.4 120 20.0 282 22.1 0.3011 
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   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total % Discont 
1st 3 
months 
% Still 
using a 
Trmt 
% pval  Total % Discon
t 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  Total % Discont 
in 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475   2072 37.8 3403     3599   1472 40.9 2127     1876   600 32.0 1276     
Medicaid 655 12.0 278 13.4 377 11.1 0.0097 284 7.9 124 8.4 160 7.5 0.3240 371 19.8 154 25.7 217 17.0 <0.0001 
Medicare 3071 56.1 1129 54.5 1942 57.1 0.0622 1968 54.7 803 54.6 1165 54.8 0.8961 1103 58.8 326 54.3 777 60.9 0.0071 
                                            
CMS comorbidities                                            
acute myocardial infarction 
(AMI) 
175 3.2 63 3.0 112 3.3 0.6091 114 3.2 42 2.9 72 3.4 0.3705 61 3.3 21 3.5 40 3.1 0.6774 
Alzheimer’s 189 3.5 80 3.9 109 3.2 0.1959 111 3.1 50 3.4 61 2.9 0.3669 78 4.2 30 5.0 48 3.8 0.2102 
atrial fibrillation 534 9.8 211 10.2 323 9.5 0.4027 362 10.1 153 10.4 209 9.8 0.5775 172 9.2 58 9.7 114 8.9 0.6081 
cancers 370 6.8 141 6.8 229 6.7 0.9139 265 7.4 110 7.5 155 7.3 0.8340 105 5.6 31 5.2 74 5.8 0.5782 
lung cancer 113 2.1 41 2.0 72 2.1 0.7295 75 2.1 29 2.0 46 2.2 0.6909 38 2.0 12 2.0 26 2.0 0.9570 
chronic kidney disease 870 15.9 334 16.1 536 15.8 0.7173 626 17.4 264 17.9 362 17.0 0.4762 244 13.0 70 11.7 174 13.6 0.2368 
diabetes 1358 24.8 556 26.8 802 23.6 0.0066 884 24.6 400 27.2 484 22.8 0.0025 474 25.3 156 26.0 318 24.9 0.6161 
heart failure 986 18.0 395 19.1 591 17.4 0.1131 645 17.9 278 18.9 367 17.3 0.2096 341 18.2 117 19.5 224 17.6 0.3082 
ischemic heart dis. (IHD; 
incl. AMI) 
1343 24.5 540 26.1 803 23.6 0.0398 908 25.2 384 26.1 524 24.6 0.3243 435 23.2 156 26.0 279 21.9 0.0478 
rheumatoid/osteo arthritis  1443 26.4 573 27.7 870 25.6 0.0889 954 26.5 411 27.9 543 25.5 0.1099 489 26.1 162 27.0 327 25.6 0.5275 
stroke/TIA 387 7.1 141 6.8 246 7.2 0.5528 256 7.1 109 7.4 147 6.9 0.5710 131 7.0 32 5.3 99 7.8 0.0546 
no CMS Comorbidity 1860 34.0 669 32.3 1191 35.0 0.0400 1194 33.2 459 31.2 735 34.6 0.0346 666 35.5 210 35.0 456 35.7 0.7558 
                                            
Elixhauser comorbidities                                            
AIDS 10 0.2 3 0.1 7 0.2 0.6087 9 0.3 2 0.1 7 0.3 0.2538     1 0.2     0.1446 
alcohol abuse 191 3.5 65 3.1 126 3.7 0.2687 108 3.0 45 3.1 63 3.0 0.8693 83 4.4 20 3.3 63 4.9 0.1151 
chronic blood loss anemia 49 0.9 20 1.0 29 0.9 0.6666 28 0.8 9 0.6 19 0.9 0.3440 21 1.1 11 1.8 10 0.8 0.0439 
coagulopathy 163 3.0 57 2.8 106 3.1 0.4422 96 2.7 40 2.7 56 2.6 0.8770 67 3.6 17 2.8 50 3.9 0.2375 
congestive heart failure 903 16.5 365 17.6 538 15.8 0.0807 616 17.1 269 18.3 347 16.3 0.1247 287 15.3 96 16.0 191 15.0 0.5627 
deficiency anemias 773 14.1 321 15.5 452 13.3 0.0228 498 13.8 224 15.2 274 12.9 0.0461 275 14.7 97 16.2 178 13.9 0.2055 
depression 917 16.7 377 18.2 540 15.9 0.0254 537 14.9 242 16.4 295 13.9 0.0333 380 20.3 135 22.5 245 19.2 0.0972 
diabetes (wo/chr 
complications) 
1304 23.8 540 26.1 764 22.5 0.0023 867 24.1 389 26.4 478 22.5 0.0064 437 23.3 151 25.2 286 22.4 0.1883 
diabetes (w/chr 
complications) 
442 8.1 185 8.9 257 7.6 0.0698 332 9.2 147 10.0 185 8.7 0.1890 110 5.9 38 6.3 72 5.6 0.5526 
drug abuse 181 3.3 88 4.2 93 2.7 0.0024 115 3.2 50 3.4 65 3.1 0.5676 66 3.5 38 6.3 28 2.2 <0.0001 
fluid and electrolyte 
disorders 
686 12.5 278 13.4 408 12.0 0.1217 422 11.7 182 12.4 240 11.3 0.3218 264 14.1 96 16.0 168 13.2 0.0997 
hypertension 3374 61.6 1282 61.9 2092 61.5 0.7693 2301 63.9 948 64.4 1353 63.6 0.6269 1073 57.2 334 55.7 739 57.9 0.3586 
hypothyroidism 1032 18.8 379 18.3 653 19.2 0.4102 684 19.0 275 18.7 409 19.2 0.6810 348 18.6 104 17.3 244 19.1 0.3525 
liver disease 212 3.9 76 3.7 136 4.0 0.5411 144 4.0 57 3.9 87 4.1 0.7429 68 3.6 19 3.2 49 3.8 0.4667 
lymphoma 46 0.8 17 0.8 29 0.9 0.9007 31 0.9 15 1.0 16 0.8 0.3945 15 0.8 2 0.3 13 1.0 0.1200 
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   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total % Discont 
1st 3 
months 
% Still 
using a 
Trmt 
% pval  Total % Discon
t 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  Total % Discont 
in 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475   2072 37.8 3403     3599   1472 40.9 2127     1876   600 32.0 1276     
metastatic cancer 56 1.0 25 1.2 31 0.9 0.2917 41 1.1 15 1.0 26 1.2 0.5719 15 0.8 10 1.7 5 0.4 0.0038 
obesity 717 13.1 280 13.5 437 12.8 0.4748 480 13.3 197 13.4 283 13.3 0.9460 237 12.6 83 13.8 154 12.1 0.2833 
other neurological disorders 514 9.4 206 9.9 308 9.1 0.2728 363 10.1 154 10.5 209 9.8 0.5334 151 8.0 52 8.7 99 7.8 0.5001 
paralysis 68 1.2 16 0.8 52 1.5 0.0143 48 1.3 11 0.7 37 1.7 0.0107 20 1.1 5 0.8 15 1.2 0.5009 
peripheral vascular disease 878 16.0 335 16.2 543 16.0 0.8362 614 17.1 253 17.2 361 17.0 0.8660 264 14.1 82 13.7 182 14.3 0.7289 
psychoses 573 10.5 228 11.0 345 10.1 0.3101 399 11.1 165 11.2 234 11.0 0.8452 174 9.3 63 10.5 111 8.7 0.2098 
pulmonary circulation 
disease 
625 11.4 238 11.5 387 11.4 0.8975 435 12.1 182 12.4 253 11.9 0.6710 190 10.1 56 9.3 134 10.5 0.4341 
renal failure 468 8.5 185 8.9 283 8.3 0.4319 338 9.4 146 9.9 192 9.0 0.3673 130 6.9 39 6.5 91 7.1 0.6153 
rheumatoid arthritis/collagen 
vas 
343 6.3 131 6.3 212 6.2 0.8909 209 5.8 90 6.1 119 5.6 0.5125 134 7.1 41 6.8 93 7.3 0.7211 
solid tumor wo/metastasis 533 9.7 204 9.8 329 9.7 0.8297 368 10.2 149 10.1 219 10.3 0.8656 165 8.8 55 9.2 110 8.6 0.6970 
ulcers 7 0.1 2 0.1 5 0.1 0.6127 3 0.1 1 0.1 2 0.1 0.7897 4 0.2 1 0.2 3 0.2 0.7644 
valvular disease 630 11.5 243 11.7 387 11.4 0.6893 478 13.3 188 12.8 290 13.6 0.4535 152 8.1 55 9.2 97 7.6 0.2467 
weight loss 327 6.0 139 6.7 188 5.5 0.0730 219 6.1 94 6.4 125 5.9 0.5300 108 5.8 45 7.5 63 4.9 0.0262 
any Elixhauser diagnosis 5028 91.8 1925 92.9 3103 91.2 0.0241 3333 92.6 1372 93.2 1961 92.2 0.2544 1695 90.4 553 92.2 1142 89.5 0.0679 
Other comorbidities                                           
asthma 1813 33.1 685 33.1 1128 33.1 0.9469 1166 32.4 483 32.8 683 32.1 0.6584 647 34.5 202 33.7 445 34.9 0.6077 
hypoxemia 1994 36.4 716 34.6 1278 37.6 0.0253 1229 34.1 481 32.7 748 35.2 0.1214 765 40.8 235 39.2 530 41.5 0.3300 
pneumonia 1908 34.8 756 36.5 1152 33.9 0.0473 1348 37.5 580 39.4 768 36.1 0.0447 560 29.9 176 29.3 384 30.1 0.7370 
influenza 178 3.3 77 3.7 101 3.0 0.1300 124 3.4 60 4.1 64 3.0 0.0844 54 2.9 17 2.8 37 2.9 0.9361 
                                            
COPD Complexity ^                                           
Low complexity 2740 50.0 1067 51.5 1673 49.2 0.0939 1761 48.9 752 51.1 1009 47.4 0.0313 979 52.2 315 52.5 664 52.0 0.8517 
Med complexity 2510 45.8 935 45.1 1575 46.3 0.4046 1686 46.8 669 45.4 1017 47.8 0.1621 824 43.9 266 44.3 558 43.7 0.8061 
High complexity 225 4.1 70 3.4 155 4.6 0.0334 152 4.2 51 3.5 101 4.7 0.0597 73 3.9 19 3.2 54 4.2 0.2658 
Emphysema diagnosis (492.x) 1210 22.1 397 19.2 813 23.9 <0.0001 694 19.3 251 17.1 443 20.8 0.0048 516 27.5 146 24.3 370 29.0 0.0349 
                                            
COPD Medications                                            
index ICSLABA 3052 55.7 1321 63.8 1731 50.9 <0.0001 2129 59.2 996 67.7 1133 53.3 <0.0001 923 49.2 325 54.2 598 46.9 0.0032 
index LAMA 1939 35.4 655 31.6 1284 37.7 <0.0001 1158 32.2 409 27.8 749 35.2 <0.0001 781 41.6 246 41.0 535 41.9 0.7037 
index triple 484 8.8 96 4.6 388 11.4 <0.0001 312 8.7 67 4.6 245 11.5 <0.0001 172 9.2 29 4.8 143 11.2 <0.0001 
SABA use                                           
no SABA use 2314 42.3 830 40.1 1484 43.6 0.0099 1479 41.1 594 40.4 885 41.6 0.4520 835 44.5 236 39.3 599 46.9 0.0020 
SABA <=15% of year 1435 26.2 599 28.9 836 24.6 0.0004 973 27.0 440 29.9 533 25.1 0.0013 462 24.6 159 26.5 303 23.7 0.1966 
SABA <=40% of year 803 14.7 342 16.5 461 13.5 0.0027 555 15.4 243 16.5 312 14.7 0.1330 248 13.2 99 16.5 149 11.7 0.0040 
SABA >40% of year 923 16.9 301 14.5 622 18.3 0.0003 592 16.4 195 13.2 397 18.7 <0.0001 331 17.6 106 17.7 225 17.6 0.9859 
SAMA use                                           
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   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total % Discont 
1st 3 
months 
% Still 
using a 
Trmt 
% pval  Total % Discon
t 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  Total % Discont 
in 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475   2072 37.8 3403     3599   1472 40.9 2127     1876   600 32.0 1276     
any ipratropium (SAMA) 632 11.5 217 10.5 415 12.2 0.0531 391 10.9 135 9.2 256 12.0 0.0066 241 12.8 82 13.7 159 12.5 0.4666 
any SABA/SAMA 876 16.0 311 15.0 565 16.6 0.1188 591 16.4 214 14.5 377 17.7 0.0112 285 15.2 97 16.2 188 14.7 0.4199 
any SAMA or 
SABA/SAMA 
1381 25.2 488 23.6 893 26.2 0.0263 901 25.0 327 22.2 574 27.0 0.0012 480 25.6 161 26.8 319 25.0 0.3960 
Other COPD medications                                           
any ICS 1752 32.0 634 30.6 1118 32.9 0.0828 1143 31.8 433 29.4 710 33.4 0.0120 609 32.5 201 33.5 408 32.0 0.5106 
any LABA 227 4.1 57 2.8 170 5.0 <0.0001 118 3.3 27 1.8 91 4.3 <0.0001 109 5.8 30 5.0 79 6.2 0.3036 
any methylxanthines 87 1.6 26 1.3 61 1.8 0.1228 29 0.8 10 0.7 19 0.9 0.4803 58 3.1 16 2.7 42 3.3 0.4658 
Any use of above COPD 
medications 
2688 49.1 977 47.2 1711 50.3 0.0248 1748 48.6 659 44.8 1089 51.2 0.0001 940 50.1 318 53.0 622 48.7 0.0857 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 4868 88.9 1825 88.1 3043 89.4 0.1251 3206 89.1 1309 88.9 1897 89.2 0.8058 1662 88.6 516 86.0 1146 89.8 0.0154 
1-2 Rxs ICSLABA (wks 27-
52) 
387 7.1 184 8.9 203 6.0 <0.0001 255 7.1 122 8.3 133 6.3 0.0193 132 7.0 62 10.3 70 5.5 0.0001 
>2 Rxs ICSLABA (wks 27-
52) 
220 4.0 63 3.0 157 4.6 0.0040 138 3.8 41 2.8 97 4.6 0.0064 82 4.4 22 3.7 60 4.7 0.3062 
No LAMA in prior year 5280 96.4 1998 96.4 3282 96.4 0.9757 3472 96.5 1423 96.7 2049 96.3 0.5886 1808 96.4 575 95.8 1233 96.6 0.3891 
1-2 Rxs LAMA (wks 27-52) 124 2.3 58 2.8 66 1.9 0.0381 86 2.4 39 2.6 47 2.2 0.3957 38 2.0 19 3.2 19 1.5 0.0161 
>2 Rxs LAMA (wks 27-52) 71 1.3 16 0.8 55 1.6 0.0074 41 1.1 10 0.7 31 1.5 0.0306 30 1.6 6 1.0 24 1.9 0.1560 
Oxygen Use                                           
no oxygen 3090 56.4 1215 58.6 1875 55.1 0.0104 2097 58.3 891 60.5 1206 56.7 0.0220 993 52.9 324 54.0 669 52.4 0.5250 
oxygen <=50% of year 876 16.0 316 15.3 560 16.5 0.2381 619 17.2 241 16.4 378 17.8 0.2741 257 13.7 75 12.5 182 14.3 0.3002 
oxygen >50% of year 1509 27.6 541 26.1 968 28.4 0.0607 883 24.5 340 23.1 543 25.5 0.0956 626 33.4 201 33.5 425 33.3 0.9342 
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 3454 63.1 1329 64.1 2125 62.4 0.2072 2101 58.4 895 60.8 1206 56.7 0.0141 1353 72.1 434 72.3 919 72.0 0.8884 
1 period breathlessness 1051 19.2 387 18.7 664 19.5 0.4470 757 21.0 299 20.3 458 21.5 0.3772 294 15.7 88 14.7 206 16.1 0.4116 
>1 period breathlessness 970 17.7 356 17.2 614 18.0 0.4181 741 20.6 278 18.9 463 21.8 0.0355 229 12.2 78 13.0 151 11.8 0.4718 
Shortness of Breath                                           
no periods shortness 
breath 
3450 63.0 1301 62.8 2149 63.2 0.7887 2260 62.8 933 63.4 1327 62.4 0.5438 1190 63.4 368 61.3 822 64.4 0.1954 
1 period shortness breath 1128 20.6 440 21.2 688 20.2 0.3664 785 21.8 322 21.9 463 21.8 0.9389 343 18.3 118 19.7 225 17.6 0.2879 
>1 period shortness breath 897 16.4 331 16.0 566 16.6 0.5238 554 15.4 217 14.7 337 15.8 0.3677 343 18.3 114 19.0 229 17.9 0.5820 
any wheezing 419 7.7 164 7.9 255 7.5 0.5692 302 8.4 127 8.6 175 8.2 0.6703 117 6.2 37 6.2 80 6.3 0.9315 
any dyspnea 3057 55.8 1144 55.2 1913 56.2 0.4687 2126 59.1 832 56.5 1294 60.8 0.0096 931 49.6 312 52.0 619 48.5 0.1586 
supplemental oxygen use 
(V46.2) 
317 5.8 109 5.3 208 6.1 0.1907 112 3.1 40 2.7 72 3.4 0.2568 205 10.9 69 11.5 136 10.7 0.5857 
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   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total % Discont 
1st 3 
months 
% Still 
using a 
Trmt 
% pval  Total % Discon
t 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  Total % Discont 
in 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475   2072 37.8 3403     3599   1472 40.9 2127     1876   600 32.0 1276     
Other symptoms                                           
chest pain unspecified 1662 30.4 705 34.0 957 28.1 <0.0001 1082 30.1 492 33.4 590 27.7 0.0003 580 30.9 213 35.5 367 28.8 0.0032 
painful respiratory 272 5.0 116 5.6 156 4.6 0.0939 165 4.6 80 5.4 85 4.0 0.0425 107 5.7 36 6.0 71 5.6 0.7043 
precordial pain 107 2.0 41 2.0 66 1.9 0.9188 72 2.0 29 2.0 43 2.0 0.9136 35 1.9 12 2.0 23 1.8 0.7681 
any chestpain 1742 31.8 739 35.7 1003 29.5 <0.0001 1137 31.6 521 35.4 616 29.0 <0.0001 605 32.2 218 36.3 387 30.3 0.0095 
chronic fatigue 85 1.6 35 1.7 50 1.5 0.5233 67 1.9 30 2.0 37 1.7 0.5148 18 1.0 5 0.8 13 1.0 0.7007 
other malaise/fatigue 1379 25.2 552 26.6 827 24.3 0.0532 884 24.6 382 26.0 502 23.6 0.1074 495 26.4 170 28.3 325 25.5 0.1894 
difficulty walking 139 2.5 53 2.6 86 2.5 0.9441 105 2.9 39 2.6 66 3.1 0.4267 34 1.8 14 2.3 20 1.6 0.2461 
memory loss 132 2.4 58 2.8 74 2.2 0.1439 94 2.6 44 3.0 50 2.4 0.2377 38 2.0 14 2.3 24 1.9 0.5165 
cough 1963 35.9 777 37.5 1186 34.9 0.0475 1394 38.7 582 39.5 812 38.2 0.4095 569 30.3 195 32.5 374 29.3 0.1610 
hemoptysis 76 1.4 24 1.2 52 1.5 0.2567 52 1.4 18 1.2 34 1.6 0.3531 24 1.3 6 1.0 18 1.4 0.4604 
Procedures                                           
chest CT 822 15.0 314 15.2 508 14.9 0.8200 551 15.3 220 14.9 331 15.6 0.6138 271 14.4 94 15.7 177 13.9 0.3023 
chest x-ray 3432 62.7 1283 61.9 2149 63.2 0.3617 2234 62.1 890 60.5 1344 63.2 0.0975 1198 63.9 393 65.5 805 63.1 0.3104 
echocardiography 1113 20.3 435 21.0 678 19.9 0.3397 819 22.8 339 23.0 480 22.6 0.7447 294 15.7 96 16.0 198 15.5 0.7885 
EKG 2452 44.8 958 46.2 1494 43.9 0.0922 1621 45.0 679 46.1 942 44.3 0.2754 831 44.3 279 46.5 552 43.3 0.1876 
heart catheterization 71 1.3 29 1.4 42 1.2 0.5998 51 1.4 21 1.4 30 1.4 0.9678 20 1.1 8 1.3 12 0.9 0.4396 
nebulizer treatment 1771 32.3 653 31.5 1118 32.9 0.3047 1326 36.8 509 34.6 817 38.4 0.0191 445 23.7 144 24.0 301 23.6 0.8454 
non-invasive ventilator 339 6.2 118 5.7 221 6.5 0.2340 210 5.8 81 5.5 129 6.1 0.4793 129 6.9 37 6.2 92 7.2 0.4049 
spirometry 2284 41.7 765 36.9 1519 44.6 <0.0001 1578 43.8 566 38.5 1012 47.6 <0.0001 706 37.6 199 33.2 507 39.7 0.0062 
any vaccination (flu or 
pneumonia) 
2632 48.1 976 47.1 1656 48.7 0.2629 1799 50.0 732 49.7 1067 50.2 0.7969 833 44.4 244 40.7 589 46.2 0.0255 
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 783 14.3 339 16.4 444 13.0 0.0007 525 14.6 228 15.5 297 14.0 0.2023 258 13.8 111 18.5 147 11.5 <0.0001 
any severe 434 7.9 187 9.0 247 7.3 0.0189 266 7.4 122 8.3 144 6.8 0.0870 168 9.0 65 10.8 103 8.1 0.0508 
any other hospitalizations* 124 2.3 63 3.0 61 1.8 0.0026 112 3.1 58 3.9 54 2.5 0.0173 12 0.6 5 0.8 7 0.5 0.4706 
Prior 2-12 weeks                                           
any moderate 894 16.3 320 15.4 574 16.9 0.1670 585 16.3 217 14.7 368 17.3 0.0407 309 16.5 103 17.2 206 16.1 0.5776 
any severe 337 6.2 110 5.3 227 6.7 0.0420 179 5.0 68 4.6 111 5.2 0.4164 158 8.4 42 7.0 116 9.1 0.1283 
any other hospitalizations* 209 3.8 82 4.0 127 3.7 0.6727 169 4.7 69 4.7 100 4.7 0.9845 40 2.1 13 2.2 27 2.1 0.9435 
Prior 13-52 weeks                                           
no moderate 4200 76.7 1536 74.1 2664 78.3 0.0004 2733 75.9 1098 74.6 1635 76.9 0.1162 1467 78.2 438 73.0 1029 80.6 0.0002 
1 moderate 1018 18.6 422 20.4 596 17.5 0.0085 694 19.3 302 20.5 392 18.4 0.1188 324 17.3 120 20.0 204 16.0 0.0320 
>1 moderate 257 4.7 114 5.5 143 4.2 0.0274 172 4.8 72 4.9 100 4.7 0.7929 85 4.5 42 7.0 43 3.4 0.0004 
any severe 409 7.5 145 7.0 264 7.8 0.2997 215 6.0 86 5.8 129 6.1 0.7819 194 10.3 59 9.8 135 10.6 0.6204 
any other hospitalizations* 384 7.0 151 7.3 233 6.8 0.5357 313 8.7 127 8.6 186 8.7 0.9025 71 3.8 24 4.0 47 3.7 0.7375 
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   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total % Discont 
1st 3 
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% pval  Total % Discon
t 1st 3 
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a 
Trmt 
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in 1st 3 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475   2072 37.8 3403     3599   1472 40.9 2127     1876   600 32.0 1276     
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 852 15.6 352 17.0 500 14.7 0.0231 687 19.1 297 20.2 390 18.3 0.1671 165 8.8 55 9.2 110 8.6 0.6970 
COPD Inpatient (Any) 1117 20.4 450 21.7 667 19.6 0.0593 636 17.7 279 19.0 357 16.8 0.0934 481 25.6 171 28.5 310 24.3 0.0517 
Total Inpatient  (Any) 1690 30.9 690 33.3 1000 29.4 0.0024 1153 32.0 502 34.1 651 30.6 0.0271 537 28.6 188 31.3 349 27.4 0.0751 
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period) 
Same as Index Trmt         3097 91.0           1919 90.2           1178 92.3   
No evidence Any Trmt     2072 100           1472 100           600 100       
Different Trmt from Index         306 9.0           208 9.8           98 7.7   
Now using Triple         150 4.4           101 4.7           49 3.8   
No longer using Triple         102 3.0           65 3.1           37 2.9   
Switched between 
ICSLABA and LAMA 
        54 1.6           42 2.0           12 0.9   
LHP enrollee 3599 65.7 1472 71.0 2127 62.5 <0.0001                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 26 Baseline Characteristics – Discontinuation in First 6 Months 
   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total % Discont 
1st 6 
months 
% Still 
using a 
Trmt 
% pval  Total % Discont 
1st 6 
months 
% Still 
using 
a 
Trmt 
% pval  Total % Discont 
in 1st 6 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475  2931 53.5 2544   3599  2055 57.1 1544   1876  876 46.7 1000   
Age Categories                      
age 40-54 584 10.7 358 12.2 226 8.9 <0.0001 332 9.2 230 11.2 102 6.6 <0.0001 252 13.4 128 14.6 124 12.4 0.1610 
age 55-64 1026 18.7 547 18.7 479 18.8 0.8752 591 16.4 345 16.8 246 15.9 0.4928 435 23.2 202 23.1 233 23.3 0.9019 
age 65-74 1637 29.9 825 28.1 812 31.9 0.0024 1059 29.4 571 27.8 488 31.6 0.0128 578 30.8 254 29.0 324 32.4 0.1111 
age 75 and older 2228 40.7 1201 41.0 1027 40.4 0.6488 1617 44.9 909 44.2 708 45.9 0.3331 611 32.6 292 33.3 319 31.9 0.5087 
age (Mean, SD) 70.55 11.51 70.33 11.96 70.80 10.95 0.1329 71.58 11.31 71.14 11.84 72.16 10.54 0.0066 68.57 11.62 68.43 12.04 68.69 11.24 0.6239 
                      
Men 2393 43.7 1252 42.7 1141 44.9 0.1122 1616 44.9 907 44.1 709 45.9 0.2870 777 41.4 345 39.4 432 43.2 0.0941 
                      
Quarter of Year for Index Date       <0.0001       0.1203       <0.0001 
Q1 1645 30.0 878 30.0 767 30.1  1111 30.9 653 31.8 458 29.7  534 28.5 225 25.7 309 30.9  
Q2 1160 21.2 675 23.0 485 19.1  800 22.2 472 23.0 328 21.2  360 19.2 203 23.2 157 15.7  
Q3 1192 21.8 654 22.3 538 21.1  846 23.5 474 23.1 372 24.1  346 18.4 180 20.5 166 16.6  
Q4 1478 27.0 724 24.7 754 29.6  842 23.4 456 22.2 386 25.0  636 33.9 268 30.6 368 36.8  
                      
Months of enrollment post-
Index 
      0.5089       0.5918       0.1422 
7 99 1.8 54 1.8 45 1.8  70 1.9 39 1.9 31 2.0  29 1.5 15 1.7 14 1.4  
8 117 2.1 63 2.1 54 2.1  95 2.6 56 2.7 39 2.5  22 1.2 7 0.8 15 1.5  
9 92 1.7 56 1.9 36 1.4  71 2.0 44 2.1 27 1.7  21 1.1 12 1.4 9 0.9  
10 99 1.8 50 1.7 49 1.9  67 1.9 35 1.7 32 2.1  32 1.7 15 1.7 17 1.7  
11 111 2.0 57 1.9 54 2.1  75 2.1 38 1.8 37 2.4  36 1.9 19 2.2 17 1.7  
12 97 1.8 56 1.9 41 1.6  62 1.7 34 1.7 28 1.8  35 1.9 22 2.5 13 1.3  
13 127 2.3 74 2.5 53 2.1  82 2.3 55 2.7 27 1.7  45 2.4 19 2.2 26 2.6  
14 114 2.1 57 1.9 57 2.2  77 2.1 43 2.1 34 2.2  37 2.0 14 1.6 23 2.3  
15 106 1.9 57 1.9 49 1.9  72 2.0 44 2.1 28 1.8  34 1.8 13 1.5 21 2.1  
16 104 1.9 61 2.1 43 1.7  69 1.9 47 2.3 22 1.4  35 1.9 14 1.6 21 2.1  
17 105 1.9 63 2.1 42 1.7  67 1.9 37 1.8 30 1.9  38 2.0 26 3.0 12 1.2  
18 105 1.9 61 2.1 44 1.7  63 1.8 38 1.8 25 1.6  42 2.2 23 2.6 19 1.9  
19 114 2.1 55 1.9 59 2.3  79 2.2 40 1.9 39 2.5  35 1.9 15 1.7 20 2.0  
20 91 1.7 49 1.7 42 1.7  64 1.8 38 1.8 26 1.7  27 1.4 11 1.3 16 1.6  
21 3765 68.8 1991 67.9 1774 69.7  2453 68.2 1387 67.5 1066 69.0  1312 69.9 604 68.9 708 70.8  
22 78 1.4 49 1.7 29 1.1  44 1.2 29 1.4 15 1.0  34 1.8 20 2.3 14 1.4  
23 66 1.2 39 1.3 27 1.1  39 1.1 25 1.2 14 0.9  27 1.4 14 1.6 13 1.3  
24 85 1.6 39 1.3 46 1.8  50 1.4 26 1.3 24 1.6  35 1.9 13 1.5 22 2.2  
Insurance at Index                      
Commercial 1778 32.5 944 32.2 834 32.8 0.6501 1376 38.2 770 37.5 606 39.2 0.2770 402 21.4 174 19.9 228 22.8 0.1219 
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   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
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using 
a 
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in 1st 6 
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% pval  
Number of Patients 5475  2931 53.5 2544   3599  2055 57.1 1544   1876  876 46.7 1000   
Medicaid 655 12.0 384 13.1 271 10.7 0.0054 284 7.9 179 8.7 105 6.8 0.0354 371 19.8 205 23.4 166 16.6 0.0002 
Medicare 3071 56.1 1619 55.2 1452 57.1 0.1716 1968 54.7 1122 54.6 846 54.8 0.9078 1103 58.8 497 56.7 606 60.6 0.0897 
                                           
CMS comorbidities                                            
acute myocardial infarction 
(AMI) 
175 3.2 88 3.0 87 3.4 0.3812 114 3.2 59 2.9 55 3.6 0.2413 61 3.3 29 3.3 32 3.2 0.8929 
Alzheimer’s 189 3.5 105 3.6 84 3.3 0.5707 111 3.1 66 3.2 45 2.9 0.6098 78 4.2 39 4.5 39 3.9 0.5501 
atrial fibrillation 534 9.8 288 9.8 246 9.7 0.8460 362 10.1 202 9.8 160 10.4 0.5988 172 9.2 86 9.8 86 8.6 0.3620 
cancers 370 6.8 196 6.7 174 6.8 0.8226 265 7.4 151 7.3 114 7.4 0.9678 105 5.6 45 5.1 60 6.0 0.4172 
lung cancer 113 2.1 60 2.0 53 2.1 0.9250 75 2.1 40 1.9 35 2.3 0.5055 38 2.0 20 2.3 18 1.8 0.4587 
chronic kidney disease 870 15.9 461 15.7 409 16.1 0.7249 626 17.4 357 17.4 269 17.4 0.9687 244 13.0 104 11.9 140 14.0 0.1716 
diabetes 1358 24.8 767 26.2 591 23.2 0.0121 884 24.6 540 26.3 344 22.3 0.0058 474 25.3 227 25.9 247 24.7 0.5463 
heart failure 986 18.0 549 18.7 437 17.2 0.1358 645 17.9 387 18.8 258 16.7 0.1004 341 18.2 162 18.5 179 17.9 0.7396 
ischemic heart dis. (IHD; 
incl. AMI) 
1343 24.5 735 25.1 608 23.9 0.3126 908 25.2 519 25.3 389 25.2 0.9666 435 23.2 216 24.7 219 21.9 0.1580 
rheumatoid/osteo arthritis  1443 26.4 814 27.8 629 24.7 0.0107 954 26.5 571 27.8 383 24.8 0.0450 489 26.1 243 27.7 246 24.6 0.1222 
stroke/TIA 387 7.1 216 7.4 171 6.7 0.3509 256 7.1 158 7.7 98 6.3 0.1213 131 7.0 58 6.6 73 7.3 0.5648 
no CMS Comorbidity 1860 34.0 956 32.6 904 35.5 0.0230 1194 33.2 653 31.8 541 35.0 0.0396 666 35.5 303 34.6 363 36.3 0.4397 
                                           
Elixhauser comorbidities                                            
AIDS 10 0.2 6 0.2 4 0.2 0.6816 9 0.3 5 0.2 4 0.3 0.9254     1 0.1     0.2852 
alcohol abuse 191 3.5 96 3.3 95 3.7 0.3560 108 3.0 62 3.0 46 3.0 0.9476 83 4.4 34 3.9 49 4.9 0.2844 
chronic blood loss anemia 49 0.9 22 0.8 27 1.1 0.2234 28 0.8 10 0.5 18 1.2 0.0217 21 1.1 12 1.4 9 0.9 0.3345 
coagulopathy 163 3.0 87 3.0 76 3.0 0.9668 96 2.7 55 2.7 41 2.7 0.9692 67 3.6 32 3.7 35 3.5 0.8586 
congestive heart failure 903 16.5 512 17.5 391 15.4 0.0369 616 17.1 372 18.1 244 15.8 0.0699 287 15.3 140 16.0 147 14.7 0.4416 
deficiency anemias 773 14.1 424 14.5 349 13.7 0.4282 498 13.8 293 14.3 205 13.3 0.3990 275 14.7 131 15.0 144 14.4 0.7349 
depression 917 16.7 519 17.7 398 15.6 0.0415 537 14.9 335 16.3 202 13.1 0.0073 380 20.3 184 21.0 196 19.6 0.4501 
diabetes (wo/chr 
complications) 
1304 23.8 740 25.2 564 22.2 0.0077 867 24.1 524 25.5 343 22.2 0.0226 437 23.3 216 24.7 221 22.1 0.1911 
diabetes (w/chr 
complications) 
442 8.1 254 8.7 188 7.4 0.0839 332 9.2 203 9.9 129 8.4 0.1180 110 5.9 51 5.8 59 5.9 0.9427 
drug abuse 181 3.3 117 4.0 64 2.5 0.0023 115 3.2 73 3.6 42 2.7 0.1601 66 3.5 44 5.0 22 2.2 0.0009 
fluid and electrolyte 
disorders 
686 12.5 391 13.3 295 11.6 0.0518 422 11.7 248 12.1 174 11.3 0.4611 264 14.1 143 16.3 121 12.1 0.0087 
hypertension 3374 61.6 1808 61.7 1566 61.6 0.9221 2301 63.9 1315 64.0 986 63.9 0.9359 1073 57.2 493 56.3 580 58.0 0.4522 
hypothyroidism 1032 18.8 554 18.9 478 18.8 0.9158 684 19.0 403 19.6 281 18.2 0.2855 348 18.6 151 17.2 197 19.7 0.1710 
liver disease 212 3.9 116 4.0 96 3.8 0.7247 144 4.0 84 4.1 60 3.9 0.7601 68 3.6 32 3.7 36 3.6 0.9512 
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in 1st 6 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475  2931 53.5 2544   3599  2055 57.1 1544   1876  876 46.7 1000   
lymphoma 46 0.8 23 0.8 23 0.9 0.6293 31 0.9 19 0.9 12 0.8 0.6358 15 0.8 4 0.5 11 1.1 0.1185 
metastatic cancer 56 1.0 30 1.0 26 1.0 0.9955 41 1.1 17 0.8 24 1.6 0.0419 15 0.8 13 1.5 2 0.2 0.0018 
obesity 717 13.1 391 13.3 326 12.8 0.5652 480 13.3 275 13.4 205 13.3 0.9271 237 12.6 116 13.2 121 12.1 0.4576 
other neurological disorders 514 9.4 298 10.2 216 8.5 0.0339 363 10.1 217 10.6 146 9.5 0.2765 151 8.0 81 9.2 70 7.0 0.0743 
paralysis 68 1.2 30 1.0 38 1.5 0.1172 48 1.3 22 1.1 26 1.7 0.1124 20 1.1 8 0.9 12 1.2 0.5463 
peripheral vascular disease 878 16.0 488 16.6 390 15.3 0.1845 614 17.1 353 17.2 261 16.9 0.8291 264 14.1 135 15.4 129 12.9 0.1187 
psychoses 573 10.5 322 11.0 251 9.9 0.1771 399 11.1 242 11.8 157 10.2 0.1284 174 9.3 80 9.1 94 9.4 0.8420 
pulmonary circulation 
disease 
625 11.4 328 11.2 297 11.7 0.5745 435 12.1 242 11.8 193 12.5 0.5097 190 10.1 86 9.8 104 10.4 0.6764 
renal failure 468 8.5 250 8.5 218 8.6 0.9582 338 9.4 192 9.3 146 9.5 0.9085 130 6.9 58 6.6 72 7.2 0.6223 
rheumatoid arthritis/collagen 
vas 
343 6.3 201 6.9 142 5.6 0.0520 209 5.8 130 6.3 79 5.1 0.1247 134 7.1 71 8.1 63 6.3 0.1299 
solid tumor wo/metastasis 533 9.7 283 9.7 250 9.8 0.8308 368 10.2 204 9.9 164 10.6 0.4960 165 8.8 79 9.0 86 8.6 0.7496 
ulcers 7 0.1 4 0.1 3 0.1 0.8481 3 0.1 2 0.1 1 0.1 0.7377 4 0.2 2 0.2 2 0.2 0.8945 
valvular disease 630 11.5 345 11.8 285 11.2 0.5113 478 13.3 266 12.9 212 13.7 0.4914 152 8.1 79 9.0 73 7.3 0.1736 
weight loss 327 6.0 190 6.5 137 5.4 0.0875 219 6.1 128 6.2 91 5.9 0.6774 108 5.8 62 7.1 46 4.6 0.0215 
any Elixhauser diagnosis 5028 91.8 2712 92.5 2316 91.0 0.0446 3333 92.6 1909 92.9 1424 92.2 0.4488 1695 90.4 803 91.7 892 89.2 0.0710 
Other comorbidities                      
asthma 1813 33.1 959 32.7 854 33.6 0.5051 1166 32.4 678 33.0 488 31.6 0.3790 647 34.5 281 32.1 366 36.6 0.0398 
hypoxemia 1994 36.4 1029 35.1 965 37.9 0.0303 1229 34.1 679 33.0 550 35.6 0.1062 765 40.8 350 40.0 415 41.5 0.4967 
pneumonia 1908 34.8 1053 35.9 855 33.6 0.0726 1348 37.5 798 38.8 550 35.6 0.0489 560 29.9 255 29.1 305 30.5 0.5114 
influenza 178 3.3 109 3.7 69 2.7 0.0362 124 3.4 86 4.2 38 2.5 0.0050 54 2.9 23 2.6 31 3.1 0.5398 
                      
COPD Complexity ^                      
Low complexity 2740 50.0 1496 51.0 1244 48.9 0.1140 1761 48.9 1027 50.0 734 47.5 0.1478 979 52.2 469 53.5 510 51.0 0.2721 
Med complexity 2510 45.8 1326 45.2 1184 46.5 0.3355 1686 46.8 953 46.4 733 47.5 0.5130 824 43.9 373 42.6 451 45.1 0.2725 
High complexity 225 4.1 109 3.7 116 4.6 0.1180 152 4.2 75 3.6 77 5.0 0.0483 73 3.9 34 3.9 39 3.9 0.9833 
Emphysema diagnosis (492.x) 1210 22.1 576 19.7 634 24.9 <0.0001 694 19.3 358 17.4 336 21.8 0.0011 516 27.5 218 24.9 298 29.8 0.0174 
                      
COPD Medications                       
index ICSLABA 3052 55.7 1791 61.1 1261 49.6 <0.0001 2129 59.2 1352 65.8 777 50.3 <0.0001 923 49.2 439 50.1 484 48.4 0.4587 
index LAMA 1939 35.4 967 33.0 972 38.2 <0.0001 1158 32.2 593 28.9 565 36.6 <0.0001 781 41.6 374 42.7 407 40.7 0.3820 
index triple 484 8.8 173 5.9 311 12.2 <0.0001 312 8.7 110 5.4 202 13.1 <0.0001 172 9.2 63 7.2 109 10.9 0.0055 
SABA use                      
no SABA use 2314 42.3 1204 41.1 1110 43.6 0.0564 1479 41.1 854 41.6 625 40.5 0.5154 835 44.5 350 40.0 485 48.5 0.0002 
SABA <=15% of year 1435 26.2 820 28.0 615 24.2 0.0014 973 27.0 589 28.7 384 24.9 0.0113 462 24.6 231 26.4 231 23.1 0.1010 
SABA <=40% of year 803 14.7 475 16.2 328 12.9 0.0005 555 15.4 338 16.4 217 14.1 0.0491 248 13.2 137 15.6 111 11.1 0.0038 
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   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total % Discont 
1st 6 
months 
% Still 
using a 
Trmt 
% pval  Total % Discont 
1st 6 
months 
% Still 
using 
a 
Trmt 
% pval  Total % Discont 
in 1st 6 
months 
% Still 
using 
a 
Trmt 
% pval  
Number of Patients 5475  2931 53.5 2544   3599  2055 57.1 1544   1876  876 46.7 1000   
SABA >40% of year 923 16.9 432 14.7 491 19.3 <0.0001 592 16.4 274 13.3 318 20.6 <0.0001 331 17.6 158 18.0 173 17.3 0.6763 
SAMA use                                           
any ipratropium (SAMA) 632 11.5 307 10.5 325 12.8 0.0079 391 10.9 187 9.1 204 13.2 <0.0001 241 12.8 120 13.7 121 12.1 0.3019 
any SABA/SAMA 876 16.0 433 14.8 443 17.4 0.0079 591 16.4 302 14.7 289 18.7 0.0013 285 15.2 131 15.0 154 15.4 0.7885 
any SAMA or SABA/SAMA 1381 25.2 678 23.1 703 27.6 0.0001 901 25.0 449 21.8 452 29.3 <0.0001 480 25.6 229 26.1 251 25.1 0.6060 
Other COPD medications                                           
any ICS 1752 32.0 899 30.7 853 33.5 0.0238 1143 31.8 603 29.3 540 35.0 0.0003 609 32.5 296 33.8 313 31.3 0.2505 
any LABA 227 4.1 93 3.2 134 5.3 0.0001 118 3.3 43 2.1 75 4.9 <0.0001 109 5.8 50 5.7 59 5.9 0.8591 
any methylxanthines 87 1.6 42 1.4 45 1.8 0.3215 29 0.8 16 0.8 13 0.8 0.8333 58 3.1 26 3.0 32 3.2 0.7721 
Any use of above COPD 
medications 
2688 49.1 1381 47.1 1307 51.4 0.0017 1748 48.6 920 44.8 828 53.6 <0.0001 940 50.1 461 52.6 479 47.9 0.0411 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 4868 88.9 2607 88.9 2261 88.9 0.9345 3206 89.1 1837 89.4 1369 88.7 0.4895 1662 88.6 770 87.9 892 89.2 0.3767 
1-2 Rxs ICSLABA (wks 27-
52) 
387 7.1 234 8.0 153 6.0 0.0046 255 7.1 159 7.7 96 6.2 0.0787 132 7.0 75 8.6 57 5.7 0.0156 
>2 Rxs ICSLABA (wks 27-
52) 
220 4.0 90 3.1 130 5.1 0.0001 138 3.8 59 2.9 79 5.1 0.0005 82 4.4 31 3.5 51 5.1 0.0989 
No LAMA in prior year 5280 96.4 2832 96.6 2448 96.2 0.4305 3472 96.5 1990 96.8 1482 96.0 0.1701 1808 96.4 842 96.1 966 96.6 0.5779 
1-2 Rxs LAMA (wks 27-52) 124 2.3 70 2.4 54 2.1 0.5100 86 2.4 48 2.3 38 2.5 0.8074 38 2.0 22 2.5 16 1.6 0.1621 
>2 Rxs LAMA (wks 27-52) 71 1.3 29 1.0 42 1.7 0.0309 41 1.1 17 0.8 24 1.6 0.0419 30 1.6 12 1.4 18 1.8 0.4587 
Oxygen Use                                           
no oxygen 3090 56.4 1718 58.6 1372 53.9 0.0005 2097 58.3 1249 60.8 848 54.9 0.0004 993 52.9 469 53.5 524 52.4 0.6220 
oxygen <=50% of year 876 16.0 449 15.3 427 16.8 0.1401 619 17.2 332 16.2 287 18.6 0.0556 257 13.7 117 13.4 140 14.0 0.6858 
oxygen >50% of year 1509 27.6 764 26.1 745 29.3 0.0079 883 24.5 474 23.1 409 26.5 0.0181 626 33.4 290 33.1 336 33.6 0.8206 
Symptoms                      
Dyspnea                      
Breathlessness                      
no periods breathlessness 3454 63.1 1864 63.6 1590 62.5 0.4019 2101 58.4 1231 59.9 870 56.3 0.0322 1353 72.1 633 72.3 720 72.0 0.9002 
1 period breathlessness 1051 19.2 566 19.3 485 19.1 0.8174 757 21.0 438 21.3 319 20.7 0.6341 294 15.7 128 14.6 166 16.6 0.2373 
>1 period breathlessness 970 17.7 501 17.1 469 18.4 0.1945 741 20.6 386 18.8 355 23.0 0.0020 229 12.2 115 13.1 114 11.4 0.2541 
Shortness of Breath                      
no periods shortness breath 3450 63.0 1851 63.2 1599 62.9 0.8194 2260 62.8 1306 63.6 954 61.8 0.2783 1190 63.4 545 62.2 645 64.5 0.3052 
1 period shortness breath 1128 20.6 616 21.0 512 20.1 0.4163 785 21.8 447 21.8 338 21.9 0.9202 343 18.3 169 19.3 174 17.4 0.2901 
>1 period shortness breath 897 16.4 464 15.8 433 17.0 0.2356 554 15.4 302 14.7 252 16.3 0.1811 343 18.3 162 18.5 181 18.1 0.8260 
any wheezing 419 7.7 232 7.9 187 7.4 0.4330 302 8.4 177 8.6 125 8.1 0.5796 117 6.2 55 6.3 62 6.2 0.9440 
any dyspnea 3057 55.8 1631 55.6 1426 56.1 0.7623 2126 59.1 1178 57.3 948 61.4 0.0139 931 49.6 453 51.7 478 47.8 0.0909 
supplemental oxygen use 317 5.8 151 5.2 166 6.5 0.0300 112 3.1 60 2.9 52 3.4 0.4435 205 10.9 91 10.4 114 11.4 0.4834 
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   LHP and PHP Combined  LHP             PHP             
LHP & PHP  
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Total % Discont 
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a 
Trmt 
% pval  
Number of Patients 5475  2931 53.5 2544   3599  2055 57.1 1544   1876  876 46.7 1000   
(V46.2) 
Other symptoms                      
chest pain unspecified 1662 30.4 960 32.8 702 27.6 <0.0001 1082 30.1 656 31.9 426 27.6 0.0050 580 30.9 304 34.7 276 27.6 0.0009 
painful respiratory 272 5.0 158 5.4 114 4.5 0.1224 165 4.6 105 5.1 60 3.9 0.0824 107 5.7 53 6.1 54 5.4 0.5446 
precordial pain 107 2.0 63 2.1 44 1.7 0.2630 72 2.0 44 2.1 28 1.8 0.4872 35 1.9 19 2.2 16 1.6 0.3636 
any chestpain 1742 31.8 1005 34.3 737 29.0 <0.0001 1137 31.6 693 33.7 444 28.8 0.0015 605 32.2 312 35.6 293 29.3 0.0035 
chronic fatigue 85 1.6 52 1.8 33 1.3 0.1545 67 1.9 46 2.2 21 1.4 0.0537 18 1.0 6 0.7 12 1.2 0.2536 
other malaise/fatigue 1379 25.2 788 26.9 591 23.2 0.0019 884 24.6 544 26.5 340 22.0 0.0021 495 26.4 244 27.9 251 25.1 0.1769 
difficulty walking 139 2.5 79 2.7 60 2.4 0.4294 105 2.9 58 2.8 47 3.0 0.6958 34 1.8 21 2.4 13 1.3 0.0755 
memory loss 132 2.4 81 2.8 51 2.0 0.0679 94 2.6 61 3.0 33 2.1 0.1218 38 2.0 20 2.3 18 1.8 0.4587 
cough 1963 35.9 1105 37.7 858 33.7 0.0022 1394 38.7 826 40.2 568 36.8 0.0378 569 30.3 279 31.8 290 29.0 0.1804 
hemoptysis 76 1.4 39 1.3 37 1.5 0.6962 52 1.4 26 1.3 26 1.7 0.2975 24 1.3 13 1.5 11 1.1 0.4603 
Procedures                      
chest CT 822 15.0 447 15.3 375 14.7 0.5981 551 15.3 308 15.0 243 15.7 0.5360 271 14.4 139 15.9 132 13.2 0.1011 
chest x-ray 3432 62.7 1841 62.8 1591 62.5 0.8356 2234 62.1 1273 61.9 961 62.2 0.8570 1198 63.9 568 64.8 630 63.0 0.4078 
echocardiography 1113 20.3 598 20.4 515 20.2 0.8842 819 22.8 460 22.4 359 23.3 0.5393 294 15.7 138 15.8 156 15.6 0.9273 
EKG 2452 44.8 1342 45.8 1110 43.6 0.1099 1621 45.0 940 45.7 681 44.1 0.3289 831 44.3 402 45.9 429 42.9 0.1933 
heart catheterization 71 1.3 43 1.5 28 1.1 0.2320 51 1.4 30 1.5 21 1.4 0.8021 20 1.1 13 1.5 7 0.7 0.0990 
nebulizer treatment 1771 32.3 931 31.8 840 33.0 0.3222 1326 36.8 727 35.4 599 38.8 0.0354 445 23.7 204 23.3 241 24.1 0.6799 
non-invasive ventilator 339 6.2 163 5.6 176 6.9 0.0377 210 5.8 107 5.2 103 6.7 0.0636 129 6.9 56 6.4 73 7.3 0.4385 
spirometry 2284 41.7 1134 38.7 1150 45.2 <0.0001 1578 43.8 831 40.4 747 48.4 <0.0001 706 37.6 303 34.6 403 40.3 0.0109 
any vaccination (flu or 
pneumonia) 
2632 48.1 1391 47.5 1241 48.8 0.3284 1799 50.0 1011 49.2 788 51.0 0.2748 833 44.4 380 43.4 453 45.3 0.4035 
COPD-related exacerbations                      
Index and 2 weeks prior                      
any moderate 783 14.3 462 15.8 321 12.6 0.0009 525 14.6 313 15.2 212 13.7 0.2069 258 13.8 149 17.0 109 10.9 0.0001 
any severe 434 7.9 261 8.9 173 6.8 0.0040 266 7.4 160 7.8 106 6.9 0.2961 168 9.0 101 11.5 67 6.7 0.0003 
any other hospitalizations* 124 2.3 81 2.8 43 1.7 0.0078 112 3.1 74 3.6 38 2.5 0.0513 12 0.6 7 0.8 5 0.5 0.4175 
Prior 2-12 weeks                      
any moderate 894 16.3 458 15.6 436 17.1 0.1311 585 16.3 316 15.4 269 17.4 0.0998 309 16.5 142 16.2 167 16.7 0.7753 
any severe 337 6.2 175 6.0 162 6.4 0.5419 179 5.0 102 5.0 77 5.0 0.9743 158 8.4 73 8.3 85 8.5 0.8968 
any other hospitalizations* 209 3.8 111 3.8 98 3.9 0.9002 169 4.7 94 4.6 75 4.9 0.6909 40 2.1 17 1.9 23 2.3 0.5909 
Prior 13-52 weeks                      
no moderate 4200 76.7 2219 75.7 1981 77.9 0.0591 2733 75.9 1559 75.9 1174 76.0 0.9046 1467 78.2 660 75.3 807 80.7 0.0050 
1 moderate 1018 18.6 569 19.4 449 17.6 0.0943 694 19.3 402 19.6 292 18.9 0.6246 324 17.3 167 19.1 157 15.7 0.0545 
>1 moderate 257 4.7 143 4.9 114 4.5 0.4877 172 4.8 94 4.6 78 5.1 0.5062 85 4.5 49 5.6 36 3.6 0.0383 
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Number of Patients 5475  2931 53.5 2544   3599  2055 57.1 1544   1876  876 46.7 1000   
any severe 409 7.5 201 6.9 208 8.2 0.0642 215 6.0 117 5.7 98 6.3 0.4128 194 10.3 84 9.6 110 11.0 0.3167 
any other hospitalizations* 384 7.0 212 7.2 172 6.8 0.4952 313 8.7 179 8.7 134 8.7 0.9733 71 3.8 33 3.8 38 3.8 0.9703 
All Inpatient Utilization                      
Non-COPD Inpatient (Any) 852 15.6 489 16.7 363 14.3 0.0140 687 19.1 401 19.5 286 18.5 0.4545 165 8.8 88 10.0 77 7.7 0.0735 
COPD Inpatient (Any) 1117 20.4 621 21.2 496 19.5 0.1216 636 17.7 378 18.4 258 16.7 0.1898 481 25.6 243 27.7 238 23.8 0.0512 
Total Inpatient (Any) 1690 30.9 948 32.3 742 29.2 0.0111 1153 32.0 678 33.0 475 30.8 0.1562 537 28.6 270 30.8 267 26.7 0.0488 
                      
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period) 
Same as Index Trmt     2238 88.0      1334 86.4      904 90.4  
No evidence Any Trmt   2931 100      2055 100      876 100    
Different Trmt from Index     306 12.0      210 13.6      96 9.6  
Now using Triple     169 6.6      107 6.9      62 6.2  
No longer using Triple     86 3.4      63 4.1      23 2.3  
Switched between ICSLABA 
and LAMA 
    51 2.0      40 2.6      11 1.1  
LHP enrollee 3599 65.7 2055 70.1 1544 60.7 <0.0001               
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 27 Baseline Characteristics –Switching from Index therapy in First 3 Months 
  LHP & PHP LHP PHP 
LHP & PHP  
Baseline Characteristic 
Total % Switch 
1st 3 
mos 
% Still 
Index 
Trmt 
% pval  Total % Switch 
1st 3 
mos 
% Still 
Index 
Trmt 
% pval  Total % Switch 
1st 3 
mos 
% Still 
Index 
Trmt 
% pval  
Number of Patients 3403   306 9.0% 3097     2127   208 9.8% 1919     1276   98 7.7% 1178     
Age Categories                                           
age 40-54 326 9.6 24 7.8 302 9.8 0.2793 170 8.0 11 5.3 159 8.3 0.1300 156 12.2 13 13.3 143 12.1 0.7437 
age 55-64 646 19.0 66 21.6 580 18.7 0.2267 348 16.4 37 17.8 311 16.2 0.5580 298 23.4 29 29.6 269 22.8 0.1288 
age 65-74 1039 30.5 102 33.3 937 30.3 0.2647 640 30.1 73 35.1 567 29.5 0.0974 399 31.3 29 29.6 370 31.4 0.7092 
age 75 and older 1392 40.9 114 37.3 1278 41.3 0.1734 969 45.6 87 41.8 882 46.0 0.2554 423 33.2 27 27.6 396 33.6 0.2204 
age (Mean, SD) 70.74 11.27 70.69 11.06 70.75 11.29 0.9255 71.86 11.06 71.97 10.64 71.85 11.11 0.8834 68.88 11.37 67.97 11.51 68.96 11.36 0.4073 
                                            
Men 1509 44.3 144 47.1 1365 44.1 0.3162 962 45.2 101 48.6 861 44.9 0.3097 547 42.9 43 43.9 504 42.8 0.8336 
                                            
Quarter of Year, Index Date             0.6699             0.7328             0.8745 
Q1 1030 30.3 88 28.8 942 30.4   645 30.3 57 27.4 588 30.6   385 30.2 31 31.6 354 30.1   
Q2 685 20.1 69 22.5 616 19.9   466 21.9 50 24.0 416 21.7   219 17.2 19 19.4 200 17.0   
Q3 725 21.3 67 21.9 658 21.2   506 23.8 52 25.0 454 23.7   219 17.2 15 15.3 204 17.3   
Q4 963 28.3 82 26.8 881 28.4   510 24.0 49 23.6 461 24.0   453 35.5 33 33.7 420 35.7   
                                            
Months enrollment post-Index             0.2316             0.4643             0.0297 
7 39 1.1 4 1.3 35 1.1   22 1.0 2 1.0 20 1.0   17 1.3 2 2.0 15 1.3   
8 40 1.2 7 2.3 33 1.1   25 1.2 4 1.9 21 1.1   15 1.2 3 3.1 12 1.0   
9 58 1.7 7 2.3 51 1.6   33 1.6 5 2.4 28 1.5   25 2.0 2 2.0 23 2.0   
10 57 1.7 8 2.6 49 1.6   37 1.7 5 2.4 32 1.7   20 1.6 3 3.1 17 1.4   
11 69 2.0 8 2.6 61 2.0   53 2.5 8 3.8 45 2.3           16 1.4   
12 51 1.5 4 1.3 47 1.5   38 1.8 3 1.4 35 1.8   13 1.0 1 1.0 12 1.0   
13 68 2.0 8 2.6 60 1.9   45 2.1 6 2.9 39 2.0   23 1.8 2 2.0 21 1.8   
14 68 2.0 6 2.0 62 2.0   47 2.2 5 2.4 42 2.2   21 1.6 1 1.0 20 1.7   
15 54 1.6 2 0.7 52 1.7           37 1.9   17 1.3 2 2.0 15 1.3   
16 71 2.1 3 1.0 68 2.2   38 1.8 2 1.0 36 1.9   33 2.6 1 1.0 32 2.7   
17 75 2.2 6 2.0 69 2.2   45 2.1 4 1.9 41 2.1   30 2.4 2 2.0 28 2.4   
18 72 2.1 6 2.0 66 2.1   47 2.2 4 1.9 43 2.2   25 2.0 2 2.0 23 2.0   
19 62 1.8 5 1.6 57 1.8   36 1.7 1 0.5 35 1.8   26 2.0 4 4.1 22 1.9   
20 59 1.7 4 1.3 55 1.8   40 1.9 3 1.4 37 1.9   19 1.5 1 1.0 18 1.5   
21 65 1.9 6 2.0 59 1.9   40 1.9 4 1.9 36 1.9   25 2.0 2 2.0 23 2.0   
22 74 2.2 5 1.6 69 2.2   47 2.2 4 1.9 43 2.2   27 2.1 1 1.0 26 2.2   
23 61 1.8 6 2.0 55 1.8   41 1.9 5 2.4 36 1.9   20 1.6 1 1.0 19 1.6   
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LHP & PHP  
Baseline Characteristic 
Total % Switch 
1st 3 
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% Still 
Index 
Trmt 
% pval  Total % Switch 
1st 3 
mos 
% Still 
Index 
Trmt 
% pval  Total % Switch 
1st 3 
mos 
% Still 
Index 
Trmt 
% pval  
Number of Patients 3403   306 9.0% 3097     2127   208 9.8% 1919     1276   98 7.7% 1178     
24 2360 69.4 211 69.0 2149 69.4   1456 68.5 143 68.8 1313 68.4   904 70.8 68 69.4 836 71.0   
Insurance at Index                                           
Commercial 1103 32.4 114 37.3 989 31.9 0.0578 821 38.6 84 40.4 737 38.4 0.5776 282 22.1 30 30.6 252 21.4 0.0345 
Medicaid 377 11.1 22 7.2 355 11.5 0.0231 160 7.5 9 4.3 151 7.9 0.0658 217 17.0 13 13.3 204 17.3 0.3049 
Medicare 1942 57.1 171 55.9 1771 57.2 0.6607 1165 54.8 116 55.8 1049 54.7 0.7610 777 60.9 55 56.1 722 61.3 0.3138 
                                            
CMS comorbidities                                            
acute myocardial infarction 
(AMI) 
112 3.3 8 2.6 104 3.4 0.4866 72 3.4 4 1.9 68 3.5 0.2196 40 3.1 4 4.1 36 3.1 0.5756 
Alzheimer’s 109 3.2 7 2.3 102 3.3 0.3404 61 2.9 4 1.9 57 3.0 0.3900 48 3.8 3 3.1 45 3.8 0.7044 
atrial fibrillation 323 9.5 29 9.5 294 9.5 0.9928 209 9.8 24 11.5 185 9.6 0.3824 114 8.9 5 5.1 109 9.3 0.1663 
cancers 229 6.7 20 6.5 209 6.7 0.8874 155 7.3 12 5.8 143 7.5 0.3752 74 5.8 8 8.2 66 5.6 0.2974 
lung cancer 72 2.1 3 1.0 69 2.2 0.1480 46 2.2 3 1.4 43 2.2 0.4521         26 2.2 0.1373 
chronic kidney disease 536 15.8 38 12.4 498 16.1 0.0934 362 17.0 29 13.9 333 17.4 0.2138 174 13.6 9 9.2 165 14.0 0.1813 
diabetes 802 23.6 60 19.6 742 24.0 0.0871 484 22.8 45 21.6 439 22.9 0.6849 318 24.9 15 15.3 303 25.7 0.0220 
heart failure 591 17.4 60 19.6 531 17.1 0.2781 367 17.3 44 21.2 323 16.8 0.1171 224 17.6 16 16.3 208 17.7 0.7394 
ischemic heart dis. (IHD; incl. 
AMI) 
803 23.6 76 24.8 727 23.5 0.5924 524 24.6 59 28.4 465 24.2 0.1887 279 21.9 17 17.3 262 22.2 0.2601 
rheumatoid/osteo arthritis  870 25.6 71 23.2 799 25.8 0.3206 543 25.5 48 23.1 495 25.8 0.3932 327 25.6 23 23.5 304 25.8 0.6106 
stroke/TIA 246 7.2 25 8.2 221 7.1 0.5052 147 6.9 16 7.7 131 6.8 0.6401 99 7.8 9 9.2 90 7.6 0.5831 
no CMS Comorbidity 1191 35.0 121 39.5 1070 34.5 0.0807 735 34.6 73 35.1 662 34.5 0.8630 456 35.7 48 49.0 408 34.6 0.0044 
Elixhauser comorbidities                                            
AIDS         7 0.2 0.4051         7 0.4 0.3829               
alcohol abuse 126 3.7 12 3.9 114 3.7 0.8316 63 3.0 6 2.9 57 3.0 0.9448 63 4.9 6 6.1 57 4.8 0.5730 
chronic blood loss anemia 29 0.9 2 0.7 27 0.9 0.6920 19 0.9 2 1.0 17 0.9 0.9123         10 0.8 0.3598 
coagulopathy 106 3.1 11 3.6 95 3.1 0.6125 56 2.6 7 3.4 49 2.6 0.4872 50 3.9 4 4.1 46 3.9 0.9310 
congestive heart failure 538 15.8 50 16.3 488 15.8 0.7898 347 16.3 34 16.3 313 16.3 0.9895 191 15.0 16 16.3 175 14.9 0.6950 
deficiency anemias 452 13.3 40 13.1 412 13.3 0.9094 274 12.9 31 14.9 243 12.7 0.3595 178 13.9 9 9.2 169 14.3 0.1564 
depression 540 15.9 43 14.1 497 16.0 0.3621 295 13.9 25 12.0 270 14.1 0.4164 245 19.2 18 18.4 227 19.3 0.8275 
diabetes (wo/chr 
complications) 
764 22.5 56 18.3 708 22.9 0.0682 478 22.5 44 21.2 434 22.6 0.6313 286 22.4 12 12.2 274 23.3 0.0120 
diabetes (w/chr complications) 257 7.6 17 5.6 240 7.7 0.1659 185 8.7 11 5.3 174 9.1 0.0662 72 5.6 6 6.1 66 5.6 0.8304 
drug abuse 93 2.7 4 1.3 89 2.9 0.1088 65 3.1 2 1.0 63 3.3 0.0647 28 2.2 2 2.0 26 2.2 0.9140 
fluid and electrolyte disorders 408 12.0 42 13.7 366 11.8 0.3271 240 11.3 29 13.9 211 11.0 0.2020 168 13.2 13 13.3 155 13.2 0.9759 
hypertension 2092 61.5 177 57.8 1915 61.8 0.1712 1353 63.6 135 64.9 1218 63.5 0.6832 739 57.9 42 42.9 697 59.2 0.0017 
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Number of Patients 3403   306 9.0% 3097     2127   208 9.8% 1919     1276   98 7.7% 1178     
hypothyroidism 653 19.2 58 19.0 595 19.2 0.9130 409 19.2 41 19.7 368 19.2 0.8525 244 19.1 17 17.3 227 19.3 0.6419 
liver disease 136 4.0 13 4.2 123 4.0 0.8136 87 4.1 10 4.8 77 4.0 0.5823 49 3.8 3 3.1 46 3.9 0.6762 
lymphoma 29 0.9 1 0.3 28 0.9 0.2946 16 0.8 1 0.5 15 0.8 0.6333         13 1.1 0.2959 
metastatic cancer 31 0.9 2 0.7 29 0.9 0.6194 26 1.2 2 1.0 24 1.3 0.7185         5 0.4 0.5181 
obesity 437 12.8 37 12.1 400 12.9 0.6810 283 13.3 26 12.5 257 13.4 0.7189 154 12.1 11 11.2 143 12.1 0.7894 
other neurological disorders 308 9.1 27 8.8 281 9.1 0.8845 209 9.8 22 10.6 187 9.7 0.7017 99 7.8 5 5.1 94 8.0 0.3062 
paralysis 52 1.5 4 1.3 48 1.5 0.7413 37 1.7 3 1.4 34 1.8 0.7299 15 1.2 1 1.0 14 1.2 0.8821 
peripheral vascular disease 543 16.0 46 15.0 497 16.0 0.6437 361 17.0 35 16.8 326 17.0 0.9531 182 14.3 11 11.2 171 14.5 0.3706 
psychoses 345 10.1 28 9.2 317 10.2 0.5484 234 11.0 19 9.1 215 11.2 0.3650 111 8.7 9 9.2 102 8.7 0.8594 
pulmonary circulation disease 387 11.4 37 12.1 350 11.3 0.6779 253 11.9 26 12.5 227 11.8 0.7765 134 10.5 11 11.2 123 10.4 0.8080 
renal failure 283 8.3 18 5.9 265 8.6 0.1060 192 9.0 14 6.7 178 9.3 0.2238 91 7.1 4 4.1 87 7.4 0.2221 
rheumatoid arthritis/collagen 
vas 
212 6.2 22 7.2 190 6.1 0.4665 119 5.6 14 6.7 105 5.5 0.4529 93 7.3 8 8.2 85 7.2 0.7288 
solid tumor wo/metastasis 329 9.7 26 8.5 303 9.8 0.4674 219 10.3 17 8.2 202 10.5 0.2888 110 8.6 9 9.2 101 8.6 0.8363 
ulcers 5 0.1 1 0.3 4 0.1 0.3892         2 0.1 0.6413 3 0.2 1 1.0 2 0.2 0.0948 
valvular disease 387 11.4 37 12.1 350 11.3 0.6779 290 13.6 27 13.0 263 13.7 0.7725 97 7.6 10 10.2 87 7.4 0.3117 
weight loss 188 5.5 21 6.9 167 5.4 0.2828 125 5.9 14 6.7 111 5.8 0.5814 63 4.9 7 7.1 56 4.8 0.2942 
any Elixhauser diagnosis 3103 91.2 279 91.2 2824 91.2 0.9960 1961 92.2 195 93.8 1766 92.0 0.3789 1142 89.5 84 85.7 1058 89.8 0.2035 
Other comorbidities                                           
asthma 1128 33.1 95 31.0 1033 33.4 0.4130 683 32.1 57 27.4 626 32.6 0.1258 445 34.9 38 38.8 407 34.6 0.3990 
hypoxemia 1278 37.6 134 43.8 1144 36.9 0.0182 748 35.2 91 43.8 657 34.2 0.0063 530 41.5 43 43.9 487 41.3 0.6244 
pneumonia 1152 33.9 106 34.6 1046 33.8 0.7601 768 36.1 74 35.6 694 36.2 0.8669 384 30.1 32 32.7 352 29.9 0.5654 
influenza 101 3.0 8 2.6 93 3.0 0.7024 64 3.0 6 2.9 58 3.0 0.9120 37 2.9 2 2.0 35 3.0 0.5979 
                                            
COPD Complexity ^                                           
Low complexity 1673 49.2 126 41.2 1547 50.0 0.0034 1009 47.4 85 40.9 924 48.2 0.0457 664 52.0 41 41.8 623 52.9 0.0354 
Med complexity 1575 46.3 166 54.2 1409 45.5 0.0034 1017 47.8 112 53.8 905 47.2 0.0667 558 43.7 54 55.1 504 42.8 0.0182 
High complexity 155 4.6 14 4.6 141 4.6 0.9857 101 4.7 11 5.3 90 4.7 0.6998 54 4.2 3 3.1 51 4.3 0.5491 
Emphysema diagnosis (492.x) 813 23.9 90 29.4 723 23.3 0.0176 443 20.8 54 26.0 389 20.3 0.0549 370 29.0 36 36.7 334 28.4 0.0789 
                                            
COPD Medications                                            
index ICSLABA 1731 50.9 89 29.1 1642 53.0 <0.0001 1133 53.3 68 32.7 1065 55.5 <0.0001 598 46.9 21 21.4 577 49.0 <0.0001 
index LAMA 1284 37.7 115 37.6 1169 37.7 0.9548 749 35.2 75 36.1 674 35.1 0.7885 535 41.9 40 40.8 495 42.0 0.8165 
index triple 388 11.4 102 33.3 286 9.2 <0.0001 245 11.5 65 31.3 180 9.4 <0.0001 143 11.2 37 37.8 106 9.0 <0.0001 
SABA use                                           
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Number of Patients 3403   306 9.0% 3097     2127   208 9.8% 1919     1276   98 7.7% 1178     
no SABA use 1484 43.6 122 39.9 1362 44.0 0.1668 885 41.6 83 39.9 802 41.8 0.5996 599 46.9 39 39.8 560 47.5 0.1400 
SABA <=15% of year 836 24.6 83 27.1 753 24.3 0.2760 533 25.1 60 28.8 473 24.6 0.1845 303 23.7 23 23.5 280 23.8 0.9466 
SABA <=40% of year 461 13.5 42 13.7 419 13.5 0.9238 312 14.7 25 12.0 287 15.0 0.2555 149 11.7 17 17.3 132 11.2 0.0689 
SABA >40% of year 622 18.3 59 19.3 563 18.2 0.6341 397 18.7 40 19.2 357 18.6 0.8254 225 17.6 19 19.4 206 17.5 0.6353 
SAMA use                                           
any ipratropium (SAMA) 415 12.2 41 13.4 374 12.1 0.5000 256 12.0 32 15.4 224 11.7 0.1181 159 12.5 9 9.2 150 12.7 0.3066 
any SABA/SAMA 565 16.6 56 18.3 509 16.4 0.4028 377 17.7 44 21.2 333 17.4 0.1727 188 14.7 12 12.2 176 14.9 0.4694 
any SAMA or SABA/SAMA 893 26.2 90 29.4 803 25.9 0.1864 574 27.0 69 33.2 505 26.3 0.0343 319 25.0 21 21.4 298 25.3 0.3954 
Other COPD medications                                           
any ICS 1118 32.9 90 29.4 1028 33.2 0.1791 710 33.4 67 32.2 643 33.5 0.7067 408 32.0 23 23.5 385 32.7 0.0602 
any LABA 170 5.0 12 3.9 158 5.1 0.3660 91 4.3 8 3.8 83 4.3 0.7457 79 6.2 4 4.1 75 6.4 0.3671 
any methylxanthines 61 1.8 4 1.3 57 1.8 0.5024 19 0.9 2 1.0 17 0.9 0.9123 42 3.3 2 2.0 40 3.4 0.4701 
Any use of above COPD 
medications 
1711 50.3 154 50.3 1557 50.3 0.9861 1089 51.2 116 55.8 973 50.7 0.1650 622 48.7 38 38.8 584 49.6 0.0399 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 3043 89.4 279 91.2 2764 89.2 0.2953 1897 89.2 187 89.9 1710 89.1 0.7258 1146 89.8 92 93.9 1054 89.5 0.1661 
1-2 Rxs ICSLABA (wks 27-
52) 
203 6.0 13 4.2 190 6.1 0.1838 133 6.3 10 4.8 123 6.4 0.3647 70 5.5 3 3.1 67 5.7 0.2726 
>2 Rxs ICSLABA (wks 27-
52) 
157 4.6 14 4.6 143 4.6 0.9732 97 4.6 11 5.3 86 4.5 0.5962 60 4.7 3 3.1 57 4.8 0.4245 
No LAMA in prior year 3282 96.4 289 94.4 2993 96.6 0.0477 2049 96.3 196 94.2 1853 96.6 0.0895 1233 96.6 93 94.9 1140 96.8 0.3227 
1-2 Rxs LAMA (wks 27-52) 66 1.9 9 2.9 57 1.8 0.1829 47 2.2 8 3.8 39 2.0 0.0910 19 1.5 1 1.0 18 1.5 0.6902 
>2 Rxs LAMA (wks 27-52) 55 1.6 8 2.6 47 1.5 0.1466 31 1.5 4 1.9 27 1.4 0.5552 24 1.9 4 4.1 20 1.7 0.0951 
Oxygen Use                                           
no oxygen 1875 55.1 172 56.2 1703 55.0 0.6822 1206 56.7 122 58.7 1084 56.5 0.5493 669 52.4 50 51.0 619 52.5 0.7713 
oxygen <=50% of year 560 16.5 46 15.0 514 16.6 0.4815 378 17.8 31 14.9 347 18.1 0.2547 182 14.3 15 15.3 167 14.2 0.7587 
oxygen >50% of year 968 28.4 88 28.8 880 28.4 0.8989 543 25.5 55 26.4 488 25.4 0.7504 425 33.3 33 33.7 392 33.3 0.9362 
                                            
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 2125 62.4 173 56.5 1952 63.0 0.0253 1206 56.7 104 50.0 1102 57.4 0.0401 919 72.0 69 70.4 850 72.2 0.7111 
1 period breathlessness 664 19.5 61 19.9 603 19.5 0.8450 458 21.5 46 22.1 412 21.5 0.8296 206 16.1 15 15.3 191 16.2 0.8145 
>1 period breathlessness 614 18.0 72 23.5 542 17.5 0.0089 463 21.8 58 27.9 405 21.1 0.0244 151 11.8 14 14.3 137 11.6 0.4342 
Shortness of Breath                                           
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Number of Patients 3403   306 9.0% 3097     2127   208 9.8% 1919     1276   98 7.7% 1178     
no periods shortness breath 2149 63.2 185 60.5 1964 63.4 0.3061 1327 62.4 123 59.1 1204 62.7 0.3078 822 64.4 62 63.3 760 64.5 0.8037 
1 period shortness breath 688 20.2 65 21.2 623 20.1 0.6400 463 21.8 54 26.0 409 21.3 0.1228 225 17.6 11 11.2 214 18.2 0.0832 
>1 period shortness breath 566 16.6 56 18.3 510 16.5 0.4114 337 15.8 31 14.9 306 15.9 0.6959 229 17.9 25 25.5 204 17.3 0.0423 
any wheezing 255 7.5 22 7.2 233 7.5 0.8324 175 8.2 18 8.7 157 8.2 0.8138 80 6.3 4 4.1 76 6.5 0.3524 
any dyspnea 1913 56.2 197 64.4 1716 55.4 0.0025 1294 60.8 147 70.7 1147 59.8 0.0022 619 48.5 50 51.0 569 48.3 0.6049 
supplemental oxygen use 
(V46.2) 
208 6.1 15 4.9 193 6.2 0.3542 72 3.4 2 1.0 70 3.6 0.0419 136 10.7 13 13.3 123 10.4 0.3841 
Other symptoms                                           
chest pain unspecified 957 28.1 85 27.8 872 28.2 0.8883 590 27.7 62 29.8 528 27.5 0.4829 367 28.8 23 23.5 344 29.2 0.2283 
painful respiratory 156 4.6 19 6.2 137 4.4 0.1542 85 4.0 11 5.3 74 3.9 0.3165 71 5.6 8 8.2 63 5.3 0.2427 
precordial pain 66 1.9 3 1.0 63 2.0 0.2022 43 2.0 3 1.4 40 2.1 0.5320         23 2.0 0.1627 
any chestpain 1003 29.5 90 29.4 913 29.5 0.9800 616 29.0 65 31.3 551 28.7 0.4435 387 30.3 25 25.5 362 30.7 0.2801 
chronic fatigue 50 1.5 9 2.9 41 1.3 0.0249 37 1.7 8 3.8 29 1.5 0.0144 13 1.0 1 1.0 12 1.0 0.9987 
other malaise/fatigue 827 24.3 82 26.8 745 24.1 0.2861 502 23.6 59 28.4 443 23.1 0.0885 325 25.5 23 23.5 302 25.6 0.6361 
difficulty walking 86 2.5 7 2.3 79 2.6 0.7795 66 3.1 4 1.9 62 3.2 0.3015 20 1.6 3 3.1 17 1.4 0.2153 
memory loss 74 2.2 9 2.9 65 2.1 0.3351 50 2.4 7 3.4 43 2.2 0.3092 24 1.9 2 2.0 22 1.9 0.9035 
cough 1186 34.9 131 42.8 1055 34.1 0.0022 812 38.2 98 47.1 714 37.2 0.0052 374 29.3 33 33.7 341 28.9 0.3234 
hemoptysis 52 1.5 4 1.3 48 1.5 0.7413 34 1.6 1 0.5 33 1.7 0.1760 18 1.4 3 3.1 15 1.3 0.1493 
                                            
Procedures                                           
chest CT 508 14.9 52 17.0 456 14.7 0.2879 331 15.6 35 16.8 296 15.4 0.5962 177 13.9 17 17.3 160 13.6 0.3002 
chest x-ray 2149 63.2 209 68.3 1940 62.6 0.0503 1344 63.2 145 69.7 1199 62.5 0.0400 805 63.1 64 65.3 741 62.9 0.6358 
echocardiography 678 19.9 69 22.5 609 19.7 0.2281 480 22.6 54 26.0 426 22.2 0.2176 198 15.5 15 15.3 183 15.5 0.9521 
EKG 1494 43.9 138 45.1 1356 43.8 0.6587 942 44.3 94 45.2 848 44.2 0.7822 552 43.3 44 44.9 508 43.1 0.7334 
heart catheterization         42 1.4 0.0404         30 1.6 0.0694         12 1.0 0.3154 
nebulizer treatment 1118 32.9 111 36.3 1007 32.5 0.1817 817 38.4 86 41.3 731 38.1 0.3595 301 23.6 25 25.5 276 23.4 0.6411 
non-invasive ventilator 221 6.5 17 5.6 204 6.6 0.4849 129 6.1 6 2.9 123 6.4 0.0431 92 7.2 11 11.2 81 6.9 0.1098 
spirometry 1519 44.6 147 48.0 1372 44.3 0.2095 1012 47.6 110 52.9 902 47.0 0.1067 507 39.7 37 37.8 470 39.9 0.6770 
any vaccination (flu or 
pneumonia) 
1656 48.7 164 53.6 1492 48.2 0.0704 1067 50.2 119 57.2 948 49.4 0.0324 589 46.2 45 45.9 544 46.2 0.9602 
                                            
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 444 13.0 43 14.1 401 12.9 0.5843 297 14.0 33 15.9 264 13.8 0.4047 147 11.5 10 10.2 137 11.6 0.6710 
any severe 247 7.3 38 12.4 209 6.7 0.0003 144 6.8 23 11.1 121 6.3 0.0096 103 8.1 15 15.3 88 7.5 0.0062 
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Number of Patients 3403   306 9.0% 3097     2127   208 9.8% 1919     1276   98 7.7% 1178     
any other hospitalizations* 61 1.8 10 3.3 51 1.6 0.0414 54 2.5 10 4.8 44 2.3 0.0285         7 0.6 0.4441 
Prior 2-12 weeks                                           
any moderate 574 16.9 48 15.7 526 17.0 0.5630 368 17.3 33 15.9 335 17.5 0.5643 206 16.1 15 15.3 191 16.2 0.8145 
any severe 227 6.7 22 7.2 205 6.6 0.7029 111 5.2 9 4.3 102 5.3 0.5427 116 9.1 13 13.3 103 8.7 0.1346 
any other hospitalizations* 127 3.7 13 4.2 114 3.7 0.6174 100 4.7 13 6.3 87 4.5 0.2666         27 2.3 0.1298 
Prior 13-52 weeks                                           
no moderate 2664 78.3 237 77.5 2427 78.4 0.7111 1635 76.9 153 73.6 1482 77.2 0.2331 1029 80.6 84 85.7 945 80.2 0.1860 
1 moderate 596 17.5 57 18.6 539 17.4 0.5911 392 18.4 45 21.6 347 18.1 0.2095 204 16.0 12 12.2 192 16.3 0.2927 
>1 moderate 143 4.2 12 3.9 131 4.2 0.7976 100 4.7 10 4.8 90 4.7 0.9393 43 3.4 2 2.0 41 3.5 0.4479 
any severe 264 7.8 19 6.2 245 7.9 0.2884 129 6.1 6 2.9 123 6.4 0.0431 135 10.6 13 13.3 122 10.4 0.3684 
any other hospitalizations* 233 6.8 12 3.9 221 7.1 0.0337 186 8.7 11 5.3 175 9.1 0.0632 47 3.7 1 1.0 46 3.9 0.1452 
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 500 14.7 47 15.4 453 14.6 0.7299 390 18.3 39 18.8 351 18.3 0.8709 110 8.6 8 8.2 102 8.7 0.8666 
COPD Inpatient (Any) 667 19.6 69 22.5 598 19.3 0.1732 357 16.8 38 18.3 319 16.6 0.5463 310 24.3 31 31.6 279 23.7 0.0779 
Total Inpatient (Any) 1000 29.4 97 31.7 903 29.2 0.3517 651 30.6 65 31.3 586 30.5 0.8321 349 27.4 32 32.7 317 26.9 0.2204 
Treatment Therapy Use (Index 
until period prior to Sev Exac  or 
end of evaluated time period) 
                                          
Same as Index Trmt         3097 100           1919 100.0           1178 100.0   
No evidence Any Trmt                                           
Different Trmt from Index     306 100           208 100           98 100       
Now using Triple     150 49.0           101 48.6           49 50.0       
No longer using Triple     102 33.3           65 31.3           37 37.8       
Switched between ICSLABA 
and LAMA 
    54 17.6           42 20.2           12 12.2       
LHP enrollee 2127 62.5 208 68.0 1919 62.0 0.0383                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity  
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Table 28 Baseline Characteristics –Switching from Index therapy in First 6 Months 
  LHP & PHP           LHP             PHP             
LHP & PHP  
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% pval  Total % Switch 
1st 6 
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Trmt 
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Number of Patients 2544   306 12.0% 2238     1544   210 13.6% 1334     1000   96 9.6% 904     
Age Categories                                           
age 40-54 226 8.9 21 6.9 205 9.2 0.1852 102 6.6 10 4.8 92 6.9 0.2470 124 12.4 11 11.5 113 12.5 0.7684 
age 55-64 479 18.8 58 19.0 421 18.8 0.9522 246 15.9 36 17.1 210 15.7 0.6062 233 23.3 22 22.9 211 23.3 0.9256 
age 65-74 812 31.9 107 35.0 705 31.5 0.2225 488 31.6 73 34.8 415 31.1 0.2900 324 32.4 34 35.4 290 32.1 0.5065 
age 75 and older 1027 40.4 120 39.2 907 40.5 0.6610 708 45.9 91 43.3 617 46.3 0.4301 319 31.9 29 30.2 290 32.1 0.7084 
age (Mean, SD) 70.80 10.95 71.01 10.48 70.77 11.02 0.7142 72.16 10.54 72.09 10.30 72.17 10.58 0.9167 68.69 11.24 68.66 10.53 68.70 11.31 0.9731 
                                            
Men 1141 44.9 147 48.0 994 44.4 0.2318 709 45.9 106 50.5 603 45.2 0.1540 432 43.2 41 42.7 391 43.3 0.9185 
                                            
Quarter of Year, Index Date             0.2852             0.3545             0.8632 
Q1 767 30.1 93 30.4 674 30.1   458 29.7 62 29.5 396 29.7   309 30.9 31 32.3 278 30.8   
Q2 485 19.1 70 22.9 415 18.5   328 21.2 54 25.7 274 20.5   157 15.7 16 16.7 141 15.6   
Q3 538 21.1 60 19.6 478 21.4   372 24.1 47 22.4 325 24.4   166 16.6 13 13.5 153 16.9   
Q4 754 29.6 83 27.1 671 30.0   386 25.0 47 22.4 339 25.4   368 36.8 36 37.5 332 36.7   
                                            
Months enrollment post-Index             0.8330             0.6069             0.3878 
7 29 1.1 4 1.3 25 1.1   15 1.0 2 1.0 13 1.0   14 1.4 2 2.1 12 1.3   
8 27 1.1 4 1.3 23 1.0   14 0.9 1 0.5 13 1.0   13 1.3 3 3.1 10 1.1   
9 46 1.8 8 2.6 38 1.7   24 1.6 4 1.9 20 1.5   22 2.2 4 4.2 18 2.0   
10 45 1.8 6 2.0 39 1.7   31 2.0 5 2.4 26 1.9   14 1.4 1 1.0 13 1.4   
11 54 2.1 7 2.3 47 2.1   39 2.5 7 3.3 32 2.4           15 1.7   
12 36 1.4 5 1.6 31 1.4   27 1.7 3 1.4 24 1.8   9 0.9 2 2.1 7 0.8   
13 49 1.9 6 2.0 43 1.9   32 2.1 5 2.4 27 2.0   17 1.7 1 1.0 16 1.8   
14 54 2.1 6 2.0 48 2.1   37 2.4 4 1.9 33 2.5   17 1.7 2 2.1 15 1.7   
15 41 1.6 5 1.6 36 1.6   28 1.8 2 1.0 26 1.9   13 1.3 3 3.1 10 1.1   
16 53 2.1 2 0.7 51 2.3   27 1.7 1 0.5 26 1.9   26 2.6 1 1.0 25 2.8   
17 57 2.2 6 2.0 51 2.3   34 2.2 3 1.4 31 2.3   23 2.3 3 3.1 20 2.2   
18 49 1.9 9 2.9 40 1.8   28 1.8 6 2.9 22 1.6   21 2.1 3 3.1 18 2.0   
19 43 1.7 7 2.3 36 1.6   22 1.4 3 1.4 19 1.4   21 2.1 4 4.2 17 1.9   
20 42 1.7 7 2.3 35 1.6   30 1.9 6 2.9 24 1.8   12 1.2 1 1.0 11 1.2   
21 44 1.7 6 2.0 38 1.7   25 1.6 6 2.9 19 1.4           19 2.1   
22 59 2.3 7 2.3 52 2.3   39 2.5 5 2.4 34 2.5   20 2.0 2 2.1 18 2.0   
23 42 1.7 8 2.6 34 1.5   26 1.7 7 3.3 19 1.4   16 1.6 1 1.0 15 1.7   
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Number of Patients 2544   306 12.0% 2238     1544   210 13.6% 1334     1000   96 9.6% 904     
24 1774 69.7 203 66.3 1571 70.2   1066 69.0 140 66.7 926 69.4   708 70.8 63 65.6 645 71.3   
Insurance at Index                                           
Commercial 834 32.8 118 38.6 716 32.0 0.0217 606 39.2 91 43.3 515 38.6 0.1922 228 22.8 27 28.1 201 22.2 0.1909 
Medicaid 271 10.7 19 6.2 252 11.3 0.0072 105 6.8 10 4.8 95 7.1 0.2068 166 16.6 9 9.4 157 17.4 0.0454 
Medicare 1452 57.1 171 55.9 1281 57.2 0.6530 846 54.8 111 52.9 735 55.1 0.5443 606 60.6 60 62.5 546 60.4 0.6886 
                                            
CMS comorbidities                                            
acute myocardial infarction 
(AMI) 
87 3.4 10 3.3 77 3.4 0.8762 55 3.6 7 3.3 48 3.6 0.8474 32 3.2 3 3.1 29 3.2 0.9650 
Alzheimer’s 84 3.3 6 2.0 78 3.5 0.1616 45 2.9 5 2.4 40 3.0 0.6209 39 3.9 1 1.0 38 4.2 0.1281 
atrial fibrillation 246 9.7 32 10.5 214 9.6 0.6191 160 10.4 27 12.9 133 10.0 0.2020 86 8.6 5 5.2 81 9.0 0.2125 
cancers 174 6.8 25 8.2 149 6.7 0.3257 114 7.4 18 8.6 96 7.2 0.4788 60 6.0 7 7.3 53 5.9 0.5752 
lung cancer 53 2.1 6 2.0 47 2.1 0.8729 35 2.3 5 2.4 30 2.2 0.9049 18 1.8 1 1.0 17 1.9 0.5567 
chronic kidney disease 409 16.1 43 14.1 366 16.4 0.3039 269 17.4 33 15.7 236 17.7 0.4827 140 14.0 10 10.4 130 14.4 0.2872 
diabetes 591 23.2 59 19.3 532 23.8 0.0811 344 22.3 40 19.0 304 22.8 0.2259 247 24.7 19 19.8 228 25.2 0.2409 
heart failure 437 17.2 54 17.6 383 17.1 0.8165 258 16.7 42 20.0 216 16.2 0.1691 179 17.9 12 12.5 167 18.5 0.1466 
ischemic heart dis. (IHD; incl. 
AMI) 
608 23.9 75 24.5 533 23.8 0.7895 389 25.2 58 27.6 331 24.8 0.3839 219 21.9 17 17.7 202 22.3 0.2963 
rheumatoid/osteo arthritis  629 24.7 62 20.3 567 25.3 0.0537 383 24.8 45 21.4 338 25.3 0.2228 246 24.6 17 17.7 229 25.3 0.0991 
stroke/TIA 171 6.7 24 7.8 147 6.6 0.4036 98 6.3 16 7.6 82 6.1 0.4160 73 7.3 8 8.3 65 7.2 0.6823 
no CMS Comorbidity 904 35.5 124 40.5 780 34.9 0.0519 541 35.0 76 36.2 465 34.9 0.7067 363 36.3 48 50.0 315 34.8 0.0033 
                                            
Elixhauser comorbidities                                            
AIDS         4 0.2 0.4592         4 0.3 0.4269               
alcohol abuse 95 3.7 13 4.2 82 3.7 0.6131 46 3.0 7 3.3 39 2.9 0.7454 49 4.9 6 6.3 43 4.8 0.5193 
chronic blood loss anemia 27 1.1 3 1.0 24 1.1 0.8829 18 1.2 3 1.4 15 1.1 0.7027         9 1.0 0.3261 
coagulopathy 76 3.0 9 2.9 67 3.0 0.9596 41 2.7 7 3.3 34 2.5 0.5110 35 3.5 2 2.1 33 3.7 0.4270 
congestive heart failure 391 15.4 49 16.0 342 15.3 0.7393 244 15.8 39 18.6 205 15.4 0.2367 147 14.7 10 10.4 137 15.2 0.2126 
deficiency anemias 349 13.7 39 12.7 310 13.9 0.5977 205 13.3 29 13.8 176 13.2 0.8068 144 14.4 10 10.4 134 14.8 0.2423 
depression 398 15.6 42 13.7 356 15.9 0.3245 202 13.1 27 12.9 175 13.1 0.9169 196 19.6 15 15.6 181 20.0 0.3021 
diabetes (wo/chr 
complications) 
564 22.2 55 18.0 509 22.7 0.0596 343 22.2 41 19.5 302 22.6 0.3128 221 22.1 14 14.6 207 22.9 0.0619 
diabetes (w/chr complications) 188 7.4 16 5.2 172 7.7 0.1234 129 8.4 11 5.2 118 8.8 0.0791 59 5.9 5 5.2 54 6.0 0.7623 
drug abuse 64 2.5 7 2.3 57 2.5 0.7859 42 2.7 4 1.9 38 2.8 0.4345 22 2.2 3 3.1 19 2.1 0.5158 
fluid and electrolyte disorders 295 11.6 47 15.4 248 11.1 0.0284 174 11.3 34 16.2 140 10.5 0.0153 121 12.1 13 13.5 108 11.9 0.6487 
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hypertension 1566 61.6 178 58.2 1388 62.0 0.1941 986 63.9 133 63.3 853 63.9 0.8643 580 58.0 45 46.9 535 59.2 0.0202 
hypothyroidism 478 18.8 52 17.0 426 19.0 0.3912 281 18.2 40 19.0 241 18.1 0.7318 197 19.7 12 12.5 185 20.5 0.0621 
liver disease 96 3.8 17 5.6 79 3.5 0.0811 60 3.9 13 6.2 47 3.5 0.0630 36 3.6 4 4.2 32 3.5 0.7539 
lymphoma 23 0.9 2 0.7 21 0.9 0.6216 12 0.8 2 1.0 10 0.7 0.7558         11 1.2 0.2771 
metastatic cancer 26 1.0 5 1.6 21 0.9 0.2565 24 1.6 5 2.4 19 1.4 0.2975         2 0.2 0.6446 
obesity 326 12.8 36 11.8 290 13.0 0.5580 205 13.3 25 11.9 180 13.5 0.5283 121 12.1 11 11.5 110 12.2 0.8393 
other neurological disorders 216 8.5 22 7.2 194 8.7 0.3840 146 9.5 20 9.5 126 9.4 0.9712 70 7.0 2 2.1 68 7.5 0.0471 
paralysis 38 1.5 4 1.3 34 1.5 0.7743 26 1.7 4 1.9 22 1.6 0.7890         12 1.3 0.2561 
peripheral vascular disease 390 15.3 51 16.7 339 15.1 0.4890 261 16.9 37 17.6 224 16.8 0.7662 129 12.9 14 14.6 115 12.7 0.6048 
psychoses 251 9.9 31 10.1 220 9.8 0.8687 157 10.2 18 8.6 139 10.4 0.4101 94 9.4 13 13.5 81 9.0 0.1436 
pulmonary circulation disease 297 11.7 46 15.0 251 11.2 0.0511 193 12.5 33 15.7 160 12.0 0.1297 104 10.4 13 13.5 91 10.1 0.2889 
renal failure 218 8.6 25 8.2 193 8.6 0.7902 146 9.5 20 9.5 126 9.4 0.9712 72 7.2 5 5.2 67 7.4 0.4272 
rheumatoid arthritis/collagen 
vas 
142 5.6 21 6.9 121 5.4 0.2980 79 5.1 16 7.6 63 4.7 0.0766 63 6.3 5 5.2 58 6.4 0.6433 
solid tumor wo/metastasis 250 9.8 31 10.1 219 9.8 0.8491 164 10.6 19 9.0 145 10.9 0.4257 86 8.6 12 12.5 74 8.2 0.1517 
ulcers 3 0.1 1 0.3 2 0.1 0.2563         1 0.1 0.6914 2 0.2 1 1.0 1 0.1 0.0522 
valvular disease 285 11.2 36 11.8 249 11.1 0.7397 212 13.7 27 12.9 185 13.9 0.6924 73 7.3 9 9.4 64 7.1 0.4111 
weight loss 137 5.4 21 6.9 116 5.2 0.2222 91 5.9 15 7.1 76 5.7 0.4083 46 4.6 6 6.3 40 4.4 0.4170 
any Elixhauser diagnosis 2316 91.0 280 91.5 2036 91.0 0.7612 1424 92.2 198 94.3 1226 91.9 0.2308 892 89.2 82 85.4 810 89.6 0.2091 
Other comorbidities                                           
asthma 854 33.6 102 33.3 752 33.6 0.9258 488 31.6 61 29.0 427 32.0 0.3909 366 36.6 41 42.7 325 36.0 0.1913 
hypoxemia 965 37.9 129 42.2 836 37.4 0.1044 550 35.6 82 39.0 468 35.1 0.2647 415 41.5 47 49.0 368 40.7 0.1188 
pneumonia 855 33.6 106 34.6 749 33.5 0.6837 550 35.6 79 37.6 471 35.3 0.5155 305 30.5 27 28.1 278 30.8 0.5950 
influenza 69 2.7 8 2.6 61 2.7 0.9105 38 2.5 7 3.3 31 2.3 0.3801 31 3.1 1 1.0 30 3.3 0.2210 
                                            
COPD Complexity ^                                           
Low complexity 1244 48.9 127 41.5 1117 49.9 0.0058 734 47.5 83 39.5 651 48.8 0.0123 510 51.0 44 45.8 466 51.5 0.2868 
Med complexity 1184 46.5 164 53.6 1020 45.6 0.0084 733 47.5 116 55.2 617 46.3 0.0154 451 45.1 48 50.0 403 44.6 0.3102 
High complexity 116 4.6 15 4.9 101 4.5 0.7596 77 5.0 11 5.2 66 4.9 0.8573 39 3.9 4 4.2 35 3.9 0.8871 
Emphysema diagnosis (492.x) 634 24.9 85 27.8 549 24.5 0.2181 336 21.8 53 25.2 283 21.2 0.1890 298 29.8 32 33.3 266 29.4 0.4260 
                                            
COPD Medications                                            
index ICSLABA 1261 49.6 112 36.6 1149 51.3 <0.0001 777 50.3 82 39.0 695 52.1 0.0004 484 48.4 30 31.3 454 50.2 0.0004 
index LAMA 972 38.2 108 35.3 864 38.6 0.2634 565 36.6 65 31.0 500 37.5 0.0679 407 40.7 43 44.8 364 40.3 0.3907 
index triple 311 12.2 86 28.1 225 10.1 <0.0001 202 13.1 63 30.0 139 10.4 <0.0001 109 10.9 23 24.0 86 9.5 <0.0001 
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SABA use                                           
no SABA use 1110 43.6 116 37.9 994 44.4 0.0314 625 40.5 84 40.0 541 40.6 0.8790 485 48.5 32 33.3 453 50.1 0.0018 
SABA <=15% of year 615 24.2 86 28.1 529 23.6 0.0869 384 24.9 59 28.1 325 24.4 0.2448 231 23.1 27 28.1 204 22.6 0.2192 
SABA <=40% of year 328 12.9 44 14.4 284 12.7 0.4082 217 14.1 23 11.0 194 14.5 0.1641 111 11.1 21 21.9 90 10.0 0.0004 
SABA >40% of year 491 19.3 60 19.6 431 19.3 0.8844 318 20.6 44 21.0 274 20.5 0.8907 173 17.3 16 16.7 157 17.4 0.8630 
SAMA use                                           
any ipratropium (SAMA) 325 12.8 45 14.7 280 12.5 0.2807 204 13.2 33 15.7 171 12.8 0.2494 121 12.1 12 12.5 109 12.1 0.8994 
any SABA/SAMA 443 17.4 64 20.9 379 16.9 0.0851 289 18.7 47 22.4 242 18.1 0.1431 154 15.4 17 17.7 137 15.2 0.5099 
any SAMA or SABA/SAMA 703 27.6 100 32.7 603 26.9 0.0353 452 29.3 72 34.3 380 28.5 0.0860 251 25.1 28 29.2 223 24.7 0.3338 
Other COPD medications                                           
any ICS 853 33.5 95 31.0 758 33.9 0.3264 540 35.0 66 31.4 474 35.5 0.2464 313 31.3 29 30.2 284 31.4 0.8083 
any LABA 134 5.3 14 4.6 120 5.4 0.5633 75 4.9 9 4.3 66 4.9 0.6784 59 5.9 5 5.2 54 6.0 0.7623 
any methylxanthines 45 1.8 6 2.0 39 1.7 0.7860 13 0.8 3 1.4 10 0.7 0.3169 32 3.2 3 3.1 29 3.2 0.9650 
Any use of above COPD 
medications 
1307 51.4 166 54.2 1141 51.0 0.2838 828 53.6 119 56.7 709 53.1 0.3420 479 47.9 47 49.0 432 47.8 0.8272 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 2261 88.9 276 90.2 1985 88.7 0.4336 1369 88.7 188 89.5 1181 88.5 0.6731 892 89.2 88 91.7 804 88.9 0.4128 
1-2 Rxs ICSLABA (wks 27-
52) 
153 6.0 12 3.9 141 6.3 0.1007 96 6.2 7 3.3 89 6.7 0.0626 57 5.7 5 5.2 52 5.8 0.8270 
>2 Rxs ICSLABA (wks 27-
52) 
130 5.1 18 5.9 112 5.0 0.5130 79 5.1 15 7.1 64 4.8 0.1516 51 5.1 3 3.1 48 5.3 0.3549 
No LAMA in prior year 2448 96.2 284 92.8 2164 96.7 0.0008 1482 96.0 195 92.9 1287 96.5 0.0130 966 96.6 89 92.7 877 97.0 0.0269 
1-2 Rxs LAMA (wks 27-52) 54 2.1 12 3.9 42 1.9 0.0199 38 2.5 8 3.8 30 2.2 0.1748 16 1.6 4 4.2 12 1.3 0.0350 
>2 Rxs LAMA (wks 27-52) 42 1.7 10 3.3 32 1.4 0.0179 24 1.6 7 3.3 17 1.3 0.0250 18 1.8 3 3.1 15 1.7 0.3044 
Oxygen Use                                           
no oxygen 1372 53.9 169 55.2 1203 53.8 0.6272 848 54.9 127 60.5 721 54.0 0.0818 524 52.4 42 43.8 482 53.3 0.0743 
oxygen <=50% of year 427 16.8 48 15.7 379 16.9 0.5836 287 18.6 32 15.2 255 19.1 0.1794 140 14.0 16 16.7 124 13.7 0.4284 
oxygen >50% of year 745 29.3 89 29.1 656 29.3 0.9348 409 26.5 51 24.3 358 26.8 0.4362 336 33.6 38 39.6 298 33.0 0.1918 
                                            
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 1590 62.5 182 59.5 1408 62.9 0.2442 870 56.3 110 52.4 760 57.0 0.2125 720 72.0 72 75.0 648 71.7 0.4911 
1 period breathlessness 485 19.1 54 17.6 431 19.3 0.5010 319 20.7 41 19.5 278 20.8 0.6616 166 16.6 13 13.5 153 16.9 0.3970 
>1 period breathlessness 469 18.4 70 22.9 399 17.8 0.0327 355 23.0 59 28.1 296 22.2 0.0587 114 11.4 11 11.5 103 11.4 0.9849 
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Shortness of Breath                                           
no periods shortness breath 1599 62.9 178 58.2 1421 63.5 0.0706 954 61.8 122 58.1 832 62.4 0.2361 645 64.5 56 58.3 589 65.2 0.1842 
1 period shortness breath 512 20.1 68 22.2 444 19.8 0.3295 338 21.9 52 24.8 286 21.4 0.2791 174 17.4 16 16.7 158 17.5 0.8420 
>1 period shortness breath 433 17.0 60 19.6 373 16.7 0.1991 252 16.3 36 17.1 216 16.2 0.7289 181 18.1 24 25.0 157 17.4 0.0648 
any wheezing 187 7.4 21 6.9 166 7.4 0.7273 125 8.1 18 8.6 107 8.0 0.7858 62 6.2 3 3.1 59 6.5 0.1888 
any dyspnea 1426 56.1 193 63.1 1233 55.1 0.0084 948 61.4 141 67.1 807 60.5 0.0659 478 47.8 52 54.2 426 47.1 0.1890 
supplemental oxygen use 
(V46.2) 
166 6.5 13 4.2 153 6.8 0.0855 52 3.4 3 1.4 49 3.7 0.0937 114 11.4 10 10.4 104 11.5 0.7498 
Other symptoms                                           
chest pain unspecified 702 27.6 84 27.5 618 27.6 0.9523 426 27.6 62 29.5 364 27.3 0.5001 276 27.6 22 22.9 254 28.1 0.2803 
painful respiratory 114 4.5 19 6.2 95 4.2 0.1193 60 3.9 10 4.8 50 3.7 0.4798 54 5.4 9 9.4 45 5.0 0.0699 
precordial pain 44 1.7 4 1.3 40 1.8 0.5457 28 1.8 4 1.9 24 1.8 0.9151         16 1.8 0.1888 
any chestpain 737 29.0 87 28.4 650 29.0 0.8247 444 28.8 63 30.0 381 28.6 0.6684 293 29.3 24 25.0 269 29.8 0.3303 
chronic fatigue 33 1.3 10 3.3 23 1.0 0.0012 21 1.4 9 4.3 12 0.9 <0.0001 12 1.2 1 1.0 11 1.2 0.8809 
other malaise/fatigue 591 23.2 64 20.9 527 23.5 0.3064 340 22.0 51 24.3 289 21.7 0.3941 251 25.1 13 13.5 238 26.3 0.0060 
difficulty walking 60 2.4 6 2.0 54 2.4 0.6250 47 3.0 4 1.9 43 3.2 0.3012 13 1.3 2 2.1 11 1.2 0.4761 
memory loss 51 2.0 6 2.0 45 2.0 0.9534 33 2.1 5 2.4 28 2.1 0.7928 18 1.8 1 1.0 17 1.9 0.5567 
cough 858 33.7 118 38.6 740 33.1 0.0564 568 36.8 88 41.9 480 36.0 0.0980 290 29.0 30 31.3 260 28.8 0.6094 
hemoptysis 37 1.5 6 2.0 31 1.4 0.4302 26 1.7 3 1.4 23 1.7 0.7570 11 1.1 3 3.1 8 0.9 0.0454 
                                            
Procedures                                           
chest CT 375 14.7 48 15.7 327 14.6 0.6188 243 15.7 33 15.7 210 15.7 0.9918 132 13.2 15 15.6 117 12.9 0.4603 
chest x-ray 1591 62.5 203 66.3 1388 62.0 0.1431 961 62.2 139 66.2 822 61.6 0.2040 630 63.0 64 66.7 566 62.6 0.4338 
echocardiography 515 20.2 76 24.8 439 19.6 0.0330 359 23.3 56 26.7 303 22.7 0.2075 156 15.6 20 20.8 136 15.0 0.1372 
EKG 1110 43.6 141 46.1 969 43.3 0.3576 681 44.1 96 45.7 585 43.9 0.6136 429 42.9 45 46.9 384 42.5 0.4079 
heart catheterization 28 1.1 2 0.7 26 1.2 0.4242 21 1.4 2 1.0 19 1.4 0.5831         7 0.8 0.3869 
nebulizer treatment 840 33.0 111 36.3 729 32.6 0.1967 599 38.8 89 42.4 510 38.2 0.2513 241 24.1 22 22.9 219 24.2 0.7756 
non-invasive ventilator 176 6.9 19 6.2 157 7.0 0.6023 103 6.7 9 4.3 94 7.0 0.1361 73 7.3 10 10.4 63 7.0 0.2170 
spirometry 1150 45.2 144 47.1 1006 45.0 0.4871 747 48.4 103 49.0 644 48.3 0.8352 403 40.3 41 42.7 362 40.0 0.6129 
any vaccination (flu or 
pneumonia) 
1241 48.8 153 50.0 1088 48.6 0.6493 788 51.0 108 51.4 680 51.0 0.9026 453 45.3 45 46.9 408 45.1 0.7444 
                                            
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 321 12.6 42 13.7 279 12.5 0.5339 212 13.7 26 12.4 186 13.9 0.5410 109 10.9 16 16.7 93 10.3 0.0565 
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any severe 173 6.8 36 11.8 137 6.1 0.0002 106 6.9 27 12.9 79 5.9 0.0002 67 6.7 9 9.4 58 6.4 0.2702 
any other hospitalizations* 43 1.7 8 2.6 35 1.6 0.1812 38 2.5 8 3.8 30 2.2 0.1748         5 0.6 0.4651 
Prior 2-12 weeks                                           
any moderate 436 17.1 53 17.3 383 17.1 0.9283 269 17.4 33 15.7 236 17.7 0.4827 167 16.7 20 20.8 147 16.3 0.2534 
any severe 162 6.4 21 6.9 141 6.3 0.7055 77 5.0 12 5.7 65 4.9 0.6025 85 8.5 9 9.4 76 8.4 0.7464 
any other hospitalizations* 98 3.9 12 3.9 86 3.8 0.9464 75 4.9 11 5.2 64 4.8 0.7825 23 2.3 1 1.0 22 2.4 0.3870 
Prior 13-52 weeks                                           
no moderate 1981 77.9 240 78.4 1741 77.8 0.8007 1174 76.0 156 74.3 1018 76.3 0.5226 807 80.7 84 87.5 723 80.0 0.0758 
1 moderate 449 17.6 52 17.0 397 17.7 0.7483 292 18.9 43 20.5 249 18.7 0.5334 157 15.7 9 9.4 148 16.4 0.0732 
>1 moderate 114 4.5 14 4.6 100 4.5 0.9324 78 5.1 11 5.2 67 5.0 0.8945 36 3.6 3 3.1 33 3.7 0.7927 
any severe 208 8.2 28 9.2 180 8.0 0.5072 98 6.3 11 5.2 87 6.5 0.4782 110 11.0 17 17.7 93 10.3 0.0271 
any other hospitalizations* 172 6.8 20 6.5 152 6.8 0.8672 134 8.7 17 8.1 117 8.8 0.7466 38 3.8 3 3.1 35 3.9 0.7160 
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 363 14.3 51 16.7 312 13.9 0.2010 286 18.5 41 19.5 245 18.4 0.6880 77 7.7 10 10.4 67 7.4 0.2937 
COPD Inpatient (Any) 496 19.5 69 22.5 427 19.1 0.1508 258 16.7 43 20.5 215 16.1 0.1155 238 23.8 26 27.1 212 23.5 0.4269 
Total Inpatient (Any) 742 29.2 102 33.3 640 28.6 0.0873 475 30.8 72 34.3 403 30.2 0.2342 267 26.7 30 31.3 237 26.2 0.2892 
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period)          
Same as Index Trmt         2238 100           1334 100           904 100   
No evidence Any Trmt                                           
Different Trmt from Index     306 100           210 100.0           96 100       
Now using Triple     169 55.2           107 51.0           62 64.6       
No longer using Triple     86 28.1           63 30.0           23 24.0       
Switched between ICSLABA 
and LAMA 
    51 16.7           40 19.0           11 11.5       
LHP enrollee 1544 60.7 210 68.6 1334 59.6 0.0024                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 29 Discontinuation Within 3 Months, Baseline Healthcare Costs (Means) 
  LHP and PHP LHP PHP 
LHP & PHP  
Baseline Characteristic 
Total SD Discont 
1st 3 
mos 
SD Still 
using a 
Trmt 
SD pval  Total SD Discont 
1st 3 
mos 
SD Still 
using a 
Trmt 
SD pval  Total SD Discont 
1st 3 
mos 
SD Still 
using a 
Trmt 
SD pval  
Number of Patients 5475  2072  3403   3599  1472  2127   1876  600  1276   
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient 5490 9457 5539 9484 5490 9457 0.7663 5426 8291 5364 8407 5469 8211 0.7075 5614 11366 5970 11710 5447 11202 0.3529 
COPD Outpatient 1961 2436 1919 2469 1961 2436 0.3139 1786 2213 1763 2388 1803 2083 0.6022 2297 2786 2301 2618 2294 2862 0.9573 
Total Outpatient 7452 10320 7458 10427 7452 10320 0.9723 7212 9094 7126 9383 7272 8891 0.6402 7911 12326 8271 12601 7741 12195 0.3852 
                      
Non-COPD Inpatient 5069 20267 5836 22792 5069 20267 0.0376 6913 24336 7514 26443 6497 22762 0.2304 1533 6606 1721 7417 1445 6189 0.43 
COPD Inpatient 6179 20753 6752 21765 6179 20753 0.1177 5019 19696 5658 20135 4577 19378 0.1053 8404 22481 9436 25142 7919 21107 0.2003 
Total Inpatient 11248 30260 12588 32459 11248 30260 0.013 11932 32612 13172 34319 11073 31356 0.0619 9937 25094 11157 27340 9364 23955 0.1688 
Total Medical Utilization 18700 33496 20046 35711 18700 33496 0.0238 19144 35393 20298 37289 18345 34005 0.1095 17848 29507 19428 31527 17105 28490 0.1253 
                      
Non-COPD Outpatient Rx 2369 4007 2551 4485 2369 4007 0.0122 2635 4381 2688 4843 2599 4030 0.5617 1859 3107 2217 3433 1691 2927 0.0012 
COPD Outpatient Rx 408 778 290 619 408 778 <0.0001 409 799 270 632 506 884 <0.0001 405 735 340 583 436 795 0.0034 
Total Outpatient Rx 2777 4148 2842 4547 2777 4148 0.3843 3043 4510 2957 4908 3103 4213 0.3539 2265 3288 2558 3498 2127 3176 0.0106 
                      
Total Healthcare Services 21477 34258 22888 36428 21477 34258 0.0204 22188 36262 23256 38109 21448 34916 0.148 20113 30003 21986 31943 19232 29018 0.0734 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient 5589 9513 5640 9540 5559 9498 0.7619 5512 8328 5453 8448 5553 8245 0.725 5740 11461 6102 11805 5569 11297 0.3531 
COPD Outpatient 2100 2463 2064 2501 2122 2439 0.4178 1928 2239 1912 2430 1939 2098 0.7438 2423 2808 2427 2632 2421 2888 0.9688 
Total Outpatient 7469 10326 7476 10433 7465 10262 0.971 7226 9097 7146 9388 7282 8893 0.6618 7936 12337 8285 12607 7772 12210 0.4013 
                      
Non-COPD Inpatient 32576 41773 34353 45634 31325 38824 0.3112 36213 45208 37239 48622 35431 42471 0.6106 17434 14833 18772 16858 16766 13743 0.4145 
COPD Inpatient 30287 37170 31091 37771 29744 36778 0.5527 28403 39151 29854 37688 27269 40274 0.4092 32778 34258 33110 37931 32594 32116 0.8804 
Total Inpatient 36441 45266 37802 47036 35502 44002 0.3047 37244 48767 38624 49731 36180 48021 0.3992 34716 36619 35608 38975 34236 35333 0.6792 
Total Medical Utilization 18710 33502 20046 35711 17896 32060 0.0249 19144 35393 20298 37289 18345 34005 0.1095 17877 29522 19428 31527 17145 28512 0.1321 
                      
Non-COPD Outpatient Rx 2462 4056 2609 4519 2370 3736 0.0457 2693 4411 2740 4875 2660 4058 0.6088 1997 3177 2286 3464 1852 3015 0.0102 
COPD Outpatient Rx 408 778 290 619 480 852 <0.0001 409 799 270 632 506 884 <0.0001 405 735 340 583 436 795 0.0034 
Total Outpatient Rx 2777 4148 2842 4547 2737 3885 0.3843 3043 4510 2957 4908 3103 4213 0.3539 2265 3288 2558 3498 2127 3176 0.0106 
                      
Total Healthcare Services 21477 34258 22888 36428 20617 32842 0.0204 22188 36262 23256 38109 21448 34916 0.148 20113 30003 21986 31943 19232 29018 0.0734 
Length of Stay (inpatient 
stays) 
6.6 7.7 6.9 8.4 6.4 7.1 0.1951 7.3 8.6 7.6 9.2 7.0 8.1 0.2655 5.3 5.0 5.2 5.4 5.3 4.8 0.7105 
  
 
1
6
0 
 
Table 30 Discontinuation Within 3 Months, Baseline Healthcare Costs (Medians) 
 
LHP & PHP LHP PHP 
  
Total   Discont 
1st 3 
months 
  Still 
using a 
Trmt 
  pval 
Comb vs 
Triple* 
Total   Discont 
1st 3 
months 
  Still 
using a 
Trmt 
  pval Comb 
vs Triple* 
Total   Discont 
1st 3 
months 
  Still 
using a 
Trmt 
  pval 
Comb vs 
Triple* 
Median 5475   2072   3403     3599   1472   2127     1876   600   1276     
Cost of Utilization ($)  
Non-COPD Outpatient 3181   3235   3163   0.2780 3361   3311   3386   0.9034 2879   3074   2838   0.2565 
COPD Outpatient 1201   1084   1287   0.0176 1038   945   1114   0.0143 1685   1761   1649   0.7647 
Total Outpatient 4931   4928   4932   0.6842 4924   4821   4971   0.3019 4964   5184   4899   0.4444 
                                            
Non-COPD Inpatient 0   0   0   0.0176 0   0   0   0.1547 0   0   0   0.6840 
COPD Inpatient 0   0   0   0.0451 0   0   0   0.0568 0   0   0   0.0611 
Total Inpatient 0   0   0   0.0010 0   0   0   0.0115 0   0   0   0.0667 
Total Medical Utilization 7398   7570   7235   0.0320 7552   7582   7542   0.2481 6998   7553   6564   0.0594 
                                            
Non-COPD Outpatient Rx 1252   1323   1226   <0.0001 1442   1336   1502   0.5082 854   1271   686   <0.0001 
COPD Outpatient Rx 68   52   81   <0.0001 68   46   101   <0.0001 66   94   57   0.2205 
Total Outpatient Rx 1685   1662   1707   0.1647 1869   1683   1981   0.0019 1295   1568   1094   <0.0001 
                                            
Total Healthcare Services 10052   10147   9968   0.0413 10559   10312   10652   0.6997 9209   9971   8766   0.0121 
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient 3285   3337   3246   0.259 3417   3385   3443   0.8491 2993   3167   2881   0.2449 
COPD Outpatient 1380   1266   1423   0.0316 1185   1078   1261   0.0223 1792   1920   1758   0.7699 
Total Outpatient 4942   4937   4948   0.6859 4928   4839   4997   0.3328 4985   5196   4910   0.4908 
                                            
Non-COPD Inpatient 17802   18799   17195   0.2593 19872   20949   19252   0.6719 13848   15004   13131   0.7348 
COPD Inpatient 17641   18317   16965   0.3107 15300   16959   13720   0.035 20654   19744   20660   0.8006 
Total Inpatient 19907   20633   19439   0.125 18979   19976   17708   0.0944 21703   21719   21650   0.6562 
Total Medical Utilization 7404   7570   7259   0.0365 7552   7582   7542   0.2481 7014   7553   6602   0.0709 
                                            
Non-COPD Outpatient Rx 1340   1373   1324   0.0081 1499   1389   1544   0.3687 1026   1335   888   <0.0001 
COPD Outpatient Rx 68   52   81   <0.0001 68   46   101   <0.0001 66   94   57   0.2205 
Total Outpatient Rx 1685   1662   1707   0.1647 1869   1683   1981   0.0019 1295   1568   1094   <0.0001 
                                            
Total Healthcare Services 10052   10147   9968   0.0413 10559   10312   10652   0.6997 9209   9971   8766   0.0121 
Length of Stay (inpatient stays) 4   4   4   0.6317 4   4   4   0.5756 4   4   4   0.568 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Table 31 Discontinuation Within 6 Months, Baseline Healthcare Costs (Means) 
  LHP and PHP LHP PHP 
LHP & PHP  
Baseline Characteristic 
Total SD Discont 
1st 6 
months 
SD Still 
using a 
Trmt 
SD pval  Total SD Discont 
1st 6 
months 
SD Still 
using a 
Trmt 
SD pval  Total SD Discont 
1st 6 
months 
SD Still 
using a 
Trmt 
SD pval  
Number of Patients 5475  2931  2544   3599  2055  1544   1876  876  1000   
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient 5490 9457 5496 9122 5484 9831 0.9632 5426 8291 5388 8129 5476 8503 0.7538 5614 11366 5748 11110 5497 11591 0.6323 
COPD Outpatient 1961 2436 1889 2482 2044 2380 0.0182 1786 2213 1712 2255 1886 2152 0.0191 2297 2786 2305 2907 2289 2677 0.8999 
Total Outpatient 7452 10320 7385 10071 7529 10602 0.609 7212 9094 7100 9017 7362 9196 0.3921 7911 12326 8054 12170 7786 12465 0.6385 
                      
Non-COPD Outpatient 5069 20267 5452 21504 4629 18736 0.1302 6913 24336 7057 25109 6720 23274 0.6774 1533 6606 1686 6937 1400 6302 0.3532 
COPD Outpatient 6179 20753 6395 20355 5930 21203 0.4098 5019 19696 5145 18315 4852 21401 0.666 8404 22481 9328 24242 7595 20794 0.0991 
Total Outpatient 11248 30260 11847 30551 10559 29912 0.1162 11932 32612 12202 32070 11572 33327 0.5663 9937 25094 11014 26648 8995 23621 0.0846 
Total Medical Utilization 18700 33496 19232 33615 18087 33354 0.2074 19144 35393 19302 34828 18934 36141 0.7577 17848 29507 19067 30599 16780 28488 0.0955 
                      
Non-COPD Outpatient Rx 2369 4007 2490 4212 2230 3752 0.0159 2635 4381 2627 4468 2645 4263 0.9048 1859 3107 2167 3521 1590 2665 <.0001 
COPD Outpatient Rx 408 778 303 621 528 911 <.0001 409 799 282 621 579 962 <.0001 405 735 354 619 450 822 0.0038 
Total Outpatient Rx 2777 4148 2793 4297 2758 3971 0.7524 3043 4510 2909 4545 3222 4458 0.0393 2265 3288 2521 3638 2041 2931 0.0018 
                      
Total Healthcare Services 21477 34258 22025 34330 20845 34170 0.2038 22188 36262 22211 35642 22156 37082 0.9642 20113 30003 21588 31049 18821 29010 0.0472 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient 5589 9513 5580 9166 5601 9902 0.936 5512 8328 5460 8159 5581 8550 0.6697 5740 11461 5862 11190 5632 11700 0.6676 
COPD Outpatient 2100 2463 2030 2517 2180 2397 0.0297 1928 2239 1856 2290 2022 2166 0.0322 2423 2808 2427 2933 2420 2694 0.9551 
Total Outpatient 7469 10326 7400 10076 7549 10609 0.5957 7226 9097 7114 9021 7376 9199 0.3918 7936 12337 8072 12178 7817 12481 0.6555 
                      
Non-COPD Outpatient 32576 41773 32677 43414 32439 39513 0.9345 36213 45208 36166 46713 36278 43088 0.9745 17434 14833 16780 15091 18182 14594 0.5465 
COPD Outpatient 30287 37170 30183 35197 30416 39538 0.9183 28403 39151 27970 34460 29038 45218 0.7484 32778 34258 33627 36118 31910 32302 0.5833 
Total Outpatient 36441 45266 36628 44487 36202 46271 0.8479 37244 48767 36984 46930 37615 51323 0.8315 34716 36619 35733 37727 33688 35504 0.5181 
Total Medical Utilization 18710 33502 19232 33615 18109 33368 0.2162 19144 35393 19302 34828 18934 36141 0.7577 17877 29522 19067 30599 16831 28516 0.1034 
                      
Non-COPD Outpatient Rx 2462 4056 2550 4245 2357 3819 0.0831 2693 4411 2673 4493 2719 4299 0.7595 1997 3177 2254 3564 1757 2749 0.0012 
COPD Outpatient Rx 408 778 303 621 528 911 <.0001 409 799 282 621 579 962 <.0001 405 735 354 619 450 822 0.0038 
Total Outpatient Rx 2777 4148 2793 4297 2758 3971 0.7524 3043 4510 2909 4545 3222 4458 0.0393 2265 3288 2521 3638 2041 2931 0.0018 
                      
Total Healthcare Services 21477 34258 22025 34330 20845 34170 0.2038 22188 36262 22211 35642 22156 37082 0.9642 20113 30003 21588 31049 18821 29010 0.0472 
Length of Stay (inpatient 
stays) 
6.6 7.7 6.8 8.1 6.4 7.0 0.2345 7.3 8.6 7.5 9.0 7.0 7.9 0.3071 5.3 5.0 5.2 5.1 5.4 4.9 0.7284 
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Table 32 Discontinuation Within 6 Months, Baseline Healthcare Costs (Medians) 
  LHP and PHP LHP PHP 
  
Total   Discont 
1st 6 
months 
  Still 
using a 
Trmt 
  pval 
Comb vs 
Triple* 
Total   Discont 
1st 6 
months 
  Still 
using a 
Trmt 
  pval 
Comb vs 
Triple* 
Total   Discont 
1st 6 
months 
  Still 
using a 
Trmt 
  pval 
Comb vs 
Triple* 
Median 85   39   46     50   26   24     35   13   22     
Cost of Utilization ($)  
Non-COPD Outpatient 3181   3251   3114   0.1085 3361   3371   3324   0.4650 2879   3000   2846   0.2537 
COPD Outpatient 1201   1078   1352   <.0001 1038   937   1187   0.0002 1685   1727   1668   0.7192 
Total Outpatient 4931   4915   4953   0.6688 4924   4880   5008   0.3593 4964   4995   4914   0.6058 
                                            
Non-COPD Outpatient 0   0   0   0.0162 0   0   0   0.4834 0   0   0   0.0849 
COPD Outpatient 0   0   0   0.1047 0   0   0   0.1469 0   0   0   0.0489 
Total Outpatient 0   0   0   0.0090 0   0   0   0.1297 0   0   0   0.0435 
Total Medical Utilization 7398   7544   7049   0.0493 7552   7579   7532   0.4453 6998   7518   6467   0.0429 
                                            
Non-COPD Outpatient Rx 1252   1366   1129   <.0001 1442   1427   1453   0.9216 854   1254   605   <.0001 
COPD Outpatient Rx 68   52   98   <.0001 68   47   129   <.0001 66   83   54   0.2402 
Total Outpatient Rx 1685   1696   1672   0.0352 1869   1773   2025   0.0011 1295   1566   935   <.0001 
                                            
Total Healthcare Services 10052   10096   9948   0.0860 10559   10193   10949   0.6796 9209   9965   8517   0.0041 
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient 3285   3343   3223   0.2052 3417   3431   3412   0.652 2993   3079   2897   0.316 
COPD Outpatient 1380   1253   1499   0.0001 1185   1081   1350   0.0003 1792   1850   1761   0.588 
Total Outpatient 4942   4927   5005   0.6352 4928   4881   5014   0.358 4985   5004   4932   0.65 
                                            
Non-COPD Outpatient 17802   17683   18358   0.6683 19872   20174   19777   0.7319 13848   13246   14252   0.231 
COPD Outpatient 17641   18114   16931   0.5004 15300   16223   13869   0.1826 20654   20836   20532   0.775 
Total Outpatient 19907   19907   19963   0.5355 18979   19305   18339   0.5447 21703   21522   21797   0.656 
Total Medical Utilization 7404   7544   7070   0.0585 7552   7579   7532   0.4453 7014   7518   6471   0.055 
                                            
Non-COPD Outpatient Rx 1340   1444   1251   0.0001 1499   1483   1514   0.659 1026   1329   770   <.0001 
COPD Outpatient Rx 68   52   98   <.0001 68   47   129   <.0001 66   83   54   0.24 
Total Outpatient Rx 1685   1696   1672   0.0352 1869   1773   2025   0.0011 1295   1566   935   <.0001 
                                            
Total Healthcare Services 10052   10096   9948   0.086 10559   10193   10949   0.6796 9209   9965   8517   0.004 
Length of Stay (inpatient stays) 4   4   4   0.9732 4   4   4   0.7915 4   4   4   0.428 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Table 33 Switching Within 3 Months, Baseline Healthcare Costs (Means) 
  LHP and PHP           LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total SD Switch 
1st 3 
mos 
SD Still 
Index 
Trmt 
SD pval  Total SD Switch 
1st 3 
mos 
SD Still 
Index 
Trmt 
SD pval  Total SD Switch 
1st 3 
mos 
SD Still 
Index 
Trmt 
SD pval  
Number of Patients 3403  306  3097   2127  208  1919   1276  98  1178   
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient  5461 9442 4701 7577 5536 9605 0.0741 5469 8211 4754 6663 5547 8359 0.114 5447 11202 4588 9261 5518 11349 0.3506 
COPD Outpatient  1987 2416 2163 2850 1970 2369 0.2518 1803 2083 1957 2372 1786 2049 0.3201 2294 2862 2601 3640 2269 2788 0.3792 
Total Outpatient  7448 10256 6864 9452 7506 10332 0.2623 7272 8891 6711 8012 7333 8980 0.2944 7741 12195 7190 11991 7787 12216 0.6415 
                      
Non-COPD Outpatient  4603 18550 4405 15665 4622 18813 0.8204 6497 22762 6182 18687 6531 23164 0.8036 1445 6189 632 2286 1513 6404 0.0033 
COPD Outpatient  5830 20106 6925 27298 5722 19253 0.452 4577 19378 6273 31271 4393 17617 0.3949 7919 21107 8310 15921 7886 21487 0.8062 
Total Outpatient  10432 28813 11330 33387 10344 28325 0.6179 11073 31356 12455 38706 10924 30461 0.5812 9364 23955 8942 17306 9399 24432 0.809 
Total Medical Utilization 17880 32050 18194 34693 17849 31783 0.8675 18345 34005 19166 39594 18257 33354 0.7499 17105 28490 16132 20805 17186 29044 0.6424 
                      
Non-COPD Outpatient Rx 2258 3682 2312 3533 2253 3697 0.7891 2599 4030 2623 3688 2596 4067 0.9261 1691 2927 1651 3095 1694 2914 0.8885 
COPD Outpatient Rx 480 852 454 944 482 843 0.6135 506 884 542 1083 502 860 0.6011 436 795 266 495 450 814 0.0011 
Total Outpatient Rx 2737 3885 2766 3763 2734 3898 0.8926 3103 4213 3166 3929 3096 4244 0.8218 2127 3176 1917 3242 2145 3171 0.4957 
                      
Total Healthcare Services 20617 32842 20960 35567 20584 32567 0.859 21448 34916 22331 40562 21353 34259 0.7378 19232 29018 18049 21305 19331 29574 0.5812 
Cost of Utilization ($ mean, SD)  - for those with utilization within category      
Non-COPD Outpatient  5559 9498 4844 7646 5629 9658 0.1006 5553 8245 4871 6702 5626 8392 0.1389 5569 11297 4784 9408 5633 11438 0.41 
COPD Outpatient  2122 2439 2372 2901 2098 2389 0.1265 1939 2098 2165 2403 1915 2063 0.1711 2421 2888 2801 3704 2391 2811 0.3035 
Total Outpatient  7465 10262 6932 9474 7518 10336 0.3092 7282 8893 6776 8023 7337 8981 0.3471 7772 12210 7264 12030 7814 12228 0.6702 
                      
Non-COPD Outpatient  31325 38824 28677 30264 31600 39623 0.544 35431 42471 32972 31555 35704 43542 0.6252 16766 13743 7737 3093 17474 14007 <0.0001 
COPD Outpatient  29744 36778 30712 51001 29632 34822 0.8644 27269 40274 34335 66942 26428 35885 0.4782 32594 32116 26271 18221 33297 33251 0.072 
Total Outpatient  35502 44002 35742 51574 35476 43142 0.961 36180 48021 39856 61126 35772 46388 0.6031 34236 35333 27385 20392 34928 36453 0.0744 
Total Medical Utilization 17896 32060 18194 34693 17867 31793 0.8741 18345 34005 19166 39594 18257 33354 0.7499 17145 28512 16132 20805 17230 29068 0.6288 
                      
Non-COPD Outpatient Rx 2370 3736 2448 3590 2362 3751 0.7091 2660 4058 2662 3701 2660 4096 0.9949 1852 3015 1926 3265 1846 2996 0.8149 
COPD Outpatient Rx 480 852 454 944 482 843 0.6135 506 884 542 1083 502 860 0.6011 436 795 266 495 450 814 0.0011 
Total Outpatient Rx 2737 3885 2766 3763 2734 3898 0.8926 3103 4213 3166 3929 3096 4244 0.8218 2127 3176 1917 3242 2145 3171 0.4957 
                      
Total Healthcare Services 20617 32842 20960 35567 20584 32567 0.859 21448 34916 22331 40562 21353 34259 0.7378 19232 29018 18049 21305 19331 29574 0.5812 
Length of Stay (inpatient stays) 6.4 7.1 6.7 5.5 6.4 7.3 0.6011 7.0 8.1 7.4 6.0 7.0 8.3 0.6458 5.3 4.8 5.4 4.2 5.3 4.9 0.93 
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Table 34 Switching Within 3 Months, Baseline Healthcare Costs (Medians) 
  LHP and PHP           LHP             PHP             
  
Total   Switch 
1st 3 
mos 
  Still 
Index 
Trmt 
  pval 
Comb vs 
Triple* 
Total   Switch 
1st 3 
mos 
  Still 
Index 
Trmt 
  pval 
Comb vs 
Triple* 
Total   Switch 
1st 3 
mos 
  Still 
Index 
Trmt 
  pval 
Comb vs 
Triple* 
Median 3403   306   3097     2127   208   1919     1276   98   1178     
Cost of Utilization ($)   
Non-COPD Outpatient  3163   2674   3223   0.0403 3386   2918   3416   0.2188 2838   1906   2866   0.0334 
COPD Outpatient  1287   1290   1284   0.7054 1114   1250   1092   0.4372 1649   1672   1649   0.9892 
Total Outpatient  4932   4379   5012   0.0867 4971   4511   5064   0.2632 4899   4023   4947   0.1433 
                                            
Non-COPD Outpatient  0   0   0   0.7755 0   0   0   0.8515 0   0   0   0.7652 
COPD Outpatient  0   0   0   0.1388 0   0   0   0.4506 0   0   0   0.0886 
Total Outpatient  0   0   0   0.2842 0   0   0   0.6591 0   0   0   0.2575 
Total Medical Utilization 7235   7909   7135   0.4715 7542   7864   7478   0.6727 6564   8693   6483   0.6380 
                                            
Non-COPD Outpatient Rx 1226   1270   1209   0.6457 1502   1513   1500   0.3562 686   323   722   0.1291 
COPD Outpatient Rx 81   57   85   0.7208 101   84   104   0.6383 57   27   62   0.1149 
Total Outpatient Rx 1707   1733   1704   0.9183 1981   2031   1975   0.5302 1094   474   1123   0.0584 
                                            
Total Healthcare Services 9968   11200   9883   0.2787 10652   11411   10586   0.4141 8766   10445   8700   0.7401 
Cost of Utilization ($)  - for those with utilization within category  
Non-COPD Outpatient  3246   2784   3300   0.0834 3443   3036   3488   0.3076 2881   2053   2958   0.0618 
COPD Outpatient  1423   1486   1420   0.1935 1261   1376   1231   0.0985 1758   1990   1751   0.7008 
Total Outpatient  4948   4401   5013   0.1372 4997   4557   5065   0.3637 4910   4056   4963   0.1727 
                                            
Non-COPD Outpatient  17195   14929   17629   0.5315 19252   17721   19440   0.827 13131   6661   14353   0.0101 
COPD Outpatient  16965   19373   16582   0.3329 13720   19221   13198   0.1592 20660   19373   20663   0.8393 
Total Outpatient  19439   20659   19263   0.4396 17708   21167   17467   0.2644 21650   19022   21734   0.7165 
Total Medical Utilization 7259   7909   7151   0.4885 7542   7864   7478   0.6727 6602   8693   6505   0.6675 
                                            
Non-COPD Outpatient Rx 1324   1390   1310   0.4285 1544   1560   1544   0.4721 888   604   896   0.5449 
COPD Outpatient Rx 81   57   85   0.7208 101   84   104   0.6383 57   27   62   0.1149 
Total Outpatient Rx 1707   1733   1704   0.9183 1981   2031   1975   0.5302 1094   474   1123   0.0584 
                                            
Total Healthcare Services 9968   11200   9883   0.2787 10652   11411   10586   0.4141 8766   10445   8700   0.7401 
Length of Stay (for inpatient 
stays) 
4   5   4   0.0193 4   6   4   0.017 4   4   4   0.5209 
* Wilcoxon signed rank sum test for differences in distributions using median 
  
 
1
6
5 
 
Table 35 Switching Within 6 Months, Baseline Healthcare Costs (Means) 
  LHP and PHP           LHP             PHP             
LHP & PHP  
Baseline Characteristic 
Total SD Switch 
1st 6 
mos 
SD Still 
Index 
Trmt 
SD pval  Total SD Switch 
1st 6 
mos 
SD Still 
Index 
Trmt 
SD pval  Total SD Switch 
1st 6 
mos 
SD Still 
Index 
Trmt 
SD pval  
Number of Patients 2544  306  2238   1544  210  1334   1000  96  904   
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient 5484 9831 5159 7149 5528 10143 0.424 5476 8503 5362 7584 5494 8641 0.818 5497 11591 4716 6103 5579 12027 0.2451 
COPD Outpatient 2044 2380 2119 2505 2034 2363 0.5603 1886 2152 1894 2218 1885 2142 0.9522 2289 2677 2610 2994 2255 2640 0.2171 
Total Outpatient 7529 10602 7278 8256 7563 10884 0.5878 7362 9196 7256 8694 7379 9276 0.8574 7786 12465 7326 7249 7834 12898 0.5531 
                      
Non-COPD Outpatient 4629 18736 4263 13720 4679 19323 0.6382 6720 23274 5579 16106 6899 24210 0.3084 1400 6302 1382 4635 1402 6456 0.9701 
COPD Outpatient 5930 21203 8329 33663 5602 18859 0.1662 4852 21401 8519 38013 4275 17353 0.1128 7595 20794 7914 21424 7561 20738 0.8744 
Total Outpatient 10559 29912 12592 38113 10281 28608 0.3075 11572 33327 14098 43097 11174 31517 0.3459 8995 23621 9296 23695 8963 23626 0.8954 
Total Medical Utilization 18087 33354 19870 39586 17844 32412 0.392 18934 36141 21355 44264 18553 34694 0.382 16780 28488 16622 26551 16797 28700 0.9545 
                      
Non-COPD Outpatient Rx 2230 3752 2294 3973 2221 3722 0.7512 2645 4263 2661 4328 2643 4254 0.9534 1590 2665 1491 2919 1601 2638 0.7022 
COPD Outpatient Rx 528 911 547 1029 526 894 0.7266 579 962 615 1142 573 931 0.6175 450 822 400 707 456 833 0.4752 
Total Outpatient Rx 2758 3971 2841 4207 2746 3938 0.6943 3222 4458 3276 4575 3214 4441 0.8517 2041 2931 1892 3073 2056 2916 0.6005 
                      
Total Healthcare Services 20845 34170 22711 40369 20590 33235 0.3798 22156 37082 24630 45187 21767 35643 0.3817 18821 29010 18514 26724 18853 29256 0.9132 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient 5601 9902 5280 7188 5644 10217 0.4379 5581 8550 5492 7629 5595 8688 0.8613 5632 11700 4817 6129 5719 12143 0.2324 
COPD Outpatient 2180 2397 2316 2530 2162 2378 0.3133 2022 2166 2105 2242 2010 2155 0.5742 2420 2694 2753 3010 2384 2658 0.2144 
Total Outpatient 7549 10609 7350 8265 7576 10889 0.6683 7376 9199 7326 8706 7384 9277 0.9321 7817 12481 7403 7248 7860 12911 0.5952 
                      
Non-COPD Outpatient 32439 39513 25576 24336 33561 41390 0.0562 36278 43088 28578 26108 37567 45224 0.0755 18182 14594 13271 7176 18915 15298 0.0669 
COPD Outpatient 30416 39538 36938 63328 29362 34180 0.3346 29038 45218 41604 76034 26524 35817 0.2096 31910 32302 29220 33115 32240 32266 0.6537 
Total Outpatient 36202 46271 37776 58531 35951 44054 0.7636 37615 51323 41121 65884 36989 48338 0.6126 33688 35504 29748 34783 34187 35635 0.5198 
Total Medical Utilization 18109 33368 19870 39586 17868 32427 0.3977 18934 36141 21355 44264 18553 34694 0.382 16831 28516 16622 26551 16853 28731 0.94 
                      
Non-COPD Outpatient Rx 2357 3819 2421 4044 2349 3788 0.7632 2719 4299 2726 4361 2718 4291 0.9803 1757 2749 1684 3051 1765 2717 0.7974 
COPD Outpatient Rx 528 911 547 1029 526 894 0.7266 579 962 615 1142 573 931 0.6175 450 822 400 707 456 833 0.4752 
Total Outpatient Rx 2758 3971 2841 4207 2746 3938 0.6943 3222 4458 3276 4575 3214 4441 0.8517 2041 2931 1892 3073 2056 2916 0.6005 
                      
Total Healthcare Services 20845 34170 22711 40369 20590 33235 0.3798 22156 37082 24630 45187 21767 35643 0.3817 18821 29010 18514 26724 18853 29256 0.9132 
Length of Stay (inpatient 
stays) 
6.4 7.0 6.7 9.9 6.3 6.4 0.733 7.0 7.9 7.8 11.6 6.8 7.0 0.5007 5.4 4.9 4.0 2.2 5.5 5.1 0.0057 
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Table 36 Switching Within 6 Months, Baseline Healthcare Costs (Medians) 
  
Total   Switch 
1st 6 
mos 
  Still 
Index 
Trmt 
  pval 
Comb vs 
Triple* 
Total   Switch 
1st 6 
mos 
  Still 
Index 
Trmt 
  pval 
Comb vs 
Triple* 
Total   Switch 
1st 6 
mos 
  Still 
Index 
Trmt 
  pval 
Comb vs 
Triple* 
Median 2544   306   2238     1544   210   1334     1000   96         
Cost of Utilization ($)  
Non-COPD Outpatient 3114   2690   3166   0.2533 3324   3028   3377   0.4373 2846   1906   2873   0.2278 
COPD Outpatient 1352   1360   1352   0.9195 1187   1257   1179   0.9566 1668   1597   1670   0.5768 
Total Outpatient 4953   4322   5066   0.3391 5008   4347   5107   0.3085 4914   4131   5014   0.7757 
                                            
Non-COPD Outpatient 0   0   0   0.2374 0   0   0   0.7537 0   0   0   0.3170 
COPD Outpatient 0   0   0   0.1112 0   0   0   0.0695 0   0   0   0.4712 
Total Outpatient 0   0   0   0.0913 0   0   0   0.1942 0   0   0   0.3781 
Total Medical Utilization 7049   8493   6786   0.1571 7532   8616   7377   0.2285 6467   8249   6366   0.5807 
                                            
Non-COPD Outpatient Rx 1129   1251   1079   0.3826 1453   1450   1453   0.6780 605   475   610   0.7945 
COPD Outpatient Rx 98   90   99   0.8861 129   97   141   0.7331 54   61   53   0.7944 
Total Outpatient Rx 1672   1733   1661   0.6261 2025   1845   2029   0.9533 935   969   931   0.7027 
                                            
Total Healthcare Services 9948   11689   9778   0.1121 10949   11911   10885   0.2157 8517   9926   8445   0.6043 
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient 3223   2728   3268   0.2662 3412   3157   3439   0.5087 2897   1969   2961   0.191 
COPD Outpatient 1499   1587   1494   0.3503 1350   1397   1340   0.2916 1761   1768   1760   0.5695 
Total Outpatient 5005   4341   5072   0.4633 5014   4400   5112   0.413 4932   4149   5027   0.8635 
                                            
Non-COPD Outpatient 18358   15789   18689   0.3338 19777   17721   21208   0.4828 14252   11419   14532   0.3754 
COPD Outpatient 16931   20659   16532   0.2066 13869   20659   12410   0.0286 20532   20196   20532   0.7004 
Total Outpatient 19963   21482   19501   0.9514 18339   23119   17908   0.5363 21797   20196   22030   0.3984 
Total Medical Utilization 7070   8493   6812   0.168 7532   8616   7377   0.2285 6471   8249   6398   0.6168 
                                            
Non-COPD Outpatient Rx 1251   1332   1238   0.3709 1514   1475   1530   0.737 770   874   767   0.9092 
COPD Outpatient Rx 98   90   99   0.8861 129   97   141   0.7331 54   61   53   0.7944 
Total Outpatient Rx 1672   1733   1661   0.6261 2025   1845   2029   0.9533 935   969   931   0.7027 
                                            
Total Healthcare Services 9948   11689   9778   0.1121 10949   11911   10885   0.2157 8517   9926   8445   0.6043 
Length of Stay (inpatient 
stays) 
4   5   4   0.5902 4   5   4   0.2378 4   4   4   0.2676 
* Wilcoxon signed rank sum test for differences in distributions using median  
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Aim 2 
Assess characteristics of individuals who have severe, and/or moderate 
exacerbations post-therapy initiation. 
Analyses performed for Aim 2 were similar to those for Aim 1. Comparisons 
were made for the 3 month and 6 month periods immediately following initiation of 
treatment between: 1) individuals who have any severe exacerbation compared to those 
without any severe exacerbation, and 2) between those who have the composite measure 
of any moderate or severe exacerbation compared to those without any exacerbation. All 
individuals included in the analyses had a minimum of 6 months of follow-up since this 
was one of the inclusion criteria.  Comparisons were of the same baseline characteristics 
reviewed in Aim 1 and included whether individuals discontinued therapy or stepped 
down therapy (triple to ICS/LABA or LAMA) or stepped up therapy (ICS/LABA or 
LAMA to triple). 
Severe Exacerbations  
Status at Three Months 
Very few patients had a severe exacerbation by three months following the index 
date.  Out of the 5,475 study sample patients, 146 (2.7%) had a severe exacerbation by 
three months (Table 37). Patients age 65-74 were less represented among those having a 
severe exacerbation (21.9% compared to 30.1%, P=0.03), while there was a higher 
percentage of patients with Medicaid coverage among those having a severe exacerbation 
(19.9% compared to 11.7%, P=0.003). 
A number of comorbidities were associated with having a severe exacerbation.  
Cardiovascular disease was more prevalent as indicated by a higher percentage of 
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patients having a history of acute myocardial infarction (6.2% compared to 3.1%, 
P=0.04), atrial fibrillation (18.5% compared to 9.5%, P=0.0003), heart failure (28.8% 
compared to 17.7%, P=0.0006), congestive heart failure (24.7% compared to 16.3%, 
P=0.007), peripheral vascular disease (21.9% compared to 15.9%, P=0.05), and valvular 
disease (18.5% compared to 11.3%, P=0.0073). Patients with RA/OA (34.9% compared 
to 26.1%, P=0.02), diabetes without chronic complications 32.2% compared to 23.6%, 
P=0.02), fluid and electrolyte disorders (20.5% compared to 12.3%, P=0.003) were also 
more likely to have had a severe exacerbation. And lastly, patients with psychoses 
(16.4% compared to 10.3%, P=0.02), drug abuse (6.8% compared to 3.2%, P=0.02), liver 
disease (7.5% compared to 3.8%, P=0.02), and to a lesser extent, depression (22.6% 
compared to 16.6%, P=0.05), were more likely to have had a severe exacerbation within 
the first three months. 
Patients with a history of pneumonia in the baseline period were more likely to be 
among those who had severe exacerbation (56.2% compared to 34.3%, P<0.0001), as 
were patients with a diagnosis of hypoxemia (52.1% compared to 36.0%, P<0.0001), and 
patients with asthma (44.5% compared to 32.8%, P=0.003).  Emphysema was not 
associated with a severe exacerbation within three months (27.4% compared to 22.0%, 
P=0.12). 
Overall, patients assessed to have low complexity COPD were less represented 
among those with a severe exacerbation (27.4% compared to 50.7%, P<0.0001). 
Patients with no claims for SABA in the baseline period were less likely to be 
among those with a severe exacerbation (27.4% compared to 42.7% with some use, 
P=0.0002), as were patients with no oxygen use (43.8% compared to 56.8%, P=0.002). 
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Patients with some use of SAMA or SABA/SAMA medications in the baseline period 
were more likely to be among those with a severe exacerbation (42.% compared to 
24.8%, P<0.0001), as were patients with some ICS use in the baseline period (41.8% 
compared to 31.7%, P=0.01), and patients who received a nebulizer treatment procedure 
(44.% compared to 32.0%, P=0.001). 
COPD-related symptoms in the baseline period that were associated with a severe 
exacerbation were breathlessness (52.1% compared to 36.5%, P=0.0001), shortness of 
breath (56.2% compared to 36.5%, P<0.0001), and wheezing (17.5% compared to 7.4%, 
P<0.0001). In keeping with the significant association of cardiovascular disease and 
severe exacerbation, a higher percentage of patients with a severe exacerbation had chest 
pain symptoms in the baseline period (43.2% compared to 31.5%, P=0.003), and had an 
EKG (58.2% compared to 44.4%, P=0.0009). 
Exacerbation experience in the baseline period was strongly associated with 
having a severe exacerbation in the first three months, particularly having had a recent 
severe exacerbation.  Among those with a severe exacerbation, 17.8% compared to 7.7% 
(P<0.0001) had a severe exacerbation within the two weeks prior to the index date, and 
14.4% compared to 5.9% (P<0.0001) had one in the 2-12 weeks before the index date.  
Overall, among those having a severe exacerbation, 40.4% had an COPD-related 
inpatient stay at some point in the year prior to the index date compared to 19.9% who 
did not (P<0.0001).  
Moderate exacerbation experience was also associated with having a severe 
exacerbation.  Among patients with a severe exacerbation, 19.9% had a moderate 
exacerbation in the two week period leading up to the index date compared to 14.1% 
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among those not having a severe exacerbation (P=0.05), and 28.1% had a moderate 
exacerbation compared to 16.0% (P<0.0001) in the 2-12 weeks prior to the index date.  
Almost all patients with a severe exacerbation in the first three months had not 
changed from their index medication (98.6%).  A higher percentage of patients having a 
severe exacerbation were patients using triple therapy at the index date (13.6% compared 
to 8.7%, P=0.04). None of the patients who discontinued therapy by the end of three 
months had a severe exacerbation during that time period. 
Table 38 provides the same summary, but only for patients still using one of the 
index therapies either at the end of three months or in the two-week period prior to a 
severe exacerbation, if one occurred before the end of three months. The 146 patients 
with a severe exacerbation were 4.3% of the 3,403 patients represented. Essentially the 
same patterns were observed in this reduced study sample. However, in this reduced 
sample, patients using triple therapy were not significantly different between those 
having a severe exacerbation and those not (13.7% compared to 11.3%, P=0.37). For the 
three index therapies, 4.9% of patients using ICS/LABA at index (n=85) had a severe 
exacerbation, 5.1% of patients using triple therapy at index (n=20) had a severe 
exacerbation, and 3.2% of patients using LAMA at index (n=41) had a severe 
exacerbation. 
Not surprisingly, patients with a severe exacerbation had higher costs for almost 
every category of healthcare utilization in the baseline period. Only non-COPD outpatient 
pharmacy costs were similar between patients having and not having a severe 
exacerbation in the first three months (P=0.99); $2,415 (SD, 2805) compared to $2,462 
(SD, $4,086) (among those with non-COPD pharmacy claims).  Patients having a severe 
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exacerbation in the first three months had mean overall baseline healthcare costs of 
$40,505 (SD, 59,086) compared to a mean baseline healthcare costs of $20,955 (SD, 
33,174) for patients not having a severe exacerbation (P<0.0001). The same comparison 
values for median costs were $21,216 compared to $9,911 (P<0.0001). 
Status at Six Months 
By six months, 352 individuals (6.4%) had a severe exacerbation (Table 39). 
Almost all the same factors observed at three months as being associated with a severe 
exacerbation were still significantly associated with having a severe exacerbation by six 
months – Medicaid insurance coverage (18.2% compared to 11.5%, P=0.0002); 
cardiovascular disease: atrial fibrillation (13.1% compared to 9.5%, P=0.03), heart failure 
(27.8% compared to 17.3%, P<0.0001), congestive heart failure (24.1% compared to 
16.0%, P<0.0001), peripheral vascular disease (21.0% compared to 15.7%, P=0.008), 
valvular disease (15.6% compared to 11.2%, P=0.01); diabetes without chronic 
complications (30.1% compared to 23.4%, P=0.004); fluid and electrolyte disorders 
(19.0% compared to 12.1%, P=0.0001); drug abuse (5.4% compared to 3.2%, P=0.02).  
RA/OA (29.0% compared to 26.2%, P=0.25) and psychoses (13.4% compared to 10.3%, 
P=0.07) were no longer a significant factors. And a few additional morbidities were now 
identified as significant factors: coagulopathy (6.8% compared to 2.7%, P<0.0001), 
deficiency anemias (21.6% compared to 13.6%, P<0.0001), pulmonary circulation 
disease (15.3% compared to 11.1%, P=0.01), and ischemic heart disease (33.0% 
compared to 24.0% , P=0.0001). 
Asthma was no longer significantly associated with a severe exacerbation (36.9% 
compared to 32.9%, P=0.12), but an emphysema diagnosis now was (30.1% compared to 
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21.5%, P=0.0002). Hypoxemia (50.3% compared to 35.5%, P<0.0001) and pneumonia 
(53.1% compared to 33.6%, P<0.0001) continued to be significant factors. And an 
assessment of low complexity was still associated with a reduced likelihood of a severe 
exacerbation (29.8% compared to 51.4%, P<0.0001). 
Among those with a severe exacerbation, 12.2% were triple therapy users at index 
compared to 8.6% among those not having a severe exacerbation (P=0.02).  Overall 6.4% 
of the 5,475 in the study sample had a severe exacerbation by six months.  Among 
ICS/LABA users the percentage was 6.7% (n=205), among LAMA users, 5.4% (n=104) 
and among triple therapy users, 8.9% (n=43). 
Patients without SABA use in the baseline period were less likely to have a severe 
exacerbation (34.1% compared to 42.8%, P=0.001), as were patients with no oxygen use 
(42.3% compared to 57.4%, P<0.0001). A large percentage of patients with a severe 
exacerbation reported breathlessness, shortness of breath or wheezing in the baseline 
period (71.0% compared to 54.8%, P<0.0001) or cough (42.3% compared to 35.4%, 
P=0.009). Similarly, a sizable number had symptoms of chest pain (42.3% compared to 
31.1%, P<0.00010 or other malaise/fatigue (33.5% compared to 24.6%, P=0.0002). 
A higher percentage of patients with a severe exacerbation had an EKG (53.7% 
compared to 44.2%, P=0.0005), chest CT (20.2% compared to 14.7%, P=0.0005), or a 
chest x-ray (69.6% compared to 62.2%, P=0.006) in the baseline period. 
As before, exacerbation experience in the baseline period was strongly associated 
with severe exacerbation experience in the follow-up period.  Significant differences 
were noted for all exacerbation categories and overall, among those with a severe 
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exacerbation by six months, 41.2% compared to 19.0% had at least one COPD-related 
inpatient stay in the baseline period (P<0.0001). 
Among those with a severe exacerbation, 73.6% were still using one of the index 
medications; 69.0% were still using the same therapy as at index.  
By six months 46.5% (n=2544) of the 5,475 in the study sample were still using 
one of the index medications, and of these 2544 patients, 259 (10.2%) had a severe 
exacerbation prior to or at six months (Table 40).  Factors found to be significantly 
associated with a severe exacerbation within six months in this reduced population were 
almost unchanged from those identified among the larger population. Differences 
included that RA/OA was now once again a significant factor (31.3% compared to 
24.0%, P=0.01), while pulmonary circulation disease now was not (14.7% compared to 
11.3%, P=0.11). 
Patients in the LAMA medication group at index were less likely to have had a 
severe exacerbation by six months; 30.1% were in the LAMA medication group 
compared to 39.1% among patents not having a severe exacerbation (P=0.005).  
As at three months, patients having a severe exacerbation had mean baseline 
health care utilization costs that were significantly higher than patients not having a 
severe exacerbation (Table 45).  Mean total health care costs for those with a severe 
exacerbation by six months were $35,701 (SD, $47,762) compared to $20,499 (SD, 
$32,910) for those without a severe exacerbation (P<0.0001).  Median total health care 
costs were $20,671 compared to $9,731 (P<0.0001). And again, mean non-COPD 
outpatient pharmacy costs did not differ ($2507 [SD, $3048] compared to $2459 [$4118], 
P=0.78.  If patients discontinuing therapy by six months are excluded (Table 47), mean 
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total costs are slightly lower ($33,941 [SD, $49,433] compared to $19,361 [$31,660], 
P<0.0001).
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Table 37 Baseline Characteristics – Severe Exacerbation in 3 Months 
  LHP& PHP LHP PHP 
 
Baseline Characteristic 
Total % Sev 
Exac 
1st 3 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
1st 3 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
1st 3 
mon 
% No 
Sev 
Exac 
% pval  
Number of Patients 5475   146   5329     3599   78   3521     1876   68   1808     
Age Categories                                           
age 40-54 584 10.7 16 11.0 568 10.7 0.9077 332 9.2 9 11.5 323 9.2 0.4753 252 13.4 7 10.3 245 13.6 0.4394 
age 55-64 1026 18.7 34 23.3 992 18.6 0.1535 591 16.4 12 15.4 579 16.4 0.8027 435 23.2 22 32.4 413 22.8 0.0681 
age 65-74 1637 29.9 32 21.9 1605 30.1 0.0327 1059 29.4 19 24.4 1040 29.5 0.3209 578 30.8 13 19.1 565 31.3 0.0334 
age 75 and older 2228 40.7 64 43.8 2164 40.6 0.4335 1617 44.9 38 48.7 1579 44.8 0.4964 611 32.6 26 38.2 585 32.4 0.3098 
age (Mean, SD) 70.55 11.51 70.46 12.29 70.55 11.48 0.9239 71.58 11.31 71.41 12.04 71.58 11.30 0.8932 68.57 11.62 69.37 12.56 68.54 11.58 0.5639 
                                            
Men 2393 43.7 65 44.5 2328 43.7 0.8409 1616 44.9 37 47.4 1579 44.8 0.6491 777 41.4 28 41.2 749 41.4 0.9672 
                                            
Quarter of Year for Index Date             0.0069             0.5153             0.0188 
Q1 1645 30.0 44 30.1 1601 30.0   1111 30.9 26 33.3 1085 30.8   534 28.5 18 26.5 516 28.5   
Q2 1160 21.2 18 12.3 1142 21.4   800 22.2 12 15.4 788 22.4   360 19.2 6 8.8 354 19.6   
Q3 1192 21.8 29 19.9 1163 21.8   846 23.5 19 24.4 827 23.5   346 18.4 10 14.7 336 18.6   
Q4 1478 27.0 55 37.7 1423 26.7   842 23.4 21 26.9 821 23.3   636 33.9 34 50.0 602 33.3   
                                            
Months of enrollment post-Index             0.1396             0.3519             0.5788 
7 78 1.4 2 1.4 76 1.4   44 1.2 1 1.3 43 1.2   34 1.8 1 1.5 33 1.8   
8 66 1.2 6 4.1 60 1.1   39 1.1 3 3.8 36 1.0   27 1.4 3 4.4 24 1.3   
9 85 1.6 3 2.1 82 1.5   50 1.4 1 1.3 49 1.4   35 1.9 2 2.9 33 1.8   
10 99 1.8 2 1.4 97 1.8   70 1.9 2 2.6 68 1.9           29 1.6   
11 117 2.1 2 1.4 115 2.2   95 2.6 2 2.6 93 2.6           22 1.2   
12 92 1.7 1 0.7 91 1.7   71 2.0 1 1.3 70 2.0           21 1.2   
13 99 1.8 4 2.7 95 1.8   67 1.9 4 5.1 63 1.8           32 1.8   
14 111 2.0 4 2.7 107 2.0   75 2.1 3 3.8 72 2.0   36 1.9 1 1.5 35 1.9   
15 97 1.8 4 2.7 93 1.7   62 1.7 1 1.3 61 1.7   35 1.9 3 4.4 32 1.8   
16         127 2.4           82 2.3           45 2.5   
17 114 2.1 4 2.7 110 2.1   77 2.1 2 2.6 75 2.1   37 2.0 2 2.9 35 1.9   
18 106 1.9 3 2.1 103 1.9   72 2.0 2 2.6 70 2.0   34 1.8 1 1.5 33 1.8   
19 104 1.9 3 2.1 101 1.9   69 1.9 2 2.6 67 1.9   35 1.9 1 1.5 34 1.9   
20 105 1.9 4 2.7 101 1.9   67 1.9 2 2.6 65 1.8   38 2.0 2 2.9 36 2.0   
21 105 1.9 6 4.1 99 1.9   63 1.8 3 3.8 60 1.7   42 2.2 3 4.4 39 2.2   
22 114 2.1 4 2.7 110 2.1   79 2.2 3 3.8 76 2.2   35 1.9 1 1.5 34 1.9   
23 91 1.7 2 1.4 89 1.7   64 1.8 1 1.3 63 1.8   27 1.4 1 1.5 26 1.4   
24 3765 68.8 92 63.0 3673 68.9   2453 68.2 45 57.7 2408 68.4   1312 69.9 47 69.1 1265 70.0   
Insurance at Index                                           
Commercial 1778 32.5 36 24.7 1742 32.7 0.0409 1376 38.2 28 35.9 1348 38.3 0.6678 402 21.4 8 11.8 394 21.8 0.0479 
Medicaid 655 12.0 29 19.9 626 11.7 0.0029 284 7.9 9 11.5 275 7.8 0.2270 371 19.8 20 29.4 351 19.4 0.0422 
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Medicare 3071 56.1 82 56.2 2989 56.1 0.9856 1968 54.7 42 53.8 1926 54.7 0.8808 1103 58.8 40 58.8 1063 58.8 0.9962 
                                            
CMS comorbidities (Baseline 
Per.) 
                                          
acute myocardial infarction 
(AMI) 
175 3.2 9 6.2 166 3.1 0.0388 114 3.2 4 5.1 110 3.1 0.3175 61 3.3 5 7.4 56 3.1 0.0521 
Alzheimer’s 189 3.5 6 4.1 183 3.4 0.6591 111 3.1 3 3.8 108 3.1 0.6939 78 4.2 3 4.4 75 4.1 0.9149 
atrial fibrillation 534 9.8 27 18.5 507 9.5 0.0003 362 10.1 15 19.2 347 9.9 0.0065 172 9.2 12 17.6 160 8.8 0.0136 
cancers 370 6.8 10 6.8 360 6.8 0.9645 265 7.4 6 7.7 259 7.4 0.9104 105 5.6 4 5.9 101 5.6 0.9170 
lung cancer 113 2.1 5 3.4 108 2.0 0.2411 75 2.1 3 3.8 72 2.0 0.2707 38 2.0 2 2.9 36 2.0 0.5851 
chronic kidney disease 870 15.9 29 19.9 841 15.8 0.1832 626 17.4 19 24.4 607 17.2 0.1009 244 13.0 10 14.7 234 12.9 0.6713 
diabetes 1358 24.8 45 30.8 1313 24.6 0.0879 884 24.6 21 26.9 863 24.5 0.6244 474 25.3 24 35.3 450 24.9 0.0526 
heart failure 986 18.0 42 28.8 944 17.7 0.0006 645 17.9 20 25.6 625 17.8 0.0723 341 18.2 22 32.4 319 17.6 0.0020 
ischemic heart dis. (IHD; incl. 
AMI) 
1343 24.5 45 30.8 1298 24.4 0.0733 908 25.2 26 33.3 882 25.0 0.0957 435 23.2 19 27.9 416 23.0 0.3441 
rheumatoid/osteo arthritis 
(RA/OA) 
1443 26.4 51 34.9 1392 26.1 0.0171 954 26.5 29 37.2 925 26.3 0.0309 489 26.1 22 32.4 467 25.8 0.2290 
stroke/TIA 387 7.1 12 8.2 375 7.0 0.5824 256 7.1 7 9.0 249 7.1 0.5179 131 7.0 5 7.4 126 7.0 0.9029 
no CMS Comorbidity 1860 34.0 33 22.6 1827 34.3 0.0033 1194 33.2 15 19.2 1179 33.5 0.0082 666 35.5 18 26.5 648 35.8 0.1129 
                                            
Elixhauser comorbidities 
(Baseline Per.) 
                                          
AIDS         10 0.2 0.6003         9 0.3 0.6548         1 0.1 0.8462 
alcohol abuse 191 3.5 11 7.5 180 3.4 0.0069 108 3.0 6 7.7 102 2.9 0.0141 83 4.4 5 7.4 78 4.3 0.2316 
chronic blood loss anemia 49 0.9 5 3.4 44 0.8 0.0010 28 0.8 2 2.6 26 0.7 0.0695 21 1.1 3 4.4 18 1.0 0.0086 
coagulopathy 163 3.0 8 5.5 155 2.9 0.0714 96 2.7 2 2.6 94 2.7 0.9543 67 3.6 6 8.8 61 3.4 0.0174 
congestive heart failure 903 16.5 36 24.7 867 16.3 0.0071 616 17.1 21 26.9 595 16.9 0.0201 287 15.3 15 22.1 272 15.0 0.1147 
deficiency anemias 773 14.1 24 16.4 749 14.1 0.4146 498 13.8 15 19.2 483 13.7 0.1631 275 14.7 9 13.2 266 14.7 0.7353 
depression 917 16.7 33 22.6 884 16.6 0.0549 537 14.9 12 15.4 525 14.9 0.9075 380 20.3 21 30.9 359 19.9 0.0264 
diabetes (wo/chr 
complications) 
1304 23.8 47 32.2 1257 23.6 0.0160 867 24.1 24 30.8 843 23.9 0.1631 437 23.3 23 33.8 414 22.9 0.0364 
diabetes (w/chr 
complications) 
442 8.1 13 8.9 429 8.1 0.7087 332 9.2 8 10.3 324 9.2 0.7502 110 5.9 5 7.4 105 5.8 0.5944 
drug abuse 181 3.3 10 6.8 171 3.2 0.0152 115 3.2 7 9.0 108 3.1 0.0033 66 3.5 3 4.4 63 3.5 0.6837 
fluid and electrolyte disorders 686 12.5 30 20.5 656 12.3 0.0030 422 11.7 14 17.9 408 11.6 0.0841 264 14.1 16 23.5 248 13.7 0.0223 
hypertension 3374 61.6 102 69.9 3272 61.4 0.0380 2301 63.9 54 69.2 2247 63.8 0.3247 1073 57.2 48 70.6 1025 56.7 0.0230 
hypothyroidism 1032 18.8 26 17.8 1006 18.9 0.7444 684 19.0 15 19.2 669 19.0 0.9591 348 18.6 11 16.2 337 18.6 0.6080 
liver disease 212 3.9 11 7.5 201 3.8 0.0201 144 4.0 7 9.0 137 3.9 0.0235 68 3.6 4 5.9 64 3.5 0.3103 
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lymphoma 46 0.8 1 0.7 45 0.8 0.8350 31 0.9 1 1.3 30 0.9 0.6844         15 0.8 0.4508 
metastatic cancer         56 1.1 0.2131         41 1.2 0.3378         15 0.8 0.4508 
obesity 717 13.1 24 16.4 693 13.0 0.2250 480 13.3 10 12.8 470 13.3 0.8921 237 12.6 14 20.6 223 12.3 0.0443 
other neurological disorders 514 9.4 16 11.0 498 9.3 0.5095 363 10.1 10 12.8 353 10.0 0.4175 151 8.0 6 8.8 145 8.0 0.8110 
paralysis 68 1.2 6 4.1 62 1.2 0.0015 48 1.3 5 6.4 43 1.2 <0.0001 20 1.1 1 1.5 19 1.1 0.7408 
peripheral vascular disease 878 16.0 32 21.9 846 15.9 0.0496 614 17.1 21 26.9 593 16.8 0.0192 264 14.1 11 16.2 253 14.0 0.6113 
psychoses 573 10.5 24 16.4 549 10.3 0.0169 399 11.1 16 20.5 383 10.9 0.0073 174 9.3 8 11.8 166 9.2 0.4710 
pulmonary circulation disease 625 11.4 22 15.1 603 11.3 0.1595 435 12.1 14 17.9 421 12.0 0.1083 190 10.1 8 11.8 182 10.1 0.6486 
renal failure 468 8.5 11 7.5 457 8.6 0.6570 338 9.4 6 7.7 332 9.4 0.6030 130 6.9 5 7.4 125 6.9 0.8887 
rheumatoid arthritis/collagen 
vas 
343 6.3 6 4.1 337 6.3 0.2760 209 5.8 3 3.8 206 5.9 0.4541 134 7.1 3 4.4 131 7.2 0.3731 
solid tumor wo/metastasis 533 9.7 14 9.6 519 9.7 0.9519 368 10.2 9 11.5 359 10.2 0.6987 165 8.8 5 7.4 160 8.8 0.6688 
ulcers 7 0.1 1 0.7 6 0.1 0.0562         3 0.1 0.7965 4 0.2 1 1.5 3 0.2 0.0220 
valvular disease 630 11.5 27 18.5 603 11.3 0.0073 478 13.3 16 20.5 462 13.1 0.0571 152 8.1 11 16.2 141 7.8 0.0129 
weight loss 327 6.0 10 6.8 317 5.9 0.6505 219 6.1 6 7.7 213 6.0 0.5483 108 5.8 4 5.9 104 5.8 0.9639 
any Elixhauser diagnosis 5028 91.8 138 94.5 4890 91.8 0.2298 3333 92.6 75 96.2 3258 92.5 0.2264 1695 90.4 63 92.6 1632 90.3 0.5138 
Other comorbidities                                           
asthma 1813 33.1 65 44.5 1748 32.8 0.0030 1166 32.4 36 46.2 1130 32.1 0.0087 647 34.5 29 42.6 618 34.2 0.1494 
hypoxemia 1994 36.4 76 52.1 1918 36.0 <0.0001 1229 34.1 42 53.8 1187 33.7 0.0002 765 40.8 34 50.0 731 40.4 0.1150 
pneumonia 1908 34.8 82 56.2 1826 34.3 <0.0001 1348 37.5 51 65.4 1297 36.8 <0.0001 560 29.9 31 45.6 529 29.3 0.0039 
influenza 178 3.3 4 2.7 174 3.3 0.7240 124 3.4 1 1.3 123 3.5 0.2896 54 2.9 3 4.4 51 2.8 0.4411 
                                            
COPD Complexity ^                                           
Low complexity 2740 50.0 40 27.4 2700 50.7 <0.0001 1761 48.9 20 25.6 1741 49.4 <0.0001 979 52.2 20 29.4 959 53.0 0.0001 
Med complexity 2510 45.8 101 69.2 2409 45.2 <0.0001 1686 46.8 56 71.8 1630 46.3 <0.0001 824 43.9 45 66.2 779 43.1 0.0002 
High complexity 225 4.1 5 3.4 220 4.1 0.6726 152 4.2 2 2.6 150 4.3 0.4613 73 3.9 3 4.4 70 3.9 0.8211 
Emphysema diagnosis (492.x) 1210 22.1 40 27.4 1170 22.0 0.1179 694 19.3 17 21.8 677 19.2 0.5697 516 27.5 23 33.8 493 27.3 0.2346 
                                            
COPD Medications                                            
index ICSLABA 3052 55.7 85 58.2 2967 55.7 0.5417 2129 59.2 51 65.4 2078 59.0 0.2578 923 49.2 34 50.0 889 49.2 0.8931 
index LAMA 1939 35.4 41 28.1 1898 35.6 0.0604 1158 32.2 19 24.4 1139 32.3 0.1352 781 41.6 22 32.4 759 42.0 0.1139 
index triple 484 8.8 20 13.7 464 8.7 0.0361 312 8.7 8 10.3 304 8.6 0.6145 172 9.2 12 17.6 160 8.8 0.0136 
SABA use                                           
no SABA use 2314 42.3 40 27.4 2274 42.7 0.0002 1479 41.1 22 28.2 1457 41.4 0.0193 835 44.5 18 26.5 817 45.2 0.0023 
SABA <=15% of year 1435 26.2 46 31.5 1389 26.1 0.1402 973 27.0 18 23.1 955 27.1 0.4262 462 24.6 28 41.2 434 24.0 0.0013 
SABA <=40% of year 803 14.7 21 14.4 782 14.7 0.9219 555 15.4 16 20.5 539 15.3 0.2081 248 13.2 5 7.4 243 13.4 0.1457 
SABA >40% of year 923 16.9 39 26.7 884 16.6 0.0013 592 16.4 22 28.2 570 16.2 0.0046 331 17.6 17 25.0 314 17.4 0.1050 
SAMA use                                           
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any ipratropium (SAMA) 632 11.5 36 24.7 596 11.2 <0.0001 391 10.9 15 19.2 376 10.7 0.0164 241 12.8 21 30.9 220 12.2 <0.0001 
any SABA/SAMA 876 16.0 36 24.7 840 15.8 0.0038 591 16.4 22 28.2 569 16.2 0.0045 285 15.2 14 20.6 271 15.0 0.2066 
any SAMA or SABA/SAMA 1381 25.2 62 42.5 1319 24.8 <0.0001 901 25.0 31 39.7 870 24.7 0.0024 480 25.6 31 45.6 449 24.8 0.0001 
Other COPD medications                                           
any ICS 1752 32.0 61 41.8 1691 31.7 0.0102 1143 31.8 31 39.7 1112 31.6 0.1257 609 32.5 30 44.1 579 32.0 0.0365 
any LABA 227 4.1 8 5.5 219 4.1 0.4127 118 3.3 3 3.8 115 3.3 0.7760 109 5.8 5 7.4 104 5.8 0.5796 
any methylxanthines 87 1.6 3 2.1 84 1.6 0.6483 29 0.8 2 2.6 27 0.8 0.0791 58 3.1 1 1.5 57 3.2 0.4315 
Any use of above COPD 
medications 
2688 49.1 97 66.4 2591 48.6 <0.0001 1748 48.6 50 64.1 1698 48.2 0.0055 940 50.1 47 69.1 893 49.4 0.0014 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 4868 88.9 126 86.3 4742 89.0 0.3083 3206 89.1 63 80.8 3143 89.3 0.0173 1662 88.6 63 92.6 1599 88.4 0.2840 
1-2 Rxs ICSLABA (wks 27-
52) 
387 7.1 11 7.5 376 7.1 0.8239 255 7.1 9 11.5 246 7.0 0.1212 132 7.0 2 2.9 130 7.2 0.1786 
>2 Rxs ICSLABA (wks 27-
52) 
220 4.0 9 6.2 211 4.0 0.1808 138 3.8 6 7.7 132 3.7 0.0728 82 4.4 3 4.4 79 4.4 0.9866 
No LAMA in prior year 5280 96.4 142 97.3 5138 96.4 0.5870 3472 96.5 75 96.2 3397 96.5 0.8779 1808 96.4 67 98.5 1741 96.3 0.3330 
1-2 Rxs LAMA (wks 27-52) 124 2.3 4 2.7 120 2.3 0.6959 86 2.4 3 3.8 83 2.4 0.3944 38 2.0 1 1.5 37 2.0 0.7407 
>2 Rxs LAMA (wks 27-52)         71 1.3 0.1604         41 1.2 0.3378         30 1.7 0.2843 
Oxygen Use                                           
no oxygen 3090 56.4 64 43.8 3026 56.8 0.0019 2097 58.3 35 44.9 2062 58.6 0.0153 993 52.9 29 42.6 964 53.3 0.0835 
oxygen <=50% of year 876 16.0 30 20.5 846 15.9 0.1287 619 17.2 18 23.1 601 17.1 0.1643 257 13.7 12 17.6 245 13.6 0.3348 
oxygen >50% of year 1509 27.6 52 35.6 1457 27.3 0.0273 883 24.5 25 32.1 858 24.4 0.1188 626 33.4 27 39.7 599 33.1 0.2589 
                                            
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 3454 63.1 70 47.9 3384 63.5 0.0001 2101 58.4 36 46.2 2065 58.6 0.0268 1353 72.1 34 50.0 1319 73.0 <0.0001 
1 period breathlessness 1051 19.2 43 29.5 1008 18.9 0.0014 757 21.0 22 28.2 735 20.9 0.1161 294 15.7 21 30.9 273 15.1 0.0004 
>1 period breathlessness 970 17.7 33 22.6 937 17.6 0.1171 741 20.6 20 25.6 721 20.5 0.2646 229 12.2 13 19.1 216 11.9 0.0762 
Shortness of Breath                                           
no periods shortness breath 3450 63.0 64 43.8 3386 63.5 <0.0001 2260 62.8 32 41.0 2228 63.3 <0.0001 1190 63.4 32 47.1 1158 64.0 0.0043 
1 period shortness breath 1128 20.6 40 27.4 1088 20.4 0.0396 785 21.8 27 34.6 758 21.5 0.0056 343 18.3 13 19.1 330 18.3 0.8562 
>1 period shortness breath 897 16.4 42 28.8 855 16.0 <0.0001 554 15.4 19 24.4 535 15.2 0.0265 343 18.3 23 33.8 320 17.7 0.0007 
any wheezing 419 7.7 26 17.8 393 7.4 <0.0001 302 8.4 14 17.9 288 8.2 0.0021 117 6.2 12 17.6 105 5.8 <0.0001 
any dyspnea 3057 55.8 110 75.3 2947 55.3 <0.0001 2126 59.1 61 78.2 2065 58.6 0.0005 931 49.6 49 72.1 882 48.8 0.0002 
supplemental oxygen use 
(V46.2) 
317 5.8 22 15.1 295 5.5 <0.0001 112 3.1 8 10.3 104 3.0 0.0002 205 10.9 14 20.6 191 10.6 0.0093 
Other symptoms                                           
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chest pain unspecified 1662 30.4 60 41.1 1602 30.1 0.0042 1082 30.1 31 39.7 1051 29.8 0.0594 580 30.9 29 42.6 551 30.5 0.0330 
painful respiratory 272 5.0 10 6.8 262 4.9 0.2890 165 4.6 8 10.3 157 4.5 0.0155 107 5.7 2 2.9 105 5.8 0.3170 
precordial pain 107 2.0 5 3.4 102 1.9 0.1933 72 2.0 5 6.4 67 1.9 0.0049         35 1.9 0.2468 
any chestpain 1742 31.8 63 43.2 1679 31.5 0.0029 1137 31.6 34 43.6 1103 31.3 0.0212 605 32.2 29 42.6 576 31.9 0.0617 
chronic fatigue 85 1.6 3 2.1 82 1.5 0.6188 67 1.9 1 1.3 66 1.9 0.7018 18 1.0 2 2.9 16 0.9 0.0877 
other malaise/fatigue 1379 25.2 52 35.6 1327 24.9 0.0033 884 24.6 25 32.1 859 24.4 0.1203 495 26.4 27 39.7 468 25.9 0.0111 
difficulty walking 139 2.5 6 4.1 133 2.5 0.2213 105 2.9 4 5.1 101 2.9 0.2408 34 1.8 2 2.9 32 1.8 0.4772 
memory loss 132 2.4 2 1.4 130 2.4 0.4058         94 2.7 0.1437 38 2.0 2 2.9 36 2.0 0.5851 
cough 1963 35.9 63 43.2 1900 35.7 0.0624 1394 38.7 37 47.4 1357 38.5 0.1107 569 30.3 26 38.2 543 30.0 0.1486 
hemoptysis 76 1.4 1 0.7 75 1.4 0.4617 52 1.4 1 1.3 51 1.4 0.9030         24 1.3 0.3390 
                                            
Procedures                                           
chest CT 822 15.0 28 19.2 794 14.9 0.1533 551 15.3 15 19.2 536 15.2 0.3309 271 14.4 13 19.1 258 14.3 0.2643 
chest x-ray 3432 62.7 102 69.9 3330 62.5 0.0691 2234 62.1 53 67.9 2181 61.9 0.2796 1198 63.9 49 72.1 1149 63.6 0.1517 
echocardiography 1113 20.3 30 20.5 1083 20.3 0.9468 819 22.8 16 20.5 803 22.8 0.6328 294 15.7 14 20.6 280 15.5 0.2559 
EKG 2452 44.8 85 58.2 2367 44.4 0.0009 1621 45.0 47 60.3 1574 44.7 0.0063 831 44.3 38 55.9 793 43.9 0.0501 
heart catheterization 71 1.3 2 1.4 69 1.3 0.9370 51 1.4 1 1.3 50 1.4 0.9188 20 1.1 1 1.5 19 1.1 0.7408 
nebulizer treatment 1771 32.3 65 44.5 1706 32.0 0.0014 1326 36.8 38 48.7 1288 36.6 0.0279 445 23.7 27 39.7 418 23.1 0.0016 
non-invasive ventilator 339 6.2 13 8.9 326 6.1 0.1681 210 5.8 7 9.0 203 5.8 0.2317 129 6.9 6 8.8 123 6.8 0.5180 
spirometry 2284 41.7 57 39.0 2227 41.8 0.5063 1578 43.8 31 39.7 1547 43.9 0.4604 706 37.6 26 38.2 680 37.6 0.9169 
any vaccination (flu or 
pneumonia) 
2632 48.1 65 44.5 2567 48.2 0.3838 1799 50.0 38 48.7 1761 50.0 0.8208 833 44.4 27 39.7 806 44.6 0.4271 
                                            
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 783 14.3 29 19.9 754 14.1 0.0517 525 14.6 15 19.2 510 14.5 0.2402 258 13.8 14 20.6 244 13.5 0.0955 
any severe 434 7.9 26 17.8 408 7.7 <0.0001 266 7.4 14 17.9 252 7.2 0.0003 168 9.0 12 17.6 156 8.6 0.0106 
any other hospitalizations* 124 2.3 6 4.1 118 2.2 0.1289 112 3.1 5 6.4 107 3.0 0.0899 12 0.6 1 1.5 11 0.6 0.3813 
Prior 2-12 weeks                                           
any moderate 894 16.3 41 28.1 853 16.0 <0.0001 585 16.3 19 24.4 566 16.1 0.0498 309 16.5 22 32.4 287 15.9 0.0003 
any severe 337 6.2 21 14.4 316 5.9 <0.0001 179 5.0 10 12.8 169 4.8 0.0013 158 8.4 11 16.2 147 8.1 0.0190 
any other hospitalizations* 209 3.8 10 6.8 199 3.7 0.0526 169 4.7 8 10.3 161 4.6 0.0189 40 2.1 2 2.9 38 2.1 0.6381 
Prior 13-52 weeks                                           
no moderate 4200 76.7 102 69.9 4098 76.9 0.0472 2733 75.9 56 71.8 2677 76.0 0.3868 1467 78.2 46 67.6 1421 78.6 0.0318 
1 moderate 1018 18.6 35 24.0 983 18.4 0.0904 694 19.3 20 25.6 674 19.1 0.1502 324 17.3 15 22.1 309 17.1 0.2873 
>1 moderate 257 4.7 9 6.2 248 4.7 0.3946 172 4.8 2 2.6 170 4.8 0.3539 85 4.5 7 10.3 78 4.3 0.0199 
any severe 409 7.5 23 15.8 386 7.2 0.0001 215 6.0 12 15.4 203 5.8 0.0004 194 10.3 11 16.2 183 10.1 0.1075 
any other hospitalizations* 384 7.0 18 12.3 366 6.9 0.0108 313 8.7 14 17.9 299 8.5 0.0034 71 3.8 4 5.9 67 3.7 0.3558 
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All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 852 15.6 36 24.7 816 15.3 0.0021 687 19.1 30 38.5 657 18.7 <0.0001 165 8.8 6 8.8 159 8.8 0.9933 
COPD Inpatient (Any) 1117 20.4 59 40.4 1058 19.9 <0.0001 636 17.7 28 35.9 608 17.3 <0.0001 481 25.6 31 45.6 450 24.9 0.0001 
Total Inpatient (Any) 1690 30.9 78 53.4 1612 30.2 <0.0001 1153 32.0 43 55.1 1110 31.5 <0.0001 537 28.6 35 51.5 502 27.8 <0.0001 
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period) 
Same as Index Trmt 3097 56.6 144 98.6 2953 55.4 <0.0001 1919 53.3 77 98.7 1842 52.3 <0.0001 1178 62.8 67 98.5 1111 61.4 <0.0001 
No evidence Any Trmt 2072 37.8 0 0.0 2072 38.9 <0.0001 1472 40.9 0 0.0 1472 41.8 <0.0001 600   0 0.0 600 33.2 <0.0001 
Different Trmt from Index 306 5.6 2 1.4 304 5.7 0.0245 208 5.8 1 1.3 207 5.9 0.0853 98 5.2 1 1.5 97 5.4 0.1565 
Now using Triple 150 2.7 2 1.4 148 2.8 0.3041 101 2.8 1 1.3 100 2.8 0.4099 49 2.6 1 1.5 48 2.7 0.5478 
No longer using Triple 102 1.9 0 0.0 102 1.9 0.0915 65 1.8 0 0.0 65 1.8 0.2259 37   0 0.0 37 2.0 0.2335 
Switched between ICSLABA 
and LAMA 
54 1.0 0 0.0 54 1.0 0.2216 42 1.2 0 0.0 42 1.2 0.3319 12   0 0.0 12 0.7 0.5003 
LHP enrollee 3599 65.7% 78 53.4% 3521 66.1% 0.0015                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 38 Severe Exacerbations Within 3 Months, Without Discontinuation 
 
LHP & PHP LHP PHP 
 
Baseline Characteristic 
Total % Sev 
Exac  
1st 3 
mon 
% No Sev 
Exac 
% pval  Total %  Sev 
Exac  
1st 3 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac  
1st 3 
mon 
% No 
Sev 
Exac 
% pval  
Number of Patients 3403   146   3257     2127   78   2049     1276   68   1208     
Age Categories                                           
age 40-54 326 9.6 16 11.0 310 9.5 0.5628 170 8.0 9 11.5 161 7.9 0.2393 156 12.2 7 10.3 149 12.3 0.6173 
age 55-64 646 19.0 34 23.3 612 18.8 0.1752 348 16.4 12 15.4 336 16.4 0.8123 298 23.4 22 32.4 276 22.8 0.0715 
age 65-74 1039 30.5 32 21.9 1007 30.9 0.0209 640 30.1 19 24.4 621 30.3 0.2609 399 31.3 13 19.1 386 32.0 0.0263 
age 75 and older 1392 40.9 64 43.8 1328 40.8 0.4616 969 45.6 38 48.7 931 45.4 0.5679 423 33.2 26 38.2 397 32.9 0.3600 
age (Mean, SD) 70.74 11.27 70.46 12.29 70.76 11.22 0.7549 71.86 11.06 71.41 12.04 71.88 11.03 0.7149 68.88 11.37 69.37 12.56 68.86 11.30 0.7186 
                                            
Men 1509 44.3 65 44.5 1444 44.3 0.9648 962 45.2 37 47.4 925 45.1 0.6898 547 42.9 28 41.2 519 43.0 0.7720 
                                            
Quarter of Year for Index Date             0.0234             0.5481             0.0516 
Q1 1030 30.3 44 30.1 986 30.3   645 30.3 26 33.3 619 30.2   385 30.2 18 26.5 367 30.4   
Q2 685 20.1 18 12.3 667 20.5   466 21.9 12 15.4 454 22.2   219 17.2 6 8.8 213 17.6   
Q3 725 21.3 29 19.9 696 21.4   506 23.8 19 24.4 487 23.8   219 17.2 10 14.7 209 17.3   
Q4 963 28.3 55 37.7 908 27.9   510 24.0 21 26.9 489 23.9   453 35.5 34 50.0 419 34.7   
                                            
Months of enrollment post-Index             0.1196             0.5020             0.2045 
7 39 1.1 2 1.4 37 1.1   22 1.0 1 1.3 21 1.0   17 1.3 1 1.5 16 1.3   
8 40 1.2 6 4.1 34 1.0   25 1.2 3 3.8 22 1.1   15 1.2 3 4.4 12 1.0   
9 58 1.7 3 2.1 55 1.7   33 1.6 1 1.3 32 1.6   25 2.0 2 2.9 23 1.9   
10 57 1.7 2 1.4 55 1.7   37 1.7 2 2.6 35 1.7           20 1.7   
11 69 2.0 2 1.4 67 2.1   53 2.5 2 2.6 51 2.5           16 1.3   
12 51 1.5 1 0.7 50 1.5   38 1.8 1 1.3 37 1.8           13 1.1   
13 68 2.0 4 2.7 64 2.0   45 2.1 4 5.1 41 2.0           23 1.9   
14 68 2.0 4 2.7 64 2.0   47 2.2 3 3.8 44 2.1   21 1.6 1 1.5 20 1.7   
15 54 1.6 4 2.7 50 1.5   37 1.7 1 1.3 36 1.8   17 1.3 3 4.4 14 1.2   
16         71 2.2           38 1.9           33 2.7   
17 75 2.2 4 2.7 71 2.2   45 2.1 2 2.6 43 2.1   30 2.4 2 2.9 28 2.3   
18 72 2.1 3 2.1 69 2.1   47 2.2 2 2.6 45 2.2   25 2.0 1 1.5 24 2.0   
19 62 1.8 3 2.1 59 1.8   36 1.7 2 2.6 34 1.7   26 2.0 1 1.5 25 2.1   
20 59 1.7 4 2.7 55 1.7   40 1.9 2 2.6 38 1.9   19 1.5 2 2.9 17 1.4   
21 65 1.9 6 4.1 59 1.8   40 1.9 3 3.8 37 1.8   25 2.0 3 4.4 22 1.8   
22 74 2.2 4 2.7 70 2.1   47 2.2 3 3.8 44 2.1   27 2.1 1 1.5 26 2.2   
23 61 1.8 2 1.4 59 1.8   41 1.9 1 1.3 40 2.0   20 1.6 1 1.5 19 1.6   
24 2360 69.4 92 63.0 2268 69.6   1456 68.5 45 57.7 1411 68.9   904 70.8 47 69.1 857 70.9   
Insurance at Index                                           
Commercial 1103 32.4 36 24.7 1067 32.8 0.0407 821 38.6 28 35.9 793 38.7 0.6175 282 22.1 8 11.8 274 22.7 0.0348 
Medicaid 377 11.1 29 19.9 348 10.7 0.0005 160 7.5 9 11.5 151 7.4 0.1706 217 17.0 20 29.4 197 16.3 0.0051 
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Baseline Characteristic 
Total % Sev 
Exac  
1st 3 
mon 
% No Sev 
Exac 
% pval  Total %  Sev 
Exac  
1st 3 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac  
1st 3 
mon 
% No 
Sev 
Exac 
% pval  
Number of Patients 3403   146   3257     2127   78   2049     1276   68   1208     
Medicare 1942 57.1 82 56.2 1860 57.1 0.8217 1165 54.8 42 53.8 1123 54.8 0.8671 777 60.9 40 58.8 737 61.0 0.7192 
                                            
CMS comorbidities                                           
acute myocardial infarction 
(AMI) 
112 3.3 9 6.2 103 3.2 0.0467 72 3.4 4 5.1 68 3.3 0.3858 40 3.1 5 7.4 35 2.9 0.0402 
Alzheimer’s 109 3.2 6 4.1 103 3.2 0.5249 61 2.9 3 3.8 58 2.8 0.5979 48 3.8 3 4.4 45 3.7 0.7722 
atrial fibrillation 323 9.5 27 18.5 296 9.1 0.0001 209 9.8 15 19.2 194 9.5 0.0045 114 8.9 12 17.6 102 8.4 0.0096 
cancers 229 6.7 10 6.8 219 6.7 0.9528 155 7.3 6 7.7 149 7.3 0.8885 74 5.8 4 5.9 70 5.8 0.9760 
lung cancer 72 2.1 5 3.4 67 2.1 0.2613 46 2.2 3 3.8 43 2.1 0.2977 26 2.0 2 2.9 24 2.0 0.5878 
chronic kidney disease 536 15.8 29 19.9 507 15.6 0.1632 362 17.0 19 24.4 343 16.7 0.0788 174 13.6 10 14.7 164 13.6 0.7917 
diabetes 802 23.6 45 30.8 757 23.2 0.0348 484 22.8 21 26.9 463 22.6 0.3710 318 24.9 24 35.3 294 24.3 0.0421 
heart failure 591 17.4 42 28.8 549 16.9 0.0002 367 17.3 20 25.6 347 16.9 0.0458 224 17.6 22 32.4 202 16.7 0.0010 
ischemic heart dis. (IHD; incl. 
AMI) 
803 23.6 45 30.8 758 23.3 0.0356 524 24.6 26 33.3 498 24.3 0.0693 279 21.9 19 27.9 260 21.5 0.2128 
rheumatoid/osteo arthritis 
(RA/OA) 
870 25.6 51 34.9 819 25.1 0.0080 543 25.5 29 37.2 514 25.1 0.0162 327 25.6 22 32.4 305 25.2 0.1917 
stroke/TIA 246 7.2 12 8.2 234 7.2 0.6367 147 6.9 7 9.0 140 6.8 0.4642 99 7.8 5 7.4 94 7.8 0.8977 
no CMS Comorbidity 1191 35.0 33 22.6 1158 35.6 0.0013 735 34.6 15 19.2 720 35.1 0.0037 456 35.7 18 26.5 438 36.3 0.1013 
                                            
Elixhauser comorbidities                                           
AIDS         7 0.2 0.5750         7 0.3 0.6051               
alcohol abuse 126 3.7 11 7.5 115 3.5 0.0122 63 3.0 6 7.7 57 2.8 0.0120 63 4.9 5 7.4 58 4.8 0.3447 
chronic blood loss anemia 29 0.9 5 3.4 24 0.7 0.0005 19 0.9 2 2.6 17 0.8 0.1101 10 0.8 3 4.4 7 0.6 0.0005 
coagulopathy 106 3.1 8 5.5 98 3.0 0.0927 56 2.6 2 2.6 54 2.6 0.9692 50 3.9 6 8.8 44 3.6 0.0322 
congestive heart failure 538 15.8 36 24.7 502 15.4 0.0027 347 16.3 21 26.9 326 15.9 0.0098 191 15.0 15 22.1 176 14.6 0.0921 
deficiency anemias 452 13.3 24 16.4 428 13.1 0.2508 274 12.9 15 19.2 259 12.6 0.0881 178 13.9 9 13.2 169 14.0 0.8612 
depression 540 15.9 33 22.6 507 15.6 0.0228 295 13.9 12 15.4 283 13.8 0.6932 245 19.2 21 30.9 224 18.5 0.0120 
diabetes (wo/chr complications) 764 22.5 47 32.2 717 22.0 0.0039 478 22.5 24 30.8 454 22.2 0.0737 286 22.4 23 33.8 263 21.8 0.0204 
diabetes (w/chr complications) 257 7.6 13 8.9 244 7.5 0.5274 185 8.7 8 10.3 177 8.6 0.6187 72 5.6 5 7.4 67 5.5 0.5299 
drug abuse 93 2.7 10 6.8 83 2.5 0.0018 65 3.1 7 9.0 58 2.8 0.0020 28 2.2 3 4.4 25 2.1 0.1996 
fluid and electrolyte disorders 408 12.0 30 20.5 378 11.6 0.0011 240 11.3 14 17.9 226 11.0 0.0580 168 13.2 16 23.5 152 12.6 0.0094 
hypertension 2092 61.5 102 69.9 1990 61.1 0.0333 1353 63.6 54 69.2 1299 63.4 0.2932 739 57.9 48 70.6 691 57.2 0.0296 
hypothyroidism 653 19.2 26 17.8 627 19.3 0.6650 409 19.2 15 19.2 394 19.2 0.9997 244 19.1 11 16.2 233 19.3 0.5255 
liver disease 136 4.0 11 7.5 125 3.8 0.0257 87 4.1 7 9.0 80 3.9 0.0265 49 3.8 4 5.9 45 3.7 0.3677 
lymphoma 29 0.9 1 0.7 28 0.9 0.8222 16 0.8 1 1.3 15 0.7 0.5811         13 1.1 0.3899 
metastatic cancer         31 1.0 0.2363         26 1.3 0.3168         5 0.4 0.5950 
obesity 437 12.8 24 16.4 413 12.7 0.1842 283 13.3 10 12.8 273 13.3 0.8978 154 12.1 14 20.6 140 11.6 0.0267 
other neurological disorders 308 9.1 16 11.0 292 9.0 0.4114 209 9.8 10 12.8 199 9.7 0.3654 99 7.8 6 8.8 93 7.7 0.7358 
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Number of Patients 3403   146   3257     2127   78   2049     1276   68   1208     
paralysis 52 1.5 6 4.1 46 1.4 0.0093 37 1.7 5 6.4 32 1.6 0.0013 15 1.2 1 1.5 14 1.2 0.8165 
peripheral vascular disease 543 16.0 32 21.9 511 15.7 0.0444 361 17.0 21 26.9 340 16.6 0.0171 182 14.3 11 16.2 171 14.2 0.6429 
psychoses 345 10.1 24 16.4 321 9.9 0.0099 234 11.0 16 20.5 218 10.6 0.0062 111 8.7 8 11.8 103 8.5 0.3566 
pulmonary circulation disease 387 11.4 22 15.1 365 11.2 0.1505 253 11.9 14 17.9 239 11.7 0.0924 134 10.5 8 11.8 126 10.4 0.7269 
renal failure 283 8.3 11 7.5 272 8.4 0.7265 192 9.0 6 7.7 186 9.1 0.6752 91 7.1 5 7.4 86 7.1 0.9419 
rheumatoid arthritis/collagen 
vas 
212 6.2 6 4.1 206 6.3 0.2786 119 5.6 3 3.8 116 5.7 0.4936 93 7.3 3 4.4 90 7.5 0.3483 
solid tumor wo/metastasis 329 9.7 14 9.6 315 9.7 0.9737 219 10.3 9 11.5 210 10.2 0.7130 110 8.6 5 7.4 105 8.7 0.7019 
ulcers 5 0.1 1 0.7 4 0.1 0.0828         2 0.1 0.7825 3 0.2 1 1.5 2 0.2 0.0306 
valvular disease 387 11.4 27 18.5 360 11.1 0.0056 290 13.6 16 20.5 274 13.4 0.0713 97 7.6 11 16.2 86 7.1 0.0061 
weight loss 188 5.5 10 6.8 178 5.5 0.4739 125 5.9 6 7.7 119 5.8 0.4873 63 4.9 4 5.9 59 4.9 0.7116 
any Elixhauser diagnosis 3103 91.2 138 94.5 2965 91.0 0.1461 1961 92.2 75 96.2 1886 92.0 0.1842 1142 89.5 63 92.6 1079 89.3 0.3841 
Other comorbidities                                           
asthma 1128 33.1 65 44.5 1063 32.6 0.0028 683 32.1 36 46.2 647 31.6 0.0068 445 34.9 29 42.6 416 34.4 0.1669 
hypoxemia 1278 37.6 76 52.1 1202 36.9 0.0002 748 35.2 42 53.8 706 34.5 0.0004 530 41.5 34 50.0 496 41.1 0.1455 
pneumonia 1152 33.9 82 56.2 1070 32.9 <0.0001 768 36.1 51 65.4 717 35.0 <0.0001 384 30.1 31 45.6 353 29.2 0.0042 
influenza 101 3.0 4 2.7 97 3.0 0.8681 64 3.0 1 1.3 63 3.1 0.3630 37 2.9 3 4.4 34 2.8 0.4450 
                                            
COPD Complexity ^                                           
Low complexity 1673 49.2 40 27.4 1633 50.1 <0.0001 1009 47.4 20 25.6 989 48.3 <0.0001 664 52.0 20 29.4 644 53.3 0.0001 
Med complexity 1575 46.3 101 69.2 1474 45.3 <0.0001 1017 47.8 56 71.8 961 46.9 <0.0001 558 43.7 45 66.2 513 42.5 0.0001 
High complexity 155 4.6 5 3.4 150 4.6 0.5032 101 4.7 2 2.6 99 4.8 0.3554 54 4.2 3 4.4 51 4.2 0.9397 
Emphysema diagnosis (492.x) 813 23.9 40 27.4 773 23.7 0.3098 443 20.8 17 21.8 426 20.8 0.8303 370 29.0 23 33.8 347 28.7 0.3673 
                                            
COPD Medications                                            
index ICSLABA 1731 50.9 85 58.2 1646 50.5 0.0693 1133 53.3 51 65.4 1082 52.8 0.0289 598 46.9 34 50.0 564 46.7 0.5944 
index LAMA 1284 37.7 41 28.1 1243 38.2 0.0139 749 35.2 19 24.4 730 35.6 0.0409 535 41.9 22 32.4 513 42.5 0.1001 
index triple 388 11.4 20 13.7 368 11.3 0.3721 245 11.5 8 10.3 237 11.6 0.7220 143 11.2 12 17.6 131 10.8 0.0836 
SABA use                                           
no SABA use 1484 43.6 40 27.4 1444 44.3 <0.0001 885 41.6 22 28.2 863 42.1 0.0144 599 46.9 18 26.5 581 48.1 0.0005 
SABA <=15% of year 836 24.6 46 31.5 790 24.3 0.0465 533 25.1 18 23.1 515 25.1 0.6807 303 23.7 28 41.2 275 22.8 0.0005 
SABA <=40% of year 461 13.5 21 14.4 440 13.5 0.7627 312 14.7 16 20.5 296 14.4 0.1372 149 11.7 5 7.4 144 11.9 0.2538 
SABA >40% of year 622 18.3 39 26.7 583 17.9 0.0070 397 18.7 22 28.2 375 18.3 0.0276 225 17.6 17 25.0 208 17.2 0.1014 
SAMA use                                           
any ipratropium (SAMA) 415 12.2 36 24.7 379 11.6 <0.0001 256 12.0 15 19.2 241 11.8 0.0466 159 12.5 21 30.9 138 11.4 <0.0001 
any SABA/SAMA 565 16.6 36 24.7 529 16.2 0.0075 377 17.7 22 28.2 355 17.3 0.0135 188 14.7 14 20.6 174 14.4 0.1615 
any SAMA or SABA/SAMA 893 26.2 62 42.5 831 25.5 <0.0001 574 27.0 31 39.7 543 26.5 0.0097 319 25.0 31 45.6 288 23.8 <0.0001 
Other COPD medications                                           
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any ICS 1118 32.9 61 41.8 1057 32.5 0.0189 710 33.4 31 39.7 679 33.1 0.2247 408 32.0 30 44.1 378 31.3 0.0273 
any LABA 170 5.0 8 5.5 162 5.0 0.7838 91 4.3 3 3.8 88 4.3 0.8476 79 6.2 5 7.4 74 6.1 0.6829 
any methylxanthines 61 1.8 3 2.1 58 1.8 0.8071 19 0.9 2 2.6 17 0.8 0.1101 42 3.3 1 1.5 41 3.4 0.3870 
Any use of above COPD 
medications 
1711 50.3 97 66.4 1614 49.6 <0.0001 1089 51.2 50 64.1 1039 50.7 0.0202 622 48.7 47 69.1 575 47.6 0.0006 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 3043 89.4 126 86.3 2917 89.6 0.2103 1897 89.2 63 80.8 1834 89.5 0.0147 1146 89.8 63 92.6 1083 89.7 0.4270 
1-2 Rxs ICSLABA (wks 27-52) 203 6.0 11 7.5 192 5.9 0.4133 133 6.3 9 11.5 124 6.1 0.0495 70 5.5 2 2.9 68 5.6 0.3436 
>2 Rxs ICSLABA (wks 27-52) 157 4.6 9 6.2 148 4.5 0.3612 97 4.6 6 7.7 91 4.4 0.1767 60 4.7 3 4.4 57 4.7 0.9074 
No LAMA in prior year 3282 96.4 142 97.3 3140 96.4 0.5863 2049 96.3 75 96.2 1974 96.3 0.9317 1233 96.6 67 98.5 1166 96.5 0.3724 
1-2 Rxs LAMA (wks 27-52) 66 1.9 4 2.7 62 1.9 0.4736 47 2.2 3 3.8 44 2.1 0.3165 19 1.5 1 1.5 18 1.5 0.9897 
>2 Rxs LAMA (wks 27-52)         55 1.7 0.1134         31 1.5 0.2738         24 2.0 0.2406 
Oxygen Use                                           
no oxygen 1875 55.1 64 43.8 1811 55.6 0.0052 1206 56.7 35 44.9 1171 57.1 0.0317 669 52.4 29 42.6 640 53.0 0.0969 
oxygen <=50% of year 560 16.5 30 20.5 530 16.3 0.1729 378 17.8 18 23.1 360 17.6 0.2117 182 14.3 12 17.6 170 14.1 0.4122 
oxygen >50% of year 968 28.4 52 35.6 916 28.1 0.0496 543 25.5 25 32.1 518 25.3 0.1783 425 33.3 27 39.7 398 32.9 0.2499 
                                            
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 2125 62.4 70 47.9 2055 63.1 0.0002 1206 56.7 36 46.2 1170 57.1 0.0555 919 72.0 34 50.0 885 73.3 <0.0001 
1 period breathlessness 664 19.5 43 29.5 621 19.1 0.0019 458 21.5 22 28.2 436 21.3 0.1441 206 16.1 21 30.9 185 15.3 0.0007 
>1 period breathlessness 614 18.0 33 22.6 581 17.8 0.1430 463 21.8 20 25.6 443 21.6 0.3983 151 11.8 13 19.1 138 11.4 0.0560 
Shortness of Breath                                           
no periods shortness breath 2149 63.2 64 43.8 2085 64.0 <0.0001 1327 62.4 32 41.0 1295 63.2 <0.0001 822 64.4 32 47.1 790 65.4 0.0021 
1 period shortness breath 688 20.2 40 27.4 648 19.9 0.0272 463 21.8 27 34.6 436 21.3 0.0051 225 17.6 13 19.1 212 17.5 0.7413 
>1 period shortness breath 566 16.6 42 28.8 524 16.1 <0.0001 337 15.8 19 24.4 318 15.5 0.0359 229 17.9 23 33.8 206 17.1 0.0005 
any wheezing 255 7.5 26 17.8 229 7.0 <0.0001 175 8.2 14 17.9 161 7.9 0.0015 80 6.3 12 17.6 68 5.6 <0.0001 
any dyspnea 1913 56.2 110 75.3 1803 55.4 <0.0001 1294 60.8 61 78.2 1233 60.2 0.0014 619 48.5 49 72.1 570 47.2 <0.0001 
supplemental oxygen use (V46.2) 208 6.1 22 15.1 186 5.7 <0.0001 72 3.4 8 10.3 64 3.1 0.0006 136 10.7 14 20.6 122 10.1 0.0064 
Other symptoms                                           
chest pain unspecified 957 28.1 60 41.1 897 27.5 0.0004 590 27.7 31 39.7 559 27.3 0.0158 367 28.8 29 42.6 338 28.0 0.0093 
painful respiratory 156 4.6 10 6.8 146 4.5 0.1810 85 4.0 8 10.3 77 3.8 0.0040 71 5.6 2 2.9 69 5.7 0.3321 
precordial pain 66 1.9 5 3.4 61 1.9 0.1835 43 2.0 5 6.4 38 1.9 0.0050         23 1.9 0.2509 
any chestpain 1003 29.5 63 43.2 940 28.9 0.0002 616 29.0 34 43.6 582 28.4 0.0037 387 30.3 29 42.6 358 29.6 0.0231 
chronic fatigue 50 1.5 3 2.1 47 1.4 0.5478 37 1.7 1 1.3 36 1.8 0.7529 13 1.0 2 2.9 11 0.9 0.1047 
other malaise/fatigue 827 24.3 52 35.6 775 23.8 0.0011 502 23.6 25 32.1 477 23.3 0.0734 325 25.5 27 39.7 298 24.7 0.0056 
difficulty walking 86 2.5 6 4.1 80 2.5 0.2130 66 3.1 4 5.1 62 3.0 0.2933 20 1.6 2 2.9 18 1.5 0.3486 
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memory loss 74 2.2 2 1.4 72 2.2 0.4956         50 2.4 0.1627 24 1.9 2 2.9 22 1.8 0.5083 
cough 1186 34.9 63 43.2 1123 34.5 0.0315 812 38.2 37 47.4 775 37.8 0.0863 374 29.3 26 38.2 348 28.8 0.0966 
hemoptysis 52 1.5 1 0.7 51 1.6 0.3959 34 1.6 1 1.3 33 1.6 0.8204         18 1.5 0.3107 
                                            
Procedures                                           
chest CT 508 14.9 28 19.2 480 14.7 0.1408 331 15.6 15 19.2 316 15.4 0.3624 177 13.9 13 19.1 164 13.6 0.1983 
chest x-ray 2149 63.2 102 69.9 2047 62.8 0.0857 1344 63.2 53 67.9 1291 63.0 0.3744 805 63.1 49 72.1 756 62.6 0.1151 
echocardiography 678 19.9 30 20.5 648 19.9 0.8469 480 22.6 16 20.5 464 22.6 0.6584 198 15.5 14 20.6 184 15.2 0.2352 
EKG 1494 43.9 85 58.2 1409 43.3 0.0004 942 44.3 47 60.3 895 43.7 0.0038 552 43.3 38 55.9 514 42.5 0.0308 
heart catheterization 42 1.2 2 1.4 40 1.2 0.8794 30 1.4 1 1.3 29 1.4 0.9220 12 0.9 1 1.5 11 0.9 0.6416 
nebulizer treatment 1118 32.9 65 44.5 1053 32.3 0.0022 817 38.4 38 48.7 779 38.0 0.0565 301 23.6 27 39.7 274 22.7 0.0013 
non-invasive ventilator 221 6.5 13 8.9 208 6.4 0.2271 129 6.1 7 9.0 122 6.0 0.2727 92 7.2 6 8.8 86 7.1 0.5970 
spirometry 1519 44.6 57 39.0 1462 44.9 0.1644 1012 47.6 31 39.7 981 47.9 0.1580 507 39.7 26 38.2 481 39.8 0.7953 
any vaccination (flu or 
pneumonia) 
1656 48.7 65 44.5 1591 48.8 0.3060 1067 50.2 38 48.7 1029 50.2 0.7946 589 46.2 27 39.7 562 46.5 0.2725 
                                            
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 444 13.0 29 19.9 415 12.7 0.0124 297 14.0 15 19.2 282 13.8 0.1715 147 11.5 14 20.6 133 11.0 0.0161 
any severe 247 7.3 26 17.8 221 6.8 <0.0001 144 6.8 14 17.9 130 6.3 <0.0001 103 8.1 12 17.6 91 7.5 0.0029 
any other hospitalizations* 61 1.8 6 4.1 55 1.7 0.0310 54 2.5 5 6.4 49 2.4 0.0268 7 0.5 1 1.5 6 0.5 0.2901 
Prior 2-12 weeks                                           
any moderate 574 16.9 41 28.1 533 16.4 0.0002 368 17.3 19 24.4 349 17.0 0.0932 206 16.1 22 32.4 184 15.2 0.0002 
any severe 227 6.7 21 14.4 206 6.3 0.0001 111 5.2 10 12.8 101 4.9 0.0021 116 9.1 11 16.2 105 8.7 0.0367 
any other hospitalizations* 127 3.7 10 6.8 117 3.6 0.0422 100 4.7 8 10.3 92 4.5 0.0182 27 2.1 2 2.9 25 2.1 0.6270 
Prior 13-52 weeks 2664 78.3 102 69.9 2562 78.7 0.0117 1635 76.9 56 71.8 1579 77.1 0.2789 1029 80.6 46 67.6 983 81.4 0.0053 
no moderate                                           
1 moderate 596 17.5 35 24.0 561 17.2 0.0358 392 18.4 20 25.6 372 18.2 0.0942 204 16.0 15 22.1 189 15.6 0.1603 
>1 moderate 143 4.2 9 6.2 134 4.1 0.2271 100 4.7 2 2.6 98 4.8 0.3636 43 3.4 7 10.3 36 3.0 0.0011 
any severe 264 7.8 23 15.8 241 7.4 0.0002 129 6.1 12 15.4 117 5.7 0.0004 135 10.6 11 16.2 124 10.3 0.1231 
any other hospitalizations* 233 6.8 18 12.3 215 6.6 0.0073 186 8.7 14 17.9 172 8.4 0.0034 47 3.7 4 5.9 43 3.6 0.3224 
                                            
All Inpatient Utilization                                           
Non-COPD Inpatient  (Any) 500 14.7 36 24.7 464 14.2 0.0005 390 18.3 30 38.5 360 17.6 <0.0001 110 8.6 6 8.8 104 8.6 0.9512 
COPD Inpatient  (Any) 667 19.6 59 40.4 608 18.7 <0.0001 357 16.8 28 35.9 329 16.1 <0.0001 310 24.3 31 45.6 279 23.1 <0.0001 
Total Inpatient  (Any) 1000 29.4 78 53.4 922 28.3 <0.0001 651 30.6 43 55.1 608 29.7 <0.0001 349 27.4 35 51.5 314 26.0 <0.0001 
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period) 
Same as Index Trmt 3097 91.0% 144 98.6% 2953 90.7% 0.0010 1919 90.2% 77 98.7% 1842 89.9% 0.0101 1178 92.3% 67 98.5% 1111 92.0% 0.0481 
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LHP & PHP LHP PHP 
 
Baseline Characteristic 
Total % Sev 
Exac  
1st 3 
mon 
% No Sev 
Exac 
% pval  Total %  Sev 
Exac  
1st 3 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac  
1st 3 
mon 
% No 
Sev 
Exac 
% pval  
Number of Patients 3403   146   3257     2127   78   2049     1276   68   1208     
No evidence Any Trmt                                           
Different Trmt from Index 306 9.0 2 1.4 304 9.3 0.0010 208 9.8 1 1.3 207 10.1 0.0101 98 7.7 1 1.5 97 8.0 0.0481 
Now using Triple 150 4.4 2 1.4 148 4.5 0.0676 101 4.7 1 1.3 100 4.9 0.1425 49 3.8 1 1.5 48 4.0 0.2960 
No longer using Triple         102 3.1 0.0299         65 3.2 0.1101         37 3.1 0.1430 
Switched between ICSLABA 
and LAMA 
        54 1.7 0.1168         42 2.0 0.2016         12 1.0 0.4089 
LHP enrollee 2127 62.5 78 53.4 2049 62.9 0.0205                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 39 Baseline Characteristics – Severe Exacerbation in 6 Months 
   LHP & PHP  LHP  PHP  
Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
1st 6 
mon 
% No Sev 
Exac 
% pval  Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  
Number of Patients 5475   352   5123     3599   187   3412     1876   165   1711     
Age Categories                                           
age 40-54 584 10.7 34 9.7 550 10.7 0.5267 332 9.2 15 8.0 317 9.3 0.5592 252 13.4 19 11.5 233 13.6 0.4494 
age 55-64 1026 18.7 74 21.0 952 18.6 0.2565 591 16.4 34 18.2 557 16.3 0.5045 435 23.2 40 24.2 395 23.1 0.7367 
age 65-74 1637 29.9 90 25.6 1547 30.2 0.0665 1059 29.4 48 25.7 1011 29.6 0.2470 578 30.8 42 25.5 536 31.3 0.1187 
age 75 and older 2228 40.7 154 43.8 2074 40.5 0.2276 1617 44.9 90 48.1 1527 44.8 0.3664 611 32.6 64 38.8 547 32.0 0.0743 
age (Mean, SD) 
70.55 11.51 71.05 11.83 70.51 11.4
8 
0.3970 71.58 11.31 72.04 11.3
4 
71.56 11.3
1 
0.5705 68.57 11.62 69.93 12.31 68.44 11.54 0.1143 
                                            
Men 2393 43.7 163 46.3 2230 43.5 0.3095 1616 44.9 97 51.9 1519 44.5 0.0491 777 41.4 66 40.0 711 41.6 0.6986 
                                            
Quarter of Year for Index Date             0.0002             0.0946             0.0211 
Q1 1645 30.0 111 31.5 1534 29.9   1111 30.9 65 34.8 1046 30.7   534 28.5 46 27.9 488 28.5   
Q2 1160 21.2 51 14.5 1109 21.6   800 22.2 30 16.0 770 22.6   360 19.2 21 12.7 339 19.8   
Q3 1192 21.8 66 18.8 1126 22.0   846 23.5 40 21.4 806 23.6   346 18.4 26 15.8 320 18.7   
Q4 1478 27.0 124 35.2 1354 26.4   842 23.4 52 27.8 790 23.2   636 33.9 72 43.6 564 33.0   
                                            
Months of enrollment post-Index             <0.0001             0.0015             0.0023 
7 78 1.4 10 2.8 68 1.3   44 1.2 8 4.3 36 1.1   34 1.8 2 1.2 32 1.9   
8 66 1.2 16 4.5 50 1.0   39 1.1 6 3.2 33 1.0   27 1.4 10 6.1 17 1.0   
9 85 1.6 8 2.3 77 1.5   50 1.4 3 1.6 47 1.4   35 1.9 5 3.0 30 1.8   
10 99 1.8 6 1.7 93 1.8   70 1.9 5 2.7 65 1.9   29 1.5 1 0.6 28 1.6   
11 117 2.1 10 2.8 107 2.1   95 2.6 7 3.7 88 2.6   22 1.2 3 1.8 19 1.1   
12 92 1.7 7 2.0 85 1.7   71 2.0 5 2.7 66 1.9   21 1.1 2 1.2 19 1.1   
13 99 1.8 9 2.6 90 1.8   67 1.9 7 3.7 60 1.8   32 1.7 2 1.2 30 1.8   
14 111 2.0 13 3.7 98 1.9   75 2.1 8 4.3 67 2.0   36 1.9 5 3.0 31 1.8   
15 97 1.8 7 2.0 90 1.8   62 1.7 2 1.1 60 1.8   35 1.9 5 3.0 30 1.8   
16 127 2.3 10 2.8 117 2.3   82 2.3 6 3.2 76 2.2   45 2.4 4 2.4 41 2.4   
17 114 2.1 6 1.7 108 2.1   77 2.1 2 1.1 75 2.2   37 2.0 4 2.4 33 1.9   
18 106 1.9 6 1.7 100 2.0   72 2.0 3 1.6 69 2.0   34 1.8 3 1.8 31 1.8   
19 104 1.9 5 1.4 99 1.9   69 1.9 3 1.6 66 1.9   35 1.9 2 1.2 33 1.9   
20 105 1.9 8 2.3 97 1.9   67 1.9 3 1.6 64 1.9   38 2.0 5 3.0 33 1.9   
21 105 1.9 9 2.6 96 1.9   63 1.8 3 1.6 60 1.8   42 2.2 6 3.6 36 2.1   
22 114 2.1 6 1.7 108 2.1   79 2.2 4 2.1 75 2.2   35 1.9 2 1.2 33 1.9   
23 91 1.7 6 1.7 85 1.7   64 1.8 4 2.1 60 1.8   27 1.4 2 1.2 25 1.5   
24 3765 68.8 210 59.7 3555 69.4   2453 68.2 108 57.8 2345 68.7   1312 69.9 102 61.8 1210 70.7   
Insurance at Index                                           
   
 
1
8
8 
   LHP & PHP  LHP  PHP  
Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
1st 6 
mon 
% No Sev 
Exac 
% pval  Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  
Number of Patients 5475   352   5123     3599   187   3412     1876   165   1711     
Commercial 1778 32.5 89 25.3 1689 33.0 0.0029 1376 38.2 66 35.3 1310 38.4 0.3957 402 21.4 23 13.9 379 22.2 0.0141 
Medicaid 655 12.0 64 18.2 591 11.5 0.0002 284 7.9 20 10.7 264 7.7 0.1441 371 19.8 44 26.7 327 19.1 0.0200 
Medicare 3071 56.1 201 57.1 2870 56.0 0.6928 1968 54.7 103 55.1 1865 54.7 0.9105 1103 58.8 98 59.4 1005 58.7 0.8701 
                                            
CMS comorbidities (Baseline Per.)                                           
acute myocardial infarction 
(AMI) 
175 3.2 14 4.0 161 3.1 0.3892 114 3.2 7 3.7 107 3.1 0.6443 61 3.3 7 4.2 54 3.2 0.4524 
Alzheimer’s 189 3.5 14 4.0 175 3.4 0.5768 111 3.1 6 3.2 105 3.1 0.9195 78 4.2 8 4.8 70 4.1 0.6417 
atrial fibrillation 534 9.8 46 13.1 488 9.5 0.0302 362 10.1 25 13.4 337 9.9 0.1221 172 9.2 21 12.7 151 8.8 0.0972 
cancers 370 6.8 24 6.8 346 6.8 0.9629 265 7.4 16 8.6 249 7.3 0.5212 105 5.6 8 4.8 97 5.7 0.6614 
lung cancer 113 2.1 12 3.4 101 2.0 0.0665 75 2.1 8 4.3 67 2.0 0.0310 38 2.0 4 2.4 34 2.0 0.7035 
chronic kidney disease 870 15.9 67 19.0 803 15.7 0.0954 626 17.4 40 21.4 586 17.2 0.1387 244 13.0 27 16.4 217 12.7 0.1795 
diabetes 1358 24.8 101 28.7 1257 24.5 0.0807 884 24.6 55 29.4 829 24.3 0.1136 474 25.3 46 27.9 428 25.0 0.4188 
heart failure 986 18.0 98 27.8 888 17.3 <0.0001 645 17.9 53 28.3 592 17.4 0.0001 341 18.2 45 27.3 296 17.3 0.0015 
ischemic heart dis. (IHD; incl. 
AMI) 
1343 24.5 116 33.0 1227 24.0 0.0001 908 25.2 61 32.6 847 24.8 0.0168 435 23.2 55 33.3 380 22.2 0.0012 
rheumatoid/osteo arthritis 
(RA/OA) 
1443 26.4 102 29.0 1341 26.2 0.2485 954 26.5 53 28.3 901 26.4 0.5593 489 26.1 49 29.7 440 25.7 0.2659 
stroke/TIA 387 7.1 29 8.2 358 7.0 0.3759 256 7.1 17 9.1 239 7.0 0.2798 131 7.0 12 7.3 119 7.0 0.8784 
no CMS Comorbidity 1860 34.0 93 26.4 1767 34.5 0.0020 1194 33.2 45 24.1 1149 33.7 0.0066 666 35.5 48 29.1 618 36.1 0.0716 
                                            
Elixhauser comorbidities (Baseline 
Per.) 
                                          
AIDS 10 0.2 1 0.3 9 0.2 0.6449 9 0.3 1 0.5 8 0.2 0.4234         1 0.1 0.7561 
alcohol abuse 191 3.5 23 6.5 168 3.3 0.0013 108 3.0 10 5.3 98 2.9 0.0534 83 4.4 13 7.9 70 4.1 0.0238 
chronic blood loss anemia 49 0.9 9 2.6 40 0.8 0.0006 28 0.8 3 1.6 25 0.7 0.1866 21 1.1 6 3.6 15 0.9 0.0013 
coagulopathy 163 3.0 24 6.8 139 2.7 <0.0001 96 2.7 11 5.9 85 2.5 0.0051 67 3.6 13 7.9 54 3.2 0.0018 
congestive heart failure 903 16.5 85 24.1 818 16.0 <0.0001 616 17.1 50 26.7 566 16.6 0.0003 287 15.3 35 21.2 252 14.7 0.0271 
deficiency anemias 773 14.1 76 21.6 697 13.6 <0.0001 498 13.8 44 23.5 454 13.3 <0.0001 275 14.7 32 19.4 243 14.2 0.0718 
depression 917 16.7 74 21.0 843 16.5 0.0264 537 14.9 26 13.9 511 15.0 0.6885 380 20.3 48 29.1 332 19.4 0.0031 
diabetes (wo/chr complications) 1304 23.8 106 30.1 1198 23.4 0.0041 867 24.1 63 33.7 804 23.6 0.0016 437 23.3 43 26.1 394 23.0 0.3787 
diabetes (w/chr complications) 442 8.1 37 10.5 405 7.9 0.0826 332 9.2 23 12.3 309 9.1 0.1356 110 5.9 14 8.5 96 5.6 0.1334 
drug abuse 181 3.3 19 5.4 162 3.2 0.0233 115 3.2 12 6.4 103 3.0 0.0101 66 3.5 7 4.2 59 3.4 0.5970 
fluid and electrolyte disorders 686 12.5 67 19.0 619 12.1 0.0001 422 11.7 29 15.5 393 11.5 0.0987 264 14.1 38 23.0 226 13.2 0.0005 
hypertension 3374 61.6 232 65.9 3142 61.3 0.0876 2301 63.9 127 67.9 2174 63.7 0.2444 1073 57.2 105 63.6 968 56.6 0.0800 
hypothyroidism 1032 18.8 70 19.9 962 18.8 0.6071 684 19.0 37 19.8 647 19.0 0.7799 348 18.6 33 20.0 315 18.4 0.6159 
liver disease 212 3.9 20 5.7 192 3.7 0.0689 144 4.0 12 6.4 132 3.9 0.0834 68 3.6 8 4.8 60 3.5 0.3785 
lymphoma 46 0.8 4 1.1 42 0.8 0.5291 31 0.9 1 0.5 30 0.9 0.6196 15 0.8 3 1.8 12 0.7 0.1240 
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   LHP & PHP  LHP  PHP  
Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
1st 6 
mon 
% No Sev 
Exac 
% pval  Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  
Number of Patients 5475   352   5123     3599   187   3412     1876   165   1711     
metastatic cancer 56 1.0 4 1.1 52 1.0 0.8268 41 1.1 4 2.1 37 1.1 0.1858         15 0.9 0.2272 
obesity 717 13.1 48 13.6 669 13.1 0.7560 480 13.3 21 11.2 459 13.5 0.3841 237 12.6 27 16.4 210 12.3 0.1310 
other neurological disorders 514 9.4 45 12.8 469 9.2 0.0239 363 10.1 27 14.4 336 9.8 0.0424 151 8.0 18 10.9 133 7.8 0.1574 
paralysis 68 1.2 8 2.3 60 1.2 0.0711 48 1.3 7 3.7 41 1.2 0.0032 20 1.1 1 0.6 19 1.1 0.5468 
peripheral vascular disease 878 16.0 74 21.0 804 15.7 0.0084 614 17.1 42 22.5 572 16.8 0.0438 264 14.1 32 19.4 232 13.6 0.0396 
psychoses 573 10.5 47 13.4 526 10.3 0.0674 399 11.1 31 16.6 368 10.8 0.0140 174 9.3 16 9.7 158 9.2 0.8449 
pulmonary circulation disease 625 11.4 54 15.3 571 11.1 0.0167 435 12.1 27 14.4 408 12.0 0.3109 190 10.1 27 16.4 163 9.5 0.0054 
renal failure 468 8.5 30 8.5 438 8.5 0.9860 338 9.4 18 9.6 320 9.4 0.9102 130 6.9 12 7.3 118 6.9 0.8558 
rheumatoid arthritis/collagen vas 343 6.3 22 6.3 321 6.3 0.9905 209 5.8 12 6.4 197 5.8 0.7142 134 7.1 10 6.1 124 7.2 0.5719 
solid tumor wo/metastasis 533 9.7 36 10.2 497 9.7 0.7475 368 10.2 25 13.4 343 10.1 0.1450 165 8.8 11 6.7 154 9.0 0.3121 
ulcers 7 0.1 3 0.9 4 0.1 <0.0001 3 0.1 1 0.5 2 0.1 0.0280 4 0.2 2 1.2 2 0.1 0.0036 
valvular disease 630 11.5 55 15.6 575 11.2 0.0123 478 13.3 35 18.7 443 13.0 0.0245 152 8.1 20 12.1 132 7.7 0.0476 
weight loss 327 6.0 29 8.2 298 5.8 0.0636 219 6.1 16 8.6 203 5.9 0.1466 108 5.8 13 7.9 95 5.6 0.2205 
any Elixhauser diagnosis 5028 91.8 331 94.0 4697 91.7 0.1194 3333 92.6 179 95.7 3154 92.4 0.0947 1695 90.4 152 92.1 1543 90.2 0.4202 
Other comorbidities                                           
asthma 1813 33.1 130 36.9 1683 32.9 0.1156 1166 32.4 68 36.4 1098 32.2 0.2340 647 34.5 62 37.6 585 34.2 0.3823 
hypoxemia 1994 36.4 177 50.3 1817 35.5 <0.0001 1229 34.1 88 47.1 1141 33.4 0.0001 765 40.8 89 53.9 676 39.5 0.0003 
pneumonia 1908 34.8 187 53.1 1721 33.6 <0.0001 1348 37.5 114 61.0 1234 36.2 <0.0001 560 29.9 73 44.2 487 28.5 <0.0001 
influenza 178 3.3 14 4.0 164 3.2 0.4271 124 3.4 7 3.7 117 3.4 0.8186 54 2.9 7 4.2 47 2.7 0.2725 
                                            
COPD Complexity ^                                           
Low complexity 2740 50.0 105 29.8 2635 51.4 <0.0001 1761 48.9 52 27.8 1709 50.1 <0.0001 979 52.2 53 32.1 926 54.1 <0.0001 
Med complexity 2510 45.8 233 66.2 2277 44.4 <0.0001 1686 46.8 125 66.8 1561 45.8 <0.0001 824 43.9 108 65.5 716 41.8 <0.0001 
High complexity 225 4.1 14 4.0 211 4.1 0.8971 152 4.2 10 5.3 142 4.2 0.4324 73 3.9 4 2.4 69 4.0 0.3076 
Emphysema diagnosis (492.x) 1210 22.1 106 30.1 1104 21.5 0.0002 694 19.3 47 25.1 647 19.0 0.0373 516 27.5 59 35.8 457 26.7 0.0129 
                                            
COPD Medications                                            
index ICSLABA 3052 55.7 205 58.2 2847 55.6 0.3300 2129 59.2 117 62.6 2012 59.0 0.3297 923 49.2 88 53.3 835 48.8 0.2662 
index LAMA 1939 35.4 104 29.5 1835 35.8 0.0173 1158 32.2 52 27.8 1106 32.4 0.1891 781 41.6 52 31.5 729 42.6 0.0058 
index triple 484 8.8 43 12.2 441 8.6 0.0211 312 8.7 18 9.6 294 8.6 0.6330 172 9.2 25 15.2 147 8.6 0.0053 
SABA use                                           
no SABA use 2314 42.3 120 34.1 2194 42.8 0.0013 1479 41.1 57 30.5 1422 41.7 0.0024 835 44.5 63 38.2 772 45.1 0.0868 
SABA <=15% of year 1435 26.2 85 24.1 1350 26.4 0.3631 973 27.0 44 23.5 929 27.2 0.2676 462 24.6 41 24.8 421 24.6 0.9448 
SABA <=40% of year 803 14.7 48 13.6 755 14.7 0.5722 555 15.4 32 17.1 523 15.3 0.5107 248 13.2 16 9.7 232 13.6 0.1618 
SABA >40% of year 923 16.9 99 28.1 824 16.1 <0.0001 592 16.4 54 28.9 538 15.8 <0.0001 331 17.6 45 27.3 286 16.7 0.0007 
SAMA use                                           
any ipratropium (SAMA) 632 11.5 76 21.6 556 10.9 <0.0001 391 10.9 36 19.3 355 10.4 0.0002 241 12.8 40 24.2 201 11.7 <0.0001 
any SABA/SAMA 876 16.0 85 24.1 791 15.4 <0.0001 591 16.4 49 26.2 542 15.9 0.0002 285 15.2 36 21.8 249 14.6 0.0130 
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Number of Patients 5475   352   5123     3599   187   3412     1876   165   1711     
any SAMA or SABA/SAMA 1381 25.2 142 40.3 1239 24.2 <0.0001 901 25.0 73 39.0 828 24.3 <0.0001 480 25.6 69 41.8 411 24.0 <0.0001 
Other COPD medications                                           
any ICS 1752 32.0 120 34.1 1632 31.9 0.3846 1143 31.8 58 31.0 1085 31.8 0.8227 609 32.5 62 37.6 547 32.0 0.1419 
any LABA 227 4.1 14 4.0 213 4.2 0.8695 118 3.3 4 2.1 114 3.3 0.3688 109 5.8 10 6.1 99 5.8 0.8855 
any methylxanthines 87 1.6 8 2.3 79 1.5 0.2890 29 0.8 3 1.6 26 0.8 0.2097 58 3.1 5 3.0 53 3.1 0.9620 
Any use of above COPD 
medications 
2688 49.1 211 59.9 2477 48.4 <0.0001 1748 48.6 107 57.2 1641 48.1 0.0151 940 50.1 104 63.0 836 48.9 0.0005 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 4868 88.9 307 87.2 4561 89.0 0.2944 3206 89.1 157 84.0 3049 89.4 0.0211 1662 88.6 150 90.9 1512 88.4 0.3271 
1-2 Rxs ICSLABA (wks 27-52) 387 7.1 24 6.8 363 7.1 0.8498 255 7.1 15 8.0 240 7.0 0.6084 132 7.0 9 5.5 123 7.2 0.4055 
>2 Rxs ICSLABA (wks 27-52) 220 4.0 21 6.0 199 3.9 0.0544 138 3.8 15 8.0 123 3.6 0.0022 82 4.4 6 3.6 76 4.4 0.6289 
No LAMA in prior year 5280 96.4 339 96.3 4941 96.4 0.8905 3472 96.5 180 96.3 3292 96.5 0.8703 1808 96.4 159 96.4 1649 96.4 0.9933 
1-2 Rxs LAMA (wks 27-52) 124 2.3 11 3.1 113 2.2 0.2621 86 2.4 6 3.2 80 2.3 0.4514 38 2.0 5 3.0 33 1.9 0.3374 
>2 Rxs LAMA (wks 27-52) 71 1.3 2 0.6 69 1.3 0.2116 41 1.1 1 0.5 40 1.2 0.4238 30 1.6 1 0.6 29 1.7 0.2870 
Oxygen Use                                           
no oxygen 3090 56.4 149 42.3 2941 57.4 <0.0001 2097 58.3 80 42.8 2017 59.1 <0.0001 993 52.9 69 41.8 924 54.0 0.0027 
oxygen <=50% of year 876 16.0 58 16.5 818 16.0 0.8007 619 17.2 37 19.8 582 17.1 0.3357 257 13.7 21 12.7 236 13.8 0.7038 
oxygen >50% of year 1509 27.6 145 41.2 1364 26.6 <0.0001 883 24.5 70 37.4 813 23.8 <0.0001 626 33.4 75 45.5 551 32.2 0.0006 
                                            
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 3454 63.1 186 52.8 3268 63.8 <0.0001 2101 58.4 91 48.7 2010 58.9 0.0056 1353 72.1 95 57.6 1258 73.5 <0.0001 
1 period breathlessness 1051 19.2 84 23.9 967 18.9 0.0215 757 21.0 43 23.0 714 20.9 0.4992 294 15.7 41 24.8 253 14.8 0.0007 
>1 period breathlessness 970 17.7 82 23.3 888 17.3 0.0046 741 20.6 53 28.3 688 20.2 0.0071 229 12.2 29 17.6 200 11.7 0.0274 
Shortness of Breath                                           
no periods shortness breath 3450 63.0 170 48.3 3280 64.0 <0.0001 2260 62.8 87 46.5 2173 63.7 <0.0001 1190 63.4 83 50.3 1107 64.7 0.0002 
1 period shortness breath 1128 20.6 88 25.0 1040 20.3 0.0350 785 21.8 53 28.3 732 21.5 0.0264 343 18.3 35 21.2 308 18.0 0.3082 
>1 period shortness breath 897 16.4 94 26.7 803 15.7 <0.0001 554 15.4 47 25.1 507 14.9 0.0002 343 18.3 47 28.5 296 17.3 0.0004 
any wheezing 419 7.7 42 11.9 377 7.4 0.0018 302 8.4 24 12.8 278 8.1 0.0244 117 6.2 18 10.9 99 5.8 0.0094 
any dyspnea 3057 55.8 250 71.0 2807 54.8 <0.0001 2126 59.1 140 74.9 1986 58.2 <0.0001 931 49.6 110 66.7 821 48.0 <0.0001 
supplemental oxygen use (V46.2) 317 5.8 50 14.2 267 5.2 <0.0001 112 3.1 14 7.5 98 2.9 0.0004 205 10.9 36 21.8 169 9.9 <0.0001 
Other symptoms                                           
chest pain unspecified 1662 30.4 142 40.3 1520 29.7 <0.0001 1082 30.1 74 39.6 1008 29.5 0.0036 580 30.9 68 41.2 512 29.9 0.0027 
painful respiratory 272 5.0 30 8.5 242 4.7 0.0015 165 4.6 21 11.2 144 4.2 <0.0001 107 5.7 9 5.5 98 5.7 0.8851 
precordial pain 107 2.0 13 3.7 94 1.8 0.0148 72 2.0 10 5.3 62 1.8 0.0008 35 1.9 3 1.8 32 1.9 0.9623 
any chestpain 1742 31.8 149 42.3 1593 31.1 <0.0001 1137 31.6 81 43.3 1056 30.9 0.0004 605 32.2 68 41.2 537 31.4 0.0099 
chronic fatigue 85 1.6 4 1.1 81 1.6 0.5138 67 1.9 2 1.1 65 1.9 0.4105 18 1.0 2 1.2 16 0.9 0.7274 
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Baseline Characteristic Total % Sev 
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1st 6 
mon 
% No 
Sev 
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% pval  Total % Sev 
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% No Sev 
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1st 6 
mon 
% No 
Sev 
Exac 
% pval  
Number of Patients 5475   352   5123     3599   187   3412     1876   165   1711     
other malaise/fatigue 1379 25.2 118 33.5 1261 24.6 0.0002 884 24.6 60 32.1 824 24.2 0.0141 495 26.4 58 35.2 437 25.5 0.0075 
difficulty walking 139 2.5 10 2.8 129 2.5 0.7095 105 2.9 5 2.7 100 2.9 0.8389 34 1.8 5 3.0 29 1.7 0.2194 
memory loss 132 2.4 3 0.9 129 2.5 0.0487 94 2.6 1 0.5 93 2.7 0.0674 38 2.0 2 1.2 36 2.1 0.4373 
cough 1963 35.9 149 42.3 1814 35.4 0.0088 1394 38.7 88 47.1 1306 38.3 0.0164 569 30.3 61 37.0 508 29.7 0.0521 
hemoptysis 76 1.4 3 0.9 73 1.4 0.3744 52 1.4 2 1.1 50 1.5 0.6587 24 1.3 1 0.6 23 1.3 0.4204 
                                            
Procedures                                           
chest CT 822 15.0 71 20.2 751 14.7 0.0051 551 15.3 38 20.3 513 15.0 0.0506 271 14.4 33 20.0 238 13.9 0.0336 
chest x-ray 3432 62.7 245 69.6 3187 62.2 0.0055 2234 62.1 131 70.1 2103 61.6 0.0209 1198 63.9 114 69.1 1084 63.4 0.1430 
echocardiography 1113 20.3 71 20.2 1042 20.3 0.9392 819 22.8 38 20.3 781 22.9 0.4146 294 15.7 33 20.0 261 15.3 0.1093 
EKG 2452 44.8 189 53.7 2263 44.2 0.0005 1621 45.0 108 57.8 1513 44.3 0.0003 831 44.3 81 49.1 750 43.8 0.1942 
heart catheterization 71 1.3 5 1.4 66 1.3 0.8321 51 1.4 4 2.1 47 1.4 0.3909 20 1.1 1 0.6 19 1.1 0.5468 
nebulizer treatment 1771 32.3 132 37.5 1639 32.0 0.0326 1326 36.8 77 41.2 1249 36.6 0.2071 445 23.7 55 33.3 390 22.8 0.0024 
non-invasive ventilator 339 6.2 24 6.8 315 6.1 0.6142 210 5.8 13 7.0 197 5.8 0.5034 129 6.9 11 6.7 118 6.9 0.9113 
spirometry 2284 41.7 133 37.8 2151 42.0 0.1219 1578 43.8 71 38.0 1507 44.2 0.0962 706 37.6 62 37.6 644 37.6 0.9873 
any vaccination (flu or 
pneumonia) 
2632 48.1 155 44.0 2477 48.4 0.1169 1799 50.0 91 48.7 1708 50.1 0.7102 833 44.4 64 38.8 769 44.9 0.1285 
                                            
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 783 14.3 70 19.9 713 13.9 0.0020 525 14.6 38 20.3 487 14.3 0.0225 258 13.8 32 19.4 226 13.2 0.0276 
any severe 434 7.9 63 17.9 371 7.2 <0.0001 266 7.4 35 18.7 231 6.8 <0.0001 168 9.0 28 17.0 140 8.2 0.0002 
any other hospitalizations* 124 2.3 10 2.8 114 2.2 0.4527 112 3.1 9 4.8 103 3.0 0.1689 12 0.6 1 0.6 11 0.6 0.9548 
Prior 2-12 weeks                                           
any moderate 894 16.3 83 23.6 811 15.8 0.0001 585 16.3 40 21.4 545 16.0 0.0506 309 16.5 43 26.1 266 15.5 0.0005 
any severe 337 6.2 55 15.6 282 5.5 <0.0001 179 5.0 22 11.8 157 4.6 <0.0001 158 8.4 33 20.0 125 7.3 <0.0001 
any other hospitalizations* 209 3.8 25 7.1 184 3.6 0.0009 169 4.7 17 9.1 152 4.5 0.0035 40 2.1 8 4.8 32 1.9 0.0114 
Prior 13-52 weeks                                           
no moderate 4200 76.7 245 69.6 3955 77.2 0.0011 2733 75.9 130 69.5 2603 76.3 0.0349 1467 78.2 115 69.7 1352 79.0 0.0056 
1 moderate 1018 18.6 75 21.3 943 18.4 0.1762 694 19.3 40 21.4 654 19.2 0.4532 324 17.3 35 21.2 289 16.9 0.1608 
>1 moderate 257 4.7 32 9.1 225 4.4 <0.0001 172 4.8 17 9.1 155 4.5 0.0045 85 4.5 15 9.1 70 4.1 0.0032 
any severe 409 7.5 61 17.3 348 6.8 <0.0001 215 6.0 31 16.6 184 5.4 <0.0001 194 10.3 30 18.2 164 9.6 0.0005 
any other hospitalizations* 384 7.0 38 10.8 346 6.8 0.0041 313 8.7 29 15.5 284 8.3 0.0007 71 3.8 9 5.5 62 3.6 0.2392 
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 852 15.6 76 21.6 776 15.1 0.0013 687 19.1 58 31.0 629 18.4 <0.0001 165 8.8 18 10.9 147 8.6 0.3155 
COPD Inpatient (Any) 1117 20.4 145 41.2 972 19.0 <0.0001 636 17.7 67 35.8 569 16.7 <0.0001 481 25.6 78 47.3 403 23.6 <0.0001 
Total Inpatient (Any) 1690 30.9 189 53.7 1501 29.3 <0.0001 1153 32.0 105 56.1 1048 30.7 <0.0001 537 28.6 84 50.9 453 26.5 <0.0001 
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period) 
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Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
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% pval  Total % Sev 
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% No Sev 
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Sev 
Exac 
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Number of Patients 5475   352   5123     3599   187   3412     1876   165   1711     
Same as Index Trmt 2238 40.9 243 69.0 1995 38.9 <0.0001 1334 37.1 121 64.7 1213 35.6 <0.0001 904 48.2 122 73.9 782 45.7 <0.0001 
No evidence Any Trmt 2931 53.5 93 26.4 2838 55.4 <0.0001 2055 57.1 55 29.4 2000 58.6 <0.0001 876 46.7 38 23.0 838 49.0 <0.0001 
Different Trmt from Index 306 5.6 16 4.5 290 5.7 0.3782 210 5.8 11 5.9 199 5.8 0.9773 96 5.1 5 3.0 91 5.3 0.2027 
Now using Triple 169 3.1 10 2.8 159 3.1 0.7828 107 3.0 6 3.2 101 3.0 0.8456 62 3.3 4 2.4 58 3.4 0.5076 
No longer using Triple 86 1.6 4 1.1 82 1.6 0.4980 63 1.8 3 1.6 60 1.8 0.8756 23 1.2 1 0.6 22 1.3 0.4486 
Switched between ICSLABA 
and LAMA 
51 0.9 2 0.6 49 1.0 0.4632 40 1.1 2 1.1 38 1.1 0.9552 11 0.6 0 0.0 11 0.6 0.3016 
LHP enrollee 3599 65.7 187 53.1 3412 66.6 <0.0001                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 40 Severe Exacerbation Within 6 Months, Without Discontinuation 
 
              LHP             PHP             
Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
in 1st 3 
months 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac in 
1st 3 
months 
% No Sev 
Exac 
% pval  
Number of Patients 2544   259   2285     1544   132   1412     1000   127   873     
Age Categories                                           
age 40-54 226 8.9 26 10.0 200 8.8 0.4906 102 6.6 11 8.3 91 6.4 0.4035 124 12.4 15 11.8 109 12.5 0.8293 
age 55-64 479 18.8 50 19.3 429 18.8 0.8361 246 15.9 19 14.4 227 16.1 0.6135 233 23.3 31 24.4 202 23.1 0.7516 
age 65-74 812 31.9 64 24.7 748 32.7 0.0086 488 31.6 32 24.2 456 32.3 0.0571 324 32.4 32 25.2 292 33.4 0.0634 
age 75 and older 1027 40.4 119 45.9 908 39.7 0.0536 708 45.9 70 53.0 638 45.2 0.0836 319 31.9 49 38.6 270 30.9 0.0838 
age (Mean, SD) 70.80 10.95 71.46 11.98 70.72 10.83 0.3448 72.16 10.54 73.01 11.44 72.08 10.46 0.3350 68.69 11.24 69.85 12.36 68.52 11.06 0.2142 
                                            
Men 1141 44.9 118 45.6 1023 44.8 0.8087 709 45.9 65 49.2 644 45.6 0.4231 432 43.2 53 41.7 379 43.4 0.7208 
                                            
Quarter of Year for Index Date             0.0063             0.4474             0.0529 
Q1 767 30.1 77 29.7 690 30.2   458 29.7 40 30.3 418 29.6   309 30.9 37 29.1 272 31.2   
Q2 485 19.1 34 13.1 451 19.7   328 21.2 22 16.7 306 21.7   157 15.7 12 9.4 145 16.6   
Q3 538 21.1 50 19.3 488 21.4   372 24.1 31 23.5 341 24.2   166 16.6 19 15.0 147 16.8   
Q4 754 29.6 98 37.8 656 28.7   386 25.0 39 29.5 347 24.6   368 36.8 59 46.5 309 35.4   
                                            
Months of enrollment post-Index             0.0045             0.0728             0.0489 
7 29 1.1 6 2.3 23 1.0   15 1.0 4 3.0 11 0.8   14 1.4 2 1.6 12 1.4   
8 27 1.1 10 3.9 17 0.7   14 0.9 4 3.0 10 0.7   13 1.3 6 4.7 7 0.8   
9 46 1.8 7 2.7 39 1.7   24 1.6 3 2.3 21 1.5   22 2.2 4 3.1 18 2.1   
10 45 1.8 3 1.2 42 1.8   31 2.0 3 2.3 28 2.0           14 1.6   
11 54 2.1 6 2.3 48 2.1   39 2.5 4 3.0 35 2.5   15 1.5 2 1.6 13 1.5   
12 36 1.4 3 1.2 33 1.4   27 1.7 1 0.8 26 1.8   9 0.9 2 1.6 7 0.8   
13 49 1.9 6 2.3 43 1.9   32 2.1 5 3.8 27 1.9   17 1.7 1 0.8 16 1.8   
14 54 2.1 9 3.5 45 2.0   37 2.4 5 3.8 32 2.3   17 1.7 4 3.1 13 1.5   
15 41 1.6 5 1.9 36 1.6   28 1.8 1 0.8 27 1.9   13 1.3 4 3.1 9 1.0   
16 53 2.1 7 2.7 46 2.0   27 1.7 5 3.8 22 1.6   26 2.6 2 1.6 24 2.7   
17 57 2.2 5 1.9 52 2.3   34 2.2 2 1.5 32 2.3   23 2.3 3 2.4 20 2.3   
18 49 1.9 6 2.3 43 1.9   28 1.8 3 2.3 25 1.8   21 2.1 3 2.4 18 2.1   
19 43 1.7 4 1.5 39 1.7   22 1.4 2 1.5 20 1.4   21 2.1 2 1.6 19 2.2   
20 42 1.7 6 2.3 36 1.6   30 1.9 3 2.3 27 1.9   12 1.2 3 2.4 9 1.0   
21 44 1.7 7 2.7 37 1.6   25 1.6 3 2.3 22 1.6   19 1.9 4 3.1 15 1.7   
22 59 2.3 6 2.3 53 2.3   39 2.5 4 3.0 35 2.5   20 2.0 2 1.6 18 2.1   
23 42 1.7 3 1.2 39 1.7   26 1.7 1 0.8 25 1.8   16 1.6 2 1.6 14 1.6   
24 1774 69.7 160 61.8 1614 70.6   1066 69.0 79 59.8 987 69.9   708 70.8 81 63.8 627 71.8   
Insurance at Index                                           
Commercial 834 32.8 60 23.2 774 33.9 0.0005 606 39.2 44 33.3 562 39.8 0.1456 228 22.8 16 12.6 212 24.3 0.0034 
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              LHP             PHP             
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Number of Patients 2544   259   2285     1544   132   1412     1000   127   873     
Medicaid 271 10.7 47 18.1 224 9.8 <0.0001 105 6.8 12 9.1 93 6.6 0.2744 166 16.6 35 27.6 131 15.0 0.0004 
Medicare 1452 57.1 154 59.5 1298 56.8 0.4134 846 54.8 78 59.1 768 54.4 0.2995 606 60.6 76 59.8 530 60.7 0.8517 
                                            
CMS comorbidities                                           
acute myocardial infarction 
(AMI) 
87 3.4 12 4.6 75 3.3 0.2569 55 3.6 6 4.5 49 3.5 0.5239 32 3.2 6 4.7 26 3.0 0.2962 
Alzheimer’s 84 3.3 11 4.2 73 3.2 0.3690 45 2.9 4 3.0 41 2.9 0.9341 39 3.9 7 5.5 32 3.7 0.3153 
atrial fibrillation 246 9.7 37 14.3 209 9.1 0.0080 160 10.4 20 15.2 140 9.9 0.0591 86 8.6 17 13.4 69 7.9 0.0395 
cancers 174 6.8 19 7.3 155 6.8 0.7385 114 7.4 11 8.3 103 7.3 0.6625 60 6.0 8 6.3 52 6.0 0.8792 
lung cancer 53 2.1 6 2.3 47 2.1 0.7815 35 2.3 3 2.3 32 2.3 0.9962 18 1.8 3 2.4 15 1.7 0.6100 
chronic kidney disease 409 16.1 47 18.1 362 15.8 0.3387 269 17.4 30 22.7 239 16.9 0.0929 140 14.0 17 13.4 123 14.1 0.8309 
diabetes 591 23.2 74 28.6 517 22.6 0.0318 344 22.3 34 25.8 310 22.0 0.3153 247 24.7 40 31.5 207 23.7 0.0573 
heart failure 437 17.2 71 27.4 366 16.0 <0.0001 258 16.7 37 28.0 221 15.7 0.0003 179 17.9 34 26.8 145 16.6 0.0053 
ischemic heart dis. (IHD; incl. 
AMI) 
608 23.9 85 32.8 523 22.9 0.0004 389 25.2 46 34.8 343 24.3 0.0075 219 21.9 39 30.7 180 20.6 0.0102 
rheumatoid/osteo arthritis 
(RA/OA) 
629 24.7 81 31.3 548 24.0 0.0099 383 24.8 44 33.3 339 24.0 0.0177 246 24.6 37 29.1 209 23.9 0.2042 
stroke/TIA 171 6.7 22 8.5 149 6.5 0.2293 98 6.3 12 9.1 86 6.1 0.1764 73 7.3 10 7.9 63 7.2 0.7901 
no CMS Comorbidity 904 35.5 67 25.9 837 36.6 0.0006 541 35.0 29 22.0 512 36.3 0.0010 363 36.3 38 29.9 325 37.2 0.1096 
                                            
Elixhauser comorbidities                                            
AIDS         4 0.2 0.5004         4 0.3 0.5403               
alcohol abuse 95 3.7 17 6.6 78 3.4 0.0113 46 3.0 8 6.1 38 2.7 0.0294 49 4.9 9 7.1 40 4.6 0.2218 
chronic blood loss anemia 27 1.1 7 2.7 20 0.9 0.0065 18 1.2 3 2.3 15 1.1 0.2154 9 0.9 4 3.1 5 0.6 0.0041 
coagulopathy 76 3.0 16 6.2 60 2.6 0.0015 41 2.7 8 6.1 33 2.3 0.0109 35 3.5 8 6.3 27 3.1 0.0662 
congestive heart failure 391 15.4 59 22.8 332 14.5 0.0005 244 15.8 35 26.5 209 14.8 0.0004 147 14.7 24 18.9 123 14.1 0.1528 
deficiency anemias 349 13.7 54 20.8 295 12.9 0.0004 205 13.3 32 24.2 173 12.3 0.0001 144 14.4 22 17.3 122 14.0 0.3153 
depression 398 15.6 54 20.8 344 15.1 0.0150 202 13.1 18 13.6 184 13.0 0.8437 196 19.6 36 28.3 160 18.3 0.0079 
diabetes (wo/chr complications) 564 22.2 75 29.0 489 21.4 0.0055 343 22.2 39 29.5 304 21.5 0.0341 221 22.1 36 28.3 185 21.2 0.0694 
diabetes (w/chr complications) 188 7.4 24 9.3 164 7.2 0.2232 129 8.4 13 9.8 116 8.2 0.5167 59 5.9 11 8.7 48 5.5 0.1575 
drug abuse 64 2.5 11 4.2 53 2.3 0.0605 42 2.7 7 5.3 35 2.5 0.0564 22 2.2 4 3.1 18 2.1 0.4349 
fluid and electrolyte disorders 295 11.6 44 17.0 251 11.0 0.0042 174 11.3 20 15.2 154 10.9 0.1402 121 12.1 24 18.9 97 11.1 0.0119 
hypertension 1566 61.6 172 66.4 1394 61.0 0.0903 986 63.9 92 69.7 894 63.3 0.1444 580 58.0 80 63.0 500 57.3 0.2225 
hypothyroidism 478 18.8 51 19.7 427 18.7 0.6950 281 18.2 27 20.5 254 18.0 0.4826 197 19.7 24 18.9 173 19.8 0.8078 
liver disease 96 3.8 13 5.0 83 3.6 0.2670 60 3.9 7 5.3 53 3.8 0.3784 36 3.6 6 4.7 30 3.4 0.4666 
lymphoma 23 0.9 3 1.2 20 0.9 0.6483 12 0.8 1 0.8 11 0.8 0.9786 11 1.1 2 1.6 9 1.0 0.5830 
metastatic cancer 26 1.0 1 0.4 25 1.1 0.2830 24 1.6 1 0.8 23 1.6 0.4390         2 0.2 0.5892 
obesity 326 12.8 34 13.1 292 12.8 0.8737 205 13.3 15 11.4 190 13.5 0.4981 121 12.1 19 15.0 102 11.7 0.2901 
   
 
1
9
5 
 
              LHP             PHP             
Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
in 1st 3 
months 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac in 
1st 3 
months 
% No Sev 
Exac 
% pval  
Number of Patients 2544   259   2285     1544   132   1412     1000   127   873     
other neurological disorders 216 8.5 28 10.8 188 8.2 0.1575 146 9.5 15 11.4 131 9.3 0.4335 70 7.0 13 10.2 57 6.5 0.1261 
paralysis 38 1.5 8 3.1 30 1.3 0.0255 26 1.7 7 5.3 19 1.3 0.0007 12 1.2 1 0.8 11 1.3 0.6476 
peripheral vascular disease 390 15.3 52 20.1 338 14.8 0.0253 261 16.9 30 22.7 231 16.4 0.0620 129 12.9 22 17.3 107 12.3 0.1115 
psychoses 251 9.9 31 12.0 220 9.6 0.2312 157 10.2 18 13.6 139 9.8 0.1680 94 9.4 13 10.2 81 9.3 0.7296 
pulmonary circulation disease 297 11.7 38 14.7 259 11.3 0.1130 193 12.5 21 15.9 172 12.2 0.2156 104 10.4 17 13.4 87 10.0 0.2381 
renal failure 218 8.6 22 8.5 196 8.6 0.9637 146 9.5 13 9.8 133 9.4 0.8720 72 7.2 9 7.1 63 7.2 0.9578 
rheumatoid arthritis/collagen 
vas 
142 5.6 14 5.4 128 5.6 0.8962 79 5.1 7 5.3 72 5.1 0.9190 63 6.3 7 5.5 56 6.4 0.6956 
solid tumor wo/metastasis 250 9.8 24 9.3 226 9.9 0.7491 164 10.6 14 10.6 150 10.6 0.9951 86 8.6 10 7.9 76 8.7 0.7548 
ulcers 3 0.1 1 0.4 2 0.1 0.1845         1 0.1 0.7597 2 0.2 1 0.8 1 0.1 0.1128 
valvular disease 285 11.2 43 16.6 242 10.6 0.0036 212 13.7 26 19.7 186 13.2 0.0373 73 7.3 17 13.4 56 6.4 0.0048 
weight loss 137 5.4 18 6.9 119 5.2 0.2392 91 5.9 9 6.8 82 5.8 0.6372 46 4.6 9 7.1 37 4.2 0.1522 
any Elixhauser diagnosis 2316 91.0 243 93.8 2073 90.7 0.0978 1424 92.2 126 95.5 1298 91.9 0.1476 892 89.2 117 92.1 775 88.8 0.2555 
Other comorbidities                                           
asthma 854 33.6 96 37.1 758 33.2 0.2086 488 31.6 50 37.9 438 31.0 0.1050 366 36.6 46 36.2 320 36.7 0.9243 
hypoxemia 965 37.9 122 47.1 843 36.9 0.0013 550 35.6 60 45.5 490 34.7 0.0136 415 41.5 62 48.8 353 40.4 0.0732 
pneumonia 855 33.6 135 52.1 720 31.5 <0.0001 550 35.6 82 62.1 468 33.1 <0.0001 305 30.5 53 41.7 252 28.9 0.0033 
influenza 69 2.7 9 3.5 60 2.6 0.4253 38 2.5 2 1.5 36 2.5 0.4632 31 3.1 7 5.5 24 2.7 0.0933 
                                            
COPD Complexity ^                                           
Low complexity 1244 48.9 80 30.9 1164 50.9 <0.0001 734 47.5 37 28.0 697 49.4 <0.0001 510 51.0 43 33.9 467 53.5 <0.0001 
Med complexity 1184 46.5 171 66.0 1013 44.3 <0.0001 733 47.5 91 68.9 642 45.5 <0.0001 451 45.1 80 63.0 371 42.5 <0.0001 
High complexity 116 4.6 8 3.1 108 4.7 0.2312 77 5.0 4 3.0 73 5.2 0.2802 39 3.9 4 3.1 35 4.0 0.6401 
Emphysema diagnosis (492.x) 634 24.9 84 32.4 550 24.1 0.0032 336 21.8 36 27.3 300 21.2 0.1086 298 29.8 48 37.8 250 28.6 0.0350 
                                            
COPD Medications                                            
index ICSLABA 1261 49.6 144 55.6 1117 48.9 0.0405 777 50.3 82 62.1 695 49.2 0.0046 484 48.4 62 48.8 422 48.3 0.9195 
index LAMA 972 38.2 78 30.1 894 39.1 0.0047 565 36.6 36 27.3 529 37.5 0.0201 407 40.7 42 33.1 365 41.8 0.0611 
index triple 311 12.2 37 14.3 274 12.0 0.2854 202 13.1 14 10.6 188 13.3 0.3775 109 10.9 23 18.1 86 9.9 0.0053 
SABA use                                           
no SABA use 1110 43.6 86 33.2 1024 44.8 0.0004 625 40.5 42 31.8 583 41.3 0.0340 485 48.5 44 34.6 441 50.5 0.0008 
SABA <=15% of year 615 24.2 65 25.1 550 24.1 0.7146 384 24.9 29 22.0 355 25.1 0.4201 231 23.1 36 28.3 195 22.3 0.1333 
SABA <=40% of year 328 12.9 34 13.1 294 12.9 0.9055 217 14.1 23 17.4 194 13.7 0.2441 111 11.1 11 8.7 100 11.5 0.3491 
SABA >40% of year 491 19.3 74 28.6 417 18.2 <0.0001 318 20.6 38 28.8 280 19.8 0.0149 173 17.3 36 28.3 137 15.7 0.0004 
SAMA use                                           
any ipratropium (SAMA) 325 12.8 57 22.0 268 11.7 <0.0001 204 13.2 25 18.9 179 12.7 0.0422 121 12.1 32 25.2 89 10.2 <0.0001 
any SABA/SAMA 443 17.4 61 23.6 382 16.7 0.0060 289 18.7 34 25.8 255 18.1 0.0301 154 15.4 27 21.3 127 14.5 0.0502 
any SAMA or SABA/SAMA 703 27.6 103 39.8 600 26.3 <0.0001 452 29.3 51 38.6 401 28.4 0.0134 251 25.1 52 40.9 199 22.8 <0.0001 
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              LHP             PHP             
Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
in 1st 3 
months 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac in 
1st 3 
months 
% No Sev 
Exac 
% pval  
Number of Patients 2544   259   2285     1544   132   1412     1000   127   873     
Other COPD medications                                           
any ICS 853 33.5 93 35.9 760 33.3 0.3925 540 35.0 44 33.3 496 35.1 0.6793 313 31.3 49 38.6 264 30.2 0.0582 
any LABA 134 5.3 12 4.6 122 5.3 0.6298 75 4.9 3 2.3 72 5.1 0.1486 59 5.9 9 7.1 50 5.7 0.5436 
any methylxanthines 45 1.8 6 2.3 39 1.7 0.4804 13 0.8 3 2.3 10 0.7 0.0599 32 3.2 3 2.4 29 3.3 0.5659 
Any use of above COPD 
medications 
1307 51.4 155 59.8 1152 50.4 0.0040 828 53.6 77 58.3 751 53.2 0.2569 479 47.9 78 61.4 401 45.9 0.0011 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 2261 88.9 223 86.1 2038 89.2 0.1339 1369 88.7 107 81.1 1262 89.4 0.0039 892 89.2 116 91.3 776 88.9 0.4059 
1-2 Rxs ICSLABA (wks 27-52) 153 6.0 16 6.2 137 6.0 0.9071 96 6.2 11 8.3 85 6.0 0.2925 57 5.7 5 3.9 52 6.0 0.3591 
>2 Rxs ICSLABA (wks 27-52) 130 5.1 20 7.7 110 4.8 0.0440 79 5.1 14 10.6 65 4.6 0.0028 51 5.1 6 4.7 45 5.2 0.8369 
No LAMA in prior year 2448 96.2 249 96.1 2199 96.2 0.9379 1482 96.0 126 95.5 1356 96.0 0.7457 966 96.6 123 96.9 843 96.6 0.8677 
1-2 Rxs LAMA (wks 27-52) 54 2.1 8 3.1 46 2.0 0.2550 38 2.5 5 3.8 33 2.3 0.3036 16 1.6 3 2.4 13 1.5 0.4638 
>2 Rxs LAMA (wks 27-52) 42 1.7 2 0.8 40 1.8 0.2416 24 1.6 1 0.8 23 1.6 0.4390 18 1.8 1 0.8 17 1.9 0.3583 
Oxygen Use                                           
no oxygen 1372 53.9 118 45.6 1254 54.9 0.0043 848 54.9 62 47.0 786 55.7 0.0548 524 52.4 56 44.1 468 53.6 0.0449 
oxygen <=50% of year 427 16.8 40 15.4 387 16.9 0.5424 287 18.6 25 18.9 262 18.6 0.9136 140 14.0 15 11.8 125 14.3 0.4467 
oxygen >50% of year 745 29.3 101 39.0 644 28.2 0.0003 409 26.5 45 34.1 364 25.8 0.0385 336 33.6 56 44.1 280 32.1 0.0074 
                                            
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 1590 62.5 132 51.0 1458 63.8 <0.0001 870 56.3 62 47.0 808 57.2 0.0231 720 72.0 70 55.1 650 74.5 <0.0001 
1 period breathlessness 485 19.1 72 27.8 413 18.1 0.0002 319 20.7 35 26.5 284 20.1 0.0823 166 16.6 37 29.1 129 14.8 <0.0001 
>1 period breathlessness 469 18.4 55 21.2 414 18.1 0.2201 355 23.0 35 26.5 320 22.7 0.3145 114 11.4 20 15.7 94 10.8 0.0989 
Shortness of Breath                                           
no periods shortness breath 1599 62.9 131 50.6 1468 64.2 <0.0001 954 61.8 64 48.5 890 63.0 0.0010 645 64.5 67 52.8 578 66.2 0.0031 
1 period shortness breath 512 20.1 63 24.3 449 19.6 0.0754 338 21.9 38 28.8 300 21.2 0.0451 174 17.4 25 19.7 149 17.1 0.4672 
>1 period shortness breath 433 17.0 65 25.1 368 16.1 0.0003 252 16.3 30 22.7 222 15.7 0.0373 181 18.1 35 27.6 146 16.7 0.0030 
any wheezing 187 7.4 33 12.7 154 6.7 0.0005 125 8.1 17 12.9 108 7.6 0.0351 62 6.2 16 12.6 46 5.3 0.0014 
any dyspnea 1426 56.1 187 72.2 1239 54.2 <0.0001 948 61.4 101 76.5 847 60.0 0.0002 478 47.8 86 67.7 392 44.9 <0.0001 
supplemental oxygen use (V46.2) 166 6.5 38 14.7 128 5.6 <0.0001 52 3.4 11 8.3 41 2.9 0.0009 114 11.4 27 21.3 87 10.0 0.0002 
Other symptoms                                           
chest pain unspecified 702 27.6 97 37.5 605 26.5 0.0002 426 27.6 48 36.4 378 26.8 0.0184 276 27.6 49 38.6 227 26.0 0.0030 
painful respiratory 114 4.5 19 7.3 95 4.2 0.0191 60 3.9 13 9.8 47 3.3 0.0002 54 5.4 6 4.7 48 5.5 0.7185 
precordial pain 44 1.7 9 3.5 35 1.5 0.0230 28 1.8 7 5.3 21 1.5 0.0017 16 1.6 2 1.6 14 1.6 0.9807 
any chestpain 737 29.0 102 39.4 635 27.8 <0.0001 444 28.8 53 40.2 391 27.7 0.0025 293 29.3 49 38.6 244 27.9 0.0139 
chronic fatigue 33 1.3 4 1.5 29 1.3 0.7106 21 1.4 2 1.5 19 1.3 0.8722 12 1.2 2 1.6 10 1.1 0.6780 
other malaise/fatigue 591 23.2 89 34.4 502 22.0 <0.0001 340 22.0 45 34.1 295 20.9 0.0005 251 25.1 44 34.6 207 23.7 0.0079 
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              LHP             PHP             
Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
in 1st 3 
months 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac in 
1st 3 
months 
% No Sev 
Exac 
% pval  
Number of Patients 2544   259   2285     1544   132   1412     1000   127   873     
difficulty walking 60 2.4 8 3.1 52 2.3 0.4138 47 3.0 5 3.8 42 3.0 0.6029 13 1.3 3 2.4 10 1.1 0.2580 
memory loss 51 2.0 2 0.8 49 2.1 0.1354         33 2.3 0.0758 18 1.8 2 1.6 16 1.8 0.8381 
cough 858 33.7 107 41.3 751 32.9 0.0064 568 36.8 63 47.7 505 35.8 0.0064 290 29.0 44 34.6 246 28.2 0.1334 
hemoptysis 37 1.5 3 1.2 34 1.5 0.6745 26 1.7 2 1.5 24 1.7 0.8748 11 1.1 1 0.8 10 1.1 0.7177 
                                            
Procedures                                           
chest CT 375 14.7 52 20.1 323 14.1 0.0106 243 15.7 27 20.5 216 15.3 0.1197 132 13.2 25 19.7 107 12.3 0.0208 
chest x-ray 1591 62.5 182 70.3 1409 61.7 0.0067 961 62.2 97 73.5 864 61.2 0.0053 630 63.0 85 66.9 545 62.4 0.3263 
echocardiography 515 20.2 53 20.5 462 20.2 0.9261 359 23.3 26 19.7 333 23.6 0.3121 156 15.6 27 21.3 129 14.8 0.0599 
EKG 1110 43.6 136 52.5 974 42.6 0.0024 681 44.1 75 56.8 606 42.9 0.0021 429 42.9 61 48.0 368 42.2 0.2111 
heart catheterization 28 1.1 3 1.2 25 1.1 0.9252 21 1.4 2 1.5 19 1.3 0.8722 7 0.7 1 0.8 6 0.7 0.8994 
nebulizer treatment 840 33.0 100 38.6 740 32.4 0.0435 599 38.8 57 43.2 542 38.4 0.2795 241 24.1 43 33.9 198 22.7 0.0059 
non-invasive ventilator 176 6.9 21 8.1 155 6.8 0.4259 103 6.7 10 7.6 93 6.6 0.6631 73 7.3 11 8.7 62 7.1 0.5279 
spirometry 1150 45.2 100 38.6 1050 46.0 0.0245 747 48.4 56 42.4 691 48.9 0.1521 403 40.3 44 34.6 359 41.1 0.1644 
any vaccination (flu or 
pneumonia) 
1241 48.8 115 44.4 1126 49.3 0.1368 788 51.0 64 48.5 724 51.3 0.5397 453 45.3 51 40.2 402 46.0 0.2128 
                                            
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 321 12.6 51 19.7 270 11.8 0.0003 212 13.7 28 21.2 184 13.0 0.0090 109 10.9 23 18.1 86 9.9 0.0053 
any severe 173 6.8 41 15.8 132 5.8 <0.0001 106 6.9 22 16.7 84 5.9 <0.0001 67 6.7 19 15.0 48 5.5 <0.0001 
any other hospitalizations* 43 1.7 7 2.7 36 1.6 0.1823 38 2.5 6 4.5 32 2.3 0.1060 5 0.5 1 0.8 4 0.5 0.6231 
Prior 2-12 weeks                                           
any moderate 436 17.1 66 25.5 370 16.2 0.0002 269 17.4 30 22.7 239 16.9 0.0929 167 16.7 36 28.3 131 15.0 0.0002 
any severe 162 6.4 37 14.3 125 5.5 <0.0001 77 5.0 14 10.6 63 4.5 0.0019 85 8.5 23 18.1 62 7.1 <0.0001 
any other hospitalizations* 98 3.9 17 6.6 81 3.5 0.0167 75 4.9 12 9.1 63 4.5 0.0180 23 2.3 5 3.9 18 2.1 0.1878 
Prior 13-52 weeks                                           
no moderate 1981 77.9 183 70.7 1798 78.7 0.0032 1174 76.0 92 69.7 1082 76.6 0.0744 807 80.7 91 71.7 716 82.0 0.0057 
1 moderate 449 17.6 56 21.6 393 17.2 0.0768 292 18.9 32 24.2 260 18.4 0.1020 157 15.7 24 18.9 133 15.2 0.2891 
>1 moderate 114 4.5 20 7.7 94 4.1 0.0078 78 5.1 8 6.1 70 5.0 0.5800 36 3.6 12 9.4 24 2.7 0.0002 
any severe 208 8.2 39 15.1 169 7.4 <0.0001 98 6.3 18 13.6 80 5.7 0.0003 110 11.0 21 16.5 89 10.2 0.0329 
any other hospitalizations* 172 6.8 29 11.2 143 6.3 0.0027 134 8.7 23 17.4 111 7.9 0.0002 38 3.8 6 4.7 32 3.7 0.5598 
                                            
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 363 14.3 58 22.4 305 13.3 <0.0001 286 18.5 47 35.6 239 16.9 <0.0001 77 7.7 11 8.7 66 7.6 0.6636 
COPD Inpatient (Any) 496 19.5 96 37.1 400 17.5 <0.0001 258 16.7 43 32.6 215 15.2 <0.0001 238 23.8 53 41.7 185 21.2 <0.0001 
Total Inpatient (Any) 742 29.2 132 51.0 610 26.7 <0.0001 475 30.8 73 55.3 402 28.5 <0.0001 267 26.7 59 46.5 208 23.8 <0.0001 
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              LHP             PHP             
Baseline Characteristic Total % Sev 
Exac 
1st 6 
mon 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac 
in 1st 3 
months 
% No 
Sev 
Exac 
% pval  Total % Sev 
Exac in 
1st 3 
months 
% No Sev 
Exac 
% pval  
Number of Patients 2544   259   2285     1544   132   1412     1000   127   873     
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period) 
Same as Index Trmt 2238 88.0 243 93.8 1995 87.3 0.0023 1334 86.4 121 91.7 1213 85.9 0.0649 904 90.4 122 96.1 782 89.6 0.0204 
No evidence Any Trmt                                           
Different Trmt from Index 306 12.0 16 6.2 290 12.7 0.0023 210 13.6 11 8.3 199 14.1 0.0649 96 9.6 5 3.9 91 10.4 0.0204 
Now using Triple 169 6.6 10 3.9 159 7.0 0.0578 107 6.9 6 4.5 101 7.2 0.2593 62 6.2 4 3.1 58 6.6 0.1271 
No longer using Triple 86 3.4 4 1.5 82 3.6 0.0845 63 4.1 3 2.3 60 4.2 0.2723 23 2.3 1 0.8 22 2.5 0.2236 
Switched between ICSLABA 
and LAMA 
51 2.0 2 0.8 49 2.1 0.1354 40 2.6 2 1.5 38 2.7 0.4160         11 1.3 0.2034 
LHP enrollee 1544 60.7 132 51.0 1412 61.8 0.0007 1544 60.7 132 51.0 1412 61.8 0.0007               
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 41 Severe Exacerbation in 3 Months: Healthcare Utilization Costs (Means) 
  LHP and PHP           LHP             PHP             
Baseline Characteristic Total SD Sev 
Exac  
1st 3 
mon 
SD No 
Sev 
Exac 
SD pval  Total SD Sev 
Exac  
1st 3 
mon 
SD No 
Sev 
Exac 
SD pval  Total SD Sev 
Exac 
1st 3 
mon 
SD No Sev 
Exac 
SD pval  
Number of Patients 5475   146   5329     3599   78   3521     1876   68   1808     
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient 5490 9457 7652 13798 5431 9305 0.0552 5426 8291 9409 17461 5338 7952 0.0433 5614 11366 5637 7342 5613 11492 0.9799 
COPD Outpatient 1961 2436 2727 2478 1940 2432 0.0001 1786 2213 2633 2475 1768 2203 0.0006 2297 2786 2834 2497 2276 2795 0.1052 
Total Outpatient 7452 10320 10379 14399 7371 10175 0.0133 7212 9094 12042 17790 7105 8780 0.0168 7911 12326 8471 8835 7890 12439 0.6023 
                                            
Non-COPD Inpatient 5069 20267 10429 31374 4923 19860 0.0366 6913 24336 17781 41075 6672 23786 0.0198 1533 6606 1995 7496 1516 6572 0.5574 
COPD Inpatient 6179 20753 16699 37688 5891 20017 0.0007 5019 19696 17514 41089 4742 18869 0.0076 8404 22481 15764 33646 8127 21916 0.0676 
Total Inpatient 11248 30260 27128 52204 10813 29317 0.0002 11932 32612 35295 62413 11414 31457 0.0012 9937 25094 17759 35417 9643 24586 0.0653 
Total Medical Utilization 18700 33496 37506 58591 18185 32393 0.0001 19144 35393 47337 70850 18520 33950 0.0006 17848 29507 26230 37668 17533 29122 0.0639 
                                            
Non-COPD Outpatient Rx 2369 4007 2415 2798 2368 4035 0.8442 2635 4381 2689 3240 2634 4403 0.8826 1859 3107 2100 2166 1850 3137 0.363 
COPD Outpatient Rx 408 778 584 931 403 773 0.021 409 799 625 891 404 796 0.0159 405 735 538 979 400 724 0.2559 
Total Outpatient Rx 2777 4148 2999 3096 2771 4173 0.3851 3043 4510 3314 3417 3037 4531 0.4848 2265 3288 2638 2660 2251 3309 0.2471 
                                            
Total Healthcare Services 21477 34258 40505 59086 20955 33174 0.0001 22188 36262 50651 71263 21557 34851 0.0006 20113 30003 28868 38235 19784 29612 0.0567 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient 5589 9513 7758 13864 5530 9360 0.0572 5512 8328 9531 17542 5422 7986 0.0437 5740 11461 5721 7364 5740 11590 0.9836 
COPD Outpatient 2100 2463 2927 2451 2078 2459 <0.0001 1928 2239 2893 2444 1907 2230 0.0002 2423 2808 2965 2476 2403 2818 0.1131 
Total Outpatient 7469 10326 10379 14399 7390 10181 0.0138 7226 9097 12042 17790 7120 8783 0.0171 7936 12337 8471 8835 7916 12451 0.6188 
                                            
Non-COPD Inpatient 32576 41773 42294 51881 32147 41257 0.2545 36213 45208 46231 55848 35755 44660 0.2148 17434 14833 22609 13917 17239 14872 0.3856 
COPD Inpatient 30287 37170 41323 50159 29671 36243 0.0836 28403 39151 48788 56855 27464 37943 0.0594 32778 34258 34580 43080 32653 33621 0.8088 
Total Inpatient 36441 45266 50777 62574 35747 44166 0.0392 37244 48767 64023 72516 36207 47354 0.0165 34716 36619 34504 43326 34731 36155 0.9717 
Total Medical Utilization 18710 33502 37506 58591 18195 32400 0.0001 19144 35393 47337 70850 18520 33950 0.0006 17877 29522 26230 37668 17562 29137 0.0647 
                                            
Non-COPD Outpatient Rx 2462 4056 2465 2805 2462 4086 0.9877 2693 4411 2689 3240 2693 4434 0.9926 1997 3177 2197 2167 1989 3210 0.4598 
COPD Outpatient Rx 408 778 584 931 403 773 0.021 409 799 625 891 404 796 0.0159 405 735 538 979 400 724 0.2559 
Total Outpatient Rx 2777 4148 2999 3096 2771 4173 0.3851 3043 4510 3314 3417 3037 4531 0.4848 2265 3288 2638 2660 2251 3309 0.2471 
                                            
Total Healthcare Services 21477 34258 40505 59086 20955 33174 0.0001 22188 36262 50651 71263 21557 34851 0.0006 20113 30003 28868 38235 19784 29612 0.0567 
Length of Stay (inpatient stays) 6.6 7.7 7.2 7.9 6.6 7.6 0.5407 7.3 8.6 7.4 6.7 7.3 8.6 0.9206 5.3 5.0 6.9 9.2 5.2 4.6 0.283 
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Table 42 Severe Exacerbation in 3 Months: Healthcare Utilization Costs (Medians) 
  LHP and PHP           LHP             PHP             
  
Total   Sev 
Exac in 
1st 3 
months 
  No 
Sev 
Exac 
  pval 
Comb vs 
Triple* 
Total   Sev 
Exac in 
1st 3 
months 
  No 
Sev 
Exac 
  pval 
Comb vs 
Triple* 
Total   Sev 
Exac in 
1st 3 
months 
  No Sev 
Exac 
  pval 
Comb 
vs 
Triple* 
Median                                           
Cost of Utilization ($ )  
Non-COPD Outpatient 3181   4419   3167   0.0048 3361   5686   3318   0.0012 2879   2985   2876   0.3652 
COPD Outpatient 1201   2242   1184   <0.0001 1038   1849   1016   0.0004 1685   2540   1645   0.0085 
Total Outpatient 4931   7392   4896   <0.0001 4924   8041   4875   <0.0001 4964   6346   4926   0.0972 
                                            
Non-COPD Inpatient 0   0   0   0.0016 0   0   0   <0.0001 0   0   0   0.9349 
COPD Inpatient 0   0   0   <0.0001 0   0   0   <0.0001 0   0   0   0.0003 
Total Inpatient 0   6801   0   <0.0001 0   9820   0   <0.0001 0   3716   0   <0.0001 
Total Medical Utilization 7398   16306   7243   <0.0001 7552   16693   7454   <0.0001 6998   16306   6771   0.0010 
                                            
Non-COPD Outpatient Rx 1252   1542   1250   0.2210 1442   1579   1441   0.5432 854   1474   836   0.0715 
COPD Outpatient Rx 68   160   66   0.0006 68   197   66   0.0038 66   147   65   0.0510 
Total Outpatient Rx 1685   2265   1676   0.0552 1869   2409   1853   0.0926 1295   2015   1287   0.0873 
                                            
Total Healthcare Services 10052   21216   9911   <0.0001 10559   21216   10356   <0.0001 9209   20446   9038   0.0015 
                                            
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient 3285   4465   3259   0.0051 3417   5786   3395   0.0011 2993   3004   2990   0.4091 
COPD Outpatient 1380   2394   1351   <0.0001 1185   2240   1160   <0.0001 1792   2554   1762   0.0067 
Total Outpatient 4942   7392   4902   <0.0001 4928   8041   4884   <0.0001 4985   6346   4953   0.1058 
                                            
Non-COPD Inpatient 17802   19983   17730   0.3889 19872   19983   19872   0.7078 13848   19758   13566   0.169 
COPD Inpatient 17641   20512   17586   0.2482 15300   21900   14973   0.0481 20654   18347   20656   0.4835 
Total Inpatient 19907   20884   19879   0.2594 18979   28858   18703   0.0314 21703   19133   21721   0.3878 
Total Medical Utilization 7404   16306   7252   <0.0001 7552   16693   7454   <0.0001 7014   16306   6779   0.0011 
                                            
Non-COPD Outpatient Rx 1340   1631   1338   0.3669 1499   1579   1499   0.7771 1026   1822   1008   0.1141 
COPD Outpatient Rx 68   160   66   0.0006 68   197   66   0.0038 66   147   65   0.051 
Total Outpatient Rx 1685   2265   1676   0.0552 1869   2409   1853   0.0926 1295   2015   1287   0.0873 
                                            
Total Healthcare Services 10052   21216   9911   <0.0001 10559   21216   10356   <0.0001 9209   20446   9038   0.0015 
Length of Stay (inpatient stays) 4   4   4   0.5703 4   4   4   0.4392 4   4   4   0.7982 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Table 43 Severe Exacerbation Within 3 Months, without Discontinuation, Baseline Healthcare Costs (Means) 
  LHP and PHP LHP PHP 
Baseline Characteristic Total SD Sev 
Exac 
1st 3 
mon 
SD No Sev 
Exac 
SD pval  Total SD Sev 
Exac 
1st 3 
mon 
SD No 
Sev 
Exac 
SD pval  Total SD Sev 
Exac 
1st 3 
mon 
SD No 
Sev 
Exac 
SD pval  
Number of Patients 3403   146   3257     2127   78   2049     1276   68   1208     
                                            
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient  5461 9442 7652 13798 5363 9190 0.0489 5469 8211 9409 17461 5319 7610 0.0426 5447 11202 5637 7342 5436 11382 0.8331 
COPD Outpatient  1987 2416 2727 2478 1954 2409 0.0002 1803 2083 2633 2475 1771 2061 0.0032 2294 2862 2834 2497 2264 2880 0.1101 
Total Outpatient  7448 10256 10379 14399 7317 10013 0.012 7272 8891 12042 17790 7090 8322 0.0166 7741 12195 8471 8835 7700 12359 0.4967 
                                            
Non-COPD Inpatient  4603 18550 10429 31374 4341 17723 0.0213 6497 22762 17781 41075 6067 21665 0.0143 1445 6189 1995 7496 1414 6110 0.5326 
COPD Inpatient  5830 20106 16699 37688 5343 18804 0.0004 4577 19378 17514 41089 4084 17881 0.0052 7919 21107 15764 33646 7477 20103 0.0482 
Total Inpatient  10432 28813 27128 52204 9684 27073 <0.0001 11073 31356 35295 62413 10151 29172 0.0007 9364 23955 17759 35417 8891 23072 0.0451 
Total Medical Utilization 17880 32050 37506 58591 17001 30039 <0.0001 18345 34005 47337 70850 17242 31280 0.0004 17105 28490 26230 37668 16591 27816 0.0413 
                                            
Non-COPD Outpatient Rx 2258 3682 2415 2798 2251 3717 0.4973 2599 4030 2689 3240 2595 4058 0.8037 1691 2927 2100 2166 1668 2963 0.1217 
COPD Outpatient Rx 480 852 584 931 475 849 0.129 506 884 625 891 501 884 0.2251 436 795 538 979 430 784 0.3765 
Total Outpatient Rx 2737 3885 2999 3096 2725 3917 0.3034 3103 4213 3314 3417 3095 4241 0.5834 2127 3176 2638 2660 2098 3201 0.173 
                                            
Total Healthcare Services 20617 32842 40505 59086 19726 30870 <0.0001 21448 34916 50651 71263 20337 32263 0.0003 19232 29018 28868 38235 18690 28334 0.034 
Cost of Utilization ($ mean, SD)  - for those with utilization within category  
Non-COPD Outpatient  5559 9498 7758 13864 5460 9244 0.0507 5553 8245 9531 17542 5401 7639 0.0429 5569 11297 5721 7364 5560 11482 0.8677 
COPD Outpatient  2122 2439 2927 2451 2086 2433 <0.0001 1939 2098 2893 2444 1903 2076 0.0012 2421 2888 2965 2476 2391 2907 0.1189 
Total Outpatient  7465 10262 10379 14399 7335 10019 0.0125 7282 8893 12042 17790 7101 8324 0.0168 7772 12210 8471 8835 7732 12374 0.5149 
                                            
Non-COPD Inpatient 31325 38824 42294 51881 30474 37562 0.1882 35431 42471 46231 55848 34531 41134 0.2701 16766 13743 22609 13917 16429 13725 0.2862 
COPD Inpatient 29744 36778 41323 50159 28621 35063 0.0619 27269 40274 48788 56855 25438 38098 0.0415 32594 32116 34580 43080 32373 30752 0.7832 
Total Inpatient 35502 44002 50777 62574 34209 41849 0.0242 36180 48021 64023 72516 34211 45241 0.0109 34236 35333 34504 43326 34206 34411 0.9689 
Total Medical Utilization 17896 32060 37506 58591 17016 30048 <0.0001 18345 34005 47337 70850 17242 31280 0.0004 17145 28512 26230 37668 16633 27838 0.0421 
                                            
Non-COPD Outpatient Rx 2370 3736 2465 2805 2365 3774 0.6819 2660 4058 2689 3240 2659 4087 0.9358 1852 3015 2197 2167 1832 3057 0.2026 
COPD Outpatient Rx 480 852 584 931 475 849 0.129 506 884 625 891 501 884 0.2251 436 795 538 979 430 784 0.3765 
Total Outpatient Rx 2737 3885 2999 3096 2725 3917 0.3034 3103 4213 3314 3417 3095 4241 0.5834 2127 3176 2638 2660 2098 3201 0.173 
                                            
Total Healthcare Services 20617 32842 40505 59086 19726 30870 <0.0001 21448 34916 50651 71263 20337 32263 0.0003 19232 29018 28868 38235 18690 28334 0.034 
Length of Stay (inpatient 
stays) 
6.4 7.1 7.2 7.9 6.4 7.1 0.3503 7.0 8.1 7.4 6.7 7.0 8.1 0.7667 5.3 4.8 6.9 9.2 5.2 4.0 0.2837 
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Table 44 Severe Exacerbation Within 3 Months, without Discontinuation, Baseline Healthcare Costs (Medians) 
  LHP and PHP LHP PHP 
  
Total   Sev 
Exac 
1st 3 
mon 
  No Sev 
Exac 
  pval 
Comb vs 
Triple* 
Total   Sev 
Exac 
1st 3 
mon 
  No 
Sev 
Exac 
  pval 
Comb vs 
Triple* 
Total   Sev 
Exac 
1st 3 
mon 
  No 
Sev 
Exac 
  pval 
Comb vs 
Triple* 
Median                                           
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient  3163   4419   3124   0.0030 3386   5686   3332   0.0012 2838   2985   2821   0.2881 
COPD Outpatient  1287   2242   1253   <0.0001 1114   1849   1087   0.0008 1649   2540   1593   0.0071 
Total Outpatient  4932   7392   4869   <0.0001 4971   8041   4901   <0.0001 4899   6346   4840   0.0751 
                                            
Non-COPD Inpatient 0   0   0   0.0003 0   0   0   <0.0001 0   0   0   0.8884 
COPD Inpatient 0   0   0   <0.0001 0   0   0   <0.0001 0   0   0   <0.0001 
Total Inpatient 0   6801   0   <0.0001 0   9820   0   <0.0001 0   3716   0   <0.0001 
Total Medical Utilization 7235   16306   6935   <0.0001 7542   16693   7390   <0.0001 6564   16306   6397   0.0004 
                                            
Non-COPD Outpatient Rx 1226   1542   1210   0.0772 1502   1579   1500   0.5843 686   1474   670   0.0093 
COPD Outpatient Rx 81   160   78   0.0064 101   197   97   0.0462 57   147   52   0.0327 
Total Outpatient Rx 1707   2265   1694   0.0362 1981   2409   1966   0.1934 1094   2015   1076   0.0170 
                                            
Total Healthcare Services 9968   21216   9720   <0.0001 10652   21216   10406   <0.0001 8766   20446   8601   0.0004 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient  3246   4465   3226   0.0031 3443   5786   3410   0.001 2881   3004   2869   0.3246 
COPD Outpatient  1423   2394   1390   <0.0001 1261   2240   1231   <0.0001 1758   2554   1717   0.0056 
Total Outpatient  4948   7392   4898   <0.0001 4997   8041   4904   <0.0001 4910   6346   4843   0.0838 
                                            
Non-COPD Inpatient 17195   19983   17044   0.2849 19252   19983   19121   0.6606 13131   19758   12626   0.1335 
COPD Inpatient 16965   20512   16754   0.1796 13720   21900   13490   0.0195 20660   18347   20663   0.461 
Total Inpatient 19439   20884   19328   0.1589 17708   28858   17612   0.015 21650   19133   21721   0.4334 
Total Medical Utilization 7259   16306   6987   <0.0001 7542   16693   7390   <0.0001 6602   16306   6405   0.0004 
                                            
Non-COPD Outpatient Rx 1324   1631   1316   0.2038 1544   1579   1544   0.8473 888   1822   862   0.0275 
COPD Outpatient Rx 81   160   78   0.0064 101   197   97   0.0462 57   147   52   0.0327 
Total Outpatient Rx 1707   2265   1694   0.0362 1981   2409   1966   0.1934 1094   2015   1076   0.017 
                                            
Total Healthcare Services 9968   21216   9720   <0.0001 10652   21216   10406   <0.0001 8766   20446   8601   0.0004 
Length of Stay (inpatient stays) 4   4   4   0.5006 4   4   4   0.3688 4   4   4   0.8727 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Table 45 Severe Exacerbation in 6 Months: Healthcare Utilization Costs (Means) 
  LHP and PHP           LHP             PHP             
Baseline Characteristic Total SD Sev 
Exac  
1st 6 
mon 
SD No Sev 
Exac 
SD pval  Total SD Sev 
Exac  
1st 6 
mon 
SD No Sev 
Exac 
SD pval  Total SD Sev 
Exac  
1st 6 
mon 
SD No Sev 
Exac 
SD pval  
Number of Patients 5475   352   5123     3599   187   3412     1876   165   1711     
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient  5490 9457 7155 12027 5376 9245 0.0068 5426 8291 8377 14982 5264 7731 0.0053 5614 11366 5770 7168 5599 11693 0.7851 
COPD Outpatient  1961 2436 2953 3273 1893 2353 <0.0001 1786 2213 2822 3346 1730 2119 <0.0001 2297 2786 3101 3191 2219 2732 0.0007 
Total Outpatient  7452 10320 10107 13704 7269 10022 0.0002 7212 9094 11198 16707 6994 8432 0.0008 7911 12326 8871 9082 7818 12593 0.1728 
                                            
Non-COPD Inpatient 5069 20267 7974 25592 4870 19836 0.0263 6913 24336 12938 33199 6582 23717 0.0105 1533 6606 2348 9579 1455 6243 0.2419 
COPD Inpatient 6179 20753 14611 30812 5600 19748 <0.0001 5019 19696 13312 32463 4565 18648 0.0003 8404 22481 16083 28855 7664 21635 0.0003 
Total Inpatient 11248 30260 22585 41526 10469 29171 <0.0001 11932 32612 26250 48108 11147 31365 <0.0001 9937 25094 18431 32142 9118 24161 0.0004 
Total Medical Utilization 18700 33496 32692 47001 17739 32145 <0.0001 19144 35393 37449 55055 18141 33715 <0.0001 17848 29507 27302 35148 16937 28753 0.0003 
                                            
Non-COPD Outpatient Rx 2369 4007 2450 3036 2364 4065 0.6158 2635 4381 2835 3539 2624 4422 0.4357 1859 3107 2014 2272 1845 3176 0.3814 
COPD Outpatient Rx 408 778 559 953 397 763 0.002 409 799 600 945 399 789 0.0046 405 735 512 964 395 709 0.131 
Total Outpatient Rx 2777 4148 3009 3290 2761 4201 0.1808 3043 4510 3435 3670 3022 4551 0.141 2265 3288 2525 2730 2240 3336 0.21 
                                            
Total Healthcare Services 21477 34258 35701 47762 20499 32910 <0.0001 22188 36262 40883 55751 21163 34602 <0.0001 20113 30003 29827 35941 19176 29210 0.0003 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient  5589 9513 7216 12060 5477 9302 0.0086 5512 8328 8422 15009 5351 7764 0.0062 5740 11461 5841 7183 5730 11797 0.8609 
COPD Outpatient  2100 2463 3102 3285 2030 2379 <0.0001 1928 2239 3033 3376 1867 2143 <0.0001 2423 2808 3178 3193 2348 2756 0.0017 
Total Outpatient  7469 10326 10107 13704 7288 10028 0.0002 7226 9097 11198 16707 7008 8435 0.0008 7936 12337 8871 9082 7846 12606 0.1844 
                                            
Non-COPD Inpatient 32576 41773 36934 44512 32149 41501 0.3409 36213 45208 41715 48735 35705 44876 0.333 17434 14833 21526 21167 16933 13880 0.381 
COPD Inpatient 30287 37170 35468 39614 29514 36751 0.0719 28403 39151 37154 45505 27373 38248 0.095 32778 34258 34021 33988 32537 34347 0.7266 
Total Inpatient 36441 45266 42063 48948 35733 44748 0.07 37244 48767 46750 56317 36292 47871 0.0686 34716 36619 36203 37285 34441 36529 0.6857 
Total Medical Utilization 18710 33502 32692 47001 17749 32152 <0.0001 19144 35393 37449 55055 18141 33715 <0.0001 17877 29522 27302 35148 16966 28770 0.0003 
                                            
Non-COPD Outpatient Rx 2462 4056 2507 3048 2459 4118 0.7831 2693 4411 2835 3539 2685 4455 0.5792 1997 3177 2116 2282 1985 3252 0.5112 
COPD Outpatient Rx 408 778 559 953 397 763 0.002 409 799 600 945 399 789 0.0046 405 735 512 964 395 709 0.131 
Total Outpatient Rx 2777 4148 3009 3290 2761 4201 0.1808 3043 4510 3435 3670 3022 4551 0.141 2265 3288 2525 2730 2240 3336 0.21 
                                            
Total Healthcare Services 21477 34258 35701 47762 20499 32910 <0.0001 22188 36262 40883 55751 21163 34602 <0.0001 20113 30003 29827 35941 19176 29210 0.0003 
Length of Stay (inpatient 
stays) 
6.6 7.7 7.2 8.4 6.6 7.6 0.337 7.3 8.6 7.8 8.9 7.2 8.5 0.4851 5.3 5.0 6.4 7.9 5.1 4.2 0.1376 
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Table 46 Severe Exacerbation in 6 Months: Healthcare Utilization Costs (Medians) 
  LHP and PHP  LHP PHP  
  
Total   Sev 
Exac  
1st 6 
mon 
  No Sev 
Exac 
  pval Comb 
vs Triple* 
Total   Sev 
Exac  
1st 6 
mon 
  No Sev 
Exac 
  pval 
Comb vs 
Triple* 
Total   Sev 
Exac  
1st 6 
mon 
  No Sev 
Exac 
  pval 
Comb 
vs 
Triple* 
Median                                           
Cost of Utilization ($)  
Non-COPD Outpatient 3181   4190   3148   0.0002 3361   4415   3311   0.0004 2879   3425   2855   0.0437 
COPD Outpatient 1201   2285   1147   <0.0001 1038   2086   999   <0.0001 1685   2537   1588   <0.0001 
Total Outpatient 4931   6719   4840   <0.0001 4924   7184   4834   <0.0001 4964   6194   4841   0.0009 
                                            
Non-COPD Inpatient 0   0   0   0.0010 0   0   0   <0.0001 0   0   0   0.2974 
COPD Inpatient 0   0   0   <0.0001 0   0   0   <0.0001 0   0   0   <0.0001 
Total Inpatient 0   7239   0   <0.0001 0   8132   0   <0.0001 0   3066   0   <0.0001 
Total Medical Utilization 7398   16087   7043   <0.0001 7552   17640   7262   <0.0001 6998   15131   6505   <0.0001 
                                            
Non-COPD Outpatient Rx 1252   1461   1243   0.0934 1442   1519   1435   0.1605 854   1262   829   0.0380 
COPD Outpatient Rx 68   144   65   <0.0001 68   146   65   0.0004 66   134   62   0.0306 
Total Outpatient Rx 1685   2015   1662   0.0100 1869   2241   1839   0.0067 1295   1724   1274   0.0451 
                                            
Total Healthcare Services 10052   20671   9731   <0.0001 10559   21064   10180   <0.0001 9209   19202   8787   <0.0001 
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient 3285   4202   3239   0.0005 3417   4452   3386   0.0007 2993   3536   2958   0.0655 
COPD Outpatient 1380   2395   1321   <0.0001 1185   2234   1144   <0.0001 1792   2554   1729   <0.0001 
Total Outpatient 4942   6719   4850   <0.0001 4928   7184   4850   <0.0001 4985   6194   4857   0.0011 
                                            
Non-COPD Inpatient 17802   19286   17707   0.494 19872   20306   19809   0.5263 13848   16989   13439   0.4952 
COPD Inpatient 17641   18927   17416   0.0516 15300   16919   14181   0.0826 20654   21937   20580   0.64 
Total Inpatient 19907   21484   19683   0.1825 18979   20327   18667   0.1473 21703   21937   21650   0.8395 
Total Medical Utilization 7404   16087   7046   <0.0001 7552   17640   7262   <0.0001 7014   15131   6553   <0.0001 
                                            
Non-COPD Outpatient Rx 1340   1517   1335   0.2148 1499   1519   1499   0.3666 1026   1516   988   0.0763 
COPD Outpatient Rx 68   144   65   <0.0001 68   146   65   0.0004 66   134   62   0.0306 
Total Outpatient Rx 1685   2015   1662   0.01 1869   2241   1839   0.0067 1295   1724   1274   0.0451 
                                            
Total Healthcare Services 10052   20671   9731   <0.0001 10559   21064   10180   <0.0001 9209   19202   8787   <0.0001 
Length of Stay (for inpatient 
stays) 
4   4   4   0.5566 4   5   4   0.3776 4   4   4   0.6667 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Table 47 Severe Exacerbation Within 6 Months, without Discontinuation, Baseline Healthcare Costs (Means) 
  LHP and PHP LHP PHP 
 
Baseline Characteristic 
Total SD Sev 
Exac  
1st 6 
mon 
SD No 
Sev 
Exac 
SD pval  Total SD Sev 
Exac  
1st 6 
mon 
SD No Sev 
Exac 
SD pval  Total SD Sev 
Exac  
1st 6 
mon 
SD No 
Sev 
Exac 
SD pval  
Number of Patients 2544   259   2285     1544   132   1412     1000   127   873     
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient  5484 9831 7137 11648 5297 9588 0.0149 5476 8503 8332 14455 5209 7670 0.0155 5497 11591 5894 7583 5439 12066 0.5632 
COPD Outpatient  2044 2380 2734 2733 1966 2324 <0.0001 1886 2152 2462 2245 1832 2136 0.0013 2289 2677 3015 3146 2183 2586 0.0051 
Total Outpatient  7529 10602 9870 12468 7263 10339 0.0013 7362 9196 10795 14846 7041 8415 0.0049 7786 12465 8910 9345 7622 12852 0.1706 
                                            
Non-COPD Inpatient 4629 18736 8350 26664 4207 17572 0.0152 6720 23274 14580 35585 5985 21644 0.0072 1400 6302 1875 7508 1331 6109 0.4364 
COPD Inpatient 5930 21203 12830 30572 5148 19722 <0.0001 4852 21401 11963 32548 4187 19932 0.0078 7595 20794 13731 28473 6702 19286 0.0079 
Total Inpatient 10559 29912 21181 43208 9355 27768 <0.0001 11572 33327 26543 51564 10172 30738 0.0005 8995 23621 15607 31574 8033 22088 0.01 
Total Medical Utilization 18087 33354 31051 48790 16618 30798 <0.0001 18934 36141 37338 58605 17214 32785 0.0002 16780 28488 24516 34912 15655 27270 0.0069 
                                            
Non-COPD Outpatient Rx 2230 3752 2282 2657 2224 3857 0.7543 2645 4263 2692 3052 2641 4360 0.8606 1590 2665 1856 2101 1551 2736 0.1451 
COPD Outpatient Rx 528 911 608 1028 519 897 0.1823 579 962 646 1014 573 957 0.4021 450 822 569 1044 433 783 0.1604 
Total Outpatient Rx 2758 3971 2890 3040 2743 4063 0.4769 3222 4458 3338 3319 3211 4551 0.6874 2041 2931 2425 2655 1985 2966 0.1135 
                                            
Total Healthcare Services 20845 34170 33941 49433 19361 31660 <0.0001 22156 37082 40676 59103 20425 33828 0.0002 18821 29010 26942 35706 17639 27730 0.0055 
Cost of Utilization ($ mean, SD)  - for those with utilization within category  
Non-COPD Outpatient  5601 9902 7220 11690 5415 9662 0.018 5581 8550 8396 14492 5314 7711 0.0177 5632 11700 5989 7606 5579 12188 0.6086 
COPD Outpatient  2180 2397 2866 2730 2101 2343 <0.0001 2022 2166 2621 2224 1966 2152 0.0013 2420 2694 3113 3149 2316 2606 0.0083 
Total Outpatient  7549 10609 9870 12468 7285 10347 0.0015 7376 9199 10795 14846 7056 8418 0.005 7817 12481 8910 9345 7657 12872 0.1829 
                                            
Non-COPD Inpatient 32439 39513 37288 46045 31517 38162 0.3723 36278 43088 40948 50029 35360 41645 0.4173 18182 14594 21651 15469 17604 14486 0.398 
COPD Inpatient 30416 39538 34615 42145 29408 38874 0.2469 29038 45218 36725 48716 27500 44447 0.2227 31910 32302 32904 36352 31626 31148 0.8002 
Total Inpatient 36202 46271 41559 53136 35043 44611 0.1911 37615 51323 47996 61593 35730 49083 0.1107 33688 35504 33594 39383 33715 34427 0.9817 
Total Medical Utilization 18109 33368 31051 48790 16640 30812 <0.0001 18934 36141 37338 58605 17214 32785 0.0002 16831 28516 24516 34912 15709 27302 0.0072 
                                            
Non-COPD Outpatient Rx 2357 3819 2345 2666 2359 3932 0.9437 2719 4299 2692 3052 2722 4401 0.9179 1757 2749 1964 2112 1725 2833 0.2738 
COPD Outpatient Rx 528 911 608 1028 519 897 0.1823 579 962 646 1014 573 957 0.4021 450 822 569 1044 433 783 0.1604 
Total Outpatient Rx 2758 3971 2890 3040 2743 4063 0.4769 3222 4458 3338 3319 3211 4551 0.6874 2041 2931 2425 2655 1985 2966 0.1135 
                                            
Total Healthcare Services 20845 34170 33941 49433 19361 31660 <0.0001 22156 37082 40676 59103 20425 33828 0.0002 18821 29010 26942 35706 17639 27730 0.0055 
Length of Stay (inpatient 
stays) 
6.4 7.0 6.1 6.6 6.5 7.1 0.6086 7.0 7.9 6.2 5.9 7.1 8.2 0.283 5.4 4.9 5.9 7.4 5.2 3.9 0.4448 
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Table 48 Severe Exacerbation Within 6 Months, without Discontinuation, Baseline Healthcare Costs (Medians) 
  LHP and PHP LHP PHP             
  
Total   Sev 
Exac  
1st 6 
mon 
  No 
Sev 
Exac 
  pval 
Comb vs 
Triple* 
Total   Sev 
Exac  
1st 6 
mon 
  No Sev 
Exac 
  pval 
Comb vs 
Triple* 
Total   Sev 
Exac  
1st 6 
mon 
  No 
Sev 
Exac 
  pval 
Comb vs 
Triple* 
Median                                           
Cost of Utilization ($)  
Non-COPD Outpatient  3114   4202   3036   0.0002 3324   5380   3231   0.0006 2846   3425   2803   0.0380 
COPD Outpatient  1352   2236   1287   <0.0001 1187   1935   1136   0.0001 1668   2537   1554   <0.0001 
Total Outpatient  4953   6965   4821   <0.0001 5008   7454   4837   <0.0001 4914   6252   4791   0.0021 
                                            
Non-COPD Inpatient  0   0   0   <0.0001 0   0   0   <0.0001 0   0   0   0.6314 
COPD Inpatient  0   0   0   <0.0001 0   0   0   <0.0001 0   0   0   <0.0001 
Total Inpatient  0   3755   0   <0.0001 0   8037   0   <0.0001 0   0   0   <0.0001 
Total Medical Utilization 7049   14076   6434   <0.0001 7532   15054   6743   <0.0001 6467   11806   5929   <0.0001 
                                            
Non-COPD Outpatient Rx 1129   1271   1098   0.0522 1453   1521   1449   0.2620 605   1143   550   0.0089 
COPD Outpatient Rx 98   166   90   0.0317 129   198   125   0.3784 54   140   46   0.0056 
Total Outpatient Rx 1672   2022   1637   0.0422 2025   2265   1983   0.1586 935   1541   840   0.0090 
                                            
Total Healthcare Services 9948   18138   9308   <0.0001 10949   20026   10357   <0.0001 8517   17272   8025   <0.0001 
                                            
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient  3223   4315   3150   0.0004 3412   5437   3354   0.001 2897   3536   2855   0.0493 
COPD Outpatient  1499   2310   1412   <0.0001 1350   2116   1280   <0.0001 1761   2554   1686   0.0002 
Total Outpatient  5005   6965   4832   <0.0001 5014   7454   4850   <0.0001 4932   6252   4803   0.0027 
                                            
Non-COPD Inpatient 18358   18908   18097   0.627 19777   19440   20069   0.9416 14252   18196   13906   0.3515 
COPD Inpatient 16931   18224   16582   0.3955 13869   15771   13490   0.2149 20532   21484   20522   0.7428 
Total Inpatient 19963   19286   20224   0.87 18339   19440   18138   0.3362 21797   19133   21925   0.3343 
Total Medical Utilization 7070   14076   6447   <0.0001 7532   15054   6743   <0.0001 6471   11806   5974   <0.0001 
                                            
Non-COPD Outpatient Rx 1251   1340   1238   0.2157 1514   1521   1513   0.5674 770   1252   730   0.0412 
COPD Outpatient Rx 98   166   90   0.0317 129   198   125   0.3784 54   140   46   0.0056 
Total Outpatient Rx 1672   2022   1637   0.0422 2025   2265   1983   0.1586 935   1541   840   0.009 
                                            
Total Healthcare Services 9948   18138   9308   <0.0001 10949   20026   10357   <0.0001 8517   17272   8025   <0.0001 
Length of Stay (inpatient 
stays) 
4   4   4   0.3008 4   4   4   0.5298 4   4   4   0.5745 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Moderate/Severe Exacerbations  
Status at Three Months 
Compared to the 146 patients with a severe exacerbation by the end of three 
months, among the 5,475 patients in the study sample, 12.0% (n=656) had at least one 
moderate or severe exacerbation by the end of three months (Table 49). Overall these 
patients were slightly younger (mean age 69.7 [SD, 12.0] compared to 70.7 [SD, 11.4], 
P=0.04), and a higher percentage were women (61.0% compared to 55.7%, P=0.01), or 
had Medicaid insurance coverage (14.8% compared to 11.6%, P=0.02). 
The association between cardiovascular disease and severe exacerbations that was 
observed at three months and six months was less apparent for the combined outcome of 
any moderate or severe exacerbation.  For example, among those having a 
moderate/severe exacerbation within three months, 18.6% had evidence of congestive 
heart failure in the baseline period compared to 16.2% among those not having any 
exacerbation (P=0.12), the percentages for heart failure were 20.6% compared to 17.7% 
(P=0.07); for atrial fibrillation the percentages were 10.7% compared to 9.6%, P=0.40.  
There was no difference in the percentages of patients with pulmonary circulation disease 
(11.6% compared to 11.4%, P=0.88), valvular disease (12.% compared to 11.4%, 
P=0.40), peripheral vascular disease (17.5% compared to 15.8%, P=0.27), or ischemic 
heart disease (23.9% compared to 24.6%, P=0.71). Having chest pain symptoms in the 
baseline period was however associated with having any exacerbation (37.2% compared 
to 31.1%, P=0.002). 
Several comorbidities continued to be significant risk factors. The prevalence of 
diabetes without chronic complications was 29.4% among patients having any moderate 
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or severe exacerbation compared to 23.1% among those without any exacerbation 
(P=0.0003); depression was 20.1% compared to 16.3% (P=0.01); deficiency anemias was 
17.8% compared to 13.6% (P=0.004); fluid and electrolyte disorders, 17.2% compared to 
11.9% (P=0.0001); psychoses, 13.9% compared to 10.0% (P=0.002). 
Asthma was found to have a significant association with severe exacerbations at 
three months and also was found to have a significant association with any exacerbation 
at three months. Its prevalence was 39.2% among those with any exacerbation compared 
to 32.3% among those not having an exacerbation (P=0.0004).  Significant prevalence 
differences were also found for emphysema (28.4% compared to 21.2%, P<0.0001), 
hypoxemia (41.5% compared to 35.7%, P=0.004), and pneumonia (46.5% compared to 
33.3%, P<0.0001). Overall, patients assessed to have a low complexity level for COPD 
were less prevalent among those having an exacerbation (37.5% compared to 51.8%, 
P<0.0001). 
Patients with no baseline period use of SABA were less prevalent among those 
having an exacerbation (36.4% compared to 43.1%, P=0.001) as were those with no 
oxygen use (53.7% compared to 42.2%, P<0.0001).  Although among those with some 
oxygen use there was a greater difference among those using oxygen for more than 50% 
of the year (35.8% compared to 26.4%, P<0.0001).  Having a “V” diagnosis (codes for 
supplementary classification of factors influencing health status and contact with health 
services) of “V46.1” indicating supplemental use of oxygen was significantly associated 
with having an exacerbation (10.1% compared to 5.2%, P<0.0001), though this code 
appeared to identify fewer people than procedure codes for durable medical equipment 
that indicated use of supplemental oxygen. 
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SAMA or SABA/SAMA use in the baseline period also was found to be more 
prevalent among those having an exacerbation (36.4% compared to 23.7%, P<0.0001), as 
was ICS use (37.3% compared to 31.3%, P<0.002). Patients who were among the triple 
therapy users at index were more prevalent among those having an exacerbation (11.3% 
compared to 8.5%, P=0.02). Among those having any exacerbation, 65.2% were using 
the same medication as at index compared to 55.0% among those not having an 
exacerbation (P<0.0001) and 26.5% had discontinued use of ICS/LABA or LAMA 
compared to 39.4% among those not having an exacerbation (P<0.0001). Patients who 
had 1-2 prescription claims for ICS/LABA or LAMA in the 27-52 weeks prior to the 
index date were also more likely to have an exacerbation (ICS/LABA: 9.5% compared to 
6.7%, P=0.01; LAMA: 3.7% compared to 2.1%, P=0.01), as were those who had a 
nebulizer treatment procedure in the baseline period (38.6% compared to 31.5%, 
P=0.0003). 
Report of dyspnea symptoms in the baseline period highlighted a higher risk for 
any exacerbation (breathlessness: 42.5% compared to 36.1%, P=0.002; shortness of 
breath: 21.0% compared to 15.8%, P=0.0006; wheezing 9.9% compared to 7.3%, 
P=0.02).  Patients with any cough symptom reported in the baseline period were also 
more prevalent among those having an exacerbation (43.8% compared to 34.8%, 
P<0.0001).  Patients who had spirometry in the baseline period were less prevalent: 
38.4% compared to 42.2%, P=0.07). 
And finally, prior exacerbation experience again was strongly associated with 
having an exacerbation in the first three months.  The prevalence among those having a 
moderate or severe exacerbation for a severe exacerbation in the two week period 
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immediately preceding the index date was 10.7% compared to 7.6% (P=0.006), and for a 
moderate exacerbation, 16.8% compared to 14.0% (P=0.05). For the 2-12 weeks prior to 
the index date, prevalences were 9.6% compared to 5.7% (P<0.0001) for a severe 
exacerbation and 22.7% compared to 15.5% for a moderate exacerbation (P<0.0001). 
Overall, 29.7% of those having a moderate and/or severe exacerbation in the first three 
months had a COPD-related inpatient stay in the year prior to the index date compared to 
19.1% of those not having an exacerbation (P<0.0001). 
Given that there was a higher prevalence of prior exacerbations among patients 
who had a moderate and/or severe exacerbation in the first three months it is not 
surprising that their mean and median COPD-related outpatient health services and 
outpatient pharmacy costs were higher than those not having an exacerbation in the first 
three months (Table 53 and Table 54). Among those incurring costs, median COPD-
related outpatient costs were $2,021 for patients having an exacerbation compared to 
$1,292 for those not having an exacerbation (P<0.0001) and median COPD-related 
outpatient pharmacy costs were $148 compared to $60 (P<0.0001).  Median COPD-
related inpatient service costs were not significantly different ($18,696 compared to 
$17,312, P=0.09). 
If the 26.5% who discontinued therapy prior to having a severe exacerbation or 
the end of the three months are excluded, the reduced study sample is 3,403 patients.  Of 
these patients, 482 had a moderate and/or severe exacerbation, or 14.2%.  This is slightly 
increased from the 12.0% that was observed for the entire sample. Table 50 provides a 
summary of baseline characteristics for this reduced study sample of those having and not 
having an exacerbation.  Almost all of the factors identified as significant for the entire 
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population of 5,475 were still significant in this reduced population, although there were 
some differences.   
There was now a significant difference in heart failure, with a higher prevalence 
observed among those having any exacerbation (20.5% compared to 16.8%, P<0.05), and 
there was now no difference in the prevalence of patients using triple therapy at index 
(13.5% compared to 11.1%, P=0.12).  Of note, the percentages with low complexity 
COPD were unchanged from the full analysis – 37.8% compared to 51.0% (P<0.0001). 
Prior exacerbation experience was still strongly associated with having a 
moderate and/or severe exacerbation in the three months following the index date, and 
differences were of similar magnitude.  For example, in the complete sample, 22.7% of 
those having an exacerbation also had a moderate exacerbation in the two weeks leading 
up to the index date compared to 15.5% among those who did not have an exacerbation 
in the three weeks following the index date (P<0.0001), and in the reduced sample the 
percentages were 16.0% compared to 12.6% (P=0.04). Percentages for prior severe 
exacerbation experience in the two weeks leading up to the index were 9.6% compared to 
5.7% (P<0.0001) and were now 10.8% compared to 6.7% (P=0.001). 
As before, baseline period costs were significantly higher for those having a 
moderate and/or severe exacerbation (Table 55 and Table 56).  Median costs for 
outpatient COPD-related services were $2,164 compared to $1,332 (P<0.0001), and for 
outpatient COPD-related pharmacy were $149 compared to $72 (P<0.0001). Mean total 
healthcare services were $28,517 (SD, $42,747) compared to $19,314 (SD, $30,719) and 
total median services were $13,865 compared to $9,445 (both statistics, P<0.0001). 
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Status at Six Months 
By six months 23.5% of the study sample (n=1,287) had experienced a moderate 
and/or severe exacerbation (Table 51). Overall, patients having an exacerbation were 
younger (mean age 69.9 years [SD, 11.8]) compared to those not having an exacerbation 
(mean age 70.7 years [SD, 11.4]) and were more likely to be women (60.7% compared to 
54.9%, P=0.0003) and to be individuals with Medicaid insurance coverage (14.1% 
compared to 11.3%, P=0.008). 
Comorbidities with significantly higher prevalences among those having an 
exacerbation were very similar to those observed at three months. High prevalences 
among those having an exacerbation were found for diabetes without chronic 
complications (27.4% compared to 22.7%, P=0.0007), heart failure (21.2% compared to 
17.0%, P=0.0006), depression (19.4% compared to 15.9%, P=0.003), deficiency anemias 
(17.6% compared to 13.1%, P<0.0001), fluid and electrolyte disorders (15.6% compared 
to 11.6%, P=0.0001), psychoses (12.7% compared to 9.8%, P=0.002), hypothyroidism 
(21.3% compared to 18.1%, P=0.01), and weight loss (7.8% compared to 5.4%, 
P=0.002). 
Asthma and emphysema continued to be more prevalent among those having an 
exacerbation (36.6% compared to 32.0%, P=0.002 and 26.6% compared to 20.7%, 
P<0.0001 respectively), as did hypoxemia and pneumonia (41.5% compared to 34.9%, 
P<0.0001 and 44.6% compared to 31.9%, p<0.0001 respectively).  Overall, among those 
having an exacerbation in the first six months, 39.5% were classified as low complexity 
COPD compared to 53.3% among those not having an exacerbation (P<0.0001). 
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As in the analysis for severe exacerbations within six months, patients who were 
using LAMA therapy at index were less prevalent among those having an exacerbation 
(31.7% compared to 36.6%, P=0.0001).  And again, patients with no baseline SABA or 
oxygen use were less prevalent among those having an exacerbation (34.8% compared to 
44.6%, P<0.0001 and 47.5% compared to 59.2%, P<0.0001 respectively). 
Among those having an exacerbation there was a higher percentage of patients 
who used SABA for more than 40% of the baseline period (23.7% compared to 14.8%, 
P<0.0001), \ any SAMA or SABA/SAMA baseline use (32.9% compared to 22.9%, 
P<0.0001), any ICS baseline use (36.5% compared to 30.6%, P<0.0001), or any baseline 
nebulizer procedure treatments (37.1% compared to 30.9%, P<0.0001). Report of 
baseline dyspnea symptoms was significantly higher among those having an 
exacerbation. For 2 or more encounters with a breathlessness diagnosis code the 
prevalence among those having an exacerbation was 20.1% compared to 17.0% (P=0.01), 
for 2 or more encounters with a shortness of breath diagnosis code the prevalences were 
20.6% compared to 15.1% (P<0.0001), and for wheezing, 10.3% compared to 6.8%, 
(P<0.0001). Report of baseline cough was prevalent P<0.0001), as was baseline report of 
chest pain (38.2% compared to 29.9%, P<0.0001), and other malaise/fatigue (28.8% 
compared to 24.1%, P=0.0006). 
Prior exacerbation experience continued to be significantly associated with 
experiencing an exacerbation after the index date.  Among those having an exacerbation 
within six months, 17.8% had a moderate exacerbation in the two weeks leading up to the 
index date compared to 13.2% of those not having an exacerbation (P<0.0001) and 10.3% 
had a severe exacerbation compared to 7.2% (P=0.0003).  Among individuals having a 
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moderate and/or severe exacerbation in the six months following the index date, 23.6% 
also had a moderate exacerbation in the 2-12 weeks prior to the index date compared to 
14.1% among those not having an exacerbation post-index (P<0.0001) and 9.3% had a 
severe exacerbation in the 2-12 weeks prior to the index date compared to 5.2% among 
those not having an exacerbation post-index (P<0.0001).  Overall, 28.7% of those having 
an exacerbation in the six months post-index had at least one COPD-related inpatient stay 
in the year prior to the index compared to 17.8% not having an exacerbation in the six 
month post-index period (P<0.0001).  Among those having an exacerbation, 45.4% had 
discontinued taking ICS/LABA or LAMA prior to having a severe exacerbation or the 
end of the six month period compared to 56.0% among those not having an exacerbation 
(P<0.0001). 
As was observed in the three month analysis, those having an exacerbation within 
six months had higher healthcare costs in the year prior to the index date.  Mean total 
health care utilization costs were estimated to be $26,616 (SD, $38,829) for those having 
an exacerbation compared to $19,897 (SD, $32,568) for those not having an exacerbation 
(P<0.0001) (Table 57). The median cost statistics were $13,074 compared to $9,281 
(P<0.0001) (Table 58).  Median baseline outpatient COPD-related utilization was $2,011 
among those having an exacerbation compared to $1,196 among those not having an 
exacerbation (p<0.0001) and median baseline outpatient COPD-related pharmacy was 
$133 compared to $53 (P<0.0001).  There was not a significant difference in baseline 
COPD-related median inpatients costs ($20,591 compared to $19,769, P=0.46). 
If the study sample is reduced to only those patients with evidence of still using 
ICS/LABA or LAMA prior to a severe exacerbation or the end of six months, the reduced 
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sample size is 2,544 patients, and of these, 27.6% (n=703) had a moderate and/or severe 
exacerbation by six months after the index date (Table 52).  For this reduced group there 
was no significant difference in mean age (70.4 years [SD, 11.3] compared to 71.0 years 
[SD, 10.8], P=0.22), but there was still a slightly lower percentage of men among those 
having an exacerbation compared to those not having an exacerbation (41.% compared to 
46.1%, P=0.04).  The percentage of patients with Medicaid coverage was still higher 
among those having an exacerbation (12.9% compared to 9.8%, P=0.02). 
Comorbidities that were more prevalent among those having an exacerbation 
compared to those not having an exacerbation consisted of: diabetes without chronic 
complications (25.7% compared to 20.8%, P=0.007), heart failure (21.9% compared to 
15.4%, P<0.0001), congestive heart failure (18.3% compared to 14.2%, P=0.01), 
depression (19.5% compared to 14.2%, P=0.001), deficiency anemias (18.3% compared 
to 12.0%, P<0.0001), fluid and electrolyte disorders (15.8% compared to 10.0%, 
P<0.0001), valvular disease (14.1% compared to 10.1%, P=0.004), and weight loss (7.8% 
compared to 4.5%, P=0.0008). 
The prevalence of asthma was no longer significantly higher among those having 
an exacerbation (36.1% compared to 32.6%, P=0.09), but the prevalence of emphysema 
remained significantly higher (29.3% compared to 23.2%, P=0.002). Prevalence of 
hypoxemia and history of pneumonia remained significantly higher (42.7% compared to 
36.1%, P=0.002 and 44.2% compared to 29.5%, P<0.0001 respectively).  Overall those 
with low complexity COPD constituted 36.4% of those having an exacerbation compared 
to 53.7% among those not having an exacerbation (P<0.0001). 
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In the reduced sample, as in the analysis of severe exacerbations, there was no 
significant difference between those having an exacerbation and those not in the use of 
triple therapy at index (13.5% compared to 11.7%, P=0.22), and the percentage with 
LAMA use at index was again lower among those having an exacerbation (32.9% 
compared to 40.2%, P=0.0006). 
The associations for baseline SABA use, SAMA and or SABA/SAMA use, 
oxygen use, ICS use, and nebulizer treatments were all similar to previous findings. Prior 
exacerbation experience also continued to be significantly associated with post-index 
moderate and/or severe exacerbation experience.  This carried through in the baseline 
healthcare costs that were estimated for the reduced study sample.  Mean total healthcare 
services for those having an exacerbation in the six months post-index were $27,443 (SD, 
$42,284) compared to $18,326 (SD, $30,143) for those not having an exacerbation 
(P<0.0001) (Table 59).  Median estimated baseline total healthcare costs were $14,125 
for those having an exacerbation compared to $8,708 for those not having an 
exacerbation (Table 60), with median COPD-related outpatient services estimated to be 
$2,206 for those having an exacerbation compared to $1,287 for those not having an 
exacerbation (P<0.0001) and median COPD-related outpatient pharmacy estimated to be 
$146 for those having an exacerbation compared to $77 for those not having an 
exacerbation (P=0.0009).
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Table 49 Baseline Characteristics: Any Moderate/Severe Exacerbation in First Three Months 
 
LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  
Number of Patients 5475   656   4819     3599   403   3196     1876   253   1623     
Age Categories                                           
age 40-54 584 10.7 82 12.5 502 10.4 0.1049 332 9.2 43 10.7 289 9.0 0.2874 252 13.4 39 15.4 213 13.1 0.3202 
age 55-64 1026 18.7 138 21.0 888 18.4 0.1081 591 16.4 67 16.6 524 16.4 0.9066 435 23.2 71 28.1 364 22.4 0.0482 
age 65-74 1637 29.9 181 27.6 1456 30.2 0.1687 1059 29.4 112 27.8 947 29.6 0.4452 578 30.8 69 27.3 509 31.4 0.1901 
age 75 and older 2228 40.7 255 38.9 1973 40.9 0.3113 1617 44.9 181 44.9 1436 44.9 0.9945 611 32.6 74 29.2 537 33.1 0.2257 
age (Mean, SD) 70.55 11.51 69.67 11.97 70.67 11.44 0.0376 71.58 11.31 71.08 11.48 71.64 11.29 0.3455 68.57 11.62 67.43 12.41 68.75 11.48 0.0937 
                                            
Men 2393 43.7 256 39.0 2137 44.3 0.0099 1616 44.9 162 40.2 1454 45.5 0.0440 777 41.4 94 37.2 683 42.1 0.1388 
                                            
Quarter of Year for Index Date             <0.0001             0.1299             <0.0001 
Q1 1645 30.0 180 27.4 1465 30.4   1111 30.9 120 29.8 991 31.0   534 28.5 60 23.7 474 29.2   
Q2 1160 21.2 113 17.2 1047 21.7   800 22.2 75 18.6 725 22.7   360 19.2 38 15.0 322 19.8   
Q3 1192 21.8 135 20.6 1057 21.9   846 23.5 99 24.6 747 23.4   346 18.4 36 14.2 310 19.1   
Q4 1478 27.0 228 34.8 1250 25.9   842 23.4 109 27.0 733 22.9   636 33.9 119 47.0 517 31.9   
                                            
Months of enrollment post-Index             0.0014             0.0545             0.0136 
7 78 1.4 10 1.5 68 1.4   44 1.2 4 1.0 40 1.3   34 1.8 6 2.4 28 1.7   
8 66 1.2 16 2.4 50 1.0   39 1.1 9 2.2 30 0.9   27 1.4 7 2.8 20 1.2   
9 85 1.6 7 1.1 78 1.6   50 1.4 3 0.7 47 1.5   35 1.9 4 1.6 31 1.9   
10 99 1.8 9 1.4 90 1.9   70 1.9 7 1.7 63 2.0   29 1.5 2 0.8 27 1.7   
11 117 2.1 9 1.4 108 2.2   95 2.6 7 1.7 88 2.8   22 1.2 2 0.8 20 1.2   
12 92 1.7 8 1.2 84 1.7   71 2.0 5 1.2 66 2.1   21 1.1 3 1.2 18 1.1   
13 99 1.8 17 2.6 82 1.7   67 1.9 14 3.5 53 1.7   32 1.7 3 1.2 29 1.8   
14 111 2.0 22 3.4 89 1.8   75 2.1 10 2.5 65 2.0   36 1.9 12 4.7 24 1.5   
15 97 1.8 18 2.7 79 1.6   62 1.7 10 2.5 52 1.6   35 1.9 8 3.2 27 1.7   
16 127 2.3 7 1.1 120 2.5   82 2.3 3 0.7 79 2.5   45 2.4 4 1.6 41 2.5   
17 114 2.1 15 2.3 99 2.1   77 2.1 9 2.2 68 2.1   37 2.0 6 2.4 31 1.9   
18 106 1.9 16 2.4 90 1.9   72 2.0 12 3.0 60 1.9   34 1.8 4 1.6 30 1.8   
19 104 1.9 10 1.5 94 2.0   69 1.9 6 1.5 63 2.0   35 1.9 4 1.6 31 1.9   
20 105 1.9 18 2.7 87 1.8   67 1.9 7 1.7 60 1.9   38 2.0 11 4.3 27 1.7   
21 105 1.9 14 2.1 91 1.9   63 1.8 8 2.0 55 1.7   42 2.2 6 2.4 36 2.2   
22 114 2.1 13 2.0 101 2.1   79 2.2 10 2.5 69 2.2   35 1.9 3 1.2 32 2.0   
23 91 1.7 6 0.9 85 1.8   64 1.8 4 1.0 60 1.9   27 1.4 2 0.8 25 1.5   
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LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  
Number of Patients 5475   656   4819     3599   403   3196     1876   253   1623     
24 3765 68.8 441 67.2 3324 69.0   2453 68.2 275 68.2 2178 68.1   1312 69.9 166 65.6 1146 70.6   
Insurance at Index                                           
Commercial 1778 32.5 221 33.7 1557 32.3 0.4791 1376 38.2 164 40.7 1212 37.9 0.2805 402 21.4 57 22.5 345 21.3 0.6463 
Medicaid 655 12.0 97 14.8 558 11.6 0.0176 284 7.9 31 7.7 253 7.9 0.8752 371 19.8 66 26.1 305 18.8 0.0067 
Medicare 3071 56.1 342 52.1 2729 56.6 0.0295 1968 54.7 212 52.6 1756 54.9 0.3742 1103 58.8 130 51.4 973 60.0 0.0100 
                                            
CMS comorbidities                                            
acute myocardial infarction 
(AMI) 
175 3.2 25 3.8 150 3.1 0.3401 114 3.2 13 3.2 101 3.2 0.9435 61 3.3 12 4.7 49 3.0 0.1504 
Alzheimer’s 189 3.5 27 4.1 162 3.4 0.3209 111 3.1 16 4.0 95 3.0 0.2749 78 4.2 11 4.3 67 4.1 0.8707 
atrial fibrillation 534 9.8 70 10.7 464 9.6 0.3986 362 10.1 45 11.2 317 9.9 0.4326 172 9.2 25 9.9 147 9.1 0.6727 
cancers 370 6.8 50 7.6 320 6.6 0.3474 265 7.4 34 8.4 231 7.2 0.3812 105 5.6 16 6.3 89 5.5 0.5886 
lung cancer 113 2.1 15 2.3 98 2.0 0.6690 75 2.1 9 2.2 66 2.1 0.8238 38 2.0 6 2.4 32 2.0 0.6745 
chronic kidney disease 870 15.9 103 15.7 767 15.9 0.8876 626 17.4 71 17.6 555 17.4 0.8998 244 13.0 32 12.6 212 13.1 0.8555 
diabetes 1358 24.8 197 30.0 1161 24.1 0.0010 884 24.6 111 27.5 773 24.2 0.1401 474 25.3 86 34.0 388 23.9 0.0006 
heart failure 986 18.0 135 20.6 851 17.7 0.0679 645 17.9 82 20.3 563 17.6 0.1779 341 18.2 53 20.9 288 17.7 0.2191 
ischemic heart dis. (IHD; incl. 
AMI) 
1343 24.5 157 23.9 1186 24.6 0.7050 908 25.2 100 24.8 808 25.3 0.8386 435 23.2 57 22.5 378 23.3 0.7898 
rheumatoid/osteo arthritis 
(RA/OA) 
1443 26.4 192 29.3 1251 26.0 0.0711 954 26.5 120 29.8 834 26.1 0.1146 489 26.1 72 28.5 417 25.7 0.3514 
stroke/TIA 387 7.1 52 7.9 335 7.0 0.3606 256 7.1 35 8.7 221 6.9 0.1927 131 7.0 17 6.7 114 7.0 0.8596 
no CMS Comorbidity 1860 34.0 202 30.8 1658 34.4 0.0668 1194 33.2 124 30.8 1070 33.5 0.2762 666 35.5 78 30.8 588 36.2 0.0951 
                                            
Elixhauser comorbidities                                            
AIDS         10 0.2 0.2429         9 0.3 0.2861         1 0.1 0.6929 
alcohol abuse 191 3.5 34 5.2 157 3.3 0.0117 108 3.0 14 3.5 94 2.9 0.5547 83 4.4 20 7.9 63 3.9 0.0038 
chronic blood loss anemia 49 0.9 11 1.7 38 0.8 0.0234 28 0.8 4 1.0 24 0.8 0.6029 21 1.1 7 2.8 14 0.9 0.0074 
coagulopathy 163 3.0 29 4.4 134 2.8 0.0204 96 2.7 15 3.7 81 2.5 0.1632 67 3.6 14 5.5 53 3.3 0.0706 
congestive heart failure 903 16.5 122 18.6 781 16.2 0.1216 616 17.1 77 19.1 539 16.9 0.2602 287 15.3 45 17.8 242 14.9 0.2372 
deficiency anemias 773 14.1 117 17.8 656 13.6 0.0036 498 13.8 73 18.1 425 13.3 0.0083 275 14.7 44 17.4 231 14.2 0.1865 
depression 917 16.7 132 20.1 785 16.3 0.0137 537 14.9 66 16.4 471 14.7 0.3839 380 20.3 66 26.1 314 19.3 0.0131 
diabetes (wo/chr complications) 1304 23.8 193 29.4 1111 23.1 0.0003 867 24.1 115 28.5 752 23.5 0.0268 437 23.3 78 30.8 359 22.1 0.0023 
diabetes (w/chr complications) 442 8.1 59 9.0 383 7.9 0.3561 332 9.2 39 9.7 293 9.2 0.7390 110 5.9 20 7.9 90 5.5 0.1373 
drug abuse 181 3.3 25 3.8 156 3.2 0.4406 115 3.2 13 3.2 102 3.2 0.9706 66 3.5 12 4.7 54 3.3 0.2555 
fluid and electrolyte disorders 686 12.5 113 17.2 573 11.9 0.0001 422 11.7 59 14.6 363 11.4 0.0536 264 14.1 54 21.3 210 12.9 0.0003 
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LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  
Number of Patients 5475   656   4819     3599   403   3196     1876   253   1623     
hypertension 3374 61.6 420 64.0 2954 61.3 0.1781 2301 63.9 266 66.0 2035 63.7 0.3583 1073 57.2 154 60.9 919 56.6 0.2042 
hypothyroidism 1032 18.8 145 22.1 887 18.4 0.0231 684 19.0 91 22.6 593 18.6 0.0522 348 18.6 54 21.3 294 18.1 0.2190 
liver disease 212 3.9 28 4.3 184 3.8 0.5751 144 4.0 15 3.7 129 4.0 0.7617 68 3.6 13 5.1 55 3.4 0.1661 
lymphoma 46 0.8 4 0.6 42 0.9 0.4907 31 0.9 3 0.7 28 0.9 0.7875 15 0.8 1 0.4 14 0.9 0.4375 
metastatic cancer 56 1.0 4 0.6 52 1.1 0.2624 41 1.1 2 0.5 39 1.2 0.1968 15 0.8 2 0.8 13 0.8 0.9861 
obesity 717 13.1 75 11.4 642 13.3 0.1784 480 13.3 39 9.7 441 13.8 0.0218 237 12.6 36 14.2 201 12.4 0.4114 
other neurological disorders 514 9.4 71 10.8 443 9.2 0.1792 363 10.1 46 11.4 317 9.9 0.3474 151 8.0 25 9.9 126 7.8 0.2494 
paralysis 68 1.2 9 1.4 59 1.2 0.7487 48 1.3 7 1.7 41 1.3 0.4539 20 1.1 2 0.8 18 1.1 0.6463 
peripheral vascular disease 878 16.0 115 17.5 763 15.8 0.2664 614 17.1 76 18.9 538 16.8 0.3085 264 14.1 39 15.4 225 13.9 0.5091 
psychoses 573 10.5 91 13.9 482 10.0 0.0024 399 11.1 57 14.1 342 10.7 0.0380 174 9.3 34 13.4 140 8.6 0.0141 
pulmonary circulation disease 625 11.4 76 11.6 549 11.4 0.8841 435 12.1 48 11.9 387 12.1 0.9084 190 10.1 28 11.1 162 10.0 0.5945 
renal failure 468 8.5 43 6.6 425 8.8 0.0516 338 9.4 26 6.5 312 9.8 0.0318 130 6.9 17 6.7 113 7.0 0.8874 
rheumatoid arthritis/collagen vas 343 6.3 47 7.2 296 6.1 0.3107 209 5.8 29 7.2 180 5.6 0.2059 134 7.1 18 7.1 116 7.1 0.9850 
solid tumor wo/metastasis 533 9.7 62 9.5 471 9.8 0.7937 368 10.2 42 10.4 326 10.2 0.8900 165 8.8 20 7.9 145 8.9 0.5909 
ulcers 7 0.1 2 0.3 5 0.1 0.1762 3 0.1 1 0.2 2 0.1 0.2238 4 0.2 1 0.4 3 0.2 0.4998 
valvular disease 630 11.5 82 12.5 548 11.4 0.3955 478 13.3 51 12.7 427 13.4 0.6942 152 8.1 31 12.3 121 7.5 0.0093 
weight loss 327 6.0 45 6.9 282 5.9 0.3068 219 6.1 30 7.4 189 5.9 0.2258 108 5.8 15 5.9 93 5.7 0.8996 
any Elixhauser diagnosis 5028 91.8 612 93.3 4416 91.6 0.1463 3333 92.6 379 94.0 2954 92.4 0.2424 1695 90.4 233 92.1 1462 90.1 0.3127 
Other comorbidities                                           
asthma 1813 33.1 257 39.2 1556 32.3 0.0004 1166 32.4 153 38.0 1013 31.7 0.0113 647 34.5 104 41.1 543 33.5 0.0173 
hypoxemia 1994 36.4 272 41.5 1722 35.7 0.0042 1229 34.1 155 38.5 1074 33.6 0.0527 765 40.8 117 46.2 648 39.9 0.0571 
pneumonia 1908 34.8 305 46.5 1603 33.3 <0.0001 1348 37.5 202 50.1 1146 35.9 <0.0001 560 29.9 103 40.7 457 28.2 <0.0001 
influenza 178 3.3 21 3.2 157 3.3 0.9387 124 3.4 13 3.2 111 3.5 0.7976 54 2.9 8 3.2 46 2.8 0.7718 
                                            
COPD Complexity ^                                           
Low complexity 2740 50.0 246 37.5 2494 51.8 <0.0001 1761 48.9 140 34.7 1621 50.7 <0.0001 979 52.2 106 41.9 873 53.8 0.0004 
Med complexity 2510 45.8 390 59.5 2120 44.0 <0.0001 1686 46.8 251 62.3 1435 44.9 <0.0001 824 43.9 139 54.9 685 42.2 0.0001 
High complexity 225 4.1 20 3.0 205 4.3 0.1446 152 4.2 12 3.0 140 4.4 0.1870 73 3.9 8 3.2 65 4.0 0.5190 
Emphysema diagnosis (492.x) 1210 22.1 186 28.4 1024 21.2 <0.0001 694 19.3 99 24.6 595 18.6 0.0043 516 27.5 87 34.4 429 26.4 0.0084 
                                            
COPD Medications                                            
index ICSLABA 3052 55.7 376 57.3 2676 55.5 0.3873 2129 59.2 244 60.5 1885 59.0 0.5467 923 49.2 132 52.2 791 48.7 0.3091 
index LAMA 1939 35.4 206 31.4 1733 36.0 0.0220 1158 32.2 116 28.8 1042 32.6 0.1220 781 41.6 90 35.6 691 42.6 0.0356 
index triple 484 8.8 74 11.3 410 8.5 0.0189 312 8.7 43 10.7 269 8.4 0.1298 172 9.2 31 12.3 141 8.7 0.0676 
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LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
Mon 
% No 
Mod 
Sev 
% pval  
Number of Patients 5475   656   4819     3599   403   3196     1876   253   1623     
SABA use                                           
no SABA use 2314 42.3 239 36.4 2075 43.1 0.0013 1479 41.1 139 34.5 1340 41.9 0.0042 835 44.5 100 39.5 735 45.3 0.0864 
SABA <=15% of year 1435 26.2 166 25.3 1269 26.3 0.5742 973 27.0 95 23.6 878 27.5 0.0968 462 24.6 71 28.1 391 24.1 0.1726 
SABA <=40% of year 803 14.7 102 15.5 701 14.5 0.4961 555 15.4 73 18.1 482 15.1 0.1121 248 13.2 29 11.5 219 13.5 0.3750 
SABA >40% of year 923 16.9 149 22.7 774 16.1 <0.0001 592 16.4 96 23.8 496 15.5 <0.0001 331 17.6 53 20.9 278 17.1 0.1382 
SAMA use                                           
any ipratropium (SAMA) 632 11.5 112 17.1 520 10.8 <0.0001 391 10.9 66 16.4 325 10.2 0.0002 241 12.8 46 18.2 195 12.0 0.0064 
any SABA/SAMA 876 16.0 151 23.0 725 15.0 <0.0001 591 16.4 99 24.6 492 15.4 <0.0001 285 15.2 52 20.6 233 14.4 0.0106 
any SAMA or SABA/SAMA 1381 25.2 239 36.4 1142 23.7 <0.0001 901 25.0 148 36.7 753 23.6 <0.0001 480 25.6 91 36.0 389 24.0 <0.0001 
Other COPD medications                                           
any ICS 1752 32.0 245 37.3 1507 31.3 0.0018 1143 31.8 149 37.0 994 31.1 0.0170 609 32.5 96 37.9 513 31.6 0.0453 
any LABA 227 4.1 31 4.7 196 4.1 0.4274 118 3.3 14 3.5 104 3.3 0.8153 109 5.8 17 6.7 92 5.7 0.5063 
any methylxanthines 87 1.6 12 1.8 75 1.6 0.6000 29 0.8 6 1.5 23 0.7 0.1036 58 3.1 6 2.4 52 3.2 0.4768 
Any use of above COPD 
medications 
2688 49.1 386 58.8 2302 47.8 <0.0001 1748 48.6 239 59.3 1509 47.2 <0.0001 940 50.1 147 58.1 793 48.9 0.0062 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 4868 88.9 560 85.4 4308 89.4 0.0020 3206 89.1 333 82.6 2873 89.9 <0.0001 1662 88.6 227 89.7 1435 88.4 0.5431 
1-2 Rxs ICSLABA (wks 27-52) 387 7.1 62 9.5 325 6.7 0.0111 255 7.1 47 11.7 208 6.5 0.0001 132 7.0 15 5.9 117 7.2 0.4590 
>2 Rxs ICSLABA (wks 27-52) 220 4.0 34 5.2 186 3.9 0.1054 138 3.8 23 5.7 115 3.6 0.0377 82 4.4 11 4.3 71 4.4 0.9845 
No LAMA in prior year 5280 96.4 624 95.1 4656 96.6 0.0525 3472 96.5 380 94.3 3092 96.7 0.0119 1808 96.4 244 96.4 1564 96.4 0.9508 
1-2 Rxs LAMA (wks 27-52) 124 2.3 24 3.7 100 2.1 0.0105 86 2.4 17 4.2 69 2.2 0.0107 38 2.0 7 2.8 31 1.9 0.3682 
>2 Rxs LAMA (wks 27-52) 71 1.3 8 1.2 63 1.3 0.8520 41 1.1 6 1.5 35 1.1 0.4828 30 1.6 2 0.8 28 1.7 0.2703 
Oxygen Use                                           
no oxygen 3090 56.4 304 46.3 2786 57.8 <0.0001 2097 58.3 194 48.1 1903 59.5 <0.0001 993 52.9 110 43.5 883 54.4 0.0012 
oxygen <=50% of year 876 16.0 117 17.8 759 15.8 0.1717 619 17.2 77 19.1 542 17.0 0.2816 257 13.7 40 15.8 217 13.4 0.2938 
oxygen >50% of year 1509 27.6 235 35.8 1274 26.4 <0.0001 883 24.5 132 32.8 751 23.5 <0.0001 626 33.4 103 40.7 523 32.2 0.0077 
                                            
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 3454 63.1 377 57.5 3077 63.9 0.0015 2101 58.4 216 53.6 1885 59.0 0.0389 1353 72.1 161 63.6 1192 73.4 0.0012 
1 period breathlessness 1051 19.2 145 22.1 906 18.8 0.0439 757 21.0 95 23.6 662 20.7 0.1844 294 15.7 50 19.8 244 15.0 0.0543 
>1 period breathlessness 970 17.7 134 20.4 836 17.3 0.0527 741 20.6 92 22.8 649 20.3 0.2380 229 12.2 42 16.6 187 11.5 0.0217 
Shortness of Breath                                           
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LHP & PHP           LHP             PHP             
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Number of Patients 5475   656   4819     3599   403   3196     1876   253   1623     
no periods shortness breath 3450 63.0 377 57.5 3073 63.8 0.0017 2260 62.8 234 58.1 2026 63.4 0.0371 1190 63.4 143 56.5 1047 64.5 0.0141 
1 period shortness breath 1128 20.6 141 21.5 987 20.5 0.5475 785 21.8 93 23.1 692 21.7 0.5139 343 18.3 48 19.0 295 18.2 0.7606 
>1 period shortness breath 897 16.4 138 21.0 759 15.8 0.0006 554 15.4 76 18.9 478 15.0 0.0408 343 18.3 62 24.5 281 17.3 0.0059 
any wheezing 419 7.7 65 9.9 354 7.3 0.0205 302 8.4 38 9.4 264 8.3 0.4251 117 6.2 27 10.7 90 5.5 0.0017 
any dyspnea 3057 55.8 413 63.0 2644 54.9 <0.0001 2126 59.1 259 64.3 1867 58.4 0.0244 931 49.6 154 60.9 777 47.9 0.0001 
supplemental oxygen use (V46.2) 317 5.8 66 10.1 251 5.2 <0.0001 112 3.1 23 5.7 89 2.8 0.0015 205 10.9 43 17.0 162 10.0 0.0009 
Other symptoms                                           
chest pain unspecified 1662 30.4 234 35.7 1428 29.6 0.0016 1082 30.1 136 33.7 946 29.6 0.0871 580 30.9 98 38.7 482 29.7 0.0038 
painful respiratory 272 5.0 47 7.2 225 4.7 0.0058 165 4.6 23 5.7 142 4.4 0.2529 107 5.7 24 9.5 83 5.1 0.0053 
precordial pain 107 2.0 17 2.6 90 1.9 0.2089 72 2.0 14 3.5 58 1.8 0.0250 35 1.9 3 1.2 32 2.0 0.3902 
any chest pain 1742 31.8 244 37.2 1498 31.1 0.0016 1137 31.6 143 35.5 994 31.1 0.0745 605 32.2 101 39.9 504 31.1 0.0050 
chronic fatigue 85 1.6 8 1.2 77 1.6 0.4621 67 1.9 6 1.5 61 1.9 0.5568 18 1.0 2 0.8 16 1.0 0.7669 
other malaise/fatigue 1379 25.2 196 29.9 1183 24.5 0.0032 884 24.6 119 29.5 765 23.9 0.0140 495 26.4 77 30.4 418 25.8 0.1162 
difficulty walking 139 2.5 22 3.4 117 2.4 0.1573 105 2.9 17 4.2 88 2.8 0.0996 34 1.8 5 2.0 29 1.8 0.8336 
memory loss 132 2.4 16 2.4 116 2.4 0.9602 94 2.6 10 2.5 84 2.6 0.8617 38 2.0 6 2.4 32 2.0 0.6745 
cough 1963 35.9 287 43.8 1676 34.8 <0.0001 1394 38.7 198 49.1 1196 37.4 <0.0001 569 30.3 89 35.2 480 29.6 0.0713 
hemoptysis 76 1.4 10 1.5 66 1.4 0.7505 52 1.4 7 1.7 45 1.4 0.6020 24 1.3 3 1.2 21 1.3 0.8868 
                                            
Procedures                                           
chest CT 822 15.0 106 16.2 716 14.9 0.3816 551 15.3 61 15.1 490 15.3 0.9183 271 14.4 45 17.8 226 13.9 0.1041 
chest x-ray 3432 62.7 453 69.1 2979 61.8 0.0003 2234 62.1 280 69.5 1954 61.1 0.0011 1198 63.9 173 68.4 1025 63.2 0.1076 
echocardiography 1113 20.3 133 20.3 980 20.3 0.9706 819 22.8 86 21.3 733 22.9 0.4717 294 15.7 47 18.6 247 15.2 0.1717 
EKG 2452 44.8 332 50.6 2120 44.0 0.0014 1621 45.0 202 50.1 1419 44.4 0.0295 831 44.3 130 51.4 701 43.2 0.0147 
heart catheterization 71 1.3 9 1.4 62 1.3 0.8561 51 1.4 5 1.2 46 1.4 0.7506 20 1.1 4 1.6 16 1.0 0.3912 
nebulizer treatment 1771 32.3 253 38.6 1518 31.5 0.0003 1326 36.8 174 43.2 1152 36.0 0.0052 445 23.7 79 31.2 366 22.6 0.0026 
non-invasive ventilator 339 6.2 48 7.3 291 6.0 0.2024 210 5.8 28 6.9 182 5.7 0.3118 129 6.9 20 7.9 109 6.7 0.4869 
spirometry 2284 41.7 252 38.4 2032 42.2 0.0675 1578 43.8 164 40.7 1414 44.2 0.1762 706 37.6 88 34.8 618 38.1 0.3143 
any vaccination (flu or 
pneumonia) 
2632 48.1 312 47.6 2320 48.1 0.7796 1799 50.0 202 50.1 1597 50.0 0.9531 833 44.4 110 43.5 723 44.5 0.7503 
                                            
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 783 14.3 110 16.8 673 14.0 0.0544 525 14.6 70 17.4 455 14.2 0.0931 258 13.8 40 15.8 218 13.4 0.3069 
any severe 434 7.9 70 10.7 364 7.6 0.0056 266 7.4 34 8.4 232 7.3 0.3945 168 9.0 36 14.2 132 8.1 0.0016 
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Number of Patients 5475   656   4819     3599   403   3196     1876   253   1623     
any other hospitalizations* 124 2.3 18 2.7 106 2.2 0.3794 112 3.1 14 3.5 98 3.1 0.6570 12 0.6 4 1.6 8 0.5 0.0435 
Prior 2-12 weeks                                           
any moderate 894 16.3 149 22.7 745 15.5 <0.0001 585 16.3 89 22.1 496 15.5 0.0008 309 16.5 60 23.7 249 15.3 0.0008 
any severe 337 6.2 63 9.6 274 5.7 <0.0001 179 5.0 34 8.4 145 4.5 0.0007 158 8.4 29 11.5 129 7.9 0.0612 
any other hospitalizations* 209 3.8 33 5.0 176 3.7 0.0839 169 4.7 22 5.5 147 4.6 0.4421 40 2.1 11 4.3 29 1.8 0.0087 
Prior 13-52 weeks                                           
no moderate 4200 76.7 423 64.5 3777 78.4 <0.0001 2733 75.9 247 61.3 2486 77.8 <0.0001 1467 78.2 176 69.6 1291 79.5 0.0003 
1 moderate 1018 18.6 176 26.8 842 17.5 <0.0001 694 19.3 119 29.5 575 18.0 <0.0001 324 17.3 57 22.5 267 16.5 0.0174 
>1 moderate 257 4.7 57 8.7 200 4.2 <0.0001 172 4.8 37 9.2 135 4.2 <0.0001 85 4.5 20 7.9 65 4.0 0.0055 
any severe 409 7.5 78 11.9 331 6.9 <0.0001 215 6.0 41 10.2 174 5.4 0.0002 194 10.3 37 14.6 157 9.7 0.0161 
any other hospitalizations* 384 7.0 65 9.9 319 6.6 0.0020 313 8.7 54 13.4 259 8.1 0.0004 71 3.8 11 4.3 60 3.7 0.6138 
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 852 15.6 120 18.3 732 15.2 0.0397 687 19.1 93 23.1 594 18.6 0.0306 165 8.8 27 10.7 138 8.5 0.2572 
COPD Inpatient (Any) 1117 20.4 195 29.7 922 19.1 <0.0001 636 17.7 102 25.3 534 16.7 <0.0001 481 25.6 93 36.8 388 23.9 <0.0001 
Total Inpatient (Any) 1690 30.9 263 40.1 1427 29.6 <0.0001 1153 32.0 161 40.0 992 31.0 0.0003 537 28.6 102 40.3 435 26.8 <0.0001 
Treatment Therapy Use (Index 
until period prior to Sev Exac  or 
end of evaluated time period) 
                                          
Same as Index Trmt 3097 56.6 428 65.2 2669 55 <0.0001 1919 53.3 244 60.5 1675 52 0.0020 1178 62.8 184 72.7 994 61 0.0004 
No evidence Any Trmt 2072 37.8 174 26.5 1898 39.4 <0.0001 1472 40.9 121 30.0 1351 42.3 <0.0001 600 32.0 53 20.9 547 33.7 <0.0001 
Different Trmt from Index 306 5.6 54 8 252 5.2 0.0017 208 5.8 38 9.4 170 5.3 0.0009 98 5.2 16 6 82 5.1 0.3978 
Now using Triple 150 2.7 33 5.0 117 2.4 0.0001 101 2.8 22 5.5 79 2.5 0.0006 49 2.6 11 4.3 38 2.3 0.0627 
No longer using Triple 102 1.9 14 2.1 88 1.8 0.5841 65 1.8 11 2.7 54 1.7 0.1396 37 2.0 3 1.2 34 2.1 0.3334 
Switched between ICSLABA 
and LAMA 
54 1.0 7 1.1 47 1.0 0.8234 42 1.2 5 1.2 37 1.2 0.8838 12 0.6 2 0.8 10 0.6 0.7462 
LHP enrollee 3599 65.7 403 61.4 3196 66.3 0.0133                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 50 Baseline Characteristics: Any Moderate/Severe Exacerbation in First 3 Months, Without Discontinuation 
 
LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 3 
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% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 3 
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% No 
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% pval  Total % Mod 
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Number of Patients 3403   482   2921     2127   282   1845     1276   200   1076     
Age Categories                                           
age 40-54 326 9.6 57 11.8 269 9.2 0.0706 170 8.0 29 10.3 141 7.6 0.1277 156 12.2 28 14.0 128 11.9 0.4042 
age 55-64 646 19.0 110 22.8 536 18.3 0.0204 348 16.4 50 17.7 298 16.2 0.5045 298 23.4 60 30.0 238 22.1 0.0156 
age 65-74 1039 30.5 129 26.8 910 31.2 0.0525 640 30.1 76 27.0 564 30.6 0.2172 399 31.3 53 26.5 346 32.2 0.1131 
age 75 and older 1392 40.9 186 38.6 1206 41.3 0.2643 969 45.6 127 45.0 842 45.6 0.8502 423 33.2 59 29.5 364 33.8 0.2324 
age (Mean, SD) 70.74 11.27 69.56 11.82 70.94 11.16 0.0129 71.86 11.06 71.05 11.60 71.98 10.98 0.1889 68.88 11.37 67.46 11.85 69.15 11.26 0.0537 
                                            
Men 1509 44.3 198 41.1 1311 44.9 0.1194 962 45.2 121 42.9 841 45.6 0.4006 547 42.9 77 38.5 470 43.7 0.1740 
                                            
Quarter of Year for Index Date             <0.0001             0.3141             <0.0001 
Q1 1030 30.3 139 28.8 891 30.5   645 30.3 89 31.6 556 30.1   385 30.2 50 25.0 335 31.1   
Q2 685 20.1 74 15.4 611 20.9   466 21.9 51 18.1 415 22.5   219 17.2 23 11.5 196 18.2   
Q3 725 21.3 92 19.1 633 21.7   506 23.8 66 23.4 440 23.8   219 17.2 26 13.0 193 17.9   
Q4 963 28.3 177 36.7 786 26.9   510 24.0 76 27.0 434 23.5   453 35.5 101 50.5 352 32.7   
                                            
Months of enrollment post-Index             0.0341             0.0306             0.0089 
7 39 1.1 7 1.5 32 1.1   22 1.0 4 1.4 18 1.0   17 1.3 3 1.5 14 1.3   
8 40 1.2 11 2.3 29 1.0   25 1.2 6 2.1 19 1.0   15 1.2 5 2.5 10 0.9   
9 58 1.7 7 1.5 51 1.7   33 1.6 3 1.1 30 1.6   25 2.0 4 2.0 21 2.0   
10 57 1.7 6 1.2 51 1.7   37 1.7 4 1.4 33 1.8   20 1.6 2 1.0 18 1.7   
11 69 2.0 8 1.7 61 2.1   53 2.5 7 2.5 46 2.5   16 1.3 1 0.5 15 1.4   
12 51 1.5 3 0.6 48 1.6   38 1.8 2 0.7 36 2.0   13 1.0 1 0.5 12 1.1   
13 68 2.0 14 2.9 54 1.8   45 2.1 13 4.6 32 1.7   23 1.8 1 0.5 22 2.0   
14 68 2.0 11 2.3 57 2.0   47 2.2 5 1.8 42 2.3   21 1.6 6 3.0 15 1.4   
15 54 1.6 10 2.1 44 1.5   37 1.7 3 1.1 34 1.8   17 1.3 7 3.5 10 0.9   
16 71 2.1 3 0.6 68 2.3   38 1.8 1 0.4 37 2.0   33 2.6 2 1.0 31 2.9   
17 75 2.2 9 1.9 66 2.3   45 2.1 5 1.8 40 2.2   30 2.4 4 2.0 26 2.4   
18 72 2.1 16 3.3 56 1.9   47 2.2 12 4.3 35 1.9   25 2.0 4 2.0 21 2.0   
19 62 1.8 9 1.9 53 1.8   36 1.7 5 1.8 31 1.7   26 2.0 4 2.0 22 2.0   
20 59 1.7 13 2.7 46 1.6   40 1.9 5 1.8 35 1.9   19 1.5 8 4.0 11 1.0   
21 65 1.9 11 2.3 54 1.8   40 1.9 6 2.1 34 1.8   25 2.0 5 2.5 20 1.9   
22 74 2.2 11 2.3 63 2.2   47 2.2 9 3.2 38 2.1   27 2.1 2 1.0 25 2.3   
23 61 1.8 5 1.0 56 1.9   41 1.9 3 1.1 38 2.1   20 1.6 2 1.0 18 1.7   
24 2360 69.4 328 68.0 2032 69.6   1456 68.5 189 67.0 1267 68.7   904 70.8 139 69.5 765 71.1   
Insurance at Index                                           
Commercial 1103 32.4 160 33.2 943 32.3 0.6920 821 38.6 117 41.5 704 38.2 0.2844 282 22.1 43 21.5 239 22.2 0.8237 
Medicaid 377 11.1 69 14.3 308 10.5 0.0145 160 7.5 20 7.1 140 7.6 0.7687 217 17.0 49 24.5 168 15.6 0.0021 
Medicare 1942 57.1 256 53.1 1686 57.7 0.0583 1165 54.8 148 52.5 1017 55.1 0.4068 777 60.9 108 54.0 669 62.2 0.0296 
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CMS comorbidities                                            
acute myocardial infarction 
(AMI) 
112 3.3 19 3.9 93 3.2 0.3874 72 3.4 9 3.2 63 3.4 0.8470 40 3.1 10 5.0 30 2.8 0.0993 
Alzheimer’s 109 3.2 18 3.7 91 3.1 0.4745 61 2.9 11 3.9 50 2.7 0.2645 48 3.8 7 3.5 41 3.8 0.8322 
atrial fibrillation 323 9.5 51 10.6 272 9.3 0.3785 209 9.8 31 11.0 178 9.6 0.4797 114 8.9 20 10.0 94 8.7 0.5650 
cancers 229 6.7 34 7.1 195 6.7 0.7588 155 7.3 23 8.2 132 7.2 0.5467 74 5.8 11 5.5 63 5.9 0.8436 
lung cancer 72 2.1 13 2.7 59 2.0 0.3385 46 2.2 7 2.5 39 2.1 0.6920 26 2.0 6 3.0 20 1.9 0.2942 
chronic kidney disease 536 15.8 80 16.6 456 15.6 0.5818 362 17.0 53 18.8 309 16.7 0.3944 174 13.6 27 13.5 147 13.7 0.9512 
diabetes 802 23.6 139 28.8 663 22.7 0.0033 484 22.8 70 24.8 414 22.4 0.3739 318 24.9 69 34.5 249 23.1 0.0006 
heart failure 591 17.4 99 20.5 492 16.8 0.0472 367 17.3 56 19.9 311 16.9 0.2141 224 17.6 43 21.5 181 16.8 0.1103 
ischemic heart dis. (IHD; incl. 
AMI) 
803 23.6 113 23.4 690 23.6 0.9320 524 24.6 70 24.8 454 24.6 0.9376 279 21.9 43 21.5 236 21.9 0.8918 
rheumatoid/osteo arthritis 
(RA/OA) 
870 25.6 139 28.8 731 25.0 0.0755 543 25.5 84 29.8 459 24.9 0.0783 327 25.6 55 27.5 272 25.3 0.5088 
stroke/TIA 246 7.2 37 7.7 209 7.2 0.6822 147 6.9 23 8.2 124 6.7 0.3762 99 7.8 14 7.0 85 7.9 0.6623 
no CMS Comorbidity 1191 35.0 148 30.7 1043 35.7 0.0329 735 34.6 88 31.2 647 35.1 0.2040 456 35.7 60 30.0 396 36.8 0.0652 
                                            
Elixhauser comorbidities                                            
AIDS         7 0.2 0.2820         7 0.4 0.3002               
alcohol abuse 126 3.7 26 5.4 100 3.4 0.0338 63 3.0 10 3.5 53 2.9 0.5344 63 4.9 16 8.0 47 4.4 0.0295 
chronic blood loss anemia 29 0.9 7 1.5 22 0.8 0.1219 19 0.9 4 1.4 15 0.8 0.3142 10 0.8 3 1.5 7 0.7 0.2109 
coagulopathy 106 3.1 21 4.4 85 2.9 0.0902 56 2.6 10 3.5 46 2.5 0.3037 50 3.9 11 5.5 39 3.6 0.2094 
congestive heart failure 538 15.8 88 18.3 450 15.4 0.1119 347 16.3 52 18.4 295 16.0 0.2996 191 15.0 36 18.0 155 14.4 0.1907 
deficiency anemias 452 13.3 84 17.4 368 12.6 0.0038 274 12.9 53 18.8 221 12.0 0.0015 178 13.9 31 15.5 147 13.7 0.4908 
depression 540 15.9 95 19.7 445 15.2 0.0127 295 13.9 43 15.2 252 13.7 0.4719 245 19.2 52 26.0 193 17.9 0.0078 
diabetes (wo/chr complications) 764 22.5 137 28.4 627 21.5 0.0007 478 22.5 75 26.6 403 21.8 0.0749 286 22.4 62 31.0 224 20.8 0.0015 
diabetes (w/chr complications) 257 7.6 40 8.3 217 7.4 0.5031 185 8.7 27 9.6 158 8.6 0.5748 72 5.6 13 6.5 59 5.5 0.5672 
drug abuse 93 2.7 18 3.7 75 2.6 0.1455 65 3.1 9 3.2 56 3.0 0.8871 28 2.2 9 4.5 19 1.8 0.0154 
fluid and electrolyte disorders 408 12.0 81 16.8 327 11.2 0.0004 240 11.3 41 14.5 199 10.8 0.0636 168 13.2 40 20.0 128 11.9 0.0019 
hypertension 2092 61.5 305 63.3 1787 61.2 0.3800 1353 63.6 183 64.9 1170 63.4 0.6307 739 57.9 122 61.0 617 57.3 0.3359 
hypothyroidism 653 19.2 110 22.8 543 18.6 0.0288 409 19.2 67 23.8 342 18.5 0.0382 244 19.1 43 21.5 201 18.7 0.3518 
liver disease 136 4.0 22 4.6 114 3.9 0.4921 87 4.1 12 4.3 75 4.1 0.8806 49 3.8 10 5.0 39 3.6 0.3526 
lymphoma 29 0.9 3 0.6 26 0.9 0.5536 16 0.8 2 0.7 14 0.8 0.9285 13 1.0 1 0.5 12 1.1 0.4262 
metastatic cancer 31 0.9 2 0.4 29 1.0 0.2160 26 1.2 2 0.7 24 1.3 0.3998         5 0.5 0.3341 
obesity 437 12.8 61 12.7 376 12.9 0.8952 283 13.3 30 10.6 253 13.7 0.1568 154 12.1 31 15.5 123 11.4 0.1048 
other neurological disorders 308 9.1 47 9.8 261 8.9 0.5630 209 9.8 29 10.3 180 9.8 0.7816 99 7.8 18 9.0 81 7.5 0.4748 
paralysis 52 1.5 8 1.7 44 1.5 0.7992 37 1.7 7 2.5 30 1.6 0.3057 15 1.2 1 0.5 14 1.3 0.3344 
peripheral vascular disease 543 16.0 89 18.5 454 15.5 0.1046 361 17.0 58 20.6 303 16.4 0.0842 182 14.3 31 15.5 151 14.0 0.5860 
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Number of Patients 3403   482   2921     2127   282   1845     1276   200   1076     
psychoses 345 10.1 60 12.4 285 9.8 0.0697 234 11.0 35 12.4 199 10.8 0.4165 111 8.7 25 12.5 86 8.0 0.0378 
pulmonary circulation disease 387 11.4 52 10.8 335 11.5 0.6629 253 11.9 32 11.3 221 12.0 0.7606 134 10.5 20 10.0 114 10.6 0.8011 
renal failure 283 8.3 33 6.8 250 8.6 0.2072 192 9.0 19 6.7 173 9.4 0.1498 91 7.1 14 7.0 77 7.2 0.9372 
rheumatoid arthritis/collagen vas 212 6.2 29 6.0 183 6.3 0.8344 119 5.6 15 5.3 104 5.6 0.8288 93 7.3 14 7.0 79 7.3 0.8643 
solid tumor wo/metastasis 329 9.7 45 9.3 284 9.7 0.7902 219 10.3 31 11.0 188 10.2 0.6793 110 8.6 14 7.0 96 8.9 0.3739 
ulcers 5 0.1 2 0.4 3 0.1 0.0973 2 0.1 1 0.4 1 0.1 0.1253 3 0.2 1 0.5 2 0.2 0.3996 
valvular disease 387 11.4 64 13.3 323 11.1 0.1549 290 13.6 40 14.2 250 13.6 0.7725 97 7.6 24 12.0 73 6.8 0.0106 
weight loss 188 5.5 34 7.1 154 5.3 0.1127 125 5.9 20 7.1 105 5.7 0.3515 63 4.9 14 7.0 49 4.6 0.1426 
any Elixhauser diagnosis 3103 91.2 450 93.4 2653 90.8 0.0689 1961 92.2 264 93.6 1697 92.0 0.3393 1142 89.5 186 93.0 956 88.8 0.0786 
Other comorbidities                                           
asthma 1128 33.1 194 40.2 934 32.0 0.0004 683 32.1 112 39.7 571 30.9 0.0033 445 34.9 82 41.0 363 33.7 0.0478 
hypoxemia 1278 37.6 209 43.4 1069 36.6 0.0045 748 35.2 117 41.5 631 34.2 0.0170 530 41.5 92 46.0 438 40.7 0.1630 
pneumonia 1152 33.9 218 45.2 934 32.0 <0.0001 768 36.1 142 50.4 626 33.9 <0.0001 384 30.1 76 38.0 308 28.6 0.0079 
influenza 101 3.0 12 2.5 89 3.0 0.5042 64 3.0 7 2.5 57 3.1 0.5783 37 2.9 5 2.5 32 3.0 0.7137 
COPD Complexity ^                                           
Low complexity 1673 49.2 182 37.8 1491 51.0 <0.0001 1009 47.4 94 33.3 915 49.6 <0.0001 664 52.0 88 44.0 576 53.5 0.0132 
Med complexity 1575 46.3 283 58.7 1292 44.2 <0.0001 1017 47.8 179 63.5 838 45.4 <0.0001 558 43.7 104 52.0 454 42.2 0.0102 
High complexity 155 4.6 17 3.5 138 4.7 0.2427 101 4.7 9 3.2 92 5.0 0.1868 54 4.2 8 4.0 46 4.3 0.8591 
Emphysema diagnosis (492.x) 813 23.9 147 30.5 666 22.8 0.0002 443 20.8 74 26.2 369 20.0 0.0162 370 29.0 73 36.5 297 27.6 0.0109 
                                            
COPD Medications                                            
index ICSLABA 1731 50.9 258 53.5 1473 50.4 0.2073 1133 53.3 159 56.4 974 52.8 0.2602 598 46.9 99 49.5 499 46.4 0.4161 
index LAMA 1284 37.7 159 33.0 1125 38.5 0.0204 749 35.2 87 30.9 662 35.9 0.0996 535 41.9 72 36.0 463 43.0 0.0643 
index triple 388 11.4 65 13.5 323 11.1 0.1203 245 11.5 36 12.8 209 11.3 0.4811 143 11.2 29 14.5 114 10.6 0.1079 
SABA use                                           
no SABA use 1484 43.6 168 34.9 1316 45.1 <0.0001 885 41.6 89 31.6 796 43.1 0.0002 599 46.9 79 39.5 520 48.3 0.0216 
SABA <=15% of year 836 24.6 132 27.4 704 24.1 0.1207 533 25.1 70 24.8 463 25.1 0.9218 303 23.7 62 31.0 241 22.4 0.0087 
SABA <=40% of year 461 13.5 69 14.3 392 13.4 0.5946 312 14.7 50 17.7 262 14.2 0.1186 149 11.7 19 9.5 130 12.1 0.2965 
SABA >40% of year 622 18.3 113 23.4 509 17.4 0.0015 397 18.7 73 25.9 324 17.6 0.0008 225 17.6 40 20.0 185 17.2 0.3389 
SAMA use                                           
any ipratropium (SAMA) 415 12.2 89 18.5 326 11.2 <0.0001 256 12.0 52 18.4 204 11.1 0.0004 159 12.5 37 18.5 122 11.3 0.0049 
any SABA/SAMA 565 16.6 113 23.4 452 15.5 <0.0001 377 17.7 72 25.5 305 16.5 0.0002 188 14.7 41 20.5 147 13.7 0.0122 
any SAMA or SABA/SAMA 893 26.2 181 37.6 712 24.4 <0.0001 574 27.0 109 38.7 465 25.2 <0.0001 319 25.0 72 36.0 247 23.0 <0.0001 
Other COPD medications                                           
any ICS 1118 32.9 188 39.0 930 31.8 0.0019 710 33.4 112 39.7 598 32.4 0.0154 408 32.0 76 38.0 332 30.9 0.0466 
any LABA 170 5.0 22 4.6 148 5.1 0.6390 91 4.3 9 3.2 82 4.4 0.3329 79 6.2 13 6.5 66 6.1 0.8436 
any methylxanthines 61 1.8 10 2.1 51 1.7 0.6143 19 0.9 5 1.8 14 0.8 0.0918 42 3.3 5 2.5 37 3.4 0.4945 
Any use of above COPD 
medications 
1711 50.3 289 60.0 1422 48.7 <0.0001 1089 51.2 175 62.1 914 49.5 <0.0001 622 48.7 114 57.0 508 47.2 0.0110 
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Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 3043 89.4 421 87.3 2622 89.8 0.1096 1897 89.2 236 83.7 1661 90.0 0.0014 1146 89.8 185 92.5 961 89.3 0.1711 
1-2 Rxs ICSLABA (wks 27-52) 203 6.0 36 7.5 167 5.7 0.1325 133 6.3 29 10.3 104 5.6 0.0027 70 5.5 7 3.5 63 5.9 0.1792 
>2 Rxs ICSLABA (wks 27-52) 157 4.6 25 5.2 132 4.5 0.5174 97 4.6 17 6.0 80 4.3 0.2046 60 4.7 8 4.0 52 4.8 0.6095 
No LAMA in prior year 3282 96.4 459 95.2 2823 96.6 0.1197 2049 96.3 264 93.6 1785 96.7 0.0092 1233 96.6 195 97.5 1038 96.5 0.4578 
1-2 Rxs LAMA (wks 27-52) 66 1.9 16 3.3 50 1.7 0.0177 47 2.2 12 4.3 35 1.9 0.0121 19 1.5 4 2.0 15 1.4 0.5159 
>2 Rxs LAMA (wks 27-52) 55 1.6 7 1.5 48 1.6 0.7580 31 1.5 6 2.1 25 1.4 0.3133 24 1.9 1 0.5 23 2.1 0.1175 
Oxygen Use                                           
no oxygen 1875 55.1 222 46.1 1653 56.6 <0.0001 1206 56.7 134 47.5 1072 58.1 0.0008 669 52.4 88 44.0 581 54.0 0.0093 
oxygen <=50% of year 560 16.5 84 17.4 476 16.3 0.5348 378 17.8 54 19.1 324 17.6 0.5159 182 14.3 30 15.0 152 14.1 0.7456 
oxygen >50% of year 968 28.4 176 36.5 792 27.1 <0.0001 543 25.5 94 33.3 449 24.3 0.0012 425 33.3 82 41.0 343 31.9 0.0119 
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 2125 62.4 270 56.0 1855 63.5 0.0017 1206 56.7 148 52.5 1058 57.3 0.1249 919 72.0 122 61.0 797 74.1 0.0002 
1 period breathlessness 664 19.5 114 23.7 550 18.8 0.0133 458 21.5 70 24.8 388 21.0 0.1490 206 16.1 44 22.0 162 15.1 0.0142 
>1 period breathlessness 614 18.0 98 20.3 516 17.7 0.1584 463 21.8 64 22.7 399 21.6 0.6854 151 11.8 34 17.0 117 10.9 0.0138 
Shortness of Breath                                           
no periods shortness breath 2149 63.2 271 56.2 1878 64.3 0.0007 1327 62.4 157 55.7 1170 63.4 0.0124 822 64.4 114 57.0 708 65.8 0.0170 
1 period shortness breath 688 20.2 105 21.8 583 20.0 0.3553 463 21.8 68 24.1 395 21.4 0.3054 225 17.6 37 18.5 188 17.5 0.7261 
>1 period shortness breath 566 16.6 106 22.0 460 15.7 0.0006 337 15.8 57 20.2 280 15.2 0.0310 229 17.9 49 24.5 180 16.7 0.0085 
any wheezing 255 7.5 52 10.8 203 6.9 0.0030 175 8.2 29 10.3 146 7.9 0.1773 80 6.3 23 11.5 57 5.3 0.0009 
any dyspnea 1913 56.2 317 65.8 1596 54.6 <0.0001 1294 60.8 191 67.7 1103 59.8 0.0109 619 48.5 126 63.0 493 45.8 <0.0001 
supplemental oxygen use (V46.2) 208 6.1 49 10.2 159 5.4 <0.0001 72 3.4 16 5.7 56 3.0 0.0225 136 10.7 33 16.5 103 9.6 0.0036 
Other symptoms                                           
chest pain unspecified 957 28.1 165 34.2 792 27.1 0.0013 590 27.7 95 33.7 495 26.8 0.0166 367 28.8 70 35.0 297 27.6 0.0338 
painful respiratory 156 4.6 34 7.1 122 4.2 0.0051 85 4.0 15 5.3 70 3.8 0.2233 71 5.6 19 9.5 52 4.8 0.0082 
precordial pain 66 1.9 14 2.9 52 1.8 0.0972 43 2.0 13 4.6 30 1.6 0.0009 23 1.8 1 0.5 22 2.0 0.1316 
any chest pain 1003 29.5 173 35.9 830 28.4 0.0009 616 29.0 100 35.5 516 28.0 0.0098 387 30.3 73 36.5 314 29.2 0.0387 
chronic fatigue 50 1.5 5 1.0 45 1.5 0.3949 37 1.7 3 1.1 34 1.8 0.3514 13 1.0 2 1.0 11 1.0 0.9770 
other malaise/fatigue 827 24.3 139 28.8 688 23.6 0.0122 502 23.6 80 28.4 422 22.9 0.0429 325 25.5 59 29.5 266 24.7 0.1543 
difficulty walking 86 2.5 19 3.9 67 2.3 0.0327 66 3.1 14 5.0 52 2.8 0.0529 20 1.6 5 2.5 15 1.4 0.2476 
memory loss 74 2.2 7 1.5 67 2.3 0.2406 50 2.4 4 1.4 46 2.5 0.2672 24 1.9 3 1.5 21 2.0 0.6659 
cough 1186 34.9 208 43.2 978 33.5 <0.0001 812 38.2 141 50.0 671 36.4 <0.0001 374 29.3 67 33.5 307 28.5 0.1563 
hemoptysis 52 1.5 8 1.7 44 1.5 0.7992 34 1.6 7 2.5 27 1.5 0.2039 18 1.4 1 0.5 17 1.6 0.2344 
Procedures                                           
chest CT 508 14.9 81 16.8 427 14.6 0.2120 331 15.6 47 16.7 284 15.4 0.5826 177 13.9 34 17.0 143 13.3 0.1633 
chest x-ray 2149 63.2 340 70.5 1809 61.9 0.0003 1344 63.2 203 72.0 1141 61.8 0.0010 805 63.1 137 68.5 668 62.1 0.0841 
echocardiography 678 19.9 95 19.7 583 20.0 0.8989 480 22.6 59 20.9 421 22.8 0.4780 198 15.5 36 18.0 162 15.1 0.2910 
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Number of Patients 3403   482   2921     2127   282   1845     1276   200   1076     
EKG 1494 43.9 237 49.2 1257 43.0 0.0119 942 44.3 142 50.4 800 43.4 0.0277 552 43.3 95 47.5 457 42.5 0.1875 
heart catheterization 42 1.2 5 1.0 37 1.3 0.6726 30 1.4 4 1.4 26 1.4 0.9902 12 0.9 1 0.5 11 1.0 0.4822 
nebulizer treatment 1118 32.9 187 38.8 931 31.9 0.0027 817 38.4 123 43.6 694 37.6 0.0536 301 23.6 64 32.0 237 22.0 0.0023 
non-invasive ventilator 221 6.5 38 7.9 183 6.3 0.1815 129 6.1 21 7.4 108 5.9 0.2965 92 7.2 17 8.5 75 7.0 0.4425 
spirometry 1519 44.6 189 39.2 1330 45.5 0.0097 1012 47.6 118 41.8 894 48.5 0.0384 507 39.7 71 35.5 436 40.5 0.1827 
any vaccination (flu or 
pneumonia) 
1656 48.7 236 49.0 1420 48.6 0.8870 1067 50.2 144 51.1 923 50.0 0.7457 589 46.2 92 46.0 497 46.2 0.9606 
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 444 13.0 77 16.0 367 12.6 0.0394 297 14.0 49 17.4 248 13.4 0.0759 147 11.5 28 14.0 119 11.1 0.2317 
any severe 247 7.3 52 10.8 195 6.7 0.0013 144 6.8 27 9.6 117 6.3 0.0442 103 8.1 25 12.5 78 7.2 0.0123 
any other hospitalizations* 61 1.8 12 2.5 49 1.7 0.2131 54 2.5 9 3.2 45 2.4 0.4544 7 0.5 3 1.5 4 0.4 0.0473 
Prior 2-12 weeks                                           
any moderate 574 16.9 121 25.1 453 15.5 <0.0001 368 17.3 74 26.2 294 15.9 <0.0001 206 16.1 47 23.5 159 14.8 0.0021 
any severe 227 6.7 50 10.4 177 6.1 0.0004 111 5.2 25 8.9 86 4.7 0.0031 116 9.1 25 12.5 91 8.5 0.0678 
any other hospitalizations* 127 3.7 22 4.6 105 3.6 0.2981 100 4.7 15 5.3 85 4.6 0.5988 27 2.1 7 3.5 20 1.9 0.1386 
Prior 13-52 weeks                                           
no moderate 2664 78.3 317 65.8 2347 80.3 <0.0001 1635 76.9 175 62.1 1460 79.1 <0.0001 1029 80.6 142 71.0 887 82.4 0.0002 
1 moderate 596 17.5 126 26.1 470 16.1 <0.0001 392 18.4 81 28.7 311 16.9 <0.0001 204 16.0 45 22.5 159 14.8 0.0062 
>1 moderate 143 4.2 39 8.1 104 3.6 <0.0001 100 4.7 26 9.2 74 4.0 0.0001 43 3.4 13 6.5 30 2.8 0.0076 
any severe 264 7.8 59 12.2 205 7.0 <0.0001 129 6.1 30 10.6 99 5.4 0.0006 135 10.6 29 14.5 106 9.9 0.0497 
any other hospitalizations* 233 6.8 47 9.8 186 6.4 0.0064 186 8.7 39 13.8 147 8.0 0.0012 47 3.7 8 4.0 39 3.6 0.7957 
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 500 14.7 90 18.7 410 14.0 0.0077 390 18.3 69 24.5 321 17.4 0.0043 110 8.6 21 10.5 89 8.3 0.3025 
COPD Inpatient (Any) 667 19.6 140 29.0 527 18.0 <0.0001 357 16.8 72 25.5 285 15.4 <0.0001 310 24.3 68 34.0 242 22.5 0.0005 
Total Inpatient (Any) 1000 29.4 193 40.0 807 27.6 <0.0001 651 30.6 117 41.5 534 28.9 <0.0001 349 27.4 76 38.0 273 25.4 0.0002 
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period)  
Same as Index Trmt 3097 91.0 428 88.8 2669 91 0.0670 1919 90.2 244 86.5 1675 91 0.0249 1178 92.3 184 92.0 994 92 0.8533 
No evidence Any Trmt                                           
Different Trmt from Index 306 9.0 54 11 252 8.6 0.0670 208 9.8 38 13.5 170 9.2 0.0249 98 7.7 16 8 82 7.6 0.8533 
Now using Triple 150 4.4 33 6.8 117 4.0 0.0049 101 4.7 22 7.8 79 4.3 0.0096 49 3.8 11 5.5 38 3.5 0.1834 
No longer using Triple 102 3.0 14 2.9 88 3.0 0.8974 65 3.1 11 3.9 54 2.9 0.3762 37 2.9 3 1.5 34 3.2 0.1989 
Switched between ICSLABA 
and LAMA 
54 1.6 7 1.5 47 1.6 0.7986 42 2.0 5 1.8 37 2.0 0.7939 12 0.9 2 1.0 10 0.9 0.9243 
LHP enrollee 2127 62.5 282 58.5 1845 63.2 0.0504                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 51 Baseline Characteristics: Any Moderate/Severe Exacerbation in First Six Months 
 
LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  
Number of Patients 5475   1287   4188     3599   789   2810     1876   498   1378     
Age Categories                                           
age 40-54 584 10.7 161 12.5 423 10.1 0.0143 332 9.2 82 10.4 250 8.9 0.1994 252 13.4 79 15.9 173 12.6 0.0635 
age 55-64 1026 18.7 257 20.0 769 18.4 0.1963 591 16.4 138 17.5 453 16.1 0.3589 435 23.2 119 23.9 316 22.9 0.6623 
age 65-74 1637 29.9 364 28.3 1273 30.4 0.1475 1059 29.4 223 28.3 836 29.8 0.4179 578 30.8 141 28.3 437 31.7 0.1591 
age 75 and older 2228 40.7 505 39.2 1723 41.1 0.2243 1617 44.9 346 43.9 1271 45.2 0.4916 611 32.6 159 31.9 452 32.8 0.7215 
age (Mean, SD) 70.55 11.51 69.92 11.87 70.74 11.39 0.0250 71.58 11.31 71.02 11.50 71.74 11.26 0.1155 68.57 11.62 68.18 12.24 68.71 11.38 0.3952 
                                            
Men 2393 43.7 506 39.3 1887 45.1 0.0003 1616 44.9 325 41.2 1291 45.9 0.0177 777 41.4 181 36.3 596 43.3 0.0073 
                                            
Quarter of Year for Index Date             <0.0001             0.0003             <0.0001 
Q1 1645 30.0 333 25.9 1312 31.3   1111 30.9 220 27.9 891 31.7   534 28.5 113 22.7 421 30.6   
Q2 1160 21.2 229 17.8 931 22.2   800 22.2 146 18.5 654 23.3   360 19.2 83 16.7 277 20.1   
Q3 1192 21.8 305 23.7 887 21.2   846 23.5 209 26.5 637 22.7   346 18.4 96 19.3 250 18.1   
Q4 1478 27.0 420 32.6 1058 25.3   842 23.4 214 27.1 628 22.3   636 33.9 206 41.4 430 31.2   
                                            
Months of enrollment post-Index             0.0201             0.3346             0.0180 
7 78 1.4 25 1.9 53 1.3   44 1.2 14 1.8 30 1.1   34 1.8 11 2.2 23 1.7   
8 66 1.2 23 1.8 43 1.0   39 1.1 10 1.3 29 1.0   27 1.4 13 2.6 14 1.0   
9 85 1.6 15 1.2 70 1.7   50 1.4 6 0.8 44 1.6   35 1.9 9 1.8 26 1.9   
10 99 1.8 19 1.5 80 1.9   70 1.9 15 1.9 55 2.0   29 1.5 4 0.8 25 1.8   
11 117 2.1 19 1.5 98 2.3   95 2.6 13 1.6 82 2.9   22 1.2 6 1.2 16 1.2   
12 92 1.7 22 1.7 70 1.7   71 2.0 14 1.8 57 2.0   21 1.1 8 1.6 13 0.9   
13 99 1.8 28 2.2 71 1.7   67 1.9 21 2.7 46 1.6   32 1.7 7 1.4 25 1.8   
14 111 2.0 36 2.8 75 1.8   75 2.1 20 2.5 55 2.0   36 1.9 16 3.2 20 1.5   
15 97 1.8 29 2.3 68 1.6   62 1.7 17 2.2 45 1.6   35 1.9 12 2.4 23 1.7   
16 127 2.3 27 2.1 100 2.4   82 2.3 18 2.3 64 2.3   45 2.4 9 1.8 36 2.6   
17 114 2.1 27 2.1 87 2.1   77 2.1 19 2.4 58 2.1   37 2.0 8 1.6 29 2.1   
18 106 1.9 30 2.3 76 1.8   72 2.0 20 2.5 52 1.9   34 1.8 10 2.0 24 1.7   
19 104 1.9 23 1.8 81 1.9   69 1.9 14 1.8 55 2.0   35 1.9 9 1.8 26 1.9   
20 105 1.9 32 2.5 73 1.7   67 1.9 14 1.8 53 1.9   38 2.0 18 3.6 20 1.5   
21 105 1.9 25 1.9 80 1.9   63 1.8 13 1.6 50 1.8   42 2.2 12 2.4 30 2.2   
22 114 2.1 22 1.7 92 2.2   79 2.2 14 1.8 65 2.3   35 1.9 8 1.6 27 2.0   
23 91 1.7 15 1.2 76 1.8   64 1.8 11 1.4 53 1.9   27 1.4 4 0.8 23 1.7   
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Number of Patients 5475   1287   4188     3599   789   2810     1876   498   1378     
24 3765 68.8 870 67.6 2895 69.1   2453 68.2 536 67.9 1917 68.2   1312 69.9 334 67.1 978 71.0   
Insurance at Index                                           
Commercial 1778 32.5 409 31.8 1369 32.7 0.5424 1376 38.2 304 38.5 1072 38.1 0.8460 402 21.4 105 21.1 297 21.6 0.8271 
Medicaid 655 12.0 181 14.1 474 11.3 0.0079 284 7.9 70 8.9 214 7.6 0.2474 371 19.8 111 22.3 260 18.9 0.1004 
Medicare 3071 56.1 703 54.6 2368 56.5 0.2249 1968 54.7 421 53.4 1547 55.1 0.3981 1103 58.8 282 56.6 821 59.6 0.2513 
                                            
CMS comorbidities (Baseline 
Per.) 
                                          
acute myocardial infarction 
(AMI) 
175 3.2 44 3.4 131 3.1 0.6039 114 3.2 24 3.0 90 3.2 0.8195 61 3.3 20 4.0 41 3.0 0.2618 
Alzheimer’s 189 3.5 46 3.6 143 3.4 0.7837 111 3.1 28 3.5 83 3.0 0.3930 78 4.2 18 3.6 60 4.4 0.4785 
atrial fibrillation 534 9.8 142 11.0 392 9.4 0.0768 362 10.1 89 11.3 273 9.7 0.1966 172 9.2 53 10.6 119 8.6 0.1835 
cancers 370 6.8 89 6.9 281 6.7 0.7971 265 7.4 64 8.1 201 7.2 0.3623 105 5.6 25 5.0 80 5.8 0.5134 
lung cancer 113 2.1 25 1.9 88 2.1 0.7261 75 2.1 17 2.2 58 2.1 0.8750 38 2.0 8 1.6 30 2.2 0.4385 
chronic kidney disease 870 15.9 207 16.1 663 15.8 0.8281 626 17.4 140 17.7 486 17.3 0.7690 244 13.0 67 13.5 177 12.8 0.7291 
diabetes 1358 24.8 354 27.5 1004 24.0 0.0103 884 24.6 217 27.5 667 23.7 0.0299 474 25.3 137 27.5 337 24.5 0.1788 
heart failure 986 18.0 273 21.2 713 17.0 0.0006 645 17.9 174 22.1 471 16.8 0.0006 341 18.2 99 19.9 242 17.6 0.2504 
ischemic heart dis. (IHD; incl. 
AMI) 
1343 24.5 322 25.0 1021 24.4 0.6406 908 25.2 204 25.9 704 25.1 0.6467 435 23.2 118 23.7 317 23.0 0.7544 
rheumatoid/osteo arthritis 
(RA/OA) 
1443 26.4 364 28.3 1079 25.8 0.0728 954 26.5 225 28.5 729 25.9 0.1478 489 26.1 139 27.9 350 25.4 0.2737 
stroke/TIA 387 7.1 95 7.4 292 7.0 0.6164 256 7.1 62 7.9 194 6.9 0.3569 131 7.0 33 6.6 98 7.1 0.7157 
no CMS Comorbidity 1860 34.0 421 32.7 1439 34.4 0.2748 1194 33.2 244 30.9 950 33.8 0.1286 666 35.5 177 35.5 489 35.5 0.9822 
                                            
Elixhauser comorbidities 
(Baseline Per.) 
                                          
AIDS 10 0.2 1 0.1 9 0.2 0.3134 9 0.3 1 0.1 8 0.3 0.4325         1 0.1 0.5476 
alcohol abuse 191 3.5 60 4.7 131 3.1 0.0087 108 3.0 27 3.4 81 2.9 0.4325 83 4.4 33 6.6 50 3.6 0.0053 
chronic blood loss anemia 49 0.9 21 1.6 28 0.7 0.0013 28 0.8 10 1.3 18 0.6 0.0766 21 1.1 11 2.2 10 0.7 0.0070 
coagulopathy 163 3.0 47 3.7 116 2.8 0.1034 96 2.7 27 3.4 69 2.5 0.1365 67 3.6 20 4.0 47 3.4 0.5327 
congestive heart failure 903 16.5 253 19.7 650 15.5 0.0005 616 17.1 167 21.2 449 16.0 0.0006 287 15.3 86 17.3 201 14.6 0.1540 
deficiency anemias 773 14.1 226 17.6 547 13.1 <0.0001 498 13.8 146 18.5 352 12.5 <0.0001 275 14.7 80 16.1 195 14.2 0.3008 
depression 917 16.7 250 19.4 667 15.9 0.0033 537 14.9 125 15.8 412 14.7 0.4107 380 20.3 125 25.1 255 18.5 0.0017 
diabetes (wo/chr complications) 1304 23.8 352 27.4 952 22.7 0.0007 867 24.1 223 28.3 644 22.9 0.0019 437 23.3 129 25.9 308 22.4 0.1080 
diabetes (w/chr complications) 442 8.1 116 9.0 326 7.8 0.1569 332 9.2 81 10.3 251 8.9 0.2526 110 5.9 35 7.0 75 5.4 0.1968 
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Number of Patients 5475   1287   4188     3599   789   2810     1876   498   1378     
drug abuse 181 3.3 48 3.7 133 3.2 0.3311 115 3.2 27 3.4 88 3.1 0.6820 66 3.5 21 4.2 45 3.3 0.3234 
fluid and electrolyte disorders 686 12.5 201 15.6 485 11.6 0.0001 422 11.7 111 14.1 311 11.1 0.0206 264 14.1 90 18.1 174 12.6 0.0027 
hypertension 3374 61.6 802 62.3 2572 61.4 0.5606 2301 63.9 517 65.5 1784 63.5 0.2921 1073 57.2 285 57.2 788 57.2 0.9862 
hypothyroidism 1032 18.8 274 21.3 758 18.1 0.0105 684 19.0 175 22.2 509 18.1 0.0101 348 18.6 99 19.9 249 18.1 0.3732 
liver disease 212 3.9 51 4.0 161 3.8 0.8473 144 4.0 29 3.7 115 4.1 0.5974 68 3.6 22 4.4 46 3.3 0.2693 
lymphoma 46 0.8 10 0.8 36 0.9 0.7765 31 0.9 6 0.8 25 0.9 0.7285 15 0.8 4 0.8 11 0.8 0.9915 
metastatic cancer 56 1.0 13 1.0 43 1.0 0.9586 41 1.1 11 1.4 30 1.1 0.4450 15 0.8 2 0.4 13 0.9 0.2446 
obesity 717 13.1 165 12.8 552 13.2 0.7378 480 13.3 97 12.3 383 13.6 0.3294 237 12.6 68 13.7 169 12.3 0.4234 
other neurological disorders 514 9.4 131 10.2 383 9.1 0.2662 363 10.1 84 10.6 279 9.9 0.5542 151 8.0 47 9.4 104 7.5 0.1838 
paralysis 68 1.2 17 1.3 51 1.2 0.7701 48 1.3 13 1.6 35 1.2 0.3843 20 1.1 4 0.8 16 1.2 0.5051 
peripheral vascular disease 878 16.0 227 17.6 651 15.5 0.0734 614 17.1 148 18.8 466 16.6 0.1514 264 14.1 79 15.9 185 13.4 0.1799 
psychoses 573 10.5 164 12.7 409 9.8 0.0023 399 11.1 108 13.7 291 10.4 0.0084 174 9.3 56 11.2 118 8.6 0.0770 
pulmonary circulation disease 625 11.4 159 12.4 466 11.1 0.2259 435 12.1 94 11.9 341 12.1 0.8661 190 10.1 65 13.1 125 9.1 0.0116 
renal failure 468 8.5 93 7.2 375 9.0 0.0525 338 9.4 66 8.4 272 9.7 0.2633 130 6.9 27 5.4 103 7.5 0.1221 
rheumatoid arthritis/collagen 
vas 
343 6.3 87 6.8 256 6.1 0.4020 209 5.8 54 6.8 155 5.5 0.1587 134 7.1 33 6.6 101 7.3 0.6016 
solid tumor wo/metastasis 533 9.7 116 9.0 417 10.0 0.3178 368 10.2 80 10.1 288 10.2 0.9284 165 8.8 36 7.2 129 9.4 0.1499 
ulcers 7 0.1 4 0.3 3 0.1 0.0357 3 0.1 2 0.3 1 0.0 0.0609 4 0.2 2 0.4 2 0.1 0.2876 
valvular disease 630 11.5 166 12.9 464 11.1 0.0737 478 13.3 110 13.9 368 13.1 0.5363 152 8.1 56 11.2 96 7.0 0.0027 
weight loss 327 6.0 100 7.8 227 5.4 0.0019 219 6.1 67 8.5 152 5.4 0.0014 108 5.8 33 6.6 75 5.4 0.3310 
any Elixhauser diagnosis 5028 91.8 1191 92.5 3837 91.6 0.2908 3333 92.6 742 94.0 2591 92.2 0.0814 1695 90.4 449 90.2 1246 90.4 0.8661 
Other comorbidities                                           
asthma 1813 33.1 471 36.6 1342 32.0 0.0024 1166 32.4 285 36.1 881 31.4 0.0114 647 34.5 186 37.3 461 33.5 0.1170 
hypoxemia 1994 36.4 534 41.5 1460 34.9 <0.0001 1229 34.1 299 37.9 930 33.1 0.0120 765 40.8 235 47.2 530 38.5 0.0007 
pneumonia 1908 34.8 574 44.6 1334 31.9 <0.0001 1348 37.5 388 49.2 960 34.2 <0.0001 560 29.9 186 37.3 374 27.1 <0.0001 
influenza 178 3.3 58 4.5 120 2.9 0.0037 124 3.4 38 4.8 86 3.1 0.0169 54 2.9 20 4.0 34 2.5 0.0765 
                                            
COPD Complexity ^                                           
Low complexity 2740 50.0 508 39.5 2232 53.3 <0.0001 1761 48.9 303 38.4 1458 51.9 <0.0001 979 52.2 205 41.2 774 56.2 <0.0001 
Med complexity 2510 45.8 737 57.3 1773 42.3 <0.0001 1686 46.8 461 58.4 1225 43.6 <0.0001 824 43.9 276 55.4 548 39.8 <0.0001 
High complexity 225 4.1 42 3.3 183 4.4 0.0804 152 4.2 25 3.2 127 4.5 0.0955 73 3.9 17 3.4 56 4.1 0.5202 
Emphysema diagnosis (492.x) 1210 22.1 342 26.6 868 20.7 <0.0001 694 19.3 175 22.2 519 18.5 0.0196 516 27.5 167 33.5 349 25.3 0.0004 
                                            
COPD Medications                                            
index ICSLABA 3052 55.7 749 58.2 2303 55.0 0.0428 2129 59.2 476 60.3 1653 58.8 0.4476 923 49.2 273 54.8 650 47.2 0.0034 
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Number of Patients 5475   1287   4188     3599   789   2810     1876   498   1378     
index LAMA 1939 35.4 408 31.7 1531 36.6 0.0014 1158 32.2 236 29.9 922 32.8 0.1234 781 41.6 172 34.5 609 44.2 0.0002 
index triple 484 8.8 130 10.1 354 8.5 0.0685 312 8.7 77 9.8 235 8.4 0.2181 172 9.2 53 10.6 119 8.6 0.1835 
SABA use                                           
no SABA use 2314 42.3 448 34.8 1866 44.6 <0.0001 1479 41.1 260 33.0 1219 43.4 <0.0001 835 44.5 188 37.8 647 47.0 0.0004 
SABA <=15% of year 1435 26.2 324 25.2 1111 26.5 0.3343 973 27.0 199 25.2 774 27.5 0.1943 462 24.6 125 25.1 337 24.5 0.7747 
SABA <=40% of year 803 14.7 210 16.3 593 14.2 0.0557 555 15.4 140 17.7 415 14.8 0.0409 248 13.2 70 14.1 178 12.9 0.5201 
SABA >40% of year 923 16.9 305 23.7 618 14.8 <0.0001 592 16.4 190 24.1 402 14.3 <0.0001 331 17.6 115 23.1 216 15.7 0.0002 
SAMA use                                           
any ipratropium (SAMA) 632 11.5 204 15.9 428 10.2 <0.0001 391 10.9 116 14.7 275 9.8 <0.0001 241 12.8 88 17.7 153 11.1 0.0002 
any SABA/SAMA 876 16.0 264 20.5 612 14.6 <0.0001 591 16.4 173 21.9 418 14.9 <0.0001 285 15.2 91 18.3 194 14.1 0.0254 
any SAMA or SABA/SAMA 1381 25.2 423 32.9 958 22.9 <0.0001 901 25.0 260 33.0 641 22.8 <0.0001 480 25.6 163 32.7 317 23.0 <0.0001 
Other COPD medications                                           
any ICS 1752 32.0 470 36.5 1282 30.6 <0.0001 1143 31.8 281 35.6 862 30.7 0.0085 609 32.5 189 38.0 420 30.5 0.0023 
any LABA 227 4.1 53 4.1 174 4.2 0.9540 118 3.3 25 3.2 93 3.3 0.8442 109 5.8 28 5.6 81 5.9 0.8345 
any methylxanthines 87 1.6 25 1.9 62 1.5 0.2463 29 0.8 10 1.3 19 0.7 0.1007 58 3.1 15 3.0 43 3.1 0.9046 
Any use of above COPD 
medications 
2688 49.1 739 57.4 1949 46.5 <0.0001 1748 48.6 450 57.0 1298 46.2 <0.0001 940 50.1 289 58.0 651 47.2 <0.0001 
Use of Index Trmts Prior Year§                                           
No ICSLABA in prior year 4868 88.9 1119 86.9 3749 89.5 0.0102 3206 89.1 683 86.6 2523 89.8 0.0104 1662 88.6 436 87.6 1226 89.0 0.3932 
1-2 Rxs ICSLABA (wks 27-52) 387 7.1 106 8.2 281 6.7 0.0616 255 7.1 69 8.7 186 6.6 0.0397 132 7.0 37 7.4 95 6.9 0.6887 
>2 Rxs ICSLABA (wks 27-52) 220 4.0 62 4.8 158 3.8 0.0951 138 3.8 37 4.7 101 3.6 0.1569 82 4.4 25 5.0 57 4.1 0.4084 
No LAMA in prior year 5280 96.4 1231 95.6 4049 96.7 0.0806 3472 96.5 750 95.1 2722 96.9 0.0148 1808 96.4 481 96.6 1327 96.3 0.7687 
1-2 Rxs LAMA (wks 27-52) 124 2.3 41 3.2 83 2.0 0.0111 86 2.4 28 3.5 58 2.1 0.0158 38 2.0 13 2.6 25 1.8 0.2797 
>2 Rxs LAMA (wks 27-52) 71 1.3 15 1.2 56 1.3 0.6340 41 1.1 11 1.4 30 1.1 0.4450 30 1.6 4 0.8 26 1.9 0.0985 
Oxygen Use                                           
no oxygen 3090 56.4 611 47.5 2479 59.2 <0.0001 2097 58.3 389 49.3 1708 60.8 <0.0001 993 52.9 222 44.6 771 56.0 <0.0001 
oxygen <=50% of year 876 16.0 218 16.9 658 15.7 0.2936 619 17.2 146 18.5 473 16.8 0.2716 257 13.7 72 14.5 185 13.4 0.5657 
oxygen >50% of year 1509 27.6 458 35.6 1051 25.1 <0.0001 883 24.5 254 32.2 629 22.4 <0.0001 626 33.4 204 41.0 422 30.6 <0.0001 
                                            
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 3454 63.1 771 59.9 2683 64.1 0.0069 2101 58.4 436 55.3 1665 59.3 0.0444 1353 72.1 335 67.3 1018 73.9 0.0048 
1 period breathlessness 1051 19.2 257 20.0 794 19.0 0.4210 757 21.0 171 21.7 586 20.9 0.6180 294 15.7 86 17.3 208 15.1 0.2526 
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Number of Patients 5475   1287   4188     3599   789   2810     1876   498   1378     
>1 period breathlessness 970 17.7 259 20.1 711 17.0 0.0097 741 20.6 182 23.1 559 19.9 0.0514 229 12.2 77 15.5 152 11.0 0.0096 
Shortness of Breath                                           
no periods shortness breath 3450 63.0 747 58.0 2703 64.5 <0.0001 2260 62.8 464 58.8 1796 63.9 0.0087 1190 63.4 283 56.8 907 65.8 0.0004 
1 period shortness breath 1128 20.6 275 21.4 853 20.4 0.4380 785 21.8 178 22.6 607 21.6 0.5645 343 18.3 97 19.5 246 17.9 0.4211 
>1 period shortness breath 897 16.4 265 20.6 632 15.1 <0.0001 554 15.4 147 18.6 407 14.5 0.0043 343 18.3 118 23.7 225 16.3 0.0003 
any wheezing 419 7.7 133 10.3 286 6.8 <0.0001 302 8.4 87 11.0 215 7.7 0.0025 117 6.2 46 9.2 71 5.2 0.0012 
any dyspnea 3057 55.8 788 61.2 2269 54.2 <0.0001 2126 59.1 501 63.5 1625 57.8 0.0042 931 49.6 287 57.6 644 46.7 <0.0001 
supplemental oxygen use (V46.2) 317 5.8 124 9.6 193 4.6 <0.0001 112 3.1 40 5.1 72 2.6 0.0003 205 10.9 84 16.9 121 8.8 <0.0001 
Other symptoms                                           
chest pain unspecified 1662 30.4 472 36.7 1190 28.4 <0.0001 1082 30.1 282 35.7 800 28.5 <0.0001 580 30.9 190 38.2 390 28.3 <0.0001 
painful respiratory 272 5.0 85 6.6 187 4.5 0.0020 165 4.6 51 6.5 114 4.1 0.0043 107 5.7 34 6.8 73 5.3 0.2071 
precordial pain 107 2.0 35 2.7 72 1.7 0.0234 72 2.0 28 3.5 44 1.6 0.0004 35 1.9 7 1.4 28 2.0 0.3760 
any chest pain 1742 31.8 491 38.2 1251 29.9 <0.0001 1137 31.6 296 37.5 841 29.9 <0.0001 605 32.2 195 39.2 410 29.8 0.0001 
chronic fatigue 85 1.6 25 1.9 60 1.4 0.1957 67 1.9 20 2.5 47 1.7 0.1133 18 1.0 5 1.0 13 0.9 0.9053 
other malaise/fatigue 1379 25.2 371 28.8 1008 24.1 0.0006 884 24.6 223 28.3 661 23.5 0.0063 495 26.4 148 29.7 347 25.2 0.0489 
difficulty walking 139 2.5 34 2.6 105 2.5 0.7883 105 2.9 25 3.2 80 2.8 0.6353 34 1.8 9 1.8 25 1.8 0.9920 
memory loss 132 2.4 27 2.1 105 2.5 0.4025 94 2.6 19 2.4 75 2.7 0.6847 38 2.0 8 1.6 30 2.2 0.4385 
cough 1963 35.9 546 42.4 1417 33.8 <0.0001 1394 38.7 370 46.9 1024 36.4 <0.0001 569 30.3 176 35.3 393 28.5 0.0045 
hemoptysis 76 1.4 19 1.5 57 1.4 0.7572 52 1.4 11 1.4 41 1.5 0.8926 24 1.3 8 1.6 16 1.2 0.4485 
                                            
Procedures                                           
chest CT 822 15.0 219 17.0 603 14.4 0.0215 551 15.3 128 16.2 423 15.1 0.4201 271 14.4 91 18.3 180 13.1 0.0046 
chest x-ray 3432 62.7 883 68.6 2549 60.9 <0.0001 2234 62.1 539 68.3 1695 60.3 <0.0001 1198 63.9 344 69.1 854 62.0 0.0047 
echocardiography 1113 20.3 262 20.4 851 20.3 0.9767 819 22.8 172 21.8 647 23.0 0.4683 294 15.7 90 18.1 204 14.8 0.0855 
EKG 2452 44.8 638 49.6 1814 43.3 <0.0001 1621 45.0 393 49.8 1228 43.7 0.0023 831 44.3 245 49.2 586 42.5 0.0102 
heart catheterization 71 1.3 17 1.3 54 1.3 0.9304 51 1.4 12 1.5 39 1.4 0.7800 20 1.1 5 1.0 15 1.1 0.8749 
nebulizer treatment 1771 32.3 477 37.1 1294 30.9 <0.0001 1326 36.8 328 41.6 998 35.5 0.0018 445 23.7 149 29.9 296 21.5 0.0001 
non-invasive ventilator 339 6.2 85 6.6 254 6.1 0.4824 210 5.8 46 5.8 164 5.8 0.9948 129 6.9 39 7.8 90 6.5 0.3258 
spirometry 2284 41.7 507 39.4 1777 42.4 0.0533 1578 43.8 323 40.9 1255 44.7 0.0625 706 37.6 184 36.9 522 37.9 0.7126 
any vaccination (flu or 
pneumonia) 
2632 48.1 617 47.9 2015 48.1 0.9136 1799 50.0 398 50.4 1401 49.9 0.7712 833 44.4 219 44.0 614 44.6 0.8229 
                                            
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
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any moderate 783 14.3 229 17.8 554 13.2 <0.0001 525 14.6 142 18.0 383 13.6 0.0021 258 13.8 87 17.5 171 12.4 0.0049 
any severe 434 7.9 133 10.3 301 7.2 0.0003 266 7.4 75 9.5 191 6.8 0.0102 168 9.0 58 11.6 110 8.0 0.0141 
any other hospitalizations* 124 2.3 30 2.3 94 2.2 0.8553 112 3.1 26 3.3 86 3.1 0.7371 12 0.6 4 0.8 8 0.6 0.5932 
Prior 2-12 weeks                                           
any moderate 894 16.3 304 23.6 590 14.1 <0.0001 585 16.3 180 22.8 405 14.4 <0.0001 309 16.5 124 24.9 185 13.4 <0.0001 
any severe 337 6.2 120 9.3 217 5.2 <0.0001 179 5.0 61 7.7 118 4.2 <0.0001 158 8.4 59 11.8 99 7.2 0.0013 
any other hospitalizations* 209 3.8 67 5.2 142 3.4 0.0030 169 4.7 49 6.2 120 4.3 0.0228 40 2.1 18 3.6 22 1.6 0.0075 
Prior 13-52 weeks                                           
no moderate 4200 76.7 839 65.2 3361 80.3 <0.0001 2733 75.9 501 63.5 2232 79.4 <0.0001 1467 78.2 338 67.9 1129 81.9 <0.0001 
1 moderate 1018 18.6 325 25.3 693 16.5 <0.0001 694 19.3 212 26.9 482 17.2 <0.0001 324 17.3 113 22.7 211 15.3 0.0002 
>1 moderate 257 4.7 123 9.6 134 3.2 <0.0001 172 4.8 76 9.6 96 3.4 <0.0001 85 4.5 47 9.4 38 2.8 <0.0001 
any severe 409 7.5 149 11.6 260 6.2 <0.0001 215 6.0 77 9.8 138 4.9 <0.0001 194 10.3 72 14.5 122 8.9 0.0004 
any other hospitalizations* 384 7.0 121 9.4 263 6.3 0.0001 313 8.7 98 12.4 215 7.7 <0.0001 71 3.8 23 4.6 48 3.5 0.2552 
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 852 15.6 231 17.9 621 14.8 0.0069 687 19.1 181 22.9 506 18.0 0.0018 165 8.8 50 10.0 115 8.3 0.2524 
COPD Inpatient (Any) 1117 20.4 370 28.7 747 17.8 <0.0001 636 17.7 196 24.8 440 15.7 <0.0001 481 25.6 174 34.9 307 22.3 <0.0001 
Total Inpatient (Any) 1690 30.9 510 39.6 1180 28.2 <0.0001 1153 32.0 319 40.4 834 29.7 <0.0001 537 28.6 191 38.4 346 25.1 <0.0001 
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period)  
Same as Index Trmt 2238 40.9 592 46.0 1646 39 <0.0001 1334 37.1 326 41.3 1008 36 0.0051 904 48.2 266 53.4 638 46 0.0065 
No evidence Any Trmt 2931 53.5 584 45.4 2347 56.0 <0.0001 2055 57.1 387 49.0 1668 59.4 <0.0001 876 46.7 197 39.6 679 49.3 0.0002 
Different Trmt from Index 306 5.6 111 9 195 4.7 <0.0001 210 5.8 76 9.6 134 4.8 <0.0001 96 5.1 35 7 61 4.4 0.0239 
Now using Triple 169 3.1 65 5.1 104 2.5 <0.0001 107 3.0 41 5.2 66 2.3 <0.0001 62 3.3 24 4.8 38 2.8 0.0274 
No longer using Triple 86 1.6 29 2.3 57 1.4 0.0244 63 1.8 21 2.7 42 1.5 0.0272 23 1.2 8 1.6 15 1.1 0.3681 
Switched between ICSLABA 
and LAMA 
51 0.9 17 1.3 34 0.8 0.0964 40 1.1 14 1.8 26 0.9 0.0444 11 0.6 3 0.6 8 0.6 0.9563 
LHP enrollee 3599 65.7% 789 61.3% 2810 67.1% 0.0001                             
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 52 Baseline Characteristics: Any Moderate/Severe Exacerbation in First 6 Months, Without Discontinuation 
  LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  
Number of Patients 2544   703   1841     1544   402   1142     1000   301   699     
Age Categories                                           
age 40-54 226 8.9 69 9.8 157 8.5 0.3075 102 6.6 26 6.5 76 6.7 0.8965 124 12.4 43 14.3 81 11.6 0.2351 
age 55-64 479 18.8 148 21.1 331 18.0 0.0762 246 15.9 71 17.7 175 15.3 0.2707 233 23.3 77 25.6 156 22.3 0.2628 
age 65-74 812 31.9 205 29.2 607 33.0 0.0652 488 31.6 118 29.4 370 32.4 0.2586 324 32.4 87 28.9 237 33.9 0.1211 
age 75 and older 1027 40.4 281 40.0 746 40.5 0.8004 708 45.9 187 46.5 521 45.6 0.7566 319 31.9 94 31.2 225 32.2 0.7652 
age (Mean, SD) 70.80 10.95 70.37 11.34 70.96 10.80 0.2262 72.16 10.54 72.09 10.88 72.19 10.43 0.8741 68.69 11.24 68.08 11.56 68.96 11.09 0.2576 
                                            
Men 1141 44.9 292 41.5 849 46.1 0.0378 709 45.9 180 44.8 529 46.3 0.5927 432 43.2 112 37.2 320 45.8 0.0121 
                                            
Quarter of Year for Index Date             <0.0001             0.0084             0.0039 
Q1 767 30.1 192 27.3 575 31.2   458 29.7 110 27.4 348 30.5   309 30.9 82 27.2 227 32.5   
Q2 485 19.1 102 14.5 383 20.8   328 21.2 67 16.7 261 22.9   157 15.7 35 11.6 122 17.5   
Q3 538 21.1 158 22.5 380 20.6   372 24.1 108 26.9 264 23.1   166 16.6 50 16.6 116 16.6   
Q4 754 29.6 251 35.7 503 27.3   386 25.0 117 29.1 269 23.6   368 36.8 134 44.5 234 33.5   
                                            
Months of enrollment post-Index             0.0289             0.2494             0.0069 
7 29 1.1 14 2.0 15 0.8   15 1.0 8 2.0 7 0.6   14 1.4 6 2.0 8 1.1   
8 27 1.1 13 1.8 14 0.8   14 0.9 5 1.2 9 0.8   13 1.3 8 2.7 5 0.7   
9 46 1.8 13 1.8 33 1.8   24 1.6 6 1.5 18 1.6   22 2.2 7 2.3 15 2.1   
10 45 1.8 7 1.0 38 2.1   31 2.0 6 1.5 25 2.2   14 1.4 1 0.3 13 1.9   
11 54 2.1 13 1.8 41 2.2   39 2.5 9 2.2 30 2.6   15 1.5 4 1.3 11 1.6   
12 36 1.4 7 1.0 29 1.6   27 1.7 3 0.7 24 2.1   9 0.9 4 1.3 5 0.7   
13 49 1.9 15 2.1 34 1.8   32 2.1 11 2.7 21 1.8   17 1.7 4 1.3 13 1.9   
14 54 2.1 19 2.7 35 1.9   37 2.4 11 2.7 26 2.3   17 1.7 8 2.7 9 1.3   
15 41 1.6 15 2.1 26 1.4   28 1.8 7 1.7 21 1.8   13 1.3 8 2.7 5 0.7   
16 53 2.1 12 1.7 41 2.2   27 1.7 9 2.2 18 1.6   26 2.6 3 1.0 23 3.3   
17 57 2.2 13 1.8 44 2.4   34 2.2 8 2.0 26 2.3   23 2.3 5 1.7 18 2.6   
18 49 1.9 20 2.8 29 1.6   28 1.8 12 3.0 16 1.4   21 2.1 8 2.7 13 1.9   
19 43 1.7 11 1.6 32 1.7   22 1.4 3 0.7 19 1.7   21 2.1 8 2.7 13 1.9   
20 42 1.7 14 2.0 28 1.5   30 1.9 7 1.7 23 2.0   12 1.2 7 2.3 5 0.7   
21 44 1.7 13 1.8 31 1.7   25 1.6 7 1.7 18 1.6   19 1.9 6 2.0 13 1.9   
22 59 2.3 14 2.0 45 2.4   39 2.5 11 2.7 28 2.5   20 2.0 3 1.0 17 2.4   
23 42 1.7 7 1.0 35 1.9   26 1.7 4 1.0 22 1.9   16 1.6 3 1.0 13 1.9   
24 1774 69.7 483 68.7 1291 70.1   1066 69.0 275 68.4 791 69.3   708 70.8 208 69.1 500 71.5   
Insurance at Index                                           
Commercial 834 32.8 227 32.3 607 33.0 0.7435 606 39.2 161 40.0 445 39.0 0.7021 228 22.8 66 21.9 162 23.2 0.6659 
Medicaid 271 10.7 91 12.9 180 9.8 0.0206 105 6.8 29 7.2 76 6.7 0.7018 166 16.6 62 20.6 104 14.9 0.0258 
Medicare 1452 57.1 388 55.2 1064 57.8 0.2356 846 54.8 215 53.5 631 55.3 0.5394 606 60.6 173 57.5 433 61.9 0.1845 
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  LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  
Number of Patients 2544   703   1841     1544   402   1142     1000   301   699     
                                            
CMS comorbidities                                            
acute myocardial infarction 
(AMI) 
87 3.4 26 3.7 61 3.3 0.6328 55 3.6 14 3.5 41 3.6 0.9203 32 3.2 12 4.0 20 2.9 0.3536 
Alzheimer’s 84 3.3 28 4.0 56 3.0 0.2349 45 2.9 16 4.0 29 2.5 0.1397 39 3.9 12 4.0 27 3.9 0.9259 
atrial fibrillation 246 9.7 80 11.4 166 9.0 0.0713 160 10.4 49 12.2 111 9.7 0.1624 86 8.6 31 10.3 55 7.9 0.2086 
cancers 174 6.8 52 7.4 122 6.6 0.4914 114 7.4 36 9.0 78 6.8 0.1611 60 6.0 16 5.3 44 6.3 0.5498 
lung cancer 53 2.1 14 2.0 39 2.1 0.8411 35 2.3 9 2.2 26 2.3 0.9650 18 1.8 5 1.7 13 1.9 0.8284 
chronic kidney disease 409 16.1 112 15.9 297 16.1 0.9019 269 17.4 72 17.9 197 17.3 0.7641 140 14.0 40 13.3 100 14.3 0.6707 
diabetes 591 23.2 179 25.5 412 22.4 0.0996 344 22.3 97 24.1 247 21.6 0.3001 247 24.7 82 27.2 165 23.6 0.2212 
heart failure 437 17.2 154 21.9 283 15.4 <0.0001 258 16.7 91 22.6 167 14.6 0.0002 179 17.9 63 20.9 116 16.6 0.1009 
ischemic heart dis. (IHD; incl. 
AMI) 
608 23.9 175 24.9 433 23.5 0.4676 389 25.2 107 26.6 282 24.7 0.4449 219 21.9 68 22.6 151 21.6 0.7287 
rheumatoid/osteo arthritis 
(RA/OA) 
629 24.7 186 26.5 443 24.1 0.2105 383 24.8 109 27.1 274 24.0 0.2127 246 24.6 77 25.6 169 24.2 0.6363 
stroke/TIA 171 6.7 53 7.5 118 6.4 0.3089 98 6.3 34 8.5 64 5.6 0.0436 73 7.3 19 6.3 54 7.7 0.4308 
no CMS Comorbidity 904 35.5 236 33.6 668 36.3 0.2009 541 35.0 124 30.8 417 36.5 0.0405 363 36.3 112 37.2 251 35.9 0.6948 
Elixhauser comorbidities                                            
AIDS         4 0.2 0.2161         4 0.4 0.2348               
alcohol abuse 95 3.7 35 5.0 60 3.3 0.0408 46 3.0 15 3.7 31 2.7 0.3024 49 4.9 20 6.6 29 4.1 0.0935 
chronic blood loss anemia 27 1.1 14 2.0 13 0.7 0.0047 18 1.2 9 2.2 9 0.8 0.0198 9 0.9 5 1.7 4 0.6 0.0944 
coagulopathy 76 3.0 25 3.6 51 2.8 0.2977 41 2.7 16 4.0 25 2.2 0.0548 35 3.5 9 3.0 26 3.7 0.5647 
congestive heart failure 391 15.4 129 18.3 262 14.2 0.0100 244 15.8 80 19.9 164 14.4 0.0088 147 14.7 49 16.3 98 14.0 0.3548 
deficiency anemias 349 13.7 129 18.3 220 12.0 <0.0001 205 13.3 80 19.9 125 10.9 <0.0001 144 14.4 49 16.3 95 13.6 0.2667 
depression 398 15.6 137 19.5 261 14.2 0.0010 202 13.1 58 14.4 144 12.6 0.3525 196 19.6 79 26.2 117 16.7 0.0005 
diabetes (wo/chr complications) 564 22.2 181 25.7 383 20.8 0.0073 343 22.2 107 26.6 236 20.7 0.0136 221 22.1 74 24.6 147 21.0 0.2140 
diabetes (w/chr complications) 188 7.4 59 8.4 129 7.0 0.2323 129 8.4 39 9.7 90 7.9 0.2566 59 5.9 20 6.6 39 5.6 0.5120 
drug abuse 64 2.5 23 3.3 41 2.2 0.1324 42 2.7 12 3.0 30 2.6 0.7042 22 2.2 11 3.7 11 1.6 0.0396 
fluid and electrolyte disorders 295 11.6 111 15.8 184 10.0 <0.0001 174 11.3 59 14.7 115 10.1 0.0120 121 12.1 52 17.3 69 9.9 0.0010 
hypertension 1566 61.6 432 61.5 1134 61.6 0.9460 986 63.9 265 65.9 721 63.1 0.3174 580 58.0 167 55.5 413 59.1 0.2897 
hypothyroidism 478 18.8 149 21.2 329 17.9 0.0549 281 18.2 88 21.9 193 16.9 0.0257 197 19.7 61 20.3 136 19.5 0.7678 
liver disease 96 3.8 29 4.1 67 3.6 0.5652 60 3.9 16 4.0 44 3.9 0.9096 36 3.6 13 4.3 23 3.3 0.4232 
lymphoma 23 0.9 6 0.9 17 0.9 0.8677 12 0.8 3 0.7 9 0.8 0.9345 11 1.1 3 1.0 8 1.1 0.8371 
metastatic cancer 26 1.0 6 0.9 20 1.1 0.6015 24 1.6 6 1.5 18 1.6 0.9072         2 0.3 0.3529 
obesity 326 12.8 92 13.1 234 12.7 0.7996 205 13.3 47 11.7 158 13.8 0.2760 121 12.1 45 15.0 76 10.9 0.0697 
other neurological disorders 216 8.5 61 8.7 155 8.4 0.8348 146 9.5 37 9.2 109 9.5 0.8409 70 7.0 24 8.0 46 6.6 0.4285 
paralysis 38 1.5 14 2.0 24 1.3 0.2009 26 1.7 12 3.0 14 1.2 0.0184 12 1.2 2 0.7 10 1.4 0.3074 
peripheral vascular disease 390 15.3 117 16.6 273 14.8 0.2561 261 16.9 74 18.4 187 16.4 0.3496 129 12.9 43 14.3 86 12.3 0.3910 
psychoses 251 9.9 82 11.7 169 9.2 0.0602 157 10.2 48 11.9 109 9.5 0.1717 94 9.4 34 11.3 60 8.6 0.1777 
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  LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  Total % Mod 
Sev 6 
Mon 
% No 
Mod 
Sev 
% pval  
Number of Patients 2544   703   1841     1544   402   1142     1000   301   699     
pulmonary circulation disease 297 11.7 91 12.9 206 11.2 0.2177 193 12.5 52 12.9 141 12.3 0.7589 104 10.4 39 13.0 65 9.3 0.0822 
renal failure 218 8.6 53 7.5 165 9.0 0.2514 146 9.5 37 9.2 109 9.5 0.8409 72 7.2 16 5.3 56 8.0 0.1303 
rheumatoid arthritis/collagen vas 142 5.6 42 6.0 100 5.4 0.5940 79 5.1 24 6.0 55 4.8 0.3664 63 6.3 18 6.0 45 6.4 0.7847 
solid tumor wo/metastasis 250 9.8 65 9.2 185 10.0 0.5430 164 10.6 44 10.9 120 10.5 0.8066 86 8.6 21 7.0 65 9.3 0.2296 
ulcers 3 0.1 2 0.3 1 0.1 0.1303     1 0.2     0.0918 2 0.2 1 0.3 1 0.1 0.5391 
valvular disease 285 11.2 99 14.1 186 10.1 0.0044 212 13.7 65 16.2 147 12.9 0.0986 73 7.3 34 11.3 39 5.6 0.0014 
weight loss 137 5.4 55 7.8 82 4.5 0.0008 91 5.9 36 9.0 55 4.8 0.0024 46 4.6 19 6.3 27 3.9 0.0899 
any Elixhauser diagnosis                                           
Other comorbidities 2316 91.0 647 92.0 1669 90.7 0.2769 1424 92.2 376 93.5 1048 91.8 0.2560 892 89.2 271 90.0 621 88.8 0.5775 
asthma 854 33.6 254 36.1 600 32.6 0.0909 488 31.6 140 34.8 348 30.5 0.1064 366 36.6 114 37.9 252 36.1 0.5832 
hypoxemia 965 37.9 300 42.7 665 36.1 0.0023 550 35.6 155 38.6 395 34.6 0.1530 415 41.5 145 48.2 270 38.6 0.0049 
pneumonia 855 33.6 311 44.2 544 29.5 <0.0001 550 35.6 200 49.8 350 30.6 <0.0001 305 30.5 111 36.9 194 27.8 0.0040 
influenza 69 2.7 24 3.4 45 2.4 0.1782 38 2.5 11 2.7 27 2.4 0.6788 31 3.1 13 4.3 18 2.6 0.1444 
COPD Complexity ^                                           
Low complexity 1244 48.9 256 36.4 988 53.7 <0.0001 734 47.5 137 34.1 597 52.3 <0.0001 510 51.0 119 39.5 391 55.9 <0.0001 
Med complexity 1184 46.5 422 60.0 762 41.4 <0.0001 733 47.5 250 62.2 483 42.3 <0.0001 451 45.1 172 57.1 279 39.9 <0.0001 
High complexity 116 4.6 25 3.6 91 4.9 0.1338 77 5.0 15 3.7 62 5.4 0.1787 39 3.9 10 3.3 29 4.1 0.5357 
Emphysema diagnosis (492.x) 634 24.9 206 29.3 428 23.2 0.0016 336 21.8 103 25.6 233 20.4 0.0292 298 29.8 103 34.2 195 27.9 0.0450 
                                            
COPD Medications                                            
index ICSLABA 1261 49.6 377 53.6 884 48.0 0.0114 777 50.3 224 55.7 553 48.4 0.0118 484 48.4 153 50.8 331 47.4 0.3128 
index LAMA 972 38.2 231 32.9 741 40.2 0.0006 565 36.6 124 30.8 441 38.6 0.0054 407 40.7 107 35.5 300 42.9 0.0295 
index triple 311 12.2 95 13.5 216 11.7 0.2201 202 13.1 54 13.4 148 13.0 0.8088 109 10.9 41 13.6 68 9.7 0.0700 
SABA use                                           
no SABA use 1110 43.6 253 36.0 857 46.6 <0.0001 625 40.5 133 33.1 492 43.1 0.0004 485 48.5 120 39.9 365 52.2 0.0003 
SABA <=15% of year 615 24.2 181 25.7 434 23.6 0.2524 384 24.9 98 24.4 286 25.0 0.7906 231 23.1 83 27.6 148 21.2 0.0276 
SABA <=40% of year 328 12.9 91 12.9 237 12.9 0.9618 217 14.1 58 14.4 159 13.9 0.8022 111 11.1 33 11.0 78 11.2 0.9281 
SABA >40% of year 491 19.3 178 25.3 313 17.0 <0.0001 318 20.6 113 28.1 205 18.0 <0.0001 173 17.3 65 21.6 108 15.5 0.0185 
SAMA use                                           
any ipratropium (SAMA) 325 12.8 117 16.6 208 11.3 0.0003 204 13.2 63 15.7 141 12.3 0.0904 121 12.1 54 17.9 67 9.6 0.0002 
any SABA/SAMA 443 17.4 154 21.9 289 15.7 0.0002 289 18.7 98 24.4 191 16.7 0.0007 154 15.4 56 18.6 98 14.0 0.0654 
any SAMA or SABA/SAMA 703 27.6 239 34.0 464 25.2 <0.0001 452 29.3 142 35.3 310 27.1 0.0019 251 25.1 97 32.2 154 22.0 0.0006 
Other COPD medications                                           
any ICS 853 33.5 259 36.8 594 32.3 0.0288 540 35.0 149 37.1 391 34.2 0.3068 313 31.3 110 36.5 203 29.0 0.0189 
any LABA 134 5.3 33 4.7 101 5.5 0.4239 75 4.9 14 3.5 61 5.3 0.1360 59 5.9 19 6.3 40 5.7 0.7165 
any methylxanthines 45 1.8 14 2.0 31 1.7 0.5987 13 0.8 6 1.5 7 0.6 0.0969 32 3.2 8 2.7 24 3.4 0.5226 
Any use of above COPD 
medications 
1307 51.4 409 58.2 898 48.8 <0.0001 828 53.6 242 60.2 586 51.3 0.0021 479 47.9 167 55.5 312 44.6 0.0016 
Use of Index Trmts Prior Year§                                           
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  LHP & PHP           LHP             PHP             
Baseline Characteristic Total % Mod 
Sev 6 
Mon 
% No 
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Sev 6 
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Number of Patients 2544   703   1841     1544   402   1142     1000   301   699     
No ICSLABA in prior year 2261 88.9 611 86.9 1650 89.6 0.0517 1369 88.7 344 85.6 1025 89.8 0.0229 892 89.2 267 88.7 625 89.4 0.7403 
1-2 Rxs ICSLABA (wks 27-52) 153 6.0 46 6.5 107 5.8 0.4878 96 6.2 31 7.7 65 5.7 0.1492 57 5.7 15 5.0 42 6.0 0.5213 
>2 Rxs ICSLABA (wks 27-52) 130 5.1 46 6.5 84 4.6 0.0425 79 5.1 27 6.7 52 4.6 0.0905 51 5.1 19 6.3 32 4.6 0.2528 
No LAMA in prior year 2448 96.2 669 95.2 1779 96.6 0.0821 1482 96.0 375 93.3 1107 96.9 0.0013 966 96.6 294 97.7 672 96.1 0.2186 
1-2 Rxs LAMA (wks 27-52) 54 2.1 21 3.0 33 1.8 0.0616 38 2.5 17 4.2 21 1.8 0.0078 16 1.6 4 1.3 12 1.7 0.6539 
>2 Rxs LAMA (wks 27-52) 42 1.7 13 1.8 29 1.6 0.6277 24 1.6 10 2.5 14 1.2 0.0786 18 1.8 3 1.0 15 2.1 0.2099 
Oxygen Use                                           
no oxygen 1372 53.9 329 46.8 1043 56.7 <0.0001 848 54.9 193 48.0 655 57.4 0.0012 524 52.4 136 45.2 388 55.5 0.0027 
oxygen <=50% of year 427 16.8 116 16.5 311 16.9 0.8129 287 18.6 76 18.9 211 18.5 0.8491 140 14.0 40 13.3 100 14.3 0.6707 
oxygen >50% of year 745 29.3 258 36.7 487 26.5 <0.0001 409 26.5 133 33.1 276 24.2 0.0005 336 33.6 125 41.5 211 30.2 0.0005 
Symptoms                                           
Dyspnea                                           
Breathlessness                                           
no periods breathlessness 1590 62.5 410 58.3 1180 64.1 0.0071 870 56.3 219 54.5 651 57.0 0.3795 720 72.0 191 63.5 529 75.7 <0.0001 
1 period breathlessness 485 19.1 153 21.8 332 18.0 0.0322 319 20.7 88 21.9 231 20.2 0.4788 166 16.6 65 21.6 101 14.4 0.0053 
>1 period breathlessness 469 18.4 140 19.9 329 17.9 0.2345 355 23.0 95 23.6 260 22.8 0.7231 114 11.4 45 15.0 69 9.9 0.0204 
Shortness of Breath                                           
no periods shortness breath 1599 62.9 407 57.9 1192 64.7 0.0014 954 61.8 233 58.0 721 63.1 0.0663 645 64.5 174 57.8 471 67.4 0.0037 
1 period shortness breath 512 20.1 145 20.6 367 19.9 0.6974 338 21.9 92 22.9 246 21.5 0.5751 174 17.4 53 17.6 121 17.3 0.9094 
>1 period shortness breath 433 17.0 151 21.5 282 15.3 0.0002 252 16.3 77 19.2 175 15.3 0.0739 181 18.1 74 24.6 107 15.3 0.0005 
any wheezing 187 7.4 66 9.4 121 6.6 0.0149 125 8.1 38 9.5 87 7.6 0.2462 62 6.2 28 9.3 34 4.9 0.0076 
any dyspnea 1426 56.1 441 62.7 985 53.5 <0.0001 948 61.4 264 65.7 684 59.9 0.0407 478 47.8 177 58.8 301 43.1 <0.0001 
supplemental oxygen use (V46.2) 166 6.5 75 10.7 91 4.9 <0.0001 52 3.4 24 6.0 28 2.5 0.0008 114 11.4 51 16.9 63 9.0 0.0003 
Other symptoms                                           
chest pain unspecified 702 27.6 237 33.7 465 25.3 <0.0001 426 27.6 134 33.3 292 25.6 0.0027 276 27.6 103 34.2 173 24.7 0.0021 
painful respiratory 114 4.5 44 6.3 70 3.8 0.0074 60 3.9 27 6.7 33 2.9 0.0006 54 5.4 17 5.6 37 5.3 0.8200 
precordial pain 44 1.7 18 2.6 26 1.4 0.0470 28 1.8 14 3.5 14 1.2 0.0035 16 1.6 4 1.3 12 1.7 0.6539 
any chest pain 737 29.0 247 35.1 490 26.6 <0.0001 444 28.8 141 35.1 303 26.5 0.0011 293 29.3 106 35.2 187 26.8 0.0070 
chronic fatigue 33 1.3 9 1.3 24 1.3 0.9628 21 1.4 6 1.5 15 1.3 0.7898 12 1.2 3 1.0 9 1.3 0.6984 
other malaise/fatigue 591 23.2 202 28.7 389 21.1 <0.0001 340 22.0 113 28.1 227 19.9 0.0006 251 25.1 89 29.6 162 23.2 0.0325 
difficulty walking 60 2.4 18 2.6 42 2.3 0.6783 47 3.0 14 3.5 33 2.9 0.5518 13 1.3 4 1.3 9 1.3 0.9578 
memory loss 51 2.0 12 1.7 39 2.1 0.5079 33 2.1 7 1.7 26 2.3 0.5232 18 1.8 5 1.7 13 1.9 0.8284 
cough 858 33.7 276 39.3 582 31.6 0.0003 568 36.8 183 45.5 385 33.7 <0.0001 290 29.0 93 30.9 197 28.2 0.3856 
hemoptysis 37 1.5 11 1.6 26 1.4 0.7739 26 1.7 8 2.0 18 1.6 0.5791 11 1.1 3 1.0 8 1.1 0.8371 
Procedures                                           
chest CT 375 14.7 126 17.9 249 13.5 0.0051 243 15.7 77 19.2 166 14.5 0.0288 132 13.2 49 16.3 83 11.9 0.0591 
chest x-ray 1591 62.5 491 69.8 1100 59.8 <0.0001 961 62.2 277 68.9 684 59.9 0.0014 630 63.0 214 71.1 416 59.5 0.0005 
echocardiography 515 20.2 148 21.1 367 19.9 0.5304 359 23.3 91 22.6 268 23.5 0.7345 156 15.6 57 18.9 99 14.2 0.0563 
EKG 1110 43.6 338 48.1 772 41.9 0.0052 681 44.1 198 49.3 483 42.3 0.0157 429 42.9 140 46.5 289 41.3 0.1300 
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heart catheterization 28 1.1 8 1.1 20 1.1 0.9112 21 1.4 6 1.5 15 1.3 0.7898 7 0.7 2 0.7 5 0.7 0.9295 
nebulizer treatment 840 33.0 260 37.0 580 31.5 0.0086 599 38.8 162 40.3 437 38.3 0.4720 241 24.1 98 32.6 143 20.5 <0.0001 
non-invasive ventilator 176 6.9 52 7.4 124 6.7 0.5566 103 6.7 25 6.2 78 6.8 0.6727 73 7.3 27 9.0 46 6.6 0.1828 
spirometry 1150 45.2 289 41.1 861 46.8 0.0103 747 48.4 174 43.3 573 50.2 0.0174 403 40.3 115 38.2 288 41.2 0.3757 
any vaccination (flu or 
pneumonia) 
1241 48.8 334 47.5 907 49.3 0.4281 788 51.0 200 49.8 588 51.5 0.5490 453 45.3 134 44.5 319 45.6 0.7445 
COPD-related exacerbations                                           
Index and 2 weeks prior                                           
any moderate 321 12.6 114 16.2 207 11.2 0.0007 212 13.7 71 17.7 141 12.3 0.0077 109 10.9 43 14.3 66 9.4 0.0242 
any severe 173 6.8 71 10.1 102 5.5 <0.0001 106 6.9 41 10.2 65 5.7 0.0021 67 6.7 30 10.0 37 5.3 0.0067 
any other hospitalizations* 43 1.7 16 2.3 27 1.5 0.1567 38 2.5 14 3.5 24 2.1 0.1243 5 0.5 2 0.7 3 0.4 0.6285 
Prior 2-12 weeks                                           
any moderate 436 17.1 172 24.5 264 14.3 <0.0001 269 17.4 97 24.1 172 15.1 <0.0001 167 16.7 75 24.9 92 13.2 <0.0001 
any severe 162 6.4 71 10.1 91 4.9 <0.0001 77 5.0 32 8.0 45 3.9 0.0015 85 8.5 39 13.0 46 6.6 0.0009 
any other hospitalizations* 98 3.9 39 5.5 59 3.2 0.0060 75 4.9 30 7.5 45 3.9 0.0047 23 2.3 9 3.0 14 2.0 0.3395 
Prior 13-52 weeks                                           
no moderate 1981 77.9 462 65.7 1519 82.5 <0.0001 1174 76.0 253 62.9 921 80.6 <0.0001 807 80.7 209 69.4 598 85.6 <0.0001 
1 moderate 449 17.6 177 25.2 272 14.8 <0.0001 292 18.9 110 27.4 182 15.9 <0.0001 157 15.7 67 22.3 90 12.9 0.0002 
>1 moderate 114 4.5 64 9.1 50 2.7 <0.0001 78 5.1 39 9.7 39 3.4 <0.0001 36 3.6 25 8.3 11 1.6 <0.0001 
any severe 208 8.2 87 12.4 121 6.6 <0.0001 98 6.3 42 10.4 56 4.9 <0.0001 110 11.0 45 15.0 65 9.3 0.0088 
any other hospitalizations* 172 6.8 65 9.2 107 5.8 0.0020 134 8.7 52 12.9 82 7.2 0.0004 38 3.8 13 4.3 25 3.6 0.5733 
All Inpatient Utilization                                           
Non-COPD Inpatient (Any) 363 14.3 135 19.2 228 12.4 <0.0001 286 18.5 111 27.6 175 15.3 <0.0001 77 7.7 24 8.0 53 7.6 0.8315 
COPD Inpatient (Any) 496 19.5 198 28.2 298 16.2 <0.0001 258 16.7 100 24.9 158 13.8 <0.0001 238 23.8 98 32.6 140 20.0 <0.0001 
Total Inpatient (Any) 742 29.2 280 39.8 462 25.1 <0.0001 475 30.8 174 43.3 301 26.4 <0.0001 267 26.7 106 35.2 161 23.0 <0.0001 
Treatment Therapy Use (Index until period prior to Sev Exac  or end of evaluated time period)  
Same as Index Trmt 2238 88.0 592 84.2 1646 89 0.0003 1334 86.4 326 81.1 1008 88 0.0003 904 90.4 266 88.4 638 91 0.1532 
No evidence Any Trmt                                           
Different Trmt from Index 306 12.0 111 16 195 10.6 0.0003 210 13.6 76 18.9 134 11.7 0.0003 96 9.6 35 12 61 8.7 0.1532 
Now using Triple 169 6.6 65 9.2 104 5.6 0.0011 107 6.9 41 10.2 66 5.8 0.0027 62 6.2 24 8.0 38 5.4 0.1270 
No longer using Triple 86 3.4 29 4.1 57 3.1 0.1991 63 4.1 21 5.2 42 3.7 0.1778 23 2.3 8 2.7 15 2.1 0.6204 
Switched between ICSLABA 
and LAMA 
51 2.0 17 2.4 34 1.8 0.3578 40 2.6 14 3.5 26 2.3 0.1906 11 1.1 3 1.0 8 1.1 0.8371 
LHP enrollee 1544 60.7 402 57.2 1142 62.0 0.0252                       
§ Inclusion criteria: no use of index medications in 6 months prior to index 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 53 Moderate or Severe Exacerbation Within 3 Months, Baseline Healthcare Costs (Means) 
  LHP and PHP           LHP             PHP             
Baseline Characteristic Total SD Mod 
Sev 3 
Mon 
SD No 
Mod 
Sev 
SD pval  Total SD Mod 
Sev 3 
Mon 
SD No 
Mod 
Sev 
SD pval  Total SD Mod 
Sev 3 
Mon 
SD No 
Mod 
Sev 
SD pval  
Number of Patients 5475   656   4819     3599   403   3196     1876   253   1623     
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient 5490 9457 6130 9395 5403 9463 0.0647 5426 8291 6370 10445 5307 7972 0.0492 5614 11366 5748 7428 5593 11865 0.7786 
COPD Outpatient 1961 2436 2601 2663 1874 2391 <.0001 1786 2213 2366 2438 1713 2172 <.0001 2297 2786 2976 2953 2191 2745 <.0001 
Total Outpatient 7452 10320 8731 10240 7277 10320 0.0007 7212 9094 8736 10894 7020 8824 0.0025 7911 12326 8724 9123 7784 12750 0.1519 
                                            
Non-COPD Inpatient 5069 20267 6389 20882 4890 20177 0.0754 6913 24336 9139 25584 6632 24164 0.0513 1533 6606 2009 7611 1459 6435 0.2768 
COPD Inpatient 6179 20753 10420 27408 5602 19606 <.0001 5019 19696 8854 27035 4536 18515 0.002 8404 22481 12915 27864 7701 21446 0.0047 
Total Inpatient 11248 30260 16809 36895 10491 29163 <.0001 11932 32612 17993 40202 11167 31450 0.0011 9937 25094 14923 30887 9160 23984 0.0049 
Total Medical Utilization 18700 33496 25540 40975 17769 32237 <.0001 19144 35393 26729 44630 18188 33939 0.0002 17848 29507 23648 34359 16944 28583 0.0034 
                                            
Non-COPD Outpatient Rx 2369 4007 2547 4300 2345 3965 0.2553 2635 4381 2802 4481 2614 4368 0.4155 1859 3107 2140 3969 1816 2949 0.2138 
COPD Outpatient Rx 408 778 546 951 389 749 <.0001 409 799 594 997 386 768 <.0001 405 735 469 869 395 712 0.2019 
Total Outpatient Rx 2777 4148 3092 4502 2734 4096 0.0533 3043 4510 3396 4603 2999 4497 0.0956 2265 3288 2609 4302 2211 3098 0.1586 
                                            
Total Healthcare Services 21477 34258 28633 41569 20503 33023 <.0001 22188 36262 30125 45202 21187 34853 0.0001 20113 30003 26256 34966 19155 29049 0.0023 
Cost of Utilization ($ mean, SD)  - for those with utilization within category  
Non-COPD Outpatient 5589 9513 6235 9441 5502 9521 0.0663 5512 8328 6466 10494 5391 8007 0.0494 5740 11461 5864 7457 5720 11968 0.797 
COPD Outpatient 2100 2463 2726 2663 2013 2421 <.0001 1928 2239 2503 2438 1854 2201 <.0001 2423 2808 3073 2951 2319 2771 <.0001 
Total Outpatient 7469 10326 8745 10242 7296 10326 0.0008 7226 9097 8736 10894 7036 8828 0.0027 7936 12337 8759 9125 7808 12763 0.1483 
                                            
Non-COPD Inpatient 32576 41773 34927 37350 32191 42465 0.5062 36213 45208 39602 40503 35682 45909 0.4372 17434 14833 18824 15258 17162 14790 0.596 
COPD Inpatient 30287 37170 35054 40846 29279 36289 0.0687 28403 39151 34981 44566 27146 37946 0.0985 32778 34258 35133 36573 32213 33705 0.4609 
Total Inpatient 36441 45266 41927 48435 35430 44602 0.0324 37244 48767 45038 53246 35979 47910 0.0287 34716 36619 37016 39425 34177 35956 0.4815 
Total Medical Utilization 18710 33502 25579 40994 17776 32242 <.0001 19144 35393 26729 44630 18188 33939 0.0002 17877 29522 23742 34395 16965 28594 0.0032 
                                            
Non-COPD Outpatient Rx 2462 4056 2639 4349 2438 4015 0.2695 2693 4411 2845 4501 2673 4400 0.4656 1997 3177 2294 4066 1950 3013 0.214 
COPD Outpatient Rx 408 778 546 951 389 749 <.0001 409 799 594 997 386 768 <.0001 405 735 469 869 395 712 0.2019 
Total Outpatient Rx 2777 4148 3092 4502 2734 4096 0.0533 3043 4510 3396 4603 2999 4497 0.0956 2265 3288 2609 4302 2211 3098 0.1586 
                                            
Total Healthcare Services 21477 34258 28633 41569 20503 33023 <.0001 22188 36262 30125 45202 21187 34853 0.0001 20113 30003 26256 34966 19155 29049 0.0023 
Length of Stay (inpatient stays) 6.6 7.7 6.7 7.2 6.6 7.7 0.9342 7.3 8.6 7.4 7.8 7.3 8.7 0.8121 5.3 5.0 5.5 6.1 5.2 4.7 0.6756 
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Table 54 Moderate or Severe Exacerbation Within 3 Months, Baseline Healthcare Costs (Median) 
 
LHP and PHP   LHP   PHP  
  
Total   Mod 
Sev 3 
Mon 
  No 
Mod 
Sev 
  pval 
Comb vs 
Triple* 
Total   Mod 
Sev 3 
Mon 
  No 
Mod 
Sev 
  pval 
Comb vs 
Triple* 
Total   Mod 
Sev 3 
Mon 
  No 
Mod 
Sev 
  pval 
Comb vs 
Triple* 
Median 5475   656   4819     3599   403   3196     1876   253         
Cost of Utilization ($)  
Non-COPD Outpatient 3181   3780   3110   0.0001 3361   4298   3248   0.0008 2879   3235   2836   0.0321 
COPD Outpatient 1201   1900   1114   <.0001 1038   1575   961   <.0001 1685   2306   1547   <.0001 
Total Outpatient 4931   6670   4790   <.0001 4924   6745   4759   <.0001 4964   6433   4836   0.0003 
                                            
Non-COPD Inpatient 0   0   0   0.0288 0   0   0   0.0187 0   0   0   0.2472 
COPD Inpatient 0   0   0   <.0001 0   0   0   <.0001 0   0   0   <.0001 
Total Inpatient 0   0   0   <.0001 0   0   0   <.0001 0   0   0   <.0001 
Total Medical Utilization 7398   10453   6958   <.0001 7552   10204   7175   <.0001 6998   10527   6470   <.0001 
                                            
Non-COPD Outpatient Rx 1252   1352   1244   0.0929 1442   1628   1416   0.0472 854   888   843   0.4486 
COPD Outpatient Rx 68   148   60   <.0001 68   176   59   <.0001 66   106   63   0.1136 
Total Outpatient Rx 1685   1984   1654   0.0034 1869   2384   1825   0.0004 1295   1366   1287   0.3232 
                                            
Total Healthcare Services 10052   13865   9647   <.0001 10559   13796   10044   <.0001 9209   14122   8842   <.0001 
Cost of Utilization ($)  - for those with utilization within category  
Non-COPD Outpatient 3285   3887   3208   0.0001 3417   4385   3340   0.0007 2993   3333  2928   0.0316 
COPD Outpatient 1380   2021   1292   <.0001 1185   1766   1111   <.0001 1792   2420  1707   <.0001 
Total Outpatient 4942   6683   4801   <.0001 4928   6745   4771   <.0001 4985   6466  4840   0.0003 
                                           
Non-COPD Inpatient 17802   20047   17554   0.1795 19872   22324   19242   0.1181 13848   15747  13707   0.6532 
COPD Inpatient 17641   18696   17312   0.0926 15300   16740   14212   0.0694 20654   22582  19815   0.6547 
Total Inpatient 19907   21708   19473   0.0585 18979   19682   18667   0.0301 21703   22319  21230   0.764 
Total Medical Utilization 7404   10508   6966   <.0001 7552   10204   7175   <.0001 7014   10530  6471   <.0001 
                                           
Non-COPD Outpatient Rx 1340   1457   1328   0.0976 1499   1662   1482   0.0721 1026   1063  1020   0.4207 
COPD Outpatient Rx 68   148   60   <.0001 68   176   59   <.0001 66   106  63   0.1136 
Total Outpatient Rx 1685   1984   1654   0.0034 1869   2384   1825   0.0004 1295   1366  1287   0.3232 
                                           
Total Healthcare Services 10052   13865   9647   <.0001 10559   13796   10044   <.0001 9209   14122  8842   <.0001 
Length of Stay (inpatient stays) 4   4   4   0.4891 4   5   4   0.2038 4   4  4   0.9097 
* Wilcoxon signed rank sum test for differences in distributions using median 
   
 
2
4
1 
Table 55 Moderate or Severe Exacerbation Within 3 Months Without Discontinuation, Baseline Healthcare Costs (Means) 
  LHP and PHP           LHP             PHP             
Baseline Characteristic Total SD Mod 
Sev 3 
Mon 
SD No 
Mod 
Sev 
SD pval  Total SD Mod 
Sev 3 
Mon 
SD No 
Mod 
Sev 
SD pval  Total SD Mod 
Sev 3 
Mon 
SD No 
Mod 
Sev 
SD pval  
Number of Patients 3403   482   2921     2127   282   1845     1276   200   1076     
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient 5461 9442 5993 9088 5373 9498 0.1819 5469 8211 6455 10458 5318 7803 0.0806 5447 11202 5341 6671 5467 11857 0.8322 
COPD Outpatient 1987 2416 2628 2633 1881 2362 <.0001 1803 2083 2427 2390 1707 2015 <.0001 2294 2862 2912 2924 2180 2837 0.0009 
Total Outpatient 7448 10256 8621 9974 7254 10291 0.0067 7272 8891 8882 10891 7026 8520 0.0065 7741 12195 8252 8529 7646 12762 0.3989 
                                            
Non-COPD Inpatient 4603 18550 6456 21936 4297 17916 0.0406 6497 22762 9614 27564 6020 21905 0.0373 1445 6189 2004 7492 1342 5914 0.2378 
COPD Inpatient 5830 20106 10505 28062 5058 18359 <.0001 4577 19378 8912 27109 3914 17822 0.0029 7919 21107 12752 29274 7020 19095 0.0082 
Total Inpatient 10432 28813 16962 37922 9355 26872 <.0001 11073 31356 18526 41290 9934 29393 0.0009 9364 23955 14755 32562 8362 21861 0.0082 
Total Medical Utilization 17880 32050 25583 42221 16609 29861 <.0001 18345 34005 27409 46290 16960 31498 0.0003 17105 28490 23008 35659 16008 26826 0.0088 
                                            
Non-COPD Outpatient Rx 2258 3682 2340 3527 2245 3707 0.5973 2599 4030 2468 2913 2619 4175 0.4487 1691 2927 2161 4247 1604 2603 0.0744 
COPD Outpatient Rx 480 852 594 1011 461 822 0.0062 506 884 679 1070 479 849 0.003 436 795 475 911 429 772 0.5046 
Total Outpatient Rx 2737 3885 2934 3840 2705 3892 0.2292 3103 4213 3146 3156 3096 4353 0.8148 2127 3176 2635 4629 2033 2817 0.0764 
                                            
Total Healthcare Services 20617 32842 28517 42747 19314 30719 <.0001 21448 34916 30555 46788 20057 32517 0.0003 19232 29018 25643 36213 18041 27329 0.0051 
Cost of Utilization ($ mean, SD)  - for those with utilization within category  
Non-COPD Outpatient 5559 9498 6107 9137 5468 9555 0.1757 5553 8245 6572 10515 5397 7834 0.0752 5569 11297 5450 6694 5591 11963 0.8146 
COPD Outpatient 2122 2439 2760 2630 2014 2389 <.0001 1939 2098 2573 2384 1840 2033 <.0001 2421 2888 3017 2923 2308 2869 0.0017 
Total Outpatient 7465 10262 8639 9977 7272 10297 0.0068 7282 8893 8882 10891 7037 8523 0.0069 7772 12210 8294 8530 7675 12777 0.3903 
                                            
Non-COPD Inpatient 31325 38824 34578 40215 30611 38525 0.3806 35431 42471 39294 44231 34601 42107 0.4057 16766 13743 19083 14707 16219 13535 0.3927 
COPD Inpatient 29744 36778 36168 42310 28038 35010 0.0378 27269 40274 34905 44593 25340 38956 0.0717 32594 32116 37505 40039 31214 29463 0.2306 
Total Inpatient 35502 44002 42360 50212 33861 42252 0.0306 36180 48021 44653 54344 34324 46371 0.0581 34236 35333 38830 43197 32957 32790 0.2738 
Total Medical Utilization 17896 32060 25636 42249 16621 29868 <.0001 18345 34005 27409 46290 16960 31498 0.0003 17145 28512 23123 35711 16038 26842 0.0083 
                                            
Non-COPD Outpatient Rx 2370 3736 2436 3566 2359 3764 0.6783 2660 4058 2503 2918 2684 4206 0.3694 1852 3015 2336 4370 1761 2676 0.0853 
COPD Outpatient Rx 480 852 594 1011 461 822 0.0062 506 884 679 1070 479 849 0.003 436 795 475 911 429 772 0.5046 
Total Outpatient Rx 2737 3885 2934 3840 2705 3892 0.2292 3103 4213 3146 3156 3096 4353 0.8148 2127 3176 2635 4629 2033 2817 0.0764 
                                            
Total Healthcare Services 20617 32842 28517 42747 19314 30719 <.0001 21448 34916 30555 46788 20057 32517 0.0003 19232 29018 25643 36213 18041 27329 0.0051 
Length of Stay (inpatient stays) 6.4 7.1 6.6 6.5 6.4 7.3 0.7228 7.0 8.1 7.1 6.4 7.0 8.4 0.9198 5.3 4.8 5.8 6.7 5.2 4.1 0.4261 
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Table 56 Moderate or Severe Exacerbation Within 3 Months Without Discontinuation, Baseline Healthcare Costs (Medians) 
  LHP and PHP           LHP             PHP             
  
Total   Mod 
Sev 3 
Mon 
  No 
Mod 
Sev 
  pval 
Comb 
vs 
Triple* 
Total   Mod 
Sev 3 
Mon 
  No 
Mod 
Sev 
  pval 
Comb vs 
Triple* 
Total   Mod 
Sev 3 
Mon 
  No 
Mod 
Sev 
  pval 
Comb 
vs 
Triple* 
Median 3403   482   2921     2127   282   1845     1276   200         
Cost of Utilization ($)  
Non-COPD Outpatient 3163   3624   3094   0.0036 3386   4326   3291   0.0093 2838   3158   2779   0.0934 
COPD Outpatient 1287   1980   1182   <.0001 1114   1690   1010   <.0001 1649   2291   1503   <.0001 
Total Outpatient 4932   6638   4780   <.0001 4971   7018   4786   <.0001 4899   5995   4764   0.0042 
                                            
Non-COPD Inpatient 0   0   0   0.0062 0   0   0   0.0034 0   0   0   0.2808 
COPD Inpatient 0   0   0   <.0001 0   0   0   <.0001 0   0   0   0.0004 
Total Inpatient 0   0   0   <.0001 0   0   0   <.0001 0   0   0   0.0002 
Total Medical Utilization 7235   10567   6557   <.0001 7542   10979   6856   <.0001 6564   9515   6072   <.0001 
                                            
Non-COPD Outpatient Rx 1226   1292   1205   0.1992 1502   1577   1496   0.5044 686   881   672   0.1031 
COPD Outpatient Rx 81   149   72   <.0001 101   209   85   <.0001 57   82   52   0.1889 
Total Outpatient Rx 1707   1979   1676   0.0391 1981   2387   1915   0.0492 1094   1206   1076   0.1225 
                                            
Total Healthcare Services 9968   13865   9445   <.0001 10652   14215   10052   <.0001 8766   12945   8467   <.0001 
Cost of Utilization ($)  - for those with utilization within category  
Non-COPD Outpatient 3246   3786   3173   0.0024 3443   4394   3362   0.006 2881   3192   2854   0.0931 
COPD Outpatient 1423   2164   1332   <.0001 1261   1827   1175   <.0001 1758   2400   1670   <.0001 
Total Outpatient 4948   6646   4790   <.0001 4997   7018   4790   <.0001 4910   6061   4778   0.0036 
                                            
Non-COPD Inpatient 17195   18672   16913   0.3895 19252   20284   19020   0.4992 13131   17028   12130   0.3838 
COPD Inpatient 16965   18949   16161   0.0196 13720   16983   12885   0.0075 20660   22636   20314   0.4703 
Total Inpatient 19439   21436   19226   0.0569 17708   18684   17608   0.0392 21650   22047   21207   0.6121 
Total Medical Utilization 7259   10601   6561   <.0001 7542   10979   6856   <.0001 6602   9741   6125   <.0001 
                                            
Non-COPD Outpatient Rx 1324   1440   1309   0.2946 1544   1628   1542   0.6858 888   1068   851   0.1309 
COPD Outpatient Rx 81   149   72   <.0001 101   209   85   <.0001 57   82   52   0.1889 
Total Outpatient Rx 1707   1979   1676   0.0391 1981   2387   1915   0.0492 1094   1206   1076   0.1225 
                                            
Total Healthcare Services 9968   13865   9445   <.0001 10652   14215   10052   <.0001 8766   12945   8467   <.0001 
Length of Stay (inpatient stays) 4   4   4   0.2404 4   5   4   0.1814 4   4   4   0.7111 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Table 57 Moderate or Severe Exacerbation Within 6 Months, Baseline Healthcare Costs (Means) 
  LHP and PHP  LHP  PHP  
Baseline Characteristic Total SD Mod 
Sev 6 
Mon 
SD No 
Mod 
Sev 
SD pval  Total SD Mod Sev 
6 Mon 
SD No 
Mod 
Sev 
SD pval  Total SD Mod 
Sev 6 
Mon 
SD No 
Mod 
Sev 
SD pval  
Number of Patients 5475   1287   4188     3599   789   2810     1876   498   1378     
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient 5490 9457 5949 8966 5349 9600 0.0391 5426 8291 6152 9728 5222 7830 0.0136 5614 11366 5627 7604 5609 12452 0.9696 
COPD Outpatient 1961 2436 2566 2856 1775 2260 <.0001 1786 2213 2294 2540 1644 2090 <.0001 2297 2786 2997 3252 2043 2552 <.0001 
Total Outpatient 7452 10320 8515 10279 7125 10312 <.0001 7212 9094 8447 10718 6866 8553 0.0001 7911 12326 8625 9553 7653 13179 0.0808 
                                            
Non-COPD Inpatient 5069 20267 5562 18743 4918 20712 0.293 6913 24336 7963 22915 6617 24716 0.1522 1533 6606 1758 7267 1452 6351 0.4061 
COPD Inpatient 6179 20753 9509 27060 5156 18267 <.0001 5019 19696 8280 28053 4104 16501 <.0001 8404 22481 11454 25313 7302 21268 0.0011 
Total Inpatient 11248 30260 15071 34676 10074 28669 <.0001 11932 32612 16244 38369 10721 30702 0.0002 9937 25094 13212 27776 8754 23952 0.0015 
Total Medical Utilization 18700 33496 23586 38006 17199 31837 <.0001 19144 35393 24691 41779 17587 33223 <.0001 17848 29507 21837 31063 16407 28800 0.0007 
                                            
Non-COPD Outpatient Rx 2369 4007 2527 4178 2321 3952 0.1162 2635 4381 2835 4408 2579 4372 0.1463 1859 3107 2040 3738 1794 2843 0.1836 
COPD Outpatient Rx 408 778 502 881 379 741 <.0001 409 799 527 915 376 760 <.0001 405 735 463 824 384 700 0.0582 
Total Outpatient Rx 2777 4148 3030 4356 2699 4080 0.0157 3043 4510 3362 4535 2954 4500 0.0245 2265 3288 2503 4004 2179 2984 0.1000 
                                            
Total Healthcare Services 21477 34258 26616 38829 19897 32568 <.0001 22188 36262 28053 42676 20541 34073 <.0001 20113 30003 24340 31704 18585 29226 0.0004 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient 5589 9513 6024 8998 5455 9664 0.053 5512 8328 6223 9761 5311 7866 0.0166 5740 11461 5708 7628 5751 12576 0.9288 
COPD Outpatient 2100 2463 2679 2866 1916 2290 <.0001 1928 2239 2423 2549 1785 2120 <.0001 2423 2808 3071 3257 2179 2578 <.0001 
Total Outpatient 7469 10326 8529 10282 7144 10319 <.0001 7226 9097 8457 10720 6881 8556 0.0002 7936 12337 8642 9555 7681 13194 0.0848 
                                            
Non-COPD Inpatient 32576 41773 30990 34247 33166 44258 0.4485 36213 45208 34714 36946 36749 47839 0.5582 17434 14833 17510 15944 17402 14396 0.9658 
COPD Inpatient 30287 37170 33074 42075 28906 34430 0.0992 28403 39151 33333 48381 26207 34084 0.0631 32778 34258 32783 33727 32774 34610 0.9978 
Total Inpatient 36441 45266 38032 46508 35753 44720 0.3423 37244 48767 40177 51803 36122 47539 0.2067 34716 36619 34449 35815 34864 37106 0.9002 
Total Medical Utilization 18710 33502 23605 38015 17207 31842 <.0001 19144 35393 24691 41779 17587 33223 <.0001 17877 29522 21881 31079 16430 28814 0.0007 
                                            
Non-COPD Outpatient Rx 2462 4056 2617 4224 2414 4003 0.1344 2693 4411 2872 4425 2642 4406 0.1995 1997 3177 2189 3830 1927 2903 0.1809 
COPD Outpatient Rx 408 778 502 881 379 741 <.0001 409 799 527 915 376 760 <.0001 405 735 463 824 384 700 0.0582 
Total Outpatient Rx 2777 4148 3030 4356 2699 4080 0.0157 3043 4510 3362 4535 2954 4500 0.0245 2265 3288 2503 4004 2179 2984 0.1000 
                                            
Total Healthcare Services 21477 34258 26616 38829 19897 32568 <.0001 22188 36262 28053 42676 20541 34073 <.0001 20113 30003 24340 31704 18585 29226 0.0004 
Length of Stay (inpatient stays) 6.6 7.7 6.7 7.6 6.6 7.7 0.7688 7.3 8.6 7.5 8.3 7.2 8.7 0.6463 5.3 5.0 5.5 6.0 5.2 4.4 0.5035 
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Table 58 Moderate or Severe Exacerbation Within 6 Months, Baseline Healthcare Costs (Median) 
  LHP and PHP   LHP  PHP  
  
Total   Mod 
Sev 6 
Mon 
  No 
Mod 
Sev 
  pval 
Comb vs 
Triple* 
Total   Mod 
Sev 6 
Mon 
  No 
Mod 
Sev 
  pval 
Comb vs 
Triple* 
Total   Mod 
Sev 6 
Mon 
  No 
Mod 
Sev 
  pval 
Comb vs 
Triple* 
Median 5475   1287   4188     3599   789   2810     1876   498         
Cost of Utilization ($)  
Non-COPD Outpatient 5490 9457 5949 8966 5349 9600 <.0001 5426 8291 6152 9728 5222 7830 0.0002 5614 11366 5627 7604 5609 12452 0.0027 
COPD Outpatient 1961 2436 2566 2856 1775 2260 <.0001 1786 2213 2294 2540 1644 2090 <.0001 2297 2786 2997 3252 2043 2552 <.0001 
Total Outpatient 7452 10320 8515 10279 7125 10312 <.0001 7212 9094 8447 10718 6866 8553 <.0001 7911 12326 8625 9553 7653 13179 <.0001 
                                            
Non-COPD Inpatient 5069 20267 5562 18743 4918 20712 0.0072 6913 24336 7963 22915 6617 24716 0.0017 1533 6606 1758 7267 1452 6351 0.2601 
COPD Inpatient 6179 20753 9509 27060 5156 18267 <.0001 5019 19696 8280 28053 4104 16501 <.0001 8404 22481 11454 25313 7302 21268 <.0001 
Total Inpatient 11248 30260 15071 34676 10074 28669 <.0001 11932 32612 16244 38369 10721 30702 <.0001 9937 25094 13212 27776 8754 23952 <.0001 
Total Medical Utilization 18700 33496 23586 38006 17199 31837 <.0001 19144 35393 24691 41779 17587 33223 <.0001 17848 29507 21837 31063 16407 28800 <.0001 
                                            
Non-COPD Outpatient Rx 1252   1321   1227   0.0454 1442   1522   1415   0.0135 854   927   828   0.3124 
COPD Outpatient Rx 68   133   53   <.0001 68   140   53   <.0001 66   122   53   0.0020 
Total Outpatient Rx 1685   1872   1620   0.0011 1869   2121   1803   <.0001 1295   1473   1247   0.1818 
                                            
Total Healthcare Services 10052   13074   9281   <.0001 10559   13184   9743   <.0001 9209   12501   8517   <.0001 
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient 3285   3741   3141   <.0001 3417   4033   3275   0.0004 2993   3425   2857   0.0064 
COPD Outpatient 1380   2011   1196   <.0001 1185   1720   1060   <.0001 1792   2397   1579   <.0001 
Total Outpatient 4942   6172   4671   <.0001 4928   6154   4690   <.0001 4985   6176   4616   <.0001 
                                            
Non-COPD Inpatient 17802   17721   17840   0.9895 19872   19682   20122   0.7519 13848   14729   13439   0.7699 
COPD Inpatient 17641   17988   17350   0.2207 15300   16329   13936   0.1938 20654   21687   20053   0.9965 
Total Inpatient 19907   20591   19769   0.4617 18979   19226   18720   0.2863 21703   22030   21219   0.7788 
Total Medical Utilization 7404   10105   6567   <.0001 7552   10204   6838   <.0001 7014   9883   6009   <.0001 
                                            
Non-COPD Outpatient Rx 1340   1410   1324   0.0624 1499   1573   1484   0.0402 1026   1149   985   0.2702 
COPD Outpatient Rx 68   133   53   <.0001 68   140   53   <.0001 66   122   53   0.002 
Total Outpatient Rx 1685   1872   1620   0.0011 1869   2121   1803   <.0001 1295   1473   1247   0.1818 
                                            
Total Healthcare Services 10052   13074   9281   <.0001 10559   13184   9743   <.0001 9209   12501   8517   <.0001 
Length of Stay (inpatient stays) 4   4   4   0.9103 4   4   4   0.376 4   4   4   0.5903 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Table 59 Moderate or Severe Exacerbation Within 6 Months Without Discontinuation, Baseline Healthcare Costs (Means) 
  
LHP and 
PHP           LHP             PHP             
Baseline Characteristic Total SD Mod 
Sev 6 
Mon 
SD No 
Mod 
Sev 
SD pval  Total SD Mod Sev 
6 Mon 
SD No 
Mod 
Sev 
SD pval  Total SD Mod Sev 
6 Mon 
SD No 
Mod 
Sev 
SD pval  
Number of Patients 2544   703   1841     1544   402   1142     1000   301   699     
Cost of Utilization ($ mean, SD)  
Non-COPD Outpatient 5484 9831 6048 8853 5269 10174 0.0571 5476 8503 6444 10097 5135 7842 0.0186 5497 11591 5520 6828 5486 13124 0.9576 
COPD Outpatient 2044 2380 2657 2724 1811 2191 <.0001 1886 2152 2375 2223 1714 2100 <.0001 2289 2677 3034 3240 1968 2324 <.0001 
Total Outpatient 7529 10602 8705 9801 7079 10861 0.0003 7362 9196 8819 10642 6849 8576 0.0009 7786 12465 8554 8566 7455 13802 0.1264 
                                            
Non-COPD Inpatient 4629 18736 6136 20142 4053 18143 0.0167 6720 23274 9722 25611 5663 22310 0.0049 1400 6302 1347 5692 1423 6551 0.8528 
COPD Inpatient 5930 21203 9753 29890 4470 16515 <.0001 4852 21401 8671 32297 3508 15678 0.0022 7595 20794 11198 26318 6043 17696 0.002 
Total Inpatient 10559 29912 15890 38147 8523 25814 <.0001 11572 33327 18394 43787 9171 28391 <.0001 8995 23621 12545 28682 7466 20910 0.0058 
Total Medical Utilization 18087 33354 24595 41504 15603 29291 <.0001 18934 36141 27212 47310 16020 30775 <.0001 16780 28488 21099 31899 14921 26696 0.0034 
                                            
Non-COPD Outpatient Rx 2230 3752 2252 3230 2222 3934 0.8414 2645 4263 2687 3602 2630 4474 0.7976 1590 2665 1671 2546 1555 2716 0.5281 
COPD Outpatient Rx 528 911 596 998 503 875 0.0295 579 962 667 1061 548 923 0.0461 450 822 501 900 429 785 0.2262 
Total Outpatient Rx 2758 3971 2848 3535 2723 4125 0.447 3222 4458 3354 3843 3176 4656 0.4495 2041 2931 2172 2950 1984 2922 0.3512 
                                            
Total Healthcare Services 20845 34170 27443 42284 18326 30143 <.0001 22156 37082 30567 48152 19196 31796 <.0001 18821 29010 23271 32465 16904 27190 0.003 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient 5601 9902 6136 8886 5395 10262 0.0746 5581 8550 6542 10142 5241 7887 0.0209 5632 11700 5594 6844 5648 13282 0.9339 
COPD Outpatient 2180 2397 2779 2724 1945 2212 <.0001 2022 2166 2512 2210 1847 2123 <.0001 2420 2694 3127 3245 2104 2342 <.0001 
Total Outpatient 7549 10609 8718 9802 7102 10871 0.0003 7376 9199 8819 10642 6867 8580 0.001 7817 12481 8582 8566 7487 13823 0.1287 
                                            
Non-COPD Inpatient 32439 39513 31954 35977 32727 41539 0.8572 36278 43088 35211 38541 36955 45834 0.7295 18182 14594 16889 12196 18767 15632 0.6043 
COPD Inpatient 30416 39538 34629 48144 27617 32377 0.0733 29038 45218 34859 57472 25353 35057 0.1389 31910 32302 34395 36554 30172 28970 0.3418 
Total Inpatient 36202 46271 39894 51965 33964 42353 0.1075 37615 51323 42496 58430 34794 46596 0.1381 33688 35504 35623 38994 32414 33071 0.471 
Total Medical Utilization 18109 33368 24630 41523 15620 29303 <.0001 18934 36141 27212 47310 16020 30775 <.0001 16831 28516 21169 31929 14963 26723 0.0033 
                                            
Non-COPD Outpatient Rx 2357 3819 2356 3267 2358 4013 0.993 2719 4299 2728 3614 2716 4521 0.9568 1757 2749 1823 2606 1728 2810 0.6349 
COPD Outpatient Rx 528 911 596 998 503 875 0.0295 579 962 667 1061 548 923 0.0461 450 822 501 900 429 785 0.2262 
Total Outpatient Rx 2758 3971 2848 3535 2723 4125 0.447 3222 4458 3354 3843 3176 4656 0.4495 2041 2931 2172 2950 1984 2922 0.3512 
                                            
Total Healthcare Services 20845 34170 27443 42284 18326 30143 <.0001 22156 37082 30567 48152 19196 31796 <.0001 18821 29010 23271 32465 16904 27190 0.003 
Length of Stay (inpatient 
stays) 
6.4 7.0 6.4 6.4 6.4 7.3 0.9353 7.0 7.9 6.8 6.5 7.1 8.6 0.7336 5.4 4.9 5.8 6.2 5.1 3.8 0.3222 
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Table 60 Moderate or Severe Exacerbation Within 6 Months Without Discontinuation, Baseline Healthcare Costs (Medians) 
  
LHP and 
PHP           LHP             PHP             
  
Total   Mod 
Sev 6 
Mon 
  No 
Mod 
Sev 
  pval 
Comb 
vs 
Triple* 
Total   Mod Sev 
6 Mon 
  No 
Mod 
Sev 
  pval 
Comb 
vs 
Triple* 
Total   Mod Sev 
6 Mon 
  No 
Mod 
Sev 
  pval 
Comb vs 
Triple* 
Median 2544   703   1841     1544   402   1142     1000   301         
Cost of Utilization ($)  
Non-COPD Outpatient 3114   3751   2888   <.0001 3324   4070   3114   0.0015 2846   3464   2572   0.0011 
COPD Outpatient 1352   2022   1128   <.0001 1187   1809   986   <.0001 1668   2301   1346   <.0001 
Total Outpatient 4953   6428   4475   <.0001 5008   6383   4586   <.0001 4914   6498   4298   <.0001 
                                            
Non-COPD Inpatient 0   0   0   <.0001 0   0   0   <.0001 0   0   0   0.8446 
COPD Inpatient 0   0   0   <.0001 0   0   0   <.0001 0   0   0   <.0001 
Total Inpatient 0   0   0   <.0001 0   0   0   <.0001 0   0   0   <.0001 
Total Medical Utilization 7049   10606   5840   <.0001 7532   11760   6207   <.0001 6467   9741   5428   <.0001 
                                            
Non-COPD Outpatient Rx 1129   1211   1063   0.1905 1453   1525   1428   0.1368 605   648   574   0.2977 
COPD Outpatient Rx 98   146   77   0.0009 129   184   107   0.0065 54   100   38   0.0190 
Total Outpatient Rx 1672   1806   1598   0.0957 2025   2295   1914   0.0341 935   1010   893   0.2923 
                                            
Total Healthcare Services 9948   14125   8708   <.0001 10949   15952   9574   <.0001 8517   12381   7422   <.0001 
Cost of Utilization ($ )  - for those with utilization within category 
Non-COPD Outpatient 3223   3792   2999   <.0001 3412   4194   3226   0.0019 2897   3487   2710   0.0028 
COPD Outpatient 1499   2206   1287   <.0001 1350   1888   1145   <.0001 1761   2366   1513   <.0001 
Total Outpatient 5005   6453   4528   <.0001 5014   6383   4600   <.0001 4932   6532   4313   <.0001 
                                            
Non-COPD Inpatient 18358   18044   18516   0.893 19777   18771   21297   0.9918 14252   16265   13964   0.7332 
COPD Inpatient 16931   17764   16134   0.1921 13869   15854   13038   0.1908 20532   21913   19713   0.6304 
Total Inpatient 19963   20904   19423   0.1882 18339   19255   17409   0.1103 21797   22047   20663   0.8643 
Total Medical Utilization 7070   10665   5847   <.0001 7532   11760   6207   <.0001 6471   9779   5451   <.0001 
                                            
Non-COPD Outpatient Rx 1251   1300   1230   0.3974 1514   1619   1501   0.302 770   885   745   0.4851 
COPD Outpatient Rx 98   146   77   0.0009 129   184   107   0.0065 54   100   38   0.019 
Total Outpatient Rx 1672   1806   1598   0.0957 2025   2295   1914   0.0341 935   1010   893   0.2923 
                                            
Total Healthcare Services 9948   14125   8708   <.0001 10949   15952   9574   <.0001 8517   12381   7422   <.0001 
Length of Stay (inpatient stays) 4   4   4   0.6775 4   4   4   0.6121 4   4   4   0.8926 
* Wilcoxon signed rank sum test for differences in distributions using median 
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Summary of Results from Aim 1 and Aim 2 
Table 61 summarizes the baseline factors that were found to have a statistically 
significant association in univariate analyses with the dependent variables reviewed in 
Aims 1 and 2. These are the baseline factors that will be considered in Aims 3 through 6. 
Shown are those factors that applied to 5% or greater of the population.  This cutoff was 
chosen because factors associated with percentages lower than that may not be 
generalizable to other populations. The criteria for statistical significance was a value of 
<0.05. Factors that were included in the model as being significantly associated with the 
index treatments were factors that in Table 18 were found to be significantly different 
between triple therapy and the combined group of patients using either ICS/LABA or 
LAMA, or where there were two comparisons with significant p-values among the 
comparisons between ICS/LABA vs LAMA, ICS/LABA vs triple, and LAMA vs triple.  
Factors included for the discontinuation analyses at three months and six months were 
those that had a significant p-value for the LHP and PHP combined population and also 
had a consistent trend within the separate analyses for LHP and PHP.  
Some variables were regrouped for further analyses.  Congestive heart failure and 
heart failure were combined into one category since the Pearson’s rho correlation 
between these two variables was 0.75, indicating very strong correlation.  The variables 
for “1 moderate exacerbation” and “>1 moderate exacerbation” in weeks 13-52 were 
combined into one variable of “>1 moderate exacerbation” since <5% of the sample had 
>1 moderate exacerbation during that time period.  For the same reason, the capture of 
ICS/LABA use in weeks 27-52 before the index date was consolidated into one variable 
“any use of ICS/LABA” for that period.
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Table 61 Summary of Results from Aims 1 and 2 
Baseline Characteristic Trmt Discont Switch Sev Exac 
Sev Exac 
wo/Disc 
Mod / Sev 
Exac 
Mod / Sev 
Exac wo/Disc 
    3 m 6 m 3 m 6 m 3 m 6 m 3 m 6 m 3 m 6 m 3 m 6 m 
Age Categories                           
age 40-54 √ √ √               √     
age 55-64 √                     √   
age 65-74     √     √   √ √         
age 75 and older √                         
                            
Men √                 √ √   √ 
Health Plan √ √ √ √ √ √ √ √ √ √ √ √ √ 
                            
Insurance at Index                           
Commercial         √ √ √ √ √         
Medicaid √ √ √ √ √ √ √ √ √ √ √ √ √ 
Medicare                   √       
                            
CMS comorbidities                           
atrial fibrillation           √ √ √ √         
cancers                           
chronic kidney disease                           
heart failure           √ √ √ √   √ √ √ 
ischemic heart disease   √     √   √ √ √         
rheumatoid/osteo arthritis √   √     √   √ √         
stroke/TIA                           
                            
Elixhauser comorbidities                            
congestive heart failure     √     √ √ √ √   √   √ 
deficiency anemias   √         √   √ √ √ √ √ 
depression   √ √       √ √ √ √ √ √ √ 
diabetes (wo/chr complications) √ √ √   √ √ √ √ √ √ √ √ √ 
diabetes (w/chr complications)                           
fluid and electrolyte disorders         √ √ √ √ √ √ √ √ √ 
hypertension           √   √           
hypothyroidism                   √ √ √   
obesity √                         
other neurological disorders     √       √   √         
peripheral vascular disease           √ √ √ √         
psychoses √         √   √   √ √     
pulmonary circulation disease √           √             
renal failure                   √ √     
rheumatoid arthritis/collagen vas                           
solid tumor wo/metastasis                           
valvular disease           √ √ √ √       √ 
weight loss                     √   √ 
Other comorbidities                           
asthma √         √   √   √ √ √   
hypoxemia √ √ √ √   √ √ √ √ √ √ √ √ 
pneumonia √ √       √ √ √ √ √ √ √ √ 
                            
Low COPD complexity √     √ √ √ √ √ √ √ √ √ √ 
Emphysema diagnosis (492.x) √ √ √ √     √   √   √ √ √ 
                            
COPD Medications                            
index ICSLABA   √ √ √ √       √   √   √ 
index LAMA   √ √       √ √ √ √ √ √ √ 
index triple   √ √ √ √ √ √     √       
                            
SABA use                           
no SABA use √ √     √ √ √ √ √ √ √ √ √ 
SABA <=15% of year √ √ √         √           
SABA <=40% of year √ √ √                     
SABA >40% of year     √   √ √ √ √ √ √ √ √ √ 
SAMA use                           
any ipratropium (SAMA)     √     √ √ √ √ √ √ √ √ 
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Baseline Characteristic Trmt Discont Switch Sev Exac 
Sev Exac 
wo/Disc 
Mod / Sev 
Exac 
Mod / Sev 
Exac wo/Disc 
    3 m 6 m 3 m 6 m 3 m 6 m 3 m 6 m 3 m 6 m 3 m 6 m 
any SABA/SAMA √   √     √ √ √ √ √ √ √ √ 
any SAMA or SABA/SAMA   √ √     √ √ √ √ √ √ √ √ 
Other COPD medications                           
any ICS √ √ √     √   √   √ √ √ √ 
any LABA                           
Use of Index Trmts Prior Year                           
No ICSLABA in prior year                   √ √     
any Rxs ICSLABA (wks 27-52) √   √           √ √     √ 
Oxygen Use                           
no oxygen √ √ √     √ √ √ √ √ √ √ √ 
oxygen <=50% of year                           
oxygen >50% of year     √     √   √ √ √ √ √ √ 
                            
Symptoms                           
Dyspnea                           
Breathlessness                           
no periods breathlessness √     √   √ √ √ √ √ √ √ √ 
1 period breathlessness           √ √ √ √ √   √ √ 
>1 period breathlessness       √ √   √       √     
Shortness of Breath                           
no periods shortness breath √         √ √ √ √ √ √ √ √ 
1 period shortness breath           √ √ √           
>1 period shortness breath √         √ √ √ √ √ √ √ √ 
any wheezing √         √ √ √ √ √ √ √ √ 
supplemental oxygen use (V46.2)           √ √ √ √ √ √ √ √ 
Other symptoms                           
any chestpain √ √ √     √ √ √ √ √ √ √ √ 
other malaise/fatigue     √     √ √ √ √ √ √ √ √ 
cough √   √       √ √ √ √ √ √ √ 
                            
Procedures                           
chest CT √           √   √   √   √ 
chest x-ray             √   √ √ √ √ √ 
echocardiography         √                 
EKG           √ √ √ √ √ √ √ √ 
nebulizer treatment √         √ √ √ √ √ √ √ √ 
non-invasive ventilator                           
spirometry √ √ √           √     √ √ 
any vaccination (flu or 
pneumonia)                           
                            
COPD-related exacerbations                           
Index and 2 weeks prior                           
any moderate   √ √     √ √ √ √   √ √ √ 
any severe √ √ √   √ √ √ √ √ √ √ √ √ 
Prior 2-12 weeks                           
any moderate           √ √ √ √ √ √ √ √ 
any severe √ √       √ √ √ √ √ √ √ √ 
Prior 13-52 weeks                           
any moderate   √       √ √ √ √ √ √ √ √ 
any severe           √ √ √ √ √ √ √ √ 
any other hospitalizations           √ √ √ √ √ √ √ √ 
                            
All Inpatient Utilization                           
Non-COPD Inpatient (Any)   √ √     √ √ √ √ √ √ √ √ 
COPD Inpatient (Any) √ √       √ √ √ √ √ √ √ √ 
Total Inpatient (Any)     √     √ √ √ √ √ √ √ √ 
                            
Same as Index Treatment             √ √ √ √ √   √ 
No evidence ICS/LABA or LAMA           √ √     √ √     
Different Treatment from Index           √   √ √ √ √   √ 
disc, discontinue; exac, exacerbation; m, month; mod, moderate; sev, severe; switch, switch from index therapy; trmt, treatment 
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Aim 3 
Create a “pseudo-population” using MSM weighting. 
Prior to constructing the weighted population, preliminary analyses were 
conducted to investigate differences in the propensity to have been prescribed the therapy 
that study subjects received at the index date. These analyses built on those performed in 
Aims 1 and 2. These analyses are discusses here and additionally, some of the nuances to 
constructing a weighted population for the MSM for the study population are discussed. 
Treatment Propensity 
Table 62 provides a summary of the odds ratios (OR) estimated from a 
multinomial logistic regression analysis, adjusted for sex, age, health insurance coverage 
and the factors summarized in Table 61. The reference group for the ORs is the triple 
therapy group.  The multinomial regression was constructed using the LOGISTIC 
procedure in SAS specifying a generalized logit (GLOGIT) link.  
For most of the baseline characteristics the odds ratios estimated for receipt of 
ICS/LABA or LAMA at index in comparison to the triple therapy group were fairly 
similar.  This is further illustrated in the histograms in Figure 9 that depict the estimated 
probabilities for receipt of each of the index therapies.  Notable differences between ORs 
estimated for the ICS/LABA and LAMA groups were (not all are significant ORs 
however): 
 in comparison to patients receiving triple therapy, asthma was more strongly 
associated with patients receiving ICS/LABA (OR=1.67, 95% CI, 1.32 to 
2.11) than patients receiving LAMA (OR=0.62, 95% CI 0.48 to 0.79)  
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 while patients receiving ICS/LABA or LAMA were more likely have diabetes 
or be obese, patients receiving ICS/LABA had a greater likelihood of diabetes 
(OR=1.20, 95% CI 0.93 to 1.55) and obesity (OR=1.68, 95% CI 1.19 to 2.38)  
than patients receiving LAMA (diabetes: OR=1.05, 95% CI 0.81 to 1.34; 
obesity OR=1.50, 95% CI 1.05 to 2.17) 
 patients receiving ICS/LABA were less likely have hypoxemia (OR=0.64, 
95% CI, 0.50 to 0.81), emphysema (OR=0.57, 95% CI, 0.46 to 0.72) , and 
similar symptoms of breathlessness (OR=1.00, 95% CI, 0.73 to 1.39) 
compared to patients receiving triple therapy than patients receiving LAMA in 
comparison to patients receiving triple therapy (hypoxemia: OR=0.77, 95% CI 
0.60 to 0.99; emphysema: OR=0.73, 95% CI 0.58 to 0.93; breathlessness: 
OR=1.46, 95% CI 1.05 to 2.05)) 
 LAMA patients were less likely to have any baseline SABA/SAMA use 
(OR=0.73, 95% CI 0.55 to 0.96), while ICS/LABA patients were more likely 
(OR=1.17, 95% CI, 0.90 to 1.52) 
 Both ICS/LABA and LAMA patients were less likely to have had spirometry, 
but the LAMA patients were slightly less likely (ICS/LABA: OR=0.57, 95% 
CI 0.45 to 0.72; LAMA: OR=0.78, 95% CI 0.62 to 0.99) 
 In relationship to patients receiving triple therapy, patients receiving LAMA 
were comparatively less likely to have had a recent severe exacerbation 
(OR=0.39, 95% CI 0.26 to 0.59) than patients receiving ICS/LABA 
(OR=0.69, 95% CI 0.48 to 1.00) 
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 Patients receiving ICS/LABA in comparison to triple therapy at index were 
more likely to be LHP patients (OR=1.14, 95% CI 0.91 to 1.43) than patients 
who received LAMA in comparison to triple therapy (OR 0.68, 95% CI 0.54 
to 0.86) 
Table 62 Estimated Odds Ratios, Receipt of Index Therapy 
Baseline Characteristic  Index Trmt OR Est LowerCL UpperCL P-value 
Male ICSLABA 0.74 0.60 0.92 0.0055 
  LAMA 0.74 0.59 0.92 0.0065 
 Age Categories       
Age 40 to 54 vs Age >75 ICSLABA 0.92 0.61 1.39 0.6843 
  LAMA 0.68 0.44 1.05 0.0835 
Age 55 to 64 vs Age >75 ICSLABA 0.65 0.49 0.88 0.0049 
  LAMA 0.55 0.40 0.75 0.0001 
Age 75 to 74 vs Age >75 ICSLABA 0.98 0.76 1.27 0.9001 
  LAMA 0.97 0.75 1.25 0.8006 
Medicaid ICSLABA 0.99 0.69 1.42 0.9554 
  LAMA 0.94 0.64 1.38 0.7477 
Comorbidities      
Atrial fibrillation ICSLABA 1.18 0.81 1.71 0.3905 
  LAMA 1.17 0.80 1.72 0.4279 
Heart failure or CHF ICSLABA 1.18 0.88 1.57 0.2729 
  LAMA 1.12 0.83 1.52 0.4543 
Ischemic Heart Disease ICSLABA 0.78 0.60 1.01 0.0587 
  LAMA 0.96 0.73 1.25 0.7354 
Rheumatoid or osteo-arthritis ICSLABA 1.38 1.07 1.77 0.0126 
  LAMA 1.44 1.11 1.86 0.0061 
Deficiency Anemias ICSLABA 1.12 0.83 1.52 0.4645 
  LAMA 1.10 0.80 1.51 0.5529 
Depression ICSLABA 0.99 0.75 1.31 0.952 
  LAMA 0.94 0.70 1.26 0.6773 
Diabetes w/o chronic complications ICSLABA 1.20 0.93 1.55 0.1533 
  LAMA 1.05 0.81 1.37 0.7081 
Fluid and electrolyte disorders ICSLABA 0.87 0.64 1.20 0.4102 
  LAMA 1.10 0.79 1.53 0.5812 
Hypertension ICSLABA 1.20 0.96 1.49 0.1082 
  LAMA 1.14 0.91 1.44 0.2452 
Hypothyroidism ICSLABA 0.84 0.65 1.09 0.1938 
  LAMA 0.81 0.62 1.05 0.1153 
Obesity ICSLABA 1.68 1.19 2.38 0.0035 
  LAMA 1.51 1.05 2.16 0.0274 
Other neurological disorders ICSLABA 1.08 0.75 1.54 0.686 
  LAMA 1.02 0.71 1.49 0.8999 
Psychoses ICSLABA 1.50 1.03 2.16 0.0326 
  LAMA 1.13 0.77 1.67 0.5323 
Pulmonary circulation disease ICSLABA 0.76 0.55 1.04 0.0894 
  LAMA 0.69 0.50 0.97 0.0304 
Renal failure ICSLABA 0.92 0.64 1.33 0.6461 
  LAMA 0.86 0.58 1.25 0.4200 
Valvular disease ICSLABA 0.95 0.67 1.33 0.7431 
  LAMA 0.83 0.58 1.18 0.293 
Weight loss ICSLABA 1.12 0.73 1.72 0.5985 
  LAMA 1.28 0.83 1.98 0.2722 
Asthma ICSLABA 1.67 1.32 2.11 <.0001 
  LAMA 0.62 0.48 0.79 0.0001 
Hypoxemia ICSLABA 0.64 0.50 0.81 0.0003 
  LAMA 0.77 0.60 0.99 0.0444 
Pneumonia ICSLABA 1.21 0.96 1.53 0.107 
  LAMA 1.10 0.86 1.40 0.4528 
Emphysema ICSLABA 0.57 0.46 0.72 <.0001 
  LAMA 0.73 0.58 0.93 0.0093 
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Baseline Characteristic  Index Trmt OR Est LowerCL UpperCL P-value 
Low COPD complexity ICSLABA 1.33 1.04 1.69 0.0238 
  LAMA 1.41 1.10 1.82 0.0075 
 COPD-related medication       
No SABA use ICSLABA 1.15 0.90 1.47 0.2769 
  LAMA 1.25 0.97 1.61 0.0909 
SABA use 15-40% ICSLABA 1.76 1.22 2.52 0.0023 
  LAMA 1.57 1.08 2.29 0.0183 
SABA use >40% ICSLABA 0.99 0.73 1.34 0.9335 
  LAMA 0.85 0.61 1.18 0.3393 
Any SAMA use ICSLABA 1.21 0.88 1.65 0.2431 
  LAMA 1.03 0.74 1.43 0.8829 
Any SABA/SAMA use ICSLABA 1.17 0.90 1.52 0.2477 
  LAMA 0.73 0.55 0.96 0.0265 
Any ICS use ICSLABA 1.10 0.87 1.39 0.4121 
  LAMA 1.23 0.97 1.56 0.0946 
Oxygen use </=50% ICSLABA 0.89 0.66 1.21 0.4611 
  LAMA 0.87 0.64 1.19 0.3814 
Oxygen use >50% ICSLABA 0.89 0.68 1.16 0.3753 
  LAMA 0.90 0.68 1.19 0.46 
Any nebulizer treatment ICSLABA 0.85 0.67 1.08 0.1756 
  LAMA 0.82 0.64 1.04 0.1024 
 Baseline Symptoms       
No breathlessness ICSLABA 0.99 0.77 1.29 0.9593 
  LAMA 1.02 0.78 1.34 0.8912 
>1 period breathlessness ICSLABA 1.01 0.73 1.39 0.9759 
  LAMA 1.47 1.05 2.05 0.0251 
No shortness of breath ICSLABA 0.99 0.76 1.28 0.9094 
  LAMA 1.01 0.77 1.33 0.9561 
>1 period shortness of breath ICSLABA 0.89 0.65 1.22 0.4617 
  LAMA 0.93 0.67 1.30 0.6795 
Any wheezing ICSLABA 0.85 0.59 1.21 0.3552 
  LAMA 0.65 0.44 0.96 0.0288 
Any chest pain ICSLABA 1.04 0.82 1.33 0.7454 
  LAMA 0.91 0.71 1.17 0.4412 
Any other malaise/fatigue ICSLABA 0.93 0.73 1.18 0.5314 
  LAMA 0.85 0.67 1.09 0.2028 
Any cough ICSLABA 1.29 1.03 1.63 0.0273 
  LAMA 1.22 0.96 1.54 0.1071 
 Baseline Procedures       
Any chest CT ICSLABA 1.00 0.76 1.33 0.9815 
  LAMA 1.07 0.80 1.44 0.6321 
Any chest x-ray ICSLABA 1.00 0.79 1.27 0.9954 
  LAMA 1.00 0.78 1.28 0.9936 
Any echocardiography ICSLABA 1.28 0.95 1.74 0.1085 
  LAMA 1.27 0.93 1.74 0.1321 
Any EKG ICSLABA 1.00 0.79 1.26 0.9804 
  LAMA 1.13 0.88 1.44 0.342 
Any spirometry ICSLABA 0.57 0.45 0.72 <.0001 
  LAMA 0.78 0.62 0.99 0.0412 
 Baseline Exacerbations       
Mod Exac at Index or 2 wks pre-index ICSLABA 0.98 0.73 1.31 0.872 
  LAMA 0.88 0.65 1.20 0.415 
Mod Exac wks 3-12 pre-index ICSLABA 0.89 0.67 1.18 0.4097 
  LAMA 1.10 0.82 1.47 0.5349 
Any Mod Exac wks 13-52 pre-index ICSLABA 0.94 0.73 1.21 0.6521 
  LAMA 0.95 0.73 1.23 0.6789 
Sev Exac within 2 wks pre-index ICSLABA 0.69 0.48 1.00 0.0489 
  LAMA 0.39 0.26 0.59 <.0001 
Sev Exac wks 3-12 pre-index ICSLABA 0.93 0.63 1.39 0.7331 
  LAMA 1.00 0.65 1.53 0.9985 
Sev Exac wks 13-52 pre-index ICSLABA 0.96 0.65 1.40 0.8162 
  LAMA 0.81 0.54 1.21 0.3073 
Any Hosp w/secondary COPD Dx wks 13-52 ICSLABA 1.17 0.77 1.78 0.4735 
  LAMA 1.07 0.69 1.66 0.7709 
Health plan ICSLABA 1.14 0.91 1.43 0.264 
  LAMA 0.68 0.54 0.86 0.0012 
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Figure 9 Histograms, Propensity for Index Therapy 
 
Figure 9 depicts the probabilities for each of the index treatment groups of the 
probability of individuals within that group to actually receive the index treatment they 
received.  Based on the baseline characteristics included in the model, most of the 
individuals who received triple therapy had a fairly low estimated probability of being in 
the triple therapy treatment group.  But this is also because the triple therapy group is 
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comprised of individuals who are using both ICS/LABA and LAMA medications. 
Overall, Table 62 and Figure 9 provide support for grouping the ICS/LABA and LAMA 
as the alternative treatment group for the triple therapy group.   
Since the MSM weights observations by an inverse of the probability for receipt 
of treatment, very low probabilities will result in fairly large weights.  If the probabilities 
graphically summarized in Figure 9 were used to determine weights for the study sample, 
each treatment group within the study sample would be fairly equivalent – 5,475 for the 
ICS/LABA or LAMA group, 5,560 for the Triple group (Table 63).  Since the total 
number of individuals receiving triple at index was only 9% of the study sample, the 
triple therapy group has the largest increase in its representative population, with each 
patient who received triple therapy at index now representing a minimum of 2 and a 
maximum of 64 study subjects.   
Because the probabilities (and thus the weights) in a MSM are multiplicative – 
that is, the probability of treatment in any one period for an individual is conditional on 
the probability of treatment received in the prior period, individuals with very small 
probabilities (and very large weights) for treatment will quickly represent very large 
numbers of study subjects.  For example, a subject with a probability of 0.02 for 
receiving the treatment she actually received, would represent 50 study subjects (50 = 
1/0.02).  If there were 6 periods for which probabilities were estimated in the follow-up 
period, and the probability for treatment remained unchanged, by the 6
th
 period, the 
individual would represent over 15 million subjects (1/0.02
6
).   
If the weights are stabilized using the unadjusted probability for treatment 
(essentially the treatment proportion of the study sample), the projected number of study 
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subjects does not differ dramatically from the original count – 5,484 compared to 5,475 
(Table 63).  Obviously some variance in the weights is desired, since the weights serve to 
capture the heterogeneity in the population. Here the stabilized weights range from 0.18 
to 5.6 for the triple therapy group and from 0.36 to 1.08 for the ICS/LABA or LAMA 
group. 
Table 63 Estimated Sample Sizes Using Baseline Propensity for Treatment 
   
Number of Subjects using 
Weighting 
Index Treatment 
Actual 
Subjects 
Unadjusted 
Probability of 
Treatment 
(Sample %) 
(ProbTrmt) 
Weighted using 
inverse of 
adjusted 
treatment 
probability 
(IPTW) 
Stabilized: 
Weighted 
using 
ProbTrmt/
IPTW 
ICS/LABA or LAMA 4991 .912 5475 4993 
Triple 484 .088 5540 491 
Total 5475  11015 5484 
 
Counterfactual Treatments 
Inherent in MSM analysis is the concept of the counterfactual event. Table 64 
illustrates counter factual treatment scenarios for the study sample. The left side of the 
table reflects actual treatments for study subjects whose index treatment was ICS/LABA 
or LAMA, the right side, those whose treatment was triple therapy.  The columns 1 
through 6 reflect the beginning treatment captured for each individual who is not lost to 
follow-up during the interval (because of discontinuation or coverage termination). The 
columns show treatments the two year period after the index date is divided into 6 time 
periods (4 for the first year, 2 for the second).  The second row summarizes the number 
of weeks for the time period from the index date (e.g., 14, 26, etc.). The # column is the 
number of individuals with the treatment therapies for the particular row.  The % column 
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is the percentage of the ICS/LABA or LAMA study subjects or triple therapy subjects 
who had the treatment scenario.   
For example, there were 541 study subjects who had ICS/LABA or LAMA as 
their index therapy and continued to have ICS/LABA or LAMA therapy for all 6 time 
periods.  These 541 study subjects were 10.8% of the initial ICS/LAMA or LAMA 
group.  Similarly, there were 59 study subjects who had triple therapy at index and 
continued to have triple therapy for all 6 time periods.  These 59 were 12.2% of the initial 
triple therapy group.  Essentially the table reflects the treatment scenarios for one group 
and the “mirror” of the treatment summary for the alternative group.  Theoretically, with 
2 treatments and 6 time periods there would be 64 distinct treatment scenarios (2
6
 = 64).  
The table shows 56 rows, so some potential sequences did not occur for either group. For 
both treatment groups – the ICS/LABA or LAMA group and the triple therapy group, the 
majority of patients utilized only the same medication as they were at index.   
For the ICS/LABA or LAMA group, 93.4% did not have evidence of switching to 
triple therapy (42.5% who used medication for only one time period, 17% for 2, 10.6% 
for 3, 6.2% for 4, 6.7% for 5, and 10.8% for 6 periods).  For the triple therapy group, the 
percentage who used triple therapy and did not switch to just use of ICS/LABA or 
LAMA was 62.6% (25.2% who used medication for only one time period, 9.9% for 2, 
7.2% for 3, 4.9% for 4, 3.1% for 5, and 12.2% for 6 periods).  
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Table 64 Example of Counter Factual Treatment Scenarios 
   
Time Periods 
       
Time Periods 
    
 
1 2 3 4 5 6 
   
1 2 3 4 5 6 
  
 
 -> 14 -> 26 -> 38 -> 52 -> 76 -> 104 # % 
 
 -> 14 -> 26 -> 38 -> 52 -> 76 -> 104 # % 
1 IL IL IL IL IL IL 541 10.8 1 TP TP TP TP TP TP 59 12.2 
2 IL IL IL IL IL TP 26 0.5 2 TP TP TP TP TP IL 18 3.7 
3 IL IL IL IL IL   335 6.7 3 TP TP TP TP TP   15 3.1 
4 IL IL IL IL TP IL 9 0.2 4 TP TP TP TP IL TP 2 0.4 
5 IL IL IL IL TP TP 12 0.2 5 TP TP TP TP IL IL 4 0.8 
6 IL IL IL IL TP   7 0.1 6 TP TP TP TP IL   5 1.0 
7 IL IL IL IL    309 6.2 7 TP TP TP TP    24 5.0 
8 IL IL IL TP IL IL 7 0.1 8 TP TP TP IL TP TP 1 0.2 
9 IL IL IL TP IL TP 2 0.0 9           
 10 IL IL IL TP IL   8 0.2 10           
 11 IL IL IL TP TP IL 4 0.1 11 TP TP TP IL IL TP 1 0.2 
12 IL IL IL TP TP TP 11 0.2 12 TP TP TP IL IL IL 4 0.8 
13 IL IL IL TP TP   5 0.1 13 TP TP TP IL IL   2 0.4 
14 IL IL IL TP    3 0.1 14 TP TP TP IL    11 2.3 
15 IL IL IL     527 10.6 15 TP TP TP     35 7.2 
16 IL IL TP IL IL IL 1 0.0 16           
 17 IL IL TP IL IL   7 0.1 17           
 18           
 
18 TP TP IL TP IL IL 1 0.2 
19 IL IL TP IL TP   1 0.0 19           
 20 IL IL TP IL    11 0.2 20 TP TP IL TP    1 0.2 
21 IL IL TP TP IL IL 2 0.0 21           
 22 IL IL TP TP IL TP 2 0.0 22           
 23 IL IL TP TP TP IL 6 0.1 23           
 24 IL IL TP TP TP TP 8 0.2 24 TP TP IL IL IL IL 8 1.7 
25 IL IL TP TP TP   5 0.1 25 TP TP IL IL IL   1 0.2 
26 IL IL TP TP    8 0.2 26 TP TP IL IL    4 0.8 
27 IL IL TP     13 0.3 27 TP TP IL     20 4.1 
28 IL IL      831 16.6 28 TP TP      48 9.9 
29 IL TP IL IL IL IL 9 0.2 29 TP IL TP TP TP TP 1 0.2 
30 IL TP IL IL IL TP 1 0.0 30           
 31 IL TP IL IL IL   5 0.1 31 TP IL TP TP TP   1 0.2 
32 IL TP IL IL    11 0.2 32           
 33           
 
33 TP IL TP TP IL TP 1 0.2 
34           
 
34 TP IL TP TP IL IL 2 0.4 
35 IL TP IL TP IL   2 0.0 35 TP IL TP TP IL   1 0.2 
36 IL TP IL TP TP TP 2 0.0 36           
 37           
 
37 TP IL TP TP    1 0.2 
38           
 
38 TP IL TP IL TP   1 0.2 
39 IL TP IL TP    1 0.0 39 TP IL TP IL    1 0.2 
40 IL TP IL     16 0.3 40 TP IL TP     2 0.4 
41 IL TP TP IL IL IL 6 0.1 41 TP IL IL TP TP TP 1 0.2 
42 IL TP TP IL IL TP 2 0.0 42           
 43 IL TP TP IL IL   3 0.1 43 TP IL IL TP TP   1 0.2 
44 IL TP TP IL TP IL 1 0.0 44 TP IL IL TP IL TP 1 0.2 
45 IL TP TP IL TP TP 1 0.0 45         1 0.2 
46 IL TP TP IL    7 0.1 46 TP IL IL TP      
 47 IL TP TP TP IL IL 5 0.1 47           
 48 IL TP TP TP IL TP 2 0.0 48 TP IL IL IL TP IL 1 0.2 
49 IL TP TP TP IL   4 0.1 49           
 50 IL TP TP TP TP IL 5 0.1 50           
 51 IL TP TP TP TP TP 28 0.6 51 TP IL IL IL IL IL 13 2.7 
52 IL TP TP TP TP   9 0.2 52 TP IL IL IL IL   5 1.0 
53 IL TP TP TP    5 0.1 53 TP IL IL IL    8 1.7 
54 IL TP TP     17 0.3 54 TP IL IL     16 3.3 
99995
5 
IL TP      28 
0.6 55 
TP IL      40 
8.3 
56 IL           2120 42.5 56 TP           122 25.2 
IL = ICSLABA or LAMA; TP = Triple therapy; # = number of study subjects with treatment scenario; % = # as a percentage of total 
study subjects for the IL group (n=4,991) or the TP group (n=484) at the study index date 
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Time Period Intervals for the Study 
Inclusion criteria had some implications in selecting the first time period. Part of 
the inclusion criteria was that individuals included in the study sample could not have a 
severe exacerbation within the first 30 days, thus no severe exacerbation event would be 
observed until after 30 days into the study. Additionally, because study subjects were 
considered to be using ICS/LABA or LAMA medications for up to twice the days’ 
supply and the minimum days’ supply was 30, for at least 60 days after the index date 
patients would not discontinue medication, a period lasting slightly longer than 8 weeks.  
Data for the follow-up period was aggregated into two week periods starting at 
the index date.  As a result, all patients were considered to still be on an ICS/LABA or 
LAMA therapy up through the 10
th
 week.  Thus, the only way subjects could be in an 
alternative therapy group for the first 60 days post-index is to have a prescription claim 
for an alternate therapy from their index therapy.  For patients in the triple therapy group, 
there was zero probability of switching to the alternative group, since a prescription for 
LAMA or ICS/LABA would not change their status from the triple therapy group (as 
both of these medications comprise the triple therapy group).  Similarly, for patients who 
did not have a second prescription for either ICS/LABA or LAMA after the index 
therapy, the earliest they would be identified as having discontinued any therapy was 
after 60 days.   
Sixty days translates into more than 8 weeks, and therefore up through the first 5 
two-week intervals, patients would still be on some medication, and would be identified 
as having discontinued therapy.  Starting with the 6
th
 two-week interval, patients in the 
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triple therapy group could switch status.  The first time interval thus reviewed treatments 
(and events) through the 12
th
 week. 
This point was chosen for the end of the first period in order to be able to model 
discontinuation of therapy since censoring is assessed looking forward to make a 
determination as to whether a patient will continue in the study or not after a given time 
point. The analyses for discontinuation of therapy in Aim 1 showed that 2072 patients 
were found to discontinue therapy at the end of three months, and that by the end of six 
months, over one-half of the study sample had discontinued use of ICS/LABA or LAMA 
medications (n=2,931).  
There are a couple of issues with having too many time periods for a MSM in that 
1) the regression models may not converge, and 2) the stabilized weights may become 
too large. The original plan of the study was to follow study subjects for up to 36 months 
from the index date.  Analyses for Aims 1 and 2 have demonstrated however that loss due 
to discontinuation of therapy is a frequent occurrence, so reviewing more frequently in 
the earlier part of the follow-up period should be more informative. With this in mind, the 
following seven time points were chosen for constructing the MSM model: 12 weeks 
(three months), 18 weeks, 26 weeks (6 months), 38 weeks, 52 weeks (one year), 78 
weeks (1.5 years), and 104 weeks (two years).  Instead of 36 months patients were 
followed for 24 months. 
Table 65 provides a summary of the number of study subjects by time period and 
whether they discontinued use of ICS/LABA and/or LAMA by the end of the time 
period, disenrolled prior to the end or had a severe exacerbation during the time period. 
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Table 65 Study Subjects by Follow-up Time Period 
 
Was not present at end of period Included in analysis 
  
Discontinued 
therapy Disenrollment 
Discontinued 
therapy and 
disenrolled 
No 
discontinuation 
or disenrollment 
Severe 
Exacerbation 
Period 
# weeks 
Total at 
Start 
N % of 
Total 
N % of 
Total 
N % of 
Total 
N % of 
Total 
N % of No 
discount or 
disenroll 
1 (12) 5475 2068 37.8 0 0.0 0 0.0 3407 62.2 146 4.3 
2 (6) 3261 261 8.0 0 0.0 0 0.0 3000 92.0 48 1.6 
3 (8) 2952 599 20.3 0 0.0 0 0.0 2353 79.7 67 2.8 
4 (12) 2286 508 22.2 49 2.1 10 0.4 1719 75.2 72 4.2 
5 (14) 1647 282 17.1 59 3.6 21 1.3 1285 78.0 47 3.6 
6 (26) 1238 248 20.0 62 5.0 52 4.2 876 70.8 59 6.7 
7 (26) 817 167 20.4 44 5.4 40 4.8 566 69.3 37 6.5 
Total 
 
4133   214   123   13206   476   
 
Out of the 855 with a severe exacerbation, 476 had a severe exacerbation while 
still considered to be using ICS/LABA and/or LAMA (or had used either or both in the 
two week period prior to the severe exacerbation).  The remaining 341 severe 
exacerbations occurred after having discontinued therapy.  As a percentage of individuals 
at risk (those who did not discontinue therapy or were disenrolled during the period), the 
percentage each period who experienced a severe exacerbation varied with the length of 
the time period, from a minimum of 1.6% for a six-week interval to 9.5% for a 26 week 
interval (Table 65). 
Thus, there were 3,407 distinct individuals included in the MSM who continued 
use of ICS/LABA or LAMA during the study period.  For these individuals there were a 
total of 13,206 observations, and for 476 of those observations, there was a severe 
exacerbation.  Study subjects were not followed after having a severe exacerbation. So 
for example, during the first time period, 146 of the 3,407 study subjects had a severe 
exacerbation and therefore there were 3,261 study subjects at the start of the second time 
period.  Out of these there were 2,353 who did not discontinue therapy or disenroll, and 
among the 2,353, 67 had a severe exacerbation, leaving 2,952 at the start of period three. 
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Discontinuation was more prevalent among the ICS/LABA or LAMA therapy 
group, at least in the first six months. Table 66 provides a summary of the 4,256 study 
subjects who discontinued therapy (3,980 ICS/LABA or LAMA + 276 triple therapy) and 
the 13,206 study subjects who did not (11,189 ICS/LABA or LAMA, 2,017 triple 
therapy) , by their treatment therapy at the beginning of each time period. In the first time 
period, 39.5% of the ICS/LABA or LAMA discontinued therapy compared to 19.8% of 
the Triple therapy.  This pattern continued across all seven time periods.  
Table 66 Study Subjects Uncensored by Time Period and Treatment Therapy 
 
ICS/LABA or LAMA Triple Therapy 
Period 
# weeks 
Total at 
Start 
Uncensored Discontinued Uncensored Discontinued 
N % N % N % N % 
1 (12) 5475 3019 60.5 1972 39.5 388 80.2 96 19.8 
2 (6) 3261 2604 91.5 243 8.5 396 95.7 18 4.3 
3 (8) 2952 1960 77.6 566 22.4 393 92.3 33 7.7 
4 (12) 2237 1422 75.0 474 25.0 297 87.1 44 12.9 
5 (14) 1588 1044 79.2 275 20.8 241 89.6 28 10.4 
6 (26) 1176 701 72.2 270 27.8 175 85.4 30 14.6 
7 (26) 773 439 70.9 180 29.1 127 82.5 27 17.5 
Total 17,462 11,189 73.8 3980 26.2 2017 88.0 276 12.0 
 
Estimated Weights 
Baseline characteristics considered in the treatment probability and censoring 
probability models were those identified in Aims 1 and 2 and were the same as those 
utilized for the propensity for baseline treatment model summarized in Table 62.  During 
the follow-up period one should theoretically consider both index therapy and prior 
period treatment for models estimating probability of treatment. However, as was 
summarized in Table 64 of the counter factual treatment scenarios, change of therapy 
actually occurred infrequently in the cohort.  When both index and prior period treatment 
were included in models, the models were overfitted.  If analyzed just by time period, the 
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c-statistics for logistic regression models were close to 0.90 – essentially prior period 
treatment was the overriding factor for estimating probability of current treatment. So 
final models only considered the index therapy treatment. 
The treatment probability model for the first period was constructed as a separate 
model from the models for the future periods.  Models for treatment at the start of each 
period after the first time period incorporated time dependent covariates – assessments of 
post-index events in the period prior to the start of each period of moderate 
exacerbations, inpatient stays that were not deemed severe exacerbations but which had a 
COPD-related diagnosis code as a secondary diagnosis, and use of SABA medications; 
while the model for the first time period post-index only incorporated baseline 
characteristics.  In estimating the denominator weight – the IPTW – the treatment models 
for periods 2-7 thus considered baseline characteristics, time-varying covariates prior to 
the start of the period, index therapy, and a variable for the number of two-week periods 
that marked the start of the time period since the index date.  The numerator – the 
stabilizing weight, was the same except without the time-varying covariates.  
Models for censoring (the probability of remaining in the study) were also 
different between the first period and later periods. In all censoring models the 
denominator weight considered the index therapy, baseline characteristics, time-varying 
covariates during the period, a variable for the number of two-week periods that marked 
the start of the time period since the index date, and an interaction term between the 
index therapy and two-week time periods. However censoring models after the first 
period also considered prior period assessments of the time-varying covariates. The 
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numerator stabilizing weight model was the same except without the time-varying 
covariates.  
An auto-regressive (AR) correlation matrix was specified for the GEE approach, 
though estimates were similar between the AR specification and an exchangeable 
specification. 
In treatment models that included time-varying covariates, three covariates were 
included:  
1. proportion of the time interval for which the study subject was considered 
to be having a moderate exacerbation (rounded to .2 – 0.0, 0.2, 0.4, 
0.6,0.8, 1.0) 
2. number of hospitalizations during the time interval that were not severe 
exacerbations but for which a COPD-related diagnosis code was listed as a 
secondary diagnosis 
3. any evidence of SABA use during the time interval 
Censoring models after the first period also incorporated assessments of these 
time-varying covariates for the prior period. 
Table 67 shows the distribution statistics by period for the finalized stabilized 
treatment weights for the study sample by treatment therapy at the beginning of the time 
period.  When the mean stabilized weights are close to 1.0, the estimated number of study 
subjects by period should be very close to the actual number, and they are in our study.  
The mean stabilized weights are close to 1.0, but still include some variation in weights.  
Figure 10 provides a box plot summary for the range of stabilized weight values, showing 
minimum and maximum, mean and interquartile range values.  The distributions showed 
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the most change between the first and second periods, when the greatest numbers of 
study subjects discontinued therapy, and then the stabilized weight ranges increased as 
the time periods progressed.  
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Table 67 Distribution Statistics for Stabilized Treatment Weights 
Period 
Treatment at 
Beginning of Period 
Actual 
N 
Weighted 
N Mean 
Std 
Dev Min Max 
1 ICSLABA LAMA 3019 3021 1.00 0.11 0.62 2.10 
 
Triple 388 389 1.00 0.63 0.20 5.60 
 
Total 3407 3410         
2 ICSLABA LAMA 2604 2631 1.01 0.18 0.27 4.41 
 
Triple 396 375 0.95 0.48 0.19 4.31 
 
Total 3000 3006         
3 ICSLABA LAMA 1960 1978 1.01 0.18 0.24 4.43 
 
Triple 393 378 0.96 0.48 0.20 4.08 
 
Total 2353 2356         
4 ICSLABA LAMA 1422 1430 1.01 0.20 0.25 4.24 
 
Triple 297 293 0.99 0.53 0.21 3.84 
 
Total 1719 1722         
5 ICSLABA LAMA 1044 1046 1.00 0.22 0.21 4.31 
 
Triple 241 240 1.00 0.57 0.22 4.56 
 
Total 1285 1286         
6 ICSLABA LAMA 701 712 1.02 0.29 0.36 5.00 
 
Triple 175 169 0.96 0.60 0.20 3.54 
 
Total 876 881         
7 ICSLABA LAMA 439 455 1.04 0.40 0.30 6.80 
 
Triple 127 121 0.95 0.63 0.21 4.72 
 
Total 566 576 
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Figure 10 Box Plots for Standardized Weights 
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Summary of Weight Estimation Probability Models  
Summarized in Table 68 are odds ratios for the factors included in the treatment 
and censoring probability models.  Results for the stabilizing weight models for the 
numerators are not shown since effect estimates were almost identical to those for the 
denominator models.  The estimates provide a summary of factors significantly 
associated with initial receipt of therapy, receipt of later therapies, and whether the 
individual continued with using ICS/LABA and/or LAMA medication.  Results are in 
line with the factors summarized in Table 61 (significant factors identified in Aims 1 and 
2).  C-statistics for the two logistic models for period 1 were above 0.5 (which would 
indicate probability was little better than flipping a coin) but below the range of 0.75 to 
0.80 which is preferred, indicating that based on the measured variables there was not a 
substantial difference in the estimate of probability for triple therapy between the two 
populations.  C-statistics were 0.675 for baseline treatment without time-varying, and 
0.671 with time-varying.  
As summarized in the counter factual scenario, prior use of a medication was 
highly correlated with future use, and use of triple therapy at index thus had a very high 
OR for continued use (OR=36.9, 95% CI 28.3 to 47.9). 
Men were more likely to be initial triple therapy users, but sex was not 
significantly related to later use, or to whether an individual continued use of any 
medication.  Compared to study subjects over age 75, those between 55 and 64 years of 
age were more likely to initially use triple therapy, but being age 40 to 54 was more 
significantly associated with using triple therapy after the index date, as well as 
discontinuing use of any ICS/LABA or LAMA medication. Having Medicaid insurance 
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coverage was associated with reduced likelihood of use of triple therapy after the index 
date (OR=0.62, 95% CI, 0.40 to 0.96). 
Having pulmonary circulation disease (OR=1.58, 95% CI 1.11 to 2.23), 
emphysema (OR=1.48, 95% CI 1.15 to 1.89), hypothyroidism (OR=1.42, 95% CI 1.08 to 
1.88) and hypoxemia (OR=1.34, 95% CI 1.03 to 1.74) were all significantly associated 
with use of triple therapy at index while obesity (HR=0.62, 95% CI 0.42 to 0.92) and 
psychoses (OR=0.64, 95% CI 0.41 to 0.92) were significantly associated with not using 
triple therapy at index.   
Having deficiency anemias (OR=0.81, 95% CI 0.68 to 0.96), depression 
(OR=0.85, 95% CI 0.72 to 1.00), and diabetes without chronic complications (OR=0.84, 
95% CI 0.73 to 0.96) were all associated with reduced likelihood of continuing 
ICS/LABA or LAMA in the first period.  After the first period, RA/OA (OR=0.86, 95% 
CI 0.77 to 0.96) and diabetes without chronic complications (OR=0.89, 95% CI 0.79 to 
1.00) were both associated with a reduced likelihood of continued use of one of the index 
therapies. Having emphysema was the only comorbidity associated with continued use of 
ICS/LABA or LAMA after the both the index date (OR=1.17, 95% CI 1.01 to 1.35) and 
for later periods (OR=1.13, 95% CI 1.01 to 1.27). 
Ischemic heart disease (OR=1.29, 95% CI 0.97 to 1.72), depression (OR=1.31, 
95% CI 0.97 to 1.76) and emphysema (OR=1.26, 95% CI 0.97 to 1.64) were all 
marginally associated with use of triple therapy for periods after the index date. 
For the first period post-index both no use of SABA medication (OR=1.62, 95% 
CI 1.35 to 1.94) and use of SABA >40% of the baseline period (OR=1.47, 95% CI 1.22 
to 1.78) were associated with increased likelihood of continuation of ICS/LABA and/or 
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LAMA medication. Additionally having any use of ICS medication in the baseline period 
was associated with increased likelihood of continuing use of one of the index therapies 
(OR=1.14, 95% CI 1.00 to 1.30). Use of SAMA or SABA/SAMA medications in the 
baseline period were both marginally associated with continued use of one the index 
therapies after the first period, and baseline use of SABA/SAMA medication was 
associated with continued use of one of the index therapies for periods 2-7 (OR=1.21, 
95% CI 1.06 to 1.38). 
Baseline symptoms associated with chest pain were associated with a reduced 
likelihood of continuing with ICS/LABA or LAMA treatment after the first period 
(OR=0.76, 95% CI, 0.66 to 0.87). Alternatively, having a spirometry procedure in the 
baseline period was significantly associated with both use of triple therapy at index 
(OR=1.44, 95% CI 1.12 to 1.86) and continued use of one of the index therapies after the 
first period (OR=1.33, 95% CI 1.16 to 1.52). 
Having a severe exacerbation in the two-week period leading up to the index date 
(OR=1.90, 95% CI 1.24 to 2.92) was significantly associated with use of triple therapy at 
index, and also with a reduced likelihood of continuing with one of the medications after 
the first 12 weeks (OR=0.73, 95% CI 0.57 to 0.94).  Having a severe exacerbation in the 
3-12 weeks prior to the index date was however associated with an increased likelihood 
of continuing with one of the therapies in the first 12 weeks post-index (OR=1.44, 95% 
CI 1.10 to 1.89), but not for time periods after the first 12 weeks.   
There were no significant associations between baseline moderate exacerbations 
and use of triple therapy, either at index or in later period. However, having a moderate 
exacerbation in the two-week period leading up to the index date (OR=0.61, 95% CI 0.51 
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to 0.74) and a having a moderate exacerbation in the 13-52 weeks prior to the index date 
(OR=0.74, 95% CI 0.64 to 0.85) were both associated with reduced likelihood of 
continuation of one of the therapies after the first period, while having a moderate 
exacerbation in the 3-12 weeks prior to the index date was associated with an increased 
likelihood of continuing therapy (OR=1.27, 95% CI 1.07 to 1.51). 
Continuation of therapy was differential between the two health plans with 
members from one having a reduced likelihood of continuing with one of the index 
therapies after the first period. 
Over time, the odds of using triple therapy increased (OR=1.02, 95% CI, 1.01 to 
1.03), while the odds of continuing one of the index therapies decreased (OR=0.96, 95% 
CI, 0.96 to 0.97). 
Among the time-varying covariates, an inpatient stay that was not a severe 
exacerbation, but for which a COPD-related diagnosis code was associated as a 
secondary diagnosis was associated with an increased likelihood of continuing therapy 
after the first period (OR=1.67, 95% CI 1.12 to 2.51), but not for later periods.  
Moderate exacerbations in the periods leading up to the start of each time period 
were associated with a greater likelihood of triple therapy at the start of each period 
(OR=1.95, 95% CI 1.22 to 3.14) as was use of SABA medication (OR=1.28, 95% CI 
1.05 to 1.16), and both were associated with continuation of one of the index therapies 
after the first period (moderate exacerbations OR=1.78, 95% CI 1.13 to 2.80; SABA use, 
OR=1.47, 95% CI 1.26 to 1.73).  SABA use was also associated with continuation of any 
of the index therapies for later periods (OR=1.63, 95% CI 1.42 to 1.87).   
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Having an inpatient stay that was not a severe exacerbation but which had a 
secondary diagnosis code that was COPD-related was associated with an increased 
likelihood of continuing use of ICS/LABA and/or LAMA (OR=1.67, 95% CI 1.12 to 
2.51) after the first period, but not later periods, and when they occurred in a prior period 
were associated with a reduced likelihood of continuing use of ICS/LABA and/or LAMA 
medications (OR=0.69, 95% CI, 0.53 to 0.90). 
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Table 68 Odds Ratios, MSM Regression Models for Stabilized Weight Estimation 
 Period 1 
 
Periods 2-7 Period 1 Periods 2-7 
 
Triple Therapy at Beginning of Period 
Not discontinuing therapy or disenrolling 
(no censoring) 
 Denominator Denominator1 Denominator1 Denominator1 
Factor OR (95% CI) 
 
OR (95% CI) 
 
OR (95% CI)   OR (95% CI) 
Triple therapy at Index     36.9 (28.3,47.9) * 2.50 (1.97,3.17) * 1.26 (0.97,1.62) ~ 
Male 1.35 (1.07,1.71) # 1.08 (0.86,1.36)  1.02 (0.91,1.16)  1.04 (0.94,1.15)   
Age              
Age 40 to 54 vs Age >75 1.18 (0.73,1.91)  1.81 (1.15,2.85) + 0.80 (0.64,1.02) ~ 0.78 (0.64,0.95) # 
Age 55 to 64 vs Age >75 1.57 (1.13,2.17) + 1.32 (0.95,1.84) ~ 0.99 (0.83,1.19)  0.87 (0.75,1.00) ~ 
Age 65 to 74 vs Age >75 0.95 (0.72,1.25)  1.15 (0.87,1.53)  0.98 (0.85,1.14)  1.00 (0.90,1.12)   
Medicaid 0.82 (0.54,1.26)  0.62 (0.40,0.96) # 0.83 (0.67,1.03) ~ 0.88 (0.74,1.05)   
Baseline Comorbidities              
Atrial fibrillation 0.91 (0.61,1.37)  1.30 (0.87,1.94)  0.94 (0.77,1.16)  1.13 (0.95,1.35)   
Heart failure or CHF 0.87 (0.63,1.21)  0.76 (0.54,1.07)  0.93 (0.79,1.10)  0.97 (0.84,1.12)   
Ischemic Heart Disease 1.02 (0.77,1.36)  1.29 (0.97,1.72) ~ 0.92 (0.79,1.07)  0.94 (0.83,1.06)   
Rheumatoid or osteo-arthritis 0.78 (0.59,1.02) ~ 0.82 (0.62,1.09)  0.95 (0.83,1.08)  0.86 (0.77,0.96) + 
Deficiency anemias 0.87 (0.61,1.23)  1.06 (0.74,1.50)  0.81 (0.68,0.96) # 1.06 (0.92,1.22)   
Depression 1.03 (0.75,1.42)  1.31 (0.97,1.76) ~ 0.85 (0.72,1.00) # 0.99 (0.87,1.13)   
Diabetes w/o chronic complications 0.93 (0.70,1.23)  0.91 (0.69,1.21)  0.84 (0.73,0.96) # 0.89 (0.79,1.00) # 
Fluid and electrolyte disorders 1.11 (0.78,1.59)  1.07 (0.72,1.60)  0.91 (0.75,1.10)  1.03 (0.87,1.21)   
Hypertension 0.82 (0.64,1.05)  0.98 (0.77,1.25)  1.10 (0.97,1.25)  0.99 (0.90,1.10)   
Hypothyroidism 1.42 (1.08,1.88) # 0.98 (0.74,1.31)  1.10 (0.95,1.28)  0.96 (0.86,1.08)   
Obesity 0.62 (0.42,0.92) # 0.72 (0.48,1.08)  1.04 (0.86,1.24)  0.99 (0.86,1.15)   
Other neurological disorders 1.13 (0.77,1.66)  0.84 (0.57,1.25)  1.00 (0.82,1.22)  0.87 (0.75,1.01) ~ 
Psychoses 0.64 (0.41,0.98) # 1.16 (0.80,1.68)  1.08 (0.89,1.31)  0.87 (0.75,1.01) ~ 
Pulmonary circulation disease 1.58 (1.11,2.23) # 0.78 (0.52,1.16)  0.90 (0.73,1.10)  0.91 (0.78,1.07)   
Renal failure 1.14 (0.76,1.71)  1.03 (0.69,1.55)  0.97 (0.79,1.20)  0.93 (0.79,1.10)   
Valvular disease 1.10 (0.76,1.60)  0.96 (0.63,1.45)  1.08 (0.88,1.32)  1.03 (0.87,1.22)   
Weight loss 0.78 (0.47,1.29)  0.89 (0.50,1.55)  0.84 (0.66,1.07)  0.96 (0.78,1.19)   
Asthma 0.87 (0.67,1.12)  0.91 (0.70,1.17)  1.00 (0.88,1.14)  1.02 (0.92,1.13)   
Hypoxemia 1.34 (1.03,1.74) # 1.10 (0.84,1.44)  1.03 (0.89,1.19)  0.91 (0.81,1.02) ~ 
Pneumonia 0.85 (0.66,1.11)  1.13 (0.87,1.46)  0.96 (0.84,1.09)  0.96 (0.86,1.08)   
Emphysema 1.48 (1.15,1.89) + 1.26 (0.97,1.64) ~ 1.17 (1.01,1.35) # 1.13 (1.01,1.27) # 
Low COPD complexity 0.79 (0.60,1.04) ~ 0.98 (0.75,1.27)  0.87 (0.76,1.00) ~ 1.04 (0.93,1.16)   
Baseline COPD Medication               
No SABA use 0.93 (0.70,1.23)  0.86 (0.64,1.16)  1.62 (1.35,1.94) * 1.08 (0.96,1.23)   
SABA use 15-40% 0.71 (0.47,1.06) ~ 0.73 (0.48,1.09)  1.08 (0.89,1.30)  0.92 (0.79,1.08)   
SABA use >40% 1.20 (0.85,1.69)  0.90 (0.64,1.28)  1.47 (1.22,1.78) * 0.99 (0.85,1.16)   
Any SAMA use 0.91 (0.64,1.28)  1.30 (0.94,1.80)  1.18 (0.98,1.43) ~ 1.11 (0.95,1.30)   
Any SABA/SAMA use 1.03 (0.77,1.37)  1.27 (0.94,1.71)  1.15 (0.98,1.36) ~ 1.21 (1.06,1.38) + 
Any ICS use 0.86 (0.67,1.11)  1.15 (0.90,1.46)  1.14 (1.00,1.30) # 1.07 (0.96,1.19)   
Oxygen use </=50% 1.15 (0.83,1.60)  0.97 (0.68,1.38)  1.06 (0.88,1.27)  1.13 (0.97,1.31)   
Oxygen use >50% 1.09 (0.81,1.47)  1.15 (0.86,1.55)  1.03 (0.88,1.20)  1.08 (0.95,1.22)   
Any nebulizer treatment 1.22 (0.94,1.58)  1.02 (0.79,1.31)  1.05 (0.92,1.21)  1.03 (0.92,1.15)   
Baseline Symptoms              
No breathlessness 1.05 (0.78,1.40)  1.15 (0.84,1.58)  0.92 (0.79,1.08)  1.02 (0.90,1.16)   
>1 period breathlessness 0.87 (0.61,1.24)  1.38 (0.94,2.02)  0.97 (0.80,1.18)  1.04 (0.89,1.22)   
No shortness of breath 1.08 (0.81,1.45)  0.93 (0.68,1.27)  1.06 (0.91,1.24)  0.92 (0.81,1.05)   
>1 period shortness of breath 1.09 (0.77,1.55)  1.18 (0.82,1.70)  1.05 (0.87,1.28)  0.98 (0.83,1.15)   
Any wheezing 1.26 (0.85,1.88)  0.88 (0.55,1.39)  1.01 (0.81,1.26)  1.09 (0.90,1.32)   
Any chest pain 1.02 (0.78,1.33)  0.92 (0.69,1.23)  0.76 (0.66,0.87) * 0.99 (0.89,1.11)   
Any other malaise/fatigue 1.16 (0.89,1.51)  0.94 (0.71,1.24)  0.93 (0.81,1.07)  0.93 (0.83,1.04)   
Any cough 0.84 (0.65,1.08)  1.16 (0.90,1.49)  0.91 (0.80,1.04)  0.94 (0.85,1.05)   
Baseline Procedures              
Any chest CT 0.99 (0.73,1.35)  1.06 (0.77,1.47)  0.91 (0.76,1.08)  0.98 (0.85,1.12)   
Any chest x-ray 0.96 (0.73,1.26)  1.03 (0.78,1.35)  1.09 (0.95,1.25)  0.96 (0.86,1.08)   
Any echocardiography 0.84 (0.60,1.17)  1.16 (0.81,1.66)  0.93 (0.78,1.10)  1.15 (1.00,1.33) # 
Any EKG 1.08 (0.83,1.41)  0.89 (0.68,1.16)  1.02 (0.89,1.16)  0.94 (0.85,1.05)   
Any spirometry 1.44 (1.12,1.86) + 1.03 (0.80,1.32)  1.33 (1.16,1.52) * 1.02 (0.92,1.14)   
Baseline Exacerbation              
Mod Exac Index,2 wks prior 1.29 (0.93,1.79)  0.86 (0.61,1.21)  0.61 (0.51,0.74) * 1.01 (0.87,1.18)   
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 Period 1 
 
Periods 2-7 Period 1 Periods 2-7 
 
Triple Therapy at Beginning of Period 
Not discontinuing therapy or disenrolling 
(no censoring) 
 Denominator Denominator1 Denominator1 Denominator1 
Factor OR (95% CI) 
 
OR (95% CI) 
 
OR (95% CI)   OR (95% CI) 
Mod Exac wks 3-12  1.05 (0.77,1.44)  0.87 (0.63,1.22)  1.27 (1.07,1.51) + 1.00 (0.87,1.15)   
Any Mod Exac wks 13-52  1.03 (0.78,1.37)  0.95 (0.72,1.26)  0.74 (0.64,0.85) * 1.04 (0.92,1.18)   
Sev Exac within 2 wks 1.90 (1.24,2.92) + 1.51 (0.92,2.46)  0.73 (0.57,0.94) # 0.92 (0.73,1.16)   
Sev Exac wks 3-12 pre-index 0.94 (0.61,1.47)  1.03 (0.64,1.64)  1.44 (1.10,1.89) + 1.06 (0.84,1.34)   
Sev Exac wks 13-52 pre-index 1.09 (0.71,1.65)  0.82 (0.51,1.30)  1.10 (0.86,1.41)  1.07 (0.87,1.31)   
Any Hosp w/sec COPD-rel Dx wks 
13-52 
1.05 (0.67,1.66)  0.85 (0.53,1.36)  1.13 (0.89,1.43)  1.09 (0.89,1.33)   
Health plan 1.11 (0.87,1.42)  1.20 (0.94,1.53)  0.65 (0.57,0.74) * 0.91 (0.82,1.01) ~ 
Number of two-week periods    1.02 (1.01,1.03) +   + 0.96 (0.96,0.97) * 
Triple therapy Index x No. two-week 
periods 
 
       1.00 (0.99,1.01)   
Time Dependent Covariates 
 
        
% of period w/moderate 
exacerbation 
 
1.95 (1.22,3.14) + 1.78 (1.13,2.80) # 0.87 (0.59,1.27)  
No. hosp w/secondary COPD-related 
DX  
 
1.01 (0.66,1.55)  1.67 (1.12,2.51) # 0.78 (0.61,1.00) ~ 
Any SABA use in period 
 
1.28 (1.05,1.56) # 1.47 (1.26,1.73) * 1.63 (1.42,1.87) * 
Prior Period: 
 
        
% of period w/moderate 
exacerbation 
   
1.12 (0.76,1.66)  
No. hosp w/secondary COPD-related 
DX  
   
0.69 (0.53,0.90) + 
Any SABA use in period 
   
0.88 (0.77,1.01)  ~ 
Note 1: Results for numerator not shown since effect estimates almost identical to denominator results 
* P<0.0001; + P<0.01; # P<0.05; ~ P<0.10 
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Analyses Using Weighted Population 
Analyses performed in Aim 1 and Aim 2 were redone using 1) the actual number 
of study subjects included in the weighted population, and 2) the weighted sample. The 
weighted sample used was the sample for the first time period in the follow-up period, for 
which there were 3,407 study subjects. Table 69 provides results for the comparison of 
study subjects by index therapy, Table 70 for the comparison of study subjects by 
whether they discontinued use of ICS/LABA and/or LAMA by 6 months of follow-up, 
and Table 71 for the comparison of study subjects who had a severe exacerbation by 6 
months of follow-up.  Included in each table are results from the original full study 
sample of 5,475 subjects.  Tables only include percentages and not counts, in order to 
more easily compare results. 
Table 69 shows that while there were significant differences in baseline 
characteristics between the treatment groups, in the weighted sample these differences are 
no longer apparent.  However while the groups were now balanced with regard to 
percentages by individual comorbidity, the groups were still different for the percentage 
of patients with any Elixhauser comorbidity.  Overall, the triple therapy group had a 
lower percentage with any comorbidity – 87.9% compared to 91.6% for the ICS/LABA 
or LAMA population (P=0.02). 
Results remained similar for discontinuation of therapy by six months (Table 70) 
and for severe exacerbation (Table 71), which is interesting since the study sample was 
smaller and excluded patients who discontinued use of ICS/LABA or LAMA by the end 
of the first time period (n=2,068).   
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Table 72 and Table 73 provide comparisons of baseline mean and median costs 
by index treatment group.  Shown are the results from the full study sample of 5,475 
study subjects and the weighted study sample, with values estimated using the sample 
weights. While some differences that were significant in the original study sample no 
longer are, there are a few differences that either remained significant or were now 
marginally significant. Additionally, some differences were now significant that were not 
previously so. For example, the mean non-COPD outpatient utilization costs were now 
significantly higher for the non-triple therapy group compared to the triple therapy 
($5,577 compared to $4,737, P=0.04), whereas previously the means were not different 
(P=0.19), mostly because the mean triple therapy costs were higher in the original 
analysis ($4,983). Changes due to weighting were more apparent in the median costs 
(Table 73).  Where originally the triple therapy group had higher overall median 
healthcare service costs (inpatient and outpatient) ($8,704 compared to $7,305, P=0.09), 
now the triple therapy group had significantly lower median costs ($6,471 compared to 
$7,325, P=0.002).
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Table 69 Baseline Characteristics, By Index Treatment, Original versus Weighted 
 Original Study Sample Weighted Sample – Actual N Weighted Sample, Weighted 
Baseline Characteristic Total  
% 
Non-
Triple 
% 
Triple 
% 
pval  Total 
% 
Non-
Triple 
% 
Triple  
% 
pval  Total  
% 
Non-
Triple 
% 
Triple  
% 
pval  
Number of Patients 5475 4991 484   3407 3019 388   3410 3021 389   
Age Categories                      
age 40-54 10.7 10.8 9.5 0.3855 9.6 9.7 8.2 0.3473 9.8 9.6 11.3 0.2869 
age 55-64 18.7 18.2 24.4 0.0009 19.0 18.3 24.2 0.0052 18.8 18.9 17.9 0.6213 
age 65-74 29.9 30.0 28.5 0.4851 30.5 30.8 28.1 0.2690 30.5 30.5 30.3 0.9204 
age 75 and older 40.7 41.0 37.6 0.1471 40.9 41.1 39.4 0.5280 40.9 40.9 40.5 0.8738 
age (Mean, SD) 70.55 70.60 70.02 0.2903 70.7 70.8 70.6 0.7815 70.7 70.7 70.7 0.9513 
                          
Men 43.7 43.0 51.2 0.0005 44.4 43.6 50.8 0.0074 44.3 44.4 44.1 0.9049 
Insurance at Index                         
Commercial 32.5 32.2 35.5 0.1319 32.4 31.8 37.1 0.0341 32.2 32.0 34.4 0.3376 
Medicaid 12.0 11.9 12.6 0.6496 11.1 11.2 10.3 0.6007 11.3 11.2 12.0 0.6162 
Medicare 56.1 56.5 52.3 0.0762 57.1 57.6 53.1 0.0912 57.0 57.4 53.9 0.1919 
                          
CMS comorbidities                          
acute myocardial infarction (AMI) 3.2 3.2 2.9 0.6907 3.3 3.3 3.1 0.8194 3.2 3.4 1.7 0.0770 
Alzheimer’s 3.5 3.5 2.5 0.2196 3.2 3.2 2.8 0.6649 3.2 3.3 2.8 0.6335 
atrial fibrillation 9.8 9.8 9.1 0.6069 9.5 9.4 9.8 0.8229 9.5 9.5 9.9 0.8058 
cancers 6.8 6.9 5.4 0.2033 6.8 6.9 5.9 0.4925 6.8 6.9 6.1 0.5746 
lung cancer 2.1 2.0 2.7 0.3134 2.1 2.2 1.5 0.4095 2.1 2.2 1.4 0.2726 
chronic kidney disease 15.9 15.8 16.7 0.5943 15.8 15.6 17.3 0.3870 15.4 15.6 14.4 0.5420 
diabetes 24.8 24.9 23.8 0.5778 23.6 23.6 23.2 0.8540 23.4 23.4 23.1 0.9029 
heart failure 18.0 17.9 19.6 0.3316 17.4 17.1 19.3 0.2806 17.5 17.3 18.8 0.4608 
ischemic heart dis. (IHD; incl. 
AMI) 
24.5 24.3 26.7 0.2555 23.6 23.5 24.7 0.5730 23.4 23.6 22.2 0.5481 
rheumatoid/osteo arthritis  26.4 27.0 19.4 0.0003 25.6 26.2 20.6 0.0177 25.4 25.5 25.3 0.9301 
stroke/TIA 7.1 7.1 7.0 0.9687 7.2 7.1 8.2 0.4064 7.3 7.1 8.8 0.2244 
no CMS Comorbidity 34.0 33.6 38.0 0.0491 35.0 34.5 38.4 0.1340 35.1 34.8 37.9 0.2255 
Elixhauser comorbidities                          
AIDS 0.2 0.2 0.2 0.8971 0.2 0.2 0.3 0.8091 0.2 0.2 0.1 0.7743 
alcohol abuse 3.5 3.4 4.3 0.2856 3.7 3.6 4.4 0.4487 3.6 3.6 3.4 0.8024 
chronic blood loss anemia 0.9 0.9 0.8 0.8668 0.9 0.9 0.8 0.8590 0.8 0.9 0.5 0.4818 
coagulopathy 3.0 2.9 3.7 0.3145 3.1 3.0 3.9 0.3630 3.1 3.1 3.4 0.7451 
congestive heart failure 16.5 16.5 16.1 0.8147 15.8 15.8 16.0 0.9274 15.8 16.0 14.3 0.3844 
deficiency anemias 14.1 14.1 14.3 0.9275 13.3 13.2 13.7 0.8085 13.3 13.3 12.6 0.7014 
depression 16.7 16.8 16.5 0.8920 15.8 15.9 15.5 0.8251 15.7 15.8 14.4 0.4569 
diabetes (wo/chr complications) 23.8 24.1 21.3 0.1701 22.5 22.7 20.6 0.3574 22.3 22.4 21.1 0.5469 
diabetes (w/chr complications) 8.1 8.1 7.4 0.5912 7.5 7.6 7.2 0.7957 7.5 7.6 6.8 0.6073 
drug abuse 3.3 3.3 3.3 0.9998 2.8 2.8 2.3 0.5745 2.6 2.8 1.5 0.1270 
fluid and electrolyte disorders 12.5 12.3 14.9 0.1024 12.0 11.7 14.7 0.0875 12.2 12.1 13.0 0.6006 
hypertension 61.6 62.1 57.0 0.0293 61.5 62.0 57.0 0.0529 61.1 61.4 58.6 0.2876 
hypothyroidism 18.8 18.8 19.8 0.5615 19.2 18.7 22.4 0.0834 19.1 19.2 18.9 0.8949 
liver disease 3.9 3.8 4.1 0.7561 4.0 4.1 3.1 0.3366 4.0 4.2 2.1 0.0472 
lymphoma 0.8 0.9 0.2 0.1097 0.9 0.9 0.3 0.1764 0.9 1.0 0.2 0.1094 
metastatic cancer 1.0 1.0 1.0 0.9813 0.9 1.0 0.5 0.3847 0.9 1.0 0.4 0.2920 
obesity 13.1 13.4 9.5 0.0142 12.8 13.2 9.5 0.0395 13.1 12.8 14.9 0.2457 
other neurological disorders 9.4 9.4 8.9 0.6906 9.1 9.0 9.8 0.5977 9.2 9.1 9.8 0.6650 
paralysis 1.2 1.3 0.6 0.1955 1.5 1.6 0.8 0.1987 1.5 1.6 0.5 0.0817 
peripheral vascular disease 16.0 15.9 17.6 0.3381 16.0 15.5 19.3 0.0547 15.8 15.6 17.0 0.4901 
psychoses 10.5 10.7 8.1 0.0699 10.1 10.5 7.2 0.0436 10.2 10.1 10.5 0.7994 
pulmonary circulation disease 11.4 10.9 16.5 0.0002 11.4 10.6 17.8 <0.0001 11.5 11.4 12.0 0.7342 
renal failure 8.5 8.5 8.9 0.7816 8.3 8.2 8.8 0.7293 8.2 8.3 7.4 0.5479 
rheumatoid arthritis/collagen vas 6.3 6.4 5.0 0.2142 6.2 6.3 5.7 0.6323 6.3 6.2 7.2 0.4779 
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 Original Study Sample Weighted Sample – Actual N Weighted Sample, Weighted 
Baseline Characteristic Total  
% 
Non-
Triple 
% 
Triple 
% 
pval  Total 
% 
Non-
Triple 
% 
Triple  
% 
pval  Total  
% 
Non-
Triple 
% 
Triple  
% 
pval  
solid tumor wo/metastasis 9.7 9.9 8.3 0.2530 9.7 10.0 7.5 0.1176 9.8 10.0 8.3 0.2955 
ulcers 0.1 0.1 0.2 0.6116 0.1 0.1 0.3 0.5441 0.2 0.1 0.4 0.1868 
valvular disease 11.5 11.4 13.0 0.2757 11.4 11.1 13.7 0.1292 11.3 11.3 11.2 0.9470 
weight loss 6.0 6.0 6.0 0.9852 5.5 5.6 5.2 0.7391 5.4 5.5 4.8 0.5420 
any Elixhauser diagnosis 91.8 92.2 88.2 0.0024 91.2 91.6 87.9 0.0146 91.2 91.6 87.9 0.0170 
Other comorbidities                         
asthma 33.1 33.4 29.8 0.0997 33.1 33.5 30.7 0.2727 33.2 33.2 33.6 0.8512 
hypoxemia 36.4 35.2 49.2 <0.0001 37.6 36.2 48.5 <0.0001 37.6 37.6 37.9 0.8936 
pneumonia 34.8 34.7 36.8 0.3513 33.9 33.8 35.3 0.5422 33.9 34.0 32.6 0.5738 
influenza 3.3 3.2 4.1 0.2523 3.0 2.8 4.1 0.1527 2.9 2.8 4.1 0.1590 
                      
COPD Complexity ^                     
Low complexity 50.0 51.2 38.0 <0.0001 49.1 50.5 38.1 <0.0001 48.9 49.1 48.0 0.6855 
Med complexity 45.8 44.9 56.0 <0.0001 46.3 45.0 56.7 <0.0001 46.5 46.4 47.9 0.5667 
High complexity 4.1 3.9 6.0 0.0289 4.5 4.5 5.2 0.5434 4.5 4.6 4.1 0.6885 
Emphysema diagnosis (492.x) 22.1 21.0 33.5 <0.0001 23.9 22.6 33.5 <0.0001 23.6 23.8 22.0 0.4325 
COPD Medications                          
Index - ICSLABA   54.2       57.4       57.3     
Index - LAMA   45.8       42.6       42.7     
SABA use                         
no SABA use 42.3 42.5 40.3 0.3568 43.6 43.8 42.3 0.5779 43.7 43.5 44.8 0.6143 
SABA <=15% of year 26.2 25.8 30.6 0.0221 24.6 24.2 27.1 0.2253 24.7 24.6 25.5 0.6947 
SABA <=40% of year 14.7 15.1 9.7 0.0012 13.6 14.0 9.8 0.0213 13.5 13.6 12.9 0.7005 
SABA >40% of year 16.9 16.6 19.4 0.1147 18.3 18.0 20.9 0.1608 18.1 18.3 16.7 0.4549 
SAMA use                         
any ipratropium (SAMA) 11.5 11.5 12.4 0.5383 12.2 12.1 13.1 0.5635 12.3 12.3 12.3 0.9853 
any SABA/SAMA 16.0 15.7 19.0 0.0587 16.6 16.2 19.6 0.0944 16.6 16.6 16.1 0.8136 
any SAMA or SABA/SAMA 25.2 24.9 28.9 0.0495 26.3 25.8 30.2 0.0647 26.3 26.2 26.7 0.8405 
Other COPD medications                         
any ICS 32.0 32.4 28.1 0.0540 32.8 33.3 29.6 0.1533 32.8 32.8 33.0 0.9548 
any LABA 4.1 4.2 3.3 0.3314 5.0 5.1 4.1 0.4052 5.0 5.1 4.2 0.4406 
any methylxanthines 1.6 1.6 1.7 0.9063 1.8 1.8 2.1 0.6684 1.7 1.8 1.4 0.6104 
Any use of above COPD 
medications 
49.1 49.3 46.9 0.3117 50.3 50.6 48.2 0.3767 50.4 50.6 49.6 0.7103 
Oxygen Use                         
no oxygen 56.4 57.1 49.4 0.0010 55.1 55.8 49.0 0.0104 55.1 55.1 55.1 0.9917 
oxygen <=50% of year 16.0 15.6 19.6 0.0226 16.5 16.0 20.4 0.0293 16.4 16.5 15.5 0.6124 
oxygen >50% of year 27.6 27.2 31.0 0.0769 28.4 28.2 30.7 0.3013 28.5 28.4 29.4 0.6863 
Symptoms                         
Dyspnea                         
Breathlessness                         
no periods breathlessness 63.1 63.5 58.7 0.0353 62.4 62.9 58.8 0.1131 62.2 62.4 60.7 0.5306 
1 period breathlessness 19.2 18.9 22.3 0.0681 19.5 19.2 21.9 0.2073 19.6 19.5 20.2 0.7572 
>1 period breathlessness 17.7 17.6 19.0 0.4358 18.1 17.9 19.3 0.4866 18.2 18.1 19.1 0.6385 
Shortness of Breath                         
no periods shortness breath 63.0 63.6 56.8 0.0031 63.1 63.7 58.0 0.0274 62.9 63.0 62.4 0.8144 
1 period shortness breath 20.6 20.5 22.1 0.3913 20.3 20.1 21.1 0.6462 20.3 20.3 20.5 0.9438 
>1 period shortness breath 16.4 15.9 21.1 0.0035 16.7 16.1 20.9 0.0182 16.8 16.7 17.2 0.8199 
any wheezing 7.7 7.5 9.3 0.1540 7.5 7.3 9.3 0.1613 7.3 7.5 5.7 0.2072 
any dyspnea 55.8 55.1 63.2 0.0006 56.3 55.4 63.1 0.0037 56.3 56.1 58.1 0.4489 
supplemental oxygen use (V46.2) 5.8 5.6 7.9 0.0420 6.2 6.0 7.2 0.3597 6.3 6.3 6.1 0.9104 
Other symptoms                         
chest pain unspecified 30.4 30.2 32.2 0.3473 28.1 27.9 30.4 0.2921 28.1 28.2 27.5 0.7758 
painful respiratory 5.0 5.0 5.0 0.9921 4.6 4.6 4.4 0.8434 4.4 4.6 3.3 0.2341 
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 Original Study Sample Weighted Sample – Actual N Weighted Sample, Weighted 
Baseline Characteristic Total  
% 
Non-
Triple 
% 
Triple 
% 
pval  Total 
% 
Non-
Triple 
% 
Triple  
% 
pval  Total  
% 
Non-
Triple 
% 
Triple  
% 
pval  
precordial pain 2.0 2.0 1.2 0.2342 1.9 2.1 1.0 0.1689 1.9 2.0 0.5 0.0313 
any chestpain 31.8 31.6 33.9 0.3065 29.5 29.2 31.7 0.3121 29.4 29.5 28.7 0.7376 
chronic fatigue 1.6 1.5 2.1 0.3384 1.5 1.4 1.8 0.5581 1.4 1.4 1.5 0.8000 
other malaise/fatigue 25.2 25.1 26.2 0.5764 24.3 24.0 26.5 0.2673 24.1 24.3 22.8 0.5090 
difficulty walking 2.5 2.6 2.1 0.4887 2.5 2.6 2.1 0.5374 2.5 2.6 1.9 0.3869 
memory loss 2.4 2.3 3.3 0.1789 2.2 2.0 3.6 0.0392 2.2 2.0 3.5 0.0676 
cough 35.9 36.1 32.9 0.1491 34.9 35.1 33.0 0.4092 34.6 34.8 33.0 0.4701 
hemoptysis 1.4 1.3 1.9 0.3532 1.5 1.5 1.8 0.6353 1.5 1.5 1.2 0.5991 
Procedures                         
chest CT 15.0 14.7 17.8 0.0756 14.9 14.5 17.8 0.0914 14.9 15.0 14.5 0.7938 
chest x-ray 62.7 62.5 64.9 0.2965 63.2 62.9 65.5 0.3184 63.3 63.1 64.3 0.6465 
echocardiography 20.3 20.4 19.4 0.6034 19.9 19.9 20.1 0.9276 19.9 20.0 19.3 0.7603 
EKG 44.8 44.8 44.2 0.7915 43.9 43.7 45.6 0.4712 44.0 43.9 44.9 0.7252 
heart catheterization 1.3 1.3 1.4 0.7608 1.2 1.2 1.3 0.9156 1.2 1.2 0.9 0.5957 
nebulizer treatment 32.3 31.8 38.2 0.0038 32.9 32.1 39.2 0.0050 33.0 32.9 33.5 0.8140 
non-invasive ventilator 6.2 6.2 6.0 0.8483 6.5 6.5 6.2 0.7981 6.5 6.4 7.2 0.5777 
spirometry 41.7 40.9 50.2 <0.0001 44.6 43.7 51.5 0.0035 44.6 44.7 44.0 0.7948 
any vaccination (flu or 
pneumonia) 
48.1 48.2 47.1 0.6561 48.6 48.9 46.6 0.4128 48.6 48.7 48.0 0.8135 
COPD-related exacerbations                         
Index and 2 weeks prior                         
any moderate 14.3 14.2 15.5 0.4318 13.0 12.6 16.2 0.0464 13.0 13.0 13.0 0.9920 
any severe 7.9 7.4 13.8 <0.0001 7.3 6.6 12.6 <0.0001 7.3 7.4 7.3 0.9775 
any other hospitalizations* 2.3 2.1 3.5 0.0533 1.8 1.7 2.6 0.2143 1.8 1.7 2.4 0.3339 
Prior 2-12 weeks                         
any moderate 16.3 16.1 18.2 0.2480 16.9 16.6 19.1 0.2201 16.7 16.8 16.0 0.6935 
any severe 6.2 5.9 9.1 0.0049 6.7 6.4 9.0 0.0547 6.6 6.7 6.2 0.7331 
any other hospitalizations* 3.8 3.8 3.9 0.8964 3.8 3.8 3.6 0.8700 3.7 3.9 2.4 0.1501 
Prior 13-52 weeks                         
no moderate 76.7 76.8 75.4 0.4788 78.3 78.5 76.8 0.4539 78.4 78.2 79.6 0.5543 
1 moderate 18.6 18.4 20.2 0.3272 17.5 17.3 19.1 0.3845 17.4 17.4 17.6 0.9109 
>1 moderate 4.7 4.7 4.3 0.6988 4.2 4.2 4.1 0.9148 4.2 4.4 2.8 0.1537 
any severe 7.5 7.2 9.9 0.0320 7.8 7.6 10.1 0.0846 7.9 7.9 8.3 0.7869 
any other hospitalizations* 7.0 7.1 6.6 0.7167 6.8 6.8 7.2 0.7542 7.0 6.8 7.8 0.4908 
All Inpatient Utilization                         
Non-COPD Inpatient (Any) 15.6 15.5 16.3 0.6287 14.7 14.5 15.7 0.5362 14.7 14.7 14.9 0.9252 
COPD Inpatient (Any) 20.4 19.7 27.7 <0.0001 19.7 18.8 26.5 0.0003 19.7 19.7 19.8 0.9689 
Total Inpatient (Any) 30.9 30.3 37.2 0.0016 29.5 28.7 35.3 0.0073 29.5 29.6 28.5 0.6683 
 * COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 70 Baseline Characteristics – Discontinuation 6 Months, Original versus Weighted 
 Original Sample Weighted Sample – Actual N Weighted Sample - 
Weighted 
Baseline Characteristic Total 
% 
Disc 
% 
Cont
% 
pval  Total
% 
Disc
% 
Cont
% 
pval  Total
% 
Disc 
% 
Cont
% 
pval  
Number of Patients 5475 2931 2544  3407 860 2547   3410 862 2549   
Age Categories                     
age 40-54 10.7 12.2 8.9 <0.0001 9.6 11.6 8.9 0.0196 9.8 11.8 9.2 0.0215 
age 55-64 18.7 18.7 18.8 0.8752 19.0 19.5 18.8 0.6795 18.8 19.3 18.6 0.6316 
age 65-74 29.9 28.1 31.9 0.0024 30.5 26.4 31.9 0.0024 30.5 26.4 31.9 0.0024 
age 75 and older 40.7 41.0 40.4 0.6488 40.9 42.5 40.4 0.2655 40.9 42.4 40.3 0.2870 
age (Mean, SD) 70.55 70.33 70.80 0.1329 70.7 70.6 70.8 0.6853 70.7 70.6 70.8 0.7280 
                     
Men 43.7 42.7 44.9 0.1122 44.4 43.1 44.9 0.3726 44.3 43.4 44.7 0.5171 
Insurance at Index                     
Commercial 32.5 32.2 32.8 0.6501 32.4 31.2 32.8 0.3816 32.2 31.0 32.7 0.3667 
Medicaid 12.0 13.1 10.7 0.0054 11.1 12.4 10.7 0.1582 11.3 12.5 10.8 0.1732 
Medicare 56.1 55.2 57.1 0.1716 57.1 57.1 57.1 0.9792 57.0 57.2 57.0 0.9316 
                         
CMS comorbidities                          
acute myocardial infarction 
(AMI) 
3.2 3.0 3.4 0.3812 3.3 2.9 3.4 0.4566 3.2 2.7 3.4 0.3401 
Alzheimer’s 3.5 3.6 3.3 0.5707 3.2 2.9 3.3 0.5591 3.2 2.9 3.3 0.5269 
atrial fibrillation 9.8 9.8 9.7 0.8460 9.5 8.9 9.7 0.5172 9.5 8.8 9.8 0.4165 
cancers 6.8 6.7 6.8 0.8226 6.8 6.5 6.8 0.7228 6.8 6.4 6.9 0.6447 
lung cancer 2.1 2.0 2.1 0.9250 2.1 2.2 2.1 0.8346 2.1 2.4 2.1 0.6184 
chronic kidney disease 15.9 15.7 16.1 0.7249 15.8 14.8 16.1 0.3857 15.4 14.5 15.8 0.3625 
diabetes 24.8 26.2 23.2 0.0121 23.6 24.6 23.2 0.4248 23.4 24.3 23.1 0.4620 
heart failure 18.0 18.7 17.2 0.1358 17.4 18.0 17.2 0.5999 17.5 18.1 17.3 0.5674 
ischemic heart dis. (IHD; incl. 
AMI) 
24.5 25.1 23.9 0.3126 23.6 22.7 23.9 0.4776 23.4 22.7 23.7 0.5762 
rheumatoid/osteo arthritis  26.4 27.8 24.7 0.0107 25.6 28.0 24.7 0.0536 25.4 27.8 24.7 0.0698 
stroke/TIA 7.1 7.4 6.7 0.3509 7.2 8.7 6.7 0.0535 7.3 8.9 6.8 0.0363 
no CMS Comorbidity 34.0 32.6 35.5 0.0230 35.0 33.4 35.5 0.2497 35.1 33.7 35.6 0.3050 
                         
Elixhauser comorbidities                          
AIDS 0.2 0.2 0.2 0.6816 0.2 0.3 0.2 0.2858 0.2 0.3 0.2 0.3956 
alcohol abuse 3.5 3.3 3.7 0.3560 3.7 3.6 3.7 0.8484 3.6 3.5 3.7 0.7787 
chronic blood loss anemia 0.9 0.8 1.1 0.2234 0.9 0.2 1.1 0.0219 0.8 0.3 1.0 0.0321 
coagulopathy 3.0 3.0 3.0 0.9668 3.1 3.5 3.0 0.4748 3.1 3.5 3.0 0.4536 
congestive heart failure 16.5 17.5 15.4 0.0369 15.8 17.1 15.4 0.2157 15.8 17.0 15.4 0.2579 
deficiency anemias 14.1 14.5 13.7 0.4282 13.3 11.9 13.7 0.1820 13.3 12.0 13.7 0.2146 
depression 16.7 17.7 15.6 0.0415 15.8 16.5 15.6 0.5736 15.7 16.8 15.3 0.2736 
diabetes (wo/chr complications) 23.8 25.2 22.2 0.0077 22.5 23.3 22.2 0.4953 22.3 23.1 22.0 0.4947 
diabetes (w/chr complications) 8.1 8.7 7.4 0.0839 7.5 8.0 7.4 0.5606 7.5 7.8 7.4 0.7129 
drug abuse 3.3 4.0 2.5 0.0023 2.8 3.5 2.5 0.1366 2.6 3.3 2.4 0.1384 
fluid and electrolyte disorders 12.5 13.3 11.6 0.0518 12.0 13.3 11.6 0.1772 12.2 13.6 11.7 0.1429 
hypertension 61.6 61.7 61.6 0.9221 61.5 61.2 61.6 0.8451 61.1 60.8 61.2 0.8686 
hypothyroidism 18.8 18.9 18.8 0.9158 19.2 20.3 18.8 0.3370 19.1 20.5 18.7 0.2356 
liver disease 3.9 4.0 3.8 0.7247 4.0 4.6 3.8 0.2640 4.0 4.6 3.7 0.2692 
lymphoma 0.8 0.8 0.9 0.6293 0.9 0.7 0.9 0.5639 0.9 0.7 0.9 0.4443 
metastatic cancer 1.0 1.0 1.0 0.9955 0.9 0.6 1.0 0.2367 0.9 0.5 1.0 0.1954 
obesity 13.1 13.3 12.8 0.5652 12.8 12.9 12.8 0.9711 13.1 13.1 13.1 0.9959 
other neurological disorders 9.4 10.2 8.5 0.0339 9.1 10.8 8.5 0.0433 9.2 10.9 8.6 0.0467 
paralysis 1.2 1.0 1.5 0.1172 1.5 1.6 1.5 0.7901 1.5 1.6 1.5 0.7038 
peripheral vascular disease 16.0 16.6 15.3 0.1845 16.0 17.8 15.3 0.0814 15.8 17.7 15.1 0.0733 
psychoses 10.5 11.0 9.9 0.1771 10.1 10.9 9.9 0.3880 10.2 10.5 10.1 0.7093 
pulmonary circulation disease 11.4 11.2 11.7 0.5745 11.4 10.5 11.7 0.3666 11.5 10.4 11.9 0.2508 
renal failure 8.5 8.5 8.6 0.9582 8.3 7.5 8.6 0.3400 8.2 7.6 8.4 0.4352 
rheumatoid arthritis/collagen 
vas 
6.3 6.9 5.6 0.0520 6.2 8.1 5.6 0.0079 6.3 8.3 5.7 0.0065 
solid tumor wo/metastasis 9.7 9.7 9.8 0.8308 9.7 9.3 9.8 0.6326 9.8 9.7 9.9 0.8889 
ulcers 0.1 0.1 0.1 0.8481 0.1 0.2 0.1 0.4504 0.2 0.3 0.1 0.2628 
valvular disease 11.5 11.8 11.2 0.5113 11.4 11.8 11.2 0.6219 11.3 11.5 11.3 0.8771 
weight loss 6.0 6.5 5.4 0.0875 5.5 5.9 5.4 0.5599 5.4 5.9 5.3 0.4562 
any Elixhauser diagnosis 91.8 92.5 91.0 0.0446 91.2 91.7 91.0 0.5791 91.2 91.6 91.0 0.6126 
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 Original Sample Weighted Sample – Actual N Weighted Sample - 
Weighted 
Baseline Characteristic Total 
% 
Disc 
% 
Cont
% 
pval  Total
% 
Disc
% 
Cont
% 
pval  Total
% 
Disc 
% 
Cont
% 
pval  
Number of Patients 5475 2931 2544  3407 860 2547   3410 862 2549   
Other comorbidities             
asthma 33.1 32.7 33.6 0.5051 33.1 31.9 33.6 0.3582 33.2 31.8 33.7 0.3136 
hypoxemia 36.4 35.1 37.9 0.0303 37.6 36.6 37.9 0.4904 37.6 36.7 37.9 0.5342 
pneumonia 34.8 35.9 33.6 0.0726 33.9 34.9 33.6 0.4960 33.9 34.8 33.6 0.5248 
influenza 3.3 3.7 2.7 0.0362 3.0 3.7 2.7 0.1361 2.9 3.7 2.7 0.1371 
             
COPD Complexity ^             
Low complexity 50.0 51.0 48.9 0.1140 49.1 49.8 48.9 0.6379 48.9 49.4 48.8 0.7486 
Med complexity 45.8 45.2 46.5 0.3355 46.3 45.7 46.5 0.6519 46.5 45.9 46.7 0.6804 
High complexity 4.1 3.7 4.6 0.1180 4.5 4.5 4.6 0.9605 4.5 4.7 4.5 0.8276 
Emphysema diagnosis (492.x) 22.1 19.7 24.9 <0.0001 23.9 20.7 24.9 0.0128 23.6 20.5 24.6 0.0153 
                     
COPD Medications                      
index ICSLABA 55.7 61.1 49.6 <0.0001 50.9 54.8 49.6 0.0078 50.8 54.7 49.5 0.0072 
index LAMA 35.4 33.0 38.2 <0.0001 37.7 36.3 38.2 0.3099 37.8 36.4 38.3 0.3180 
index triple 8.8 5.9 12.2 <0.0001 11.4 8.9 12.2 0.0083 11.4 8.9 12.3 0.0069 
SABA use                     
no SABA use 42.3 41.1 43.6 0.0564 43.6 43.5 43.6 0.9270 43.7 43.6 43.7 0.9883 
SABA <=15% of year 26.2 28.0 24.2 0.0014 24.6 25.7 24.2 0.3608 24.7 25.9 24.3 0.3505 
SABA <=40% of year 14.7 16.2 12.9 0.0005 13.6 15.5 12.9 0.0508 13.5 15.2 12.9 0.0864 
SABA >40% of year 16.9 14.7 19.3 <0.0001 18.3 15.3 19.3 0.0085 18.1 15.2 19.1 0.0108 
SAMA use                         
any ipratropium (SAMA) 11.5 10.5 12.8 0.0079 12.2 10.7 12.8 0.1014 12.3 10.7 12.8 0.1016 
any SABA/SAMA 16.0 14.8 17.4 0.0079 16.6 14.3 17.4 0.0311 16.6 14.6 17.2 0.0720 
any SAMA or SABA/SAMA 25.2 23.1 27.6 0.0001 26.3 22.2 27.6 0.0019 26.3 22.5 27.5 0.0038 
Other COPD medications                         
any ICS 32.0 30.7 33.5 0.0238 32.8 30.8 33.5 0.1434 32.8 31.5 33.3 0.3130 
any LABA 4.1 3.2 5.3 0.0001 5.0 4.2 5.3 0.2014 5.0 4.2 5.3 0.2049 
any methylxanthines 1.6 1.4 1.8 0.3215 1.8 1.9 1.8 0.8705 1.7 1.7 1.7 0.9663 
Any use of above COPD 
medications 
49.1 47.1 51.4 0.0017 50.3 47.2 51.4 0.0324 50.4 47.7 51.4 0.0667 
Oxygen Use                         
no oxygen 56.4 58.6 53.9 0.0005 55.1 58.4 53.9 0.0225 55.1 58.2 54.1 0.0360 
oxygen <=50% of year 16.0 15.3 16.8 0.1401 16.5 15.6 16.8 0.4350 16.4 15.6 16.7 0.4591 
oxygen >50% of year 27.6 26.1 29.3 0.0079 28.4 26.0 29.3 0.0611 28.5 26.3 29.3 0.0886 
Symptoms                     
Dyspnea                     
Breathlessness                     
no periods breathlessness 63.1 63.6 62.5 0.4019 62.4 62.2 62.5 0.8853 62.2 61.7 62.4 0.7150 
1 period breathlessness 19.2 19.3 19.1 0.8174 19.5 20.9 19.1 0.2508 19.6 21.4 19.0 0.1285 
>1 period breathlessness 17.7 17.1 18.4 0.1945 18.1 16.9 18.4 0.3165 18.2 17.0 18.6 0.2692 
Shortness of Breath                     
no periods shortness breath 63.0 63.2 62.9 0.8194 63.1 63.7 62.9 0.6444 62.9 63.4 62.7 0.7264 
1 period shortness breath 20.6 21.0 20.1 0.4163 20.3 20.6 20.1 0.7522 20.3 20.7 20.2 0.7283 
>1 period shortness breath 16.4 15.8 17.0 0.2356 16.7 15.6 17.0 0.3482 16.8 15.8 17.1 0.4082 
any wheezing 7.7 7.9 7.4 0.4330 7.5 8.0 7.4 0.5347 7.3 7.9 7.1 0.4075 
any dyspnea 55.8 55.6 56.1 0.7623 56.3 56.9 56.1 0.6669 56.3 57.2 56.1 0.5716 
supplemental oxygen use (V46.2) 5.8 5.2 6.5 0.0300 6.2 5.1 6.5 0.1321 6.3 5.3 6.6 0.1679 
Other symptoms                     
chest pain unspecified 30.4 32.8 27.6 <0.0001 28.1 29.8 27.6 0.2173 28.1 30.2 27.4 0.1100 
painful respiratory 5.0 5.4 4.5 0.1224 4.6 4.9 4.5 0.6396 4.4 4.7 4.3 0.6432 
precordial pain 2.0 2.1 1.7 0.2630 1.9 2.5 1.7 0.1311 1.9 2.5 1.6 0.1097 
any chestpain 31.8 34.3 29.0 <0.0001 29.5 31.1 29.0 0.2460 29.4 31.4 28.7 0.1325 
chronic fatigue 1.6 1.8 1.3 0.1545 1.5 2.0 1.3 0.1556 1.4 1.9 1.2 0.1439 
other malaise/fatigue 25.2 26.9 23.2 0.0019 24.3 27.3 23.2 0.0148 24.1 27.3 23.1 0.0123 
difficulty walking 2.5 2.7 2.4 0.4294 2.5 3.0 2.4 0.2897 2.5 3.0 2.4 0.3517 
memory loss 2.4 2.8 2.0 0.0679 2.2 2.7 2.0 0.2501 2.2 2.7 2.0 0.2542 
cough 35.9 37.7 33.7 0.0022 34.9 38.2 33.7 0.0162 34.6 38.0 33.4 0.0151 
hemoptysis 1.4 1.3 1.5 0.6962 1.5 1.7 1.5 0.5569 1.5 1.8 1.4 0.4564 
Procedures             
chest CT 15.0 15.3 14.7 0.5981 14.9 15.4 14.7 0.6326 14.9 15.7 14.7 0.4397 
chest x-ray 62.7 62.8 62.5 0.8356 63.2 65.0 62.5 0.1943 63.3 64.9 62.7 0.2544 
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 Original Sample Weighted Sample – Actual N Weighted Sample - 
Weighted 
Baseline Characteristic Total 
% 
Disc 
% 
Cont
% 
pval  Total
% 
Disc
% 
Cont
% 
pval  Total
% 
Disc 
% 
Cont
% 
pval  
Number of Patients 5475 2931 2544  3407 860 2547   3410 862 2549   
echocardiography 20.3 20.4 20.2 0.8842 19.9 19.0 20.2 0.4306 19.9 19.4 20.1 0.6456 
EKG 44.8 45.8 43.6 0.1099 43.9 44.7 43.6 0.5752 44.0 44.9 43.7 0.5439 
heart catheterization 1.3 1.5 1.1 0.2320 1.2 1.6 1.1 0.2301 1.2 1.5 1.1 0.3182 
nebulizer treatment 32.3 31.8 33.0 0.3222 32.9 32.4 33.0 0.7565 33.0 32.5 33.2 0.6907 
non-invasive ventilator 6.2 5.6 6.9 0.0377 6.5 5.2 6.9 0.0791 6.5 5.2 6.9 0.0721 
spirometry 41.7 38.7 45.2 <0.0001 44.6 42.9 45.2 0.2340 44.6 43.0 45.2 0.2748 
any vaccination (flu or 
pneumonia) 
48.1 47.5 48.8 0.3284 48.6 48.1 48.8 0.7247 48.6 48.1 48.7 0.7522 
COPD-related exacerbations                     
Index and 2 weeks prior                     
any moderate 14.3 15.8 12.6 0.0009 13.0 14.3 12.6 0.2177 13.0 14.3 12.6 0.1916 
any severe 7.9 8.9 6.8 0.0040 7.3 8.8 6.8 0.0504 7.3 8.9 6.8 0.0484 
any other hospitalizations* 2.3 2.8 1.7 0.0078 1.8 2.1 1.7 0.4490 1.8 2.0 1.7 0.5184 
Prior 2-12 weeks                     
any moderate 16.3 15.6 17.1 0.1311 16.9 16.1 17.1 0.4844 16.7 15.9 17.0 0.4728 
any severe 6.2 6.0 6.4 0.5419 6.7 7.8 6.4 0.1571 6.6 7.6 6.3 0.1716 
any other hospitalizations* 3.8 3.8 3.9 0.9002 3.8 3.5 3.9 0.6157 3.7 3.4 3.8 0.5875 
Prior 13-52 weeks                     
no moderate 76.7 75.7 77.9 0.0591 78.3 79.5 77.9 0.3184 78.4 79.2 78.1 0.5139 
1 moderate 18.6 19.4 17.6 0.0943 17.5 17.0 17.6 0.6807 17.4 17.3 17.4 0.9256 
>1 moderate 4.7 4.9 4.5 0.4877 4.2 3.5 4.5 0.2048 4.2 3.5 4.4 0.2444 
any severe 7.5 6.9 8.2 0.0642 7.8 6.8 8.2 0.2058 7.9 7.1 8.2 0.2828 
any other hospitalizations* 7.0 7.2 6.8 0.4952 6.8 7.1 6.8 0.7572 7.0 7.1 6.9 0.7960 
All Inpatient Utilization                     
Non-COPD Inpatient (Any) 15.6 16.7 14.3 0.0140 14.7 15.9 14.3 0.2493 14.7 15.5 14.5 0.4597 
COPD Inpatient (Any) 20.4 21.2 19.5 0.1216 19.7 20.3 19.5 0.6180 19.7 20.6 19.4 0.4416 
Total Inpatient (Any) 30.9 32.3 29.2 0.0111 29.5 30.4 29.2 0.5067 29.5 30.4 29.1 0.4833 
             
Same as Index Trmt   88.0      88.0       87.6   
LHP enrollee 65.7 70.1 60.7 <0.0001 62.5 67.9 60.7 0.0002 62.6 67.8 60.8 0.0002 
* COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 71 Severe Exacerbation in 6 Months, Original versus Weighted 
 Original Sample Weighted Sample – Actual N Weighted Sample - 
Weighted 
Baseline Characteristic Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  
Number of Patients 5475 352 5123  3407 261 3146   3410 256 3154   
Age Categories                         
age 40-54 10.7 9.7 10.7 0.5267 9.6 10.0 9.5 0.8222 9.8 10.1 9.8 0.8764 
age 55-64 18.7 21.0 18.6 0.2565 19.0 19.2 19.0 0.9430 18.8 19.0 18.8 0.9448 
age 65-74 29.9 25.6 30.2 0.0665 30.5 24.9 31.0 0.0402 30.5 25.7 30.9 0.0805 
age 75 and older 40.7 43.8 40.5 0.2276 40.9 46.0 40.5 0.0835 40.9 45.2 40.5 0.1367 
age (Mean, SD) 70.6 71.0 70.5 0.3970 70.7 71.5 70.7 0.2719 70.7 71.4 70.7 0.2941 
                          
Men 43.7 46.3 43.5 0.3095 44.4 46.0 44.3 0.5956 44.3 46.5 44.2 0.4652 
Insurance at Index                         
Commercial 32.5 25.3 33.0 0.0029 32.4 23.4 33.1 0.0012 32.2 23.5 33.0 0.0019 
Medicaid 12.0 18.2 11.5 0.0002 11.1 18.0 10.5 0.0002 11.3 18.5 10.7 0.0002 
Medicare 56.1 57.1 56.0 0.6928 57.1 59.4 56.9 0.4349 57.0 58.8 56.9 0.5454 
                          
CMS comorbidities                          
acute myocardial infarction 
(AMI) 
3.2 4.0 3.1 0.3892 3.3 4.6 3.2 0.2166 3.2 4.7 3.1 0.1692 
Alzheimer’s 3.5 4.0 3.4 0.5768 3.2 4.2 3.1 0.3321 3.2 4.5 3.1 0.2164 
atrial fibrillation 9.8 13.1 9.5 0.0302 9.5 13.8 9.1 0.0133 9.5 13.8 9.2 0.0155 
cancers 6.8 6.8 6.8 0.9629 6.8 6.9 6.7 0.9222 6.8 6.8 6.8 0.9980 
lung cancer 2.1 3.4 2.0 0.0665 2.1 2.3 2.1 0.8283 2.1 2.0 2.2 0.8674 
chronic kidney disease 15.9 19.0 15.7 0.0954 15.8 18.0 15.6 0.3001 15.4 17.9 15.2 0.2511 
diabetes 24.8 28.7 24.5 0.0807 23.6 28.7 23.1 0.0407 23.4 27.6 23.0 0.0989 
heart failure 18.0 27.8 17.3 <0.0001 17.4 27.2 16.6 <0.0001 17.5 28.4 16.6 <0.0001 
ischemic heart disease 24.5 33.0 24.0 0.0001 23.6 32.6 22.9 0.0004 23.4 32.9 22.7 0.0002 
rheumatoid/osteo arthritis  26.4 29.0 26.2 0.2485 25.6 31.0 25.1 0.0350 25.4 30.9 25.0 0.0357 
stroke/TIA 7.1 8.2 7.0 0.3759 7.2 8.4 7.1 0.4324 7.3 7.8 7.3 0.7433 
no CMS Comorbidity 34.0 26.4 34.5 0.0020 35.0 26.4 35.7 0.0026 35.1 27.1 35.8 0.0052 
                          
Elixhauser comorbidities                          
AIDS 0.2 0.3 0.2 0.6449     0.2 0.4456     0.2 0.4569 
alcohol abuse 3.5 6.5 3.3 0.0013 3.7 6.5 3.5 0.0121 3.6 6.7 3.4 0.0055 
chronic blood loss anemia 0.9 2.6 0.8 0.0006 0.9 2.7 0.7 0.0008 0.8 2.7 0.7 0.0006 
coagulopathy 3.0 6.8 2.7 <0.0001 3.1 6.1 2.9 0.0035 3.1 5.7 2.9 0.0110 
congestive heart failure 16.5 24.1 16.0 <0.0001 15.8 22.6 15.3 0.0018 15.8 23.1 15.2 0.0008 
deficiency anemias 14.1 21.6 13.6 <0.0001 13.3 20.7 12.7 0.0002 13.3 21.0 12.6 0.0001 
depression 16.7 21.0 16.5 0.0264 15.8 20.3 15.5 0.0402 15.7 19.7 15.3 0.0663 
diabetes (wo/chr complications) 23.8 30.1 23.4 0.0041 22.5 29.1 21.9 0.0072 22.3 27.7 21.8 0.0287 
diabetes (w/chr complications) 8.1 10.5 7.9 0.0826 7.5 9.2 7.4 0.2929 7.5 9.2 7.4 0.2875 
drug abuse 3.3 5.4 3.2 0.0233 2.8 4.2 2.6 0.1352 2.6 3.8 2.5 0.2390 
fluid and electrolyte disorders 12.5 19.0 12.1 0.0001 12.0 16.9 11.6 0.0127 12.2 17.3 11.8 0.0097 
hypertension 61.6 65.9 61.3 0.0876 61.5 65.5 61.1 0.1612 61.1 65.3 60.7 0.1496 
hypothyroidism 18.8 19.9 18.8 0.6071 19.2 19.5 19.1 0.8731 19.1 20.0 19.1 0.7207 
liver disease 3.9 5.7 3.7 0.0689 4.0 5.0 3.9 0.3957 4.0 5.3 3.8 0.2644 
lymphoma 0.8 1.1 0.8 0.5291 0.9 1.1 0.8 0.5852 0.9 1.1 0.8 0.6235 
metastatic cancer 1.0 1.1 1.0 0.8268 0.9 0.4 1.0 0.3510 0.9 0.4 0.9 0.3378 
obesity 13.1 13.6 13.1 0.7560 12.8 13.0 12.8 0.9198 13.1 12.8 13.1 0.8819 
other neurological disorders 9.4 12.8 9.2 0.0239 9.1 10.7 8.9 0.3316 9.2 11.2 9.1 0.2658 
paralysis 1.2 2.3 1.2 0.0711 1.5 3.1 1.4 0.0348 1.5 3.1 1.4 0.0340 
peripheral vascular disease 16.0 21.0 15.7 0.0084 16.0 20.7 15.6 0.0302 15.8 20.0 15.4 0.0533 
psychoses 10.5 13.4 10.3 0.0674 10.1 11.5 10.0 0.4458 10.2 11.5 10.1 0.4690 
pulmonary circulation disease 11.4 15.3 11.1 0.0167 11.4 14.9 11.1 0.0600 11.5 15.4 11.2 0.0447 
renal failure 8.5 8.5 8.5 0.9860 8.3 8.4 8.3 0.9404 8.2 8.3 8.2 0.9320 
rheumatoid arthritis/collagen vas 6.3 6.3 6.3 0.9905 6.2 5.4 6.3 0.5502 6.3 5.5 6.4 0.5801 
solid tumor wo/metastasis 9.7 10.2 9.7 0.7475 9.7 9.2 9.7 0.7804 9.8 8.7 9.9 0.5454 
ulcers 0.1 0.9 0.1 <0.0001 0.1 0.4 0.1 0.2992 0.2 0.4 0.1 0.3764 
valvular disease 11.5 15.6 11.2 0.0123 11.4 16.5 10.9 0.0067 11.3 16.1 10.9 0.0120 
weight loss 6.0 8.2 5.8 0.0636 5.5 6.9 5.4 0.3101 5.4 6.9 5.3 0.2889 
any Elixhauser diagnosis 91.8 94.0 91.7 0.1194 91.2 93.5 91.0 0.1739 91.2 93.5 91.0 0.1645 
Other comorbidities                         
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 Original Sample Weighted Sample – Actual N Weighted Sample - 
Weighted 
Baseline Characteristic Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  
Number of Patients 5475 352 5123  3407 261 3146   3410 256 3154   
asthma 33.1 36.9 32.9 0.1156 33.1 36.8 32.8 0.1931 33.2 36.2 33.0 0.2842 
hypoxemia 36.4 50.3 35.5 <0.0001 37.6 47.5 36.8 0.0006 37.6 46.9 36.8 0.0014 
pneumonia 34.8 53.1 33.6 <0.0001 33.9 52.1 32.4 <0.0001 33.9 53.5 32.3 <0.0001 
influenza 3.3 4.0 3.2 0.4271 3.0 3.4 2.9 0.6315 2.9 3.8 2.9 0.3692 
                          
COPD Complexity ^                         
Low complexity 50.0 29.8 51.4 <0.0001 49.1 31.0 50.6 <0.0001 48.9 31.5 50.4 <0.0001 
Med complexity 45.8 66.2 44.4 <0.0001 46.3 65.9 44.7 <0.0001 46.5 65.5 45.0 <0.0001 
High complexity 4.1 4.0 4.1 0.8971 4.5 3.1 4.7 0.2311 4.5 3.0 4.7 0.2225 
Emphysema diagnosis (492.x) 22.1 30.1 21.5 0.0002 23.9 33.0 23.1 0.0003 23.6 33.3 22.8 0.0001 
                          
COPD Medications                          
index ICSLABA 55.7 58.2 55.6 0.3300 50.9 54.8 50.6 0.1903 50.8 56.7 50.3 0.0510 
index LAMA 35.4 29.5 35.8 0.0173 37.7 30.7 38.3 0.0143 37.8 30.7 38.4 0.0152 
index triple 8.8 12.2 8.6 0.0211 11.4 14.6 11.1 0.0933 11.4 12.6 11.3 0.5258 
SABA use                         
no SABA use 42.3 34.1 42.8 0.0013 43.6 33.3 44.4 0.0005 43.7 32.7 44.5 0.0002 
SABA <=15% of year 26.2 24.1 26.4 0.3631 24.6 24.9 24.5 0.8952 24.7 24.8 24.7 0.9925 
SABA <=40% of year 14.7 13.6 14.7 0.5722 13.6 13.0 13.6 0.7933 13.5 13.2 13.5 0.8868 
SABA >40% of year 16.9 28.1 16.1 <0.0001 18.3 28.7 17.4 <0.0001 18.1 29.3 17.2 <0.0001 
SAMA use                         
any ipratropium (SAMA) 11.5 21.6 10.9 <0.0001 12.2 22.6 11.4 <0.0001 12.3 23.8 11.4 <0.0001 
any SABA/SAMA 16.0 24.1 15.4 <0.0001 16.6 23.8 16.0 0.0013 16.6 23.9 16.0 0.0009 
any SAMA or SABA/SAMA 25.2 40.3 24.2 <0.0001 26.3 40.6 25.1 <0.0001 26.3 41.6 25.0 <0.0001 
Other COPD medications                         
any ICS 32.0 34.1 31.9 0.3846 32.8 36.0 32.6 0.2563 32.8 35.6 32.6 0.3316 
any LABA 4.1 4.0 4.2 0.8695 5.0 4.6 5.0 0.7621 5.0 5.0 5.0 0.9809 
any methylxanthines 1.6 2.3 1.5 0.2890 1.8 2.7 1.7 0.2583 1.7 2.6 1.6 0.2556 
Any use of above COPD 
medications 
49.1 59.9 48.4 <0.0001 50.3 60.2 49.5 0.0009 50.4 60.4 49.6 0.0010 
Oxygen Use                         
no oxygen 56.4 42.3 57.4 <0.0001 55.1 44.8 55.9 0.0005 55.1 45.3 55.9 0.0011 
oxygen <=50% of year 16.0 16.5 16.0 0.8007 16.5 15.7 16.6 0.7216 16.4 15.4 16.5 0.6724 
oxygen >50% of year 27.6 41.2 26.6 <0.0001 28.4 39.5 27.5 <0.0001 28.5 39.2 27.7 <0.0001 
Symptoms                         
Dyspnea                         
Breathlessness                         
no periods breathlessness 63.1 52.8 63.8 <0.0001 62.4 50.6 63.4 <0.0001 62.2 50.7 63.1 <0.0001 
1 period breathlessness 19.2 23.9 18.9 0.0215 19.5 28.0 18.8 0.0003 19.6 27.6 19.0 0.0008 
>1 period breathlessness 17.7 23.3 17.3 0.0046 18.1 21.5 17.8 0.1367 18.2 21.7 17.9 0.1324 
Shortness of Breath                         
no periods shortness breath 63.0 48.3 64.0 <0.0001 63.1 50.6 64.1 <0.0001 62.9 50.0 64.0 <0.0001 
1 period shortness breath 20.6 25.0 20.3 0.0350 20.3 24.5 19.9 0.0741 20.3 25.1 19.9 0.0467 
>1 period shortness breath 16.4 26.7 15.7 <0.0001 16.7 24.9 16.0 0.0002 16.8 24.9 16.1 0.0003 
any wheezing 7.7 11.9 7.4 0.0018 7.5 12.6 7.1 0.0011 7.3 12.1 6.9 0.0021 
any dyspnea 55.8 71.0 54.8 <0.0001 56.3 72.4 54.9 <0.0001 56.3 72.5 55.0 <0.0001 
supplemental oxygen use (V46.2) 5.8 14.2 5.2 <0.0001 6.2 14.6 5.5 <0.0001 6.3 14.5 5.6 <0.0001 
Other symptoms                         
chest pain unspecified 30.4 40.3 29.7 <0.0001 28.1 37.5 27.4 0.0004 28.1 36.7 27.4 0.0014 
painful respiratory 5.0 8.5 4.7 0.0015 4.6 7.3 4.4 0.0298 4.4 7.1 4.2 0.0298 
precordial pain 2.0 3.7 1.8 0.0148 1.9 3.4 1.8 0.0653 1.9 3.3 1.7 0.0744 
any chestpain 31.8 42.3 31.1 <0.0001 29.5 39.5 28.7 0.0002 29.4 38.7 28.7 0.0007 
chronic fatigue 1.6 1.1 1.6 0.5138 1.5 1.5 1.5 0.9276 1.4 1.4 1.4 0.9506 
other malaise/fatigue 25.2 33.5 24.6 0.0002 24.3 34.1 23.5 0.0001 24.1 34.3 23.3 <0.0001 
difficulty walking 2.5 2.8 2.5 0.7095 2.5 3.1 2.5 0.5621 2.5 2.8 2.5 0.7490 
memory loss 2.4 0.9 2.5 0.0487 2.2 0.8 2.3 0.1050 2.2 1.2 2.3 0.2589 
cough 35.9 42.3 35.4 0.0088 34.9 41.4 34.3 0.0216 34.6 41.7 34.0 0.0130 
hemoptysis 1.4 0.9 1.4 0.3744 1.5 1.1 1.6 0.6053 1.5 1.1 1.5 0.5699 
                          
Procedures                         
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 Original Sample Weighted Sample – Actual N Weighted Sample - 
Weighted 
Baseline Characteristic Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  Total 
% 
Sev 
Exac
% 
No 
Sev% 
pval  
Number of Patients 5475 352 5123  3407 261 3146   3410 256 3154   
chest CT 15.0 20.2 14.7 0.0051 14.9 20.3 14.5 0.0109 14.9 20.0 14.5 0.0170 
chest x-ray 62.7 69.6 62.2 0.0055 63.2 70.5 62.6 0.0106 63.3 70.0 62.7 0.0207 
echocardiography 20.3 20.2 20.3 0.9392 19.9 19.9 19.9 0.9979 19.9 19.1 20.0 0.7312 
EKG 44.8 53.7 44.2 0.0005 43.9 52.1 43.2 0.0055 44.0 50.8 43.5 0.0233 
heart catheterization 1.3 1.4 1.3 0.8321 1.2 1.1 1.2 0.8990 1.2 1.2 1.2 0.9916 
nebulizer treatment 32.3 37.5 32.0 0.0326 32.9 38.3 32.4 0.0515 33.0 39.0 32.5 0.0334 
non-invasive ventilator 6.2 6.8 6.1 0.6142 6.5 8.0 6.4 0.2871 6.5 7.8 6.4 0.3737 
spirometry 41.7 37.8 42.0 0.1219 44.6 39.1 45.1 0.0613 44.6 39.2 45.1 0.0708 
any vaccination (flu or 
pneumonia) 
48.1 44.0 48.4 0.1169 48.6 44.8 48.9 0.2038 48.6 44.4 48.9 0.1651 
COPD-related exacerbations                         
Index and 2 weeks prior                         
any moderate 14.3 19.9 13.9 0.0020 13.0 19.5 12.5 0.0012 13.0 19.3 12.5 0.0020 
any severe 7.9 17.9 7.2 <0.0001 7.3 15.7 6.6 <0.0001 7.3 16.6 6.6 <0.0001 
any other hospitalizations* 2.3 2.8 2.2 0.4527 1.8 2.7 1.7 0.2583 1.8 2.9 1.7 0.1424 
Prior 2-12 weeks                         
any moderate 16.3 23.6 15.8 0.0001 16.9 25.3 16.2 0.0002 16.7 25.6 16.0 <0.0001 
any severe 6.2 15.6 5.5 <0.0001 6.7 14.2 6.1 <0.0001 6.6 14.0 6.0 <0.0001 
any other hospitalizations* 3.8 7.1 3.6 0.0009 3.8 6.5 3.5 0.0148 3.7 6.5 3.5 0.0127 
Prior 13-52 weeks                         
no moderate 76.7 69.6 77.2 0.0011 78.3 70.1 79.0 0.0009 78.4 71.4 79.0 0.0047 
1 moderate 18.6 21.3 18.4 0.1762 17.5 21.5 17.2 0.0795 17.4 20.2 17.2 0.2219 
>1 moderate 4.7 9.1 4.4 <0.0001 4.2 8.4 3.9 0.0004 4.2 8.4 3.8 0.0005 
any severe 7.5 17.3 6.8 <0.0001 7.8 15.3 7.2 <0.0001 7.9 15.2 7.4 <0.0001 
any other hospitalizations* 7.0 10.8 6.8 0.0041 6.8 11.1 6.5 0.0044 7.0 10.5 6.7 0.0216 
All Inpatient Utilization                         
Non-COPD Inpatient (Any) 15.6 21.6 15.1 0.0013 14.7 22.2 14.0 0.0003 14.7 22.2 14.1 0.0004 
COPD Inpatient (Any) 20.4 41.2 19.0 <0.0001 19.7 37.2 18.2 <0.0001 19.7 37.2 18.3 <0.0001 
Total Inpatient (Any) 30.9 53.7 29.3 <0.0001 29.5 51.0 27.7 <0.0001 29.5 50.5 27.8 <0.0001 
             
Same as Index Trmt 40.9 69.0 38.9 <0.0001 65.7 92.7 63.4 <0.0001 65.5 93.2 63.2 <0.0001 
LHP enrollee 65.7 53.1 66.6 <0.0001 62.5 51.0 63.5 <0.0001 62.6 51.2 63.5 <0.0001 
* COPD as secondary diagnosis 
^ from Mapel et al.; uses diagnosis codes, to include 491.21 and 491.22 for moderate complexity 
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Table 72 Combined Baseline Healthcare Costs (Means), Original versus Weighted 
 Original Sample Weighted Sample - Weighted 
 Total SD Non-
Triple 
SD Triple SD pval  Total SD Non-
Triple 
SD Triple SD pval 
Number of Patients 5475  4991  484   3410  3021  389   
Cost of Utilization ($ mean, SD) 
Non-COPD Outpatient Utilization 5490 9457 5540 9522 4983 8756 0.1854 5481 9514 5577 9786 4737 7013 0.0350 
COPD Outpatient Utilization 1961 2436 1931 2398 2277 2781 0.0085 1987 2420 1988 2405 1975 2532 0.9170 
Total Outpatient Utilization 7452 10320 7470 10330 7259 10222 0.6672 7468 10347 7566 10540 6712 8682 0.0759 
                     
Non-COPD Inpatient Utilization 5069 20267 5091 20580 4849 16714 0.7665 4582 18396 4594 18620 4492 16564 0.9102 
COPD Inpatient Utilization 6179 20753 5970 20088 8335 26583 0.0573 5748 19327 5784 19052 5470 21369 0.7823 
Total Inpatient Utilization 11248 30260 11061 29994 13184 32848 0.1719 10330 28089 10378 28021 9961 28645 0.7831 
Total Medical Utilization 18700 33496 18531 33340 20443 35048 0.2305 17799 31429 17944 31540 16673 30563 0.4531 
                     
Non-COPD Outpatient Rx 2369 4007 2408 4093 1971 2946 0.0029 2243 3637 2281 3722 1955 2881 0.0434 
COPD Outpatient Rx 408 778 401 753 482 995 0.0819 475 842 475 821 480 998 0.9292 
Total Outpatient Rx 2777 4148 2808 4228 2453 3201 0.0243 2718 3838 2755 3917 2434 3144 0.0670 
Total Healthcare Services 21477 34258 21339 34100 22896 35854 0.3398 20517 32200 20698 32304 19108 31384 0.3591 
Cost of Utilization ($ mean, SD)  - for those with utilization within category 
Non-COPD Outpatient Utilization 5589 9513 5626 9571 5197 8880 0.3234 5573 9572 5659 9832 4890 7119 0.0603 
COPD Outpatient Utilization 2100 2463 2067 2424 2443 2810 0.0062 2118 2444 2121 2429 2098 2561 0.8676 
Total Outpatient Utilization 7469 10326 7484 10335 7320 10243 0.7392 7485 10353 7581 10544 6734 8696 0.0788 
                     
Non-COPD Inpatient Utilization 32576 41773 32869 42702 29708 31336 0.4129 31072 38474 31194 39321 30134 31982 0.8181 
COPD Inpatient Utilization 30287 37170 30311 36222 30106 43657 0.9585 29137 34850 29333 34732 27621 35641 0.6852 
Total Inpatient Utilization 36441 45266 36559 45189 35451 46018 0.7563 35058 42552 35076 42920 34910 40297 0.9690 
Total Medical Utilization 18710 33502 18542 33347 20443 35048 0.2334 17814 31438 17961 31551 16673 30563 0.4472 
                     
Non-COPD Outpatient Rx 2462 4056 2494 4140 2120 3003 0.0153 2351 3691 2383 3772 2100 2947 0.0961 
COPD Outpatient Rx 408 778 401 753 482 995 0.0819 475 842 475 821 480 998 0.9292 
Total Outpatient Rx 2777 4148 2808 4228 2453 3201 0.0243 2718 3838 2755 3917 2434 3144 0.0670 
Total Healthcare Services 22188 36262 22008 36016 24078 38763 0.3354 20517 32200 20698 32304 19108 31384 0.3591 
Length of Stay (for inpatient stays) 6.6 7.7 6.6 7.6 6.7 8.0 0.8101 6.4 7.1 6.4 7.3 6.5 6.0 0.8331 
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Table 73 Combined Baseline Healthcare Costs (Medians), Original versus Weighted 
 
Original Sample Weighted Sample - Weighted 
  
Total  Non-
Triple 
 Triple  pval Total  Non-
Triple 
 Triple  pval 
Number of Patients 5475  4991  484   3410  3021  389   
Cost of Utilization ($)                
Non-COPD Outpatient Utilization 3181   3239   2600   0.0029 3174   3226   2654   0.9477 
COPD Outpatient Utilization 1201   1180   1405   0.0048 1291   1297   1244   0.0019 
Total Outpatient Utilization 4931   4977   4388   0.2520 4948   5027   4392   0.2206 
               
              
Non-COPD Inpatient Utilization 0   0   0   0.6365 0   0   0   0.8390 
COPD Inpatient Utilization 0   0   0   <.0001 0   0   0   0.0003 
Total Inpatient Utilization 0   0   0   0.0017 0   0   0   0.0019 
Total Medical Utilization 7398   7305   8704   0.0922 7197   7325   6471   0.0015 
               
              
Non-COPD Outpatient Rx 1252   1270   1056   0.0002 1211   1231   1128   0.6620 
COPD Outpatient Rx 68   70   55   0.0079 82   87   53   0.2637 
Total Outpatient Rx 1685   1696   1539   0.0166 1696   1708   1554   0.7165 
Total Healthcare Services 10052   9977   10777   0.3284 9968   10052   9064   0.0009 
Cost of Utilization ($)  - for those with utilization within category 
Non-COPD Outpatient Utilization 3285   3337   2735   0.0341 3265   3312   2835   0.9493 
COPD Outpatient Utilization 1380   1351   1697   0.0013 1426   1435   1369   0.0009 
Total Outpatient Utilization 4942   4998   4401   0.3595 4954   5048   4400   0.2011 
               
              
Non-COPD Inpatient Utilization 17802   17764   18196   0.9315 17052   17028   17707   0.4003 
COPD Inpatient Utilization 17641   17642   17429   0.9755 16738   17047   15372   0.0646 
Total Inpatient Utilization 19907   19864   20186   0.8112 19438   19529   18725   0.7720 
Total Medical Utilization 7404   7318   8704   0.0963 7220   7363   6471   0.0014 
               
              
Non-COPD Outpatient Rx 1340   1357   1228   0.0105 1310   1325   1251   0.7823 
COPD Outpatient Rx 68   70   55   0.0079 82   87   53   0.2637 
Total Outpatient Rx 1685   1696   1539   0.0166 1696   1708   1554   0.7165 
               
              
Total Healthcare Services 10052   9977   10777   0.3284 9968   10052   9064   0.0009 
Length of Stay (for inpatient stays) 4   4   5   0.0919 4.0   4.0   4.0   0.9124 
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Aim 4 
Compare risk for severe COPD exacerbations among patients using triple 
therapy compared to use of either ICS/LABA combination or LAMA monotherapy.  
Comparisons are made using both conventional methods and MSM methods.  
For the Intent to Treat and As Protocol analyses, risk of a severe exacerbation was 
estimated using Cox proportional hazard regression models. Time until a severe 
exacerbation was measured in days and began on day 30 after the index date and patients 
were followed up to 2 years after the index date. Regression models contained a variable 
for use of triple therapy in comparison to use of ICS/LABA or LAMA (reference therapy 
group).  Covariates included were the variables listed in Table 61. 
Intent to Treat 
Table 74 provides a summary of the data modeled in the ITT analysis and Figure 
11 a plot of the unadjusted survival functions by index treatment. Note that “survival” 
time begins on day 30. Of the 5,475 study subjects, 855 (15.6%) had a severe 
exacerbation event in the first two years. 
Table 74 Summary of Severe Exacerbation Events and Censored Values, ITT 
  Severe Exac Events over 700 days Days to Severe Exac 
Index Category 
Total 
Patients 
Severe Exac 
Events  Censored 
Percent 
Censored 
700 days 
Mean (SE) 
335 days 
Mean (SE) 
ICSLABA or LAMA 4991 753 4238 84.92 627.2 (2.6) 314.1 (1.0) 
Triple 484 102 382 78.93 597.7 (9.6) 298.0 (3.5) 
Total 5475 855 4620 84.38   
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Figure 11 Lifetest Survival Distribution Function by Index Treatment, ITT 
 
In Figure 11, the top line is for ICS/LABA or LAMA therapy, indicating the least 
risk for severe exacerbation, and the bottom, the triple therapy group, indicating the 
greatest risk for severe exacerbation.  
Hazard ratio estimates from the Cox proportional hazard regression model 
indicated similar findings (Table 75). 
 
Table 75 Hazard Ratio Estimates Severe Exacerbation, ITT 
 
 
HR 95% LL 95% UL P-value 
Triple therapy at Index 1.24 1.00 1.53 0.0500 
Male 1.12 0.97 1.29 0.1399 
Age         
Age 40 to 54 vs Age >75 0.56 0.41 0.78 0.0005 
Age 55 to 64 vs Age >75 0.75 0.60 0.95 0.0161 
Age 65 to 74 vs Age >75 0.85 0.72 1.01 0.0637 
Medicaid 1.55 1.20 2.00 0.0008 
Baseline Comorbidities         
Atrial fibrillation 0.87 0.70 1.09 0.2369 
Heart failure or CHF 1.23 1.03 1.46 0.0253 
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HR 95% LL 95% UL P-value 
Ischemic Heart Disease 1.04 0.88 1.22 0.681 
Rheumatoid or osteo-arthritis 0.96 0.82 1.12 0.5806 
Deficiency Anemias 1.04 0.86 1.25 0.7146 
Depression 0.98 0.82 1.18 0.8614 
Diabetes w/o chronic complications 1.10 0.94 1.29 0.2262 
Fluid and electrolyte disorders 1.11 0.92 1.35 0.2873 
Hypertension 1.07 0.91 1.26 0.3925 
Hypothyroidism 0.97 0.81 1.15 0.697 
Obesity 0.92 0.75 1.14 0.4565 
Other neurological disorders 1.12 0.90 1.38 0.3149 
Psychoses 1.06 0.85 1.33 0.5942 
Pulmonary circulation disease 0.97 0.79 1.19 0.7426 
Renal failure 0.93 0.73 1.18 0.5525 
Valvular disease 1.23 1.00 1.52 0.0501 
Weight loss 1.14 0.88 1.46 0.321 
Asthma 1.02 0.87 1.19 0.7903 
Hypoxemia 1.01 0.86 1.18 0.9441 
Pneumonia 1.19 1.02 1.39 0.0257 
Emphysema 1.19 1.02 1.39 0.029 
Low COPD complexity 0.70 0.59 0.83 <.0001 
COPD Medication Baseline Use         
No SABA use 0.98 0.81 1.17 0.7882 
SABA use 15-40% 0.89 0.70 1.13 0.3279 
SABA use >40% 1.34 1.09 1.66 0.0054 
Any SAMA use 1.35 1.12 1.62 0.0013 
Any SABA/SAMA use 1.27 1.07 1.50 0.0059 
Any ICS use 0.95 0.81 1.11 0.5042 
Any ICSLABA use 6 mo preindex 1.07 0.87 1.33 0.5088 
Oxygen use </=50% 1.18 0.95 1.45 0.1372 
Oxygen use >50% 1.64 1.38 1.95 <.0001 
Any nebulizer treatment 0.95 0.80 1.11 0.5034 
Baseline Symptoms         
No breathlessness 0.91 0.76 1.09 0.2988 
>1 period breathlessness 1.05 0.85 1.30 0.6688 
No shortness of breath 0.89 0.74 1.06 0.1855 
>1 period shortness of breath 0.93 0.76 1.14 0.4862 
Any wheezing 0.98 0.76 1.26 0.8729 
Any chest pain 1.03 0.88 1.21 0.7176 
Any other malaise/fatigue 1.08 0.92 1.26 0.3605 
Any cough 1.04 0.89 1.21 0.6548 
Baseline Procedures         
Any chest CT 1.10 0.91 1.33 0.3088 
Any chest x-ray 0.94 0.80 1.12 0.4987 
Any echocardiography 0.87 0.71 1.05 0.1449 
Any EKG 1.02 0.86 1.19 0.858 
Any spirometry 0.84 0.72 0.99 0.0337 
Baseline Exacerbation         
Mod Exac at Index or 2 wks pre-index 1.11 0.92 1.35 0.2816 
Mod Exac wks 3-12 pre-index 1.14 0.96 1.37 0.1461 
Any Mod Exac wks 13-52 pre-index 1.15 0.98 1.35 0.089 
Sev Exac within 2 wks pre-index 1.01 0.79 1.28 0.9706 
Sev Exac wks 3-12 pre-index 1.53 1.23 1.91 0.0002 
Sev Exac wks 13-52 pre-index 1.21 0.98 1.50 0.0796 
Any Hosp w/secondary COPD Dx wks 13-52 1.19 0.94 1.50 0.1571 
Health plan 0.66 0.56 0.76 <.0001 
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Patients using triple therapy medication at the index date had a significantly 
higher HR of 1.24 (95% CI, 1.00 to 1.53) compared to patients using ICS/LABA or 
LAMA therapy.  
Baseline factors found to be significantly associated with a lower risk of severe 
exacerbation after adjustment for index treatment were younger age (Age 40 to 54 vs Age 
>75: HR 0.56, 95% CI 0.41 to 0.78; Age 55 to 64 vs Age >75: HR 0.75, 95% CI, 0.60 to 
0.95), an assessment of low complexity of COPD (HR 0.70, 95% CI 0.59 to 0.83, 
P<0.0001) and having had a spirometry procedure in the baseline period (HR 0.85, 95% 
CI, 0.72 to 0.99).   
Patients with Medicaid insurance coverage had an approximately 50% higher risk 
for a severe exacerbation (HR 1.55, 95% CI 1.20 to 2.00, P=0.0008). Additionally, 
baseline comorbidities significantly associated with greater risk of severe exacerbation 
were heart failure/CHF (HR 1.23, 95% CI 1.03 to 1.46, P=0.03), emphysema (HR 1.19, 
95% CI 1.02 to 1.39, P=0.03), and a history of pneumonia (HR 1.19, 95% CI 1.02 to 
1.39, P=0.03).  Valvular disease was associated with a higher risk, but not a significantly 
higher risk (HR 1.23, 95% CI 1.00 to 1.51, P=0.05). Baseline period use of SABA more 
than 40% of the time (HR 1.34, 95% CI 1.09 to 1.65, P=0.006), any use of SAMA (HR 
1.35, 95% CI 1.12 to 1.62, P=0.002), any use of SABA/SAMA medication (HR 1.27, 
95% CI 1.07 to 1.50, P=0.006), or oxygen use more than 50% of the time in the baseline 
year (HR 1.64, 95% CI 1.38 to 1.95, P=<0.0001) – all were associated with higher severe 
exacerbation risk. Having had a severe exacerbation in the 3-12 weeks prior to the index 
date also was a factor associated with significantly higher risk (HR 1.53, 95% CI 1.23 to 
1.90, P=0.0002). Having had a severe exacerbation or a moderate exacerbation in the 13-
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52 weeks prior to the index date were also associated with higher risk, but not a 
significantly higher risk (HR 1.21, 95% CI 0.98 to 1.50, P=0.08 and HR 1.15, 95% CI 
0.98 to 1.35, P=0.09 respectively).  Health plan was also a significant factor in that 
patients from one health plan overall had a lower risk of severe exacerbation (HR 0.66, 
95% CI 0.56 to 0.76, P<0.0001). 
In order to obtain survival plots by index therapy, a stratified Cox regression 
model was constructed using all the same baseline factors that are summarized in Table 
75. Figure 12 shows the resulting plots.  As in Figure 11, the ICS/LABA or LAMA group 
has the lower risk for severe exacerbation.  There is some crossing of lines early in the 
follow-up period, but overall, the lines are parallel and demonstrate proportionality. 
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Figure 12 Log-Log Survival Plot, Severe Exacerbations, ITT 
 
Analysis Using GEE Method 
Using a pooled logistic model as an alternative to the Cox Proportional Hazards 
Model, the population average risk of severe exacerbation was modeled by assessing risk 
of a severe exacerbation for each of the two week follow-up periods.  The covariates 
included in the model were exactly the same as those listed in Table 75, with the addition 
of a variable for the sequential number of the two week period.  The generalized 
estimating equation approach was used with autoregressive (AR) as the working 
correlation matrix for correlation between individual successive observations.  The model 
yielded risk ratios almost identical to those in the Cox proportional hazard model.  Again, 
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the triple therapy group had an elevated risk of severe exacerbation compared to the 
ICS/LABA or LAMA group.  The odds ratio for the triple therapy group was 1.24 (95% 
CI 1.00 to 1.55, P =0.0546). The p=value listed in the Type 3 summary was slightly 
higher – 0.0683 for the estimated triple therapy effect.   
As Protocol 
In the As Protocol analysis, patients remained in the study sample until the earlier 
of two events – a severe exacerbation or discontinuation of the index therapy. For the 
complete study sample there were 855 severe exacerbation events.  For the reduced As 
Protocol study sample, the number of severe events was less than 50% of that, 411 (Table 
76).  Mean days until the first severe exacerbation were 598.3 (standard error 4.3) for the 
ICS/LABA or LAMA group and 608.6 (13.0 standard error) for the triple therapy. 
Table 76 Summary of Severe Exacerbation Events and Censored Values, As Protocol 
  Severe Exac Events over 700 days Days to Severe Exac 
Index Category 
Total 
Patients 
Severe Exac 
Events  Censored 
Percent 
Censored 
700 days 
Mean (SE) 
335 days 
Mean (SE) 
ICSLABA or LAMA 4991 363 4628 92.73 598.3 (4.3) 336.3 (1.5) 
Triple 484 48 436 90.08 608.6 (13.0) 312.9 (4.3) 
Total 5475 411 5064 92.49   
 
In contrast to Figure 11 where the survival distribution function curves for the 
therapies were distinctly separate, the survival distribution functions for the therapy 
groups depicted in Figure 13 for the As Protocol analysis are not distinctly different.  The 
ICS/LABA or LAMA therapy group is still the top most line, indicating reduced risk for 
severe exacerbation, but there is little distinction between the two therapy groups. 
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Figure 13 Lifetest Survival Distribution Function by Index Treatment, As Protocol 
 
There was potentially an issue with the handling of tied events in the Cox 
regression approximation of effect estimates for this reduced sample, in that a large 
number were being censored around the same time period after the index date (those with 
no prescription claims after the index date).  One underlying assumption in the Cox 
regression analysis is that events do not occur at the same time.  The Breslow method is a 
commonly used method for managing tied data in survival analysis and works well when 
ties are few, but in this reduced data set there were several time points for which that was 
not the case. The EXACT method is an alternative method that assumes there is an 
underlying order for the tied event times that is not measured (in contrast to the 
DISCRETE method which assumes that event times actually occurred simultaneously) 
and there is also the EFRON method, which tends to produce effect estimates that are 
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midway between the BRESLOW and EXACT methods (Allison 1995).  For the As 
Protocol data, the EXACT and EFRON method yielded the same results. Table 77 shows 
that no significant differences between LAMA and triple therapy or between ICS/LABA 
and triple therapy were found for the As Protocol sample over the 24 month period after 
the index date. 
Table 77 Hazard Ratio Estimates Severe Exacerbation, As Protocol 
Factor HR 95% LL 95% UL P-value 
Triple therapy at Index 1.00 0.73 1.36 0.9745 
Male 1.12 0.91 1.38 0.299 
Age         
Age 40 to 54 vs Age >75 0.44 0.27 0.71 0.0009 
Age 55 to 64 vs Age >75 0.56 0.39 0.79 0.0009 
Age 65 to 74 vs Age >75 0.72 0.56 0.92 0.0098 
Medicaid 1.96 1.36 2.83 0.0003 
Baseline Comorbidities         
Atrial fibrillation 1.04 0.76 1.43 0.7977 
Heart failure or CHF 0.99 0.76 1.30 0.9548 
Ischemic Heart Disease 1.11 0.87 1.42 0.3938 
Rheumatoid or osteo-arthritis 1.08 0.86 1.35 0.5008 
Deficiency Anemias 1.25 0.96 1.64 0.0975 
Depression 1.18 0.91 1.53 0.2132 
Diabetes w/o chronic complications 1.08 0.85 1.37 0.5236 
Fluid and electrolyte disorders 0.86 0.64 1.16 0.3217 
Hypertension 0.96 0.76 1.21 0.7437 
Hypothyroidism 0.95 0.74 1.22 0.6859 
Obesity 1.06 0.78 1.44 0.6936 
Other neurological disorders 0.88 0.62 1.24 0.4714 
Psychoses 1.05 0.76 1.47 0.7551 
Pulmonary circulation disease 1.03 0.76 1.40 0.8627 
Renal failure 0.94 0.66 1.36 0.7555 
Valvular disease 1.37 1.01 1.85 0.04 
Weight loss 1.29 0.90 1.87 0.167 
Asthma 1.11 0.88 1.38 0.3798 
Hypoxemia 0.90 0.71 1.14 0.3843 
Pneumonia 1.44 1.15 1.79 0.0013 
Emphysema 1.24 0.99 1.55 0.0597 
Low COPD complexity 0.75 0.58 0.96 0.0232 
COPD Medication Baseline Use         
No SABA use 0.89 0.68 1.17 0.4042 
SABA use 15-40% 0.81 0.56 1.16 0.2499 
SABA use >40% 1.31 0.97 1.76 0.0743 
Any SAMA use 1.38 1.06 1.79 0.0175 
Any SABA/SAMA use 1.34 1.05 1.70 0.0176 
Any ICS use 0.89 0.71 1.11 0.2835 
Any ICSLABA use 6 mo preindex 1.10 0.80 1.50 0.565 
Oxygen use </=50% 0.99 0.72 1.35 0.9313 
Oxygen use >50% 1.38 1.07 1.77 0.0135 
Any nebulizer treatment 1.08 0.86 1.36 0.505 
Baseline Symptoms         
No breathlessness 0.79 0.61 1.02 0.0656 
>1 period breathlessness 0.86 0.63 1.17 0.3242 
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Factor HR 95% LL 95% UL P-value 
No shortness of breath 0.84 0.65 1.09 0.186 
>1 period shortness of breath 0.92 0.68 1.24 0.579 
Any wheezing 1.01 0.71 1.43 0.9689 
Any chest pain 1.05 0.83 1.32 0.6978 
Any other malaise/fatigue 1.17 0.93 1.47 0.1878 
Any cough 1.13 0.90 1.41 0.2986 
Baseline Procedures         
Any chest CT 1.19 0.91 1.56 0.2096 
Any chest x-ray 0.87 0.68 1.12 0.2923 
Any echocardiography 0.90 0.68 1.19 0.4642 
Any EKG 1.08 0.85 1.37 0.5195 
Any spirometry 0.82 0.65 1.03 0.0831 
Baseline Exacerbation         
Mod Exac at Index or 2 wks pre-index 1.12 0.84 1.48 0.4491 
Mod Exac wks 3-12 pre-index 1.18 0.91 1.53 0.2093 
Any Mod Exac wks 13-52 pre-index 1.09 0.87 1.38 0.4507 
Sev Exac within 2 wks pre-index 1.17 0.81 1.68 0.4139 
Sev Exac wks 3-12 pre-index 1.24 0.89 1.73 0.1956 
Sev Exac wks 13-52 pre-index 0.98 0.71 1.35 0.9077 
Any Hosp w/secondary COPD Dx wks 13-52 1.37 0.98 1.90 0.0656 
Health plan 0.57 0.46 0.70 <.0001 
 
All age groups less than age 75 years had lower risk of severe exacerbation 
compared to patients >75.  As before, patients with Medicaid insurance had a higher risk, 
almost twice that of Medicare and Commercial insurance patients (HR1.96, 95% CI, 1.36 
to 2.83, P=0.0003).  
Valvular disease and pneumonia were the only morbidities found to be 
significantly associated with having a severe exacerbation (HR 1.37, 95% CI 1.01 to 
1.85, P=0.04 and HR 1.44, 95% CI 1.15 to 1.79, P=0.001 respectively). Although the 
higher risk estimated for patients with emphysema was close to being statistically 
significant (HR 1.24, 95% CI, 0.99 to 1.55, P=0.06). Having low COPD disease 
complexity was again associated with reduced risk (HR 0.75, 95% CI 0.58 to 0.96, 
P=0.02). 
Use of SABA in the baseline period for more than 40% of the time was again 
associated with an increased severe exacerbation risk, although the difference was no 
longer statistically significant (HR 1.31, 95% CI 0.97 to 1.76, P=0.07).  SAMA use and 
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SABA/SAMA use in the baseline period were again found to be factors significantly 
associated with higher risk (HR 1.38, 95% CI 1.06 to 1.79, P=0.02 and HR 1.34, 95% CI 
1.05 to 1.70, P=0.02 respectively), as was oxygen use for more than 50% of the baseline 
period (HR 1.38, 95% CI 1.07 to 1.77, P=0.01). 
No evidence of breathlessness and having had a spirometry procedure in the 
baseline period were both associated with a reduced risk for severe exacerbation, but not 
a significantly lower risk (HR 0.79, 95% CI 0.61 to 1.02, P=0.07 and HR 0.82, 95% CI 
0.65 to 1.03, P=0.08 respectively). 
Exacerbations occurring prior to the index were not significantly associated with 
severe exacerbation risk in this reduced study sample, but having had any hospitalization 
where COPD was recorded as a secondary diagnosis was close to being significantly 
associated with a higher severe exacerbation risk (HR 1.37, 95% CI 0.98 to 1.90, 
P=0.07).   
Patients from the two health plans were again found to be significantly different 
in their severe exacerbation risk, with the one health plan have a reduced risk (HR 0.57, 
0.46 to 0.70, P<0.0001). 
Status at 12 months Post-Index 
After 24 months there were 411 severe exacerbations (Table 76), 84% of which 
(n=346) of which occurred by the end of 12 months (Table 78). A concern is that the 
longer follow-up is biasing effect estimates. Figure 14 shows the survival plots for the 
three therapies up through the first 12 months.  Hazard ratio estimates for the index 
therapies for the period up to one year post-index (data not shown) however were no 
different than those estimated over 24 months (Triple therapy HR=1.02, 95% CI 0.73 to 
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1.42). However, baseline SABA use of more than 40%, no evidence of breathlessness, 
and baseline spirometry, which were significant in the 24 month analysis using a p-value 
of 0.10 were now significantly associated with severe exacerbation risk using a p-value of 
<0.05. 
Table 78 Severe Exacerbation Events and Censored Values, As Protocol, One Year 
Follow-up 
  Severe Exac Events over 335 days Days to Severe Exac 
Index Category 
Total 
Patients 
Severe Exac 
Events  Censored 
Percent 
Censored 
335 days 
Mean (SE) 
ICSLABA or LAMA 4991 291 4700 94.17 311.9 (1.3) 
Triple 484 44 443 91.53 281.8 (3.6) 
Total 5475 332 5143 93.94  
 
Figure 14 Lifetest Survival Distribution Function by Index Treatment, As Protocol 
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Given that the effect estimates were almost identical in the intent-to-treat analysis 
between the Cox proportional hazard model and the pooled logistic regression analysis, a 
pooled logistic regression was not repeated for the As Protocol sample. 
Weighted MSM Analysis 
Using the stabilized weights, a pooled logistic regression model was constructed, 
regressing severe exacerbation on sex, age, insurance coverage, triple therapy at the start 
of the time period, time elapsed since the index date (number of two-week periods), and 
an interaction term between triple therapy at the start of the time period and time elapsed 
since the index date. The GEE approach was used, with an exchangeable correlation 
specification.  
In all there were 13,206 observations for 3,407 distinct study subjects reviewed. 
There were 476 severe exacerbation events. Two methods were used for models, one 
included only sex, age and insurance type from the baseline covariates, the other included 
all the same baseline covariates as were included in the ITT and As Protocol models. 
Time-varying covariates were not included in the analyses since they had been included 
in the weight estimations. In addition, the models with all covariates were run for risk of 
severe exacerbation over one year in addition to the model for exacerbations over two 
years since the last two time intervals used for constructing the weighted population each 
spanned 26 weeks. Results for the one and two year models with all covariates were 
highly similar and were actually very similar to results from the As Protocol analysis.  
Table 79 provides a summary of the MSM analysis that only includes the baseline 
covariates of sex, age and insurance coverage. In that analysis, after adjustment with the 
weights that consider baseline characteristics and the time-varying covariates of moderate 
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exacerbations and SABA use, a greater risk of severe exacerbation was associated with 
use of triple therapy, that was somewhat lower than that estimated from the ITT analysis 
(HR=1.18, 95% CI 0.74 to 1.87). 
Table 79 Hazard Ratio Estimates Severe Exacerbation, MSM 
Factor OR (95% CI) P-value 
Triple therapy at start of time period 1.18 (0.74,1.87) 0.4916 
Male 1.08 (0.89,1.31) 0.4224 
Age   
Age 40 to 54 vs Age >75 0.39 (0.24,0.62) <.0001 
Age 55 to 64 vs Age >75 0.55 (0.41,0.75) 0.0002 
Age 65 to 74 vs Age >75 0.61 (0.48,0.77) <.0001 
Medicaid 2.64 (1.82,3.83) <.0001 
No. of two-week periods since Index 1.02 (1.01,1.03) <.0001 
Triple therapy at start of time period x 
No. of two-week periods since Index 
0.99 (0.96,1.02) 0.5504 
 
If all the same baseline covariates are included in the model, as they were for the 
ITT and As Protocol analysis, the estimated risk is lower (HR=1.11, 95% CI 0.68 to 
1.81).  
Table 80 Hazard Ratio Estimates Severe Exacerbation, all baseline covariates, MSM 
 For 52 weeks For 104 weeks 
 
 
HR (95% CI) P-value HR (95% CI) P-value 
Triple therapy at Index 1.08 (0.60,1.94) 0.7914 1.11 (0.68,1.81) 0.6666 
Male 1.24 (0.98,1.57) 0.0738 1.16 (0.93,1.44) 0.1806 
Age     
Age 40 to 54 vs Age >75 0.44 (0.26,0.75) 0.0023 0.45 (0.27,0.75) 0.0021 
Age 55 to 64 vs Age >75 0.55 (0.37,0.80) 0.0018 0.59 (0.42,0.84) 0.0031 
Age 65 to 74 vs Age >75 0.67 (0.51,0.89) 0.0061 0.69 (0.53,0.89) 0.004 
Medicaid 1.86 (1.23,2.83) 0.0035 1.78 (1.21,2.62) 0.0033 
Baseline Comorbidities     
Atrial fibrillation 0.91 (0.62,1.34) 0.6461 0.92 (0.65,1.30) 0.6282 
Heart failure or CHF 1.14 (0.82,1.59) 0.4396 1.10 (0.82,1.49) 0.525 
Ischemic Heart Disease 1.14 (0.85,1.52) 0.3857 1.17 (0.90,1.51) 0.2373 
Rheumatoid or osteo-arthritis 1.18 (0.92,1.52) 0.1804 1.09 (0.87,1.37) 0.464 
Deficiency Anemias 1.22 (0.91,1.63) 0.19 1.20 (0.91,1.57) 0.1893 
Depression 1.05 (0.78,1.41) 0.7659 1.13 (0.86,1.48) 0.3833 
Diabetes w/o chronic complications 1.23 (0.95,1.59) 0.1121 1.13 (0.89,1.43) 0.3287 
Fluid and electrolyte disorders 0.95 (0.68,1.34) 0.7742 0.92 (0.66,1.26) 0.5872 
Hypertension 0.88 (0.68,1.13) 0.3146 0.94 (0.74,1.19) 0.596 
Hypothyroidism 0.93 (0.69,1.24) 0.6072 0.93 (0.72,1.22) 0.616 
Obesity 1.04 (0.74,1.46) 0.8096 1.02 (0.75,1.38) 0.9048 
Other neurological disorders 1.03 (0.72,1.49) 0.8524 1.01 (0.72,1.43) 0.934 
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 For 52 weeks For 104 weeks 
 
 
HR (95% CI) P-value HR (95% CI) P-value 
Psychoses 1.06 (0.72,1.57) 0.761 1.07 (0.76,1.52) 0.7013 
Pulmonary circulation disease 1.11 (0.79,1.55) 0.5597 1.16 (0.85,1.59) 0.34 
Renal failure 0.92 (0.62,1.36) 0.6787 0.91 (0.64,1.31) 0.6222 
Valvular disease 1.23 (0.87,1.75) 0.2389 1.29 (0.94,1.77) 0.1162 
Weight loss 1.46 (0.99,2.13) 0.0532 1.39 (0.97,2.00) 0.077 
Asthma 1.04 (0.82,1.33) 0.7299 1.03 (0.82,1.29) 0.7949 
Hypoxemia 1.06 (0.81,1.38) 0.6792 0.99 (0.78,1.25) 0.9137 
Pneumonia 1.36 (1.06,1.76) 0.0166 1.34 (1.07,1.69) 0.0109 
Emphysema 1.22 (0.96,1.56) 0.105 1.29 (1.03,1.61) 0.0265 
Low COPD complexity 0.85 (0.64,1.12) 0.2452 0.81 (0.63,1.04) 0.0937 
COPD Medication Baseline Use     
No SABA use 0.97 (0.71,1.33) 0.8644 0.87 (0.66,1.14) 0.3158 
SABA use 15-40% 0.93 (0.62,1.40) 0.7183 0.78 (0.53,1.13) 0.1896 
SABA use >40% 1.44 (1.02,2.03) 0.0376 1.32 (0.98,1.79) 0.0684 
Any SAMA use 1.55 (1.17,2.05) 0.0021 1.43 (1.10,1.86) 0.0084 
Any SABA/SAMA use 1.44 (1.10,1.87) 0.007 1.37 (1.07,1.74) 0.011 
Any ICS use 0.88 (0.69,1.13) 0.3274 0.84 (0.67,1.06) 0.141 
Any ICSLABA use 6 mo preindex 1.38 (1.00,1.91) 0.051 1.24 (0.91,1.69) 0.1684 
Oxygen use </=50% 1.01 (0.71,1.43) 0.9672 0.99 (0.72,1.37) 0.97 
Oxygen use >50% 1.27 (0.95,1.69) 0.1125 1.41 (1.08,1.84) 0.0109 
Any nebulizer treatment 1.14 (0.89,1.46) 0.2956 1.07 (0.85,1.34) 0.5633 
Baseline Symptoms     
No breathlessness 0.83 (0.62,1.12) 0.2239 0.83 (0.63,1.09) 0.1711 
>1 period breathlessness 0.95 (0.67,1.34) 0.7762 0.99 (0.73,1.36) 0.9687 
No shortness of breath 0.85 (0.64,1.13) 0.2677 0.89 (0.68,1.15) 0.3702 
>1 period shortness of breath 0.80 (0.56,1.13) 0.2043 0.84 (0.61,1.15) 0.272 
Any wheezing 1.06 (0.71,1.56) 0.7872 1.00 (0.69,1.43) 0.9862 
Any chest pain 1.15 (0.89,1.49) 0.2905 1.10 (0.87,1.40) 0.4142 
Any other malaise/fatigue 1.21 (0.94,1.56) 0.1371 1.24 (0.99,1.57) 0.0642 
Any cough 1.22 (0.96,1.55) 0.104 1.15 (0.92,1.44) 0.2211 
Baseline Procedures     
Any chest CT 1.31 (0.97,1.78) 0.0804 1.21 (0.91,1.60) 0.1852 
Any chest x-ray 0.80 (0.61,1.05) 0.1117 0.85 (0.66,1.09) 0.2085 
Any echocardiography 0.85 (0.62,1.17) 0.3224 0.83 (0.63,1.11) 0.2095 
Any EKG 1.01 (0.77,1.32) 0.9382 1.00 (0.78,1.28) 0.978 
Any spirometry 0.73 (0.56,0.96) 0.0219 0.79 (0.62,1.01) 0.059 
Baseline Exacerbation     
Mod Exac at Index or 2 wks pre-index 1.34 (0.99,1.82) 0.0595 1.32 (0.98,1.77) 0.0645 
Mod Exac wks 3-12 pre-index 1.16 (0.86,1.56) 0.3235 1.12 (0.86,1.46) 0.4103 
Any Mod Exac wks 13-52 pre-index 1.15 (0.90,1.49) 0.2701 1.16 (0.92,1.46) 0.219 
Sev Exac within 2 wks pre-index 1.30 (0.85,1.98) 0.2209 1.35 (0.92,1.97) 0.1222 
Sev Exac wks 3-12 pre-index 1.34 (0.92,1.95) 0.1238 1.33 (0.94,1.87) 0.108 
Sev Exac wks 13-52 pre-index 0.87 (0.61,1.26) 0.463 0.93 (0.66,1.30) 0.6547 
Any Hosp w/secondary COPD Dx wks 13-52 1.27 (0.87,1.86) 0.2227 1.22 (0.85,1.75) 0.2787 
Health plan 0.58 (0.46,0.74) <.0001 0.60 (0.48,0.74) <.0001 
No. of two-week periods since Index 1.00 (0.98,1.02) 0.9648 1.03 (1.02,1.04) <.0001 
Triple therapy at start of time period x No. of two-
week periods since Index 
1.00 (0.95,1.06) 0.8779 0.99 (0.96,1.02) 0.5175 
 
There were some differences in effect estimates for covariates that were also 
included in the model compared to the As Protocol model.  For example, valvular disease 
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had a significant association with increased risk in the As Protocol model, but not in the 
MSM models, although that it is insignificant in the MSM model may be because of 
larger standard errors from the GEE approach.  For the two-year MSM model (104 
weeks), the p-value for valvular disease was 0.12.  The effect estimates for baseline use 
of the COPD medications SAMA or SABA/SAMA was increased, and the effect estimate 
for spirometry was lower.   
Factors that were close to being significantly related to higher risk for severe 
exacerbation in the MSM model were baseline weight loss (P=0.05 for 52 weeks, 0.08 for 
104 weeks), baseline symptoms of other malaise/fatigue (P=0.14, for 52 weeks, 0.06 for 
104 weeks) and cough (P=0.10 for 52 weeks, 0.22 for 104 weeks), and having had a 
severe exacerbation in the 3-12 weeks prior to the index date (P=0.12 for 52 weeks, 0.10 
for 104 weeks) 
While there was a significant association for number of weeks in the two-year 
model there was none in the one-year model.  The effect may have been due to the 
construction of the time periods, with more exacerbations occurring in the later time 
periods simply because they were longer. 
Aim 5 
Compare risk for moderate exacerbations experienced up to and including the 
first severe COPD exacerbation among patients using triple therapy compared to use of 
either ICS/LABA combination or LAMA monotherapy. Comparisons are made using both 
conventional methods and MSM methods.  
Moderate exacerbations were compared for the time period prior to and including 
the first severe exacerbation, the end of the 24 months or the individual being lost to 
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follow-up, whichever occurred first. This composite endpoint was chosen to capture 
individuals who might not have evidence in the claims data of a moderate exacerbation 
prior to the severe exacerbation. There were a combined total of 4,574 moderate and 
severe events for the 5,475 study sample subjects.  For the 5,475 subjects, 49.9% 
(n=2,731) did not have any moderate or severe exacerbation over their follow-up period 
(Figure 15).   
As for Aim 4, risk for the composite event was assessed using the three different 
study design populations: ITT, As Protocol, and MSM methods.  Effect estimates for the 
composite outcome event of moderate or severe exacerbation were estimated for the ITT 
study sample using both a negative binomial regression model and a pooled logistic 
regression model. Negative binomial was used instead of Poisson regression since the 
mean number of exacerbations, 0.84, was not close to the exacerbation variance of 1.23 
(Figure 15), and near equivalence is an assumption that should be met when using 
Poisson models. 
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Figure 15 Composite Moderate and Severe Exacerbation Endpoint, ITT 
 
Intent to Treat 
Risk for moderate and or severe exacerbation was modeled using a negative 
binomial model.  The model was constructed using Proc GENMOD, specifying the 
negative binomial distribution with a log link.  The log of the number of two week time 
periods of follow-up was used as the offset variable to adjust for the differing lengths of 
follow-up time.   
The effect estimate for triple therapy was again higher in comparison to 
ICS/LABA or LAMA treatments.  The incidence rate ratio (IRR) was 1.15 (95% CI 1.01 
to 1.31) for patients using triple therapy in comparison to patients using ICS/LABA or 
LAMA therapy (Table 81). 
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Table 81 Incidence Rate Ratio Estimates Moderate/Severe Exacerbation, ITT 
Factor IRR 95% LL 95% UL P-value 
Triple therapy at Index 1.15 1.01 1.31 0.0291 
Male 0.94 0.87 1.02 0.1373 
Age         
Age 40 to 54 vs Age >75 1.01 0.87 1.17 0.9296 
Age 55 to 64 vs Age >75 0.97 0.86 1.09 0.602 
Age 65 to 74 vs Age >75 0.95 0.86 1.04 0.2418 
Medicaid 1.16 1.01 1.32 0.0334 
Baseline Comorbidities         
Atrial fibrillation 0.91 0.79 1.04 0.1693 
Heart failure or CHF 1.10 0.99 1.22 0.0748 
Ischemic Heart Disease 0.94 0.86 1.04 0.241 
Rheumatoid or osteo-arthritis 0.98 0.90 1.06 0.6012 
Deficiency Anemias 0.94 0.84 1.05 0.2788 
Depression 1.03 0.94 1.14 0.5165 
Diabetes w/o chronic complications 1.02 0.94 1.12 0.6088 
Fluid and electrolyte disorders 1.05 0.93 1.18 0.4056 
Hypertension 1.05 0.96 1.14 0.2804 
Hypothyroidism 0.98 0.89 1.08 0.7345 
Obesity 0.85 0.75 0.95 0.0056 
Other neurological disorders 0.99 0.87 1.13 0.9032 
Psychoses 1.08 0.96 1.22 0.2224 
Pulmonary circulation disease 0.93 0.82 1.05 0.2514 
Renal failure 0.84 0.73 0.97 0.0206 
Valvular disease 1.07 0.94 1.21 0.3133 
Weight loss 1.16 1.00 1.35 0.0486 
Asthma 1.04 0.96 1.13 0.3191 
Hypoxemia 0.98 0.90 1.08 0.7269 
Pneumonia 1.18 1.08 1.28 0.0001 
Emphysema 1.12 1.02 1.23 0.0126 
Low COPD complexity 0.87 0.79 0.95 0.0014 
COPD Medication Baseline Use         
No SABA use 0.97 0.88 1.06 0.4828 
SABA use 15-40% 1.09 0.97 1.23 0.1352 
SABA use >40% 1.29 1.15 1.44 <.0001 
Any SAMA use 1.29 1.16 1.43 <.0001 
Any SABA/SAMA use 1.18 1.07 1.30 0.001 
Any ICS use 1.10 1.02 1.20 0.0181 
Any ICSLABA use 6 mo preindex 1.02 0.91 1.15 0.7063 
Oxygen use </=50% 1.07 0.96 1.21 0.2248 
Oxygen use >50% 1.49 1.36 1.64 <.0001 
Any nebulizer treatment 1.03 0.95 1.13 0.455 
Baseline Symptoms         
No breathlessness 0.94 0.85 1.04 0.2085 
>1 period breathlessness 0.96 0.85 1.09 0.5525 
No shortness of breath 1.08 0.98 1.19 0.1317 
>1 period shortness of breath 1.00 0.88 1.13 0.9858 
Any wheezing 1.08 0.94 1.23 0.2763 
Any chest pain 1.07 0.98 1.16 0.1594 
Any other malaise/fatigue 1.09 0.99 1.18 0.065 
Any cough 1.13 1.04 1.22 0.0046 
Baseline Procedures         
Any chest CT 1.02 0.91 1.13 0.7643 
Any chest x-ray 0.97 0.88 1.06 0.4613 
Any echocardiography 0.98 0.88 1.09 0.712 
Any EKG 1.02 0.93 1.11 0.7319 
Any spirometry 0.92 0.84 1.00 0.0442 
Baseline Exacerbation         
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Factor IRR 95% LL 95% UL P-value 
Mod Exac at Index or 2 wks pre-index 1.22 1.10 1.35 0.0002 
Mod Exac wks 3-12 pre-index 1.31 1.19 1.44 <.0001 
Any Mod Exac wks 13-52 pre-index 1.46 1.34 1.59 <.0001 
Sev Exac within 2 wks pre-index 1.01 0.87 1.18 0.8673 
Sev Exac wks 3-12 pre-index 1.30 1.11 1.52 0.0011 
Sev Exac wks 13-52 pre-index 1.09 0.94 1.25 0.2552 
Any Hosp w/secondary COPD Dx wks 13-52 1.15 1.00 1.33 0.0562 
Health plan 0.88 0.81 0.96 0.0025 
 
Patient age and sex were not identified as significant risk factors.  Having 
Medicaid insurance however was again associated with higher risk (IRR 1.16, 95% CI 
1.01 to 1.32). 
Obesity (IRR 0.85, 95% CI 0.75 to 0.95) and renal failure (IRR 0.84, 95% CI 0.73 
to 0.97) were associated with a lower risk of moderate or severe exacerbation, while 
pneumonia (IRR 1.18, 95% CI 1.08 to 1.28), emphysema (IRR 1.12, 95% CI 1.02 to 
1.23), and significant weight loss (IRR 1.16, 95% CI 1.00 to 1.35) were associated with 
higher risk.  Heart failure or CHF was marginally associated with higher risk (1.10, 95% 
CI 0.99 to 1.22). Overall low COPD complexity was again associated with a lower risk 
(IRR 0.87, 95% CI 0.79 to 0.95). 
Frequent baseline use of SABA (IRR 1.29, 95% CI 1.15 to 1.44) and any baseline 
use of SAMA (IRR 1.29, 95% CI 1.16 to 1.43) or SABA/SAMA (IRR 1.18, 95% CI 1.07 
to 1.30) was again associated with a higher risk of exacerbation. Any ICS baseline use 
(1.10, 95% CI 1.02 to 1.20) and baseline use of oxygen for more than 50% of the period 
(1.49, 95% CI 1.36 to 1.64) were also found to be significant factors. 
Baseline cough (1.13, 95% CI 1.04 to 1.23) was a symptom found to be 
associated with higher risk, and malaise/fatigue was marginally a factor (1.09, 95% CI 
0.99  to 1.18). Having spirometry in the baseline period was again associated with 
reduced risk (0.92, 95% CI 0.84 to 1.00). 
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Prior exacerbation experience was strongly associated with exacerbation 
experience post-index.  Patients who had a moderate exacerbation in the two week period 
leading up to the index date had a 22% increase in risk (IRR 1.22, 95% CI 1.10 to 1.35), 
those with a moderate exacerbation in the 3-12 weeks prior to that had an increase in risk 
of 32% (IRR 1.31, 95% CI 1.19 to 1.44), and those with a moderate exacerbation in the 
13-52 weeks prior to that had a 46% increase in risk (IRR 1.30, 95% CI 1.11 to 1.52). 
Severe exacerbations immediately prior to the index or in the 13-52 weeks prior were not 
found to be associated with risk, but severe exacerbation in the 3-12 weeks prior was 
(1.30, 95% CI 1.11 to 1.52).  Having any hospitalization in the 13-52 weeks where there 
was a secondary diagnosis of COPD was also almost significant (IRR 1.15, 95% CI 1.00 
to 1.33). 
Health plan was again found to be significant (0.88, 95% CI 0.81 to 0.96). 
Analysis Using GEE method 
As an alternative analysis, risk for any moderate or severe exacerbation was 
reviewed separately for each two-week period in the follow-up period.  Because 
moderate exacerbations for the study had been defined as episodes that were estimated to 
last 14 days, one exacerbation could span more than one two-week period, and in some 
cases more than two two-week periods if the exacerbation continued based on successive 
prescriptions for antibiotics or corticosteroids. Two week intervals which represented a 
continuation of a moderate exacerbation event were thus excluded since individuals could 
not be at risk for a new moderate exacerbation. 
Using this method of summing events by period instead of tracking by day as in 
the ITT approach resulted in a lower count of total events.  In the ITT analysis, 4,574 
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events were modeled.  In the GEE analysis 4,530 events were modeled.  The difference in 
counts arose because in the GEE analysis, a period could have only one event and 
therefore if a period contained a moderate event that preceded a severe event, only the 
severe event was counted.  
Table 82 summarizes the effect estimates for the GEE model, which were very 
similar to those shown in Table 81 for the negative binomial model.  Patients using triple 
therapy at index were estimated to have a higher, but only marginally higher risk than 
patients using ICS/LABA or LAMA therapy (IRR 1.12, 95% CI, 0.99 to 1.28). 
Overall the effect estimates for covariates in Table 82 were almost equivalent to 
those in Table 81.  
Table 82 Incidence Rate Ratio Estimates Moderate/Severe Exacerbation, GEE, ITT 
Factor IRR 95% LL 95% UL P-value 
Triple therapy at Index 1.12 0.99 1.28 0.0711 
Time Period (1 to a max of 52) 0.99 0.99 1.00 <.0001 
Male 0.93 0.86 1.01 0.0971 
Age         
Age 40 to 54 vs Age >75 1.02 0.87 1.19 0.8102 
Age 55 to 64 vs Age >75 0.99 0.88 1.12 0.8794 
Age 65 to 74 vs Age >75 0.97 0.88 1.06 0.4807 
Medicaid 1.15 1.00 1.31 0.0458 
Baseline Comorbidities         
Atrial fibrillation 0.90 0.79 1.03 0.1259 
Heart failure or CHF 1.09 0.97 1.21 0.135 
Ischemic Heart Disease 0.94 0.85 1.04 0.2203 
Rheumatoid or osteo-arthritis 0.97 0.89 1.05 0.4566 
Deficiency Anemias 0.93 0.84 1.04 0.2191 
Depression 1.03 0.93 1.14 0.5722 
Diabetes w/o chronic complications 1.02 0.93 1.11 0.7437 
Fluid and electrolyte disorders 1.04 0.93 1.18 0.4812 
Hypertension 1.05 0.96 1.14 0.2969 
Hypothyroidism 0.98 0.89 1.08 0.7027 
Obesity 0.84 0.75 0.94 0.0032 
Other neurological disorders 1.01 0.89 1.14 0.8797 
Psychoses 1.07 0.95 1.21 0.2524 
Pulmonary circulation disease 0.90 0.79 1.03 0.1344 
Renal failure 0.85 0.73 0.99 0.0324 
Valvular disease 1.10 0.97 1.26 0.1379 
Weight loss 1.15 1.00 1.33 0.0559 
Asthma 1.05 0.96 1.14 0.2737 
Hypoxemia 0.99 0.90 1.08 0.7521 
Pneumonia 1.17 1.08 1.27 0.0002 
Emphysema 1.11 1.02 1.22 0.0206 
Low COPD complexity 0.87 0.80 0.95 0.002 
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Factor IRR 95% LL 95% UL P-value 
COPD Medication Baseline Use         
No SABA use 0.97 0.88 1.07 0.5103 
SABA use 15-40% 1.11 0.99 1.25 0.0777 
SABA use >40% 1.27 1.13 1.43 <.0001 
Any SAMA use 1.30 1.17 1.45 <.0001 
Any SABA/SAMA use 1.16 1.05 1.28 0.0025 
Any ICS use 1.11 1.03 1.21 0.0093 
Any ICSLABA use 6 mo preindex 1.01 0.89 1.13 0.9224 
Oxygen use </=50% 1.08 0.97 1.21 0.1771 
Oxygen use >50% 1.51 1.37 1.65 <.0001 
Any nebulizer treatment 1.01 0.93 1.10 0.8181 
Baseline Symptoms         
No breathlessness 0.96 0.86 1.06 0.3712 
>1 period breathlessness 0.97 0.86 1.09 0.6013 
No shortness of breath 1.06 0.97 1.17 0.2043 
>1 period shortness of breath 0.97 0.86 1.10 0.6354 
Any wheezing 1.06 0.93 1.22 0.3748 
Any chest pain 1.06 0.97 1.16 0.2116 
Any other malaise/fatigue 1.09 1.00 1.18 0.0624 
Any cough 1.12 1.03 1.22 0.0055 
Baseline Procedures         
Any chest CT 1.01 0.90 1.13 0.8552 
Any chest x-ray 0.97 0.88 1.06 0.4755 
Any echocardiography 1.00 0.90 1.11 0.992 
Any EKG 1.02 0.93 1.11 0.6875 
Any spirometry 0.93 0.86 1.01 0.1004 
Baseline Exacerbation         
Mod Exac at Index or 2 wks pre-index 1.21 1.09 1.35 0.0003 
Mod Exac wks 3-12 pre-index 1.31 1.19 1.45 <.0001 
Any Mod Exac wks 13-52 pre-index 1.48 1.36 1.61 <.0001 
Sev Exac within 2 wks pre-index 1.00 0.85 1.16 0.9595 
Sev Exac wks 3-12 pre-index 1.24 1.07 1.45 0.0059 
Sev Exac wks 13-52 pre-index 1.05 0.90 1.21 0.5308 
Any Hosp w/secondary COPD Dx wks 13-52 1.13 0.97 1.30 0.1065 
Health plan 0.91 0.84 0.99 0.0205 
 
As Protocol 
As for Aim 4, events for the study sample under the As Protocol criteria were 
greatly reduced.  While in the ITT analysis, there were 4,574 overall events, in the As 
Protocol analyses, the number was 28% of that (n=1,295).  An overwhelming majority, 
76% of the population, had no exacerbation event, and 18% had 1 event (Figure 16). 
Overall the mean number of exacerbations was 0.32 with a variance of 0.47. 
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Figure 16 Composite Moderate and Severe Exacerbation Endpoint, As Protocol 
 
Similar to the ITT analysis, exacerbation events were modeled for the As Protocol 
sample using Proc GENMOD, specifying the negative binomial distribution with a log 
link.  The log of the number of two week time periods of follow-up was used as the offset 
variable to adjust for the differing lengths of follow-up time.  Table 83 summarizes the 
results. Overall there was not much difference between the results for the ITT analysis 
and those shown in Table 83.  For the As Protocol analysis, the risk for any exacerbation 
for patients using triple therapy compared to that for patients using ICS/LABA or LAMA 
at Index was 1.16 (95% CI, 0.98 to 1.38).   
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Table 83 Incidence Rate Ratio Estimates Moderate/Severe Exacerbation, As Protocol 
Factor IRR 95% LL 95% UL P-value 
Triple therapy at index 1.16 0.98 1.38 0.0748 
Male 0.97 0.86 1.08 0.5634 
Age         
Age 40 to 54 vs Age >75 0.87 0.69 1.09 0.2244 
Age 55 to 64 vs Age >75 0.94 0.79 1.10 0.4304 
Age 65 to 74 vs Age >75 0.90 0.79 1.03 0.1267 
Medicaid 1.10 0.90 1.33 0.3459 
Baseline Comorbidities         
Atrial fibrillation 0.95 0.79 1.15 0.6134 
Heart failure or CHF 1.02 0.87 1.19 0.8293 
Ischemic Heart Disease 0.89 0.77 1.02 0.1017 
Rheumatoid or osteo-arthritis 1.04 0.92 1.17 0.5467 
Deficiency Anemias 1.09 0.93 1.27 0.2848 
Depression 1.05 0.91 1.22 0.5030 
Diabetes w/o chronic complications 1.07 0.94 1.22 0.2964 
Fluid and electrolyte disorders 1.05 0.89 1.25 0.5593 
Hypertension 1.02 0.90 1.14 0.8029 
Hypothyroidism 1.01 0.88 1.16 0.8936 
Obesity 0.83 0.70 0.99 0.0393 
Other neurological disorders 0.92 0.76 1.11 0.3774 
Psychoses 1.14 0.96 1.36 0.1450 
Pulmonary circulation disease 0.88 0.73 1.06 0.1756 
Renal failure 0.79 0.64 0.98 0.0336 
Valvular disease 1.18 0.98 1.41 0.0775 
Weight loss 1.19 0.97 1.48 0.0998 
Asthma 1.05 0.93 1.19 0.3993 
Hypoxemia 0.92 0.81 1.05 0.2019 
Pneumonia 1.22 1.08 1.38 0.0010 
Emphysema 1.15 1.01 1.30 0.0289 
Low COPD complexity 0.80 0.71 0.91 0.0009 
COPD Medication Baseline Use         
No SABA use 1.00 0.87 1.16 0.9901 
SABA use 15-40% 1.02 0.85 1.22 0.8212 
SABA use >40% 1.25 1.06 1.47 0.0084 
Any SAMA use 1.22 1.05 1.42 0.0098 
Any SABA/SAMA use 1.13 0.98 1.29 0.0842 
Any ICS use 1.09 0.97 1.23 0.1441 
Any ICSLABA use 6 mo preindex 1.10 0.94 1.30 0.2362 
Oxygen use </=50% 1.04 0.88 1.23 0.6810 
Oxygen use >50% 1.41 1.23 1.62 <.0001 
Any nebulizer treatment 1.03 0.91 1.17 0.5949 
Baseline Symptoms         
No breathlessness 0.91 0.79 1.05 0.2171 
>1 period breathlessness 0.96 0.80 1.14 0.6333 
No shortness of breath 1.07 0.93 1.24 0.3423 
>1 period shortness of breath 0.96 0.80 1.14 0.6267 
Any wheezing 1.06 0.88 1.28 0.5405 
Any chest pain 1.09 0.96 1.24 0.1638 
Any other malaise/fatigue 1.04 0.92 1.18 0.5498 
Any cough 1.16 1.03 1.31 0.0125 
Baseline Procedures         
Any chest CT 1.07 0.92 1.25 0.3600 
Any chest x-ray 0.94 0.82 1.08 0.3728 
Any echocardiography 0.96 0.82 1.13 0.6396 
Any EKG 1.07 0.95 1.22 0.2772 
Any spirometry 0.87 0.77 0.98 0.0224 
Baseline Exacerbation         
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Factor IRR 95% LL 95% UL P-value 
Mod Exac at Index or 2 wks pre-index 1.15 0.99 1.34 0.0604 
Mod Exac wks 3-12 pre-index 1.32 1.15 1.52 <.0001 
Any Mod Exac wks 13-52 pre-index 1.55 1.37 1.75 <.0001 
Sev Exac within 2 wks pre-index 1.05 0.84 1.32 0.6465 
Sev Exac wks 3-12 pre-index 1.24 1.01 1.53 0.0443 
Sev Exac wks 13-52 pre-index 1.02 0.84 1.24 0.8459 
Any Hosp w/secondary COPD Dx wks 13-52 1.20 0.98 1.47 0.0764 
Health plan 0.80 0.71 0.90 0.0002 
 
Weighted MSM Analysis 
For the ITT analysis, a GEE approach was able to be used by reviewing whether 
an event occurred or not in a two-week period.  For the MSM analysis, the time intervals 
were larger. Additionally, in estimating the weights moderate exacerbation as a time-
varying confounder had been included in both the treatment probability models and the 
censoring models.  For these reasons a suitable population to analysis moderate/severe 
exacerbations as an outcome could not be constructed using the weighted population 
since the population had been constructed in order to assess effectiveness of treatment 
using severe exacerbation as the outcome. 
 In hindsight, analysis of this outcome using MSM methods would require 
construction of a different model – in particular to the size of the time intervals.   
Summary of Aim 4 and Aim5 – ITT and As Protocol 
Table 84 was created in order to better understand the differences between the 
ITT and As Protocol analyses for severe exacerbation risk and the composite index point 
of moderate/severe exacerbation risk. This table summarizes the factors included in 
analyses and highlights those found to be significantly associated with the measured 
outcome. 
Some factors that were strongly associated with severe exacerbation were 
attenuated or not significant for moderate exacerbation.  For example, age was strongly 
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associated with severe exacerbation risk, with older patients more likely to have a severe 
exacerbation, but age was not a significant factor for the composite event of moderate 
and/or severe exacerbations. Similarly, having Medicaid insurance coverage was strongly 
associated with increased risk of a severe exacerbation, but was not found to be a 
significant factor for moderate/severe exacerbations in the As Protocol analysis. 
Among the comorbidities, valvular disease was found to be strongly associated 
with a higher risk of severe exacerbation, but was only marginally associated with 
moderate/severe exacerbations. 
Other factors however were associated with higher risk for both outcome 
measures.  Having emphysema or a history of pneumonia were associated with higher 
risk, as was total days supply of SABA that comprised more than 40% of the baseline 
period, use of oxygen for more than 50% of the baseline period, and any use of SAMA or 
SABA/SAMA in the baseline period.  
Having moderate exacerbations in the baseline period was strongly associated 
with moderate exacerbations in the follow-up period, as was a severe exacerbation in the 
3-12 weeks prior to the index date. 
Having spirometry was associated with a reduced risk for both outcomes, and the 
two health plan populations had differential exacerbation experiences. 
Table 84 Summary of Aim 4 and 5 Results, ITT and As Protocol 
 
Intent-to-Treat As Protocol 
Factor Sev Exac Mod/Sev Exac Sev Exac Mod/Sev Exac 
Triple therapy at Index 1.24 (1.00, 1.53) 1.15 (1.01, 1.31) 1.00 (0.73, 1.36) 1.16 (0.98, 1.38) 
Male 1.12 (0.97, 1.29) 0.94 (0.87, 1.02) 1.12 (0.91, 1.38) 0.97 (0.86, 1.08) 
Age         
Age 40 to 54 vs Age >75 0.56 (0.41, 0.78) 1.01 (0.87, 1.17) 0.44 (0.27, 0.71) 0.87 (0.69, 1.09) 
Age 55 to 64 vs Age >75 0.75 (0.60, 0.95) 0.97 (0.86, 1.09) 0.56 (0.39, 0.79) 0.94 (0.79, 1.10) 
Age 75 to 74 vs Age >75 0.85 (0.72, 1.01) 0.95 (0.86, 1.04) 0.72 (0.56, 0.92) 0.90 (0.79, 1.03) 
Medicaid 1.55 (1.20, 2.00) 1.16 (1.01, 1.32) 1.96 (1.36, 2.83) 1.10 (0.90, 1.33) 
Baseline Comorbidities         
Atrial fibrillation 0.87 (0.70, 1.09) 0.91 (0.79, 1.04) 1.04 (0.76, 1.43) 0.95 (0.79, 1.15) 
Heart failure or CHF 1.23 (1.03, 1.46) 1.10 (0.99, 1.22) 0.99 (0.76, 1.30) 1.02 (0.87, 1.19) 
Ischemic Heart Disease 1.04 (0.88, 1.22) 0.94 (0.86, 1.04) 1.11 (0.87, 1.42) 0.89 (0.77, 1.02) 
Rheumatoid or osteo-arthritis 0.96 (0.82, 1.12) 0.98 (0.90, 1.06) 1.08 (0.86, 1.35) 1.04 (0.92, 1.17) 
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Intent-to-Treat As Protocol 
Factor Sev Exac Mod/Sev Exac Sev Exac Mod/Sev Exac 
Deficiency Anemias 1.04 (0.86, 1.25) 0.94 (0.84, 1.05) 1.25 (0.96, 1.64) 1.09 (0.93, 1.27) 
Depression 0.98 (0.82, 1.18) 1.03 (0.94, 1.14) 1.18 (0.91, 1.53) 1.05 (0.91, 1.22) 
Diabetes w/o chronic complications 1.10 (0.94, 1.29) 1.02 (0.94, 1.12) 1.08 (0.85, 1.37) 1.07 (0.94, 1.22) 
Fluid and electrolyte disorders 1.11 (0.92, 1.35) 1.05 (0.93, 1.18) 0.86 (0.64, 1.16) 1.05 (0.89, 1.25) 
Hypertension 1.07 (0.91, 1.26) 1.05 (0.96, 1.14) 0.96 (0.76, 1.21) 1.02 (0.90, 1.14) 
Hypothyroidism 0.97 (0.81, 1.15) 0.98 (0.89, 1.08) 0.95 (0.74, 1.22) 1.01 (0.88, 1.16) 
Obesity 0.92 (0.75, 1.14) 0.85 (0.75, 0.95) 1.06 (0.78, 1.44) 0.83 (0.70, 0.99) 
Other neurological disorders 1.12 (0.90, 1.38) 0.99 (0.87, 1.13) 0.88 (0.62, 1.24) 0.92 (0.76, 1.11) 
Psychoses 1.06 (0.85, 1.33) 1.08 (0.96, 1.22) 1.05 (0.76, 1.47) 1.14 (0.96, 1.36) 
Pulmonary circulation disease 0.97 (0.79, 1.19) 0.93 (0.82, 1.05) 1.03 (0.76, 1.40) 0.88 (0.73, 1.06) 
Renal failure 0.93 (0.73, 1.18) 0.84 (0.73, 0.97) 0.94 (0.66, 1.36) 0.79 (0.64, 0.98) 
Valvular disease 1.23 (1.00, 1.52) 1.07 (0.94, 1.21) 1.37 (1.01, 1.85) 1.18 (0.98, 1.41) 
Weight loss 1.14 (0.88, 1.46) 1.16 (1.00, 1.35) 1.29 (0.90, 1.87) 1.19 (0.97, 1.48) 
Asthma 1.02 (0.87, 1.19) 1.04 (0.96, 1.13) 1.11 (0.88, 1.38) 1.05 (0.93, 1.19) 
Hypoxemia 1.01 (0.86, 1.18) 0.98 (0.90, 1.08) 0.90 (0.71, 1.14) 0.92 (0.81, 1.05) 
Pneumonia 1.19 (1.02, 1.39) 1.18 (1.08, 1.28) 1.44 (1.15, 1.79) 1.22 (1.08, 1.38) 
Emphysema 1.19 (1.02, 1.39) 1.12 (1.02, 1.23) 1.24 (0.99, 1.55) 1.15 (1.01, 1.30) 
Low COPD complexity 0.70 (0.59, 0.83) 0.87 (0.79, 0.95) 0.75 (0.58, 0.96) 0.80 (0.71, 0.91) 
COPD Medication Baseline Use         
No SABA use 0.98 (0.81, 1.17) 0.97 (0.88, 1.06) 0.89 (0.68, 1.17) 1.00 (0.87, 1.16) 
SABA use 15-40% 0.89 (0.70, 1.13) 1.09 (0.97, 1.23) 0.81 (0.56, 1.16) 1.02 (0.85, 1.22) 
SABA use >40% 1.34 (1.09, 1.66) 1.29 (1.15, 1.44) 1.31 (0.97, 1.76) 1.25 (1.06, 1.47) 
Any SAMA use 1.35 (1.12, 1.62) 1.29 (1.16, 1.43) 1.38 (1.06, 1.79) 1.22 (1.05, 1.42) 
Any SABA/SAMA use 1.27 (1.07, 1.50) 1.18 (1.07, 1.30) 1.34 (1.05, 1.70) 1.13 (0.98, 1.29) 
Any ICS use 0.95 (0.81, 1.11) 1.10 (1.02, 1.20) 0.89 (0.71, 1.11) 1.09 (0.97, 1.23) 
Oxygen use </=50% 1.18 (0.95, 1.45) 1.07 (0.96, 1.21) 0.99 (0.72, 1.35) 1.04 (0.88, 1.23) 
Oxygen use >50% 1.64 (1.38, 1.95) 1.49 (1.36, 1.64) 1.38 (1.07, 1.77) 1.41 (1.23, 1.62) 
Any nebulizer treatment 0.95 (0.80, 1.11) 1.03 (0.95, 1.13) 1.08 (0.86, 1.36) 1.03 (0.91, 1.17) 
Baseline Symptoms         
No breathlessness 0.91 (0.76, 1.09) 0.94 (0.85, 1.04) 0.79 (0.61, 1.02) 0.91 (0.79, 1.05) 
>1 period breathlessness 1.05 (0.85, 1.30) 0.96 (0.85, 1.09) 0.86 (0.63, 1.17) 0.96 (0.80, 1.14) 
No shortness of breath 0.89 (0.74, 1.06) 1.08 (0.98, 1.19) 0.84 (0.65, 1.09) 1.07 (0.93, 1.24) 
>1 period shortness of breath 0.93 (0.76, 1.14) 1.00 (0.88, 1.13) 0.92 (0.68, 1.24) 0.96 (0.80, 1.14) 
Any wheezing 0.98 (0.76, 1.26) 1.08 (0.94, 1.23) 1.01 (0.71, 1.43) 1.06 (0.88, 1.28) 
Any chest pain 1.03 (0.88, 1.21) 1.07 (0.98, 1.16) 1.05 (0.83, 1.32) 1.09 (0.96, 1.24) 
Any other malaise/fatigue 1.08 (0.92, 1.26) 1.09 (0.99, 1.18) 1.17 (0.93, 1.47) 1.04 (0.92, 1.18) 
Any cough 1.04 (0.89, 1.21) 1.13 (1.04, 1.22) 1.13 (0.90, 1.41) 1.16 (1.03, 1.31) 
Baseline Procedures         
Any chest CT 1.10 (0.91, 1.33) 1.02 (0.91, 1.13) 1.19 (0.91, 1.56) 1.07 (0.92, 1.25) 
Any chest x-ray 0.94 (0.80, 1.12) 0.97 (0.88, 1.06) 0.87 (0.68, 1.12) 0.94 (0.82, 1.08) 
Any echocardiography 0.87 (0.71, 1.05) 0.98 (0.88, 1.09) 0.90 (0.68, 1.19) 0.96 (0.82, 1.13) 
Any EKG 1.02 (0.86, 1.19) 1.02 (0.93, 1.11) 1.08 (0.85, 1.37) 1.07 (0.95, 1.22) 
Any spirometry 0.84 (0.72, 0.99) 0.92 (0.84, 1.00) 0.82 (0.65, 1.03) 0.87 (0.77, 0.98) 
Baseline Exacerbation         
Mod Exac at Index or 2 wks pre-index 1.11 (0.92, 1.35) 1.22 (1.10, 1.35) 1.12 (0.84, 1.48) 1.15 (0.99, 1.34) 
Mod Exac wks 3-12 pre-index 1.14 (0.96, 1.37) 1.31 (1.19, 1.44) 1.18 (0.91, 1.53) 1.32 (1.15, 1.52) 
Any Mod Exac wks 13-52 pre-index 1.15 (0.98, 1.35) 1.46 (1.34, 1.59) 1.09 (0.87, 1.38) 1.55 (1.37, 1.75) 
Sev Exac within 2 wks pre-index 1.01 (0.79, 1.28) 1.01 (0.87, 1.18) 1.17 (0.81, 1.68) 1.05 (0.84, 1.32) 
Sev Exac wks 3-12 pre-index 1.53 (1.23, 1.91) 1.30 (1.11, 1.52) 1.24 (0.89, 1.73) 1.24 (1.01, 1.53) 
Sev Exac wks 13-52 pre-index 1.21 (0.98, 1.50) 1.09 (0.94, 1.25) 0.98 (0.71, 1.35) 1.02 (0.84, 1.24) 
Any Hosp w/secondary COPD Dx wks 13-52 1.19 (0.94, 1.50) 1.15 (1.00, 1.33) 1.37 (0.98, 1.90) 1.20 (0.98, 1.47) 
Health plan 0.66 (0.56, 0.76) 0.88 (0.81, 0.96) 0.57 (0.46, 0.70) 0.80 (0.71, 0.90) 
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Aim 6 
Compare costs and effectiveness of therapy in extending time until first COPD-
related hospitalization among patients using triple therapy compared to use of either 
ICS/LABA combination or LAMA monotherapy. 
Time until the first severe exacerbation was estimated in Aim 4. The time until 
the first severe exacerbation was shorter for the triple therapy patients compared to the 
ICS/LABA or LAMA study subjects at both the one-year and two-year end points, for 
both the ITT and As Protocol analyses. Time until the first severe exacerbation could not 
be estimated from the MSM analysis. 
Because of the large percentage of study subjects discontinuing use of ICS/LABA 
or LAMA by the end of 6 months, costs were only reviewed for one-year after the index 
date.  Medical services (outpatient and/or inpatient) and outpatient pharmacy costs were 
summarized by four week periods and were categorized by whether they were COPD-
related or non-COPD related.   
In the ITT analysis, complete cost history was available for all study subjects up 
to six months post-index since no censoring occurred until after 6 months. Up through the 
7
th
 four-week period, the probability of remaining uncensored was assumed to be 1.00. 
For the 8
th
 though the 13
th
 periods, the Kaplan-Meier estimated probability, by index 
treatment group (triple therapy or not), of remaining uncensored at the beginning of each 
period was used to weight estimated costs by treatment group to arrive at an annual 
estimate of the treatment costs for the complete subject group, since the total costs would 
be divided by 5,475 to arrive at an estimated average cost.  Unweighted annual costs 
were also estimated to compare how the use of this method might alter cost estimates. 
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In the As Protocol analysis, study subjects were censored quickly. 
For the ITT and As Protocol analyses, PROC GENMOD was used to estimate 
costs for each of the 13 four-week periods.  The models specified a log link function and 
assumed a gamma distribution for the cost distribution. Covariates were the same as those 
used for the estimation of severe exacerbation risk.  
For the MSM population, costs were summarized for study subjects by the 5 
periods that comprised the first year post-index. As with the ITT analysis, PROC 
GENMOD was used – with a log link function, a gamma distribution assumption for the 
cost distribution, and the stabilized weights for observations – to estimate costs for each 
of the 5 periods.  Factors, besides the binary variable for use of triple therapy or 
ICS/LABA or LAMA at the beginning of each period, included in analyses for the MSM 
were 1) all the baseline covariates included in the ITT and As Protocol analyses, and 2) 
only sex, age, and type of insurance.  Effect estimates for use of triple therapy in each 
period were compared to those for index use of triple therapy for the 13 four-week 
periods in the ITT analysis. 
ITT Estimates 
Table 85 summarizes by index treatment the estimates for the annual healthcare 
costs for the ITT sample.  Shown are the weighted mean estimates using the Kaplan-
Meier probability estimates, and the costs without weighting.  P-values are for differences 
between the unweighted values. 
For the ITT analysis, the percentage of study subjects who were censored by the 
end of the first year due to disenrollment was not a large percentage and thus the 
weighted mean estimates were not substantially different than the unweighted.  Because 
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of the difficulty in estimated confidence intervals for the weighted values, the discussion 
here focuses on the unweighted values. 
Table 85 Estimated Annual Healthcare Costs, ITT 
 
Triple therapy at Index ICS/LABA or LAMA at Index P- values 
Cost Category 
Weighted 
Mean 
Unweighted Estimate Weighted 
Mean 
Unweighted Estimate 
 Mean  Med* Mean (SD) Med Mean (SD) Med 
Non-COPD Utilization:           
Medical Services  10,302 10,135 (8,535) 7,715 10,953 10,772 (8,833) 8,446 0.1287 0.0303 
Outpatient Pharmacy 2,216 2,174 (1,638) 1,707 2,667 2,625 (1,874) 2,087 <.0001 <.0001 
Total Non-COPD  12,357 12,149 (9,361) 9,748 13,515 13,294 (9,828) 10,697 0.0141 0.0005 
COPD Utilization:                     
Medical Services  6,036 5,908 (6,352) 4,036 4,384 4,303 (4,647) 2,891 <.0001 <.0001 
Outpatient Pharmacy 2,466 2,427 (940) 2,283 1,374 1,356 (526) 1,256 <.0001 <.0001 
Total COPD  8,131 7,981 (5,017) 6,728 5,338 5,250 (3,295) 4,380 <.0001 <.0001 
Overall Utilization:                     
Medical Services  15,694 15,421 (12,294) 12,014 15,037 14,784 (11,564) 11,540 0.2493 0.3059 
Outpatient Pharmacy 4,673 4,592 (1,919) 4,269 3,983 3,924 (1,677) 3,607 <.0001 <.0001 
Total Overall 20,369 20,013 (12,865) 17,110 18,774 18,468 (11,619) 15,373 0.0112 0.0024 
Med, median; SD, standard deviation 
* Wilcoxon rank sum test for differences in distribution 
 
Patients who were prescribed triple therapy at index were estimated over the first 
year to have marginally higher mean total health care costs ($20,013 compared to 
$18,468, P=0.01).  The overall difference was due to the differences in outpatient 
pharmacy costs as there no significant differences in overall medical services (P=0.25).  
Estimated medical services costs for both groups was approximately $15,000, with 
outpatient pharmacy averaging close to $4,600 for study subjects  using triple therapy at 
index and $4,000 for study subjects using ICS/LABA or LAMA at index. 
However, while overall total costs were higher, that was primarily due to COPD-
related health care costs.  Costs for non-COPD services were actually lower for study 
subjects with triple therapy at index than for subjects with ICS/LABA or LAMA.  Total 
non-COPD costs were $12,149 for subjects using triple therapy at index compared to 
$13,294 for subjects using ICS/LABA or LAMA (P=0.01).  Total COPD costs on the 
other hand were $7,981 for subjects using triple therapy at index compared to $5,250 for 
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subjects using ICS/LABA or LAMA (P=<0.0001).  COPD costs for triple therapy 
subjects were higher for both medical services ($5,908 compared to $4,303, P<0.0001) 
and for outpatient pharmacy ($2,427 compared to $1,356, P<0.0001). 
Monthly actual costs were highly skewed and estimated costs reflected the same 
right-skew distribution. Figure 17 shows the distribution of estimated costs by index 
therapy with a normal distribution superimposed.  Visually, one can see that for the 
ICS/LABA or LAMA study subjects there were more estimated values in the right tail. 
Figure 17 Histogram of Estimated Annual Costs, ITT 
 
As Protocol Estimates 
Table 87 summarizes by index treatment the estimates for the annual healthcare 
costs for the As Protocol sample.  Shown are the weighted mean estimates using the 
Kaplan-Meier probability estimates, and the costs without weighting.  Theoretically the 
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Kaplan-Meier method can be used when censoring is administrative and unrelated to cost 
or outcomes. That assumption is not valid with the As Protocol group, but the weighted 
values are again provided for comparison purposes. Censoring was very heavy for this 
sample. By the last four-week period, the probability of being observed for the 
ICS/LABA or LAMA group was 22.0% and for the triple therapy group, 28.5%. As in 
Table 85, P-values are for differences between the unweighted values.  And as for the 
ITT analysis, because of the difficulty in estimated confidence intervals for the weighted 
values, the discussion here focuses mostly on the unweighted values. 
Table 86 Estimated Annual Healthcare Costs, As Protocol 
 
Triple therapy at Index ICS/LABA or LAMA at Index P- values 
Cost Category 
Weighted 
Mean 
Unweighted Estimate Weighted 
Mean 
Unweighted Estimate 
 Mean  Med* Mean (SD) Med Mean (SD) Med 
Non-COPD Utilization:           
Medical Services  9,171 5,935 (6,409) 4,226 9,178 4,730 (5,545) 3,009 <.0001 <.0001 
Outpatient Pharmacy 2,217 1,390 (1,276) 1,044 2,618 1,322 (1,350) 873 0.2872 0.0008 
Total Non-COPD  11,216 7,244 (7,205) 5,352 11,612 5,978 (6,283) 3,972 0.0002 <.0001 
COPD Utilization:                     
Medical Services  4,868 3,528 (3,959) 2,181 3,664 1,906 (3,131) 988 <.0001 <.0001 
Outpatient Pharmacy 3,094 1,964 (1,068) 1,662 2,057 1,017 (750) 655 <.0001 <.0001 
Total COPD  7,521 5,158 (3,453) 4,150 5,197 2,706 (2,308) 1,862 <.0001 <.0001 
Overall Utilization:                     
Medical Services  13,865 9,285 (9,044) 6,653 12,629 6,566 (7,751) 4,248 <.0001 <.0001 
Outpatient Pharmacy 5,296 3,356 (1,993) 2,899 4,606 2,307 (1,761) 1,578 <.0001 <.0001 
Total Overall 19,133 12,586 (9,991) 10,161 16,814 8,688 (7,896) 5,988 <.0001 <.0001 
Med, median; SD, standard deviation 
* Wilcoxon rank sum test for differences in distribution 
 
Table 86 highlights that using either method for comparing the costs – 
unweighted or weighted, COPD-related costs for the study subjects who continue using 
triple therapy are substantially higher than those for patients who continue using 
ICS/LABA or LAMA.  Confidence intervals were not calculated for the weighted mean 
values, and so whether the weighted differences are significant cannot be assessed, but 
the P-values for the unweighted provide some approximation of the effect. Values for 
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Non-COPD costs seem to indicate that there is less evidence for stating the two groups 
differ for those costs. While the unweighted non-COPD medical services costs differ 
between the two groups, the weighted estimates are very similar. 
Weighted MSM Analysis 
In the MSM analysis, study subjects were allowed to switch therapies between 
time periods and consequently annual healthcare costs associated with therapy use cannot 
be easily estimated.  Instead healthcare costs were estimated by period based on therapy 
used at the beginning of the period.  Estimated cost models were similar to those for the 
ITT and As Protocol analyses.  PROC GENMOD was used specifying a gamma 
distribution and a log link.  The stabilized weights were used and a model was 
constructed that included all the same covariates as the ITT and As Protocol analysis as 
well as one that only included sex, age and Medicaid insurance coverage.   
Summarized in Table 87 are the model parameter estimates for the intercept and 
for the effect of triple therapy for the ITT, As Protocol and MSM models with all the 
same covariates. Parameter estimates were converted using the exponential function.  The 
model uses a log link function and is a multiplicative model.  Therefore the intercept 
represents a base cost value upon which the factors in the model have a multiplier effect.  
The ITT and As Protocol were for the same four-week periods. For the MSM analysis the 
first year post-index was divided into 5 time periods; the first was 12 weeks, but the 
second time period was 6 weeks, and the third, fourth and fifth periods were 8, 12, and 14 
weeks respectively (Table 66).  
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Table 87 Comparison of Mean Cost Effect Estimates, ITT, As Protocol, MSM 
 
ITT - Unweighted As Protocol - Unweighted MSM  Sample 
Weeks 
post-
index 
Intercept 
(Base Cost , $) 
Effect of Index 
Triple Therapy 
Intercept 
(Base Cost , $) 
Effect of Index 
Triple Therapy 
Intercept 
(Base Cost, $) 
Effect of 
Beginning   
Period  with 
Triple Therapy 
4 684 (586, 799) 1.33 (1.21, 1.46) 327 (280, 382) 1.35 (1.22, 1.48) 
  
8 615 (523, 723) 1.31 (1.19, 1.45) 193 (165, 226) 1.45 (1.32, 1.59) 
  
12 745 (633, 878) 1.03 (0.94, 1.14) 169 (144, 199) 1.53 (1.39, 1.69) 778 (638, 948) 1.32 (1.19, 1.47) 
16 571 (485, 672) 1.29 (1.17, 1.42) 210 (170, 260) 1.29 (1.15, 1.44) 
315 (254, 390) 1.32 (1.18, 1.47) 
20 690 (586, 812) 1.45 (1.31, 1.61) 203 (162, 253) 1.31 (1.16, 1.47) 
  24 544 (461, 642) 0.99 (0.90, 1.09) 202 (159, 258) 1.26 (1.11, 1.43) 
410 (321, 522) 1.27 (1.14, 1.42) 
28 516 (435, 611) 1.37 (1.23, 1.52) 196 (151, 256) 1.46 (1.25, 1.70) 
  32 480 (405, 569) 1.25 (1.12, 1.39) 206 (155, 275) 1.34 (1.14, 1.57) 
  36 670 (567, 791) 0.97 (0.87, 1.07) 268 (199, 361) 1.30 (1.10, 1.53) 
699 (528, 926) 1.27 (1.12, 1.45) 
40 519 (434, 622) 1.01 (0.90, 1.12) 212 (155, 291) 1.43 (1.19, 1.72) 
  44 675 (565, 806) 0.95 (0.85, 1.05) 200 (144, 279) 1.35 (1.12, 1.63) 
  48 634 (532, 757) 1.12 (1.01, 1.25) 240 (170, 338) 1.42 (1.17, 1.74) 
  52 577 (481, 692) 1.06 (0.94, 1.18) 249 (173, 358) 1.38 (1.12, 1.69) 724 (520, 1,009) 1.30 (1.13, 1.50) 
  
The sum of the intercept values for the 52 weeks in the ITT model is $7,922, for 
the As Protocol model, $2,877, and for the MSM model, $2,926.  For the one-year 
period, the mean total costs if only the intercept and triple therapy factor are considered 
are $9,193 for the ITT model, $3,937 for the As Protocol, and $3,796 for the MSM 
model. Discontinuation of therapy in the As Protocol and MSM models could be related 
to other adverse non-COPD related events that impact COPD patients. 
For the impact of triple therapy on costs the effect estimates for the As Protocol 
and MSM models were similar, with a sustained association between triple therapy and 
higher costs.  In the ITT model, the effect of triple therapy in the latter part of the first 
year is minimal since everyone is still included in the analysis whether or not they still 
have evidence of use of ICS/LABA and/or LAMA. 
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CHAPTER 5 DISCUSSION 
Chapter 5 
Discussion 
In this chapter findings from the results presented in Chapter 4 are discussed 
starting with an overall summary of the results and then followed by a discussion of the 
results for each study aim.  After highlighting study limitations and strengths, the 
implications of results from study analyses for future research will be reviewed and 
finally a summary of conclusions drawn from the study. 
Summary 
The goal of this research was to develop better methods for describing the 
effectiveness of COPD treatment in the general population.  In specific this study sought 
to assess the usefulness of a MSM approach in managing inherent bias that may be 
present in a retrospective observational study due to confounding by indication and due 
to confounding by time-varying covariates related to both treatment changes post-index 
and to the outcome of interest.  This study compared results from three different methods 
of assessing treatment effectiveness of triple therapy to individual use of the components 
of triple therapy, the LAMA bronchodilator tiotropium or an ICS/LABA combination 
inhaler. Treatment post-index was considered differently in the three methods, with 
treatment considered under an ITT approach, an As Protocol approach, and an As Treated 
that utilized a MSM approach incorporating time-varying covariates.   
In the end all three approaches offered some insight into treatment effectiveness 
analyses for COPD patients that include ICS/LABA and/or LAMA. Contrary to results 
from the two prior retrospective observational treatment effectiveness studies, in this 
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study sample triple therapy was not more effective than use of either ICS/LABA or 
LAMA in reducing the risk of severe exacerbation. There was no significant difference in 
estimated risk of severe exacerbation for patients using triple therapy in comparison to 
patients using ICS/LABA or LAMA using either the As Protocol or the MSM approach 
(As Protocol HR 1.00, 95% CI 0.73 to 1.36; MSM HR 1.11, 95% CI 0.68 to 1.81).  Use 
of triple therapy however was associated with a marginally significant higher estimate for 
severe exacerbation risk in the 24 month period following treatment initiation in the ITT 
analysis (HR=1.24, 95% CI 1.00 to 1.53). While the ITT estimate was from a regression 
analysis that included covariates for baseline differences between triple therapy and 
ICS/LABA or LAMA treatment groups, it is highly likely that the estimate is misleading.  
The lower estimate found in the As Protocol and MSM analyses suggest that the ITT risk 
estimate may be biased by inclusion of events for study subjects who had discontinued 
use of ICS/LABA or LAMA, as over 50% of the study subjects had discontinued use of 
one or both of these treatments by six months post-index (36%, triple therapy and 55%, 
ICS/LABA or LAMA). The differences in effect estimates between the ITT and As 
Protocol analyses highlight that discontinuation of treatment post-index is an important 
consideration when assessing treatment effectiveness.   
The main reason for use of the MSM approach in this study was the belief that 
there were intermediate events that were confounders for both treatment choices and risk 
of a severe exacerbation event. The impact of the potential confounders (moderate 
exacerbation events, use of SABA and inpatient stays with a secondary diagnosis that 
was COPD-related) were considered by incorporating the effect of these through the 
stabilized weights in the MSM analysis.  SABA use was found to have the strongest 
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associations with use of triple therapy and with continuation of treatment. Having some 
SABA use in a prior period was significantly associated with use of triple therapy at the 
beginning of all follow-up time periods (P<0.05), and having SABA use during a period 
was significantly associated with continued use of ICS/LABA and/or LAMA in that time 
period for all time periods (P<0.0001). Moderate exacerbations on the other hand were 
only found to be significantly associated with triple therapy use during the follow-up 
period, not with continued use of treatment. Study subjects using triple therapy at the 
beginning of each time interval were more likely to have had moderate exacerbations in 
the prior period, and moderate exacerbations were associated with a greater likelihood of 
continuation of use of ICS/LABA and/or LAMA in the first 12 weeks post-index, but in 
later time periods there was no significant association between moderate exacerbations 
and discontinuation of ICS/LABA and/or LAMA.  An inpatient stay with a secondary 
diagnosis that was COPD-related during the first 12 weeks post-index was significantly 
associated with continuation of treatment during the first 12 weeks (P<0.05), but for later 
periods was weakly associated with discontinuation of treatment (P<0.10).  For subjects 
included in this dataset, the relationship between moderate exacerbations as and treatment 
choice was not as strong as the relationship between SABA use and treatment choice, a 
finding that was unexpected.  
Baseline period use of SABA that was more than 40% of the baseline period was 
significantly associated with higher severe exacerbation risk in the ITT analysis and 
marginally associated in the As Protocol and MSM analyses (P<0.10). Baseline period 
moderate exacerbations were not found to be significantly associated with severe 
exacerbation risk in either the ITT or As Protocol analyses, but having had a moderate 
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exacerbation in the 2-week period leading up to the index date was marginally associated 
with higher risk in the MSM analysis (P=0.07).  Not finding a more significant 
association between moderate exacerbations and severe exacerbation risk could be due to 
the moderate exacerbation measure used in the study.  Mild exacerbation events were not 
considered in the study and there may have been moderate exacerbation events that were 
not captured because they did not result in an outpatient pharmacy prescription claim.  
Identification of exacerbation events and factors related to exacerbation events is an 
active area of COPD research and this study provides additional support that better 
measures of capturing events and factors significantly associated with severe 
exacerbation events are needed. 
In the end all three approaches offered some insight into treatment effectiveness 
analyses for COPD patients that include ICS/LABA and/or LAMA. Contrary to results 
from the two prior retrospective observational treatment effectiveness studies, in this 
study sample triple therapy was not more effective than use of either ICS/LABA or 
LAMA in reducing the risk of severe exacerbation. There was no significant difference in 
estimated risk of severe exacerbation for patients using triple therapy in comparison to 
patients using ICS/LABA or LAMA using either the As Protocol or the MSM approach 
(As Protocol HR=1.00, 95% CI 0.73 to 1.36; MSM HR=1.11, 95% CI 0.68 to 1.81).  Use 
of triple therapy however was associated with a marginally significant higher estimate for 
severe exacerbation risk in the 24 month period following treatment initiation in the ITT 
analysis (HR=1.24, 95% CI 1.00 to 1.53). While the ITT estimate was from a regression 
analysis that included covariates for baseline differences between triple therapy and 
ICS/LABA or LAMA treatment groups, it is highly likely that the estimate is misleading.  
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The lower estimate found in the As Protocol and MSM analyses suggest that the ITT risk 
estimate may be biased by inclusion of events for study subjects who had discontinued 
use of ICS/LABA or LAMA, as over 50% of the study subjects had discontinued use of 
one or both of these treatments by six months post-index (36%, triple therapy and 55%, 
ICS/LABA or LAMA). The differences in effect estimates between the ITT and As 
Protocol analyses highlight that discontinuation of treatment post-index is an important 
consideration when assessing treatment effectiveness.   
The main reason for use of the MSM approach in this study was the belief that 
there were intermediate events that were confounders for both treatment choices and risk 
of a severe exacerbation event. The impacts of the potential confounders (moderate 
exacerbation events, use of SABA and inpatient stays with a secondary diagnosis that 
was COPD-related) were considered by incorporating the effect of these through the 
stabilized weights in the MSM analysis.  SABA use was found to have the strongest 
associations with use of triple therapy and with continuation of treatment. Having some 
SABA use in a prior period was significantly associated with use of triple therapy at the 
beginning of all follow-up time periods (P<0.05), and having SABA use during a period 
was significantly associated with continued use of ICS/LABA and/or LAMA in that time 
period for all time periods (P<0.0001). Moderate exacerbations on the other hand were 
only found to be significantly associated with triple therapy use during the follow-up 
period, not with continued use of treatment. Study subjects using triple therapy at the 
beginning of each time interval were more likely to have had moderate exacerbations in 
the prior period, and moderate exacerbations were associated with a greater likelihood of 
continuation of use of ICS/LABA and/or LAMA in the first 12 weeks post-index, but in 
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later time periods there was no significant association between moderate exacerbations 
and discontinuation of ICS/LABA and/or LAMA.  An inpatient stay with a secondary 
diagnosis that was COPD-related during the first 12 weeks post-index was significantly 
associated with continuation of treatment during the first 12 weeks (P<0.05), but for later 
periods was weakly associated with discontinuation of treatment (P<0.10).  For subjects 
included in this dataset, the relationship between moderate exacerbations as and treatment 
choice was not as strong as the relationship between SABA use and treatment choice, a 
finding that was unexpected.  
Baseline period use of SABA that was more than 40% of the baseline period was 
significantly associated with higher severe exacerbation risk in the ITT analysis and 
marginally associated in the As Protocol and MSM analyses (P<0.10). Baseline period 
moderate exacerbations were not found to be significantly associated with severe 
exacerbation risk in either the ITT or As Protocol analyses, but having had a moderate 
exacerbation in the 2-week period leading up to the index date was marginally associated 
with higher risk in the MSM analysis (P=0.07).  Not finding a more significant 
association between moderate exacerbations and severe exacerbation risk could be due to 
the moderate exacerbation measure used in the study.  Mild exacerbation events were not 
considered in the study and there may have been moderate exacerbation events that were 
not captured because they did not result in an outpatient pharmacy prescription claim.  
Identification of exacerbation events and factors related to exacerbation events is an 
active area of COPD research and this study provides additional support that better 
measures of capturing events and factors significantly associated with severe 
exacerbation events are needed. 
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Table 88summarizes the three analysis approaches used in this research study.  
An MSM approach is best appreciated  in situations that have 1) numerous time-varying 
covariates (Cole and Hernan 2004), 2) when there is evidence of strong confounding by 
time-dependent covariates, and 3) past treatment has a sizable effect on the covariates 
(Hernan et al. 2008). In our study sample there was substantial discontinuation of 
treatment, and there was some switching from subjects in the triple therapy group to the 
ICS/LABA or LAMA group, but there was minimal switching of study subjects from the 
ICS/LABA or LAMA group to the triple therapy group.  It may be that an MSM 
approach offers more benefit when there is more movement between treatment groups 
than was present in this study.  In addition, treatment choice in this study was a binary 
option – triple therapy, or ICS/LABA or LAMA. Discontinuation of therapy was 
considered a censoring event.   Use of a multinomial treatment model (more than two 
treatment choices), with inclusion of “no treatment” as an option, may have provided 
even more insight into factors related to both treatment choice and outcome events. 
Future research should explore the potential for using a multinomial treatment probability 
model that includes no treatment as an option instead of the binary treatment choice used 
in this analysis.  
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Table 88 Summary of Analysis Approach Features 
 
Comparison groups 
Limiting criteria for 
inclusion in analyses Comments on Use 
ITT 
approach 
Treatment at Index None 
Minimal loss to follow-up, or 
movement between treatment 
groups; Minimal confounding by 
factors related to both post-index 
treatment choices and measured 
outcomes 
As 
Protocol 
Treatment at Index 
Continuation of index 
treatment 
Minimal confounding by factors 
related to both post-index 
treatment choices and measured 
outcomes 
MSM 
Analysis 
Treatments as chosen 
during follow-up – 
allows for switching 
between treatment 
groups 
Dependent on analyses; 
discontinuation could be 
considered a treatment 
choice, or it could be a 
reason for censoring 
Confounding exists from factors 
related to both post-index 
treatment choices and measured 
outcomes; best suited for study 
samples where there is substantial 
movement between treatment 
groups.   
 
Discussion of the Results 
Prior to conducting analyses related to the study aims, extensive reviews of the 
data were conducted.  As a result of these reviews there were two re-pulls of data from 
one health plan, with each re-pull resulting in a more complete capture of its COPD 
population and their healthcare utilization. Ultimately data for 7.25 years was included 
from that health plan, which contributed 1,876 study subjects, and data for 8.25 years was 
included from the second health plan, which contributed 3,599 study subjects.   
For the two health plans there were approximately 48,000 patients with at least 
one COPD diagnosis code in their claims history, and of these, slightly less than 9,000 
were identified who had a prescription for ICS/LABA or LAMA during the time period 
July 1, 2005 through March 31, 2012.  After further review for age, enrollment and other 
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inclusion criteria, 5,475 patients were included in the study sample (484 with triple 
therapy use, 3052 with ICS/LABA use and 1,939 with LAMA use) 
Aim 1 
Analyses for Aim 1 reviewed the baseline characteristics associated with three 
measures: 1) index use of ICS/LABA, LAMA or triple therapy, 2) discontinuation of any 
index therapy, and 3) switching between index therapies. In both health plans the 
percentage of patients identified in the triple therapy group was approximately 9% of the 
health plan sample.   
Index Treatment 
The main finding from comparisons of index treatment groups in Aim 1 is that 
among the variables considered in the analyses there were only a small number of 
individual factors that were strongly associated with receipt of triple therapy at index in 
comparison to ICS/LABA or LAMA at the index date. Baseline factors among patients 
that were the most strongly associated with receipt of triple therapy at index (all with 
P<0.0001) were a diagnosis of hypoxemia or emphysema, having an overall measure of 
COPD complexity other than low, having had a spirometry procedure in the baseline 
period, having been discharged from a severe exacerbation in the two weeks leading up 
to the index date, or having had any hospitalization with a primary or secondary COPD-
related diagnosis code in the baseline period.  Absolute percentage differences between 
the two index treatment groups for these factors however were not that large. The largest 
percentage difference was 14%, for hypoxemia and low COPD complexity. C-statistics 
for the baseline probability models were also low (<0.70). 
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Otherwise, triple therapy patients were more likely to be male, and while overall 
there was no age difference between the triple therapy and ICS/LABA or LAMA groups, 
there was a higher percentage of patients age 55-64 in the triple therapy group.  With 
regard to baseline use of COPD medications, study subjects in the triple therapy index 
group were more likely in the baseline period to have had frequent SABA use, or any use 
of SAMA or SABA/SAMA medications, more likely to have had oxygen use or nebulizer 
use, and less likely to have had ICS use. A greater percentage of subjects in the triple 
therapy index group in the baseline period had evidence of dyspnea symptoms but there 
were no differences between those in the triple therapy group and those in the ICS/LABA 
or LAMA with regard to baseline moderate exacerbations. 
As a comparison study sample, the IMS LifeLink Health Plans Claims Database 
based study sample in the retrospective analysis by Chatterjee and colleagues (Chatterjee 
et al. 2012), comprised 3,333 patients (852 with use of the ICS/LABA combination 
therapy [fluticasone-salmeterol] in conjunction with LAMA therapy, and 2,481 with 
LAMA use). This study sample was identified from a population of 85,153 patients with 
at least one prescription for LAMA in the time period January 1, 2004 through March 30, 
2008.  The study sample is not directly comparable since that study additionally required 
study subjects to have evidence in the 12-month pre-index period of at least one COPD-
related exacerbation event and at least one prescription claim for SAMA and/or 
SABA/SAMA, and post-index to have at least two prescription claims for LAMA. 
Despite these additional requirements though this study population was similar to our 
study sample in that the triple therapy patients were more likely to be younger (64.6 years 
compared to 66.1 years, P=0.0008) and to have had a baseline period hospital visit for 
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COPD (26.8% compared to 18.8%, P<0.0001; and in our study 27.7% for triple 
compared to 19.7% for ICS/LABA or LAMA). But in the Chatterjee study, triple therapy 
patients were more likely to have asthma (38.4% compared to 30.5%, P<0.0001), to have 
higher Charlson index (mean 1.28 compared to 1.91, P=0.002), and additionally the mean 
number of SABA canisters, OCS prescriptions, and SABA/SAMA canisters, were all 
lower among patients in the triple therapy group compared to the LAMA group 
(Chatterjee et al. 2012) – all associations that were reversed in direction for our study 
between the triple therapy group and the ICS/LABA or LAMA group. 
Disparities in LAMA use by severity of disease were highlighted by Hernandez 
and colleagues in 2006 and 2007 when they surveyed 437 patients with COPD about their 
knowledge and attitudes about their disease. Figure 18 is a summary of findings from that 
study with regard to use of prescribed LAMA or ICS/LABA medications.  Of note is that 
while for the Medical Research Council scales <5, LAMA was less used than 
ICS/LABA; for the most severe score 5, LAMA was used by a higher percentage of 
patients than ICS/LABA. 
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Figure 18 Relationship Between Drug Therapy and Symptom Severity, Hernandez et al. 
 
MRC, Medical Research Council 
 
The study sample in the other retrospective analysis by Short and colleagues 
drawn from a United Kingdom population is difficult to compare to our study sample 
(Short et al. 2012).  All patients in that analysis were required to have had a spirometry 
procedure to be included in the analysis, and other than cardiovascular disease and 
diabetes, no other baseline characteristics were measured.  The study compared patients 
using triple therapy to patients using ICS/LABA. The triple therapy group was more 
severe as measured by spirometry and pulse oximetry, and there was a slightly higher 
percentage of cardiovascular disease among the patients using triple therapy (47.1% 
compared to 43.1%, no P-value stated). Oddly the triple therapy patient group was twice 
the size of the ICS/LABA group, making one wonder if that was due to the spirometry 
requirement, and whether the triple therapy group was a symptomatically more severe 
group. 
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Discontinuation of Therapy 
Discontinuation was defined as the point at which a study subject had no days 
supply for ICS/LABA or LAMA.  In calculating days supply, study subjects were 
considered to have a days supply that was twice the actual days supply, so an allowance 
had already been made for less than optimal use of the medications. Patients may have 
had a claim for one of the index therapies after that point, but they were still counted as 
having discontinued medication. A more generous allowance for days supply was not 
considered as that would have introduced even more heterogeneity in the study as use of 
the treatment medications could have varied from 1/3 of the time to 100% of the time. 
Among patients in the study sample a sizable percentage of patients (37.8%) by 
three months no longer had evidence of using ICS/LABA or LAMA based on 
prescription claims data. Among the triple therapy patients 19.8% (96 out of 484) had 
discontinued any use, while 39.6% of the ICS/LABA or LAMA group had discontinued 
use (43.3% of those with ICS/LABA and 33.8% of those with LAMA). By six months 
53.5% of the study sample had discontinued use – 35.7% of the triple therapy group (173 
out of 484) and 55.3% of the ICS/LABA or LAMA group (49.9% of those with 
ICS/LABA and 58.7% of those with LAMA).  
The factors most strongly associated with continuation of treatment (P<0.0001) at 
three months were having a baseline diagnosis of emphysema, having a spirometry 
procedure in the baseline period and not having any baseline period symptoms related  to 
chest pain. By six months those same factors were still strongly associated with 
continuation of treatment, and additionally there were the following factors: being 40 to 
54 years of age, and having days supply for SABA that was greater than 40% of the 
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baseline period.  There was also a difference between the two health plan samples, with 
patients in one health plan being less likely to discontinue therapy compared to patients in 
the other health plan. Discontinuation at three months was higher among those with 
Medicaid insurance coverage (42.4% compared to 37.8% overall). 
Otherwise, patients who discontinued use tended to be those with comorbidities. 
Discontinuation by three months was associated with having baseline diabetes, ischemic 
heart disease, depression, deficiency anemias, and pneumonia. At six months having 
rheumatoid/osteo-arthritis was also weakly associated with discontinuation, as was 
having neurological disorders and having had influenza. SABA use had a kind of U-
relationship, with patients who had no SABA use or those who had frequent use being 
more likely to continue therapy and those with some SABA use more likely to 
discontinue.   
Factors associated with COPD severity had mixed associations with COPD 
treatment. Hypoxemia was associated with continuation of one of the index treatments. 
But then a moderate or severe exacerbation in the two weeks leading up to the index date, 
or having had an inpatient stay with a COPD-related diagnosis as a secondary diagnosis 
was associated with discontinuation at three months. Overall, having had any inpatient 
stay in the baseline period was associated with discontinuation of therapy.  
In this population, discontinuation was less among the triple therapy index group. 
It is interesting to note that in the OPTIMAL randomized trial, a one-year trial comparing 
LAMA+placebo, LAMA+LABA, or LAMA+ICS/LABA (fluticasone-salmeterol) among 
moderate or severe COPD patients, withdrawal was also the lowest in the triple therapy 
arm.  In the OTPIMAL triple therapy arm 26% withdrew from the study before the end of 
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one year compared to 47% in the LAMA+placebo arm, and 43% in the LAMA+LABA 
arm.  Among those withdrawing, approximately 58% of each of the LAMA+placebo and 
LAMA+LABA arms withdrew because of “patient perception of worsening COPD” 
compared to 40% in the triple therapy arm (Aaron et al. 2007).  
 Health status also appeared to be a potential factor in early withdrawal in the 
INSPIRE randomized trial comparing ICS/LABA and LAMA over a two-year period 
(Wedzicha et al. 2008).  Patients in both arms who withdrew had higher scores on the St. 
George’s Respiratory Questionnaire, indicating more limitations associated with COPD 
disease.  In that study, by 13 weeks there was a differential in withdrawal rates between 
patients randomized to LAMA and those to ICS/LABA that persisted through the 104 
weeks of the study. By 13 weeks the withdrawal rate among LAMA users was 
approximately 17% compared to 14% among ICS/LABA users, by 26 weeks the 
percentages were approximately 23% and 18%, respectively.   
In comparison to the INSPIRE trial in which patients using ICS/LABA had better 
persistence than LAMA, other retrospective studies have found higher rates of treatment 
persistence among COPD patients using LAMA in comparison to ICS/LABA.  Cramer 
and colleagues reviewed one-year use of COPD medications among a population of 
31,368 Canadian patients and found that by 6 months 63% of LAMA users were still 
continuing, whereas the percentage for the ICS/LABA fluticasone-salmeterol was closer 
to 43%  (Cramer et al. 2007). Approximately one-half of the study patients were on 
LAMA medication, and about one-sixth were on fluticasone- salmeterol. Patients using 
LAMA were also older than those on the ICS/LABA fluticasone- salmeterol (73.6 
compared to 68.7 years of age). The study did not appear to consider disease severity, not 
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did it consider medication cost as a factor.  A Netherlands study similarly found higher 
persistence rates for LAMA users (25%) compared to ICS/LABA combination therapy 
(14%) (Penning-van Bees et al. 2011). 
Identification of factors related to adherence among COPD patients is an area that 
has been understudied, primarily because of a lack of informative data that includes 
measures of disease severity.  However a reanalysis of data from the TORCH trial, a 
three-year study comparing use four treatment arms: a placebo arm, and then arms for use 
of the ICS/LABA fluticasone-salmeterol and each component, did find some interesting 
results.  Surprisingly, the percentage of patients adherent to their randomized treatment 
was similar in all treatment arms – even the placebo arm, with approximately 80% of 
study subjects having an adherence percentage of >80% (Vestbo et al. 2009).  There was 
no association between lung function impairment, but a higher percentage of study 
subjects with poor adherence had responded in the affirmative to the Medical Research 
Council dyspnea scale statements “I stop for breath after walking about 100 yards or after 
a few minutes on the level” or “I am too breathless to leave the house or I am breathless 
when dressing or undressing” (Vestbo et al. 2009).  Mortality and severe exacerbation 
rates were similar across all four treatment arms for patients with good and poor 
adherence.  The three-year admission rates for adherent patients in the LABA, ICS, 
ICS/LABA and placebo arms were 0.14, 0.15, 0.14, and 0.16  respectively, while for 
patients with poor adherence the rates were 0.26, 0.26, 0.25, and 0.36 respectively 
(Vestbo et al. 2009).  The authors posited that this observed “healthy adherer effect” may 
be the result of patients identified as good adherers being better at recognizing 
exacerbations early and in general being more pro-active about their health. 
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A 2005 study by Johnson and colleagues using a purposive sample of COPD 
patients in Australia found that adherent patients had greater understanding about their 
illness and the options for managing illness, and that patients reporting suboptimal 
adherence found their medications to be more physically challenging and tended to be 
less satisfied with their treating physician (George et al. 2005). Medication cost was not a 
identified as a significant factor, but in Australia prescription medications are subsidized. 
As opposed to a clinical trial, economic factors may also have influenced whether 
patients in our study sample continued with medications, or how frequently they refilled 
prescriptions. Cost for the COPD treatments in this study are fairly substantial and even 
with insurance paying for some of the medication, the co-pay amounts could be 
prohibitive for some patients, particularly if they have multiple conditions that require 
pharmaceutical treatment.  Affordability of medications is a factor in McHorney’s brief 
adherence estimator (McHorney 2009). But it has also been demonstrated that patients 
will continue to pay for medications they otherwise might not be able to afford if they 
perceive the medication is important, or discontinue medications they can afford if the 
perceived value of the medication is low (Piette et al. 2011). Unfortunately our data did 
not include any information that would allow us to measure these aspects of patient 
choice. 
Treatment Switching 
The percentage of patients switching treatment therapies was small, 9% of study 
subjects who did not discontinue ICS/LABA or LAMA had switched to an alternative 
index treatment group by three months (6% of the total sample of 5,475), and 12% by six 
months.  The low percentage may also be an artifact of not following patients once they 
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discontinued any use of ICS/LABA or LAMA medications.  Cramer and colleagues in 
their review of use of COPD medications in a Canadian population found that most 
patients switched or added another drug in the first six months of their study and felt that 
this reflected a global dissatisfaction with the efficacy of the index drug (Cramer et al. 
2007).  
In our study patients who switched therapies by six months were more likely to 
not have a low level of COPD complexity (P=0.006), to have had some dyspnea 
symptoms in the baseline period (P=0.008), or to have been discharged from a severe 
exacerbation in the two weeks pre-index (P=0.0002). They were also more likely to have 
Commercial insurance and less likely to have Medicaid insurance.   
Patients who were in the triple therapy index group were more likely to switch 
than patients in the ICS/LABA or LAMA group, but then patients in the triple therapy 
group had to have days supply for two medications to remain in the triple therapy group 
as opposed to just one medication for the ICS/LABA or LAMA group.   
The switching analysis did not distinguish between study subjects who were 
“stepping down” therapy (triple to ICS/LABA or LAMA) versus subjects who were 
“stepping up” therapy (ICS/LABA or LAMA to triple) and this may be why so few 
factors were identified with switching. 
Aim 2 
Aim2 included analyses both for severe exacerbations and for having any 
moderate or severe exacerbation. 
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Severe Exacerbations 
Severe exacerbations by three months and by six months were examined using 
both the full study sample, and a reduced sample of study subjects who had not 
discontinued use of ICS/LABA or LAMA.  For the most part baseline factors that were 
significantly associated with having a severe exacerbation were consistent across all four 
analyses, however there were some differences between the three and six month analyses, 
while there were few differences between analyses with the full and reduced samples at 
the two time points. 
As expected, having any baseline period inpatient stay was strongly associated 
with having a severe exacerbation.  At three months, among those with a severe 
exacerbation, 53.4% compared to 30.2% of those not having a severe exacerbation had at 
least one baseline period inpatient stay.  Percentages were almost identical in the reduced 
sample of study subjects who had not discontinued therapy. At six months the 
percentages were similar – 53.7% compared to 29.3%, and again, among those who had 
not discontinued therapy (2,544 out of 5,475), the percentages were almost unchanged – 
51.0% compared to 26.7%.  Other factors strongly associated (P<0.0001) with having a 
severe exacerbation in all analyses included: pneumonia history, having baseline use of 
SAMA or SABA/SAMA therapies, having any baseline report of dyspnea to include 
shortness of breath, and in particular, more than one incidence of shortness of breath, and 
having been discharged from a severe exacerbation in the two week period leading up to 
the index date. 
Factors that were found in all analyses to be significantly associated with having a 
severe exacerbation at an alpha level of 0.01 or less included: having Medicaid insurance; 
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comorbidities of: heart failure or congestive heart failure, chronic blood loss anemia, 
fluid and electrolyte disorders, valvular disease, asthma, and hypoxemia; having a days 
supply for SABA that was >40% of the baseline period; having some use of oxygen or 
any nebulizer treatment in the baseline period; having baseline symptoms of 
breathlessness, any chest pain, or other malaise/fatigue; having an EKG in the baseline 
period;  and having a moderate or severe exacerbation in the 3-12 weeks prior to the 
index date. Atrial fibrillation and valvular disease were significantly (P<0.01) identified 
with severe exacerbation by three months – but were not as significantly associated later 
at six months.  
Only a few differences were found between the full and reduced samples.  
Pulmonary circulation disease was associated with having a severe exacerbation at six 
months in the full sample (P=0.02), but no other analyses, and having spirometry in the 
baseline period was associated with not having a severe exacerbation by six months in the 
reduced sample (P=0.02), but a significant association was not found in other analyses. 
The percentage of patients in the full sample having a severe exacerbation at three 
and six months was 2.7% and 6.4% respectively (Table 89).  For the reduced sample the 
percentages were 4.3% and 10.2% respectively. Triple therapy at index was significantly 
associated with having a severe exacerbation at three and six months for the full sample 
(P=0.04 and P=0.02 respectively), but not for the reduced sample (P=0.37 and P=0.29, 
respectively).  The study focused on the comparison between triple therapy patients and 
patients who used either of those medications alone, but it is interesting to note that in 
this study sample the lowest percentages for severe exacerbation in analyses were for 
patients in the LAMA group.  In analyses without individuals who discontinued therapy, 
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the percentages of triple therapy subjects having a severe exacerbation were similar to 
those for subjects using ICS/LABA at index.  
Table 89 Severe Exacerbations by Index Therapy 
 
Full Sample  Without Discontinuation 
 
  
Severe 
Exacerbation   Severe Exacerbation 
At 3 months: 
All 
Subjects N % 
All 
Subjects N % 
All Subjects 5475 146 2.7% 3403 146 4.3% 
Triple 484 20 4.1% 388 20 5.2% 
ICS/LABA or LAMA 4991 126 2.5% 3015 126 4.2% 
ICS/LABA 3052 85 2.8% 1731 85 4.9% 
LAMA 1939 41 2.1% 1284 41 3.2% 
At 6 months:             
All Subjects 5475 352 6.4% 2544 259 10.2% 
Triple 484 43 8.9% 311 37 11.9% 
ICS/LABA or LAMA 4991 309 6.2% 2233 222 9.9% 
ICS/LABA 3052 205 6.7% 1261 144 11.4% 
LAMA 1939 104 5.4% 972 78 8.0% 
 
In the baseline period LAMA patients also had the lowest percentages for severe 
exacerbations immediately preceding the index date, 3-12 weeks prior to the index date 
and 13-52 weeks prior to the index date ( Table 18).  LAMA patients also had the lowest 
percentages for any non-COPD inpatient stay, any COPD-related inpatient stay (17.1% 
compared to 27.7%) or any inpatient stay overall.  The percentages of ICS/LABA 
patients who had a severe exacerbation were higher than those for LAMA patients, 
however they were still significantly lower than those for triple therapy patients – at least 
for the period immediately preceding the index date, and 2-12 weeks prior (and 
marginally significantly lower for the period 13-52 weeks prior). The percentage of 
ICS/LABA study subjects having any COPD-related inpatient stay was also significantly 
lower than that for triple therapy patients (21.3% compared to 27.7%). 
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It is interesting that note that in the study by Chatterjee and colleagues comparing 
use of triple therapy to use of LAMA alone among patients who had at least one 
exacerbation in the baseline period and who had at least two prescription claims for the 
index treatment, these patterns were reversed. In that study the LAMA group had the 
higher percentage of baseline COPD-related hospitalizations (26.8% compared to 18.8% 
for the triple therapy group, P<0.0001). Rates for the follow-up period were stated as 
person-years (follow-up varied from 31 days to one year), and so are not directly 
comparable, but are similar. The percentage of study subjects who had any severe 
exacerbation in the one-year follow-up period was 7.9% for the LAMA group and 5.1% 
for the triple therapy group; for any COPD-related hospitalization, 11.1% for the LAMA 
group and 7.4% for the triple therapy group. It is striking how similar these percentages 
are to those observed in this study – but that the treatment groups are reversed.  An 
adjusted regression analysis for the risk of severe exacerbation that included baseline 
covariates found a lower hazard ratio for triple therapy (HR=0.62), but it was not 
significantly lower (P=0.15).  This suggests that selection criteria and model construction 
can substantially affect the apparent treatment benefits, and illustrates the importance of 
developing better analysis methods that reduce this type of bias. 
Any Moderate or Severe Exacerbation 
Table 90 summarizes the percentage of study subjects by index therapy that had 
any moderate or severe exacerbation at three months and at six months by the full 
sample, and the reduced sample of those who did not discontinue therapy.  As in the 
summary of severe exacerbations, in the reduced sample the percentages are higher. 
Those higher numbers could be because study subjects did not incur events prior to 
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discontinuing, and discontinuation was related to factors other than exacerbations, or be 
due to the abbreviated period for those discontinuing, or be a combination of both factors.  
Table 90 Any Moderate or Severe Exacerbation, by Index Therapy 
 
Full Sample  Without Discontinuation 
 
  Mod/Sev Exacerbation   Mod/Sev Exacerbation 
At 3 months: Subjects N % 
 
N % 
All Subjects 5475 656 12.0% 3403 482 14.2% 
Triple 484 74 15.3% 388 65 16.8% 
ICS/LABA or LAMA 4991 582 11.7% 3015 417 13.8% 
ICS/LABA 3052 376 12.3% 1731 258 14.9% 
LAMA 1939 206 10.6% 1284 159 12.4% 
At 6 months:             
All Subjects 5475 1287 23.5% 2544 703 27.6% 
Triple 484 130 26.9% 311 95 30.5% 
ICS/LABA or LAMA 4991 1157 23.2% 2233 608 27.2% 
ICS/LABA 3052 749 24.5% 1261 377 29.9% 
LAMA 1939 408 21.0% 972 231 23.8% 
Mod/Sev, Any Moderate or Severe Exacerbation 
Percentages for the triple therapy group were again more similar to those for the 
ICS/LABA than for the LAMA group. The percentage of triple therapy patients was 
again higher in all analyses, but only significantly so for the full sample at three months 
(P=0.02), although marginally significant for the full sample at six months (P=0.07).  
As with the severe exacerbation analyses, analyses showed that having any 
moderate or severe exacerbation in the baseline period was strongly associated with 
having one in the follow-up period, in particular having had an exacerbation in the 2-12 
weeks or 13-52 weeks prior to the index date.  Other factors strongly associated 
(P<0.0001) with having any exacerbation in all analyses included: having pneumonia 
history, having baseline use of SABA/SAMA therapies or oxygen, and having any 
baseline report of dyspnea. 
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Again there were few if any differences in significant factors between the full 
sample and the reduced sample.  There were some differences between factors identified 
as significant for severe exacerbations and those for moderate however.  For example in 
the any exacerbation analysis, atrial fibrillation, ischemic heart disease, 
rheumatoid/osteo-arthritis, other neurological disorders, peripheral vascular disease, 
hypertension, and pulmonary circulation disease were not found to be significantly 
related in any of the analyses, whereas they were in the severe exacerbation analyses.  
Hypothyroidism and renal failure on the hand were significant in the any exacerbation 
analyses, but not in the severe exacerbation analyses. 
Several of the comorbidity factors found in the severe exacerbation analyses but 
not in the any exacerbation analyses relate to cardiovascular disease.  In 2003 the 
European Respiratory Journal published articles and a discussion from a symposium on 
COPD.  In one of the discussions Pierre Ernst, a pulmonologist and COPD researcher at 
McGill University at the time, commented that in observational studies he was 
“concerned about all the hospitalizations for heart failure, which are actually COPD, right 
heart failure, or cor pulmonale”; commenting that in his clinical experience “the 
diagnosis of heart failure is often made when it is actually COPD” (Burney et al. 2003).  
Many COPD studies now recognize this and include a primary diagnosis of heart failure 
along with a secondary COPD diagnosis as an indication of a severe COPD exacerbation, 
but cardiovascular disease continues to be a substantive confounder for adverse COPD 
events. 
Rabe and Wedzicha highlighted this issue in a recent article summarizing 
controversies in the treatment of COPD (Rabe and Wedzicha 2011). They posit that one 
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approach to improving outcomes for patients with COPD would be to focus on 
comorbidities that might modify the progression of COPD, such as cardiovascular and 
metabolic disorders. They reference studies that have shown for example that use of 
statins in conjunction with angiotensin-converting-enzyme inhibitors or angiotensin-
receptor blockers, and use of cardioselective beta-blockers may reduce the decline in 
pulmonary lung function and by helping to reduce the risk of myocardial infarction, may 
improve pulmonary outcomes for COPD patients.  This is an area for further research. 
Aim 3 
In Aim 3 the weights were estimated for the MSM model, which analyzed 
patients in the follow-up period as they were treated.  In most of the treatment 
effectiveness studies published using MSM models to date, there have been two 
treatment scenarios being evaluated.  A few studies have used multiple treatment 
scenarios to include the option for periods when no treatment is in evidence.  Including a 
no treatment group in this analysis would have been problematic for several reasons.  
One is the potentially large size this group would be in comparison to the treatment 
groups, another is the divergent reasons patients might discontinue therapy – ranging 
from mild disease and not perceiving a need for therapy to those with multiple 
comorbidities impacting their treatment for COPD.  The choice was made to model 
discontinuation as a censoring, but even this choice may not be optimal.  Gaining a better 
understanding about factors related to discontinuation of therapy is definitely an area in 
which more research is needed. 
The advantage of MSM methods is that all study subjects are retained thus 
reducing of selection bias and improving generalizability. In models that incorporate 
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propensity matching or propensity scores, the goal is to produce a study sample that is 
roughly equivalent in its probability for using treatment A (in the case of a two-treatment 
study – treatments A and B).  In propensity matched analyses, study subjects are matched 
on their probability for receipt of treatment A.  Excluded are those who can’t be matched 
– usually on the very high or low end of the propensity score; optimally few are 
excluded.  Another issue is when there is little overlap in the propensity for treatment 
between groups and few from each group are able to be matched. 
In the MSM approach, the intent is different.  Here weights are used to balance 
the entire population.  So that individuals with low likelihood of using treatment A (and 
theoretically higher likelihood of using treatment B) are given more weight, as are 
individuals with low likelihood of using treatment B.  The objective is to generate 
populations who did not use treatment A, but appeared to have the characteristics of those 
who did, and similarly, populations who did not use treatment B, but appeared to have the 
characteristics of those who did. If the weights and model are constructed well, there are 
no unmeasured confounders, and all study subjects have a positive probability of 
treatment, one should be able to make a determination about treatment effectiveness.  If 
no significant differences in treatment are found, an implication would be that all study 
subjects were treated optimally.  If there is a differential in outcomes between treatments 
in the weighted population, then the implication is that among study subjects who are 
equally likely to have received treatment A as opposed to treatment B, differences were 
observed between outcomes.   
Table 69 summarized baseline characteristics for the weighted population at 
index, comparing differences between the unweighted population and the weighted.  In 
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the weighted population there were few, if any differences between the two.  An issue 
however in this study was that almost all the triple therapy study subjects had a low 
probability for receiving triple therapy as opposed to ICS/LABA or LAMA.  Figure 9 
illustrated this in the form of histograms for probability of triple therapy in comparison to 
ICS/LABA or LAMA therapy. 
The MSM approach is fairly new and so there is little in the published literature 
that speaks to the issue of how well an MSM approach might work in the scenario of 
poor discrimination between treatment groups, although this may fall under the quality of 
the model specification and whether the assumption of no unmeasured confounders has 
been met.   
In the MSM approach, weights are based on conditional probabilities of 
treatment.  Inherent in a conditional probability is that prior probabilities are incorporated 
and consequently there is a multiplicative effect.  Because of this, weights over time can 
end up very large and usually stabilized weights are used.  Even so, the variance in the 
stabilized weights over time can increase, and with a large number of time intervals it is 
increasingly difficult to meet the requirement that the mean of weights should 
approximate 1.0 (Cole and Hernan 2008).  Another issue for constructing the weighted 
population was the determination of time periods for a longitudinal analysis.  It is known 
that as the time periods increase, the confidence intervals around the mean stabilized 
weight will also increase and thus may be increasingly difficult to meet the 1.0 mean 
requirement.  In our analysis, this was observed with the time periods for 6 and 7.   
Model building for the MSM approach is an intensive process and as discussed by 
Cole and Hernan incorporates as much “art” as science (Cole and Hernan 2008).  
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Methods for verifying models are still evolving, so it is useful to perform MSM analysis 
in conjunction with traditional methods. This study highlighted that the factors related to 
initial use of triple therapy and to use of triple therapy in later periods may differ, and 
similarly, factors may differ between initial discontinuation and later discontinuation – 
particularly when a sizable percentage discontinues therapy fairly soon after the index 
date and then the discontinuation rate levels off. 
Table 68 showed for example, that hypothyroidism may have been significantly 
associated with use of triple therapy at index, but it was not for later periods. Similarly, 
psychoses were significantly associated with not receiving triple therapy at index, but had 
no significant association later on, while pulmonary circulation disease and having had a 
spirometry procedure were significantly associated with triple therapy at index, but not 
later use of triple therapy. 
Subjects who did not have any SABA use in the baseline period were more likely 
to not discontinue use of ICS/LABA and/or LAMA in the first 12 weeks, as were subjects 
with high frequency of SABA use, but after that, SABA baseline use was not 
significantly associated with discontinuation – presumably because those study subjects 
with minimal use of SABA in the baseline period had discontinued therapy use.   
Spirometry is an interesting factor associated with a reduced risk of exacerbation 
during the follow-up period.  Inherently it is hard to imbue spirometry itself with 
protective properties, but evidence of spirometry points to several aspects of patient care 
– that the patient is being seen specifically for COPD, and that the patient probably has 
access to specialist care – as opposed to primary care, since spirometry is still mostly 
performed in pulmonology clinics in New Mexico.  Evidence of spirometry could be a 
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proxy for several patient characteristics and this attribute warrants further investigation.  
For example, spirometry could be a proxy variable for access to care, patient involvement 
in care, or even economic status.  
There are some relationships that were found that appear contradictory.  For 
example, for the first 12 weeks post-index, the baseline covariate of having a moderate or 
severe exacerbation in the two weeks leading up to the index date was associated with 
reduced likelihood of continuing on ICS/LABA or LAMA therapy (OR=0.61, 95% CI 
0.51 to 0.74), while having a higher proportion of two-week periods in the first 12 weeks 
post-index that were considered as moderate exacerbations was associated with an 
increased likelihood of continuing therapy (OR=1.78, 95% CI 1.13 to 2.80) (Table 68).  
Another complex association was that study subjects who had been discharged 
from a severe exacerbation in the two weeks leading up to the index date were more 
likely to be in the triple therapy group at index (OR=1.90, 95% CI 1.24 to 2.92) and less 
likely to continue therapy in the first 12 weeks (OR=0.73, 95% CI 0.57 to 0.94). But 
study subjects who had been discharged from a severe exacerbation in the 3-12 weeks 
prior to the index date were more likely to continue therapy in the first 12 weeks 
(OR=1.44, 95% CI 1.10 to 1.89) (Table 68). Retrospective study design limits our ability 
to make causal inferences about these relationships. Nevertheless, these are previously 
unappreciated nuances of exacerbation history as a predictor of future exacerbations, and 
it reveals a potential selection bias that should be considered in observational analyses. 
In all periods, any use of SABA in the time period was associated with 
continuation of therapy.  Having a COPD-related hospitalization was also associated with 
continuation of therapy in the first period, but not later periods, and in fact in later periods 
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having had a COPD-related hospitalization was associated with reduced likelihood of 
continuation of therapy.  
Aim 4 
Aim 4 encompassed the analyses for assessing risk of severe exacerbation.  The 
ITT analysis showed that if severe exacerbation events for individuals are compared 
solely on the basis of treatment at index there were differences between the two treatment 
groups that remained consistent for the first two years after the index date.  Given the 
high percentages of discontinuation, there exists the possibility that these observed 
differences in risk for severe exacerbation may be related to factors other than the index 
treatment.  In the Kaplan-Meier plot of the time to first severe exacerbation (“survival 
time”) for the ITT model the survival curves for the triple therapy and the ICS/LABA or 
LAMA group were fairly consistent in their differential through time even though there 
was wide variation in the degree to which index medications were used post-index.  
Alternatively, the As Protocol Kaplan-Meier plot showed that if only study subjects are 
included who continuously had a supply of the index medication, the story is not so clear.  
The As Protocol analysis found no significant difference between groups for severe 
exacerbation risk (HR=1.00, 95% CI 0.73 to 1.36, P=0.97), while the ITT analysis found 
a significant risk estimate of 1.24 (95% CI, 1.00 to 1.53).  A second analysis for the As 
Protocol sample reviewing severe exacerbations over only one year found similar results 
to the two-year analysis (HR=1.02, 95% 0.73 to 1.42). 
In the retrospective analysis by Short and colleagues comparing triple therapy use 
to ICS/LABA use over a ten year period, the published article is brief in its methods 
description, but it appears as if the study was undertaken assuming an ITT approach.  The 
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Kaplan-Meier curve for hospital admissions for respiratory disease makes a clear 
delineation between the lower risk among patients using triple therapy compared to 
patients using ICS/LABA, with the curves diverging early and continuing to diverge over 
the 10-year follow-up period.  However the results do not include any discussion about 
discontinuation of therapy after assignment to a particular therapy group, or whether the 
design was an intent-to-treat, but there is no information to indicate the study not 
performed using an ITT approach.  The authors state that the mean follow-up was 4.65 
years, a period over which one could assume a great many changes in therapy might have 
occurred. 
The GEE ITT analysis demonstrated, consistent with the earlier demonstration  by 
Cole and Hernan (Cole and Hernan 2004), that an estimated inverse probability hazard 
ratio without consideration of time-varying covariates will be indistinguishable from a 
the results obtained from a conventional logistic multiple regression model that includes 
all of the same covariates used in the probability for treatment model.  In both of these 
ITT models the estimated effect estimate for risk of severe exacerbation was estimated to 
be 1.24 with only very slight differences in the confidence interval (HR 95% CI 1.00 to 
1.55, 1.00 to 1.55 for the GEE analysis). 
The same covariates were included in both the ITT and As Protocol models, and 
one of the main differences in the models was that heart failure/CHF was associated with 
a significant risk of severe exacerbation in the ITT model (HR=1.23, 95% CI 1.03 to 
1.46) but not in the As Protocol model (HR=0.99, 95% CI 0.76 to 1.43).  Heart failure/ 
CHF was not identified as a significant factor for discontinuation in the first 12 weeks or 
in subsequent period in the regression analyses for the weight estimates in Aim 3 (Table 
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68).  The censoring probability model for the first period did result in a lower effect 
estimate for heart failure/CHF for not discontinuing therapy, but it was not significant 
(OR=0.93, 95% CI 0.79 to 1.10). In the ITT model, having a severe exacerbation in the 
baseline period in the 3-12 weeks prior to the index date or in the 13-52 weeks prior to 
the index date was also significantly associated with risk of severe exacerbation post-
index (HR=1.53, 95% CI 1.23 to 1.91 and HR=1.21, 95% CI 0.98 to 1.50, respectively).  
In the As Protocol model the association between severe exacerbation in 3-12 weeks pre-
index and severe exacerbation risk post-index was attenuated (HR=1.24, 95% CI 0.89 to 
1.73), and for severe exacerbation 13-52 weeks prior to index and severe exacerbation 
risk post-index the risk there was no relationship (HR=0.98, 95% CI 0.71 to 1.35). Future 
investigations may want to investigate further the relationship between severe 
exacerbations and heart failure/CHF morbidity, or the potential of cardiovascular events 
to confound COPD outcomes. The ITT approach that is traditionally used in randomized 
trials if applied to observational studies without consideration of time-varying covariates 
affecting treatment and censoring may perpetuate selection and confounding biases, 
misclassification errors. 
In both the ITT and As Protocol analyses, factors indicative of higher levels of 
disease instability were found to be associated with risk of severe exacerbation: having 
some history of pneumonia, some degree of COPD complexity, and any SAMA or 
SABA/SAMA use or oxygen use in the baseline period. Baseline SABA use of >40% 
was also significantly associated with risk in the ITT model (P=0.005) and marginally 
influential in the As Protocol model (P=0.07).  In conjunction with all other covariates, 
spirometry was again found to be significantly associated in the ITT model (HR=0.84, 
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95% CI 0.72 to 0.99, P=0.03) and marginally associated in the As Protocol with reduced 
risk of severe exacerbation (HR=0.82, 95% CI 0.65 to 1.03, P=0.08). 
In the ITT model 855 severe exacerbations occurring over a two-year period were 
modeled, in the As Protocol, 411.  For both of these models the full sample of 5,475 
study subjects was used. In the MSM analysis for severe exacerbation events, only 
individuals who did not discontinue therapy by 12 weeks were included – 3,407 subjects.  
For these subjects, there were 476 severe exacerbation events.  A logistic pooled model 
with a minimal number of covariates estimating risk for severe exacerbation within each 
time period (covariates were: sex, age, insurance and a variable for the number of weeks 
from the index date to the beginning of each time period) found that patients who were 
using triple therapy at the beginning of each time period had higher, but not significantly 
higher odds of having a severe exacerbation compared to those using ICS/LABA or 
LAMA (OR=1.18, 95% CI 0.74 to 1.87, P=0.49).  When the model was expanded to 
include additional baseline covariates about comorbidities, symptoms, procedures, and 
exacerbation experience, the risk estimate was lower for both a two-year time period 
(OR=1.11, 95% CI 0.68 to 1.81) and a one-year time period (OR=1.08, 95% CI 0.60 to 
1.94). As with the ITT and As Protocol models, model covariates that were significant 
were those associated with more difficult to manage disease – use of COPD medications 
and oxygen, comorbidities (pneumonia, emphysema), and prior exacerbation experience.  
Significance of effect estimates differed between the one-year and two-year models, but 
that was probably due to the lower number of events being modeled in the one-year 
compared to the two-year model. 
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In this study the percentage of patients who switched treatments without having 
an intervening period with no treatment was not that sizable, and this may be one reason 
why the results between the As Protocol and the MSM models were so similar.  An issue 
however in all models is that unmeasured confounders cannot be ignored.  Some of the 
potential confounding may be able to be assessed fairly easily from the claims data; for 
example, cardiovascular events.  Some may be a little more difficult; for example, 
information about patient geographical location and co-pays). Other confounders simply 
cannot be known through claims data, even electronic medical records – for example, 
patient perceptions about the importance of their medications. 
Aim 5 
Aim 5 reviewed the number of exacerbation events that occurred in the two years 
post-index, to include a severe exacerbation event.  In the ITT analysis of 5,475 subjects, 
49.9% of the subjects did not have any moderate or severe exacerbation. This is actually 
similar to data from other COPD cohorts.  In a study of resource use of COPD patients in 
Canada that followed 524 patients with COPD that had predominantly moderate or severe 
disease at 50 sites for a 52 week period from 2001 through 2003, 46.9% experienced no 
exacerbation (FitzGerald et al. 2007). Moderate and severe exacerbations were defined 
similarly to events in this study, as events requiring antibiotics or oral corticosteroid use 
or hospitalization due to COPD.  Treatment at that time did not include tiotropium 
(LAMA), but approximately 45% were using corticosteroids. Poisson models regressing 
number of exacerbations on treatment and comorbidity did not find any significant 
associations.  An association was found however between prior exacerbations.  This was 
one of the early studies highlighting the presence of a “frequent exacerbator” phenotype. 
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As COPD becomes more severe, the percentage of patients having severe and or 
moderate exacerbations increase, but as the ECLIPSE study demonstrated, the rate at 
which exacerbations occur reflects an “independent susceptibility phenotype” (Hurst et 
al. 2010). In that study COPD patients with moderate or worse disease were observed 
over a three year period for frequency and associations of exacerbations.  A total of 2,138 
patients were observed and of these patients, 61.6% reported having no baseline 
exacerbations or at most one, and of these patients, 79% also had infrequent 
exacerbations in the first year of the study. Emphysema was associated with a higher 
odds ratio for any exacerbation in the first year, as were patient reported symptoms of 
wheezing and chronic cough. Of interest was that 29% of patients with very severe 
COPD had no exacerbations in the baseline period or in the first year.  
In conceptualizing our study, it was thought that the same weighted study sample 
could be used for both assessment of any severe exacerbation risk and the assessment of 
number of exacerbation events (moderate and severe).  In practice however it was not 
feasible to use the same weighted sample for both.  The MSM approach necessitates a 
pooled analysis approach involving partitioning the follow-up period. An optimal model 
would have equal sized small partitions (two-week period) and assess whether 
individuals had or did not have an exacerbation in the period.  Because of the issues 
relating to the stabilized weights, the time periods had to be longer.  Furthermore, 
uncertainty about the duration of exacerbation made it difficult to construct a model that 
could be easily explained.  
Incidence rate ratios for exacerbations estimated from the ITT and As Protocol 
models were very similar; the IRR for the ITT model was 1.15 (95% CI 1.01 to 1.31) and 
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for the As Protocol, 1.16 (0.98 to 1.38).  Covariates identified in these models as being 
significantly associated with total number of exacerbations were also very similar, with 
baseline moderate exacerbation experience being strongly related to post-index 
exacerbation experience. The time-varying models utilized for estimating probability of 
treatment and censoring further showed that there was a strong association between the 
proportion of two-week periods in a time interval a patient was considered to have been 
having a moderate exacerbation and their probability of being on triple therapy at the start 
of the next time period (OR=1.94, 95% CI 1.22 to 3.14).  Of note also is that patients who 
had a high proportion of two-week periods where a moderate exacerbation was occurring 
in the first 12 weeks post-index were more likely to discontinue therapy (OR=1.78, 95% 
CI 1.13 to 2.80).  Unfortunately the analyses in this study were not able to shed more 
light on the relationship between treatment and moderate exacerbations, but the summary 
of findings from the ITT and As Protocol models for Aim 4 and Aim 5 (Table 84) 
showed that significant factors were somewhat different for the rate of exacerbation 
models than for the risk for severe exacerbation models.  One item of interest is that in 
the severe exacerbation models no significant association was found for baseline 
moderate exacerbations. Binary event variables were used in order to determine 
associations between the temporal nature of exacerbation events, but in using binary 
variables some aspects of exacerbations such as frequency of exacerbations were not able 
to be reviewed.   
In this study sample age was not related to any exacerbation experience. The 
association between Medicaid insurance and exacerbation risk was also greatly reduced 
from the severe exacerbation models in the ITT model and found to not be a significant 
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factor in the As Protocol model.  Obesity and renal failure were found to be significantly 
associated with a reduced rate of exacerbations (As Protocol estimates: obesity 
IRR=0.83, 95% CI 0.70 to 0.99 and renal failure IRR=0.79, 95% CI 0.64 to 0.98) and 
baseline cough symptom significantly associated with increased risk (As Protocol 
estimate: IRR=1.16, 95% CI 1.03 to 1.31).   
As in the severe exacerbation models, having had pneumonia, having 
emphysema, and baseline use of SAMA, SABA/SAMA, oxygen use for more than 50% 
of the baseline period, and SABA use for more than 40% of the baseline period were 
found to be significantly associated with higher moderate exacerbation rates. 
Severe exacerbation was included with moderate exacerbations to account for 
scenarios where individuals have no moderate exacerbations, only a severe exacerbation.  
This method however was not able to make distinction of varying degrees of moderate or 
severe exacerbations.  Related to this is that in modeling a rate, the length of exacerbation 
was not considered.  Patel and colleagues found that COPD patients with ischemic heart 
disease (IHD) may have the same rate of exacerbations as those without, but that 
recovery time is a median five days longer (Patel et al. 2012).  The longer recovery time 
may be due to several factors, among them that patients with IHD tend have a reduced 
health status with a lower exercise capacity, and a greater severity of dyspnea than those 
without IHD (Patel et al. 2012). In our study IHD was not significantly associated with 
exacerbation rate, but heart failure/CHF was significantly associated with risk of severe 
exacerbation in the ITT model.  
Some individuals could have had one exacerbation that lasted for two months, 
while others could have had a cluster of two or three exacerbations over the same time 
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period. Hurst and colleagues in a study investigating clustering of exacerbations found 
that exacerbations that were isolated were on average 25% more severe than initial 
exacerbations using duration of exacerbation as a measure of severity  (Hurst, Donaldson, 
and Wedzicha 2009).   
Modeling of exacerbations has been an ongoing focus of COPD research over the 
last decade, with most models assuming negative binomial distribution as was done in 
this analysis to account for between subject variability in COPD exacerbations (Aaron et 
al. 2008; Keene et al. 2008).  The impact exacerbations may have on continued use of 
bronchodilator treatment has not been well studied however and the probability models in 
this study highlight that investigations into whether switching of treatment after an 
exacerbation events is beneficial, and which patients benefit, is another area of study that 
may serve to improve outcomes for patients with COPD.   
 Aim 6 
For the cost analyses, NCQA standardized costs were used.  To be accurate, the 
cost analyses utilized NCQA standardized prices that were multiplied by the unit of 
service to arrive at standardized costs.  The NCQA price per service is a standardized 
allowed payment level for provider services that represents average service pricing levels 
for organizations (NCQA 2011). Estimated costs were comparable to costs published for 
other studies.  For example, in the study by Chatterjee and colleagues comparing triple 
therapy to LAMA alone, total COPD-related baseline costs using the IMS Lifelink Health 
Plan Claims Database were estimated to be $9,108 ($7,665 medical services and $1,444 
COPD-related pharmacy costs) (Chatterjee et al. 2012) and in our study were estimated to 
be $8,548 ($8,140 medical services and $408 outpatient pharmacy).  Baseline outpatient 
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pharmacy costs for the Chatterjee study were probably higher due to the SAMA baseline 
use inclusion criteria, but having the estimates so similar for the baseline periods offers 
support for the use of the NCQA standardized costs in this study. 
There were differences in estimated post-index costs for the non-triple therapy 
group between the Chatterjee study and ours, but these may be due to the more restrictive 
inclusion criteria in the Chatterjee study.  In that study, post-index adjusted monthly 
COPD-related costs were estimated to be comparable between the triple therapy group 
and the LAMA group, both on average $721 per month or $8,652 if extrapolated to 12 
months, with the triple therapy having higher mean COPD-related pharmacy costs ($223 
compared to $190 [extrapolated to12 months, $2,676 compared to $2,280], though the 
difference was not significant) and the LAMA group having higher COPD-related 
medical service costs ($543 compared to $490 [extrapolated to12 months, $6,516 
compared to $5,880], again not significant).  In our study we estimated total adjusted 
mean COPD related-costs for the one year period post-index to be $8,131 for the full 
sample for the ITT analysis.  Total estimated COPD-related costs for the triple therapy 
group were $8,335 and were comparable to that estimated by Chatterjee and colleagues - 
$2,427 for our COPD-related pharmacy services compared to $2,676 for the Chatterjee 
study and $5,908 for our COPD-related medical services compared to $5,880 for the 
Chatterjee study.  However costs for the ICS/LABA or LAMA group were considerably 
less, at $5,338 for our mean estimate for COPD-related total costs compared to $8,652 
for the Chatterjee study - $1,356 for our estimate for pharmacy compared to $2,280 for 
the Chatterjee study and $4,303 for medical services compared to $6,515 for the 
Chatterjee study.   
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Najafzadeh and colleagues performed a concurrent economic analysis with a 
clinical trial examining the effectiveness of adding salmeterol (LAMA) or 
fluticasone/salmeterol (ICS/LABA) to tiotropium (LAMA) (Najafzadeh et al. 2008).  The 
clinical trial was the Canadian OPTIMAL study and cost outcomes were priced in 2006 
Canadian $. Canadian sources were used for the standardized costs and so the estimated 
costs are not directly comparable to a U.S. study.  While the OPTIMAL study found that 
exacerbation rates were slightly lower and quality of life improved for patients using 
triple therapy, study findings were that neither adding LABA nor ICS/LABA to LAMA 
was cost-effective.  The estimated ICER found the cost to be $6,000 for one avoided 
exacerbation for triple therapy, and more than $200,000 per quality-adjusted life year 
gained for triple therapy. Total COPD-related costs for one year for the triple therapy 
group were estimated to be $4,042 compared to $2,801 for the LAMA+LABA group and 
$2,678 for the LAMA+placebo group (Najafzadeh et al. 2008). In all our analyses the 
COPD-related costs for triple therapy patients were also higher.   
The effectiveness of triple therapy versus the individual components in impacting 
clinical measures has been demonstrated in randomized clinical trials; for example,  in 
improvement of lung function as measured by trough FEV1(the measure taken in the 
morning prior to the first inhaler treatment of the day), and reduction of chronic 
symptoms such as dyspnea.  In the study by Cazzola and colleagues reviewing clinical 
outcomes over a three month period with approximately 20 severe to very-severe COPD 
patients in each arm, trough FEV1 was significantly improved over baseline in all three 
groups, but to a higher degree in the triple therapy arm – by approximately 140 mL in 
each of the ICS/LABA and LAMA arms compared to 186 mL in the triple therapy arm 
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(Cazzola et al. 2007). A greater reduction in dyspnea symptoms was perceived by 
patients in the triple therapy and LAMA arms than in the ICS/LABA arm as measured by 
Visual Analog Scores.  Exacerbations were not examined.  This same improvement in 
lung function by patients using triple therapy over those using LAMA+placebo was 
demonstrated by Hanania and colleagues in a 24 week clinical trial among 264 
symptomatic moderate to severe COPD patients (Hanania et al. 2012). Although the latter 
study did include an assessment of moderate exacerbations and no difference was found 
in the mean exacerbation rate among patients; though improvement was more 
pronounced in patients with severe disease (Hanania et al. 2012).  Alternatively, in the 12 
week randomized trial by Welte and colleagues examining effectiveness of adding 
budesonide/formoterol (ICS/LABA) to LAMA therapy among approximately 600 
patients with severe COPD, a 62% lower risk of an exacerbation event was observed in 
the triple therapy arm compared to the LAMA arm (Welte et al. 2009). 
The observational studies by Chatterjee and Short also showed a beneficial effect 
of triple therapy in comparison to ICS/LABA and to TIO therapy respectively, but these 
studies may not have adequately adjusted for underlying confounding by indication bias. 
In our study greater percentages of patients in the triple therapy group had baseline 
moderate and severe exacerbations and using an ITT approach, a higher risk for severe 
exacerbation was observed among patients taking triple therapy compared to patients 
taking ICS/LABA or LAMA (HR=1.24, 95% CI 1.00 to 1.53), but not using an As 
Protocol approach (HR=1.00, 95% CI 0.73 to 1.36).    Using a MSM approach resulted in 
an estimate that was between the ITT and As Protocol approaches (HR=1.11, 95% CI 
0.68 to 1.81). 
   
364 
Estimated one-year post-index mean cost analyses for the 5,475 study subjects 
using an ITT approach found that while the total health care costs for the triple therapy 
group were higher, the triple therapy patients actually had a lower estimated total non-
COPD cost of care. Non-COPD utilization costs had also been lower for the triple 
therapy group in the baseline period.   Post-index, triple therapy patients had higher 
COPD-related resource utilization as was summarized by both higher medical services 
costs and higher outpatient pharmacy costs.  
In the As Protocol analyses, study subjects were only included as long as they had 
evidence of having some days supply of ICS/LABA and/or LAMA, but  discontinuation 
of therapy was not uniform between the study groups.  Patients in the triple therapy group 
were more likely to continue with triple therapy, or ICS/LABA or LAMA alone. At six 
months 53.5% of the study sample had discontinued use – 35.7% of the triple therapy 
group (173 out of 484) and 55.3% of the ICS/LABA or LAMA group (49.9% of those 
with ICS/LABA and 58.7% of those with LAMA). These censoring differentials have 
important implications for cost estimates from the remaining pool of patients, with bias 
potentially going in both directions.  Higher cost patients may discontinue medication 
because of non-COPD related adverse events, or alternatively patients with more severe 
COPD disease may continue taking medication because of a perceived need, or elements 
of both scenarios may exist.  In our analyses of costs for the As Protocol analysis, mean 
estimated non-COPD costs for individuals included in the analyses were higher for the 
triple therapy group than for the ICS/LABA or LAMA group, potentially because of this 
censoring differential between the groups. Alternatively, if the weighted method that 
adjusts for that censoring differential is used, non-COPD mean costs estimated were 
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found to be similar to those obtained by the ITT method.  COPD-related costs on the 
other hand were estimated to be higher for the triple therapy group using either the 
weighted or unweighted costs. And costs estimated using the MSM sample found that 
triple therapy patients were again estimated to have higher costs in each of the time 
intervals periods in comparison to costs for patients using ICS/LABA or LAMA. 
The analyses for cost served to reiterate that there are important underlying 
characteristics that must be considered in treatment effectiveness analyses about the 
patients who have prescriptions for one treatment versus another, and also about the time-
varying confounders that affect use of treatments and risk for outcome events post-index. 
Limitations of the Study 
Major limitations of this study are those related to internal validity – potential for 
unmeasured confounders, and to external validity – the small sample size and sample 
drawn from a regional population as opposed to a one from a national population. Using 
the available data, probability treatment models were not able to discriminate well 
between those receiving triple therapy and those receiving ICS/LABA or LAMA therapy.  
A fundamental aspect of the MSM approach is the estimation of treatment probability in 
order to approximate a randomized study, and while this study made use of the 
information available, additional information on provider specialty, disease severity, 
economic status of patients, and more detailed information about patient copays may 
have improved probability of treatment models.  
As previously mentioned, it has been suggested that the full power of the MSM 
approach is best appreciated with numerous time-varying covariates (Cole and Hernan 
2004), 2) when there is evidence of strong confounding by time-dependent covariates, 
   
366 
and 3) past treatment has a sizable effect on the covariates (Hernan et al. 2008). In our 
study sample there was substantial discontinuation of treatment, and there was some 
switching from subjects in the triple therapy group to the ICS/LABA or LAMA group, 
but there was minimal switching of study subjects from the ICS/LABA or LAMA group 
to the triple therapy group.  It may be that an MSM approach offers more benefit when 
there is more movement between treatment groups than was present in this study.  Future 
research should explore the potential for using a multinomial treatment probability model 
that included no treatment as an option instead of the binary treatment choice used in this 
analysis. 
A substantial portion of the study sample discontinued therapy by three months 
into the study and by six months, slightly more than 50% of the study sample had 
discontinued use of ICS/LABA or LAMA therapy.  Discontinuation was treated as 
censoring, but reasons for discontinuation encompass a wide range from patient 
perceived lack of need for medication or ineffectiveness of medication, to adverse events 
from COPD that are not apparent in the claims data or adverse events from comorbid 
conditions that were not included in the study design.  Patients may be more likely to 
discontinue who have very mild or very severe disease.   
More sensitivity analyses could have been performed to test for some of the 
factors that have been found in other effectiveness studies of triple therapy.  For example, 
an analysis limiting the population to only those with a moderate or severe baseline 
exacerbation may have helped to elucidate better some of the relationships between 
treatment and outcomes.  But this was not a pre-specified analysis and the problem with 
post-hoc analyses is that they can quickly turn one study into two studies. Limiting the 
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analysis to just individuals who had a claims based exacerbation in the baseline period 
also changes the nature of the study. The goal of this research study was to develop better 
methods for describing the effectiveness of COPD treatment in the general population.  
By limiting the study to only those individuals with a pre-index exacerbation, we would 
have less of an understanding about individuals using triple therapy who did not have any 
baseline exacerbation.  
The study sample combined patients from two health plans operating in New 
Mexico. While much was similar between the two health plan populations, there were 
also differences. Both health plans contained a mix of Medicare, Medicaid and 
Commercial insurance, although Medicaid patients constituted a larger percentage of the 
insured COPD population in one health compared to the other and patients with COPD in 
that health plan also were on average older younger.  There were formulary differences 
between the two health plans and formulary differences may have been a factor in the 
larger percentage of patients using the LAMA medication tiotropium in the one health 
plan compared to the other. The structure of the claims data for the two health plans 
differed slightly between the two health plans.  Data for both included the universally 
used code fields for procedures (CPT, HCPCS, ICD-9), diagnoses, revenue codes, DRGs, 
and NDCs. While the total percentage of baseline COPD-related inpatient stays (severe 
exacerbations and hospitalizations where a COPD-related diagnosis was a secondary 
diagnosis) was similar between the two health plan populations, percentages for each of 
those specific events differed slightly between the populations, with patients from one 
having a higher number of severe exacerbations and a lower number of hospitalizations.  
The categorization of events was reviewed extensively in the preliminary reviews of the 
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data, but if there was any information that allowed a different categorization of these 
inpatient stays it was not present in the data. All models considered sex, age and type of 
insurance and additionally included a binary variable for health plan.  Health plan was 
consistently a significant variable. In future studies structure of the claims data pull is an 
area that should be given added scrutiny.  
Lastly, there may be misclassification due to the exacerbation measures used for 
severe and moderate exacerbations.  The definitions and criteria for these events were the 
same as has been used for other COPD treatment effectiveness studies, however that does 
not discount the chance that the measures may have missed some exacerbation events and 
misclassified some events as exacerbation events that were not.  Still, if misclassification 
was present there is little reason to suggest that the degree of misclassification would be 
differential between the two treatment comparison groups. 
Strengths of the Study 
Few studies have been conducted using an MSM approach.  This study provided a 
comparison of three different approaches to analysis that could be used in a retrospective 
observational study and showed how each is useful in highlighting characteristics of the 
study sample that may otherwise be missed.  Discontinuation of therapy was prevalent in 
this study sample, and the ITT and As Protocol analyses for time to severe exacerbation 
showed that there are underlying differences in the two treatment groups that were 
present regardless of treatment.  The MSM analysis on the other hand helped to highlight 
what some of the factors related to discontinuation of therapy are and emphasize how 
prior period moderate exacerbations and SABA use are associated with use of triple 
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therapy. The MSM analysis also highlighted how the factors significant for initial use of 
treatment may be different from factors significant for later use of that same treatment. 
The use of a regional population was a limitation in terms of the generalizability 
of the study, but it was also a strength.  Analyses of treatment groups in this study helped 
to highlight that characterizations of treatment groups from using national databases are 
not always applicable to regional populations.  In our study sample the percentage of 
patients using LAMA medication who had exacerbations in the baseline period or post-
index period was lower than that compared to patients using ICS/LABA or triple therapy.  
In other studies the percentage of patients using LAMA medication who have 
exacerbations has been higher.  This characteristic helped to highlight that including as a 
covariate a variable for baseline exacerbation experience may not completely adjust for 
underlying severity differences in treated sample groups. 
Most significantly this study highlighted the importance of understanding post-
index events that may be confounding unbiased assessment of treatment effectiveness 
regarding the measured outcomes.  While there is still room for improvement in the way 
this study adjusted for those post-index confounders, this study has provided a first step 
in that process. 
Implications for Future Research 
The study has demonstrated that there are confounding factors for both treatment 
and outcome that should be considered in treatment effectiveness analyses. The ITT 
approach that is traditionally used in randomized trials if applied to observational studies 
without consideration of these time-varying covariates may result in biased estimates of 
treatment effects. 
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In this study there were many covariate factors that were repeatedly identified as 
being related to either treatment or exacerbations.  For example there were several claims 
based utilization and diagnostic factors that could be interpreted as characterizing COPD 
disease severity – use of SABA, SAMA, SABA/SAMA medications, oxygen, and 
nebulizer treatment; dyspnea symptoms; diagnoses of hypoxemia and emphysema, and 
history of pneumonia; having had a spirometry procedure.  Additionally heart 
failure/CHF and valvular disease were identified in the ITT and As Protocol analyses as 
being significant covariates in severe exacerbation risk models, but not in the MSM 
analysis.  Understanding better how these characteristics of patients may cluster and how 
the clusters relate to both propensity for treatment and to outcomes may help to improve 
disease management for patients with COPD.  It has been highlighted repeatedly 
elsewhere, but bears repeating, that “exacerbations are heterogeneous events occurring in 
a heterogeneous disease” (Hurst and Wedzicha 2009).   
The MSM approach may be a useful tool in helping to identify the relationship 
between those clusters of characteristics and treatment and outcomes.  To the extent 
possible, additional factors should be collected for use in analyses that may help to 
explain discontinuation of treatment or treatment switching. If possible in future research 
studies, being able to have access to a sub-sample of patient medical records to abstract 
clinical information about the severity COPD disease may also help to support findings. 
Conclusions 
Contrary to results from the two prior retrospective observational treatment 
effectiveness studies, in this study sample triple therapy was not more effective than use 
of either ICS/LABA or LAMA in reducing the risk of severe exacerbation.  It was 
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hypothesized that the use of a MSM approach that included time-varying covariates 
would help to reduce the bias from confounders related to both treatment choices and 
severe exacerbation events. The MSM analysis did suggest a strong positive relationship 
between rescue inhaler use (SABA use) and both choice of triple therapy and 
continuation of use of any of the compared treatments.  The MSM analysis also 
highlighted that there was a significant relationship between moderate exacerbations and 
choice of triple therapy.  
This study and study sample may not have been well suited for illustrating the full 
advantages of the MSM approach as there was minimal switching from the ICS/LABA to 
the triple therapy group and the existence of unmeasured confounders could not be 
discounted. The MSM approach however offered some insights into the relationships 
between treatment and outcomes in this observational database that would have been 
difficult to identify using either the traditional ITT approach or the As Protocol approach.  
MSM is a useful and informative complementary analysis to include in studies of 
treatment effectiveness. 
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APPENDIX A: ABBREVIATIONS 
Appendix A 
Abbreviations 
 
AHFS, American Hospital Formulary System 
AHRQ, Agency for Healthcare Research and Quality 
BETOS, Berenson-Eggers Type of Service 
CDC, Centers for Disease Control 
CHF, congestive heart failure 
CMS, Center for Medicare and Medicaid Services 
COPD, chronic obstructive pulmonary disease 
CPT4, Current Procedural Terminology, 4
th
 edition 
DRG, diagnosis related group 
ED, emergency department 
FEV1, forced expiratory volume in one second 
FVC, forced vital capacity 
GOLD, Global Initiative for Chronic Obstructive Lung Disease  
HCPCS, Healthcare Common Procedure Coding System 
HCUP, Healthcare Cost and Utilization Project 
HEDIS, Healthcare Effectiveness Data and Information Set 
ICD-9, International Classification of Diseases, Ninth Revision 
ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical 
Modification  
ICER, incremental cost-effectiveness ratio 
ICS, inhaled corticosteroid 
ICU, intensive care unit 
ISPOR, International Society for Pharmacoeconomics and Outcomes Research 
IV, instrumental variable 
LABA, long-acting beta-agonist 
LABD, long-acting bronchodilator 
LAMA, long-acting antimuscarinic agent (also called a long-acting anticholinergic) 
LOS, length of stay 
MCO, managed care organization 
MDC, major diagnostic category 
MS-DRG, Medicare Severity Diagnosis Related Group 
NCQA, National Committee for Quality Assurance 
NDC, National Drug Code 
NDI, National Death Index 
NPV, negative predictive value 
OCS, oral corticosteroid 
PRN, Latin phrase pro re nata, meaning “as needed” 
RCT, randomized controlled trial 
SABA, short-acting beta-agonist 
SABD, short-acting bronchodilator 
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SAMA, short-acting antimuscarinic agent (also called a short-acting anticholinergic) 
SCS, systemic corticosteroid 
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Appendix B: Formulary Summaries 
Appendix B 
Formulary Summaries 
Presbyterian 2012 Coverage: 
Obtained from http://www.phs.org/PHS/programs/pharmacy/formulary/index.htm  
December 12, 2012 
Drug Plan Tier Notes 
Spiriva Commercial Group 2 None 
Spiriva Medicare HMO 2 None 
Spiriva Medicaid  None 
Advair Diskus Commercial Group 3 QL, ST 
Advair HFA Commercial Group 3 QL, ST 
Advair Diskus Medicare HMO 3 QL (60/30), ST 
Advair HFA Medicare HMO 3 ST 
Advair Diskus Medicaid/SCI 3 QL, PA 
Advair HFA Medicaid/SCI 3 QL, PA 
Symbicort Commercial Group 2 QL, ST 
Symbicort Medicare 2 ST 
Symbicort Medicaid/SCI 2 QL, ST 
 
Tier 2 = Preferred Brand Drugs Covered at a Second Tier Copayment (some medications 
may be excluded as determined by benefit)  
Tier 3 = Non-Preferred Drugs covered at a Third Tier Copayment (some medications 
may be excluded as determined by benefit)  
Prior Authorization (PA) - a drug that requires prior approval before the Plan will cover 
it, and when the patient meets the established criteria. The doctor must submit a Prior 
Authorization Request Form. The doctor can submit the request by fax, phone, or regular 
mail. 
Quantity Limit (QL) -- a coverage limit on the medication quantity covered for a 
defined days' supply (usually 30 or 90 days) based on safety, efficacy and/or dose 
optimization issues. 
SCI – State Coverage Insurance 
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Step Edit (ST) -- a drug that requires a prescription history of specific drugs in the 
pharmacy claims or data system, and these specific drugs must be taken during a given 
time frame. After the specific drugs have been taken within the given time frame, online 
coverage of the newly-prescribed drug occurs at the pharmacy. Step Edits make it easier 
to access drugs that would normally require a Prior Authorization. 
Explanation of Drug Tiers and Cost Sharing 
Drug Tier Description 
Retail Pharmacy 
Copayment (30-day 
supply) 
Mail Order 
Copayment (90-day 
supply) 
Tier 1 Preferred Generic $5 $10 
Tier 2 Preferred Brand $40 $100 
Tier 3 Non-preferred $75 $225 
Tier 4 Specialty 
Pharmaceuticals 
30% coinsurance Not Available 
All Tiers Pre-packaged Drugs 
(i.e., inhalers, insulin, 
topical creams, etc.) 
Copayment is the 
applicable tiered retail 
copayment for a 30-day 
supply 
Copayment is the 
applicable tiered mail 
copayment for a 90-day 
supply 
 
Details: 
Advair (fluticasone/salmeterol)  
APPLIES TO COMMERCIAL PLANS ONLY  
Step Edit Criteria:  
The patient must have a prescription claim history of an orally inhaled corticosteroid or 
an orally inhaled anticholinergic within the past 120 days.  
Quantity limit: One inhaler for 30 days.  
Alternatives for asthma: Asmanex, Flovent, Pulmicort, QVAR.  
Alternatives for COPD: Atrovent, Combivent, Spiriva.  
Approved by the P&T Committee 11/28/2007.  
Revised 09/21/2011.  
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Advair (fluticasone/salmeterol)  
APPLIES TO MEDICAID PLANS ONLY  
Indications for Approval:  
1. Documented trial and failure of either mometasone/formoterol MDI (Dulera®)* or  
budesonide/formoterol MDI (Symbicort®)* in the past 120 days.  
OR  
2. Patient is under the age of 12 and has a documented trial and failure of an orally 
inhaled corticosteroid.  
Quantity limit: One inhaler for 30 days.  
Alternatives for asthma: Dulera, Symbicort, Asmanex, Flovent, Pulmicort, QVAR.  
Alternatives for COPD: Atrovent, Combivent, Spiriva  
* Step Edit criteria applies for Dulera and Symbicort.  
Approved by the P&T Committee on 11/28/2007.  
Revised on 09/21/2011. 
Advair (fluticasone/salmeterol) - 
APPLIES TO MEDICARE ONLY  
Step Edit Criteria:  
Asthma Treatment: Patient must have claim history of a formulary inhaled corticosteroid 
in the previous four months. 
COPD Treatment: Patient must have a claim history of Spiriva, Atrovent (ipratropium), 
or Combivent (albuterol/ipratropium) in the previous four months.  
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Symbicort (budesonide/formoterol)  
APPLIES TO COMMERCIAL MEDICAID PLANS ONLY  
Step Edit Criteria:  
The patient must have a prescription claim history of an orally inhaled corticosteroid or 
orally inhaled anticholinergic within the past 120 days.  
Quantity Limit: One inhaler for 30 days.  
Alternatives for Asthma: Asmanex, Flovent, Pulmicort, QVAR.  
Alternatives for COPD: Atrovent, Combivent, Spiriva  
Approved by the P&T Committee 09/21/2011. 
Symbicort (budesonide/formoterol)  
APPLIES TO MEDICARE ONLY  
Step Edit Criteria:  
Asthma Treatment: Patient must have claim history of a formulary inhaled corticosteroid 
in the previous four months.  
COPD Treatment: Patient must have a claim history of Spiriva, Atrovent (ipratropium), 
or Combivent (albuterol/ipratropium) in the previous four months.  
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Lovelace Formulary Coverage 2012: 
Medicare http://www.lovelacemedicareplan.com/medicare-nm-2013/drug-formularies  
LHP  http://www.lovelacehealthplan.com/members/your-employee-health-plan/drug-
formularies 
Drug Plan Tier Notes 
Spiriva Commercial Group 2 None 
Spiriva Medicare HMO 2 None 
Spiriva Medicaid/SCI 2 None 
Advair Diskus Commercial Group 2 QL  (some plans) 
Advair HFA Commercial Group 2 QL  (some plans) 
Advair Diskus Medicare HMO 2 QL (60 ea/30d) 
Advair HFA Medicare HMO 2 QL (48 gm/30d) 
Advair Diskus Medicaid/SCI 2 QL 
Advair HFA Medicaid/SCI 2 QL 
Symbicort Commercial Group 2 None 
Symbicort Medicare 2 None 
Symbicort Medicaid/SCI 2 None 
Tier 2 = Covered brand name drugs (not self-injectable other than insulin) on the 
Preferred Drug List.  
Tier 3 = Covered generic and brand name drugs (not self-injectable other than insulin) 
not on the Preferred Drug List 
Above was also applicable for Lovelace prior formularies
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APPENDIX C: ADDITIONAL PROCEDURE AND DIAGNOSIS CODES 
Appendix C 
Additional Procedure and Diagnosis Codes 
 Table C-1 COPD-Related Service Procedure Codes 
Description Code Code type 
Arterial Blood Gas:   
gases blood ph only 82800 CPT 
blood gases any combination ph pco2 po2 co2 hco3 82803 CPT 
gases blood ph direct measure except pulse oximetry 82805 CPT 
gases blood o2 saturation only direct measure 82810 CPT 
Bronchoscopy:   
brnchsc incl fluor gid dx w/cell washg spx 31622 CPT 
brnchsc brushing/protected brushings 31623 CPT 
brnchsc w/brncl alveolar lavage 31624 CPT 
bronchoscopy bronchial/endobrncl bx 1+ sites 31625 CPT 
electromagnetic tip tracked 31626 CPT 
bronchoscopy w/cptr-asst image-guided navigation 31627 CPT 
bronchoscopy w/transbronchial lung bx 1 lobe 31628 CPT 
bronchoscopy needle bx trachea main stem&/bron 31629 CPT 
balloon dilatation 31630 CPT 
bronchoscopy w/placement tracheal stent 31631 CPT 
bronchoscopy w/transbronchial lung bx each lobe 31632 CPT 
bronchoscopy w/transbroncl ndl aspir bx ea lobe 31633 CPT 
bronchoscopy balloon occlusion 31634 CPT 
balloon dilatation/stenting 31636 CPT 
balloon dilatation/stenting 31637 CPT 
balloon dilatation/stenting 31638 CPT 
bronchoscopy w/tumor excise 31640 CPT 
brnchsc w/dstrj tum relief stenosis oth/thn exc 31641 CPT 
diag bronchoscope/catheter 31643 CPT 
brnchsc w/ther aspir tracheobrncl tree 1st 31645 CPT 
brnchsc w/ther aspir tracheobrncl tree sbsq 31646 CPT 
bronchoscopy, inj for x-ray 31656 CPT 
Chest CT:   
CT chest w/o contrast 71250 CPT 
CT chest w/contrast 71260 CPT 
CT chest w and w/o contrast 71270 CPT 
CT chest w and w/o contrast 71275 CPT 
Chest xray:   
chest xray, single view 71010 CPT 
chest xray, two views, frontal and lateral 71020 CPT 
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Description Code Code type 
chest xray, complete, minimum of four views 71030 CPT 
radiologic exam, chest, special views 71035 CPT 
Echocardiography:   
complete tthrc echo congenital cardiac anomaly 93303 CPT 
echocardiography 93304 CPT 
echo tthrc r-t 2d w/wom-mode compl spec&colr d 93306 CPT 
echo transthorac r-t 2d w/wo m-mode rec comp 93307 CPT 
echo transthorc r-t 2d w/wo m-mode rec f-up/lmtd 93308 CPT 
echo transesophag r-t 2d w/prb img acquisj i&r 93312 CPT 
echo r-t 2d w/probe placement only 93313 CPT 
echo transesophag r-t 2d img acquisj i&r only 93314 CPT 
echo transesophag congen probe plcmt imgng i&r 93315 CPT 
echo transesophag image acquisj interp&report 93316 CPT 
echo tthrc r-t 2d w/wom-mode compl spec&colr d 93317 CPT 
doppler echocard pulse wave w/spectral display 93320 CPT 
dop echocard pulse wave w/spectral f-up/lmtd std 93321 CPT 
dop echocard color flow velocity mapping 93325 CPT 
echo tthrc r-t 2d w/wo m-mode complete rest&st 93350 CPT 
echo tthrc r-t 2d w/wo m-mode rest&strs cont ecg 93351 CPT 
EKG:   
ecg routine ecg w/least 12 lds w/i&r 93000 CPT 
ecg routine ecg w/least 12 lds trcg only w/o i&r 93005 CPT 
ecg routine ecg w/least 12 lds i&r only 93010 CPT 
ph1 ecg rhythm strip 24-hr mntr 30 d trcg 93012 CPT 
ph1 ecg rhythm strip 24-hr mntr 30 d phys i&r 93014 CPT 
cv strs tst xers&/or rx cont ecg w/si&r 93015 CPT 
cv strs tst xers&/or rx cont ecg w/o i&r 93016 CPT 
cv strs tst xers&/or rx cont ecg trcg only 93017 CPT 
cv strs tst xers&/or rx cont ecg i&r only 93018 CPT 
rhythm ecg 1-3 leads w/interpretation & report 93040 CPT 
rhythm ecg 1-3 leads tracing only w/o i&r 93041 CPT 
rhythm ecg 1-3 leads interpretation & reprt on 93042 CPT 
xtrnl ecg & 48 hr record scan stor w/r&i 93224 CPT 
xtrnl ecg & 48 hr recording 93225 CPT 
external ecg scanning analysis report 93226 CPT 
xtrnl ecg continuous rhythm w/i&r up to 48 hrs 93227 CPT 
wr ecg 24 hr w/o supimpos w/mini tracg phys r&i 93230 CPT 
wr ecg 24 hr w/o supimpos w/mini tracg w/rec 93231 CPT 
wr ecg 24 hr w/o supimpos w/mini tracg w/reprt 93232 CPT 
wr ecg 24 hr w/o supimpos wmini tracg phys r&i 93233 CPT 
wr ecg 24 hr full-size trcg w/mntr/a/phys r&i 93235 CPT 
wr ecg 24 hr full size trcg phys r&i 93237 CPT 
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Description Code Code type 
   
Nebulizer treatment:   
pressurized/nonpressurized inhalation treatment 94640 CPT 
continuous inhalation treatment 1st hr 94644 CPT 
demo/eval of pt utiliz aersl gen/neb/inhlr/ip 94664 CPT 
areo mask used w/ dme nebulizer A7015 HCPCS 
dome&mouthpiece used w/small volume us nebulizr A7016 HCPCS 
nebulizer not used w oxygen A7017 HCPCS 
water distilled w/nebulizer A7018 HCPCS 
nebulized administration 93.94 ICD-9 
non-invasive ventilator:   
vntj assist&mgmt initiation 1st 94656 CPT 
vntj assist mgmt initiation sbsq 94657 CPT 
cpap initiation and mgmt 94660 CPT 
cnp initiation and mgmt 94662 CPT 
home visit mechanical ventilation care 99504 CPT 
combination oral/nasal mask A7027 HCPCS 
repl oral cushion combo mask A7028 HCPCS 
repl nasal pillow comb mask A7029 HCPCS 
full face mask used w/pos arway press device ea A7030 HCPCS 
face mask interface replcmt full face mask ea A7031 HCPCS 
cushn nasal mask interface replacement only each A7032 HCPCS 
nasl intrfce pos arway prss devc w/wo head strap A7033 HCPCS 
headgear used w/positive airway pressure device A7034 HCPCS 
chinstrap used w/positive airway pressure device A7035 HCPCS 
tubing used with positive airway pressure device A7036 HCPCS 
filter dispbl used w/pos arway pressure device A7037 HCPCS 
filter non dispbl used w/pos arway press device A7038 HCPCS 
full face mask used w/pos arway press device ea A7039 HCPCS 
non-invasive ventilator 93.90 ICD-9 
intermittent positive pressure breathing 93.91 ICD-9 
Oximetry:   
noninvasive single determination 94760 CPT 
noninvasive multiple determination 94761 CPT 
noninvasive continuous monitoring 94762 CPT 
oximeter device for measuring blood oxygen levels E0445 HCPCS 
Oxygen:   
physician attendance supervision hyperbaric oxygen therapy, per session 99183 CPT 
home visit for respiratory therapy care 99503 CPT 
stationary compressed gaseous oxygen system, rental E0424 HCPCS 
stationary compressed gas system, purchase E0425 HCPCS 
portable gaseous oxygen system, purchase E0430 HCPCS 
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Description Code Code type 
portable gaseous oxygen system, rental E0431 HCPCS 
portable gaseous oxygen system, rental E0433 HCPCS 
portable liquid oxygen system, rental E0434 HCPCS 
portable liquid oxygen system, purchase E0435 HCPCS 
stationary liquid oxygen system, rental E0439 HCPCS 
stationary liquid oxygen system, purchase E0440 HCPCS 
stationary oxygen contents, gaseous, 1 month's supply E0441 HCPCS 
stationary oxygen contents, liquid, 1 month's supply E0442 HCPCS 
portable oxygen contents, gaseous, 1 month's supply E0443 HCPCS 
portable oxygen contents, liquid, 1 month's supply E0444 HCPCS 
oxygen concentrator E1390 HCPCS 
oxygen concentrator E1391 HCPCS 
portable oxygen concentrator, rental E1392 HCPCS 
portable gaseous oxygen system, rental K0738 HCPCS 
oxygen contents, gaseous S8120 HCPCS 
oxygen contents, liquid S8121 HCPCS 
Spirometry:   
spirometry w/vc expiratory flo w/wo mxml vol vntj 94010 CPT 
pt-intit spirometric rec 30 d pd phys r&i 94014 CPT 
pt-intit spirometric rec 30 d pd recording 94015 CPT 
pt-intit spirometric rec 30-d pd phys r&i only 94016 CPT 
bronchodilation responsiveness 94060 CPT 
brncspsm provocation eval mlt spmtry w/admn agt 94070 CPT 
vital capacity total separate procedure 94150 CPT 
lung function test 94200 CPT 
functional residual capacity or residual volume 94240 CPT 
exp gas collj quan 1 px spx 94250 CPT 
thoracic gas volume 94260 CPT 
deter maldistribj of inspired gas n wshot curve 94350 CPT 
deter resist to airflo oscillatory/plethysmograp 94360 CPT 
deter airwy closing vol 1 brth tsts 94370 CPT 
respiratory flow volume loop 94375 CPT 
brthing rspse co2 co2 rspse curve 94400 CPT 
brthing rspse hypoxia hypoxia rspse curve 94450 CPT 
pulmonary stress testing 94620 CPT 
pulmonary stress testing complex 94621 CPT 
carbon monoxide diff w/cap 94720 CPT 
plethysmography lung volumes w/wo airway resist 94726 CPT 
gas dilut/washout lung vol w/wo distrib vent 94727 CPT 
CO diffusing capacity 94729 CPT 
Influenza and pneumonia vaccinations:   
influenza vaccine split virus prsrv free id 90654 CPT 
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Description Code Code type 
influenza virus vacc split prsrv free 3 yrs/> 90656 CPT 
influenza virus vaccine split virus 3/> yrs 90658 CPT 
influenza vaccine – intranasal (flumist) 90660 CPT 
influenza vaccine splt prsrv free inc antigen 90662 CPT 
influenza vaccine pandemic formulation h1n1 90663 CPT 
pneumococcal conj vaccine 7 valent 90669 CPT 
pneumococcal conj vaccine 13 valent 90670 CPT 
pneumococcal polysacvaccine, 23 valent, adult dosage 90732 CPT 
pneumonia vaccination V03.82 ICD-9 
influenza vaccination V04.81 ICD-9 
administration of influenza virus vaccine G0008 HCPCS 
administration of pneumococcal vaccine G0009 HCPCS 
flu virus vac split virus intramuscular agriflu Q2034 HCPCS 
influenza vacc split virus 3 yrs & > afluria Q2035 HCPCS 
influenza vacc split virus 3 yrs & > flulaval Q2036 HCPCS 
influenza vacc split virus 3 yrs & > fluvirin Q2037 HCPCS 
influenza vacc split virus 3 yrs & > fluzone Q2038 HCPCS 
influenza vacc split virus 3 yrs & older nos Q2039 HCPCS 
prophylactic vaccination against influenza 99.52 ICD-9 
Ventilation and perfusion:   
pulmonary ventilation imaging 78579 CPT 
pulmonary perfusion imaging 78580 CPT 
pulmonary ventilation & perfusion imaging 78582 CPT 
pulm pi part vntj 1 brth 78584 CPT 
pulm pi part vntj rbrthing wshot brth 78585 CPT 
pulm vi aersl mlt prjcj 78587 CPT 
ventilation/perfusion scan 78588 CPT 
quan diffial funcj vntj/prfuj std 78596 CPT 
quantitative diff pulm perfusion 78597 CPT 
quantitative diff pulm perfusion and ventilation 78598 CPT 
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Table C-2 COPD-Complexity Diagnosis Codes 
Mild Complexity: 
 kyphoscoliotic heart disease (416.1) 
 other chronic pulmonary heart disease (416.8) 
 chronic pulmonary heart disease unspecified (416.9) 
 SARS-associated viral pneumonia (480.3) 
 pneumococcal pneumonia (481) 
 other bacterial pneumonia (482) 
 klebsiella pneumoniae (482.0) 
 pseudomonal pneumonia (482.1) 
 hemophilus influenzae pneumonia (482.2) 
 streptococcal pneumonia (482.3) 
 streptococcal pneumonia not specified(482.30) 
 streptococcal group A pneumonia (482.31) 
 streptococcal group B pneumonia (482.32) 
 streptococcal pneumonia other (482.39) 
 staphylococcal pneumonia (482.4) 
 pneumonia due to staphylococcal unspecified (482.40) 
 pneumonia due to staphylococcus aureus (482.41) 
 other staphylococcus pneumonia (482.49) 
 bacterial pneumonia other specified (482.8) 
 pneumonia due to anaerobes (482.81) 
 escherichia coli pneumonia (482.82) 
 gram negative pneumonia other unspecified (482.83) 
 Legionnaires' disease (482.84) 
 bacterial pneumonia other unspecified (482.89) 
 bacterial pneumonia not specified (482.9) 
 pneumonia: organism other specified (483) 
 Chlamydia pneumonia (483.1) 
 pneumonia: organism other specified (483.8) 
 pneumonia in other infectious disease (484) 
 pneumonia with cytomegalic inclusion disease (484.1) 
 pneumonia in whooping cough (484.3) 
 pneumonia in anthrax (484.5) 
 pneumonia in aspergillosis (484.6) 
 pneumonia in other system mycoses (484.7) 
 pneumonia in infectious disease classified elsewhere (484.8) 
 influenza with pneumonia (487.0) 
 obstructive chronic bronchitis with acute exacerbation (491.21) 
 obstructive chronic bronchitis with acute bronchitis (491.22) 
 emphysematous bleb (492.0) 
 extrinsic asthma with status asthma (493.01) 
 extrinsic asthma with acute exacerbation (493.02) 
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 Intrinsic asthma with status asthmaticus (493.11) 
 intrinsic asthma with acute exacerbation (493.12) 
 chronic obstructive asthma with status asthmaticus (493.21) 
 chronic obstructive asthma with acute exacerbation (493.22) 
 asthma with status asthmaticus (493.91) 
 unspecified asthma with acute exacerbation (493.92) 
 bronchiectasis (494) 
 bronchiectasis without acute exacerbation (494.0) 
 bronchiectasis with acute exacerbation (494.1) 
 extrinsic allergic alveolitis (495) 
 Farmers' lung (495.0) 
 allergic alveolitis and pneumonitis not specified (495.9) 
 asbestosis (501) 
 Pneumonitis due to solids and liquids (507) 
 food/vomit pneumonitis (507.0) 
 empyema (510) 
 empyema with fistula (510.0) 
 empyema without fistula (510.9) 
 Pleurisy with effusion with a bacterial cause other than TB (511.1) 
 pneumothorax (512) 
 spontaneous tension pneumothorax (512.0) 
 spontaneous pneumothorax other (512.8) 
 abscess of lung and mediastinum (513) 
 abscess of lung (513.0) 
 abscess of mediastinum (513.1) 
 pulmonary congestive hypostasis (514) 
 postinflammatory pulmonary fibrosis (515) 
 other alveolar and parietoalveolar pneumonopathy (516) 
 pulmonary alveolar proteinosis (516.0) 
 idiopathic pulmonary hemosiderosis (516.1) 
 idiopathic fibrosing alveolitis (516.3) 
 other specified alveolar and parietoalveolar pneumonopathies (516.8) 
 unspecified alveolar and parietoalveolar pneumonopathy (516.9) 
 lung involving other condition (517) 
 rheumatic pneumonia (517.1) 
 systemic sclerosis lung disease (517.2) 
 lung involvement in other disease classified elsewhere (517.8) 
 pulmonary collapse (518.0) 
 pulmonary eosinophilia (518.3) 
 acute lung edema not specified (518.4) 
 post traumatic pulmonary insufficiency (518.5) 
 acute bronchopulmony aspergillosis (518.6) 
 acute respiratory failure (518.8) 
   
387 
 acute respiratory failure (518.81) 
 other pulmonary insufficiency (518.82) 
 chronic respiratory failure (518.83) 
 acute and chronic respiratory failure (518.84) 
 tracheostomy complications (519.0) 
 tracheostomy complication unspecified (519.00) 
 infection of tracheostomy (519.01) 
 mechanical complication of tracheostomy (519.02) 
 other tracheostomy complication (519.09) 
 cyanosis (782.5) 
 orthopnea (786.02) 
 hemoptysis (786.3) 
 respiratory arrest (799.1) 
 tracheostomy status (V44.0) 
 acquired absence lung (V457.6) 
 dependence on respirator (V46.1) 
 machine dependence supplemental oxygen (V46.2) 
 attention to tracheostomy (V55.0)     
High Complexity: 
  pulmonary TB (011) 
 TB of lung, infiltrate (011.0) 
 TB lung infiltrate -unspecified (011.00) 
 TB lung infiltrate-no exam (011.01) 
 TB lung infiltrate -exam unknown (011.02) 
 TB lung infiltrate -microscopy dx (011.03) 
 TB lung infiltrate -culture dx (011.04) 
 TB lung infiltrate-histology dx (011.05) 
 TB lung infiltrate-other test (011.06) 
 TB of lung, nodular (011.1) 
 TB lung nodular-unspecified (011.10) 
 TB lung nodular-no exam (011.11) 
 TB lung nodule-exam unknown (011.12) 
 TB lung nodular-microscopy dx (011.13) 
 TB lung nodular-culture dx (011.14) 
 TB lung nodular-histology dx (011.15) 
 TB lung nodular-other test (011.16) 
 TB of lung with cavitation (011.2) 
 TB lung with cavity-unspecified (011.20) 
 TB lung with cavity-no exam (011.21) 
 TB lung cavitation-exam unknown (011.22) T 
B lung with cavitation-microscopy dx (011.23)  
TB lung with cavitation-culture dx (011.24) 
 TB lung with cavitation -histology dx (01125) 
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 TB lung with cavitation-other test (011.26) 
 tuberculosis of bronchus (011.3) 
 TB of bronchus-unspecified (011.30) 
 TB of bronchus-no exam (011.31) 
 TB of bronchus-exam unknown (011.32) 
 TB of bronchus-microscopy dx (011.33) 
 TB of bronchus-culture dx (01134) 
 TB of bronchus-histology dx (011.35) 
 TB of bronchus-other test (011.36) 
 TB bronchiectasis (011.5) 
 TB bronchiectasis-unspecified (011.50) 
 TB bronchiectasis-no exam (011.51) 
 TB bronchiectasis-exam unknown (011.52) 
 TB bronchiectasis-microscopy dx (011.53) 
 TB bronchiectasis-culture dx (011.54) 
 TB bronchiectasis-histology dx (011.55) 
 TB bronchiectasis-other test (011.56) 
 tuberculous pneumonia (011.6) 
 TB pneumonia-unspecified (011.60) 
 TB pneumonia-no exam (011.61) 
 TB pneumonia-exam unknown (011.62) 
 TB pneumonia-microscopy dx (011.63) 
TB pneumonia-culture dx (011.64) 
TB pneumonia-histology dx (011.65) 
 TB pneumonia- other test (011.66) 
 tuberculous pneumothorax (011.7) 
 TB pneumothorax-unspecified (011.70) 
 TB pneumothorax-no exam (011.71) 
 TB pneumothorax-exam unknown (011.72) 
 TB pneumothorax-microscopy dx (011.73) 
 TB pneumothorax-bacterial culture dx (011.74) 
 TB pneumothorax-histology dx (011.75) 
 TB pneumothorax-other test (011.76) 
 pulmonary TB nec (011.8) 
 other pulmonary TB unspecified (011.80) 
 pulmonary TB no bacteriological or histological examination (011.81) 
 other pulmonary TB bacteriological or histological examination unknown (011.82) 
 other specified pulmonary TB tubercle bacilli found (in sputum) by microscopy dx 
(011.83) 
 other specified pulmonary TB tubercle bacilli not found (in sputum) by microscopy but 
found by bacterial culture dx (011.84) 
 other specified pulmonary tuberculosis tubercle bacilli not found by bacteriological 
examination but tuberculosis confirmed histology dx (011.85) 
 other specified pulmonary TB tubercle bacilli not found by bacteriological or histological 
examination but tuberculosis confirmed by other methods (011.86) 
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 tuberculous pleurisy (012.0) 
 aspergillosis (117.3) 
 pneumocystosis (136.3) 
 malignant neoplasm trachea/lung (162) 
 malignant neoplasm trachea (162.0) 
 malignant neoplasm main bronchus (162.2) 
 malignant neoplasm upper lobe lung (162.3) 
 malignant neoplasm middle lobe lung (162.4) 
 malignant neoplasm lower lobe lung (162.5) 
 malignant neoplasm of other parts of bronchus or lung (162.8) 
 malignant neoplasm of bronchus and lung unspecified (162.9) 
 malignant neoplasm pleura (163) 
 malignant neoplasm parietal pleura (163.0) 
 malignant neoplasm visceral pleura (163.1) 
 malignant neoplasm of other specified sites of pleura (163.8) 
 malignant neoplasm pleura not specified (163.9) 
 second malignant neoplasm pleura (197.2) 
 cystic fibrosis (277.0) 
 cystic fibros without meconium ileus (277.00) 
 cystic fibrosis with pulmonary (277.02) 
 cystic fibrosis with gastrointestinal (277.03) 
 cystic fibrosis with other manifestations (277.09) 
 secondary polycythemia (289.0) 
 acute pulmonary heart disease (415) 
 acute cor pulmonale (415.0) 
 pulmonary embolism/infarct (415.1) 
 iatrogenic pulmonary embolism and infarction (415.11) 
 other pulmonary embolism and infarction (415.19) 
 chronic pulmonary heart disease (416) 
 primary pulmonary hypertension (416.0)     
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Appendix D: NCQA Standardized Prices by BETOS Categories 
Appendix D 
NCQA and LHP Standardized Prices by BETOS Categories 
 
Table D-1 NCQA Standardized Prices for BETOS categories 
BETOS Category BETOS Description Minimum 10th Percentile Median Mean 90th Percentile Maximum 
(1) EVALUATION 
AND MANAGEMENT 
Consultations 40 100 201 171 246 246 
Emergency room visit 61 146 239 260 314 624 
Home visit 59 105 239 194 239 239 
Hospital visit - critical care 115 136 303 266 303 303 
Hospital visit - initial 87 147 222 212 222 514 
Hospital visit - subsequent 41 43 79 91 117 264 
Nursing home visit 33 75 114 125 183 237 
Office visits - established 14 48 80 92 118 162 
Office visits - new 30 82 119 135 183 226 
Specialist - opthamology 8 50 60 66 80 136 
Specialist - other 15 37 90 74 94 313 
Specialist - psychiatry 10 37 56 71 134 159 
(2) PROCEDURES Ambulatory procedures - groin hernia repair 141 882 882 851 882 1323 
Ambulatory procedures - lithotripsy 974 1405 1405 1380 1405 1405 
Ambulatory procedures - musculoskeletal 92 500 891 938 1248 3852 
Ambulatory procedures - other 16 16 39 206 732 2979 
Ambulatory procedures - skin 8 12 139 231 548 1747 
Anesthesia 40 113 236 305 516 1495 
Dialysis services (Medicare Fee Schedule) 250 329 401 375 401 401 
Dialysis services (Non-Medicare Fee Schedule) 3 3 32 91 304 1385 
Endoscopy - arthroscopy 49 172 941 824 1847 1847 
Endoscopy - bronchoscopy 47 253 544 652 2072 2072 
Endoscopy - colonoscopy 144 459 822 716 925 1073 
Endoscopy - cystoscopy 35 354 354 423 675 1469 
Endoscopy - laryngoscopy 100 200 200 234 373 597 
Endoscopy - other 5 149 384 533 890 2896 
Endoscopy - sigmoidoscopy 32 110 244 254 302 595 
Endoscopy - upper gastrointestinal 123 299 601 506 601 891 
(2) PROCEDURES Eye procedure - cataract removal/lens insertion 260 1301 1301 1315 1301 1803 
Eye procedure - corneal transplant 1939 1939 2075 2033 2078 2078 
Eye procedure - other 49 198 198 446 1006 2507 
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BETOS Category BETOS Description Minimum 10th Percentile Median Mean 90th Percentile Maximum 
Eye procedure - retinal detachment 888 888 2562 2174 2952 2952 
Eye procedure - treatment of retinal lesions 489 489 896 1116 1782 1782 
(2) PROCEDURES Major procedure - Other 61 189 397 1072 2478 13002 
Major procedure - breast 175 611 1098 1375 2015 2901 
Major procedure - cardiovascualr-Coronary angioplasty (PTCA) 284 408 1432 1033 1432 1432 
Major procedure - cardiovascular-Aneurysm repair 165 533 797 840 886 3422 
Major procedure - cardiovascular-CABG 53 117 687 1331 3335 4292 
Major procedure - cardiovascular-Other 14 88 592 1032 2245 16257 
Major procedure - cardiovascular-Pacemaker insertion 314 391 850 875 1582 1582 
Major procedure - cardiovascular-Thromboendarterectomy 288 304 1902 1536 1902 2926 
Major procedure - cholecystectomy 294 294 1836 1544 1836 1836 
Major procedure - colectomy 206 365 2280 1834 3095 3600 
Major procedure - explor/decompr/excis disc 53 59 379 980 2370 4222 
Major procedure - hysterctomy 230 268 1520 1285 2225 3372 
Major procedure - orthopedic - Hip fracture repair 328 339 2106 1787 2117 2117 
Major procedure - orthopedic - Hip replacement 310 395 2472 2018 2472 3301 
Major procedure - orthopedic - Knee replacement 238 422 2641 1821 2641 3961 
Major procedure - orthopedic - other 31 113 708 1236 2415 13105 
Major procedure - turp 537 1320 1449 2168 3379 3379 
(2) PROCEDURES Minor procedures - musculoskeletal 19 92 119 186 357 1879 
Minor procedures - other (Medicare fee schedule) 10 17 38 63 124 11476 
Minor procedures - other (non-Medicare fee schedule) 70 102 188 204 234 1862 
Minor procedures - skin 26 74 89 148 193 1583 
Oncology - other 40 44 190 131 190 190 
Oncology - radiation therapy 23 48 250 349 753 3140 
(3) IMAGING Advanced imaging - CAT/CT/CTA: brain/head/neck 65 65 88 178 381 913 
Advanced imaging - CAT/CT/CTA: other 66 79 147 254 501 999 
Advanced imaging - MRI/MRA: brain/head/neck 93 114 182 473 1041 1260 
Advanced imaging - MRI/MRA: other 104 106 563 581 1134 2338 
Echography/ultrasonography - abdomen/pelvis 30 45 62 121 227 227 
Echography/ultrasonography - carotid arteries 182 182 182 182 182 182 
Echography/ultrasonography - eye 45 45 45 51 58 147 
Echography/ultrasonography - heart 52 76 176 131 176 523 
Echography/ultrasonography - other 14 45 162 155 261 327 
Echography/ultrasonography - prostate 54 54 220 171 220 279 
Imaging/procedure - heart including cardiac catheter 19 169 169 171 231 231 
Imaging/procedure - other 13 64 102 147 191 2897 
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BETOS Category BETOS Description Minimum 10th Percentile Median Mean 90th Percentile Maximum 
Standard imaging - breast 5 17 63 60 88 162 
Standard imaging - chest 5 14 17 30 49 233 
Standard imaging - contrast gastrointestinal 29 36 70 117 252 560 
Standard imaging - musculoskeletal 10 13 34 37 64 173 
Standard imaging - nuclear medicine 2 6 98 189 480 796 
Standard imaging - other 13 14 40 70 255 617 
(4) TESTS Lab tests - automated general profiles 3 10 13 13 13 41 
Lab tests - bacterial cultures 2 10 10 12 12 83 
Lab tests - blood counts 0 8 10 9 10 33 
Lab tests - glucose 1 3 4 4 6 61 
Lab tests - other (Medicare fee schedule) 4 14 103 93 138 1280 
Lab tests - other (non-Medicare fee schedule) 0 5 12 16 28 1278 
Lab tests - routine venipuncture (non Medicare fee schedule) 5 10 10 10 10 10 
Lab tests - urinalysis 1 3 4 4 10 29 
(4) TESTS Other tests - EKG monitoring 25 25 65 94 211 258 
Other tests - cardiovascular stress tests 18 18 27 100 302 302 
Other tests - electrocardiograms 10 11 11 29 74 74 
Other tests - other 7 7 49 74 86 889 
(5) DURABLE 
MEDICAL 
EQUIPMENT 
Drugs Administered through DME 1 1 2 3 6 6 
Hospital beds 102 102 102 102 102 102 
Medical/surgical supplies 1 11 178 488 865 5820 
Other DME 3 28 94 156 343 5250 
Oxygen and supplies 5 56 98 86 98 174 
Prosthestic/Orthotic devices 2 17 59 75 124 1171 
Wheelchairs 43 43 51 416 83 6112 
(6) OTHER Ambulance 14 19 72 161 315 6759 
Chemotherapy 1 50 390 909 2242 4941 
Chiropractic 23 23 27 27 28 38 
Enteral and parenteral 81 81 212 237 468 468 
Immunizations/Vaccinations 12 16 16 19 32 61 
Other drugs 0.6 4 12 170 465 4668 
(7) EXCEPTIONS/ 
UNCLASSIFIED 
Other - Medicare fee schedule 22 22 38 44 74 375 
Other - non-Medicare fee schedule 4 4 4 4 4 4 
Undefined codes 5 41 104 97 111 1222 
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Table D-2 Standardized Prices LHP Utilization 
  Total Procedures Total Distinct Procedure Code Values 
 
BETOS Category BETOS Description Total Matched to 
NCQA Price  
No Match: NCQA 
or LHP Std Price  
Total Matched to 
NCQA Price   
No Match: NCQA 
or LHP Std Price   
    N N % N % N N % N % 
 
(1) EVALUATION 
AND 
MANAGEMENT (E 
& M) 
Consultations 9,450 9,190 97.2% 39 0.4% 22 10 45.5% 2 9.1% 
 
Emergency room visit 13,686 0 0.0% 5 0.0% 11  0  0.0% 4 36.4% 
 
Home visit 1,716 1,373 80.0% 6 0.3% 16 9 56.3% 2 12.5% 
 
Hospital visit - critical care 1,357 1,231 90.7% 28 2.1% 6 3 50.0% 2 33.3% 
 
Hospital visit - initial 4,802 3,981 82.9% 2 0.0% 8 3 37.5% 1 12.5% 
 
Hospital visit - subsequent 11,994 11,660 97.2% 7 0.1% 15 12 80.0% 2 13.3% 
 
Nursing home visit 2,070 2,066 99.8% 0 0.0% 21 17 81.0% 0 0.0% 
 
Office visits - established 122,529 118,708 96.9% 35 0.0% 32 16 50.0% 4 12.5% 
 
Office visits - new 7,445 7,230 97.1% 12 0.2% 16 9 56.3% 1 6.3% 
 
Specialist - opthamology 13,623 106 0.8% 44 0.3% 27 1 3.7% 10 37.0% 
 
Specialist - other 8,846 839 9.5% 4,263 48.2% 80 7 8.8% 60 75.0% 
 
Specialist - psychiatry 4,582 0 0.0% 48 1.0% 28 0 0.0% 14 50.0% 
 
(1) E &M Subtotal 202,100 156,384 77.4% 4,489 2.2% 282 87 30.9% 102 36.2% 
 
(2) PROCEDURES Ambulatory procedures - groin hernia repair 104 104 100.0% 0 0.0% 5 5 100.0% 0 0.0% 
 
Ambulatory procedures - lithotripsy 17 17 100.0% 0 0.0% 1 1 100.0% 0 0.0% 
 
Ambulatory procedures - musculoskeletal 735 727 98.9% 8 1.1% 146 145 99.3% 1 0.7% 
 
Ambulatory procedures - other 3,889 1,021 26.3% 14 0.4% 149 136 91.3% 8 5.4% 
 
Ambulatory procedures - skin 5,697 5,696 100.0% 1 0.0% 97 96 99.0% 1 1.0% 
 
(2) PROCEDURES Subtotal 10,442 7,565 72.4% 23 0.2% 398 383 96.2% 10 2.5% 
 
(2) PROCEDURES Anesthesia 3,338 0 0.0% 428 12.8% 139     86 61.9% 
 
(2) PROCEDURES Subtotal 3,338 0 0.0% 428 12.8% 139 0 0.0% 86 61.9% 
 
(2) PROCEDURES Dialysis services (Medicare Fee Schedule) 4,446 0 0.0% 50 1.1% 12     7 58.3% 
 
Dialysis services (Non-Medicare Fee Schedule) 1,202 0 0.0% 51 4.2% 16     7 43.8% 
 
(2) PROCEDURES Subtotal 5,648 0 0.0% 101 1.8% 28 0 0.0% 14 50.0% 
 
(2) PROCEDURES Endoscopy - arthroscopy 390 385 98.7% 0 0.0% 27 26 96.3% 0 0.0% 
 
Endoscopy - bronchoscopy 382 382 100.0% 0 0.0% 18 18 100.0% 0 0.0% 
 
Endoscopy - colonoscopy 1,480 1,051 71.0% 0 0.0% 13 11 84.6% 0 0.0% 
 
Endoscopy - cystoscopy 613 613 100.0% 0 0.0% 25 25 100.0% 0 0.0% 
 
Endoscopy - laryngoscopy 289 289 100.0% 0 0.0% 14 14 100.0% 0 0.0% 
 
Endoscopy - other 438 420 95.9% 18 4.1% 49 46 93.9% 3 6.1% 
 
Endoscopy - sigmoidoscopy 96 96 100.0% 0 0.0% 11 11 100.0% 0 0.0% 
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  Total Procedures Total Distinct Procedure Code Values 
 
BETOS Category BETOS Description Total Matched to 
NCQA Price  
No Match: NCQA 
or LHP Std Price  
Total Matched to 
NCQA Price   
No Match: NCQA 
or LHP Std Price   
    N N % N % N N % N % 
 
Endoscopy - upper gastrointestinal 1,282 1,282 100.0% 0 0.0% 32 32 100.0% 0 0.0% 
 
(2) PROCEDURES Subtotal 4,970 4,518 90.9% 18 0.4% 189 183 96.8% 3 1.6% 
 
(2) PROCEDURES Eye procedure - cataract removal/lens insertion 1,671 1,671 100.0% 0 0.0% 4 4 100.0% 0 0.0% 
 
Eye procedure - corneal transplant 17 16 94.1% 1 5.9% 4 3 75.0% 1 25.0% 
 
Eye procedure - other 1,252 1,213 96.9% 39 3.1% 59 52 88.1% 7 11.9% 
 
Eye procedure - retinal detachment 66 66 100.0% 0 0.0% 7 7 100.0% 0 0.0% 
 
Eye procedure - treatment of retinal lesions 75 75 100.0% 0 0.0% 4 4 100.0% 0 0.0% 
 
(2) PROCEDURES Subtotal 3,081 3,041 98.7% 40 1.3% 78 70 89.7% 8 10.3% 
 
(2) PROCEDURES Major procedure - Other 1,299 1,128 86.8% 60 4.6% 250 227 90.8% 21 8.4% 
 
Major procedure - breast 69 69 100.0% 0 0.0% 16 16 100.0% 0 0.0% 
 
Major procedure - cardiovascualr-Coronary 
angioplasty (PTCA) 
297 262 88.2% 8 2.7% 8 6 75.0% 1 12.5% 
 
Major procedure - cardiovascular-Aneurysm repair 57 56 98.2% 1 1.8% 8 7 87.5% 1 12.5% 
 
Major procedure - cardiovascular-CABG 91 91 100.0% 0 0.0% 8 8 100.0% 0 0.0% 
 
Major procedure - cardiovascular-Other 1,664 1,185 71.2% 164 9.9% 139 108 77.7% 23 16.5% 
 
Major procedure - cardiovascular-Pacemaker 
insertion 
251 250 99.6% 1 0.4% 21 20 95.2% 1 4.8% 
 
Major procedure - cardiovascular-
Thromboendarterectomy 
25 25 100.0% 0 0.0% 3 3 100.0% 0 0.0% 
 
Major procedure - cholecystectomy 8 8 100.0% 0 0.0% 2 2 100.0% 0 0.0% 
 
Major procedure - colectomy 31 31 100.0% 0 0.0% 9 9 100.0% 0 0.0% 
 
Major procedure - explor/decompr/excis disc 255 255 100.0% 0 0.0% 18 18 100.0% 0 0.0% 
 
Major procedure - hysterctomy 30 30 100.0% 0 0.0% 11 11 100.0% 0 0.0% 
 
Major procedure - orthopedic - Hip fracture repair 113 113 100.0% 0 0.0% 5 5 100.0% 0 0.0% 
 
Major procedure - orthopedic - Hip replacement 74 74 100.0% 0 0.0% 5 5 100.0% 0 0.0% 
 
Major procedure - orthopedic - Knee replacement 139 139 100.0% 0 0.0% 3 3 100.0% 0 0.0% 
 
Major procedure - orthopedic - other 838 819 97.7% 19 2.3% 125 118 94.4% 7 5.6% 
 
Major procedure - turp 27 27 100.0% 0 0.0% 4 4 100.0% 0 0.0% 
 
(2) PROCEDURES Subtotal 5,268 4,562 86.6% 253 4.8% 635 570 89.8% 54 8.5% 
 
(2) PROCEDURES Minor procedures - musculoskeletal 8,618 8,613 99.9% 5 0.1% 113 112 99.1% 1 0.9% 
 
Minor procedures - other (Medicare fee schedule) 54,957 4,606 8.4% 14,192 25.8% 269 157 58.4% 40 14.9% 
 
Minor procedures - other (non-Medicare fee 
schedule) 
360 141 39.2% 31 8.6% 14 7 50.0% 2 14.3% 
 
Minor procedures - skin 6,096 6,095 100.0% 1 0.0% 86 85 98.8% 1 1.2% 
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  Total Procedures Total Distinct Procedure Code Values 
 
BETOS Category BETOS Description Total Matched to 
NCQA Price  
No Match: NCQA 
or LHP Std Price  
Total Matched to 
NCQA Price   
No Match: NCQA 
or LHP Std Price   
    N N % N % N N % N % 
 
(2) PROCEDURES Subtotal 70,031 19,455 27.8% 14,229 20.3% 482 361 74.9% 44 9.1% 
 
(2) PROCEDURES Oncology - other 2,014 94 4.7% 2 0.1% 10 1 10.0% 1 10.0% 
 
Oncology - radiation therapy 4,033 3,911 97.0% 7 0.2% 48 32 66.7% 2 4.2% 
 
(2) PROCEDURES Subtotal 6,047 4,005 66.2% 9 0.1% 58 33 56.9% 3 5.2% 
 
(3) IMAGING Advanced imaging - CAT/CT/CTA: 
brain/head/neck 
3,134 3,107 99.1% 0 0.0% 17 14 82.4% 0 0.0% 
 
Advanced imaging - CAT/CT/CTA: other 12,482 12,354 99.0% 17 0.1% 62 39 62.9% 5 8.1% 
 
Advanced imaging - MRI/MRA: brain/head/neck 1,096 1,083 98.8% 1 0.1% 14 10 71.4% 1 7.1% 
 
Advanced imaging - MRI/MRA: other 3,455 3,214 93.0% 31 0.9% 61 39 63.9% 8 13.1% 
 
Echography/ultrasonography - abdomen/pelvis 2,558 2,527 98.8% 3 0.1% 16 8 50.0% 2 12.5% 
 
Echography/ultrasonography - carotid arteries 915 0 0.0% 4 0.4% 2     1 50.0% 
 
Echography/ultrasonography - eye 1,284 183 14.3% 0 0.0% 5 2 40.0% 0 0.0% 
 
Echography/ultrasonography - heart 9,530 15 0.2% 34 0.4% 18 3 16.7% 9 50.0% 
 
Echography/ultrasonography - other 6,283 1,943 30.9% 53 0.8% 39 18 46.2% 6 15.4% 
 
Echography/ultrasonography - prostate 120 107 89.2% 0 0.0% 3 2 66.7% 0 0.0% 
 
Imaging/procedure - heart including cardiac 
catheter 
1,370 1 0.1% 20 1.5% 15 1 6.7% 7 46.7% 
 
Imaging/procedure - other 3,931 2,892 73.6% 309 7.9% 99 61 61.6% 17 17.2% 
 
Standard imaging - breast 3,800 415 10.9% 3 0.1% 14 2 14.3% 1 7.1% 
 
Standard imaging - chest 27,610 27,404 99.3% 1 0.0% 26 17 65.4% 1 3.8% 
 
Standard imaging - contrast gastrointestinal 1,336 1,252 93.7% 3 0.2% 27 16 59.3% 1 3.7% 
 
Standard imaging - musculoskeletal 21,526 19,205 89.2% 12 0.1% 129 80 62.0% 5 3.9% 
 
Standard imaging - nuclear medicine 10,764 2,128 19.8% 133 1.2% 105 51 48.6% 26 24.8% 
 
Standard imaging - other 3,311 2,867 86.6% 71 2.1% 77 52 67.5% 7 9.1% 
 
(3) IMAGING Subtotal 114,505 80,697 70.5% 695 0.6% 729 415 56.9% 97 13.3% 
 
(4) TESTS Lab tests - automated general profiles 24,735 24,599 99.5% 1 0.0% 10 5 50.0% 1 10.0% 
 
Lab tests - bacterial cultures 7,412 7,145 96.4% 0 0.0% 22 13 59.1% 0 0.0% 
 
Lab tests - blood counts 24,813 24,511 98.8% 4 0.0% 25 16 64.0% 2 8.0% 
 
Lab tests - glucose 3,720 3,325 89.4% 11 0.3% 18 7 38.9% 5 27.8% 
 
Lab tests - other (Medicare fee schedule) 10,265 7,686 74.9% 1,039 10.1% 101 60 59.4% 10 9.9% 
 
Lab tests - other (non-Medicare fee schedule) 135,657 121,212 89.4% 535 0.4% 996 579 58.1% 161 16.2% 
 
Lab tests - routine venipuncture (non Medicare fee 
schedule) 
487 487 100.0% 0 0.0% 1 1 100.0% 0 0.0% 
 
Lab tests - urinalysis 10,971 9,689 88.3% 0 0.0% 16 8 50.0% 0 0.0% 
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  Total Procedures Total Distinct Procedure Code Values 
 
BETOS Category BETOS Description Total Matched to 
NCQA Price  
No Match: NCQA 
or LHP Std Price  
Total Matched to 
NCQA Price   
No Match: NCQA 
or LHP Std Price   
    N N % N % N N % N % 
 
(4) TESTS Subtotal 218,060 198,654 91.1% 1,590 0.7% 1,189 689 57.9% 179 15.1% 
 
(4) TESTS Other tests - EKG monitoring 1,007 0 0.0% 212 21.1% 24 0 0.0% 11 45.8% 
 
Other tests - cardiovascular stress tests 1,688 0 0.0% 0 0.0% 8 0 0.0% 0 0.0% 
 
Other tests - electrocardiograms 15,691 0 0.0% 0 0.0% 4 0 0.0% 0 0.0% 
 
Other tests - other 41,462 0 0.0% 1,737 4.2% 158 0 0.0% 94 59.5% 
 
(4) TESTS Subtotal 59,848 0 0.0% 1,949 3.3% 194 0 0.0% 105 54.1% 
 
(5) DURABLE 
MEDICAL 
EQUIPMENT 
Drugs Administered through DME 1,314 0 0.0% 112 8.5% 19 0 0.0% 14 73.7% 
 
Hospital beds 594 0 0.0% 20 3.4% 5 0 0.0% 4 80.0% 
 
Medical/surgical supplies 3,514 0 0.0% 1,240 35.3% 157 0 0.0% 124 79.0% 
 
Other DME 11,967 0 0.0% 630 5.3% 130 0 0.0% 78 60.0% 
 
Oxygen and supplies 92,670 0 0.0% 111 0.1% 17 0 0.0% 11 64.7% 
 
Prosthestic/Orthotic devices 7,841 0 0.0% 1,241 15.8% 333 0 0.0% 247 74.2% 
 
Wheelchairs 1,760 0 0.0% 203 11.5% 37 0 0.0% 30 81.1% 
 
(6) OTHER Ambulance 15,727 0 0.0% 75 0.5% 33 0 0.0% 9 27.3% 
 
Chemotherapy 1,635 0 0.0% 296 18.1% 54 0 0.0% 26 48.1% 
 
Chiropractic 2,984 0 0.0% 0 0.0% 4 0 0.0% 0 0.0% 
 
Enteral and parenteral 316 0 0.0% 22 7.0% 10 0 0.0% 4 40.0% 
 
Hearing and speech services 151 0 0.0% 151 100.0% 23 0 0.0% 23 100.0% 
 
Immunizations/Vaccinations 42,202 0 0.0% 33,578 79.6% 44 0 0.0% 33 75.0% 
 
Other drugs 33,508 0 0.0% 1,125 3.4% 267 0 0.0% 136 50.9% 
 
(7) EXCEPTIONS/ 
UNCLASSIFIED 
Other - Medicare fee schedule 3,691 15 0.4% 258 7.0% 33 3 9.1% 21 63.6% 
 
Other - non-Medicare fee schedule 296 0 0.0% 103 34.8% 9 0 0.0% 8 88.9% 
 
NCQA undefined codes 23,952 0 0.0% 1,776 7.4% 133 0 0.0% 109 82.0% 
 
(8) UNKNOWN Other codes not included in NCQA lists 860 0 0.0% 531 61.7% 104 0 0.0% 96 92.3% 
 
  Subtotal 244,982 15 0.0% 41,472 16.9% 1,412 3 0.2% 973 68.9% 
 
  Total 948,320 478,896 50.5% 65,296 6.9% 5,813 2,794 48.1% 1,678 28.9% 
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Table D-3 Standardized Prices PHP Utilization 
  Total Procedures Total Distinct Procedure Code Values 
 
BETOS Category BETOS Description Total Matched to 
NCQA Price  
No Match: NCQA 
or LHP Std Price  
Total Matched to 
NCQA Price   
No Match: NCQA 
or LHP Std Price   
    N N % N % N N % N % 
 
(1) EVALUATION 
AND 
MANAGEMENT 
Consultations 6,141 6,035 98.3% 42 0.7% 16 10 62.5% 2 12.5% 
 
Emergency room visit 14,828 0 0.0% 5 0.0% 9 0 0.0% 2 22.2% 
 
Home visit 894 605 67.7% 259 29.0% 17 9 52.9% 3 17.6% 
 
Hospital visit - critical care 1,606 1,549 96.5% 22 1.4% 6 2 33.3% 3 50.0% 
 
Hospital visit - initial 3,156 2,718 86.1% 0 0.0% 7 3 42.9% 0 0.0% 
 
Hospital visit - subsequent 17,719 17,556 99.1% 8 0.0% 16 13 81.3% 2 12.5% 
 
Nursing home visit 2,223 2,223 100.0% 0 0.0% 17 17 100.0% 0 0.0% 
 
Office visits - established 93,457 91,413 97.8% 3 0.0% 26 14 53.8% 2 7.7% 
 
Office visits - new 5,831 5,773 99.0% 2 0.0% 15 8 53.3% 1 6.7% 
 
Specialist - opthamology 8,112 84 1.0% 41 0.5% 24 1 4.2% 7 29.2% 
 
Specialist - other 4,418 235 5.3% 1,310 29.7% 51 3 5.9% 38 74.5% 
 
Specialist - psychiatry 3,784 0 0.0% 111 2.9% 19 0 0.0% 6 31.6% 
 
(1) EVALUATION 
AND MANAGEMENT 
Subtotal 162,169 128,191 79.0% 1,803 0.9% 223 80 35.9% 66 23.4% 
 
(2) PROCEDURES Ambulatory procedures - groin hernia repair 55 55 100.0% 0 0.0% 2 2 100.0% 0 0.0% 
 
Ambulatory procedures - lithotripsy 10 10 100.0% 0 0.0% 1 1 100.0% 0 0.0% 
 
Ambulatory procedures - musculoskeletal 582 565 97.1% 17 2.9% 121 120 99.2% 1 0.8% 
 
Ambulatory procedures - other 2,788 1,357 48.7% 115 4.1% 124 112 90.3% 6 4.8% 
 
Ambulatory procedures - skin 4,346 4,346 100.0% 0 0.0% 103 103 100.0% 0 0.0% 
 
(2) PROCEDURES Subtotal 7,781 6,333 81.4% 132 1.3% 351 338 96.3% 7 1.8% 
 
(2) PROCEDURES Anesthesia 3,354 0 0.0% 350 10.4% 135 0 0.0% 83 61.5% 
 
(2) PROCEDURES Subtotal 3,354 0 0.0% 350 10.5% 135 0 0.0% 83 59.7% 
 
(2) PROCEDURES Dialysis services (Medicare Fee Schedule) 6,075 0 0.0% 102 1.7% 12 0 0.0% 6 50.0% 
 
Dialysis services (Non-Medicare Fee Schedule) 4,050 0 0.0% 63 1.6% 18 0 0.0% 10 55.6% 
 
(2) PROCEDURES Subtotal 10,125 0 0.0% 165 2.9% 30 0 0.0% 16 57.1% 
 
(2) PROCEDURES Endoscopy - arthroscopy 320 293 91.6% 0 0.0% 21 20 95.2% 0 0.0% 
 
Endoscopy - bronchoscopy 271 271 100.0% 0 0.0% 15 15 100.0% 0 0.0% 
 
Endoscopy - colonoscopy 1,996 1,527 76.5% 0 0.0% 11 9 81.8% 0 0.0% 
 
Endoscopy - cystoscopy 339 339 100.0% 0 0.0% 23 23 100.0% 0 0.0% 
 
Endoscopy - laryngoscopy 243 243 100.0% 0 0.0% 10 10 100.0% 0 0.0% 
 
Endoscopy - other 349 332 95.1% 17 4.9% 34 33 97.1% 1 2.9% 
 
Endoscopy - sigmoidoscopy 59 59 100.0% 0 0.0% 6 6 100.0% 0 0.0% 
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  Total Procedures Total Distinct Procedure Code Values 
 
BETOS Category BETOS Description Total Matched to 
NCQA Price  
No Match: NCQA 
or LHP Std Price  
Total Matched to 
NCQA Price   
No Match: NCQA 
or LHP Std Price   
    N N % N % N N % N % 
 
Endoscopy - upper gastrointestinal 1,440 1,440 100.0% 0 0.0% 30 30 100.0% 0 0.0% 
 
(2) PROCEDURES Subtotal 5,017 4,504 89.8% 17 0.3% 150 146 97.3% 1 0.5% 
 
(2) PROCEDURES Eye procedure - cataract removal/lens insertion 1,299 1,299 100.0% 0 0.0% 4 4 100.0% 0 0.0% 
 
Eye procedure - corneal transplant 12 10 83.3% 2 16.7% 4 3 75.0% 1 25.0% 
 
Eye procedure - other 971 951 97.9% 20 2.1% 45 42 93.3% 3 6.7% 
 
Eye procedure - retinal detachment 60 60 100.0% 0 0.0% 8 8 100.0% 0 0.0% 
 
Eye procedure - treatment of retinal lesions 30 30 100.0% 0 0.0% 4 4 100.0% 0 0.0% 
 
(2) PROCEDURES Subtotal 2,372 2,350 99.1% 22 0.7% 65 61 93.8% 4 5.1% 
 
(2) PROCEDURES Major procedure - Other 1,181 1,117 94.6% 36 3.0% 202 187 92.6% 14 6.9% 
 
Major procedure - breast 48 48 100.0% 0 0.0% 9 9 100.0% 0 0.0% 
 
Major procedure - cardiovascualr-Coronary 
angioplasty (PTCA) 
124 103 83.1% 16 12.9% 10 7 70.0% 2 20.0% 
 
Major procedure - cardiovascular-Aneurysm repair 20 16 80.0% 4 20.0% 11 8 72.7% 3 27.3% 
 
Major procedure - cardiovascular-CABG 61 61 100.0% 0 0.0% 6 6 100.0% 0 0.0% 
 
Major procedure - cardiovascular-Other 1,159 742 64.0% 118 10.2% 110 84 76.4% 18 16.4% 
 
Major procedure - cardiovascular-Pacemaker 
insertion 
102 102 100.0% 0 0.0% 14 14 100.0% 0 0.0% 
 
Major procedure - cardiovascular-
Thromboendarterectomy 
21 21 100.0% 0 0.0% 1 1 100.0% 0 0.0% 
 
Major procedure - cholecystectomy 6 6 100.0% 0 0.0% 1 1 100.0% 0 0.0% 
 
Major procedure - colectomy 47 47 100.0% 0 0.0% 6 6 100.0% 0 0.0% 
 
Major procedure - explor/decompr/excis disc 109 109 100.0% 0 0.0% 11 11 100.0% 0 0.0% 
 
Major procedure - hysterctomy 36 36 100.0% 0 0.0% 6 6 100.0% 0 0.0% 
 
Major procedure - orthopedic - Hip fracture repair 76 76 100.0% 0 0.0% 4 4 100.0% 0 0.0% 
 
Major procedure - orthopedic - Hip replacement 45 45 100.0% 0 0.0% 5 5 100.0% 0 0.0% 
 
Major procedure - orthopedic - Knee replacement 132 132 100.0% 0 0.0% 2 2 100.0% 0 0.0% 
 
Major procedure - orthopedic - other 607 596 98.2% 11 1.8% 110 105 95.5% 5 4.5% 
 
Major procedure - turp 28 28 100.0% 0 0.0% 5 5 100.0% 0 0.0% 
 
(2) PROCEDURES Subtotal 3,802 3,285 86.4% 185 3.5% 513 461 89.9% 42 6.6% 
 
(2) PROCEDURES Minor procedures - musculoskeletal 5,974 5,972 100.0% 2 0.0% 108 107 99.1% 1 0.9% 
 
Minor procedures - other (Medicare fee schedule) 37,359 3,269 8.8% 643 1.7% 251 147 58.6% 30 12.0% 
 
Minor procedures - other (non-Medicare fee 
schedule) 
168 105 62.5% 5 3.0% 14 7 50.0% 2 14.3% 
 
Minor procedures - skin 3,924 3,922 99.9% 2 0.1% 78 77 98.7% 1 1.3% 
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  Total Procedures Total Distinct Procedure Code Values 
 
BETOS Category BETOS Description Total Matched to 
NCQA Price  
No Match: NCQA 
or LHP Std Price  
Total Matched to 
NCQA Price   
No Match: NCQA 
or LHP Std Price   
    N N % N % N N % N % 
 
(2) PROCEDURES Subtotal 47,425 13,268 28.0% 652 0.9% 451 338 74.9% 34 7.1% 
 
(2) PROCEDURES Oncology - other 1,283 68 5.3% 209 16.3% 9 1 11.1% 1 11.1% 
 
Oncology - radiation therapy 2,976 2,857 96.0% 24 0.8% 45 30 66.7% 4 8.9% 
 
(2) PROCEDURES Subtotal 4,259 2,925 68.7% 233 3.9% 54 31 57.4% 5 8.6% 
 
(3) IMAGING Advanced imaging - CAT/CT/CTA: 
brain/head/neck 
2,595 2,562 98.7% 0 0.0% 20 14 70.0% 0 0.0% 
 
Advanced imaging - CAT/CT/CTA: other 8,379 8,147 97.2% 46 0.5% 61 36 59.0% 9 14.8% 
 
Advanced imaging - MRI/MRA: brain/head/neck 939 926 98.6% 1 0.1% 17 12 70.6% 1 5.9% 
 
Advanced imaging - MRI/MRA: other 2,223 2,029 91.3% 12 0.5% 57 39 68.4% 5 8.8% 
 
Echography/ultrasonography - abdomen/pelvis 2,738 2,619 95.7% 35 1.3% 20 10 50.0% 3 15.0% 
 
Echography/ultrasonography - carotid arteries 585 0 0.0% 2 0.3% 2 0 0.0% 1 50.0% 
 
Echography/ultrasonography - eye 922 39 4.2% 1 0.1% 6 2 33.3% 1 16.7% 
 
Echography/ultrasonography - heart 4,145 7 0.2% 71 1.7% 20 2 10.0% 11 55.0% 
 
Echography/ultrasonography - other 4,152 1,501 36.2% 50 1.2% 34 15 44.1% 5 14.7% 
 
Echography/ultrasonography - prostate 67 45 67.2% 0 0.0% 3 2 66.7% 0 0.0% 
 
Imaging/procedure - heart including cardiac 
catheter 
974 0 0.0% 5 0.5% 11 0 0.0% 4 36.4% 
 
Imaging/procedure - other 2,843 2,313 81.4% 58 2.0% 84 53 63.1% 11 13.1% 
 
Standard imaging - breast 2,475 214 8.6% 0 0.0% 11 2 18.2% 0 0.0% 
 
Standard imaging - chest 23,758 23,173 97.5% 0 0.0% 21 14 66.7% 0 0.0% 
 
Standard imaging - contrast gastrointestinal 1,052 903 85.8% 1 0.1% 23 16 69.6% 1 4.3% 
 
Standard imaging - musculoskeletal 15,309 12,470 81.5% 2 0.0% 119 74 62.2% 2 1.7% 
 
Standard imaging - nuclear medicine 3,950 1,140 28.9% 263 6.7% 105 47 44.8% 31 29.5% 
 
Standard imaging - other 2,696 2,290 84.9% 116 4.3% 65 42 64.6% 9 13.8% 
 
(3) IMAGING Subtotal 79,802 60,378 75.7% 663 0.6% 679 380 56.0% 94 12.9% 
 
(4) TESTS Lab tests - automated general profiles 22,573 21,178 93.8% 1 0.0% 10 5 50.0% 1 10.0% 
 
Lab tests - bacterial cultures 6,911 6,440 93.2% 0 0.0% 19 12 63.2% 0 0.0% 
 
Lab tests - blood counts 19,689 19,492 99.0% 1 0.0% 23 16 69.6% 1 4.3% 
 
Lab tests - glucose 2,188 1,970 90.0% 29 1.3% 15 7 46.7% 4 26.7% 
 
Lab tests - other (Medicare fee schedule) 7,720 7,488 97.0% 20 0.3% 82 49 59.8% 8 9.8% 
 
Lab tests - other (non-Medicare fee schedule) 104,368 91,888 88.0% 569 0.5% 866 562 64.9% 125 14.4% 
 
Lab tests - routine venipuncture (non Medicare fee 
schedule) 
30,914 30,914 100.0% 0 0.0% 2 2 100.0% 0 0.0% 
 
Lab tests - urinalysis 8,992 8,334 92.7% 4 0.0% 17 9 52.9% 2 11.8% 
 
  
 
4
0
0 
  Total Procedures Total Distinct Procedure Code Values 
 
BETOS Category BETOS Description Total Matched to 
NCQA Price  
No Match: NCQA 
or LHP Std Price  
Total Matched to 
NCQA Price   
No Match: NCQA 
or LHP Std Price   
    N N % N % N N % N % 
 
(4) TESTS Subtotal 203,355 187,704 92.3% 624 0.3% 1,034 662 64.0% 141 11.9% 
 
(4) TESTS Other tests - EKG monitoring 484 0 0.0% 62 12.8% 24 0 0.0% 10 41.7% 
 
Other tests - cardiovascular stress tests 1,160 0 0.0% 0 0.0% 9 0 0.0% 0 0.0% 
 
Other tests - electrocardiograms 13,091 0 0.0% 0 0.0% 6 0 0.0% 0 0.0% 
 
Other tests - other 14,287 0 0.0% 1,531 10.7% 149 0 0.0% 86 57.7% 
 
(4) TESTS Subtotal 29,022 0 0.0% 1,593 2.7% 188 0 0.0% 96 49.5% 
 
(5) DURABLE 
MEDICAL 
EQUIPMENT 
Drugs Administered through DME 819 0 0.0% 184 22.5% 15 0 0.0% 10 66.7% 
 
Hospital beds 630 0 0.0% 72 11.4% 7 0 0.0% 6 85.7% 
 
Medical/surgical supplies 3,096 0 0.0% 1,818 58.7% 142 0 0.0% 112 78.9% 
 
Other DME 9,453 0 0.0% 1,076 11.4% 120 0 0.0% 71 59.2% 
 
Oxygen and supplies 80,281 0 0.0% 1,084 1.4% 18 0 0.0% 12 66.7% 
 
Prosthestic/Orthotic devices 3,951 0 0.0% 1,178 29.8% 263 0 0.0% 193 73.4% 
 
Wheelchairs 2,222 0 0.0% 2,198 98.9% 95 0 0.0% 93 97.9% 
 
(6) OTHER Ambulance 8,219 0 0.0% 38 0.5% 27 0 0.0% 6 22.2% 
 
Chemotherapy 733 0 0.0% 31 4.2% 27 0 0.0% 8 29.6% 
 
Chiropractic 2,649 0 0.0% 0 0.0% 4 0 0.0% 0 0.0% 
 
Enteral and parenteral 267 0 0.0% 38 14.2% 11 0 0.0% 7 63.6% 
 
Hearing and speech services 63 0 0.0% 63 100.0% 19 0 0.0% 19 100.0% 
 
Immunizations/Vaccinations 7,370 0 0.0% 201 2.7% 39 0 0.0% 27 69.2% 
 
Other drugs 26,128 1 0.0% 1,361 5.2% 245 1 0.4% 116 47.3% 
 
(7) 
EXCEPTIONS/UNCL
ASSIFIED 
Other - Medicare fee schedule 1,233 10 0.8% 145 11.8% 37 3 8.1% 26 70.3% 
 
Other - non-Medicare fee schedule 25,393 0 0.0% 25,041 98.6% 17 0 0.0% 16 94.1% 
 
Undefined codes 5,315 0 0.0% 4,383 82.5% 83 0 0.0% 70 84.3% 
 
(8) UNKNOWN Other codes not included in NCQA lists 0 0   0   0 0   0   
 
  Subtotal 177,822 11 0.0% 38,911 15.9% 1,169 4 0.3% 792 56.1% 
 
  Total 736,305 408,949 55.5% 45,350 4.8% 5,042 2,501 49.6% 1,381 23.8% 
 
 
 
 
 
  
401 
REFERENCES 
References 
 
Aaron, S. D., D. Fergusson, G. B. Marks, S. Suissa, K. L. Vandemheen, S. Doucette, F. 
Maltais, J. F. Bourbeau, R. S. Goldstein, M. Balter, D. O'Donnell, M. FitzGerald, and R. 
Canadian Thoracic Soc Canadian. 2008. “Counting, analysing and reporting 
exacerbations of COPD in randomised controlled trials.” Thorax 63(2): 122-28. 
Aaron, S. D., K. L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. 
Balter, D. O'Donnell, A. McIvor, S. Sharma, G. Bishop, J. Anthony, R. Cowie, S. Field, 
A. Hirsch, P. Hernandez, R. Rivington, J. Road, V. Hoffstein, R. Hodder, D. Marciniuk, 
D. McCormack, G. Fox, G. Cox, H. B. Prins, G. Ford, D. Bleskie, S. Doucette, I. Mayers, 
K. Chapman, N. Zamel, and M. FitzGerald. 2007. “Tiotropium in combination with 
placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive 
pulmonary disease: a randomized trial.” Ann Intern Med 146(8): 545-55. 
Allison, P. D. 1995. Survival analysis using the SAS system: a practical guide. Cary, NC 
SAS Institute, Inc. 
Allison, P. D. 2001. Logistic regression using the SAS system : theory and application: 
Cary, N.C: SAS Institute, New York: Wiley. 
Anstrom, K. J. and A. A. Tsiatis. 2001. “Utilizing propensity scores to estimate causal 
treatment effects with censored time-lagged data.” Biometrics 57(4): 1207-18. 
Anthonisen, N. R. 2004. “The British hypothesis revisited.” European Respir J 23(5): 
657-58. 
Anzueto, A. 2010. “Impact of exacerbations on COPD.” Eur Respir Rev 19(116): 113-8. 
Austin, P. C. 2008. “A critical appraisal of propensity-score matching in the medical 
literature between 1996 and 2003.” Stat Med 27(12): 2037-49. 
Bahadori, K. and J. M. FitzGerald. 2007. “Risk factors of hospitalization and readmission 
of patients with COPD exacerbation--systematic review.” Int J Chron Obstruct Pulmon 
Dis 2(3): 241-51. 
Baldwin, L. M., C. N. Klabunde, P. Green, W. Barlow, and G. Wright. 2006. “In search 
of the perfect comorbidity measure for use with administrative claims data - Does it 
exist?” Med Care 44(8): 745-53. 
Bang, H. and A. A. Tsiatis. 2000. “Estimating medical costs with censored data.” 
Biometrika 87(2): 329-43. 
Baser, O. 2009. “Too much ado about instrumental variable approach: is the cure worse 
than the disease?” Value in Health 12(8): 1201-09. 
  
402 
Basu, A., D. Polsky, and W. G. Manning. 2011. “Estimating treatment effects on 
healthcare costs under exogeneity: is there a 'magic bullet'?” Health Serv Outcomes Res 
Methodol 11(1-2): 1-26. 
Bjerg, A., B. Lundback, and J. Lotvall. 2012. “The future of combining inhaled drugs for 
COPD.” Curr Opin Pharmacol 12(3): 252-5. 
Blackhouse, G., A. H. Briggs, and B. J. O'Brien. 2002. “A note on the estimation of 
confidence intervals for cost-effectiveness when costs and effects are censored.” Med 
Decis Making 22(2): 173-7. 
Blanchette, C. M., M. H. Roberts, H. Petersen, A. A. Dalal, and D. W. Mapel. 2011. 
“Economic burden of chronic bronchitis in the United States: a retrospective case-control 
study.” Int J Chron Obstruct Pulmon Dis 6: 73-81. 
Brookhart, M. A., J. A. Rassen, P. S. Wang, C. Dormuth, H. Mogun, and S. Schneeweiss. 
2007. “Evaluating the validity of an instrumental variable study of neuroleptics: can 
between-physician differences in prescribing patterns be used to estimate treatment 
effects?” Med Care 45(10 Supl 2): S116-22. 
Brooks, J. M. and R. L. Ohsfeldt. 2012. “Squeezing the balloon: propensity scores and 
unmeasured covariate balance.” Health Serv Res. 
Brumback, B. A., M. A. Hernan, S. J. Haneuse, and J. M. Robins. 2004. “Sensitivity 
analyses for unmeasured confounding assuming a marginal structural model for repeated 
measures.” Stat Med 23(5): 749-67. 
Buist, A. S., M. A. McBurnie, W. M. Vollmer, S. Gillespie, P. Burney, D. M. Mannino, 
A. M. B. Menezes, S. D. Sullivan, T. A. Lee, K. B. Weiss, R. L. Jensen, G. B. Marks, A. 
Gulsvik, E. Nizankowska-Mogilnicka, and B. C. R. Grp. 2007. “International variation in 
the prevalence of COPD (The BOLD Study): a population-based prevalence study.” 
Lancet 370(9589): 741-50. 
Burney, P., S. Suissa, J. B. Soriano, W. M. Vollmer, G. Viegi, S. D. Sullivan, L. M. 
Fabbri, D. D. Sin, P. Ernst, D. Coultas, J. Bourbeau, D. W. Mapel, K. Weiss, T. 
McLaughlin, D. Price, M. C. Sturkenboom, R. Taylor, and G. W. Hagan. 2003. “The 
pharmacoepidemiology of COPD: recent advances and methodological discussion.” Eur 
Respir J Suppl 43: 1s-44s. 
Busso, M., J. DiNardo, and J. McCrary. 2009. “New evidence on the finite sample 
properties of propensity score matching and reweighting estimators.” The Institute for the 
Study of Labor (IZA) Discussion Paper 3998. 
Bustacchini, S., C. Chiatti, G. Furneri, F. Lattanzio, and L. G. Mantovani. 2011. “The 
economic burden of chronic obstructive pulmonary disease in the elderly: results from a 
systematic review of the literature.” Curr Opin Pulm Med 17 Suppl 1: S35-41. 
  
403 
Cazzola, M., F. Ando, P. Santus, P. Ruggeri, F. Di Marco, A. Sanduzzi, and M. D'Amato. 
2007. “A pilot study to assess the effects of combining fluticasone propionate/salmeterol 
and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.” 
Pulm Pharmacol Ther 20(5): 556-61. 
CCW. "Centers for Medicare and Medicaid (CMS) Chronic Condition Data Warehouse 
Condition Categories" [accessed on October 5, 2011. Available at: 
http://www.ccwdata.org/cs/groups/public/documents/document/ccw_conditioncategories.
pdf. 
Celli, B., R. ZuWallack, S. Wang, and S. Kesten. 2003. “Improvement in resting 
inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased 
static lung volumes.” Chest 124(5): 1743-8. 
Chatterjee, A., M. Shah, A. O. D'Souza, B. Bechtel, G. Crater, and A. A. Dalal. 2012. 
“Observational study on the impact of initiating tiotropium alone versus tiotropium with 
fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic 
obstructive pulmonary disease.” Respir Res 13: 15. 
Chen, Y., P. Stewart, R. Dales, H. Johansen, S. Bryan, and G. Taylor. 2005. “In a 
retrospective study of chronic obstructive pulmonary disease inpatients, respiratory 
comorbidities were significantly associated with prognosis.” J Clin Epidemiol 58(11): 
1199-205. 
Choi, H. K., M. A. Hernan, J. D. Seeger, J. M. Robins, and F. Wolfe. 2002. 
“Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.” 
Lancet 359(9313): 1173-7. 
Christensson, C., A. Thoren, and B. Lindberg. 2008. “Safety of inhaled budesonide: 
clinical manifestations of systemic corticosteroid-related adverse effects.” Drug Saf 
31(11): 965-88. 
CMS. 2012. "Berenson-Eggers Type of Service (BETOS) " [accessed on June 3, 2013, 
2012]. Available at: 
http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/BETOS.html. 
Cole, S. R. and M. A. Hernan. 2004. “Adjusted survival curves with inverse probability 
weights.” Comput Methods Programs Biomed 75(1): 45-9. 
Cole, S. R. and M. A. Hernan. 2008. “Constructing inverse probability weights for 
marginal structural models.” Am J Epidemiol 168(6): 656-64. 
Cope, S., G. Capkun-Niggli, R. Gale, C. Lassen, R. Owen, M. J. Ouwens, G. Bergman, 
and J. P. Jansen. 2012. “Efficacy of once-daily indacaterol relative to alternative 
bronchodilators in COPD: a patient-level mixed treatment comparison.” Value in health 
15(3): 524-33. 
  
404 
Cramer, J. A., C. Bradley-Kennedy, and A. Scalera. 2007. “Treatment persistence and 
compliance with medications for chronic obstructive pulmonary disease.” Can Respir J 
14(1): 25-29. 
Crown, W. H., E. R. Berndt, O. Baser, S. N. Finkelstein, W. P. Witt, J. Maguire, and K. 
E. Haver. 2004. “Benefit plan design and prescription drug utilization among asthmatics: 
do patient copayments matter?” Front Health Policy Res 7: 95-127. 
Curtis, L. H., B. G. Hammill, E. L. Eisenstein, J. M. Kramer, and K. J. Anstrom. 2007. 
“Using inverse probability-weighted estimators in comparative effectiveness analyses 
with observational databases.” Med Care 45(10 Supl 2): S103-7. 
D'Agostino, R. 2007. “Estimating treatment effects using observational data.” JAMA 297: 
314 - 16. 
D'Agostino, R. B. 1998. “Propensity score methods for bias reduction in the comparison 
of a treatment to a non-randomized control group.” Stat Med 17(19): 2265-81. 
D'Agostino, R. B., M. L. Lee, A. J. Belanger, L. A. Cupples, K. Anderson, and W. B. 
Kannel. 1990. “Relation of pooled logistic regression to time dependent Cox regression 
analysis: the Framingham Heart Study.” Stat Med 9(12): 1501-15. 
Dalal, A. A., M. Shah, A. O. D'Souza, and P. Rane. 2011. “Costs of COPD exacerbations 
in the emergency department and inpatient setting.” Respir Med 105(3): 454-60. 
Decramer, M., B. Celli, S. Kesten, T. Lystig, S. Mehra, and D. P. Tashkin. 2009. “Effect 
of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary 
disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.” 
Lancet 374(9696): 1171-8. 
Decramer, M., S. Rennard, T. Troosters, D. W. Mapel, N. Giardino, D. Mannino, E. 
Wouters, S. Sethi, and C. B. Cooper. 2008. “COPD as a Lung Disease with Systemic 
Consequences - Clinical Impact, Mechanisms, and Potential for Early Intervention.” 
COPD 5(4): 235-56. 
Disantostefano, R. L., H. Li, D. B. Rubin, and D. A. Stempel. 2013. “Which patients with 
chronic obstructive pulmonary disease benefit from the addition of an inhaled 
corticosteroid to their bronchodilator? A cluster analysis.” BMJ Open 3(4). 
Donaldson, G. C., T. A. Seemungal, A. Bhowmik, and J. A. Wedzicha. 2002. 
“Relationship between exacerbation frequency and lung function decline in chronic 
obstructive pulmonary disease.” Thorax 57(10): 847-52. 
Eddy, D. M. 1990. “Guidelines for policy statements - The explicit approach.” JAMA 
263(16): 2239. 
  
405 
Effing, T. W., H. A. M. Kerstjens, E. M. Monninkhof, P. van der Valk, E. F. M. Wouters, 
D. S. Postma, G. A. Zielhuis, and J. van der Palen. 2009. “Definitions of Exacerbations 
Does It Really Matter in Clinical Trials on COPD?” Chest 136(3): 918-23. 
Elixhauser, A., D. H. Au, and J. Podulka. 2011. “Readmissions for Chronic Obstructive 
Pulmonary Disease, 2008: Statistical Brief #121.” In Healthcare Cost and Utilization 
Project (HCUP) Statistical Briefs. Rockville (MD). 
Elixhauser, A., C. Steiner, D. R. Harris, and R. N. Coffey. 1998. “Comorbidity measures 
for use with administrative data.” Med Care 36(1): 8-27. 
Fang, H., H. Liu, and J. A. Rizzo. 2009. “Has the use of physician gatekeepers declined 
among HMOs? Evidence from the United States.” Int J Health Care Finance  Econ 9(2): 
183-95. 
Faries, D., H. Ascher-Svanum, and M. Belger. 2007. “Analysis of treatment effectiveness 
in longitudinal observational data.” J Biopharm Stat 17(5): 809-26. 
Faries, D. E. and Z. A. Kadziola. 2010. “Analysis of longitudinal observational data using 
marginal structural models.” In Analysis of Observational Health Care Data Using SAS, 
edited by D. E. Faries, A. C. Leon, J. M. Haro, and R. L. Obenchain, pp. 211-30. Cary, 
North Carolina: SAS Institute. 
FitzGerald, J. M., J. M. Haddon, C. Bradley-Kennedy, L. Kuramoto, G. T. Ford, and R. 
S. Grp. 2007. “Resource use study in COPD (RUSIC): A prospective study to, quantify 
the effects of COPD exacerbations on health care resource use among COPD patients.” 
Can Respir J 14(3): 145-52. 
Foster, T. S., J. D. Miller, J. P. Marton, J. P. Caloyeras, M. W. Russell, and J. Menzin. 
2006. “Assessment of the economic burden of COPD in the U.S.: a review and synthesis 
of the literature.” COPD 3(4): 211-8. 
Frölich, M. 2004. “Finite-sample properties of propensity score matching and weighting 
estimators.” Rev Econ Stat 86(1): 77-90. 
Gagnon, Y. M., A. R. Levy, M. D. Spencer, J. S. Hurley, F. J. Frost, D. W. Mapel, and A. 
H. Briggs. 2005. “Economic evaluation of treating chronic obstructive pulmonary disease 
with inhaled corticosteroids and long-acting beta(2)-agonists in a health maintenance 
organization.” Respir Med 99(12): 1534-45. 
Gelb, A. F., C. F. Taylor, C. Cassino, C. M. Shinar, M. J. Schein, and N. Zamel. 2009. 
“Tiotropium induced bronchodilation and protection from dynamic hyperinflation is 
independent of extent of emphysema in COPD.” Pulm Pharmacol Ther 22(3): 237-42. 
George, J., D. C. Kong, R. Thoman, and K. Stewart. 2005. “Factors associated with 
medication nonadherence in patients with COPD.” Chest 128(5): 3198-204. 
  
406 
Ginde, A. A., C. L. Tsai, P. G. Blanc, and C. A. Camargo, Jr. 2008. “Positive predictive 
value of ICD-9-CM codes to detect acute exacerbation of COPD in the emergency 
department.” Jt Comm J Qual Patient Saf 34(11): 678-80. 
GOLD. 2011. "Global strategy for the diagnosis, management, and prevention of COPD, 
global initiative for chronic obstructive lung disease (GOLD) (Updated 2011)" [accessed 
on May 8, 2012, 2011]. Available at: www.goldcopd.org. 
Guyatt, G. 1992. “Evidence-based medicine - A new approach to teaching the practice of 
medicine.” JAMA 268(17): 2420-25. 
Hale, D. 2010. “Respiratory failure in COPD patients.” ACP Hospitalist. American 
College of Physicians. 
Hanania, N. A., G. D. Crater, A. N. Morris, A. H. Emmett, D. M. O'Dell, and D. E. 
Niewoehner. 2012. “Benefits of adding fluticasone propionate/salmeterol to tiotropium in 
moderate to severe COPD.” Respir Med 106(1): 91-101. 
Hernan, M. A., A. Alonso, R. Logan, F. Grodstein, K. B. Michels, W. C. Willett, J. E. 
Manson, and J. M. Robins. 2008. “Observational studies analyzed like randomized 
experiments: an application to postmenopausal hormone therapy and coronary heart 
disease.” Epidemiology 19(6): 766-79. 
Hernan, M. A., B. A. Brumback, and J. M. Robins. 2002. “Estimating the causal effect of 
zidovudine on CD4 count with a marginal structural model for repeated measures.” Stat 
Med 21(12): 1689-709. 
Hernan, M. A., E. Lanoy, D. Costagliola, and J. M. Robins. 2006. “Comparison of 
dynamic treatment regimes via inverse probability weighting.” Basic Clin Pharmacol 
Toxicol 98(3): 237-42. 
Holguin, F., E. Folch, S. C. Redd, and D. A. Mannino. 2005. “Comorbidity and mortality 
in COPD-related hospitalizations in the United States, 1979 to 2001.” Chest 128(4): 
2005-11. 
Hurst, J., G. Donaldson, and J. Wedzicha. 2009. “"Temporal Clustering" of COPD 
Exacerbations May Reflect Corticosteroid Withdrawal.” Am J Respir Crit Care Med 
180(5): 483-83. 
Hurst, J. R., J. Vestbo, A. Anzueto, N. Locantore, H. Mullerova, R. Tal-Singer, B. Miller, 
D. A. Lomas, A. Agusti, W. MacNee, P. Calverley, S. Rennard, E. F. M. Wouters, J. A. 
Wedzicha, and C. L. Evaluation. 2010. “Susceptibility to exacerbation in chronic 
obstructive pulmonary disease.” N Engl J Med 363(12): 1128-38. 
Hurst, J. R. and J. A. Wedzicha. 2009. “Management and prevention of chronic 
obstructive pulmonary disease exacerbations: a state of the art review.” BMC Med 7. 
  
407 
Iyer Parameswaran, G. and T. F. Murphy. 2009. “Chronic obstructive pulmonary disease: 
role of bacteria and updated guide to antibacterial selection in the older patient.” Drugs 
Aging 26(12): 985-95. 
Jenkins, C. R., P. W. Jones, P. M. Calverley, B. Celli, J. A. Anderson, G. T. Ferguson, J. 
C. Yates, L. R. Willits, and J. Vestbo. 2009. “Efficacy of salmeterol/fluticasone 
propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the 
randomised, placebo-controlled TORCH study.” Respir Res 10: 59. 
Jones, P. W. 1995. “Issues concerning health-related quality of life in COPD.” Chest 
107(5 Suppl): 187S-93S. 
Jones, P. W. 2001. “Health status measurement in chronic obstructive pulmonary 
disease.” Thorax 56(11): 880-7. 
Jones, P. W. 2009. “Triple therapy for chronic obstructive pulmonary disease: trials 
catching up with clinical practice?” Am J Respir Crit Care Med 180(8): 689-90. 
Jones, P. W., G. Harding, P. Berry, I. Wiklund, W. H. Chen, and N. Kline Leidy. 2009. 
“Development and first validation of the COPD Assessment Test.” European Respir J 
34(3): 648-54. 
Kanel, K., S. Elster, and C. Vrbin. 2010. “Brief 1: Overview of Six Target Chronic 
Diseases.” Pittsburgh Regional Health Initiative Readmission Briefs. Pittsburgh, PA: 
Pittsburgh Regional Health Initiative. 
Keene, O. N., P. M. A. Calverley, P. W. Jones, J. Vestbo, and J. A. Anderson. 2008. 
“Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited.” 
European Respiratory Journal 32(1): 17-24. 
Kessler, R., E. Stahl, C. Vogelmeier, J. Haughney, E. Trudeau, C. G. Lofdahl, and M. R. 
Partridge. 2006. “Patient understanding, detection, and experience of COPD 
exacerbations: an observational, interview-based study.” Chest 130(1): 133-42. 
Kostikas, K. and D. Bouros. 2010. “"Show me the money": a fair criticism of economic 
studies on inhaled bronchodilators for COPD.” BMC Pulm Med 10: 48. 
Lefebvre, G., J. A. Delaney, and R. W. Platt. 2008. “Impact of mis-specification of the 
treatment model on estimates from a marginal structural model.” Stat Med 27(18): 3629-
42. 
Lin, D. Y., E. J. Feuer, R. Etzioni, and Y. Wax. 1997. “Estimating medical costs from 
incomplete follow-up data.” Biometrics 53(2): 419-34. 
Little, R. J. and D. B. Rubin. 2000. “Causal effects in clinical and epidemiological studies 
via potential outcomes: Concepts and analytical approaches.” Annu Rev Public Health 
21: 121-45. 
  
408 
Mackay, A. J., G. C. Donaldson, A. R. Patel, P. W. Jones, J. R. Hurst, and J. A. 
Wedzicha. 2012. “Usefulness of the Chronic Obstructive Pulmonary Disease Assessment 
Test to evaluate severity of COPD exacerbations.” Am J Respir Crit Care Med 185(11): 
1218-24. 
Maclay, J. D., D. A. McAllister, and W. MacNee. 2007. “Cardiovascular risk in chronic 
obstructive pulmonary disease.” Respirology 12(5): 634-41. 
Mannino, D. M. and A. S. Buist. 2007. “Global burden of COPD: risk factors, 
prevalence, and future trends.” Lancet 370(9589): 765-73. 
Mapel, D. W., M. P. Dutro, J. P. Marton, K. Woodruff, and B. Make. 2011. “Identifying 
and characterizing COPD patients in US managed care. A retrospective, cross-sectional 
analysis of administrative claims data.” BMC Health Serv Res 11: 43. 
Marcus, P. and S. S. Braman. 2010. “International classification of disease coding for 
obstructive lung disease: does it reflect appropriate clinical documentation?” Chest 
138(1): 188-92. 
Mascarenhas, J., A. Azevedo, and P. Bettencourt. 2010. “Coexisting chronic obstructive 
pulmonary disease and heart failure: implications for treatment, course and mortality.” 
Curr Opin Pulm Med 16(2): 106-11. 
McGhan, R., T. Radcliff, R. Fish, E. R. Sutherland, C. Welsh, and B. Make. 2007. 
“Predictors of rehospitalization and death after a severe exacerbation of COPD.” Chest 
132(6): 1748-55. 
McHorney, C. A. 2009. “The Adherence Estimator: a brief, proximal screener for patient 
propensity to adhere to prescription medications for chronic disease.” Curr Med Res Opin 
25(1): 215-38. 
Menzin, J., L. Boulanger, J. Marton, L. Guadagno, H. Dastani, R. Dirani, A. Phillips, and 
H. Shah. 2008. “The economic burden of chronic obstructive pulmonary disease (COPD) 
in a U.S. Medicare population.” Respir Med 102(9): 1248-56. 
Moodie, E. E. and D. A. Stephens. 2011. “Marginal structural models: unbiased 
estimation for longitudinal studies.” Int J Public Health 56(1): 117-9. 
Mortimer, K. M., R. Neugebauer, M. van der Laan, and I. B. Tager. 2005. “An 
application of model-fitting procedures for marginal structural models.” Am J Epidemiol 
162(4): 382-88. 
Naimi, A. I., S. R. Cole, D. J. Westreich, and D. B. Richardson. 2011. “A comparison of 
methods to estimate the hazard ratio under conditions of time-varying confounding and 
nonpositivity.” Epidemiology 22(5): 718-23. 
  
409 
Najafzadeh, M., C. Marra, M. Sadatsafavi, S. Aaron, S. Sullivan, K. Vandemheen, P. 
Jones, and J. Fitzgerald. 2008. “Cost effectiveness of therapy with combinations of long 
acting bronchodilators and inhaled steroids for treatment of COPD.” Thorax 63: 962 - 67. 
NCQA. 2011. "HEDIS Technical Updates 2011 Cost of Care Specs" [accessed on June 3, 
2013, 2011]. Available at: 
http://www.ncqa.org/portals/0/PolicyUpdates/HEDIS%20Technical%20Updates/2011%2
0Cost%20of%20Care%20Specs.pdf. 
NHLBI. 2009. "Morbidity & mortality: 2009 chart book on cardiovascular, lung, and 
blood diseases" [accessed on October 17, 2011, 2009]. Available at: 
http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf. 
Normand, S. L. T., N. B. Landrum, E. Guadagnoli, J. Z. Ayanian, T. J. Ryan, P. D. 
Cleary, and B. J. McNeil. 2001. “Validating recommendations for coronary angiography 
following acute myocardial infarction in the elderly: A matched analysis using propensity 
scores.” J Clin Epidemiol 54(4): 387-98. 
Patel, A. R., G. C. Donaldson, A. J. Mackay, J. A. Wedzicha, and J. R. Hurst. 2012. “The 
impact of ischemic heart disease on symptoms, health status, and exacerbations in 
patients with COPD.” Chest 141(4): 851-7. 
Penning-van Bees, F., M. van Herk-Sukel, R. Gale, J. W. Lammers, and R. Herings. 
2011. “Three-year dispensing patterns with long-acting inhaled drugs in COPD: A 
database analysis.” Respir Med 105(2): 259-65. 
Piette, J. D., A. Beard, A. M. Rosland, and C. A. McHorney. 2011. “Beliefs that 
influence cost-related medication non-adherence among the "haves" and "have nots" with 
chronic diseases.” Patient Prefer Adherence 5: 389-96. 
Platt, R. W., J. A. Delaney, and S. Suissa. 2012. “The positivity assumption and marginal 
structural models: the example of warfarin use and risk of bleeding.” Eur J Epidemiol 
27(2): 77-83. 
Porta, M. S. and International Epidemiological Association. 2008. A dictionary of 
epidemiology. Oxford ; New York: Oxford University Press. 
Rabe, K. F., W. Timmer, A. Sagkriotis, and K. Viel. 2008. “Comparison of a 
combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate 
COPD.” Chest 134(2): 255-62. 
Rabe, K. F. and J. A. Wedzicha. 2011. “Controversies in treatment of chronic obstructive 
pulmonary disease.” Lancet 378(9795): 1038-47. 
Ranieri, P., A. Bianchetti, A. Margiotta, A. Virgillo, E. M. Clini, and M. Trabucchi. 
2008. “Predictors of 6-month mortality in elderly patients with mild chronic obstructive 
pulmonary disease discharged from a medical ward after acute nonacidotic 
exacerbation.” J Am Geriatr Soc 56(5): 909-13. 
  
410 
Restrepo, R. D., M. T. Alvarez, L. D. Wittnebel, H. Sorenson, R. Wettstein, D. L. Vines, 
J. Sikkema-Ortiz, D. D. Gardner, and R. L. Wilkins. 2008. “Medication adherence issues 
in patients treated for COPD.” Int J Chron Obstruct Pulmon Dis 3(3): 371-84. 
Roberts, M., D. Mapel, H. Petersen, C. Blanchette, and S. Ramachandran. 2011. 
“Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for 
COPD management.” J Med Econ 14(6): 769-76. 
Robins, J. M., M. A. Hernan, and B. Brumback. 2000. “Marginal structural models and 
causal inference in epidemiology.” Epidemiology 11(5): 550-60. 
Rosenbaum, P. R. and D. B. Rubin. 1983. “The central role of the propensity score in 
observational studies for causal effects.” Biometrika 70(1): 41-55. 
Sackett, D. L., W. M. C. Rosenberg, J. A. M. Gray, R. B. Haynes, and W. S. Richardson. 
1996. “Evidence based medicine: What it is and what it isn't - It's about integrating 
individual clinical expertise and the best external evidence.” Br Med J 312(7023): 71-72. 
Salas, M., A. Hofman, and B. H. C. Stricker. 1999. “Confounding by indication: An 
example of variation in the use of epidemiologic terminology.” Am J Epidemiol 149(11): 
981-83. 
Schweiger, T. A. and M. Zdanowicz. 2010. “Systemic corticosteroids in the treatment of 
acute exacerbations of chronic obstructive pulmonary disease.” Am J Health Syst Pharm 
67(13): 1061-9. 
Seemungal, T. A., J. R. Hurst, and J. A. Wedzicha. 2009. “Exacerbation rate, health 
status and mortality in COPD--a review of potential interventions.” Int J Chron Obstruct 
Pulmon Dis 4: 203-23. 
Seemungal, T. A. R., G. C. Donaldson, A. Bhowmik, D. J. Jeffries, and J. A. Wedzicha. 
2000. “Time Course and Recovery of Exacerbations in Patients with Chronic Obstructive 
Pulmonary Disease.” Am J Respir Crit Care Med 161(5): 1608-13. 
Segal, J. B., M. Griswold, A. Achy-Brou, R. Herbert, E. B. Bass, S. M. Dy, A. E. 
Millman, A. W. Wu, and C. E. Frangakis. 2007. “Using propensity scores 
subclassification to estimate effects of longitudinal treatments: an example using a new 
diabetes medication.” Med Care 45(10 Supl 2): S149-57. 
Sharma, G., Y. F. Kuo, J. L. Freeman, D. D. Zhang, and J. S. Goodwin. 2010. 
“Outpatient follow-up visit and 30-day emergency department visit and readmission in 
patients hospitalized for chronic obstructive pulmonary disease.” Arch Intern Med 
170(18): 1664-70. 
Short, P. M., P. A. Williamson, D. H. Elder, S. I. Lipworth, S. Schembri, and B. J. 
Lipworth. 2012. “The impact of tiotropium on mortality and exacerbations when added to 
inhaled corticosteroids and long-acting beta-agonist therapy in COPD.” Chest 141(1): 81-
6. 
  
411 
Siddiqi, A. and S. Sethi. 2008. “Optimizing antibiotic selection in treating COPD 
exacerbations.” Int J Chron Obstruct Pulmon Dis 3(1): 31-44. 
Simoni-Wastila, L., Y. J. Wei, J. Qian, I. H. Zuckerman, B. Stuart, T. Shaffer, A. A. 
Dalal, and L. Bryant-Comstock. 2012. “Association of chronic obstructive pulmonary 
disease maintenance medication adherence with all-cause hospitalization and spending in 
a medicare population.” Am J Geriatr Pharmacother 10(3): 201-10. 
Singh, D., J. Brooks, G. Hagan, A. Cahn, and B. J. O'Connor. 2008. “Superiority of 
"triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus 
individual components in moderate to severe COPD.” Thorax 63(7): 592-8. 
Steer, J., G. J. Gibson, and S. C. Bourke. 2010. “Predicting outcomes following 
hospitalization for acute exacerbations of COPD.” QJM 103(11): 817-29. 
Stein, B. D., A. Bautista, G. T. Schumock, T. A. Lee, J. T. Charbeneau, D. S. Lauderdale, 
E. T. Naureckas, D. O. Meltzer, and J. A. Krishnan. 2012. “The validity of International 
Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for 
identifying patients hospitalized for COPD exacerbations.” Chest 141(1): 87-93. 
Stokes, M. E., C. S. Davis, and G. G. Koch. 2000. Categorical data analysis using the 
SAS system. Cary, NC: SAS Institute, Inc. 
Stuart, B. C., L. Simoni-Wastila, I. H. Zuckerman, A. Davidoff, T. Shaffer, H. W. Yang, 
J. Qian, A. A. Dalal, D. W. Mapel, and L. Bryant-Comstock. 2010. “Impact of 
maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with 
chronic obstructive pulmonary disease.” Am J Geriatr Pharmacother 8(5): 441-53. 
Stuart, E. A. 2010. “Matching Methods for Causal Inference: A Review and a Look 
Forward.” Stat Sci 25(1): 1-21. 
Sturmer, T., M. Joshi, R. J. Glynn, J. Avorn, K. J. Rothman, and S. Schneeweiss. 2006. 
“A review of the application of propensity score methods yielded increasing use, 
advantages in specific settings, but not substantially different estimates compared with 
conventional multivariable methods.” J Clin Epidemiol 59(5): 437-47. 
Suarez, D., J. M. Haro, D. Novick, and S. Ochoa. 2008. “Marginal structural models 
might overcome confounding when analyzing multiple treatment effects in observational 
studies.” J Clin Epidemiol 61(6): 525-30. 
Suissa, S., P. Ernst, K. L. Vandemheen, and S. D. Aaron. 2008. “Methodological issues 
in therapeutic trials of COPD.” Eur Respir J 31(5): 927-33. 
Tashkin, D. P. 2010. “Preventing and managing exacerbations in COPD--critical 
appraisal of the role of tiotropium.” Int J Chron Obstruct Pulmon Dis 5: 41-53. 
  
412 
Toy, E. L., K. F. Gallagher, E. L. Stanley, A. R. Swensen, and M. S. Duh. 2010. “The 
economic impact of exacerbations of chronic obstructive pulmonary disease and 
exacerbation definition: a review.” COPD 7(3): 214-28. 
Tunis, S. R., D. B. Stryer, and C. M. Clancy. 2003. “Practical clinical trials - Increasing 
the value of clinical research for decision making in clinical and health policy.” JAMA 
290(12): 1624-32. 
Vestbo, J., J. A. Anderson, P. M. A. Calverley, B. Celli, G. T. Ferguson, C. Jenkins, K. 
Knobil, L. R. Willits, J. C. Yates, and P. W. Jones. 2009. “Adherence to inhaled therapy, 
mortality and hospital admission in COPD.” Thorax 64(11): 939-43. 
Wedzicha, J. A., P. M. A. Calverley, T. A. Seemungal, G. Hagan, Z. Ansari, R. A. 
Stockley, and I. Investigators. 2008. “The prevention of chronic obstructive pulmonary 
disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.” Am J 
Respir Crit Care Med 177(1): 19-26. 
Wedzicha, J. A. and T. A. R. Seemungal. 2007. “COPD exacerbations: defining their 
cause and prevention.” Lancet 370(9589): 786-96. 
Weitzen, S., K. L. Lapane, A. Y. Toledano, A. L. Hume, and V. Mor. 2005. “Weaknesses 
of goodness-of-fit tests for evaluating propensity score models: the case of the omitted 
confounder.” Pharmacoepidemiol Drug Saf 14(4): 227-38. 
Welte, T., M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, and R. 
Kessler. 2009. “Efficacy and tolerability of budesonide/formoterol added to tiotropium in 
patients with chronic obstructive pulmonary disease.” Am J Respir Crit Care Med 180(8): 
741-50. 
Wier, L. M., A. Elixhauser, A. Pfuntner, and D. H. Au. 2011. “Overview of 
Hospitalizations among Patients with COPD, 2008: Statistical Brief #106.” In Healthcare 
Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD). 
Wong, A. W. M., W. Q. Gan, J. Burns, D. D. Sin, and S. F. van Eeden. 2008. “Acute 
exacerbation of chronic obstructive pulmonary disease: influence of social factors in 
determining length of hospital stay and readmission rates.” Can Respir J 15(7): 361-64. 
Xu, S., C. Ross, M. A. Raebel, S. Shetterly, C. Blanchette, and D. Smith. 2010. “Use of 
stabilized inverse propensity scores as weights to directly estimate relative risk and its 
confidence intervals.” Value in Health 13(2): 273-7. 
Xu, S., S. Shetterly, D. Powers, M. A. Raebel, T. T. Tsai, P. M. Ho, and D. Magid. 2012. 
“Extension of Kaplan-Meier methods in observational studies with time-varying 
treatment.” Value in Health 15(1): 167-74. 
Young, J. G., M. A. Hernan, S. Picciotto, and J. M. Robins. 2010. “Relation between 
three classes of structural models for the effect of a time-varying exposure on survival.” 
Lifetime Data Anal 16(1): 71-84. 
  
413 
Yu, A. P., Y. F. Yu, and M. B. Nichol. 2010. “Estimating the effect of medication 
adherence on health outcomes among patients with type 2 diabetes--an application of 
marginal structural models.” Value in Health 13(8): 1038-45. 
Zvezdin, B., S. Milutinov, M. Kojicic, M. Hadnadjev, S. Hromis, M. Markovic, and O. 
Gajic. 2009. “A postmortem analysis of major causes of early death in patients 
hospitalized with COPD exacerbation.” Chest 136(2): 376-80. 
 
 
 
 
